0001906324-23-000014.txt : 20230223 0001906324-23-000014.hdr.sgml : 20230223 20230223171650 ACCESSION NUMBER: 0001906324-23-000014 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 126 CONFORMED PERIOD OF REPORT: 20230101 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QuidelOrtho Corp CENTRAL INDEX KEY: 0001906324 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 874496285 FISCAL YEAR END: 0101 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41409 FILM NUMBER: 23661008 BUSINESS ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 552-1100 MAIL ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Coronado Topco, Inc. DATE OF NAME CHANGE: 20220124 10-K 1 qdel-20230101.htm 10-K qdel-20230101
00019063242022FYfalsehttp://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInteresthttp://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInteresthttp://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInteresthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent00019063242022-01-032023-01-0100019063242022-07-01iso4217:USD00019063242023-02-10xbrli:shares00019063242023-01-0100019063242022-01-02iso4217:USDxbrli:shares00019063242021-01-042022-01-0200019063242019-12-302021-01-030001906324us-gaap:CommonStockMember2019-12-290001906324us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-12-290001906324us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-290001906324us-gaap:RetainedEarningsMember2019-12-2900019063242019-12-290001906324us-gaap:CommonStockMember2019-12-302021-01-030001906324us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2019-12-302021-01-030001906324us-gaap:CommonStockMemberus-gaap:ConvertibleDebtMember2019-12-302021-01-030001906324us-gaap:RetainedEarningsMember2019-12-302021-01-030001906324us-gaap:CommonStockMember2021-01-030001906324us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-01-030001906324us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-030001906324us-gaap:RetainedEarningsMember2021-01-0300019063242021-01-030001906324us-gaap:CommonStockMember2021-01-042022-01-020001906324us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2021-01-042022-01-020001906324us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-042022-01-020001906324us-gaap:RetainedEarningsMember2021-01-042022-01-020001906324us-gaap:CommonStockMember2022-01-020001906324us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-01-020001906324us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-020001906324us-gaap:RetainedEarningsMember2022-01-020001906324us-gaap:CommonStockMember2022-01-032023-01-010001906324us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-01-032023-01-010001906324us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-032023-01-010001906324us-gaap:RetainedEarningsMember2022-01-032023-01-010001906324us-gaap:CommonStockMember2023-01-010001906324us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-01-010001906324us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-010001906324us-gaap:RetainedEarningsMember2023-01-01qdel:country0001906324us-gaap:CostOfSalesMember2021-01-042022-01-020001906324us-gaap:CostOfSalesMember2019-12-302021-01-030001906324qdel:SellingMarketingAndAdministrativeExpenseMember2021-01-042022-01-020001906324qdel:SellingMarketingAndAdministrativeExpenseMember2019-12-302021-01-030001906324us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2022-01-032023-01-010001906324srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2022-01-032023-01-010001906324us-gaap:EquipmentMembersrt:MinimumMember2022-01-032023-01-010001906324us-gaap:EquipmentMembersrt:MaximumMember2022-01-032023-01-010001906324qdel:InstrumentsAvailableForLeaseMembersrt:MinimumMember2022-01-032023-01-010001906324srt:MaximumMemberqdel:InstrumentsAvailableForLeaseMember2022-01-032023-01-010001906324us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2022-01-032023-01-010001906324srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-01-032023-01-01qdel:segment00019063242020-07-012023-01-010001906324us-gaap:ShippingAndHandlingMember2022-01-032023-01-010001906324us-gaap:ShippingAndHandlingMember2021-01-042022-01-020001906324us-gaap:ShippingAndHandlingMember2019-12-302021-01-030001906324us-gaap:AdvertisingMember2022-01-032023-01-010001906324us-gaap:AdvertisingMember2021-01-042022-01-020001906324us-gaap:AdvertisingMember2019-12-302021-01-030001906324qdel:OrthoMember2022-05-262022-05-260001906324qdel:OrthoMember2022-05-260001906324qdel:OrthoMemberqdel:OrthoMember2022-05-262022-05-260001906324qdel:OrthoMemberqdel:QuidelOrthoMember2022-05-262022-05-260001906324qdel:OrthoMember2022-05-272022-05-270001906324qdel:OrthoMember2022-05-270001906324qdel:OrthoMember2022-05-272023-01-010001906324qdel:OrthoMember2023-01-010001906324qdel:SeniorNotesDue2025Memberqdel:OrthoMemberus-gaap:SeniorNotesMember2022-05-27xbrli:pure0001906324qdel:OrthoMemberqdel:SeniorNotesDue2028Memberus-gaap:SeniorNotesMember2022-05-2700019063242022-05-272022-05-270001906324qdel:OrthoMember2022-01-032023-01-010001906324qdel:OrthoMembersrt:NorthAmericaMember2023-01-010001906324us-gaap:EMEAMemberqdel:OrthoMember2023-01-010001906324qdel:OrthoMembercountry:CN2023-01-010001906324qdel:OrthoMemberqdel:LocationsNotIncludingNorthAmericaEMEAAndChinaMember2023-01-010001906324qdel:OrthoMemberus-gaap:CustomerRelationshipsMember2022-05-272023-01-010001906324qdel:OrthoMemberus-gaap:CustomerRelationshipsMember2023-01-010001906324qdel:OrthoMemberus-gaap:DevelopedTechnologyRightsMember2022-05-272023-01-010001906324qdel:OrthoMemberus-gaap:DevelopedTechnologyRightsMember2023-01-010001906324us-gaap:TrademarksMemberqdel:OrthoMember2022-05-272023-01-010001906324us-gaap:TrademarksMemberqdel:OrthoMember2023-01-010001906324qdel:OrthoMember2021-01-042022-01-020001906324qdel:OrthoMemberqdel:AmortizationExpenseMember2022-01-032023-01-010001906324qdel:OrthoMemberqdel:AmortizationExpenseMember2021-01-042022-01-020001906324qdel:OrthoMemberus-gaap:CostOfSalesMember2021-01-042022-01-020001906324qdel:OrthoMemberus-gaap:InterestExpenseMember2022-01-032023-01-010001906324qdel:OrthoMemberus-gaap:InterestExpenseMember2021-01-042022-01-020001906324qdel:OrthoMemberqdel:OrthoMemberqdel:LossOnExtinguishmentOfDebtMember2022-01-032023-01-010001906324qdel:OrthoMemberqdel:LossOnExtinguishmentOfDebtMember2022-01-032023-01-010001906324qdel:OrthoMemberqdel:LossOnExtinguishmentOfDebtMember2021-01-042022-01-020001906324qdel:ShareBasedCompensationExpenseMemberqdel:OrthoMember2022-01-032023-01-010001906324qdel:ShareBasedCompensationExpenseMemberqdel:OrthoMember2021-01-042022-01-020001906324us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-01-010001906324qdel:Customer1Member2023-01-010001906324qdel:ExpectedValueContractCustomersMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-01-010001906324qdel:Customer2Member2023-01-010001906324us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-032023-01-010001906324us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementAndThirdPartyMember2022-01-032023-01-010001906324qdel:LabsMember2022-01-032023-01-010001906324qdel:LabsMember2021-01-042022-01-020001906324qdel:LabsMember2019-12-302021-01-030001906324qdel:TransfusionMedicineMember2022-01-032023-01-010001906324qdel:TransfusionMedicineMember2021-01-042022-01-020001906324qdel:TransfusionMedicineMember2019-12-302021-01-030001906324qdel:PointOfCareMember2022-01-032023-01-010001906324qdel:PointOfCareMember2021-01-042022-01-020001906324qdel:PointOfCareMember2019-12-302021-01-030001906324qdel:MolecularDiagnosticsMember2022-01-032023-01-010001906324qdel:MolecularDiagnosticsMember2021-01-042022-01-020001906324qdel:MolecularDiagnosticsMember2019-12-302021-01-030001906324qdel:CustomerAMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2022-01-032023-01-010001906324qdel:CustomerAMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2021-01-042022-01-020001906324qdel:CustomerAMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2019-12-302021-01-030001906324us-gaap:SalesMemberqdel:CustomerBMemberus-gaap:CustomerConcentrationRiskMember2022-01-032023-01-010001906324us-gaap:SalesMemberqdel:CustomerBMemberus-gaap:CustomerConcentrationRiskMember2021-01-042022-01-020001906324us-gaap:SalesMemberqdel:CustomerBMemberus-gaap:CustomerConcentrationRiskMember2019-12-302021-01-030001906324qdel:CustomerCMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2022-01-032023-01-010001906324qdel:CustomerCMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2021-01-042022-01-020001906324qdel:CustomerCMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2019-12-302021-01-030001906324us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberqdel:CustomerDMember2022-01-032023-01-010001906324us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberqdel:CustomerDMember2021-01-042022-01-020001906324us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberqdel:CustomerDMember2019-12-302021-01-030001906324us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberqdel:CustomerEMember2022-01-032023-01-010001906324us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberqdel:CustomerEMember2021-01-042022-01-020001906324us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMemberqdel:CustomerEMember2019-12-302021-01-030001906324us-gaap:SalesMemberqdel:CustomersInExcessOf10TotalRevenueMemberus-gaap:CustomerConcentrationRiskMember2022-01-032023-01-010001906324us-gaap:SalesMemberqdel:CustomersInExcessOf10TotalRevenueMemberus-gaap:CustomerConcentrationRiskMember2021-01-042022-01-020001906324us-gaap:SalesMemberqdel:CustomersInExcessOf10TotalRevenueMemberus-gaap:CustomerConcentrationRiskMember2019-12-302021-01-030001906324qdel:CustomersWithBalancesDueInExcessOf10OfAccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-010001906324qdel:CustomersWithBalancesDueInExcessOf10OfAccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-020001906324us-gaap:SalesRevenueNetMemberqdel:COVID19Memberus-gaap:ProductConcentrationRiskMember2022-01-032023-01-010001906324us-gaap:SalesRevenueNetMemberqdel:COVID19Memberus-gaap:ProductConcentrationRiskMember2021-01-042022-01-020001906324us-gaap:SalesRevenueNetMemberqdel:COVID19Memberus-gaap:ProductConcentrationRiskMember2019-12-302021-01-030001906324qdel:InfluenzaMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2022-01-032023-01-010001906324qdel:InfluenzaMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-042022-01-020001906324qdel:InfluenzaMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2019-12-302021-01-030001906324qdel:NorthAmericaSegmentMember2022-01-032023-01-010001906324qdel:NorthAmericaSegmentMember2021-01-042022-01-020001906324qdel:NorthAmericaSegmentMember2019-12-302021-01-030001906324qdel:EMEASegmentMember2022-01-032023-01-010001906324qdel:EMEASegmentMember2021-01-042022-01-020001906324qdel:EMEASegmentMember2019-12-302021-01-030001906324qdel:ChinaMember2022-01-032023-01-010001906324qdel:ChinaMember2021-01-042022-01-020001906324qdel:ChinaMember2019-12-302021-01-030001906324qdel:OtherMember2022-01-032023-01-010001906324qdel:OtherMember2021-01-042022-01-020001906324qdel:OtherMember2019-12-302021-01-030001906324us-gaap:CorporateAndOtherMember2022-01-032023-01-010001906324us-gaap:CorporateAndOtherMember2021-01-042022-01-020001906324us-gaap:CorporateAndOtherMember2019-12-302021-01-030001906324us-gaap:DomesticCountryMember2023-01-010001906324us-gaap:DomesticCountryMember2022-01-020001906324us-gaap:DomesticCountryMember2022-01-032023-01-010001906324us-gaap:DomesticCountryMember2021-01-042022-01-020001906324us-gaap:DomesticCountryMember2019-12-302021-01-030001906324us-gaap:ForeignCountryMember2023-01-010001906324us-gaap:ForeignCountryMember2022-01-020001906324us-gaap:ForeignCountryMember2022-01-032023-01-010001906324us-gaap:ForeignCountryMember2021-01-042022-01-020001906324us-gaap:ForeignCountryMember2019-12-302021-01-030001906324us-gaap:DomesticCountryMember2023-01-010001906324qdel:SubjectToExpirationThrough2037Memberus-gaap:DomesticCountryMember2023-01-010001906324qdel:NotSubjectToExpirationMemberus-gaap:DomesticCountryMember2023-01-010001906324us-gaap:DomesticCountryMember2023-01-010001906324us-gaap:StateAndLocalJurisdictionMember2023-01-010001906324us-gaap:ForeignCountryMember2023-01-010001906324us-gaap:ForeignCountryMemberqdel:NotSubjectToExpirationMember2023-01-010001906324us-gaap:ForeignCountryMemberqdel:SubjectToExpirationThrough2042Member2023-01-010001906324us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-01-010001906324us-gaap:CorporateDebtSecuritiesMember2023-01-010001906324us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2022-01-020001906324us-gaap:CorporateDebtSecuritiesMember2022-01-020001906324us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2023-01-010001906324us-gaap:AssetBackedSecuritiesMember2023-01-010001906324us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2022-01-020001906324us-gaap:AssetBackedSecuritiesMember2022-01-020001906324us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentDebtSecuritiesMember2023-01-010001906324us-gaap:USGovernmentDebtSecuritiesMember2023-01-010001906324us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentDebtSecuritiesMember2022-01-020001906324us-gaap:USGovernmentDebtSecuritiesMember2022-01-020001906324us-gaap:ShortTermInvestmentsMemberqdel:AgencyBondsMember2023-01-010001906324qdel:AgencyBondsMember2023-01-010001906324us-gaap:ShortTermInvestmentsMemberqdel:AgencyBondsMember2022-01-020001906324qdel:AgencyBondsMember2022-01-020001906324us-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-01-010001906324us-gaap:ForeignGovernmentDebtSecuritiesMember2023-01-010001906324us-gaap:ShortTermInvestmentsMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-01-020001906324us-gaap:ForeignGovernmentDebtSecuritiesMember2022-01-020001906324us-gaap:ShortTermInvestmentsMemberus-gaap:OtherDebtSecuritiesMember2023-01-010001906324us-gaap:OtherDebtSecuritiesMember2023-01-010001906324us-gaap:ShortTermInvestmentsMemberus-gaap:OtherDebtSecuritiesMember2022-01-020001906324us-gaap:OtherDebtSecuritiesMember2022-01-020001906324us-gaap:ShortTermInvestmentsMember2023-01-010001906324us-gaap:ShortTermInvestmentsMember2022-01-020001906324qdel:LongTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-01-010001906324qdel:LongTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2022-01-020001906324qdel:LongTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2023-01-010001906324qdel:LongTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2022-01-020001906324qdel:QuidelConsolidatedEntitiesMember2023-01-010001906324qdel:QuidelConsolidatedEntitiesMember2022-01-020001906324qdel:OrthoMember2022-05-270001906324us-gaap:EquipmentMember2023-01-010001906324us-gaap:EquipmentMember2022-01-020001906324us-gaap:BuildingAndBuildingImprovementsMember2023-01-010001906324us-gaap:BuildingAndBuildingImprovementsMember2022-01-020001906324qdel:InstrumentsAvailableForLeaseMember2023-01-010001906324qdel:InstrumentsAvailableForLeaseMember2022-01-020001906324us-gaap:LandMember2023-01-010001906324us-gaap:LandMember2022-01-020001906324us-gaap:ConstructionInProgressMember2023-01-010001906324us-gaap:ConstructionInProgressMember2022-01-020001906324srt:NorthAmericaMember2022-01-020001906324us-gaap:EMEAMember2022-01-020001906324country:CN2022-01-020001906324qdel:OtherNotIncludingNorthAmericaEMEAAndChinaMember2022-01-020001906324srt:NorthAmericaMember2022-01-032023-01-010001906324us-gaap:EMEAMember2022-01-032023-01-010001906324country:CN2022-01-032023-01-010001906324qdel:OtherNotIncludingNorthAmericaEMEAAndChinaMember2022-01-032023-01-010001906324srt:NorthAmericaMember2023-01-010001906324us-gaap:EMEAMember2023-01-010001906324country:CN2023-01-010001906324qdel:OtherNotIncludingNorthAmericaEMEAAndChinaMember2023-01-010001906324qdel:PurchasedTechnologyMember2022-01-032023-01-010001906324qdel:PurchasedTechnologyMember2023-01-010001906324qdel:PurchasedTechnologyMember2022-01-020001906324us-gaap:CustomerRelationshipsMember2022-01-032023-01-010001906324us-gaap:CustomerRelationshipsMember2023-01-010001906324us-gaap:CustomerRelationshipsMember2022-01-020001906324us-gaap:LicensingAgreementsMember2022-01-032023-01-010001906324us-gaap:LicensingAgreementsMember2023-01-010001906324us-gaap:LicensingAgreementsMember2022-01-020001906324qdel:PatentsAndTrademarksMember2022-01-032023-01-010001906324qdel:PatentsAndTrademarksMember2023-01-010001906324qdel:PatentsAndTrademarksMember2022-01-020001906324us-gaap:ComputerSoftwareIntangibleAssetMember2022-01-032023-01-010001906324us-gaap:ComputerSoftwareIntangibleAssetMember2023-01-010001906324us-gaap:ComputerSoftwareIntangibleAssetMember2022-01-020001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:SecuredDebtMember2023-01-010001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:SecuredDebtMember2022-01-020001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-01-010001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-01-020001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:SecuredDebtMember2022-05-270001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-05-270001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-08-042022-08-040001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-08-040001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:LetterOfCreditMember2023-01-010001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMember2023-01-010001906324qdel:DebtInstrumentPaymentPeriodOneMemberus-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-01-010001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberqdel:DebtInstrumentPaymentPeriodTwoMemberus-gaap:RevolvingCreditFacilityMember2023-01-01qdel:covenant0001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberqdel:EndingAfterTheClosingDateOfTheCreditAgreementMember2023-01-010001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberqdel:EndingAfterInitialMeasurementPeriodMember2023-01-010001906324us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-05-272022-05-270001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:SecuredDebtMember2022-01-032023-01-010001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:SecuredDebtMember2021-01-042022-01-020001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:SecuredDebtMember2019-12-302021-01-030001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-01-032023-01-010001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2021-01-042022-01-020001906324us-gaap:LineOfCreditMemberqdel:BankOfAmericaCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2019-12-302021-01-03qdel:buildingqdel:term0001906324qdel:SummersRidgeMember2022-11-300001906324qdel:EquityIncentivePlanMemberus-gaap:EmployeeStockOptionMember2022-01-032023-01-010001906324qdel:EquityIncentivePlanMembersrt:MinimumMember2023-01-010001906324srt:MaximumMemberqdel:EquityIncentivePlanMember2023-01-010001906324qdel:EquityIncentivePlanMember2023-01-010001906324us-gaap:RestrictedStockMember2022-01-032023-01-010001906324us-gaap:RestrictedStockMember2021-01-042022-01-020001906324us-gaap:RestrictedStockMember2019-12-302021-01-030001906324us-gaap:RestrictedStockMemberqdel:NonEmployeeDirectorMember2022-01-032023-01-010001906324us-gaap:RestrictedStockMemberqdel:NonEmployeeDirectorMember2021-01-042022-01-020001906324us-gaap:RestrictedStockMemberqdel:NonEmployeeDirectorMember2019-12-302021-01-030001906324qdel:EmployeeDeferredBonusCompensationProgramMembersrt:MinimumMember2022-01-032023-01-010001906324srt:MaximumMemberqdel:EmployeeDeferredBonusCompensationProgramMember2022-01-032023-01-010001906324qdel:EmployeeDeferredBonusCompensationProgramMemberus-gaap:RestrictedStockMember2022-01-032023-01-010001906324qdel:EmployeeDeferredBonusCompensationProgramMember2022-01-032023-01-010001906324qdel:QuidelOrthoCorporationAmendedAndRestated1983EmployeeStockPurchasePlanESPPMemberus-gaap:EmployeeStockMember2023-01-010001906324qdel:QuidelOrthoCorporationAmendedAndRestated1983EmployeeStockPurchasePlanESPPMemberus-gaap:EmployeeStockMember2022-01-032023-01-010001906324qdel:StockRepurchaseProgramMember2018-12-120001906324qdel:StockRepurchaseProgramMember2020-08-280001906324qdel:StockRepurchaseProgramMember2022-08-170001906324qdel:StockRepurchaseProgramMember2022-01-032023-01-010001906324qdel:StockRepurchaseProgramMember2023-01-010001906324qdel:StockRepurchaseProgramMember2021-01-042022-01-020001906324qdel:StockRepurchaseProgramMember2019-12-302021-01-030001906324us-gaap:CostOfSalesMember2022-01-032023-01-010001906324us-gaap:ResearchAndDevelopmentExpenseMember2022-01-032023-01-010001906324us-gaap:ResearchAndDevelopmentExpenseMember2021-01-042022-01-020001906324us-gaap:ResearchAndDevelopmentExpenseMember2019-12-302021-01-030001906324us-gaap:SellingAndMarketingExpenseMember2022-01-032023-01-010001906324us-gaap:SellingAndMarketingExpenseMember2021-01-042022-01-020001906324us-gaap:SellingAndMarketingExpenseMember2019-12-302021-01-030001906324us-gaap:AcquisitionRelatedCostsMember2022-01-032023-01-010001906324us-gaap:AcquisitionRelatedCostsMember2021-01-042022-01-020001906324us-gaap:AcquisitionRelatedCostsMember2019-12-302021-01-030001906324us-gaap:DeferredBonusMember2022-01-032023-01-010001906324us-gaap:DeferredBonusMember2021-01-042022-01-020001906324us-gaap:DeferredBonusMember2019-12-302021-01-030001906324us-gaap:EmployeeStockOptionMember2023-01-010001906324us-gaap:EmployeeStockOptionMember2022-01-032023-01-010001906324srt:MaximumMember2022-01-032023-01-010001906324us-gaap:RestrictedStockMember2023-01-010001906324us-gaap:RestrictedStockUnitsRSUMember2022-01-032023-01-010001906324us-gaap:RestrictedStockUnitsRSUMember2021-01-042022-01-020001906324us-gaap:FairValueInputsLevel1Member2023-01-010001906324us-gaap:FairValueInputsLevel2Member2023-01-010001906324us-gaap:FairValueInputsLevel3Member2023-01-010001906324us-gaap:FairValueInputsLevel1Member2022-01-020001906324us-gaap:FairValueInputsLevel2Member2022-01-020001906324us-gaap:FairValueInputsLevel3Member2022-01-020001906324qdel:ConsiderationBMemberqdel:BNPBusinessMember2023-01-010001906324us-gaap:FairValueInputsLevel3Member2021-01-030001906324us-gaap:FairValueInputsLevel3Member2019-12-302021-01-030001906324us-gaap:FairValueInputsLevel3Member2022-01-032023-01-010001906324us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-01-010001906324qdel:InterestRateSwapOneMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-010001906324us-gaap:DesignatedAsHedgingInstrumentMemberqdel:InterestRateSwapTwoMember2023-01-010001906324qdel:InterestRateSwapThreeMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-010001906324qdel:InterestRateSwapFourMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-010001906324us-gaap:DesignatedAsHedgingInstrumentMemberqdel:InterestRateSwapFiveMember2023-01-010001906324us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:SubsequentEventMember2023-12-300001906324us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2023-01-010001906324us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2022-01-032023-01-010001906324us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-010001906324us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-01-010001906324us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2022-01-032023-01-010001906324us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember2022-01-032023-01-010001906324us-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2022-01-032023-01-010001906324us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-01-020001906324us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-020001906324us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-01-02qdel:post-employmentBenefitPlan0001906324us-gaap:PensionPlansDefinedBenefitMember2022-01-020001906324us-gaap:PensionPlansDefinedBenefitMember2022-01-032023-01-010001906324us-gaap:PensionPlansDefinedBenefitMember2023-01-010001906324us-gaap:PostemploymentRetirementBenefitsMember2022-01-020001906324us-gaap:PostemploymentRetirementBenefitsMember2022-01-032023-01-010001906324us-gaap:PostemploymentRetirementBenefitsMember2023-01-010001906324us-gaap:PensionPlansDefinedBenefitMember2022-05-270001906324us-gaap:PostemploymentRetirementBenefitsMember2022-05-270001906324qdel:PostretirementHealthCoveragePre65Member2023-01-010001906324qdel:PostretirementHealthCoveragePost65Member2023-01-010001906324us-gaap:DefinedBenefitPostretirementHealthCoverageMember2023-01-010001906324us-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324us-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324us-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324us-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesJapanMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324qdel:DebtSecurityGovernmentJapanMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324qdel:DebtSecurityGovernmentJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324qdel:DebtSecurityGovernmentJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324qdel:DebtSecurityGovernmentJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324qdel:DebtSecurityGovernmentNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324qdel:DebtSecurityGovernmentNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324qdel:DebtSecurityGovernmentNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324qdel:DebtSecurityGovernmentNonUSAndNonJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324qdel:DefinedBenefitPlanInsuranceContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324qdel:DefinedBenefitPlanInsuranceContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324qdel:DefinedBenefitPlanInsuranceContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324qdel:DefinedBenefitPlanInsuranceContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324us-gaap:FairValueMeasurementsRecurringMember2023-01-010001906324us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-01-010001906324us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-010001906324qdel:DefinedBenefitPlanOtherAssetsJapanMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-01-010001906324qdel:OrthoMemberqdel:QuotientMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-010001906324us-gaap:SalesRevenueNetMemberqdel:OrthoMemberqdel:MosaicQMember2023-01-010001906324qdel:QuotientSubsidiaryMember2022-01-032023-01-010001906324qdel:QuotientSubsidiaryMember2023-01-010001906324us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-020001906324us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-020001906324us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-01-020001906324us-gaap:AccumulatedTranslationAdjustmentMember2022-01-020001906324us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-032023-01-010001906324us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-032023-01-010001906324us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-01-032023-01-010001906324us-gaap:AccumulatedTranslationAdjustmentMember2022-01-032023-01-010001906324us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-010001906324us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-01-010001906324us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-01-010001906324us-gaap:AccumulatedTranslationAdjustmentMember2023-01-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM 10-K
(Mark One)
☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended January 1, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission file number: 001-41409

QUIDELORTHO CORPORATION
(Exact name of registrant as specified in its charter)
Delaware87-4496285
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
9975 Summers Ridge Road, San Diego, California 92121
(Address of principal executive offices, including zip code)
858-552-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.001 par valueQDELThe Nasdaq Stock Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒


The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was $6,008,202,595 based on the closing sale price at which the common stock was last sold, as of the last business day of the registrant’s most recently completed second fiscal quarter.
As of February 10, 2023, 66,505,546 shares of the registrant’s common stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE:
(To the Extent Indicated Herein)
Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission in connection with the registrant’s 2023 Annual Meeting of Stockholders (scheduled to be held on May 16, 2023) are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Annual Report on Form 10-K.




QUIDELORTHO CORPORATION
FORM 10-K
FOR THE FISCAL YEAR ENDED JANUARY 1, 2023
TABLE OF CONTENTS
Page
Part I
Part II
Part III
Part IV
3

Future Uncertainties and Forward-Looking Statements
This Annual Report on Form 10-K (this “Annual Report”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Without limiting the foregoing, the words “may,” “will,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue,” or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. These statements include any statements contained herein that are not statements of historical fact, including, but not limited to, certain statements under Part I, Item 1, “Business,” Part I, Item 1A, “Risk Factors,” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and located elsewhere herein, regarding our commercial, integration and other strategic or sustainability-related goals, industry prospects, expected results of operations or financial position, and future plans, objectives, strategies, expectations and intentions. Such statements are based on the beliefs and expectations of our management as of the date of this Annual Report and are subject to significant risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements: the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the Combinations (as defined in this Annual Report); the ability to retain key employees; and other economic, business, competitive and/or regulatory factors affecting our business generally, including those discussed under Part I, Item 1A, “Risk Factors.” Investors should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. We have no obligation to update any of the forward-looking information or time-sensitive information included in this Annual Report, whether as a result of new information, future events, changed expectations or otherwise, except as required by law. All forward-looking statements are based on information currently available to us and speak only as of the date of this Annual Report.
4

Part I
Item 1. Business
All references to “the Company,” “we,” “our” and “us” in this Annual Report refer to QuidelOrtho Corporation (“QuidelOrtho”) and its subsidiaries. References to “fiscal year 2022” in this Annual Report refer to the Company’s fiscal year ended January 1, 2023.
Overview
Our mission is to develop and manufacture intelligent diagnostic solutions that transform the power of diagnostics into a healthier future for everyone. Our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine helps clinicians and patients make better informed decisions across the globe. Our global infrastructure and commercial reach support our customers across more than 130 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S. and U.K. and with sales centers, administrative offices and warehouses located throughout the world.
We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (“POC”) settings, blood banks and donor centers, as well as for individual, non-professional, over-the-counter (“OTC”) use. We reached significant new markets as we introduced our QuickVue® At-Home OTC COVID-19 test for at-home consumer use, school districts, health departments and many other locations.
On May 27, 2022, pursuant to a Business Combination Agreement entered into as of December 22, 2021 (the “BCA”), by and among Quidel Corporation (“Quidel”), Ortho Clinical Diagnostics Holdings plc (“Ortho”), QuidelOrtho (formerly Coronado Topco, Inc.), Orca Holdco, Inc., Laguna Merger Sub, Inc. (“U.S. Merger Sub”), and Orca Holdco 2, Inc., Quidel and Ortho consummated a business combination (the “Combinations”) by way of (i) a scheme of arrangement undertaken by Ortho under Part 26 of the U.K. Companies Act 2006 (the “Ortho Scheme”), pursuant to which each issued and outstanding share of Ortho was acquired by a nominee of QuidelOrtho, such that Ortho became a wholly owned subsidiary of QuidelOrtho, and (ii) a merger of U.S. Merger Sub with and into Quidel, with Quidel surviving the merger as a wholly owned subsidiary of QuidelOrtho. The High Court of Justice of England and Wales (the “Court”) sanctioned the Ortho Scheme on May 26, 2022 and a sealed order of the Court was delivered to the Registrar of Companies at Companies House on May 27, 2022, satisfying the final condition to closing of the Combinations.
Beginning in the second quarter of 2022, in connection with the Combinations and in order to manage our business to better align with the market dynamics of the specific geographic regions in which we operate, we changed the manner in which we review our performance and allocate resources. As a result, we changed from one reportable segment to the following three geographically-based reportable segments: North America; Europe, the Middle East and Africa (“EMEA”); and China. Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” We generate our revenue primarily in the following business units: Labs, Transfusion Medicine, Point of Care and Molecular Diagnostics. Information concerning revenues attributable to our reportable segments and business units is set forth in Note 4 and Note 5 to the Consolidated Financial Statements.
Business Units and Products
In connection with the Combinations, we reorganized our former product categories into four business units. Revenues from our former Specialized Diagnostic Solutions product category have been included in a new Labs business unit described below. Our former Rapid Immunoassay and Cardiometabolic Immunoassay product categories now represent our Point of Care business unit. The Molecular Diagnostics business unit represents the former Molecular Diagnostic Solutions product category. In addition, we added a Transfusion Medicine business unit.
We provide diagnostic testing solutions under various brand names, including, among others, the following: AdenoPlus™, BIOVUE®, D3®, ELVIRA®, ELVIS®, FastPoint®, FreshCells™, InflammaDry®, Lyra®, MicroVue™, Ortho®, Ortho Clinical Diagnostics®, Ortho Vision™, Quidel®, QuickVue, QuickVue+®, QVue™, ReadyCells®, Savanna®, Sofia®, Solana®, Thyretain®, Triage®, Virena® and Vitros®. Solely for convenience, in some cases, the trademarks, service marks and trade names referred to in this Annual Report are listed without the applicable ® and ™ symbols, but we will assert, to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names.
5

Following the Combinations, we generate product revenue in the following business units:
Business UnitFocus
LabsClinical chemistry laboratory instruments and tests, which measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients
Immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health
Testing to detect and monitor disease progression across a broad spectrum of therapeutic areas
Other product revenues primarily from contract manufacturing
Specialized diagnostic solutions
Collaboration and license agreements pursuant to which we derive collaboration and royalty revenues
Molecular DiagnosticsTests for Polymerase Chain Reaction (“PCR”) thermocyclers with reduced process time and ready-to-use reagent configurations
Molecular amplification systems with the ability to run multiple assays at the same time and tests for infectious disease diagnostics
Sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics
Point of Care Instruments and tests to provide rapid results across a broad continuum of POC settings, including tests for professional healthcare providers and tests that can be taken at home
Tests that are run on a range of portable, POC analyzers
Tests that are visually read
Transfusion Medicine Immunohematology instruments and tests used for blood typing and antibody identification to help ensure patient-donor compatibility in blood transfusions
Donor screening instruments and tests used for blood and plasma screening for infectious diseases for global customers
The products and platforms under each business unit are described below. Certain products and platforms are not available in all regions where we do business.

6

LABS
ProductPrimary Application
VirologyWide variety of traditional cell lines, specimen collection devices, media and controls for use in laboratories that culture and test for human viruses, including, among others, respiratory and herpes family viruses
Cell-based products under the FreshCells brand in multiple formats, including tubes, shell vials and multi-well plates
U.S. Food and Drug Administration (“FDA”)-cleared bioassay, Thyretain, which is used for the differential diagnosis of an autoimmune disease called Graves’ Disease
Specialty ProductsVariety of biomarkers for bone health
Clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation, which, including our metabolic bone markers, are used to monitor the effectiveness of therapy in pharmaceutical and related research
Enzyme-linked immunosorbent assays and reagents for the detection of activation products from the three main complement pathways in autoimmune disease
Assays developed on a microwell platform and marketed to clinicians and researchers under the Quidel and MicroVue brands
Clinical ChemistryUnique, postage-stamp-sized, dry slide technology that combines the spreading, masking, scavenger and reagent layers into one slide, which provides:
• high-quality results quickly, efficiently and economically;
• improved storage, with longer shelf life and less shelf space required;
• an eco-friendly design that eliminates water usage and reduces chemical waste and biohazards; and
• a comprehensive menu covering 24 therapeutic areas and approximately 90% of a typical laboratory’s testing needs
ImmunodiagnosticsEnhanced chemiluminescent technology provides precision and accuracy along with a wide, dynamic testing range across over 60 immunoassay tests. Reagents are packaged in ready-to-use integrated packs that can be loaded continuously while testing is underway for high-throughput applications. These integrated packs also feature extended on-analyzer stability, enabling lower-throughput labs to maintain a broader test menu without incurring reagent waste due to expiry.
VITROS PlatformSeven clinical chemistry, immunoassay and integrated (combined chemistry and immunoassay) systems for use in centralized, higher-throughput (hospitals and laboratories) and decentralized, lower-throughput (physician offices, clinics and specialty settings) testing sites
VITROS
XT Platform		VITROS XT 7600 integrated system and VITROS XT 3400 clinical chemistry analyzer for use with new XT chemistry slides, combining two tests that are frequently used together, offering advancements over prior generations:
• 40% greater test throughput when using XT slides;
• 96% first-pass yield on test results; and
• designed to offer high reliability with a 98% up-time guarantee for e-connected U.S. customers
VITROS Automation SolutionsA flexible and scalable track-based system that combines VITROS analyzers with a number of robotic modules to help laboratories enhance their operations by reducing or eliminating repetitive and redundant laboratory tasks and the total number of human interventions required to complete typical laboratory testing
Testing Menu
Anemia, Bone Disease, Cardiac, Diabetes, Drugs of Abuse, General Chemistry, Hepatic, Immunosuppressant Drugs, Infectious Diseases, Inflammatory, Lipids, Nutritional Assessment, Oncology, Pancreatic, Prenatal, Renal, Reproductive Endocrinology, Respiratory, Sepsis, Spinal, Therapeutic Drug Monitoring, Thyroid/Metabolic, Toxicology, Urine
7

MOLECULAR DIAGNOSTICS
ProductPrimary Application
LyraOpen platform, real-time PCR assays for high throughput, high quality molecular testing to detect and identify infectious diseases, offering room-temperature storage, reduced processing time, and ready-to-use reagent configurations
SolanaSimplified molecular testing platform using our proprietary isothermal helicase-dependent amplification (“HDA”) technology that is easy to run and can process 12 patient samples at the same time
SavannaCE-marked, multiplex, real-time PCR platform, with customizable flexible syndromic panels that run up to 12 unique analytes from a single patient sample in less than 25 minutes
Savanna RVP4 assay offers simultaneous qualitative detection and differentiation of influenza A, influenza B, respiratory syncytial virus (“RSV”), and SARS-CoV-2 RNA isolated from human nasal or nasopharyngeal swabs
Testing Menu
Adenovirus, Bordetella, Clostridium Difficile (organism), HSV 1+2/VZV, Influenza A+B, Parainfluenza Virus, RSV, Respiratory Viral Panel (Flu A+B, RSV, hMPV), Respiratory Viral Panel 4 (Flu A+B), SARS-CoV-2, Strep A, Strep B, Strep Complete, Trichomonas
8

POINT OF CARE
ProductPrimary Application
Rapid Immunoassay
Sofia, Sofia 2
and Sofia Q		Easy-to-use, rapid testing using lateral-flow technology and advanced fluorescent immunoassay (“FIA”) chemistry
Combines unique software and Sofia FIA tests to yield automatic, objective results that are readily available on the instrument’s screen, in a hard-copy printout and in a transmissible electronic form that can network via a lab information system to hospital and medical center databases
Different operational modes to accommodate both small and large laboratories, as well as other features designed to facilitate use in a variety of healthcare settings, including hospitals, medical centers and small clinics
Sofia 2 systems include additional benefits and features, such as enhanced optics for improved performance and speed, at a cost point that better addresses the lower-volume segment of the diagnostic testing market
Emergency use authorization (“EUA”) to market Sofia Q platform that offers similar features and benefits as the other Sofia analyzers in a smaller and less expensive format
QuickVueBroad portfolio of rapid, visually read, lateral flow immunoassay products to diagnose a wide variety of infectious diseases and medical conditions, including the QuickVue At-Home OTC COVID-19 test, a leading at-home COVID-19 product available through many retail and online outlets
InflammaDry and AdenoPlusRapid, lateral-flow-based POC products for the detection of infectious and inflammatory diseases and conditions of the eye
Cardiometabolic Immunoassay
Triage and
Triage MeterPro®		Portable, rapid testing platform offering a comprehensive menu of tests for diagnosis of critical diseases and health conditions, as well as the detection of certain drugs of abuse
Aids in the diagnosis, assessment and risk stratification of patients having critical care issues, including congestive heart failure, acute coronary syndromes and acute myocardial infarction, and can reduce hospital admissions and improve clinical and economic outcomes
Triage B-type Natriuretic Peptide (“BNP”) test for use on Beckman Coulter (“Beckman”) lab analyzers (“BNP Business”) in connection with the transition of the BNP Business to Beckman
Testing Menu
CardiacBNP, Creatine Kinase-MB, D-Dimer, hsTroponin, Myoglobin, Troponin I ES
Drugs of AbuseAmphetamines, Barbiturates, Benzodiazepines, Cocaine, Methadone Metabolite (EDDP), Methamphetamines, Opiates, PCP, THC/Cannabinoids, Tricyclic Antidepressants
Eye HealthAcute Conjunctivitis, MMP-9 (a key inflammatory marker for dry eye)
Infectious DiseasesAdenoviral Conjunctivitis, Anti-SARS-CoV-2 IgG, Campylobacter, Chlamydia, Clostridium Difficile (organism), H. pylori Ab, H. pylori Ab (stool), Influenza A+B, Influenza A+B & SARS-CoV-2 Ag, Legionella, Lyme Disease, RSV, S. pneumoniae, Strep A
InflammatoryLactoferrin
OncologyColorectal Cancer
Reproductive EndocrinologyHuman Chorionic Gonadotrophin, Placental Growth Factor
9

TRANSFUSION MEDICINE
ProductPrimary Application
Immunohematology
ORTHO VISION PlatformFlagship immunohematology analyzers that automate blood typing, antibody identification and crossmatching for patient and donor blood banks
Models include ORTHO VISION, ORTHO VISION Max, and next-generation ORTHO VISION Swift and ORTHO VISION Swift Max, which are designed to be faster, quieter and even more cyber-secure than previous generations
Ortho WorkstationSemi-automated immunohematology benchtop analyzer for lower-volume blood centers or centers that need semi-automated testing
Ortho OptixSemi-automated testing platform used to read manual test results, designed with improved software and ability to integrate with laboratory information systems and offers improved workflow and 99% concordance with ORTHO VISION test results
ID-Micro Typing System (ID-MTS) Gel CardsTest consumables that utilize column agglutination technology (“CAT”) for our immunohematology instruments sold in the U.S., designed to provide reliable test results and simplify test workflow
BIOVUE CassettesTest consumables that utilize CAT for our immunohematology instruments sold outside of the U.S., designed to provide reliable test results and simplify test workflow
Ortho Sera ReagentsComprehensive immunohematology test menu that we believe covers more than 99% of most tested blood antigens regularly required for transfusion screening globally
Donor Screening
ORTHO VERSEIA Integrated Processor (“VIP”)Automated pipetting and processing system that combines the ORTHO VERSEIA pipettor and ORTHO Summit Processor to enable end-to-end pipetting and processing for tests used for blood and plasma screening for infectious diseases
Donor Testing SerologyComprehensive set of infectious disease screens, including important tests for tropical diseases like Chagas that are critical for care in emerging markets
Services and Informatics
In addition to the products we provide, our services and informatics are a critical element of how we deliver value to our customers. As of January 1, 2023, we had approximately 1,000 service teammates globally. We employ highly trained service professionals, including laboratory specialists with advanced qualifications.
Our highly valued suite of ORTHOCARE service offerings includes:
•Guarantee 98% up-time to our e-connected U.S. customers−High instrument reliability and a proactive maintenance program.
•E-CONNECTIVITY Remote Monitoring Software−More than 80% of our installed base of VITROS 5600, XT 7600 and ORTHO VISION platforms are e-connected, enabling remote monitoring and improved analyzer availability.
•Laboratory Informatics−Solutions designed to deliver incremental value to the laboratory, including inventory planning, laboratory productivity metrics and technical documentation.
•ValuMetrix−A highly valued consulting service proven to increase laboratory workflow, productivity and laboratory service levels utilizing lean principles and process excellence. This service offering provides actionable insights into demand for new products, services and workflow.
•Global Technical Solution Center−Seven technical solution centers delivering first-line support in over 15 languages, meaning we can resolve service issues remotely without an on-site visit approximately two-thirds of the time.
•Smart Service Mobile App−First-in-class technology enabled on iPhone and Android devices that allows our service teams to receive up-to-date analyzer health checks, proactive alerts and performance monitoring to help ensure the highest level of reliability is achieved.
10

•Training and Education−Flexible educational resources for the lifetime of the customer relationship, including virtual technical training, continuing education and professional development.
•Smart Start−Concierge implementation program led by certified project managers. Easier implementation using collaborative software to keep up to date with real-time progress reports, customized dashboards and status updates.
•Merged Reality−Enables product experts to provide remote ‘side by side’ assistance to field service engineers and customers through mobile devices, including smart glasses. This allows both parties to see the same thing at the same time and provide guided instruction leading to better and faster fix rates.
We also provide our Virena wireless cellular data management and surveillance system that operates as a cloud-based solution connecting Sofia and Solana instruments across a healthcare system and automatically transmitting de-identified test results to a secure database. With Virena, a health system, physician office laboratory (“POL”), urgent care center or retail clinic has the ability to compile, analyze, map and generate reports of de-identified test results, improving operational efficiencies, quality and patient outcome initiatives.
Digital Solutions and Innovation
We are developing a growing portfolio of digital and data solutions, which we believe improve our customers’ clinical and operational outcomes. Our focus is on enabling our customers to deliver smart, connected care across various clinical environments. We strive to turn our instruments into data assets for healthcare providers, labs and policymakers through proprietary and third-party connectivity solutions, such as laboratory information systems and middleware partnerships and connectivity to our information systems. Building on this interoperability, we offer a number of solutions to simplify and automate the testing and instrument management process, including ORTHO Connect, Ortho Plus and Virena. We also plan to develop other digital solutions that turn test results into specific clinical insights and actions via physician or patient facing solutions, such as the QVue mobile application for COVID-19 at-home testing.
Our Strategic Capabilities and Competitive Strengths
There is significant competition in the development and marketing of IVD products, and innovation, product development, regulatory clearance to market and commercial introduction of new IVD technologies can occur rapidly. We believe that some of the most significant competitive factors in the rapid diagnostic market include convenience, speed to result, specimen flexibility, product menu, clinical needs, price, reimbursement levels, product performance and customer service, as well as effective distribution, advertising, promotion and brand recognition. The competitive factors in the central laboratory market are also significant and include price, product performance, reimbursement, compatibility with routine specimen procurement methods, and manufacturing products in testing formats that meet the workflow demands of larger volume laboratories. There are several global companies with whom we compete, as well as regional and local companies focused on particular markets and/or technologies. Our principal competitors include, among others, Abbott Laboratories, Thermo Fisher Scientific, Danaher, Siemens Healthineers, Diasorin, Bio-Rad, Hologic, Qiagen, bioMérieux and PerkinElmer. Some of these competitors have substantially greater financial, marketing and other resources than we have.
We believe we are well positioned to drive sustained and profitable growth through an ethos of customer-centric decision making and behavior, which informs everything we do from product development to commercial execution. This disciplined focus on serving customers has resulted in, and we believe will continue to create, a business model that can deliver profitable growth and shareholder returns. The cash we generate allows us to reinvest in and reinforce our competitive strengths and strategic capabilities, which then benefit from our global footprint to enable us to be a leader across profitable and high-growth market segments. The competitive strengths that serve as our foundation of success today and can drive future growth include four key aspects, all of which benefit from our talented people and loyal customers:
1.Superior customer experience and brand loyalty. Over our more than 80 years supporting the IVD testing needs of our customers, we have developed deep and enduring relationships with our customers. Our ORTHOCARE service program allows us to retain and grow our customer base by providing an industry-leading customer experience driven by quality of service, continuous innovation and access to a diverse product portfolio.
2.Innovation and research and development (“R&D”) capabilities that address unmet needs in new and existing market segments. We intend to continue to invest in the next generation of instrumentation for each of our business units while keeping abreast of emerging technologies and use-cases, some of which may lead to new business units or revenue streams. Our key strengths include new assay format development, new instrument systems development and the complex integration of the two. In addition, to create new opportunities, manage costs and adapt to a rapidly changing industry, we also enter into strategic partnerships as part of our R&D process.
11

3.Operational scale driven by recent investments in U.S. manufacturing capabilities and an extensive and balanced global commercial footprint across more than 130 countries. We leverage our global footprint of approximately 2,800 commercial sales, service and regional marketing teammates to facilitate successful delivery of innovative solutions to meet our customers’ needs in both developed and emerging markets.
4.Leadership team dedicated to preserving a culture of employee focus and happiness. We understand that our success relies upon the talent and dedication of our employees. That is why we are committed to attracting, retaining and developing the best talent in the industry. Our culture puts our team members first and prioritizes actions that support happiness, inspiration and engagement. We strive to build meaningful connections with each other as we believe that employee happiness and business success are symbiotic.
Strategy
We are driven to transform diagnostics into action for more people in more places. As we look to the future, we see many opportunities for continued growth. In the short term, our strategy is to invest in R&D to offer a broader test menu to more settings for more patients. Both routine and novel tests are important for leveraging our large and growing installed base of instruments in both laboratories and POC settings. We have also entered the at-home testing market and see opportunities to benefit from additional at-home tests, such as for the flu and RSV.
Additionally, we have made investments to design and develop solutions that are intended to drive laboratory automation and efficiency, improve access to new and novel diagnostics, and enable patients and providers to experience the full benefits of a remote and digitized healthcare system. For example, with the onset of the COVID-19 pandemic, physicians and patients experienced a rapid shift to telemedicine and at-home testing. Going forward, we believe it is important to continue to build digital capabilities and solutions into our offerings to take advantage of this trend and our expectations that it will continue to emerge and evolve.
Longer term, we intend to continue to invest in areas with unmet clinical needs. We are aware of additional markets in which we do not yet compete, but that may benefit from our R&D capabilities and larger operational scale. We also plan to continue to explore the technology and content landscapes for strategic assets. Given the rapid pace of change and deep expertise needed within some of these areas, we expect to leverage third-party partnerships and acquisitions to reduce some of the technical and commercial risks and potentially increase our speed to market with innovative offerings.
As a result of the Combinations, we have increased leverage, cash and optionality. We intend to use a portion of such cash for additional R&D investments. We may also pursue potential business development opportunities, partnerships and acquisitions to support our strategic initiatives. We intend to pursue strategic opportunities that could result in new and relevant technologies and capabilities, or accelerate our commercial growth in attractive end-markets and geographies. We expect to maintain a disciplined approach to inorganic growth.
Current initiatives to execute on this strategy include the following:
•develop and deliver products that represent significant market opportunities, and compete effectively in market segments where service and quality are important;
•focus our R&D efforts;
•leverage our large direct sales team to enhance our cross-selling capabilities across our four business units, and strengthen our relationships with integrated delivery networks, laboratories and hospitals;
•continue to invest in our digital health solutions, including our mobile applications, to expand into new and growing markets; and
•pursue potential acquisitions to support our strategic initiatives.
Research and Development
We continue to focus our R&D efforts on the following areas:
•creation of new and improved products for use on our installed base;
•development of new proprietary product platforms for all of our business units; and
•pursuit of collaboration with other companies for new and existing products and markets.
We balance our R&D efforts against our R&D team’s capacity, development timelines and overall cost. Our R&D team is comprised of a balanced mix of experienced professionals with years of experience in the diagnostics industry and recently trained technologists, and together, they have know-how and technical capabilities in key areas, such as biomedical science, information technology (“IT”) and engineering. Key strengths of our team include new assay format development, new
12

instrument systems development and the complex integration of the two. In addition, in order to create new opportunities, manage costs and adapt to a rapidly changing industry, we also plan to enter into strategic partnerships as part of our R&D process.
R&D expenses were $190.5 million for fiscal year 2022, which includes the impact of Ortho’s operations from the date of the Combinations. R&D expenses were $95.7 million, and $84.3 million for fiscal years 2021 and 2020, respectively. We anticipate significant investment of our financial resources to product and technology R&D in the foreseeable future.
Sales, Marketing and Distribution
Our current business strategy is designed to serve the continuum of healthcare delivery needs globally, from POC clinicians located in doctor’s office practices, to moderately complex POLs, and to highly complex hospitals, laboratories and blood and plasma centers. We are also increasingly prioritizing retail and online outlets, such as large pharmacies, to market and distribute our QuickVue At-Home OTC COVID-19 tests. Within the inherent operational diversity of these various segments, we focus on differentiating ourselves and enhancing our market leadership by specializing in the diagnosis and monitoring of select disease states, conditions and wellness categories.
Certain of our revenue is driven by a “razor/razor blade” business model. Through this model, we generally sell or place instruments under long-term contracts, which support the ongoing sale of our assays, reagents and consumables. Our instruments are closed systems, requiring customers to purchase the assays, reagents and consumables from us. These sales generate a high proportion of our recurring revenues.
Our sales team is comprised of highly skilled and experienced professionals. We sell products globally and market and distribute products worldwide in a variety of ways, including through a mix of direct, indirect and hybrid distribution strategies. Across our global footprint, we operate a region-specific sales model. Our developed markets, specifically in North America and Western Europe, are served primarily through direct sales; however, we generally utilize a combination of direct sales and third-party distributors in emerging markets, such as China, Asia Pacific, the Middle East, Africa, Eastern Europe and Latin America, as we believe this model is more commercially effective in those regions. Our primary distribution centers are located in North America and Europe.
In North America, we use a generalized sales force for each of our business units other than for donor screening within Transfusion Medicine, which utilizes a separate specialist sales force. Our North America distribution strategy takes into account the highly fragmented POC market, with many small or medium-sized customers. To reach customers using POC diagnostic tests, a network of national and regional distributors is employed, as well as our own sales force. We have expanded the size of our North America sales force in the past few years. This sales force works closely with our key distributors to drive market penetration of our products.
In Europe, our employees support sales and marketing activities in key countries, such as Germany, Italy, France and the U.K. In addition, we have created shared service centers in Galway, Ireland, Prague, Czech Republic and Strasbourg, France to support general and administrative, technical support and customer service functions in Europe.
In the Asia Pacific region, which includes China, Japan and India, our employees support sales and marketing activities, primarily for the Point of Care, Labs and Transfusion Medicine business units. In addition, we have created shared service centers in Shanghai, China and Hyderabad, India to support general and administrative, technical support and customer service functions.
In Latin America, our employees support sales and marketing activities in key countries, such as Brazil and Mexico.
Our global team strives to deliver best-in-class customer service and support by surrounding our customers with devoted and experienced professionals. Our call center team and laboratory specialists serve as the first line of contact for our customers and are available to provide customer training and ongoing customer support. In addition, our network of field engineers is responsible for installing our instruments and providing onsite customer support if necessary.
Our marketing strategy is focused on ensuring that our key product portfolios are supported by clinical validation and health economic and outcomes research that show that our tests deliver fast, high-quality results, are cost-effective to use with lower total cost of ownership, and improve patient outcomes. Our marketing strategy also focuses on effectively marketing to customers a differentiated value proposition and maintaining our brand strength as further discussed above in the section entitled “Our Strategic Capabilities and Competitive Strengths.”
We derive a significant portion of our total revenues from a few customers and distributors. Two of our customers, including one of our distributors, which is considered to be among the market leaders, exceeded 10% of our total revenues for fiscal year 2022. In fiscal year 2021, one distributor exceeded 10% of our total revenues. In fiscal year 2020, four of our distributors exceeded 10% of our total revenues. See Note 4 to the Consolidated Financial Statements.
13

Manufacturing
Our manufacturing operations benefit from our broad global footprint, scale and workforce capabilities. We believe our plant capacity and available space are sufficient to accommodate growth, maintain quality and help ensure continuity. Our primary manufacturing facilities are located in San Diego, California, Carlsbad, California, Athens, Ohio, Raritan, New Jersey, Rochester, New York, Pompano Beach, Florida, Pencoed, Wales and Galway, Ireland.
Our McKellar Court, San Diego, California and our Carlsbad, California lateral flow manufacturing facilities consist of laboratories devoted to tissue culture, cell culture, protein purification or immunochemistry, and production areas dedicated to manufacturing and assembly. In the manufacturing process, biological and chemical supplies and equipment are used. We have invested in a high degree of automated equipment for the assembly and inspection processes. These facilities operate under a Quality Management System (“QMS”) per International Organization for Standardization (“ISO”) standard and regulatory regulations. These facilities are certified to ISO 13485:2016 and Medical Device Single Audit Program (“MDSAP”) medical device standards. Many of the immunoassay products manufactured at these facilities are packaged and shipped by a local third party.
Our Summers Ridge, San Diego, California facility consists of laboratories that are involved in mammalian cell culture, bacterial fermentation, protein purification and modification, as well as other techniques involved in immunoassay reagent manufacturing. These reagents are used in the manufacture of devices made at this facility and some are also supplied to Beckman as key active ingredients for BNP products that run on Beckman analyzers. In addition, this facility has production areas dedicated to creating and processing plastic components that are subsequently transformed into finished devices (cardiac and drugs of abuse products) using customized manufacturing equipment, including specialized automation. This facility is certified to ISO 13485:2016 and MDSAP medical device standards. Most of the products are packaged and subsequently distributed by our San Diego distribution center.
Our Athens, Ohio facility consists of a variety of clean room and chemistry laboratories and customized reagent filling and packaging areas to support the manufacturing at the facility of all products under current good manufacturing practices (“cGMPs”). This facility supports the manufacturing of our molecular nucleic acid amplification products, our living tissue cell culture and antibody-based products, as well as our enzyme linked immunosorbent assays (ELISA). We use a wide variety of biological and chemical supplies in our manufacturing processes. We also utilize specialized equipment for the lyophilization of reagents, cell culture growth, protein purification and a variety of automation for dispensing of antibodies, reagents and solutions. This facility is certified to ISO 13485:2016 and MDSAP medical device standards. Packaging, warehousing and shipping logistics with cold chain storage capability are handled at this facility.
Our Raritan, New Jersey facility manufactures our in vitro diagnostic donor screening and immunohematology products that are distributed globally. Manufacturing processes consist of formulation, filtration, filling, labeling, chemistry analysis, serological and microbial testing, as well as packaging. The product filling process occurs in a microbially controlled filling area using highly automated equipment and systems. This facility is a CBER licensed biologics/510(k) facility, certified to ISO 13485 and MDSAP medical device standards, ISO14001:2015, Environmental Management System, and the OSHA Voluntary Protection Program (“VPP”) Star Site. This facility is recognized for environmental stewardship by the New Jersey Department of Environmental Protection. Warehousing, direct shipping and shipping logistics with cold chain storage capability are handled at this facility with products transported to our distribution facilities for onward handling to end customers.
Our Rochester, New York facility consists of three sites for slide manufacturing, fluid manufacturing and CNP equipment manufacturing. This facility manufactures the slides and fluids used for clinical diagnostic assays run on our VITROS analyzers. Manufacturing capabilities include formulation, lyophilization, filling, coating, slitting, custom featuring, assembly and packaging, all under cGMPs. This facility is certified to ISO 13485:2016 and MDSAP medical device standards and ISO 14001 and is part of the OSHA VPP program for safety. Warehousing and shipping logistics with cold chain storage capability are handled at this facility with products transported to our distribution facilities for onward handling to end customers.
Our Pompano Beach, Florida facility manufactures our immunohematology CAT products that are distributed to the North American market, encompassing the U.S., Canada and Puerto Rico. The manufacturing processes include subassembly activities required for reagent formulation, product filling, chemistry analysis, serological testing and product packaging. The product filling process occurs in a microbially controlled filling area using highly automated, state-of-the-art equipment and systems. This facility is a CBER licensed biologics/510(k) facility, certified to ISO 13485 and MDSAP medical device standards, ISO 14001 and ISO 45001. Warehousing and shipping logistics with cold chain storage capability are handled at this facility with products transported to our distribution facilities for onward handling to end customers.
Our Pencoed, Wales facility manufactures certain of our immunoassay and immunohematology products that are distributed globally. The immunoassay manufacturing processes include conjugation, purification, biological formulation, lyophilization, dispensing, testing and packaging. The processes are highly automated with state-of-the-art systems and key processes are executed in an environmentally controlled area. By utilizing electronic batch records, each product is manufactured with high quality and consistency. This facility is certified to ISO 13485 and MDSAP medical device standards, ISO 14001 and ISO
14

45001. Warehousing and shipping logistics with cold chain storage capability are handled at this facility with products transported to our distribution facilities for onward handling to end customers.
Our Galway, Ireland facility manufactures in vitro diagnostic test kits. This facility also provides sales and technical support and warehouses and distributes products from many of our manufacturing locations into the EMEA markets. This facility operates under and is certified to ISO 13485:2016.
We seek to conduct our manufacturing in compliance with QMS regulatory requirements of the U.S., Australia, Brazil, Canada, Japan, Europe, South Korea and certain other countries. Our manufacturing facilities have passed routine regulatory inspections confirming compliance with the QMS regulatory requirements. Our facilities are registered with various regulatory bodies, including the FDA and other international and local public health and regulatory agencies.
Suppliers and Raw Materials
We obtain raw materials from reputable outside suppliers and believe our business relationships with them are good. Some of our raw materials are available from a limited number of sources. During 2022, we encountered some increasing pressures on raw material pricing. To help mitigate these supply chain challenges, we are (i) partnering with suppliers to invest in additional capacity and raw material inventory, (ii) diversifying our supply base, where possible, to minimize reliance on a single source of supply for key raw materials and components and (iii) creating redundancy in our global supply chain. In addition, we routinely evaluate our supply chain for potential gaps and continue to take other steps intended to help address continuity. For more information related to our supply chain, see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Impact of the COVID-19 Pandemic—Supply Chains,” Part I, Item 1A, “Risk Factors—Risks Relating to Our Business, Strategy and Operations—The COVID-19 global pandemic has adversely affected, and may continue to adversely affect, our business operations, strategy, financial performance and results of operations, the extent of which is uncertain and difficult to predict” and Part I, Item 1A, “Risk Factors—Risks Relating to Our Business, Strategy and Operations—Interruptions and delays in the supply of raw materials, components, equipment and other products and services could adversely affect our operations and financial results.”
Collaboration Arrangements
We have various collaboration arrangements, which provide us with the rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. These arrangements are often entered into in order to share risks and rewards related to a specific program or product. Our collaborative arrangements include a number of ongoing relationships for test development, instrument development and automation track design and distribution.
In connection with the Combinations, we acquired the ongoing collaboration arrangement (the “Joint Business”) between Ortho and Grifols Diagnostic Solutions, Inc. (“Grifols”), under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho’s Hepatitis and HIV diagnostics business. The arrangement is governed by an agreement (as amended, the “Grifols Agreement”) originally entered into in 1989 with a 50-year term, which, among other things, provides for a profit sharing arrangement whereby, the profits we generate from our production and sale of Hepatitis and HIV diagnostics products are shared with Grifols, and the profits generated by Grifols from its sale of certain antigens and licensing of certain intellectual property rights are shared with us. The Grifols Agreement also gives us the right to use such intellectual property. The majority of the patents underlying these intellectual property rights have expired. Grifols also supplies us with a portion of the antigens used in its production of these diagnostics products.
Today, the most significant benefit to us under the Grifols Agreement is the manufacture and sale by us of HIV and Hepatitis tests, which are solely performed by us. During the fiscal year ended January 1, 2023, the revenue associated with the use of this patented intellectual property was less than 1% of our total revenues and the expense associated with the antigens supplied to us by Grifols was less than 2% of our cost of goods sold.
The initial 50-year term of the Grifols Agreement will expire on December 31, 2039, at which time it will automatically renew for successive five-year periods unless either party has notified the other at least five years in advance of such date that it wishes to terminate the Grifols Agreement. Notwithstanding the initial term, in Europe, the Grifols Agreement will terminate on a country-by-country basis upon the expiration of the last patent right with respect to such country, provided that either party has a right to extend the Grifols Agreement for successive one-year terms by giving the other party notice prior to the termination date. To date, the parties have extended the Grifols Agreement for Europe on an annual basis. The Grifols Agreement may also be terminated by the non-breaching party if there is a breach or default of the agreement which is not cured during a 60-day cure period.
Seasonality
Sales of our respiratory products are subject to, and significantly affected by, the seasonal demands of the cold and flu seasons, typically prevalent during the fall and winter. Historically, sales of our influenza products have varied from year to year in
15

volume and timing based, in large part, on the severity, length and timing of the onset of the cold and flu season. In addition, the SARS-CoV-2 virus may have similar seasonal demands and impacts on our revenues in the future.
Government Regulations
U.S. Regulations of Medical Devices
The testing, manufacture and commercialization of the majority of our diagnostics products and analyzers in the U.S. are subject to regulation by numerous governmental authorities, principally the FDA as medical devices and corresponding state regulatory agencies. Pursuant to the U.S. Federal Food, Drug, and Cosmetic Act (the “FDCA”) and the regulations promulgated thereunder, the FDA regulates the preclinical and clinical testing, manufacture, labeling, distribution and promotion of medical devices.
In the U.S., medical devices are classified into one of three classes (Class I, II or III) depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class I devices are those with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA’s General Controls for medical devices, which include compliance with the applicable portions of cGMPs for medical devices known as the Quality System Regulation (“QSR”) facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising and promotional materials. Class II devices are subject to the FDA’s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device, like performance standards, post-market surveillance, patient registries and FDA guidance documents. Class III devices generally pose the highest risks, such as life sustaining, life supporting or some implantable devices, and are typically subject to premarket approval to ensure their safety and effectiveness. Our current products are all Class I or II.
While most Class I devices are exempt from the premarket notification requirement under Section 510(k) of the FDCA (“510(k)”), manufacturers of most Class II devices are required to submit to the FDA a premarket notification under 510(k) requesting permission to commercially distribute the device. The FDA’s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance, which can be a lengthy, expensive and uncertain process. The FDA has been requiring more rigorous demonstration of product performance as part of the 510(k) process, including submission of extensive clinical data. It generally takes from three months to one year to obtain clearance, but may take longer. A premarket approval (“PMA”) application must be supported by valid scientific evidence to demonstrate the safety and effectiveness of the device, typically including the results of clinical investigations, bench tests and reference laboratory studies. In addition, modifications or enhancements for existing products that could significantly affect their safety or effectiveness or constitute a major change in the intended use of the device, will require new submissions to the FDA. Class III devices require approval of a PMA application evidencing safety and effectiveness of the device. We currently market the majority of our diagnostic products in the U.S. pursuant to 510(k) clearances and PMA approvals.
The FDA can authorize the emergency use of an unapproved medical product or an unapproved use of an approved medical product, referred to as emergency use authorization (“EUA”), for certain emergency circumstances after the Secretary of the U.S. Department of Health and Human Services (“HHS”) has made a declaration of emergency justifying authorization of emergency use. An EUA allows use in an emergency to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by emerging infectious disease threats when there are no adequate, approved and available alternatives. The FDA may also waive otherwise applicable cGMPs requirements to accommodate emergency response needs. Products subject to an EUA must still comply with the conditions of the EUA, including labeling and marketing requirements. Moreover, the authorization to market products under an EUA is limited to the period of time the public health emergency declaration is in effect as determined by HHS. On February 4, 2020, the HHS Secretary determined that the novel coronavirus presented a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and declared that circumstances existed justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the novel coronavirus that causes COVID-19. All of our current products for testing for the COVID-19 virus are sold in the U.S. under EUA.
The FDA’s Clinical Laboratory Improvement Amendment of 1988 (“CLIA”) regulates laboratory testing and requires clinical laboratories to be certified by their state, as well as the Centers for Medicare & Medicaid Services (“CMS”), before diagnostic testing can be conducted. Laboratories using our assays must obtain a CLIA certificate. Waived testing is designated by CLIA as simple testing that carries a low risk for an incorrect result. The CLIA-waived designation is critical for most of our products that are intended for POC settings. The FDA’s current guidance entitled “Guidance for Industry and FDA Staff: Recommendations for Clinical Laboratory Improvement Amendments of 1988 CLIA Waiver Applications for Manufacturers of In Vitro Diagnostic Devices” sets forth requirements for obtaining a CLIA waiver, which are onerous and have increased the time and cost we are required to spend to obtain a CLIA waiver.
16

Any devices we manufacture or distribute pursuant to FDA clearance or approvals are subject to continuing regulation by the FDA and certain state agencies, including adherence to QSR relating to testing, control, documentation and other quality assurance requirements. We must also comply with Medical Device Reporting requirements, which mandates reporting to the FDA of any incident in which a device may have caused or contributed to a death or serious injury, or in which a device malfunctioned and, if the malfunction were to recur, would be likely to cause or contribute to a death or serious injury. Labeling and promotional activities are also subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission (“FTC”). Current FDA enforcement policy prohibits the marketing of approved medical devices for unapproved uses.
U.S. Regulation of Biological Products
Certain of our blood screening products are regulated by the FDA as biological products, also called biologics. In the U.S., biologics are subject to regulation under the FDCA and the Public Health Service Act (“PHSA”), and other federal, state, local and foreign statutes and regulations. The process required by the FDA before biologics may be marketed in the U.S. generally involves the following:
•completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s Good Laboratory Practice requirements;
•submission to the FDA of an Investigational New Drug application (“IND”) which must become effective before human clinical trials may begin. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans;
•approval by an Institutional Review Board or ethics committee at each clinical site before the trial is commenced;
•performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;
•preparation of and submission to the FDA of a Biologics License Application (“BLA”) after completion of all pivotal clinical trials;
•satisfactory completion of an FDA Advisory Committee review, if applicable;
•a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
•satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is to be produced to assess compliance with cGMPs and to assure that the facilities, methods and controls are adequate to preserve the biological product’s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices; and
•FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the U.S.
Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.
After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced and of select clinical trial sites, the FDA may issue an approval letter or a Complete Response Letter (“CRL”). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.
If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more post-market studies and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.
Any biologics manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic
17

reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.
FDA Enforcement
The FDA may withdraw a marketing authorization if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions. Other potential consequences include, among other things: restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, product recalls, fines, warning letters, untitled letters, clinical holds on clinical studies, refusal of the FDA to approve pending applications or supplements to approved applications, product seizures or detention, refusal to permit the import or export of products, consent decrees, corporate integrity agreements, the issuance of corrective information, injunctions, or the imposition of civil or criminal penalties.
In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of biologics and medical devices. A company can make only those claims relating to safety and efficacy, purity and potency that are cleared or approved by the FDA and in accordance with the provisions of the authorized label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.
Regulations Outside of the U.S.
For marketing outside the U.S., we are subject to foreign regulatory requirements governing human clinical testing and marketing approval for our products. These requirements vary by jurisdiction, differ from those in the U.S., and may require us to perform additional or different preclinical or clinical testing regardless of whether we have obtained FDA clearance or approval. The amount of time required to obtain necessary approvals varies from that required for FDA clearance or approval. In many foreign countries, pricing and reimbursement approvals are also required.
Our initial focus for obtaining marketing approval outside the U.S. is typically in the European Union (“EU”), Australia, Brazil, Canada, China, Japan and the U.K. EU regulations and directives generally classify healthcare products either as medicinal products, medical devices or IVD. In order for medical devices to be placed on the European market or put into service, they must bear a CE marking. The CE marking may only be affixed if the product meets the essential safety and performance requirements. Manufacturers must establish a specific quality management system that ensures that a risk management procedure and a clinical evaluation are carried out for each device. The conformity assessment usually involves an audit of the manufacturer’s quality system by a notified body accredited by an EU member state and, depending on the type of device, a review of the technical file from the manufacturer on the safety and performance of the device. In some other cases, the notified body must seek a scientific opinion from specific expert panels or the European Medical Agency before issuing a CE certificate.
In addition, the EU has adopted the EU Medical Device Regulation (EU 2017/745) (the “EU MDR”) and the In Vitro Diagnostic Regulation (EU 2017/746) (the “EU IVDR”), each of which impose stricter requirements for the marketing and sale of medical devices than in the U.S., including in the area of clinical evaluation requirements, quality systems and post-market surveillance. The compliance deadlines for the EU MDR and EU IVDR were May 2021 and May 2022, respectively. The transition period provided for in the EU MDR for existing certifications issued under the previous Medical Devices Directive will end on May 26, 2024. The EU IVDR has been applicable since May 26, 2022. In January 2022, the European Parliament and the Council adopted a staggered extension of its transition period, ranging from May 26, 2025 for high risk in vitro diagnostics to May 26, 2027 for lower risk in vitro diagnostics, and to May 26, 2028 for certain provisions concerning devices manufactured and used in health institutions (Regulation (EU) 2022/112). However, the transition periods might still be subject to change.
18

Complying with these regulations may require us to incur significant expenditures. Failure to meet these regulatory requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements.
Chinese regulations require registration of diagnostic products with China’s National Medical Products Administration (“NMPA,” formerly CFDA), including NMPA’s Announcement (No. 104, 2020), which provides an accelerated pathway for the localization of imported medical devices and IVD products in China by permitting (for certain classes or products) the same medical approval license previously approved by the mainland authorities to apply to provincial domestic enterprises in China, providing for the same product design and equivalent quality system that is traceable to the imported licensed product. Additional clinical trials in China are typically required for registration purposes. ISO certification is included in applications for registration to NMPA. Japanese regulations require registration of IVD products with the Japanese Ministry of Health, Labor and Welfare. For products marketed in Canada, registration is required with Health Canada. For products marketed in the U.K., approvals must be obtained from the U.K.’s Medicine and Healthcare Products Regulatory Agency. For products marketed in Australia, registration is required with the Therapeutic Goods Administration. IVD products in Brazil are regulated by the Agencia Nacional de Vigilancia Sanitaria. For our products marketed in Canada, Japan, Brazil, Australia and the U.S., the MDSAP is a single regulatory audit of our QMS that satisfies the requirements of all five of these jurisdictions.
Other Healthcare Laws
Our products are subject to various healthcare-related laws regulating fraud and abuse, R&D, pricing, sales and marketing practices, and the privacy and security of health information. Among other things, these laws and others generally (a) prohibit the provision of anything of value in exchange for the referral of patients or for the purchase, order, or recommendation of any item or service reimbursed by a federal healthcare program, including Medicare and Medicaid; (b) require that claims for payment submitted to federal healthcare programs be truthful; and (c) require the maintenance of certain government licenses and permits. Specific health-care laws and regulations that we are subject to include:
•the federal Physician Self-Referral Law, which prohibits a physician from making referrals for certain designated health services payable by Medicare to an entity with which he or she (or an immediate family member) has a financial relationship, and prohibits the entity from presenting or causing to be presented claims to Medicare for those referred services;
•the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, where one purpose is to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The U.S. government has interpreted this law broadly to apply to the marketing and sales activities of medical device manufacturers;
•the federal civil and criminal false claims laws, including the False Claims Act (“FCA”), which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal healthcare programs that are false or fraudulent. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;
•the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
•the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters.
•the federal Physician Payments Sunshine Act which requires certain applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under certain federal healthcare programs, to monitor and report to CMS, certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare providers, including physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;
•the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices, and regulates device marketing;
•U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities that potentially harm customers; and
19

•state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to item or services reimbursed by any third-party payor, including commercial insurers; state laws requiring device companies to comply with specific compliance standards, restrict payments made to healthcare providers and other potential referral sources, and report information related to payments and other transfers of value to healthcare providers or marketing expenditures and state laws related to insurance fraud in the case of claims involving private insurers.
Data Privacy and Security Laws
We are subject to data privacy and security laws and regulations in numerous jurisdictions, as well as customer-imposed controls, as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. Specific data privacy and security laws that we are subject to include:
•HIPAA, which imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA;
•the California Consumer Privacy Act of 2018 (“CCPA”), which creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. Further, the California Privacy Rights Act, which amends the CCPA, became operative on January 1, 2023 and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for certain higher risk data processing, and opt outs for certain transfers of personal information and uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations, which are in the process of finalization, and could result in increased privacy and information security enforcement. A similar law in Virginia also took effect January 1, 2023, and similar laws also have passed in other states, including Colorado, Utah, and Connecticut. Comprehensive privacy laws also have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the U.S.;
•the FTC Act, and state consumer protection laws, enforced by many state Attorneys General for online collection, use, dissemination and security practices that appear to be unfair or deceptive;
•outside the U.S., the General Data Protection Regulation 2016/679 (the “GDPR”) and the U.K. data protection regime consisting primarily of the U.K. General Data Protection Regulation and the U.K. Data Protection Act 2018 (collectively, the “U.K. GDPR”), which govern the processing of information in those jurisdictions, and could result in significant fines (up to the greater of €20 million / £17.5 million or 4% of total annual revenue), regulatory investigations, reputational damage, orders to cease or change our processing of our data, enforcement notices or assessment notices (for a compulsory audit), civil claims including representative actions and other class action type litigation;
•E.U. and U.K. rules with respect to cross-border transfers of personal data out of the European Economic Area (the “EEA”) and the U.K., respectively, which are in flux, including in light of a decision by the Court of Justice of the E.U. invalidating the E.U.-U.S. Privacy Shield Framework, and the European Commission’s recent publishing of revised standard contractual clauses, which we must now consider and apply, where applicable. In light of these changing requirements, we could suffer additional costs, complaints, regulatory investigations or fines, and if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services and the geographical location or segregation of our relevant systems and operations, which could adversely affect our financial results, including because we rely on third parties in other countries;
•evolving privacy laws on cookies and e-marketing. In the E.U., regulators are increasingly focusing on compliance with requirements in the online behavioral advertising ecosystem, and current national laws that implement the ePrivacy Directive will be replaced by an E.U. regulation known as the ePrivacy Regulation which will significantly increase fines for non-compliance. While the text of the ePrivacy Regulation is still under development, a recent European court decision and regulators’ recent guidance are driving increased attention to cookies and tracking technologies. In the U.S., the FTC and many state laws have increasingly focused on the collection and use of behavioral data, including geolocation and biometric information. As regulators start to enforce a stricter approach, this could lead to substantial costs, require significant systems changes, limit the effectiveness of our marketing activities, divert the attention of our technology personnel, adversely affect our margins, increase costs and subject us to additional liabilities;
•China’s multiple pieces of legislation governing the healthcare industry involve prescribing complex regulatory requirements governing different types of data across a continuum of care, and various supervisory authorities frequently conduct inspections and investigations. These include:
20

◦China’s Cybersecurity Law, including data localization requirements that require operators of critical information infrastructure (“CIIOs”) to store personal information and important data collected and generated from the critical information infrastructure within China. Failure to do so can result in fines of up to RMB 100,000 for the relevant entity as well as for the personnel directly responsible;
◦China’s Data Security Law (“Data Security Law”), which became effective on September 1, 2021, and applies extraterritorially and to a broad range of activities that involve “data” (not only personal or sensitive data). Under the Data Security Law, entities and individuals carrying out data activities must abide by various data security obligations, including implementing the appropriate level of protective measures for each respective class of data and storing data locally in China (or in compliance with certain data transfer restrictions);
◦China’s Personal Information Protection Law (“PIPL”), which is similar to the GDPR and also applies extraterritorially. The PIPL provides the legality of personal information processing and the basic requirements of notice and consent, sets out data localization requirements for CIIOs and personal information processors who process personal information above a certain threshold prescribed by the relevant authorities, and provides a list of rules for transferring personal information outside of China. Failure to comply with PIPL can result in fines of up to RMB 50 million or 5% of the prior year’s total annual revenue for the personal information processor and/or a suspension of services or data processing activities, among other fines and criminal liabilities, including ones that can be placed on responsible personnel; and
◦several regulations and draft regulations for public comments, promulgated by the People’s Republic of China, which are designed to provide further supplemental guidance in accordance with the laws mentioned above;
•self-regulatory standards that privacy advocacy groups, the technology industry and other industries have established or may establish and various new, additional or different self-regulatory standards that may place additional burdens on us. Our customers may expect us to meet voluntary certifications or adhere to other standards established by them or other third parties, and we may be required or otherwise find it advisable to obtain certain of these certifications or adhere to these standards. If we are unable to maintain these certifications or meet these standards, it could reduce demand for our solutions and adversely affect our business; and
•enacted or considered legislation similar to the above in other countries around the world, in which we do business.
Environmental, Health and Safety Laws
We are subject to various environmental, health and safety laws and regulations both within and outside the U.S., such as those related to safe working conditions and laboratory practices. Like other companies in our industry, our manufacturing and research activities involve the purchase, storage, movement, use and disposal of substances regulated under environmental, health and safety laws, including those related to hazardous or potentially hazardous substances.
Laws Governing Reimbursement Activities
Healthcare providers that purchase medical devices generally rely on third-party payors, including the Medicare and Medicaid programs and private payors, such as indemnity insurers, employer group health insurance programs and managed care plans, to reimburse all or part of the cost of the products. As a result, demand for our products is and will continue to be dependent in part on the coverage and reimbursement policies of these payors. Reimbursement from Medicare, Medicaid and other third-party payors may be subject to periodic adjustments as a result of legislative, regulatory and policy changes as well as budgetary pressures in the U.S. and globally. For example, in the U.S.:

•the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the “PPACA”) implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models;

•the Budget Control Act of 2011 reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020, through March 31, 2022, unless additional Congressional action is taken;

•the Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”), enacted in 2015, repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual
21

updates and a new system of incentive payments that are based on various performance measures and physicians’ participation in alternative payment models such as accountable care organizations; and

•certain provisions of the Protecting Access to Medicare Act of 2014 (“PAMA”) were implemented by CMS in 2018, which made substantial changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA, the revised Medicare reimbursement rates were scheduled to apply to clinical diagnostic laboratory tests furnished on or after January 1, 2018. The revised reimbursement methodology is expected to generally result in relatively lower reimbursement under Medicare for clinical diagnostic lab tests than has been historically available. Any reduction to payment rates resulting from the new methodology is limited to 10% per test per year in 2018 through 2020, and to 15% per test per year in 2021 through 2023.
Other Laws and Regulations Governing Our Sales, Marketing, and Shipping
We are subject to the U.S. Foreign Corrupt Practices Act (the “FCPA”), the U.K. Bribery Act of 2010 (the “Bribery Act”), the Brazilian Anti-Bribery Act (also known as the Brazilian Clean Company Act) and various other similar anti-corruption and anti-bribery laws. Among other things, these laws generally prohibit us and our intermediaries from offering, promising or making payments to foreign government entities or officials for the purpose of obtaining or retaining business. We are also subject to pertinent U.S. and foreign laws relating to the import and export of finished goods, raw materials and supplies. We also must comply with various export control and trade embargo laws, which may require licenses or other authorizations for transactions within some countries or with some counterparties. Additionally, we are subject to laws and regulations and certain environmental, social and governance (“ESG”) requirements applicable to our government contracts, and failure to address these laws and regulations, ESG requirements, or to comply with government contracts could result in fines, debarment or exclusion from federal healthcare or global tender programs, or harm our business by a reduction in revenue associated with these customers. We are also subject to audits for compliance with the regulations governing government contracts. A failure to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
Intellectual Property
The healthcare industry has traditionally placed considerable importance on obtaining and maintaining patent, trade secret and trademark protection for commercially relevant technologies, devices, products, tradenames and processes. In the aggregate, our intellectual property is of material importance in the operation of our business. However, although we possess numerous patents, trade secrets and trademarks that are important to our business, we believe that no single patent, trade secret or trademark by itself is material to our business as a whole.
We actively pursue patents for technologies that are considered patentable. We have issued patents in the U.S. and internationally, and have patent applications pending throughout the world. However, important factors, many of which are not within our control, can affect whether and to what extent patent protection in the U.S. and in other important markets worldwide is obtained. For example, the speed, accuracy and consistency in application of the law in a patent office within any particular jurisdiction are beyond our control and can be unpredictable. The resolution of issues such as these and their effect on our long-term success are also indeterminable.
It has been our policy to file for patent protection in the U.S. and other countries with significant markets for our products, such as Western European countries and Japan, if the economics are deemed to justify such filing and our patent counsel advises that relevant patent protection may be obtained.
A large number of individuals and commercial enterprises seek patent protection for technologies, products and processes in fields in, or related to, our areas of product development. To the extent such efforts are successful, we may be required to obtain licenses and pay royalties (some of which may be significant) in order to exploit certain of our product strategies. Moreover, licenses to such patents may not be available to us at all or may not be available on acceptable terms.
We are aware of certain patents issued to various developers of diagnostic products with potential applicability to our diagnostic technologies. We have entered into agreements with third parties to license and use their intellectual property, although no one such license is material to our business as a whole. In the future, we expect that we will require or desire additional licenses from other parties in order to refine our products further and to allow us to develop, manufacture and market commercially viable or superior products effectively.
In addition to seeking patent protection where appropriate, we also protect some of our intellectual property as trade secrets. We seek to protect our trade secrets and proprietary technologies in many ways, including by entering into confidentiality agreements with employees and third parties with which we do business (such as potential licensees, customers, vendors, strategic partners and consultants). In addition, we have implemented certain security measures in our laboratories and offices to protect the confidential and proprietary nature of these technologies.
22

In addition to patent and trade secret protection, we have also registered or applied to register certain trademarks and service marks in the U.S. and in foreign countries that are used in our business and in conjunction with the sale of our products. Our principal trademarks and the products they cover are discussed above in the section entitled “Business Units and Products.”
Under many of our contractual agreements that involve the sale of our products, we have agreed to indemnify the counterparty against costs and liabilities arising out of any patent infringement claims and other intellectual property claims asserted by a third party relating to our products sold under those agreements.
Human Capital and ESG Strategies
Human Capital Resources
As of January 1, 2023, we had approximately 7,000 employees worldwide, with approximately 4,200 employees in the U.S. and approximately 2,800 employees outside of the U.S. We employ approximately 1,700 manufacturing employees and approximately 2,800 employees in commercial sales, service and regional marketing positions worldwide, including approximately 1,000 service teammates. Approximately 15% of our associates globally are covered by a union, collective bargaining agreement or works council, including associates in Austria, Belgium, Brazil, France, Germany, Italy, Spain, Sweden and the U.K. To date, we have experienced no work stoppages and believe that our employee relations are good.
Diversity, Equity and Inclusion
Our employees are one of our most important assets and set the foundation for our ability to achieve our strategic objectives, drive operational execution, deliver strong financial performance, advance innovation, and maintain our quality and compliance programs. The success and growth of our business depend in large part on our ability to attract, retain, develop and motivate a diverse population of talented and high-performing employees at all levels of our organization. We strive to provide a positive work environment for all employees, consultants, contingent workers, vendors, and customers. One of the ways we accomplish this is by embracing a variety of diverse experiences and perspectives and being inclusive team players. We are dedicated to fostering a culture that supports diverse talents, experiences and perspectives and an environment of mutual respect, equity and collaboration that helps drive our business. As a global organization, our unique perspectives, diverse backgrounds and collective strengths drive creative solutions, breakthrough innovation and highly productive teams.
In September 2022, we invited all of our employees to participate in a confidential, global survey to gather feedback and gain insights on key cultural and engagement factors. Nearly 75% of global employees participated in the survey, and results show positive sentiment around engagement and workplace culture. Respondents indicated a strong alignment to our strategic priorities and found meaning and purpose in their work. We believe we are stronger together and will prioritize actions that support happy, inspired and engaged team members. We plan to conduct periodic pulse surveys with employees throughout 2023 to measure progress and focus on continuous improvement.
We are committed to maintaining an environment of equal employment opportunities for all job applicants and members of our team. We fulfill this commitment through a variety of measures, including internal and external posting of job openings, hiring, training and promoting employees without regard to race, color, religion, gender identity or expression, pregnancy, national origin, ancestry, citizenship, military or veteran status, disability, medical condition, marital or domestic partner status, sexual orientation, age or any other considerations made unlawful by federal, state or local law. We prohibit discrimination based on a perception that anyone has any of these characteristics or is associated with a person who has or is perceived as having any of these characteristics. In keeping with our core values, we are steadfast in taking action to provide equal employment opportunity in accordance with all applicable federal, state and local laws.
In addition, we review Company programs, policies, procedures and activities with diversity and inclusion in mind. We have established newly defined core behaviors based on the QuidelOrtho Way, which define our core values as a company and our ways of working together. These core behaviors include “bring your best,” which reflects each individual contributing to their highest potential, “embrace inclusion,” which reinforces the role each team member plays in creating a diverse, equitable and inclusive work environment, and “commit to service,” which reflects our value of serving our customers and communities in the core of everything we do. We plan to expand upon the foundation of diversity and inclusion by incorporating other inclusive behaviors into these core behaviors and providing training to support all of our employees in being authentic in their self-expression and open to the self-expression of others.
As of January 1, 2023, 43% of our U.S. employees identified as female and 39% of our U.S. employees identified as having a racial and ethnic background other than white. As of January 1, 2023, our executive management team consisted of 8 members, of whom 25% identified as female. In addition, as of January 1, 2023, our board of directors (the “Board”) consisted of 12 members, of whom 25% identified as female and 17% identified as having a racial and ethnic background other than white.
23

Employee Benefits
To succeed in a competitive labor market, we have recruitment and retention strategies that we focus on as part of the overall management of our business, including designing our compensation and benefits programs to be competitive and to align with our strategic and stockholders’ interests. Accordingly, we use a mix of competitive base salary, cash-based annual incentive compensation, equity compensation awards and other employee benefits. Some of our key employee benefits include eligibility for health insurance, vacation time, a retirement plan with an employer match, an employee assistance program and life and disability coverage. We also offer a variety of voluntary benefits that allow employees to select the options that meet their needs, which vary by country, and may include flexible spending accounts, hospital care, accident insurance, prepaid legal benefits, backup childcare, family forming benefits, homework support for students, student loan benefits, tuition reimbursement and a wellness program. These benefits are designed to offer employees a menu of options so that each employee can select benefits most meaningful to their personal situation. We consider our employee benefits to be an important component of total compensation for our employees.
Health, Safety and Environmental
Our operations and facilities are subject to various laws and regulations domestically and around the world governing the protection of the environment and health and safety, including the discharge and emissions of pollutants to air and water and the handling, management and disposal of hazardous substances. We are committed to employee health and safety in the workplace. In the U.S., our manufacturing facilities hold various certifications depending on the site. We also maintain health and safety programs conforming to best practices in the diagnostics industry. We are focused on minimizing risk and protecting our employees and communities by employing safe technologies and operating procedures, and in turn minimizing recordable incidents and improving safety across our organization.
We believe that all of our manufacturing and distribution facilities are operated in compliance with existing environmental requirements in all material respects, including the operating permits required thereunder. Although we do not currently expect the costs of compliance with existing environmental requirements to have a material impact on our financial position, we may incur additional costs or obligations to comply with environmental and health and safety requirements as a result of changes in law or customer demands, including those related to our products. In addition, many of our manufacturing sites have a long history of industrial operations, and remediation is or may be required at a number of these locations. Although we do not currently expect outstanding remediation obligations to have a material impact on our financial position, the ultimate cost of remediation is subject to a number of variables and is difficult to accurately predict.
Corporate Philanthropy
We listen to our internal and external stakeholders and aim to translate their needs into innovative solutions, in the products we offer and in our corporate philanthropy work. Our charitable giving programs operate under the QuidelOrtho Community Action Review and Endowment Squad (“QCARES”) committee, which is responsible for quarterly review and approval of charitable contributions proposed by employees. Our charitable giving programs and activities in the U.S. consist of the following:
•Matching gifts−We match charitable contributions by full-time, regular employees to qualifying non-profit organizations of up to $250 per employee annually.
•Volunteer incentive program−When an employee volunteers at an organization for a minimum of 20 hours in a calendar year, we donate $100 to that organization.
•General QCARES fund−We may donate up to $2,000 to an organization proposed by an employee.
•Community partnerships−As part of our commitment to expanding equitable access to healthcare, we have partnered with several major organizations to donate COVID-19 testing products to various communities across the nation to promote increased testing within communities to help prevent the spread of COVID-19.
ESG Strategy
As a world leader of in vitro diagnostics, we develop and manufacture innovative diagnostic technologies and solutions that transform data into answers and understanding into actions to enhance clinical outcomes for more people in more places every day. We bring fast, accurate and reliable diagnostics when and where they are needed most – from home to hospital, lab to clinic.
As part of our ESG strategy, we are focused on the following cornerstones:
•monitoring the impacts of waste generation and energy and water usage consumption;
•implementing efficiencies at our global facilities and in our product manufacturing that mitigate risks, reduce costs and address impacts;
24

•supporting equitable access to healthcare in our communities;
•fostering a culture of happy people that welcomes and promotes diversity and inclusion;
•advancing good corporate governance that aids our long-term business success; and
•being accountable, fair and transparent.
We believe these cornerstones contribute to the value created by our Company for all of its stakeholders and to fulfilling their expectations.
Information Available on Our Website
This Annual Report and each of our other periodic and current reports, including any amendments thereto, are available, free of charge, on our website, www.quidelortho.com, as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (the “SEC”). From time to time, we may use our website as a channel of distribution of material information related to the Company. Financial and other material information regarding the Company is routinely posted on and accessible at https://ir.quidelortho.com/. The information contained on or connected to our website is not deemed to be incorporated by reference into this Annual Report or filed with or furnished to the SEC and should not be considered part of this Annual Report.
25

Item 1A. Risk Factors
In addition to the other information contained in this Annual Report and the exhibits hereto, the following risk factors should be considered carefully in evaluating our business. The risks and uncertainties described below are not the only risks and uncertainties that we face. Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations. The occurrence of any of the following risks may materially and adversely affect our business, financial condition, results of operations and future prospects.
Risk Factors Summary
The following is a summary of the principal risks that could adversely affect our business, results of operations and financial condition:
•risks related to the consummation of the Combinations, including (i) failure to integrate successfully the businesses of Quidel and Ortho in the expected timeframe, or at all; (ii) the synergies attributable to the Combinations may vary from expectations; (iii) continued incurrence of significant transaction and merger-related costs; (iv) disruption of our business relationships; and (v) business issues of Quidel or Ortho prior to the Combinations being imputed to the other;
•outbreaks of contagious diseases and other adverse public health developments, such as the COVID-19 global pandemic;
•the highly competitive nature of our industry and market segment;
•failure to research and successfully develop new technologies, products and services and develop new markets;
•adverse developments in global market, macroeconomic and geopolitical conditions;
•fluctuations or a decline in sales of our COVID-19 and influenza diagnostics tests;
•the loss of any key distributor or the failure to retain or expand our customer relationships;
•interruptions and delays in the supply of raw materials, components, equipment and other products and services provided to us, and manufacturing or warehousing problems or delays;
•the failure of our collaboration partners to fulfill their obligations to us;
•our inability to meet demand for our products and services;
•decreases in the number of surgical procedures performed, and the resulting decrease in blood demand;
•fluctuations in our cash flows as a result of our reagent rental model;
•our inability to achieve market acceptance of our products;
•significant changes in the healthcare industry and related industries that we serve, in an effort to reduce costs;
•consolidation of our customer base and the formation of group purchasing organizations;
•inability to realize the anticipated benefits of acquisitions and divestitures;
•the occurrence of natural disasters, public health crises, geopolitical crises and other catastrophic events that may adversely affect our results of operations;
•risks associated with our non-U.S. operations and international sales, including currency translation risks, the impact of possible new tariffs, trade embargoes or trade wars and compliance with applicable trade measures;
•our inability to protect our information systems from cyber-based attacks, security breaches or privacy violations and failure to protect our cloud-based solutions;
•our inability to develop, obtain and protect our proprietary technology rights or defend against intellectual property infringement suits against us by third parties;
•the loss of EUA by the FDA on our COVID-19 products;
•our inability to obtain or maintain required clearances or approvals for our products, including approval requirements of the foreign countries in which we sell our products;
•our ability to adequately manage our clinical studies;
•failure to comply with applicable regulations, which may result in significant costs or the suspension or withdrawal of previously obtained clearances or approvals;
•disruptions at government agencies that prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner;
•inability to procure government contracts, including due to government-sponsored tendering requirements, lack of funding and compliance and possible sanctions risks associated with our contracts with government entities;
•liability claims and harm to our reputation resulting from claims that our products are defective;
26

•failure to comply with laws and regulations, including healthcare regulations, laws and regulations associated with our use of hazardous materials, anti-corruption laws and regulations, and federal, state and foreign data protection laws and regulations;
•risks related to changes in U.S. and foreign income tax laws and regulations;
•changes in our tax rates or exposure to additional income tax liabilities or assessments;
•need to raise additional funds to finance our future capital or operating needs or other business purposes;
•risks related to our indebtedness, which as of January 1, 2023, includes indebtedness of $2,638.3 million, as well as remaining availability under our Revolving Credit Facility (as defined in this Annual Report) of $786.9 million (net of $13.1 million of outstanding letters of credit);
•our ability to generate cash flow to service our debt obligations;
•restrictions imposed under the agreements governing our indebtedness from time to time, which may limit our operating flexibility;
•difficulty attracting, motivating and retaining executives and other key employees;
•unexpected payments to any pension plans applicable to our employees;
•work stoppages, union negotiations, labor disputes and other matters associated with our labor force;
•the outcomes of legal proceedings instituted against us;
•risks that the insurance we maintain may not fully cover any or all potential exposures;
•certain provisions of our amended and restated certificate of incorporation (our “Charter”), Delaware law and our amended and restated bylaws (our “Bylaws”) that may make takeover attempts difficult, which could depress the price of our common stock, or limit our stockholders’ ability to obtain a favorable judicial forum for disputes;
•additional costs and new risks associated with ESG matters;
•the volatility of the market price of our common stock;
•risks associated with future sales of our common stock by us or our stockholders in the public market; and
•failure to develop or maintain an effective system of internal controls.
The following is a more complete discussion of the risks facing our business that we have determined are currently material.
Risks Relating to the Consummation of the Combinations
The failure to integrate successfully the businesses of Quidel and Ortho in the expected timeframe, or at all, would adversely affect our future business and financial performance.
The combination of two previously independent companies, Quidel and Ortho, is a complex, costly and time-consuming process. As a result of the Combinations, we will be required to devote significant management attention and resources to integrate the business practices and operations of Quidel and Ortho. The integration process may disrupt the business of either or both of Quidel and Ortho and, if implemented ineffectively, could preclude realization of the full benefits, or any benefits, we expect to result from the Combinations. Any failure to meet the challenges involved in successfully integrating the operations of Quidel and Ortho or otherwise to realize the anticipated benefits of the Combinations could also seriously harm our results of operations. In addition, the overall integration of Quidel and Ortho may result in material unanticipated problems, expenses, liabilities, competitive responses, loss of or harm to customer or other partner relationships and diversion of management’s attention, and may cause our stock price to decline. The difficulties of combining the operations of Quidel and Ortho include, among others:
•managing a significantly larger company and expanded business, which will pose substantial challenges for management, including challenges related to the management and monitoring of the current and expanded operations and associated increased costs and complexity;
•coordinating geographically separate organizations, including extensive international operations;
•the potential diversion of management’s focus and resources from other strategic opportunities and from operational matters;
•performance shortfalls as a result of the diversion of management’s attention;
•aligning and executing our strategy;
•the disruption of relationships with, or the loss of customers, potential customers and other business partners and potential business partners;
•maintaining employee morale and retaining and attracting key management and other employees;
27

•the disruption of, or the loss of momentum in, Quidel’s and Ortho’s ongoing business or inconsistencies in standards, controls, systems, procedures and policies;
•integrating two unique business cultures;
•the possibility of faulty assumptions underlying expectations regarding the integration process and results;
•consolidating corporate and administrative infrastructures and addressing duplicative operations;
•coordinating sales, distribution and marketing efforts;
•integrating IT, communications and other systems;
•changes in applicable laws and regulations and addressing multiple laws and regulations across the globe;
•managing tax costs or inefficiencies associated with integrating the operations of Quidel and Ortho;
•unforeseen expenses associated with the Combinations; and
•taking actions that may be required in connection with obtaining regulatory approvals.
Many of these factors are outside of our control and any one of them could result in increased costs, decreased revenues and diversion of management’s time and energy, which could materially impact our business, financial condition and results of operations. In addition, even if the operations of Quidel and Ortho are integrated successfully, we may not realize the full benefits of the Combinations, including the synergies, cost savings or sales or growth opportunities that we expect. These benefits may not be achieved within the anticipated timeframe, or at all.
The synergies attributable to the Combinations may vary from expectations.
We may fail to realize the anticipated benefits and synergies expected from the Combinations, which could adversely affect our business, financial condition and operating results. The success of the Combinations will depend, in significant part, on our ability to successfully integrate the businesses of Quidel and Ortho and realize the anticipated strategic benefits and synergies from the Combinations. We believe that the combination of the businesses of Quidel and Ortho will complement each party’s strategy by providing a balanced and diversified product portfolio, operational efficiencies, supply chain optimization, complementary geographic footprints, product development synergies and cash flow and margin enhancement opportunities. However, achieving these goals requires, among other things, successful integration and realization of the targeted cost synergies expected from the Combinations. The successful integration and anticipated benefits of the Combinations and actual operating, technological, strategic and revenue opportunities may not be realized fully or at all, or may take longer to realize than expected. If we are unable to achieve these objectives and realize the anticipated benefits and synergies expected from the Combinations within the anticipated timeframe or at all, our business, financial condition and operating results may be adversely affected.
We will continue to incur significant transaction and merger-related costs in connection with the Combinations.
We have incurred and expect to continue to incur a number of non-recurring direct and indirect costs associated with the Combinations. These costs and expenses include fees paid to financial, legal and accounting advisors, severance, retention and other employment-related costs, including payments that may be made to certain of our executives, filing fees, travel expenses and other related charges. There are also processes, policies, procedures, operations, technologies and systems that must be integrated in connection with the Combinations and the integration of Quidel’s and Ortho’s businesses. While we have assumed that a certain level of expenses would be incurred in connection with the Combinations and continue to assess the magnitude of these costs, there are many factors beyond our control that could affect the total amount or the timing of the integration and implementation expenses.
In addition, there may be additional unanticipated significant costs and expenses in connection with the Combinations. Although we expect that the strategic benefits of the Combinations will offset the transaction expenses and implementation costs over time, this net benefit may not be achieved in the near term or at all.
Our business relationships may be subject to disruption due to uncertainty associated with the Combinations.
Companies with which we do business may experience uncertainty associated with the Combinations, including with respect to current or future business relationships. Our business relationships may be subject to disruption as customers, distributors, suppliers, vendors and others may attempt to negotiate changes in existing business relationships or consider terminating their business relationships with us. These disruptions could have an adverse effect on our business, financial condition, results of operations or prospects, including an adverse effect on our ability to realize the anticipated benefits of the Combinations.
28

Business issues faced by Quidel or Ortho prior to the Combinations may be imputed to the operations of the other.
To the extent either Quidel or Ortho had, or was perceived by customers to have, operational challenges, such as product availability, product or service performance, quality, workforce or other issues, those challenges may raise concerns by existing customers of the other company, which may limit or impede our future ability to obtain additional business from those customers.
Risks Relating to Our Business, Strategy and Operations
The COVID-19 global pandemic has adversely affected, and may continue to adversely affect, our business operations, strategy, financial performance and results of operations, the extent of which is uncertain and difficult to predict.
Any significant outbreak of contagious diseases and other adverse public health developments in countries where we operate could have a material and adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic and the related responses from government authorities, our business operations, strategy, financial performance and results of operations have been affected in a number of ways and may be further adversely impacted in a number of ways, including, but not limited to, the following:
•increased costs in our manufacturing, production and shipping processes;
•a slowdown or stoppage in the supply chain of our raw materials, components, including but not limited to the key components of our instruments and assays, equipment and packaging services used to manufacture our products or our inability to secure additional or alternate sources of supplies or services needed to manufacture our products;
•our inventory might be requisitioned, diverted or allocated by government order such as under emergency, disaster and civil defense declarations. For example, government actions in response to the COVID-19 pandemic affected and may in the future affect our supply allocation, and those and our own allocation decisions can impact our customer relationships;
•interruptions or delays in global shipping to transport and deliver our products to our distributors and customers;
•interruptions in normal operations of certain customers that could result in reductions in demand for routine, elective and other non-COVID-19 related healthcare procedures and testing;
•disruptions to our operations, sales, distribution, R&D and other important business activities and those of our business partners, including a shutdown of one or more of our facilities, warehouses or product lines;
•our ability to meet any increased demand for our COVID-19 testing products;
•limitations on employee resources and availability, including due to sickness or personal quarantine;
•disruptions encountered by health regulatory agencies globally in their operations. For example, the FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced, and as a result, review and approval of product registrations may be materially delayed;
•an adverse impact on collections and timing of cash receipts from our customers, which could result in significant fluctuations in our cash flows from period to period; and
•an increase in the volatility of our stock price, fluctuations in foreign currency exchange rates or rising interest rates.
In response to increased demand of some of our products brought on by COVID-19, we rapidly and significantly expanded our manufacturing capacity, including expanding and scaling our infrastructure to support existing and anticipated COVID-19 testing demand and commercial activities. This rapid expansion has placed and may continue to place significant strain on our management, personnel, operations, systems and financial resources. Failure to successfully manage this expansion could negatively affect our operating results, including due to decreases in demand for our products, inefficiencies in implementing such expansion or higher costs for materials, technology, equipment and human capital. Moreover, we may not realize the revenue growth and profitability we anticipate for our COVID-19 and other diagnostic products, which could cause, among other results, a failure to realize the benefits of our manufacturing capacity expansion, excess capacity and the value of those investments being written down or written off. Similarly, we have experienced significant volatility in demand for our COVID-19 products since they launched, with periods of significant demand and periods where we experienced dramatic decreases in demand. Demand has fluctuated as a result of various factors, including the resurgences of COVID-19 and its variants, the supply of COVID-19 tests generally, the purchasing activity of government entities, and the dissemination and effectiveness of vaccinations. As the COVID-19 pandemic reaches an endemic stage, the extent to which it may continue to impact demand for our products depends on these and future developments, which are highly uncertain and difficult to predict.
The COVID-19 pandemic has also resulted in global supply chain challenges. For instance, we have experienced shortages and delays in receiving certain raw materials and other components for our products and have experienced logistics and distribution
29

challenges, as well as challenges in labor availability and rising labor costs, all of which have affected our ability to fulfill customer orders, including instrument placements, on a timely basis. Supply chain, production, logistics and distribution challenges have impacted, and we expect will continue for some period of time to impact, our results of operations. Although we and our contract manufacturer partners, suppliers of raw materials and other third-party vendors are pursuing additional sources for certain of these components, we may be unable to identify additional suppliers. We have also encountered and may continue to encounter increases in idle facility costs and freight and distribution costs, which in some instances have affected the pricing of our products. Any prolonged and significant supply chain disruptions or inability to provide products in countries adversely impacted by the COVID-19 pandemic could impact our revenues, increase our costs and negatively affect our business relationships and reputation, as well as our operating results.
The effects of COVID-19 may exacerbate the impact of other risks described in this Annual Report. As the COVID-19 pandemic reaches an endemic state, the degree to which it continues to impact our business operations, strategy, financial condition and results of operations will depend on future developments that are uncertain and difficult to predict. Although COVID-19 infection rates and severity have decreased recently, the occurrence, spread, severity and duration of any new outbreaks or resurgences, including the emergence and spread of new variants of COVID-19, actions taken to contain the resurgences or variants, and economic repercussions of the virus remain uncertain. We continue to evaluate the nature and extent to which COVID-19 may impact our business and operations.
The industry and market segment in which we operate are highly competitive, and our failure to compete effectively could adversely affect our sales and results of operations.
Our diagnostic tests and services compete with similar products made by our competitors. We may not be able to supply customers with products and services that they deem superior or at competitive prices, and we may lose business to our competitors. There are a large number of multinational and regional competitors making investments in competing technologies and products, including several large pharmaceutical and diagnostics companies and diagnostic divisions of diversified healthcare companies and conglomerates. We also face competition from our distributors and retail customers as some have created, and others may decide to create, their own products to compete with ours. A number of our competitors have competitive advantages, such as substantially greater financial, managerial, technical, R&D, clinical, manufacturing, and regulatory resources, capabilities and experience, and larger, more established marketing, sales, distribution and service organizations and other resources than we have. Moreover, some competitors offer broader product lines and have greater name recognition than we have. Our operating results could be materially and adversely affected if:
•customers and potential customers believe our competitors’ products and services better address their needs and expectations through product performance, product offerings, cost, automation or work-flow efficiencies, and even if we can demonstrate that our products meet their needs and expectations, they may resist changing to our products;
•our competitors take market share from our products, or we may not win opportunities because our competitors have or are perceived to have more effective servicing or marketing or greater or more timely product availability;
•our competitors are able to obtain regulatory approvals for products or services or otherwise bring competing products to market earlier than us; or
•our competitors offer more competitive pricing or we fail to manufacture, in a cost-effective way, or at all, sufficient quantities of our products to meet customer demand.
Competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover through price increases, higher costs of acquired goods and services resulting from inflation, and other drivers of cost increases. Furthermore, the introduction of counterfeit products into the markets we serve may have the effect of eroding confidence in our products or in our industry as a whole. In addition, there has been a trend toward industry consolidation in our markets over the last few years. We may not be able to compete successfully in an increasingly consolidated industry. We expect this trend toward industry consolidation to continue as companies attempt to strengthen or hold their market positions in an evolving industry. If we are unable to compete successfully in this highly competitive industry, it could have a material effect on our business, financial condition and results of operations.
In order to remain competitive and profitable, we must expend considerable resources to research and successfully develop new technologies, products and services and develop new markets, and there is no assurance our research efforts and our efforts to develop new technologies, products and services or markets will be successful or such technologies, products and services or markets will be commercially viable or accepted.
Our ability to retain customers, attract new customers, grow our business and enhance our brand depends on our success in developing and delivering products and services that meet our customers’ needs and expectations. We devote a significant amount of financial and other resources to researching and developing new technologies, products, services and markets. The development, manufacture and sale of diagnostic products and services and new technologies require a significant investment of
30

resources, such as employee time, offices and R&D and manufacturing facilities, and development of new partners and channels. Furthermore, developing and manufacturing new products and services require us to anticipate customers’ and patients’ needs and emerging technology trends accurately. We may experience R&D, manufacturing, regulatory, marketing and other difficulties that could delay or prevent our introduction of new or enhanced products and services. The R&D process in the healthcare industry generally takes a significant amount of time from design stage to product launch. This process is conducted in various stages, and each stage presents the risk that we will not achieve our goals. In addition, innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursements. In the event of such failure, we may need to abandon a product or service in which we have invested substantial resources.
We cannot be certain that:
•any of our products or services under development will be successfully developed, or if developed, will be timely introduced to the market;
•any of our products or services under development will prove to be safe and effective in clinical trials;
•we will be able to obtain, in a timely manner or at all, necessary regulatory approvals;
•the products and services we develop can be manufactured or provided at acceptable cost and with appropriate quality; or
•these products and services, if and when approved, can be successfully marketed or will be adopted in the market.
These factors, as well as supply, manufacturing or distribution problems or other factors beyond our control, could delay the launch of new products or services. If we are unable to deliver reliable products in a timely manner, promptly respond to and address quality issues, provide expected levels of customer service, and comply with applicable regulations and rules, our ability to deliver products that meet our customers’ needs and expectations and our competitive position, branding and results of operations may be adversely and materially affected.
Global market, macroeconomic and geopolitical conditions may adversely affect our operations and performance.
The growth of our business and demand for our products and services are affected by changes in the health of the overall global economy and, in particular, of the healthcare industry. Demand for our products and services could change more dramatically than in previous years based on funding and reimbursement constraints and support levels from governments, universities, hospitals and the private industry, including laboratories. Our global business is adversely affected by decreases in the general level of economic activity, such as decreases in business and consumer spending, increases in unemployment rates, the inflationary environment, rising interest rates, the recessionary environment, and budgeting constraints of governmental entities. Disruptions in the U.S., Europe or in other economies, including due to geopolitical conflict, including the ongoing conflict in Ukraine and rising tensions between China and Taiwan, or weakening of emerging markets, including China, could adversely affect our sales, profitability and/or liquidity.
A future deterioration in financial markets or confidence in major economies or other macroeconomic developments could affect businesses such as ours in a number of ways. A tightening of credit in financial markets could adversely affect the ability of our customers and suppliers to obtain financing for significant purchases and operations, could result in a decrease in or cancellation of orders for our products and services and could impact the ability of our customers to make payments. Similarly, a tightening of credit may adversely affect our supplier base, increase the potential for one or more of our suppliers to experience financial distress or bankruptcy, and could also impact our operations more directly, including any outstanding or contemplated credit facility or other borrowings. Our financial position, results of operations and cash flows could be materially adversely affected by difficult conditions and volatility in the capital, credit and commodities markets.
Fluctuations or a decline in sales of our COVID-19 and influenza diagnostic tests can have a significant impact on our operating results and if sales or revenues of our COVID-19 or influenza tests fluctuate or decline for any reason, our operating results could be materially and adversely affected.
A significant percentage of our total revenues is generated from a limited number of our product families. In particular, revenues from the sales of our COVID-19 tests have represented a significant portion of our total revenues. Sales of our COVID-19 products accounted for approximately 44% of our total revenues for the year ended January 1, 2023, which includes the impact of Ortho’s operations from the date of the Combinations. Demand for our COVID-19 testing products has and may continue to fluctuate or decline as a result of a number of factors, including but not limited to the emergence and impact of new variants or resurgences, the effectiveness of global containment efforts, and the increased market supply of COVID-19 tests by our competitors. Sales of our influenza tests accounted for approximately 11% of our total revenues for the year ended January 1, 2023, which includes the impact of Ortho’s operations from the date of the Combinations. Demand for our influenza tests can fluctuate or decline based on the severity of the flu season. The gross margins derived from sales of our COVID-19 and influenza tests are generally significantly higher than the gross margins from many of our other core products. As a result,
31

if sales or revenues of our COVID-19 or influenza tests fluctuate or decline for any reason, whether as a result of a waning of the COVID-19 pandemic, a mild flu season, market share loss or price pressure, obsolescence, regulatory matters, such as loss of EUAs from the FDA for our COVID-19 products, or any other reason, our operating results would be materially and adversely affected on a disproportionate basis.
A significant portion of our total revenues are from a relatively small number of customers, and if we fail to retain or expand our customer relationships or significant customers terminate or do not renew their contracts, our business, operating results and financial condition could be adversely affected.
A significant portion of our revenues are from sales of products and services to distributors. Although we have many distributor relationships in the U.S. and globally, the market is dominated by a small number of these distributors and as a result, we rely on certain key distributors for the sales of some of our products. The loss or termination of our relationship with any of these key distributors could significantly disrupt our business unless suitable alternatives are timely found or lost sales to a distributor are taken up by another distributor. Finding a suitable alternative to a lost or terminated distributor may pose challenges in our industry’s competitive environment, and another suitable distributor may not be found on satisfactory terms, if at all. For instance, some distributors already have exclusive arrangements with our competitors, and others do not have the same level of penetration into our target markets as our existing distributors. In addition, our efforts to distribute our products directly in some markets may be unsuccessful. The loss of any key distributor or an unsuccessful effort by us to directly distribute our products could lead to reduced sales.
In addition to distributors, we also have a number of other customers who are significant. If our relationships with such customers are terminated, or such customers do not renew their contracts with us, or substantially reduce or stop ordering from us, and if we do not add new large customers over time, our business could be harmed. Our ability to continue to generate revenue from our significant customers will depend on our ability to maintain strong relationships with these customers and introduce competitive new products and services at competitive prices. Moreover, customer consolidation could reduce the number of customers and may increase the risk of our dependence on a small number of customers. Government agencies are also important customers, and in fiscal year 2022, have represented significant revenues. Our ability to procure further government contracts will depend on a number of factors, including the general level of support for testing, including for COVID-19, other macroeconomic and geopolitical conditions, budgeting constraints of governmental entities, tendering requirements and funding, and there can be no assurance that we will procure additional contracts, or if procured, the timing, pricing or amount contracted.
If total revenues from some of our significant customers were to decrease or not continue in any material amount in the future, or if we are not successful in growing our current or new customer relationships or timely transitioning our business from a lost or terminated distributor to one or more new distributors, our business, operating results and financial condition could be materially and adversely affected.
Interruptions and delays in the supply of raw materials, components, equipment and other products and services could adversely affect our operations and financial results.
We depend on third-party manufacturers, suppliers and vendors for some of our materials, components, equipment, packaging and other products and services. Any change in our relationship with our contract manufacturers, suppliers of raw materials and other third-party vendors or changes to contractual terms of our agreements with any of them could adversely affect our financial condition and results of operations. Further, unexpected increases in demand for our products or supply shortfalls could require us to obtain additional supplies or services in order to manufacture products to meet the demand. Some supplies require significant ordering lead time and we may not be able to timely access sufficient supplies in the event of an unexpected increase in demand or supply shortfall, or the cost of such supplies may be significantly greater. Our reliance on a small number of contract manufacturers and a large number of single and sole source suppliers makes us vulnerable to possible capacity or other production constraints of such suppliers or in their supply chain, reduced control over product availability, delivery schedules and costs and reduced ability to monitor compliance with our product manufacturing specifications.
As a result of the COVID-19 pandemic and other macroeconomic and geopolitical conditions, including inflationary pressures, general economic slowdown or a recession, rising interest rates, foreign exchange rate volatility and changes in monetary policy, we have experienced shortages and delays in receiving certain raw materials and other components for our products and have experienced logistics and distribution challenges, as well as challenges in labor availability and rising labor costs, all of which have affected our ability to fulfill customer orders, including instrument placements, on a timely basis. Supply chain, production, logistics and distribution challenges, including shortages of raw materials and components, cost inflation, shipping delays, labor availability constraints and rising labor costs, have impacted, and we expect will continue for some period of time to impact, our results of operations. As a result, we are currently encountering, and may continue to encounter, increased customer backlogs of orders and inventory shipments out of our warehouse facilities. If these increased customer backlogs continue, they may adversely impact customer relationships and affect our financial performance.
32

Our business is also subject to risks associated with U.S. and foreign legislation, regulations and trade agreements relating to the materials we import, including quotas, duties, tariffs or taxes, and other charges or restrictions on imports, which could adversely affect our operations and our ability to import materials used in our products at current or increased levels, if at all. We cannot predict whether additional U.S. and foreign customs quotas, duties (including antidumping or countervailing duties), tariffs, taxes or other charges or restrictions, requirements as to where raw materials must be purchased, or other restrictions on our imports will be imposed in the future or adversely modified, or what effect such actions would have on our costs of operations. Future quotas, duties or tariffs may have a material adverse effect on our business, financial condition, results of operations or cash flows. Future trade agreements could also provide our competitors with an advantage over us or increase our costs, either of which could have a material adverse effect on our business, financial condition, results of operations or cash flows.
In addition, due to regulatory requirements relating to the qualification of suppliers, we may not be able to establish additional or replacement sources on a timely basis or without excessive cost. For example, stringent requirements of the FDA and other regulatory authorities regarding the manufacture of certain of our products may prevent us from quickly establishing additional or replacement sources for the raw materials, products, components or manufacturing services that we use, or from doing so without excessive cost. Further, our suppliers may be subject to regulation by the FDA and other regulatory authorities that could hinder their ability to produce necessary raw materials, products and components. The SEC also requires disclosure for public companies whose products contain conflict minerals, such as tin, tantalum, tungsten and gold, that originate from the Democratic Republic of Congo and/or adjoining countries. The implementation of these requirements has caused and will continue to cause increased costs to comply with these disclosure requirements and may inhibit our ability to source these materials.
If our current contract manufacturers, suppliers of raw materials and other third-party vendors are unable or unwilling to manufacture or supply our products or components or requirements for raw materials in required volumes and at required quality levels or renew existing terms under supply agreements, we may be required to replace such manufacturers, suppliers and vendors and may be unable to do so in a timely or cost-effective manner, or at all. Any shortfall in our supply of raw materials, equipment or components, or our inability to quickly and cost-effectively obtain alternative sources for this supply, could have a material adverse effect on our business, financial condition and operating results.
We may experience manufacturing or warehousing problems or delays due to, among other reasons, our volume, specialized processes, and macroeconomic and geopolitical conditions.
The global supply of some of our products depends on the uninterrupted efficient operation of our manufacturing facilities, and the continued performance of our contract manufacturers, suppliers of raw materials and other third-party vendors under our contractual arrangements. Many of our manufacturing processes are complex and involve sensitive scientific processes involving the use of unique and often proprietary antibodies and other raw materials that cannot be replicated or acquired through alternative sources without undue delay or expense. Other processes present difficult technical challenges to obtain the manufacturing yields necessary to operate profitably. In addition, our manufacturing processes may require complex and specialized equipment, which can be expensive to maintain, repair or replace with required lead times of up to a year.
The manufacturing of certain of our products is concentrated in one or more of our manufacturing plants or those of our suppliers, with no or limited alternate facilities. Weather, natural disasters, public health emergencies, fires, terrorism, political change or unrest, failure to follow specific internal protocols and procedures, equipment malfunction, environmental factors, damage to our equipment or one or more of our facilities, or any other event that negatively impacts our manufacturing process, facilities, systems or equipment, or the process, facilities, systems or equipment of our contract manufacturers or suppliers, could delay, reduce, suspend or terminate shipments of products or the release of new products or could result in the delivery of inferior products. In such circumstances, our revenue from the affected products would decline and we could incur losses until such time as we or our contract manufacturers are able to restore or rebuild our or their production processes or we are able to put in place alternative contract manufacturers or suppliers. Similarly, any disruption or other operational challenges to one of our primary warehouse facilities could result in decreased revenue or increased costs given the challenge in finding suitable alternative facilities.
Our collaboration arrangements may not operate according to our business strategy if our collaboration arrangement partners fail to fulfill their obligations.
As part of our business, we are party to collaboration arrangements with other companies, including the Joint Business with Grifols, and we may enter into additional collaboration arrangements in the future. The nature of a collaboration arrangement requires us to share control over significant decisions with unaffiliated third parties. For example, governance of the Joint Business is shared with Grifols through a supervisory board made up of equal representation by us and Grifols. The supervisory board is responsible for all significant decisions relating to the Joint Business that are not exclusively assigned to either us or Grifols under the contract that established the Joint Business. Since we may not exercise exclusive control over our current or
33

future collaboration arrangements, we may not be able to require our collaboration arrangement partners to take actions that we believe are necessary to implement our business strategy. Disputes between us and our collaboration arrangement partners could also result in litigation, which can be expensive and time-consuming. Additionally, differences in views among collaboration arrangement partners may result in delayed decisions or failures to agree on major issues. If these differences cause our collaboration arrangements to deviate from our business strategy, our results of operations could be materially adversely affected.
Unexpected increases in, or inability to meet, demand for our products and services could require us to spend considerable resources to meet such demand or harm our reputation and customer relationships if we are unable to meet demand.
Our inability to meet customer demand for our products and services, including as a result of manufacturing or warehousing problems or supply shortages or shortfalls, could harm our customer relationships and impair our reputation within the industry. For instance, we are currently encountering, and may continue to encounter, increased customer backlogs of orders and inventory shipments out of our warehouse facilities, due to a number of factors. Further, if we experience unexpected increases in the demand for our products or services or supply shortages or shortfalls, we may be required to incur additional costs to meet these demands. These costs could involve purchasing or producing safety stock of components or products, purchasing new machinery or obtaining additional labor resources or even the cost of acquiring or constructing new manufacturing facilities. This would increase our capital and other costs, which could adversely affect our earnings and cash resources. If we are unable to develop or obtain necessary manufacturing and production capabilities in a timely manner, our total revenues could be adversely affected. Failure to increase production volumes in a cost-effective manner, lower than anticipated yields or production problems could result in shipment delays, as well as increased manufacturing costs, which could also have a material adverse effect on our business, reputation, operating results and financial condition.
A decrease in the number of surgical procedures performed, and the resulting decrease in blood demand, could negatively impact our financial results.
Our immunohematology and donor screening products are frequently used in connection with the testing of blood prior to transfusion, which is typically associated with surgical procedures. A decrease in the number of surgeries being performed in the markets in which we operate could result in decreased demand for blood for transfusions, which would in turn result in lower testing volumes and, therefore, decreased sales of our products. For example, we believe markets in developed countries have, at times, seen a decrease in the number of surgical procedures and lower demand for blood in recent years. A decrease in the number of surgical procedures performed could result from a variety of factors, such as fewer elective procedures and the improved efficacy and popularity of non-surgical treatments. In addition to lower surgical volumes, blood demand could also be negatively affected by more efficient blood utilization by hospitals. Blood is a large expense for hospital laboratories and pressure on hospital budgets due to macroeconomic factors and healthcare reform could force changes in the ways in which blood is used. Fewer surgeries and lower blood demand could negatively impact our revenue, profitability and cash flows.
Our reagent rental model reduces our cash flows during the initial part of the applicable contract, which causes our cash flows to fluctuate from quarter to quarter.
Leases, rather than sales, of instruments under our reagent rental model have the effect of reducing cash flows during the initial part of the applicable contract as we support those commercial transactions until we are able to recover our investment over the life of the contract. The use of cash in connection with this model causes our cash flows to fluctuate from quarter to quarter and may have a negative effect on our financial condition.
We may not achieve market acceptance of our products among physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, individual, non-professional OTC customers, or other customers, and this would have a negative effect on future sales.
We maintain customer relationships with numerous physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, individual, non-professional OTC customers and other customers. We believe that sales of our products depend significantly on our customers’ confidence in, and recommendations of, our products. In addition, in a number of cases, our success depends on technicians’ acceptance and confidence in the effectiveness and ease-of-use of our products, including our new products. If we do not capture sales at the levels anticipated in our budget, our total revenues will not be at the levels that we expect and the costs we incur or have incurred may be disproportionate to our sales levels.
In order to achieve acceptance by healthcare professionals, we seek to educate the healthcare community as to the distinctive characteristics, perceived benefits, clinical efficacy and cost-effectiveness of our products compared to alternative products, including the products offered by our competitors. Acceptance of our products also requires effective training of healthcare
34

professionals in the proper use and application of our products. Failure to effectively educate and train our technician end-users, continue to develop relationships with leading healthcare professionals or achieve market acceptance from healthcare providers or other customers with respect to the use of our diagnostic products could result in less frequent acceptance or recommendations of our products, which may adversely affect our sales and profitability.
The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce costs, which could adversely affect our business, financial condition and results of operations.
The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce costs. Many of our customers, and the end-customers to whom our customers provide products, rely on private or government funding of and reimbursement for healthcare products and services and research activities. In the U.S., healthcare providers such as hospitals and physicians who purchase diagnostic products generally rely on third-party payors, principally private health insurance plans and federal Medicare and Medicaid, to reimburse all or part of the cost of the procedure. For example, MACRA repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that are based on various performance measures and physicians’ participation in alternative payment models such as accountable care organizations. In 2018, CMS implemented certain provisions of PAMA, which made substantial changes to the way in which clinical laboratory services are paid under Medicare. The revised reimbursement methodology under PAMA results in relatively lower reimbursement under Medicare for clinical diagnostic lab tests than has been historically available. These legislative changes in the U.S., healthcare austerity measures in Europe and other potential global healthcare reform changes and government austerity measures may reduce the amount of government funding or reimbursement available to customers or end-customers of our products and services and/or the volume of medical procedures using our products and services. Third-party reimbursement and coverage may not be available or adequate in either the U.S. or foreign markets, current reimbursement amounts may be decreased in the future and future legislation, legislative amendments, regulation or reimbursement policies of third-party payors may reduce the demand for our products or adversely impact our ability to sell our products on a profitable basis.
Governmental and private healthcare providers and payors around the world are increasingly utilizing managed care for the delivery of healthcare services, forming group purchasing organizations to improve their purchasing leverage and using competitive bid processes to procure healthcare products and services.
Health insurance premiums, co-payments and deductibles have also generally increased in recent years. These increases may cause individuals to forgo health insurance, as well as medical attention. This behavior may reduce the demand for certain of our diagnostics products and services.
The foregoing changes in the healthcare industry and related industries that we serve may cause participants in the healthcare industry to purchase fewer of our products and services, reduce the prices they are willing to pay for our products or services, reduce the amounts of reimbursement and funding available for our products or services from governmental agencies or third-party payors, reduce the volume of medical procedures that use our products and services and increase our compliance and other costs. Moreover, we believe the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures on the healthcare industry, both foreign and domestic, to reduce the cost of products and services.
Any of the factors described above could adversely affect our business, financial condition and results of operations.
Consolidation of our customer base and the formation of group purchasing organizations could materially adversely affect our sales and results of operations.
Consolidation among healthcare providers and the formation of buying groups and, with respect to our international operations, government-sponsored tendering processes, have put pressure on pricing and sales of our products, and in some instances, required payment of fees to group purchasing organizations or required us to provide lower pricing in the tendering process. Our success in these areas depends partly on our ability to enter into contracts with integrated health networks and group purchasing organizations. If we are unable to enter into contracts with these group purchasing organizations and integrated health networks on terms acceptable to us or if we fail to have our pricing terms accepted in the tendering process, our sales and results of operations may be adversely affected. Even if we are able to enter into these contracts or have our pricing terms accepted in the tendering process, they may be on terms that negatively affect our current or future profitability. Furthermore, given the average industry contract length for our Ortho instruments is five to seven years, if we are unable to enter into a contract with a new customer or renew a given contract with an existing customer, it may be several years before we have an opportunity to acquire or reacquire, as applicable, such customer’s business, which may have a material adverse effect on our results of operations in the interim period.
35

We may engage in acquisitions and divestitures, and may encounter difficulties integrating acquired businesses with, or disposing of divested businesses from, our current operations; therefore, we may not realize the anticipated benefits of these acquisitions and divestitures.
We may seek to grow through strategic acquisitions. Our due diligence reviews of our acquisition targets may not identify all of the material issues necessary to accurately estimate the cost or potential loss contingencies with respect to a particular transaction, including potential exposure to regulatory sanctions resulting from an acquisition target’s previous activities as well as potential vulnerability to cybersecurity risks. We may incur unanticipated costs or expenses, including post-closing asset impairment charges, expenses associated with eliminating duplicate facilities, litigation and other liabilities. We also may encounter difficulties in integrating acquisitions with our operations, applying our internal controls processes to these acquisitions, retaining key technical and management personnel, complying with regulatory requirements, or in managing strategic investments. Additionally, we may not achieve the benefits we anticipate when we first enter into a transaction in the amount or timeframe anticipated, if at all. Any of the foregoing could adversely affect our business and results of operations. In addition, accounting requirements relating to business combinations, including the requirement to expense certain acquisition costs as incurred, may cause us to experience greater earnings volatility and generally lower earnings during periods in which we acquire new businesses. We may also make strategic divestitures from time to time. These divestitures may result in continued financial involvement in the divested businesses, such as through guarantees, indemnity obligations or other financial arrangements, following those transactions. Under these arrangements, nonperformance by those divested businesses could result in financial obligations imposed upon us and could affect our future financial results.
Natural disasters, public health crises, geopolitical crises and other catastrophic events or other events outside of our control may disrupt our facilities or the facilities of third parties on which we depend and adversely affect our results of operations.
We have significant operations in California, near major earthquake faults and areas vulnerable to wildfire, which make us susceptible to earthquake and fire risk. We also have significant operations in Rochester, New York, Raritan, New Jersey, Pencoed, Wales and Pompano Beach, Florida. An earthquake, fire or other natural disaster or power shortages or outages could disrupt our operations or impair our critical systems, which could have an adverse effect on our results of operations.
Further, as a multinational company with a large international footprint, we are also subject to increased risk of damage or disruption to us, our employees, facilities, partners, suppliers, distributors, resellers or customers due to terrorist acts, civil unrest, conflicts, wars, adverse weather conditions, natural disasters, power outages, pandemics, endemics or other public health crises and environmental incidents, wherever located around the world. The potential for future terrorist attacks and natural disasters, the national and international responses to such attacks and natural disasters or perceived threats to national security and other actual or potential conflicts or wars may create macroeconomic and geopolitical uncertainties. In addition, as a multinational company with headquarters and significant operations located in the U.S., actions against or by the U.S., including sanctions, could result in a decrease in demand for our products, make it difficult or impossible to deliver products to our customers or to receive components from our suppliers, create delays and inefficiencies in our supply chain and pose risks to our employees, resulting in the need to impose travel restrictions. Any interruption in production capability could require us to make substantial capital expenditures to remedy the situation, if it can be remedied, which could negatively affect our profitability and financial condition. Moreover, these types of events could negatively impact customer spending in the impacted regions or depending on the severity, globally, which could also adversely impact our operating results.
Risks Relating to Our International Operations
As a global business, we face risks relating to our non-U.S. operations and international sales, including inherent macroeconomic, geopolitical and regulatory risks, that could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy.
We conduct our business on a global basis, as our products are sold internationally, with the majority of our international sales to our customers in our EMEA and China regions. Our international operations are subject to inherent macroeconomic, geopolitical and regulatory risks, which could impact our financial performance, cause interruptions in our business operations and impede our international growth. These foreign risks include, among others:
•compliance with multiple different registration requirements and new and changing product registration requirements, our inability to benefit from registration for our products inasmuch as registrations may be controlled by a distributor, and the difficulty in transitioning our product registrations;
•compliance with complex foreign and U.S. laws and regulations that apply to our international operations, including U.S. laws on import/export limitations, the FCPA, and local laws prohibiting corrupt payments to governmental officials, could expose us or our employees to fines and criminal sanctions and damage our reputation;
36

•lost revenue as a result of macroeconomic developments, including the inflationary environment and recessionary fears;
•the imposition by foreign governments of trade barriers such as tariffs, quotas, preferential bidding, import restrictions or other barriers;
•exposure to currency exchange fluctuations against the U.S. dollar;
•decreased liquidity resulting from longer payment cycles, generally lower average selling prices and greater difficulty in accounts receivable collection and enforcing agreements through foreign legal systems;
•lower productivity resulting from difficulties we may encounter in staffing and managing sales, support and R&D operations across many countries;
•difficulties associated with navigating foreign laws and legal systems;
•difficulties in identifying potential third-party distributors or distribution channels;
•import or export licensing requirements, both by the U.S. and foreign countries;
•international sanctions regimes, including sanctions imposed by the U.S. on foreign countries;
•reduced, or lack of, protection for, and enforcement of, our intellectual property rights;
•social, geopolitical or macroeconomic instability in some of the regions where we currently sell our products or operate or that we may expand into in the future, including as a result of acts of war, including the ongoing conflict in Ukraine, and rising tensions between China and Taiwan, acts of terrorism, health pandemics, natural disasters and disruptions in global transportation;
•increased financial accounting and reporting burdens and complexities;
•complex and potentially adverse tax consequences resulting from international tax laws;
•transportation difficulties and delays resulting from inadequate local infrastructure; and
•diversion to the U.S. of our products sold into international markets at lower prices.
The occurrence of any of these, or other factors over which we do not have control, could lead to reduced revenue and profitability.
Currency translation risk and currency transaction risk may adversely affect our financial condition, results of operations and cash flows.
We transact business in numerous countries around the world and expect that a significant portion of our business will continue to take place in international markets. Because our financial statements are presented in U.S. dollars, we must translate earnings as well as assets and liabilities into U.S. dollars at exchange rates in effect during or at the end of each reporting period, as applicable. Therefore, increases or decreases in the value of the U.S. dollar against other currencies in countries where we operate will affect our results of operations and the value of balance sheet items denominated in foreign currencies. Furthermore, many of our local businesses generate revenues and incur costs in a currency other than their functional currency, which can impact the operating results for these operations if we are unable to mitigate the impact of foreign currency fluctuations. Accurately predicting the effects of exchange rate fluctuations upon our future operating results is difficult because of the number of currencies involved, the variability of currency exposures and the potential volatility of currency exchange rates. Accordingly, our profitability could be affected by fluctuations in foreign exchange rates. Given the volatility of exchange rates, we may not be able to effectively manage our currency transaction and/or translation risks, and any volatility in currency exchange rates may have an adverse effect on our financial condition, results of operations and cash flows. We have entered into hedging agreements to address certain of our currency risks and intend to utilize local currency funding of expansions when appropriate. We do not intend to hold financial instruments for trading or speculative purposes.
Continuing worldwide geopolitical and social uncertainty, including tariffs and trade measures, trade embargoes, trade wars and social tensions, may adversely affect our business, financial results and prospects, both domestically and internationally.
Geopolitical and social uncertainty in the U.S. and throughout the world, including due to the ongoing conflict in Ukraine and rising tensions between China and Taiwan, could impair political, trade and economic relations worldwide. Changes in policy in the U.S. and other countries regarding international trade, including import and export regulation and international trade agreements, could limit the countries in which some of our products may be manufactured or sold, or could restrict our access to, or increase the cost of obtaining, products from foreign sources. The occurrence of any of the foregoing could negatively impact our business, financial condition and results of operations.
Governments sometimes impose additional duties, tariffs or taxes on certain imported products. The imposition of import tariffs or restrictions, or other changes in U.S. trade policy, could trigger retaliatory actions by affected countries. For instance, the
37

U.S. and China have implemented import tariffs and retaliatory tariffs on certain categories of goods, including from time to time, some of our reagent products sold in China. These tariffs, depending upon their ultimate scope and value and how they are implemented, could negatively impact our business by affecting the demand for our products and services or the supply of materials we use to manufacture our products and increasing our costs, thereby making our products less cost competitive.
Risks Relating to Our IT Systems
Our ability to protect our information systems and electronic transmissions of personal data and sensitive data from data corruption, cyber-based attacks, security breaches or privacy violations is critical to the success of our business.
We are highly dependent on IT networks and systems, including our office networks, operational environment, special purpose networks, systems and software used to operate our instruments and devices and those networks and systems managed by vendors or third parties, to securely process, transmit and store electronic information (including sensitive personal information and proprietary or confidential information). Our systems may prove inadequate to our business needs and necessary upgrades may not be available or operate as designed, which could result in excessive costs or disruptions in portions of our business. These risks may be heightened as we integrate the combined systems and operations of Quidel and Ortho. Like any large corporation, from time to time the information systems on which we rely, including those controlled and managed by third parties, may be subject to computer viruses, malicious software, attacks by hackers and other forms of cyber intrusions or unauthorized access, any of which can create system disruptions, shutdowns or unauthorized disclosure of sensitive data. In addition, a security breach that leads to disclosure of information protected by privacy laws could require us to comply with breach notification requirements under applicable laws, result in litigation or regulatory action, or otherwise subject us to liability under laws that protect personal data.
If we experience a significant technology incident, such as a serious product vulnerability or security breach, or any other disruptions, delays or deficiencies from our enterprise resource planning systems, it could adversely affect our ability to, among other matters, process orders, procure supplies, manufacture and ship products, track inventory, provide services and customer support, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. If this happens, our revenues could decline and our business could suffer, and we may need to make significant further investments to protect data and infrastructure. An actual or perceived vulnerability, failure, disruption or breach of our network or privileged account security in our systems also could adversely affect the market perception of our products and services, as well as our perception among new and existing customers. Additionally, a significant security breach could result in theft of trade secrets and intellectual property, cause us to incur increased costs for insurance premiums and security remediation and subject us to potential liability, litigation and regulatory or other government action. If any of the foregoing were to occur, our business may suffer.
We attempt to mitigate the above risks by employing a number of measures, including monitoring and testing of our security controls, employee training and maintenance of protective systems and contingency plans. Further, our contractual arrangements with service providers aim to ensure that third-party cybersecurity risks are appropriately mitigated. We also maintain insurance relating to cybersecurity incidents, which we cannot guarantee will be adequate. It is impossible to eliminate all cybersecurity risk and thus our systems, products and services, as well as those of our service providers, remain potentially vulnerable to known or unknown threats. Additionally, our IT systems may also be vulnerable to damage or interruption from circumstances beyond our control, including fire, natural disasters, power outages and system failures.
Information security risks have generally increased in recent years because of the increased proliferation, sophistication and availability of complex malware and hacking tools to carry out cyber-attacks. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees with flexible work arrangements, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period of time. As cyber threats continue to evolve, we may be required to expend additional resources to mitigate new and emerging threats while continuing to enhance our information security capabilities or to investigate and remediate security vulnerabilities.
Interruptions to our third-party IT service providers and/or the inability of our digital solutions to interoperate with certain operating systems could impair the delivery of our cloud-based solutions and negatively impact our business.
We rely on a small number of third-party service providers to host and deliver our cloud-based solutions, and any interruptions or delays in services from these service providers could impair the delivery of our cloud-based solutions. We do not control the hosting of these solutions, including data center facilities or our or other parties’ access to the Internet. These facilities are vulnerable to damage or interruption from weather, natural disasters, fires, power loss, telecommunications failures, global
38

pandemics and similar events. They are also subject to break-ins, computer viruses, sabotage, intentional acts of vandalism and other misconduct.
We also depend on the interoperability of our mobile applications with popular mobile operating systems that we do not control, such as Android and iOS. Any changes in such systems that degrade the functionality of our digital solutions or give preferential treatment to competitors could negatively impact our business.
Risks Relating to Our Intellectual Property
To remain competitive, we must continue to develop, obtain and protect proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with ours.
Our ability to compete successfully in the diagnostic market depends on continued development and introduction of new proprietary technology and the improvement of existing technology, and our competitive position is therefore heavily dependent on obtaining and protecting our own proprietary technology or obtaining licenses to proprietary technology from others. We own significant intellectual property, including patents, patent applications, technology, trade secrets, know-how and trademarks in the U.S. and other countries, including, among others, Australia, Canada, China, various European countries, India, Japan and South Africa. We make strategic decisions on whether to apply for intellectual property protection and what kind of protection to pursue based on a cost-benefit analysis. While we endeavor to protect our intellectual property rights in certain jurisdictions in which our products are produced or used and in jurisdictions into which our products are imported, the decision to file for intellectual property protection is made on a case-by-case basis. Because of the differences in foreign trademark, patent and other laws concerning proprietary rights, our intellectual property rights may not receive the same degree of protection in foreign countries as they would in the U.S. Certain of our intellectual property rights are held through license agreements and collaboration arrangements with third parties. We also rely on trade secrets and certain other unpatented proprietary technology and it is possible that others will independently develop the same technology or otherwise obtain access to our unpatented technology. We license some of the rights to use our patents and know-how to third parties. Further, we rely on confidentiality agreements and other similar arrangements with our employees, consultants, advisors, collaborators and other persons who have access to our proprietary and confidential information, which may not provide meaningful protection for our proprietary technology.
If we cannot continue to improve upon or develop, obtain and protect proprietary technology, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with our products. Failure to obtain or maintain adequate protection of our intellectual property rights for any reason, including failure to file patent or trademark applications successfully or at all, failure to obtain licenses on commercially reasonable terms if at all, failure to retain intellectual property rights upon termination of our licenses or collaboration agreements, or failure to police our intellectual property through our licensees, could have a material adverse effect on our business, results of operations and financial condition.
Intellectual property risks and third-party claims of infringement, misappropriation of proprietary rights or other claims against us could adversely affect our ability to market our products and services, require us to redesign our products or services or attempt to seek licenses from third parties, and materially adversely affect our operating results. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.
Companies in or related to our industry often aggressively protect and pursue their intellectual property rights. We are and have been subject to litigation with parties that claim, among other matters, that we infringed their patents or misappropriated intellectual property rights. We have hired and will continue to hire individuals or contractors who have experience in medical diagnostics and these individuals or contractors may have confidential trade secret or proprietary information of third parties. These individuals or contractors may use third-party information in connection with performing services for us or otherwise reveal this third-party information to us. For these and other reasons, we could be sued for misappropriation of proprietary information and trade secrets. Such claims are expensive to defend and could result in substantial damage awards and injunctions that could have a material adverse effect on our business, financial condition or results of operations. In addition, to the extent that individuals or contractors apply technical or scientific information independently developed by them to our projects, disputes may arise as to the proprietary rights to such data and may result in litigation.
Our customers may also be sued by other parties that claim that our products have infringed their patents or misappropriated their proprietary rights or that may seek to invalidate one or more of our patents. The defense and prosecution of patent and trade secret claims are both costly and time consuming and could divert management’s attention from other business concerns. Moreover, an adverse determination in any of these types of disputes could prevent us from developing, using, manufacturing or selling some of our products or processes; limit or restrict the type of work that employees involved with such products may perform for us; require us to obtain a license on the disputed rights, which may not be available on commercially reasonable
39

terms, if at all; subject us to significant liability in the form of royalty payments, penalties, special and punitive damages and attorneys’ fees; cause our distributors or end users to reduce or terminate purchases of our products; or require us to re-design our products or processes, any of which could materially and adversely affect our business, financial condition and results of operations.
In addition to the foregoing, we may also be required to indemnify certain customers, distributors and strategic partners under our agreements with such parties if a third party alleges or if a court finds that our products or activities have infringed upon, misappropriated or misused another person’s proprietary rights. Further, our products may contain technology provided to us by other parties such as contractors, suppliers or customers. We may have little or no ability to determine in advance whether such technology infringes the intellectual property rights of a third party. Our contractors, suppliers and licensors may not be required or financially able to indemnify us in the event that a claim of infringement is asserted against us, or they may be required to indemnify us only up to a maximum amount, above which we would be responsible for any further costs or damages.
Risks Relating to Government Regulations
Our COVID-19 products were approved by the FDA through an EUA and the loss of such authorization could have a material adverse impact on our business, results of operations, financial position and cash flows.
The FDA can authorize the emergency use of an unapproved medical product or an unapproved use of an approved medical product for certain emergency circumstances after the HHS Secretary has made a declaration of emergency justifying authorization of emergency use. An EUA allows use in a public health emergency to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by emerging infectious disease threats when there are no adequate, approved and available alternatives. These EUA standards for marketing authorization are lower than if the FDA had reviewed our tests under its traditional marketing authorization pathways, and we cannot assure you that our tests would be cleared or approved under those more onerous clearance and approval standards. The FDA has also established certain conditions that must be met in order to maintain authorization under these EUAs. The requirements that apply to the manufacture and sale of these products may be unclear and are subject to change. The FDA may also waive otherwise applicable Consumer Good Manufacturing Practice requirements to accommodate emergency response needs. All of our current COVID-19 products used for testing for the COVID-19 virus were obtained under EUAs. We may also seek EUA approvals for our other products. EUAs are only effective until the emergency declaration by the HHS Secretary ends and EUAs can also be revised or revoked by the FDA at any time as the FDA continues to evaluate the available data concerning the efficacy and safety of the product, including with respect to whether superior approved products exist. Changes to FDA regulations or requirements could require changes to our authorized tests, necessitate additional measures or make it impractical or impossible for us to continue to market our tests. The loss of one or more of our EUAs for our COVID-19 products, or any of our other products that receive EUAs, could have a material adverse effect on our business, results of operations, financial condition or cash flows.
If we are unable to obtain or maintain required clearances or approvals for the commercialization of our products in the U.S. and certain foreign countries, we will not be able to sell those products in such jurisdictions, which could negatively impact our results of operations.
Our future performance depends on, among other matters, if, when and at what cost we will receive regulatory approval, clearances or authorizations for new products in the U.S. and certain foreign countries where we intend to sell our products. The testing, manufacture and sale of our products are subject to regulation by numerous governmental authorities in the U.S. and globally. Regulatory clearance and approval can be a lengthy, expensive and uncertain process, making the timing and costs of clearances and approvals difficult to predict. Conducting clinical studies that may be required for regulatory approvals or clearances is a complex, time-consuming and expensive process, requiring months or years to complete, and our studies are not guaranteed to generate data that demonstrate safety and effectiveness or substantial equivalence of the evaluated product. In addition, regulatory processes are subject to change, and new or changed regulations can result in increased costs, unanticipated delays, or lengthened review times of our products. We may not be able to obtain U.S. and foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause us to incur additional costs or prevent us from selling our products in the U.S. or certain foreign countries, which may have a material adverse effect on our business, financial condition and results of operations.
In the U.S., the FDA regulates most of our products. Clearance or approval to commercially distribute new medical devices is received from the FDA through a 510(k) clearance, or through approval of a PMA application. Approval to commercially distribute biologics is received from the FDA through approval of a BLA and may also require state licensing for the movement of biologics products in interstate commerce. The FDA may deny 510(k) clearance because, among other reasons, it determines that our product is not substantially equivalent to another U.S. legally marketed device. The FDA may deny approval of a PMA or BLA because, among other reasons, it determines that our product is not sufficiently safe or effective. Failure to obtain FDA
40

clearance or approval would preclude commercialization in the U.S., which could materially and adversely affect our future results of operations.
In addition, even after we obtain necessary authorizations, clearances or approvals to market our products, the FDA and other regulatory agencies may require post-market testing and additional surveillance to monitor the performance and use of approved products or may place conditions on any product approvals that could restrict the commercial applications of those products. Our results of operations would be negatively affected by failures or delays in the receipt of regulatory authorizations, approvals or clearances, changes in laws and regulations, the loss of previously received authorizations, approvals or clearances or the placement of limits on the manufacture, marketing and use of our products.
Modifications or enhancements to a cleared or approved product that could significantly affect safety or effectiveness, or that constitute a major change in the intended use of the product, could require new 510(k) clearances or possibly approval of a new PMA or BLA, or a supplement to those applications. Manufacturers determine in the first instance whether a change to a product requires a new 510(k) clearance or premarket submission, but the FDA may review any manufacturer’s decision not to seek a new 510(k). If the FDA disagrees with our determinations and requires us to submit a new 510(k), PMA or PMA supplement, or BLA or BLA supplement for any product modification, we may be required to cease marketing such product or to recall the modified product until we obtain clearance, and we may be subject to civil, criminal, monetary and non-monetary penalties and damage to our reputation.
The advertising, marketing and labeling of medical devices is highly regulated by the FDA and FTC. Our efforts to promote our products, including via direct-to-consumer marketing or social media initiatives, could subject us to additional scrutiny of our communication of risk information, benefits or claims by the FDA, FTC or both.
If the results of clinical studies required to gain regulatory approval to sell our products are not available when expected, or do not demonstrate the safety and effectiveness of those products, we may be unable to sell those products.
Before we can sell certain of our products, we must conduct clinical studies intended to demonstrate that those products are safe and effective and perform as expected. The results of these clinical studies (which are experiments involving human patients having the diseases or medical conditions that the product is trying to evaluate or diagnose) are used to obtain regulatory clearance or approval from government authorities, such as the FDA. Conducting clinical studies is a complex, time-consuming and expensive process. In some cases, we may spend several years completing the necessary clinical studies.
If we fail to adequately manage our clinical studies, those clinical studies and corresponding regulatory clearances or approvals may be delayed or we may fail to gain clearance or approval for our products altogether. Even if we successfully manage our clinical studies, we may not obtain favorable results and may not obtain regulatory clearance or approval for the applicable product. If we are unable to market and sell our new products or are unable to obtain clearances or approvals in the time frame needed to execute our product strategies, our business and results of operations would be materially and adversely affected.
Our business is subject to substantial regulatory oversight, and our failure to comply with applicable regulations may result in significant costs or, in certain circumstances, the suspension or withdrawal of previously obtained clearances or approvals.
Our businesses are extensively regulated by the FDA and other federal, state and foreign regulatory agencies. These regulations impact many aspects of our operations, including development, manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, physician interaction and record-keeping. Any material failure by us to comply with such applicable governmental regulations could result in product recalls, the imposition of fines, restrictions on our ability to conduct or expand our operations or the cessation of all or a portion of our operations.
The FDA and corresponding foreign regulatory agencies may require post-market testing and surveillance to monitor the performance of cleared or approved products or may place conditions on any product clearances or approvals that could restrict the commercial applications of those products. The discovery of problems with a product may result in restrictions on the product, including withdrawal of the product from the market. In addition, in some cases we may sell products or provide services that are reliant on the use or commercial availability of third-party products, including medical devices or equipment, and regulatory restrictions placed upon any such third-party products could have a material adverse impact on the sales or commercial viability of our related products or services.
We are subject to routine inspection by the FDA and other agencies for compliance with such agency’s requirements applicable to our products, including, without limitation, the FDA’s Quality System Regulation and Medical Device Reporting requirements in the U.S., and other applicable regulations worldwide. Our manufacturing facilities and those of our suppliers and distributors also are, or can be, subject to periodic regulatory inspections.
We are also subject to laws relating to matters such as privacy, safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. We may incur
41

significant costs to comply with these laws and regulations. If we fail to comply with applicable regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products or injunctions against our distribution of products, termination of our service agreements by our customers, disgorgement of money, operating restrictions and criminal prosecution.
Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved or commercialized in a timely manner or at all, which could negatively impact our business.
The ability of the FDA to review and approve new or modified products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result of these factors. In addition, government funding of other government agencies that fund R&D activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may increase the time it takes for new or modified medical devices and biologics to be reviewed and/or cleared or approved by necessary government agencies, which would adversely affect our business.
We may encounter challenges entering into contracts with government entities due to government-sponsored tendering requirements, and any contracts that we have entered into or will enter into with government entities may involve future funding, compliance and possible sanctions risks.
We endeavor to enter into contracts with government entities for grant-funded projects or the sale of our products. This may require us to follow government-sponsored tendering processes involving stringent restrictions, including pricing restrictions, ESG requirements, and other compliance obligations. As a result, we may face challenges meeting such government sponsored-tendering requirements, and ultimately, may not be awarded such contracts with government entities.
In addition, any government contract that we have entered into or will enter into may expose us to higher potential liability than do other types of contracts due to government funding shortfalls, the government’s right to terminate for convenience, heightened legal compliance requirements, and our inability to meet key deliverables and milestones. Government funding applicable to our government grant contracts may be limited, and there is no guarantee that budget pressure at the federal, state and local level or changing governmental priorities will not eliminate funding availability. In addition, government contracts typically are subject to procurement laws that include socio-economic, employment practices, environmental protection, recordkeeping and accounting and other requirements. For example, our contracts with the U.S. government generally require us to comply with the Federal Acquisition Regulations, the FCA, the Procurement Integrity Act, the Buy American Act and the Trade Agreements Act. Government contracts subject us to government audits, compliance investigations and oversight proceedings. Government agencies routinely review and audit government contractors to determine whether they are complying with applicable contractual and legal requirements. Implementing policies, procedures and controls relating to the accounting and recordkeeping requirements is expensive and could divert management’s attention from other concerns. If we fail to comply with these requirements relating to any government contract that we have entered into or will enter into, or we fail an audit, we could be subject to various sanctions, including monetary damages, criminal and civil penalties, termination of contracts and suspension or debarment from government contract work. These requirements complicate our business and increase our compliance burden. The failure to meet key deliverables, milestones or compliance requirements could harm our reputation and might have a materially adverse impact on our business operations and our financial position or results of operations.
If one or more of our products is claimed to be defective, we could be subject to claims of liability and harm to our reputation that could adversely affect our business.
Our product development and production processes are complex and could expose our products to claims of defectiveness. Alleged manufacturing and design defects could lead to recalls (either voluntary or required by the FDA or other government authorities) and could result in the removal of one or more of our products from the market. Similarly, our diagnostic products could lead to a false positive or false negative result, affecting the eventual diagnosis or treatment of a patient and could lead to allegations that our products have caused injury or are found to be unsuitable for their intended use. Our immunohematology business in particular is subject to the risk of product liability claims, as even the slightest inaccuracies in a specimen’s analysis can lead to critical outcomes in the life of a patient, thereby leaving little to no room for error in the precision and accuracy of such testing. In addition, our marketing of monitoring services may cause us to be subjected to various product liability or other claims, including, among others, claims that inaccurate monitoring results lead to injury or death, or, in the case of our toxicology monitoring services, the imposition of criminal sanctions. The risk of a product liability claim is also heightened for at-home tests that may be purchased and administered by the end-user customer and not a medical professional and our
42

communication of risk information, benefits or claims, which is highly regulated by the FTC and the FDA could be alleged to be misleading or erroneous. If the FTC or the FDA alleges or establishes that any of our communications are misleading, we could be subject to litigation and material penalties and fines.
Depending on the corrective action we take to redress a product’s deficiencies, we may be required to obtain new clearances or approvals before we may market or distribute the corrected device. A defect or claim of a defect in the design or manufacture of our products could also have a material adverse effect on our reputation in the industry and decrease sales of our products, and we could also face additional regulatory enforcement action, including FDA warning letters, untitled letters, product seizure, injunctions, administrative penalties, or civil or criminal fines. Moreover, any product liability or other claim brought against us, regardless of merit, could be costly to defend and could result in an increase to our insurance premiums. If we are held liable for a claim, that claim could materially affect our business and financial condition.
We are subject to healthcare regulations that could result in liability, require us to change our business practices and restrict our operations in the future.
We are subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the governments of states and foreign countries in which we conduct our business. In the U.S., these healthcare laws and regulations include the federal Physician Self-Referral Law, federal Anti-Kickback Statute, federal civil and criminal false claims laws, including the FCA, the federal Civil Monetary Penalties Law, the Health Insurance Portability and Accountability Act of 1996, the federal Physician Payments Sunshine Act, the federal Food, Drug, and Cosmetics Act, U.S. federal consumer protection and unfair competition laws, and state law equivalents of each of the foregoing, as further described in Part I, Item 1, “Business—Government Regulations” of this Annual Report.
These laws and regulations, among other things, constrain our business, marketing and other promotional and research activities by limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers of our products. In particular, these laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commissions, customer incentive programs and other business arrangements, as well as interactions with healthcare professionals through consultant arrangements, product training, sponsorships or other activities. Efforts to help ensure that our business arrangements with third parties comply with applicable healthcare and other laws and regulations involve substantial costs. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, governmental authorities may conclude that our business practices do not comply with healthcare laws and regulations.
To enforce compliance with the healthcare regulatory laws, certain enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. For example, the medical device industry’s relationship with physicians has been under increasing scrutiny by the U.S. Office of Inspector General (“OIG”), the U.S. Department of Justice (“DOJ”), the state attorney generals and other foreign and domestic government agencies. Responding to investigations can be time- and resource-consuming and can divert management’s attention from the business. We may be subject to private qui tam actions brought by individual whistleblowers on behalf of federal or state governments, with potential liability under the FCA, including mandatory treble damages and significant per-claim penalties. Additionally, as a result of these investigations and qui tam actions, we may need to agree to additional compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation, or failure to comply with such investigation, including those led by the OIG or the DOJ, or settlement could increase our costs or otherwise have an adverse effect on our business, financial condition and results of operations. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to respond to.
If our operations are found to be in violation of any of the federal and state laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to significant penalties, including significant criminal, civil and administrative penalties, damages, fines, exclusion from participation in government programs, such as Medicare and Medicaid, imprisonment, contractual damages, reputational harm, oversight if we become subject to a consent decree or corporate integrity agreement, and disgorgement, and we could be required to curtail, restructure or cease our operations. Any of the foregoing consequences will negatively affect our business, financial condition and results of operations.
We use hazardous materials in our business that may result in substantial compliance costs or claims against us relating to handling, storage or disposal.
Our operations and facilities are subject to various foreign, federal, state and local environmental, health and safety laws, rules, regulations and other requirements, including those governing the generation, use, manufacture, handling, transport, storage, treatment and disposal of, or exposure to, regulated materials, discharges and emissions to air and water, the cleanup of contamination and occupational health and safety matters. Compliance with such laws and regulations requires significant effort and costs. For example, our R&D and manufacturing activities involve the controlled use of hazardous materials that may be
43

subject to federal statutes commonly known as the Comprehensive Environmental Response, Compensation, and Liability Act, the Resource Conservation and Recovery Act, and the Clean Water Act, among other laws and regulations. Noncompliance with such laws and regulations can result in fines or penalties or limitations on our operations or liability for remediation costs, as well as claims alleging personal injury, property, natural resource or environmental damages.
We may also incur liability as a result of any contamination or injury arising from a release of or exposure to such regulated hazardous materials. Under some environmental laws and regulations, we could also be held responsible for costs relating to any contamination at our past or present facilities and at third-party disposal sites where we have sent wastes for treatment or disposal. Liability for contamination at contaminated sites may be imposed without regard to whether we knew of, or caused, the release or disposal of such regulated substances and, in some cases, liability may be joint or several. Any such future expenses or liability could have a negative impact on our financial condition and results of operations.
In addition, if any governmental authorities impose new regulations with additional compliance burdens or alter their interpretation of the requirements of such existing regulations, such requirements or regulations could impair our research, development or production efforts by imposing additional, and possibly substantial, costs, restrictions or compliance procedures on our business or operations.
Given the nature of the penalties provided for in some of these regulations, we could be required to pay sizable fines, penalties or damages in the event of noncompliance with laws. Any violation or remediation requirement could also partially or completely shut down our research and manufacturing facilities and operations, which would have a material adverse effect on our business.
Further, our workers, properties and equipment may be exposed to potential operational hazards such as fires, safety incidents, releases of regulated materials, malfunction of equipment, accidents and natural disasters, which could result in personal injury or loss of life, damage to or destruction of property and equipment or environmental damage, and could potentially result in a suspension of operations, harm to our reputation and the imposition of civil or criminal fines or penalties, all of which could adversely affect our business.
We will be exposed to significant risks in relation to compliance with anti-corruption laws and regulations and economic sanctions programs.
Doing business on a worldwide basis requires us to comply with the laws and regulations of the U.S. government and those of various international and sub-national jurisdictions, and our failure to successfully comply with these rules and regulations may expose us to liabilities. These laws and regulations apply to companies and individual directors, officers, employees and agents, and may restrict our operations, trade practices, investment decisions and partnering activities. In particular, our international operations are subject to U.S. and foreign anti-corruption laws and regulations, such as the FCPA, the Bribery Act and the Brazilian Anti-Bribery Act, among others, and economic and trade sanctions, including those administered by the United Nations, the E.U., the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) and the U.S. Department of State. The FCPA prohibits providing anything of value to foreign officials for the purposes of obtaining or retaining business or securing any improper business advantage. We may deal with state-owned business enterprises, the employees and representatives of which may be considered foreign officials for purposes of the FCPA. We are subject to the jurisdiction of various governments and regulatory agencies outside of the U.S., which may bring our personnel into contact with foreign officials responsible for issuing or renewing permits, licenses or approvals or for enforcing other governmental regulations. The provisions of the Bribery Act extend beyond bribery of foreign public officials and are more onerous than the FCPA in a number of other respects, including jurisdiction, non-exemption of facilitation payments and penalties. Economic and trade sanctions restrict our transactions or dealings with certain sanctioned countries, territories and designated persons, absent authorizations or exemptions under applicable law, such as OFAC’s licenses permitting certain humanitarian trade.
While we endeavor to have a strong culture of compliance and an adequate system of internal controls, including procedures to minimize and detect fraud in a timely manner, as well as processes for complying with OFAC authorizations or exemptions, there can be no assurance that our policies and procedures will be followed at all times or will effectively detect and prevent violations of the applicable laws by one or more of our employees, consultants, agents or partners and, as a result, we could be subject to penalties and material adverse consequences on our business, financial condition or results of operations.
Our collection, use and disclosure of personal information, including health information, is subject to federal and state privacy and security regulations, as well as data privacy and security laws outside the U.S., including in the EEA, the U.K. and the People’s Republic of China, and our failure to comply with those laws and regulations or to adequately secure the information we hold could result in significant liability or reputational harm.
We and our partners may be subject to federal, state and foreign data protection laws, regulations and other obligations as further described in Part I, Item 1, “Business—Government Regulations” of this Annual Report.
44

The legislative and regulatory landscape for privacy and data protection continues to evolve, with jurisdictions in which we operate and in which our customers operate adopting or considering adopting new privacy and data security laws and regulations regarding the collection, use, processing and storage of information obtained from consumers and other end users, including health-related information. We may also be bound by contractual obligations with our customers relating to privacy, data protection and information security that are more stringent than applicable privacy laws and regulations, and some companies often will not contract with vendors that do not meet more rigorous standards.
Complying with these various laws, regulations, standards and contractual obligations could cause us to incur substantial costs, require us to change our business practices in a manner adverse to our business (including limiting our ability to collect, control, process, share, disclose and otherwise use personal data (including health and medical information which are subject to strict requirements)), reduce demand for certain of our digital solutions, restrict our ability to offer certain digital solutions in certain jurisdictions or subject us to sanctions, investigations, fines, penalties or other inquiries by U.S., federal, state and foreign data protection regulations, all of which could negatively impact our business or reputation. Moreover, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply, further increasing costs to comply, and increasing risks of potential failures or perceived failures to comply. Because many of these laws and regulations are new, it is also generally unclear how the laws will be interpreted and enforced in practice by the relevant government authorities as many of the laws are drafted broadly and leave great discretion to the relevant government authorities to exercise.
Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, including as a cost of doing business, or due to new or increasing fines or penalties for privacy and cybersecurity violations, damage our reputation, and adversely affect our business and results of operations. Further, a cyber-attack or other data breach affecting sensitive personal information, including health information, could also result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business, including under these same laws and contractual obligations.
We continue to monitor the evolving data protection landscape to support our efforts to comply with the requirements in the countries in which we do business.
We are subject to U.S. and foreign tax laws, and changes to such tax laws or differing interpretation of those laws by the relevant governmental authorities could adversely affect us.
The U.S. Congress, the Organisation for Economic Co-operation and Development and other government agencies in jurisdictions where we do business have had an extended focus on issues related to the taxation of multinational corporations. One example is in the area of “base erosion and profit shifting,” where payments are made between affiliates from a jurisdiction with high tax rates to a jurisdiction with lower tax rates. Thus, the tax laws in the U.S., the U.K. and other countries in which we do business could change on a prospective or retroactive basis, and any such changes could adversely affect us.
In addition, the tax laws and regulations in the U.S., the U.K. and the numerous other jurisdictions in which we operate are inherently complex, and we are and will be obligated to make judgments and interpretations about the application of these laws and regulations to us and our operations and businesses. Our interpretation and application of these laws and regulations could be challenged by the relevant governmental authorities, which could result in material administrative or judicial procedures, actions or sanctions.
Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability.
We are subject to income taxes in the U.S. and in various non-U.S. jurisdictions. In addition, the amount of income taxes we pay is subject to ongoing audits by U.S. federal, state and local tax authorities and by non-U.S. tax authorities. Due to the potential for changes to tax laws (or changes to the interpretation thereof) and the ambiguity of tax laws, the subjectivity of factual interpretations, the complexity of our foreign operations and intercompany arrangements and other factors, our estimates of income tax assets or liabilities may differ from actual payments, assessments or receipts. If these audits result in payments or assessments different from our reserves, our future results may include unfavorable adjustments to our tax liabilities and our financial statements could be adversely affected. If we determine to repatriate earnings from foreign jurisdictions that have been considered permanently re-invested under existing accounting standards, it could also increase our effective tax rate. In addition, any significant change to the tax system in the U.S. or in other jurisdictions could adversely affect our financial statements.
We continue to monitor changes in tax laws in the U.S. and the impact of proposed and enacted legislation in the various foreign jurisdictions in which we operate. President Biden has provided informal guidance on tax law changes he may support.
45

Among other things, proposed changes would raise the rate on both domestic and foreign income. If any of these proposals are ultimately enacted into legislation, they could materially impact our tax provision, cash tax liability and effective tax rate.
Legislative or taxation changes or HM Revenue & Customs (“HMRC”) enforcement actions may have a material adverse impact on our business, results of operations and financial condition.
We are subject to the laws of England and Wales and the taxation rules administered by HMRC. Changes in legislation or regulations and actions by regulators, including changes in administration and enforcement policies, could from time to time require operational improvements or modifications, including in relation to the conduct of reviews and audits, that could result in higher costs or restrict our ability to operate our business and, as a result, have a material adverse effect on our business, results of operations and financial condition. HMRC may also take enforcement actions against us which may result in fines, penalties and/or interest charges being imposed on us which may have a material adverse effect on its business, results of operations and financial condition.
Risks Relating to Corporate Finance
We may need to raise additional funds to finance our future capital or operating needs or other business purposes, which could have adverse consequences on the interests of our stockholders, and may not be available on acceptable terms or at all.
We may need to seek to raise funds through the issuance of public or private debt or the sale of equity to achieve our business strategy or for other business purposes. In addition, we may need debt or equity financing to complete acquisitions. If we raise funds or acquire other technologies or businesses through issuance of equity, this could dilute the interests of our stockholders. Such financing activities may also depress the market price of shares of our common stock and impair our ability to raise capital through the sale of additional equity securities. Moreover, the availability of additional capital, whether debt or equity from private capital sources (including banks) or the public capital markets, fluctuates as our financial condition and industry or market conditions in general change. There may be times when the private capital markets and the public debt or equity markets lack sufficient liquidity or when we cannot otherwise raise additional capital or issue additional debt on acceptable terms, or at all.
Our indebtedness could adversely affect our financial condition, limit our ability to raise additional capital to fund our operations and prevent us from fulfilling our obligations under our indebtedness.
Our Credit Agreement governs our senior secured credit facilities, which consists of (i) a Term Loan in an original amount of $2,750.0 million and (ii) a $800.0 million Revolving Credit Facility (each capitalized term as defined in this Annual Report). As a result of our indebtedness, a portion of our cash flows will be required to pay interest and principal on our outstanding indebtedness, and we may not generate sufficient cash flows from operations, or have future borrowings available under the Revolving Credit Facility, to enable us to repay our indebtedness or to fund our other liquidity needs. As of January 1, 2023, we had total indebtedness of $2,638.3 million, and we had availability under our Revolving Credit Facility of $786.9 million (net of $13.1 million of outstanding letters of credit).
Subject to the limits contained in the Credit Agreement, we may incur additional debt from time to time to finance working capital, capital expenditures, investments or business acquisitions, or for other purposes. If we do so, the risks related to our higher level of debt would increase. Specifically, our higher level of debt could have important consequences to us and our stockholders, including:
•making it more difficult for us to satisfy our obligations with respect to our debt, and if we fail to comply with these obligations, an event of default could result and our credit worthiness may be impacted;
•limiting our ability to refinance or obtain additional financing to fund future working capital, capital expenditures, investments or other general corporate requirements;
•limiting us from making strategic acquisitions or causing us to make non-strategic divestitures;
•requiring a substantial portion of our cash flows to be dedicated to debt service payments instead of other purposes, thereby reducing the amount of cash flows available for working capital, capital expenditures, investments and other general corporate purposes;
•exposing us to the risk of increased interest rates as our borrowings under the credit facilities are at variable rates of interest;
•the Credit Agreement contains, and any agreements to refinance our debt likely will contain, financial and other restrictive covenants, and our failure to comply with them may result in an event of default, which, if not cured or waived, could have a material adverse effect on us;
46

•increasing our vulnerability to, and reducing our flexibility to respond to, changes in our business and industry, general economic downturns and adverse industry and business conditions;
•to the extent the debt we incur requires collateral to secure such indebtedness, exposing our assets to risks and limiting our flexibility related to such assets;
•any default under our Credit Agreement may result in proceedings against collateral we have used to secure the credit facilities, including substantially all of our and our guarantor subsidiaries’ assets;
•limiting our flexibility in planning for and reacting to changes in the industry in which we compete and to changing business and economic conditions;
•placing us at a disadvantage compared to less leveraged competitors and affecting our ability to compete; and
•increasing our cost of borrowing.
The occurrence of any one of the foregoing risks could have a material adverse effect on our business, financial condition, results of operations and ability to satisfy our obligations in respect of our outstanding debt.
Furthermore, borrowings under our credit facilities are at variable rates of interest and expose us to interest rate risk. Recently, interest rates have increased from historically low levels. If interest rates continue to increase, our debt service obligations on our variable rate indebtedness will increase even though the amount borrowed may remain the same, and our net income and cash flows, including cash available for servicing our indebtedness, will correspondingly decrease. We have entered into a series of interest rate cap and interest rate swap agreements to hedge our interest rate exposures related to our variable rate borrowings under the credit facilities. However, it is possible that these interest rate cap and interest rate swap agreements or any future interest rate cap agreements or swaps we enter into may not fully or effectively mitigate our interest rate risk and we may decide not to maintain interest rate swaps in the future.
We may not be able to generate sufficient cash flows from operating activities to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.
Our inability to generate sufficient cash flows to satisfy our debt obligations, or to refinance our indebtedness on commercially reasonable terms or at all, would materially and adversely affect our business, financial position and results of operations and our ability to satisfy our debt obligations.
Additionally, if we cannot make scheduled payments on our debt, we will be in default, and the lenders under the credit facilities could terminate their commitments to loan additional money to us, the lenders could foreclose against the assets securing their borrowings and we could be forced into bankruptcy or liquidation. All of these events could result in our stockholders losing all or a part of their investment.
Our ability to make scheduled payments on or refinance our debt obligations depends on our financial condition and operating performance, which are subject to prevailing economic and competitive conditions and to financial, business, legislative, regulatory and other factors beyond our control. We might not be able to maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness.
If our cash flows and capital resources are insufficient to fund our debt service obligations, we could face substantial liquidity problems and could be forced to reduce or delay investments and capital expenditures or to dispose of material assets or operations, seek additional debt or equity capital or restructure or refinance our indebtedness. We may not be able to effect any such alternative measures on commercially reasonable terms or at all and, even if successful, those alternative actions may not allow us to meet our scheduled debt service obligations. The Credit Agreement restricts our ability to dispose of assets and use the proceeds from such dispositions and may also restrict our ability to raise debt or equity capital to be used to repay other indebtedness when it becomes due. Because of these restrictions, we may not be able to consummate those dispositions or to obtain proceeds in an amount sufficient to meet any debt service obligations then due.
In addition, we conduct all of our operations through our subsidiaries, some of which are not guarantors of our indebtedness. Accordingly, repayment of our indebtedness is dependent on the generation of cash flows by our subsidiaries and their ability to make such cash available to us, by dividend, debt repayment or otherwise. Unless they are guarantors of our indebtedness, our subsidiaries do not have any obligation to pay amounts due on our indebtedness or to make funds available for that purpose. Our subsidiaries may not be able to, or may not be permitted to, make distributions to enable us to make payments in respect of our indebtedness. Each subsidiary is a distinct legal entity, and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from our subsidiaries. While the Credit Agreement limits the ability of our subsidiaries to incur consensual restrictions on their ability to pay dividends or make other intercompany payments to us, these limitations are subject to qualifications and exceptions. In the event that we do not receive distributions from our subsidiaries, we may be unable to make required principal and interest payments on our indebtedness.
47

The terms of the Credit Agreement impose restrictions that may limit our current and future operating flexibility, particularly our ability to respond to changes in the economy or our industry or to take certain actions, which could harm our long-term interests and may limit our ability to make payments on our indebtedness.
The Credit Agreement contains a number of restrictive covenants that impose significant operating and financial restrictions on us and may limit our ability to engage in acts that may be in our long-term best interest, including restrictions on our ability, and the ability of our subsidiaries, to:
•incur additional indebtedness and guarantee indebtedness;
•pay dividends or make other distributions in respect of, or repurchase or redeem, capital stock;
•prepay, redeem or repurchase certain indebtedness;
•make business acquisitions;
•make loans and investments;
•sell, transfer or otherwise dispose of assets;
•incur liens;
•enter into transactions with affiliates;
•enter into new lines of business or alter the businesses we conduct;
•designate any of our subsidiaries as unrestricted subsidiaries;
•enter into agreements restricting our subsidiaries’ ability to pay dividends; and
•consolidate, merge, transfer or sell all or substantially all of our assets or the assets of our subsidiaries.
In addition, the Credit Agreement requires us to comply with two financial covenants consisting of a maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) and a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement). See Note 8 to the Consolidated Financial Statements for more information related to our financial covenants.
Our ability to comply with these covenants may be affected by circumstances and events beyond our control, such as prevailing economic conditions and changes in regulations, and we cannot assure you that we will be able to comply with such covenants. These restrictions also limit our ability to obtain future financings to withstand a future downturn in our business or the economy in general. Further, in order to respond to market conditions, we may need to seek waivers of various provisions in the Credit Agreement and we might not be able to obtain such waivers on reasonable terms, if at all.
Risks Relating to Our Employees
We may have difficulty attracting, motivating and retaining executives and other key employees.
Our success will depend in part upon our ability to attract, retain and motivate executives and sales, marketing, manufacturing, technical, scientific, technology and other key personnel. Competition for qualified personnel can be intense, both in the industry in which we operate and where our operations are located. Further, our current and prospective employees may experience uncertainty about the effect of the Combinations, which may impair our ability to attract, retain and motivate executives and other key personnel. The loss of any executive or other key personnel, particularly key manufacturing, R&D and technical personnel, could harm our business and prospects and could impede the achievement of our R&D, operations or strategic objectives.
While we may employ the use of certain retention programs, there can be no guarantee that they will prove to be successful. If our key employees depart, the integration of Quidel and Ortho may be more difficult and our business may be harmed. Furthermore, we may be required to incur significant costs in identifying, hiring, training and retaining replacements for departing employees and may lose significant expertise and talent relating to our business, which may adversely affect our business and ability to realize the anticipated benefits of the Combinations. In addition, there could be disruptions to or distractions for the workforce and management associated with activities of labor unions or works councils or integrating employees into the Company. Accordingly, no assurance can be given that we will be able to attract or retain key employees to the same extent that Quidel and Ortho were able to attract or retain employees in the past.
In addition, pursuant to severance provisions in legacy Quidel and Ortho executive employment agreements, certain of our employees are entitled to receive severance payments upon certain qualifying terminations of their employment. These employees potentially could terminate their employment following specified circumstances set forth in the applicable executive employment agreement, including certain changes in such key employees’ title, status, authority, duties, responsibilities or compensation, and be entitled to receive severance. For example, such circumstances could occur in connection with the integration of Quidel and Ortho as a result of changes in roles and responsibilities.
48

If we are required to make unexpected payments to any pension plans applicable to our employees, our financial condition may be adversely affected.
Some of our current and former employees participate or participated in defined benefit pension plans that were sponsored by Ortho prior to the closing of the Combinations. We assumed certain underfunded and unfunded net pension liabilities of approximately $33.0 million in relation to these plans. Several of these plans are unfunded and, while we do not believe the liabilities in relation to these plans are significant, they will need to be satisfied as they mature from our cash resources. In jurisdictions where the defined benefit pension plans are intended to be funded with assets in a trust or other funding vehicle, we expect that, while not significant, the liabilities will exceed the corresponding assets in each of the plans. Various factors, such as changes in actuarial estimates and assumptions (including in relation to life expectancy, discount rates and rates of return on assets), as well as actual return on assets, can increase the expenses and liabilities of the defined benefit pension plans. The assets and liabilities of the plans must be valued from time to time under applicable funding rules and as a result we may be required to increase the cash payments we make in relation to these defined benefit pension plans.
We could also be required in some jurisdictions to make accelerated payments up to the full buy-out deficit in our defined benefit pension plans, which would likely be far higher than the normal ongoing funding cost of the plans. Our operations and financial condition may be adversely affected to the extent that we are required to (i) make any additional payments to any relevant defined benefit pension plans in excess of the amounts assumed in our current projections and assumptions or (ii) report higher pension plan expenses under relevant accounting rules.
We are subject to work stoppages, union negotiations, labor disputes and other matters associated with our labor force, which may adversely impact our operations and cause us to incur incremental costs.
As of January 1, 2023, we had approximately 7,000 employees located around the world consisting of commercial, supply chain, quality, regulatory and compliance, R&D and general administrative personnel. Approximately 15% of our employees globally are covered by a union, collective bargaining agreement or works council. Historically, we have not experienced work stoppages; however, in the future, we may be subject to potential union campaigns, work stoppages, union negotiations and other potential labor disputes. Additionally, future negotiations with unions or works councils in connection with existing labor agreements may (i) result in significant increases in our cost of labor, (ii) divert management’s attention away from operating our business or (iii) break down and result in the disruption of our operations. The occurrence of any of the preceding outcomes could impair our ability to manufacture our products and result in increased costs and/or decreased operating results. Further, we may be subject to work stoppages at our suppliers or customers that are beyond our control.
General Risk Factors
We are subject to, and may in the future become subject to, claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us.
From time to time, we are involved in litigation and other proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment and other claims related to our business. We may become subject to more proceedings as we expand our business, suppliers, customers and markets. Litigation related to the Company, our business and our operations or financial performance may also involve customers, competitors, suppliers, patients, stockholders, governmental authorities or other third parties. Litigation can be lengthy, expensive and disruptive to our operations, and results cannot be predicted with certainty. An adverse decision could result in significant settlement amounts, monetary damages, fines or injunctive relief that could affect our financial condition or results of operations. Even if lawsuits do not result in an unfavorable outcome, the costs of defending or prosecuting such lawsuits may be material to our business and our operations. Moreover, these lawsuits may divert management’s attention from the operation of our business, which could adversely affect our business and results of operations.
Furthermore, in the ordinary course of business, we must frequently make subjective judgments with respect to compliance with applicable laws and regulations. If regulators disagree with the manner in which we have sought to comply with applicable laws and regulations, we could be subjected to substantial civil and criminal penalties, as well as corrective actions, product recalls, seizures or injunctions with respect to the sale of our products. The assessment of any civil and criminal penalties against us could severely impair our reputation within the industry and affect our operating results, and any limitation on our ability to manufacture and market our products could also have a material adverse effect on our business.
We are exposed to business risk which, if not covered by insurance, could have an adverse effect on our results of operations.
We face a number of business risks, including exposure to product liability, property, business interruption and cybersecurity claims. Although we maintain insurance for a number of these risks, we may face claims for types of damages, or for amounts
49

of damages, that are not covered by our insurance, or our insurance coverage may not be sufficient to offset the costs of any losses, lost sales or increased costs experienced during business interruptions. For some risks, we may not obtain insurance if we believe the cost of available insurance is excessive related to the risks presented. Due to market conditions, premiums and deductibles for certain insurance policies can increase substantially and, in some instances, certain insurance policies may become unavailable or available only for reduced amounts of coverage. Further, our existing insurance may not be renewed at the same cost and level of coverage as currently in effect or may not be renewed at all. As a result, we may not be able to renew our insurance policies or procure other desirable insurance on commercially reasonable terms, if at all. Losses and liabilities from uninsured or underinsured events and delay in the payment of insurance proceeds could have a material adverse effect on our financial condition and results of operations.
Some provisions of our Charter, our Bylaws and Delaware law may make takeover attempts difficult, which could depress the price of our common stock and inhibit our stockholders’ ability to receive a premium price for their shares.
Provisions of our Charter could make it more difficult for a third party to acquire control of our business, even if such change in control would be beneficial to our stockholders. Our Charter allows our Board to issue up to five million shares of preferred stock and to fix the rights and preferences of such shares without stockholder approval. Any such issuance could make it more difficult for a third party to acquire our business and may adversely affect the rights of our stockholders. Our Bylaws include advance notice requirements for stockholder proposals that require stockholders to give written notice of any proposal or director nomination to us within a specified period of time prior to any stockholder meeting and do not permit stockholders to call a special meeting of the stockholders, unless such stockholders hold at least 50% of our stock entitled to vote at the meeting. We are also subject to anti-takeover provisions under Delaware law. These provisions may delay, deter or prevent a change in control of us, adversely affecting the market price of our common stock.
Our Bylaws designate the Court of Chancery of the State of Delaware (the “Court of Chancery”) as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
Our Bylaws provides that, unless we consent in writing to the selection of an alternative forum, (i) the Court of Chancery (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware) will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for any claims (other than any cause of action arising under the Securities Act), including claims in the right of the Company that are based on a violation of duty by a current or former director, officer, employee or stockholder in such capacity, or as to which the Delaware General Corporation Law confers jurisdiction upon the Court of Chancery, and (ii) the federal district courts of the U.S. will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for any cause of action arising under the Securities Act, but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our common stock will be deemed to have notice of, and to have consented to, the provisions of our Bylaws described in the preceding sentence. This forum selection provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and such persons and result in increased costs for a stockholder to bring a claim. There is uncertainty as to whether a court would enforce such provisions and stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If a court were to find these provisions of our Bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations.
Expectations of our performance related to ESG matters, or the reporting of such matters, may impose additional costs on us and expose us to new risks.
There is an increasing focus and scrutiny from certain investors, customers, vendors, employees and other stakeholders concerning corporate responsibility, specifically related to ESG factors. In addition, government organizations are enhancing or advancing legal and regulatory requirements, including disclosure requirements, specific to ESG matters. Many investors may use these factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our ESG performance is inadequate. Third-party providers of corporate responsibility ratings and reports have increased in number to meet growing investor demand for measurement of ESG performance. The criteria by which our corporate responsibility practices are assessed must be continuously monitored and may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our performance related to corporate responsibility and ESG matters is inadequate. Moreover, our market capitalization has increased significantly in the last few years. Accordingly, we may be benchmarked against larger peer companies, some of which may have more resources than us and thus may have achieved better ESG performance and/or a higher ESG rating profile. We may face reputational damage if our ESG performance or ESG rating profile is, or is perceived
50

as being, below that of our competitors or peer companies. In addition, we could fail, or be perceived as failing, in our achievement of certain ESG-related initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors, customers, vendors, employees and other stakeholders related to our ESG performance or our ESG initiatives are not executed as planned, we may not realize the anticipated benefits of implementing such ESG initiatives and our reputation, business, stock price, financial condition or results of operation could be adversely impacted.
The market price of our common stock may be volatile.
The market price of our common stock may be volatile. Broad general economic, political, market and industry factors may adversely affect the market price of our common stock, regardless of our actual operating performance and the success of the integration of Quidel and Ortho. Factors that could cause fluctuations in the price of our common stock include:
•global macroeconomic, geopolitical or market conditions;
•actual or anticipated variations in quarterly operating results and the results of competitors;
•changes in financial projections by us, if any, or by any securities analysts that may cover our shares;
•conditions or trends in the industry, including regulatory changes or changes in the securities marketplace;
•announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures;
•announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us;
•our inability to execute on our stock repurchase program as planned, including failure to meet internal or external expectations around the timing or price of stock repurchases, and any reductions or discontinuances of repurchases thereunder;
•additions or departures of key personnel; and
•issuances or sales of our common stock, including sales of common stock by our directors and officers or our significant investors.
Future sales of our common stock by us or our stockholders in the public market, or the perception that such sales may occur, could reduce the price of our common stock, and any additional capital raised by us through the sale of equity or convertible securities may dilute ownership in the Company.
The sale of our common stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.
All of our issued shares of common stock are freely tradable without restriction or further registration under the Securities Act, except for any shares held by our affiliates, as that term is defined under Rule 144 of the Securities Act (“Rule 144”), including certain of our directors, executive officers and other affiliates, which shares may be sold in the public market only if they are registered under the Securities Act or are sold pursuant to an exemption from registration such as Rule 144. Shares of our common stock covered by registration rights represent approximately 19% of our outstanding shares as of January 1, 2023. Registration of any of these outstanding shares of common stock would result in such shares becoming freely tradable without compliance with Rule 144 upon effectiveness of the registration statement. As restrictions on resale end or if these stockholders exercise their registration rights, the market price of our common stock could drop significantly if the holders of these shares sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of our shares of common stock or other securities.
In addition, we filed a registration statement with the SEC on Form S-8 providing for the registration of approximately 5.5 million shares of common stock issued or available for issuance under the QuidelOrtho Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”) and the QuidelOrtho Amended and Restated 1983 Employee Stock Purchase Plan (the “ESPP”). Subject to the satisfaction of vesting conditions, shares of common stock registered under the registration statement on Form S-8 may be made available for resale immediately in the public market without restriction.
In the future, we may also issue our securities in connection with investments or acquisitions, or otherwise. We cannot predict the size of future issuances of shares of our common stock or securities convertible into shares of our common stock or the effect, if any, that future issuances and sales of shares of our common stock will have on the market price of our common stock. Sales of substantial amounts of our common stock (including shares issued in connection with an acquisition), or the perception that such sales could occur, may adversely affect prevailing market prices of our common stock.
51

If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial reporting, which would harm our business and the trading price of our common stock.
Effective internal controls are necessary for us to provide reliable financial reports, prevent fraud and operate successfully as a public company. If we cannot provide reliable financial reports or prevent fraud, our reputation and operating results would be harmed. We cannot be certain that our efforts to develop and maintain an effective system of internal controls will be successful, that we will be able to maintain adequate controls over our financial processes and reporting in the future, or that we will be able to comply with our obligations under Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to develop or maintain effective internal controls, including due to the Combinations or otherwise, or difficulties encountered in implementing or improving internal controls, could harm our operating results or cause us to fail to meet our reporting obligations. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which would likely have a negative effect on the trading price of our common stock.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
At January 1, 2023, our material operating locations, which we define as the facilities we lease with more than 75,000 square feet plus all owned facilities of more than 20,000 square feet, were as follows:
LocationStatusLease TermSquare
Footage		Primary Use
Raritan, NJOwnedN/A569,000 Administrative offices, R&D and manufacturing
Rochester, NY (513 Technology Blvd)OwnedN/A438,628 Manufacturing
San Diego, CA (Summers Ridge)Leased2033 - options to extend for two additional 5-year periods316,531 Administrative offices, sales and marketing, R&D and manufacturing (principal executive offices)
Rochester, NY (100 Indigo Creek)OwnedN/A260,221 Office, R&D
Pencoed, WalesOwnedN/A198,380 Office, manufacturing
Athens, OHLeased2027132,993 Administrative offices, sales and marketing, R&D and manufacturing
Carlsbad, CA (Rutherford)Leased2036 - options to extend for two additional 5-year periods128,745 Manufacturing
Memphis, TNLeased2026116,500 Warehouse
San Diego, CA (Waples Ct.)Leased2031 - options to extend for two additional 5-year periods106,412 Office, light manufacturing, storage, packaging, assembly and distribution
Rochester, NY (130 Indigo Creek)OwnedN/A103,138 Office, R&D
Strasbourg, FranceOwnedN/A97,951 Warehouse, service
Ibaraki, JapanLeased202392,988 Land
Rochester, NY (1000 Lee Road)Leased202489,114 Manufacturing
San Diego, CA (McKellar)OwnedN/A72,863 Administrative offices, R&D and manufacturing
Pompano Beach, FLOwnedN/A21,500 Manufacturing
We believe that our facilities are adequate for our current needs, and we currently do not anticipate any material difficulty in renewing any of our leases as they expire or securing additional or replacement facilities, in each case, on commercially reasonable terms. However, in anticipation of our growth strategy, we may pursue additional facilities.
52

Item 3. Legal Proceedings
The information set forth in “Litigation and Other Legal Proceedings” in Note 12 to the Consolidated Financial Statements is incorporated herein by reference.
Item 4. Mine Safety Disclosures
Not applicable.
53

Part II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is traded on the Nasdaq Global Select Market under the symbol “QDEL.”
As of February 10, 2023, we had approximately 69 common stockholders of record and we do not anticipate paying any cash dividends in the foreseeable future.
Issuer Purchases of Equity Securities    
The table below sets forth information regarding repurchases of our common stock by us during the three months ended January 1, 2023:
PeriodTotal Number of Shares Purchased (1)Average Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (2)
October 3, 2022 - October 30, 2022931 $78.45 — $225,677,460 
October 31, 2022 - November 27, 20224,632 88.23 — 225,677,460 
November 28, 2022 - January 1, 20231,103 89.99 — 225,677,460 
Total6,666 $87.16 — $225,677,460 
(1) Includes shares surrendered, if any, to the Company to satisfy the payment of minimum tax withholding obligations.
(2) On December 18, 2018, Quidel announced a stock repurchase program to repurchase up to $50.0 million of its common stock, which was authorized by Quidel’s board of directors (the “Quidel Board”) on December 12, 2018. On August 28, 2020, the Quidel Board authorized an increase of an additional $150.0 million to Quidel’s existing stock repurchase program authorization, which was announced on September 1, 2020. The Quidel Board also extended the stock repurchase program through August 28, 2022. In connection with the consummation of the Combinations, Quidel’s $150.0 million stock repurchase program was terminated. On August 17, 2022, the Board authorized a stock repurchase program, allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024.
54

STOCKHOLDER RETURN PERFORMANCE GRAPH
Set forth below is a line graph comparing the yearly percentage change in the cumulative total stockholder return on our common stock with the cumulative total returns of the Nasdaq Composite Index and Nasdaq Health Care Index for the five years ended January 1, 2023. The graph assumes (i) an initial investment of $100 as of the market close on December 29, 2017 in our common stock, the Nasdaq Composite Index and the Nasdaq Health Care Index and (ii) reinvestment of dividends. The graph represents stock price performance of Quidel, from fiscal year 2018 through May 27, 2022, and QuidelOrtho following the closing date of the Combinations. The stock price performance of our common stock depicted in the graph represents past performance only and is not necessarily indicative of future performance.
COMPARISON OF 5 YEAR TOTAL CUMULATIVE RETURN
Among QuidelOrtho Corporation, the Nasdaq Composite and the Nasdaq Health Care Composite Indices
qdel-20230101_g1.jpg
Base Period
Company/Index12/31/201712/31/201812/31/201912/31/202012/31/202112/31/2022
QuidelOrtho Corporation$100.00 $112.62 $173.08 $414.42 $311.40 $197.62 
Nasdaq Composite Index$100.00 $97.16 $132.81 $192.47 $235.15 $158.65 
Nasdaq Health Care Composite Index$100.00 $96.37 $121.99 $159.49 $154.53 $123.77 
Item 6. [Reserved]
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion of our financial condition and results of operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve material risks and uncertainties. This discussion should be read in conjunction with the section entitled “Future Uncertainties and Forward-Looking Statements” on page 4 and the “Risk Factors” starting on page 26 of this Annual Report. In addition, our discussion of QuidelOrtho’s financial condition and results of operation
55

s in this Item 7 should be read in conjunction with our Consolidated Financial Statements and the related Notes included elsewhere in this Annual Report.
Overview
Our mission is to develop and manufacture intelligent diagnostic solutions that transform the power of diagnostics into a healthier future for everyone. Our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine helps clinicians and patients make better informed decisions across the globe. Our global infrastructure and commercial reach support our customers across more than 130 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S. and U.K. and with sales centers, administrative offices and warehouses located throughout the world.
We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as for individual, non-professional, OTC use. We reached significant new markets as we introduced our QuickVue At-Home OTC COVID-19 test for at-home consumer use, school districts, health departments and many other locations.
Beginning in the second quarter of 2022, in connection with the Combinations and in order to manage our business to better align with the market dynamics of the specific geographic regions in which we operate, we changed the manner in which we review our performance and allocate resources. As a result, we changed from one reportable segment to the following three geographically-based reportable segments: North America; EMEA; and China. Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” We generate our revenue primarily in the following business units: Labs, Transfusion Medicine, Point of Care and Molecular Diagnostics.
For fiscal year 2022, Total revenues increased by 92% to $3,266.0 million as compared to the prior year. Currency exchange rates had an unfavorable impact of 300 basis points on our growth rate. For fiscal year 2021, Total revenues increased by 2% to $1,698.6 million as compared to the prior year. Currency exchange rates had a minimal impact on the growth rate. Our revenues can be highly concentrated over a small number of products. For fiscal years 2022, 2021 and 2020, sales of our COVID-19 products accounted for approximately 44%, 75% and 70% of our Total revenues, respectively. For fiscal years 2022, 2021 and 2020, sales of our influenza products accounted for 11%, 4% and 8% of our Total revenues, respectively. Two of our customers, including one of our distributors, exceeded 10% of our Total revenues for fiscal year 2022. In fiscal year 2021, one distributor exceeded 10% of our Total revenues. In fiscal year 2020, four of our distributors exceeded 10% of our Total revenues.
Recent Developments
On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. For additional information about the Combinations, see Note 1 under the section “Organization and Business” and Note 2 under the section “Business Combination” to the Consolidated Financial Statements.
The Combinations were completed for total consideration of approximately $4.3 billion (which is based on the May 26, 2022 closing price of $99.60 per share of Quidel common stock), including $1.7 billion of cash, funded through cash on our balance sheet and incremental borrowings. The Combinations have been accounted for as a business combination using the acquisition method of accounting in conformity with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations.
Commencing from the closing date of the Combinations, our financial statements include the assets, liabilities, operating results and cash flows of Ortho. The revenues related to Ortho are included in the Labs and Transfusion Medicine business units and the results of operations are included within each of our reportable segments, as described in Note 5 to the Consolidated Financial Statements.
Impact of the COVID-19 Pandemic
The healthcare challenge and other impacts surrounding the SARS-CoV-2 virus that emerged in late 2019 and the ensuing global pandemic have presented significant business uncertainty and had a dramatic impact on businesses globally, including ours. As the COVID-19 pandemic reaches an endemic state, the degree to which it continues to impact our business operations, strategy, financial condition and results of operations will depend on future developments that are uncertain and difficult to predict. Although COVID-19 infection rates and severity have decreased recently, the occurrence, spread, severity and duration of any new outbreaks or resurgences, including the emergence and spread of new variants of COVID-19, actions taken to contain the resurgences or variants, and economic repercussions of the virus remain uncertain. We continue to evaluate the nature and extent to which COVID-19 may impact our business and operations and adjust risk mitigation planning and business continuity activities as needed.
56

SARS-CoV-2 Diagnostic Products
As a leader in POC diagnostics and with established expertise in respiratory infectious disease products, we were and remain well-positioned to respond to the COVID-19 pandemic. We have and continue to work closely with national and local governments, agencies, and industry partners to develop, manufacture and supply critical diagnostic products to support testing initiatives to help curb the spread of the SARS-CoV-2 virus, including resurgences and variants. In particular, we developed molecular and antigen products to diagnose the SARS-CoV-2 virus. We also committed significant resources toward the expansion of our production capacity to manufacture and supply these products. We have experienced significant volatility in demand for these products since their launch, with periods of significant demand and periods where we experienced dramatic decreases in demand. At the same time, we also have observed fluctuating demand for certain of our other diagnostic products. Demand for our products to identify the SARS-CoV-2 virus has fluctuated in line with a range of factors, including the prevalence of the SARS-CoV-2 virus and its variants, the supply of COVID-19 tests generally, the purchasing activity of government entities, and the dissemination and effectiveness of vaccinations. The extent to which COVID-19 will continue to impact demand for our products depends on these and future developments, which are highly uncertain and difficult to predict, including new information that may emerge concerning the severity of COVID-19 resurgences, regulatory changes in any of the markets in which we serve, the impact of new SARS-CoV-2 variants and actions to contain and treat their impact.
Operations and Employee Safety
We have been able to maintain our operations without significant interruption and have been able to develop and quickly scale manufacturing capacity for new products related to the COVID-19 pandemic. However, pandemic-related lockdowns and other responses to the pandemic in a number of countries have adversely impacted, and for some continue to adversely impact, our business operations in those countries. For example, lockdowns in China have impacted our business operations in that country. The adverse impacts of these measures were not material to our results of operations for the fiscal year ended January 1, 2023. We continue to monitor potential further impacts from these measures and the other issues noted above regarding our business.
As a result of the COVID-19 pandemic, we have implemented steps to protect our employees. Our office-based work sites in the U.S. are subject to operating restrictions consistent with applicable health guidelines.
Supply Chains
As a result of the COVID-19 pandemic and other macroeconomic and geopolitical conditions, including inflationary pressures, general economic slowdown or a recession, rising interest rates, foreign exchange rate volatility and changes in monetary policy, we have experienced shortages and delays in receiving certain raw materials and other components for our products and have experienced logistics and distribution challenges, as well as challenges in labor availability and rising labor costs, all of which have affected our ability to fulfill customer orders, including instrument placements, on a timely basis. Supply chain, production, logistics and distribution challenges, including shortages of raw materials and components, cost inflation, shipping delays, labor availability constraints and rising labor costs, have impacted, and we expect will continue for some period of time to impact, our results of operations.
Some of our raw materials are available from a limited number of sources. During 2022, we encountered some increasing pressures on raw material pricing. To mitigate these supply chain challenges, we are (i) partnering with suppliers to invest in additional capacity and raw material inventory, (ii) diversifying our supply base, where possible, to minimize reliance on a single source of supply for key raw materials and components and (iii) creating redundancy in our global supply chain. In addition, we routinely evaluate our supply chain for potential gaps and continue to take other steps intended to help address continuity. In our distribution operations, we are investing in automation capabilities to help improve accuracy and timeliness of customer shipments.
We continue to monitor these developments, as well as other international developments, including the Russia-Ukraine conflict, rising tensions between China and Taiwan and localization efforts, and the impact of such factors on our business. We cannot currently predict the frequency, duration or scope of these supply, production, logistics, distribution and labor disruptions and challenges. However, we proactively work with our suppliers, manufacturers, distributors, industry partners and government agencies to address these challenges in our efforts to meet the needs of our customers. Despite our mitigation efforts, such disruptions and challenges have and could further materially affect our ability to timely manufacture and distribute our products and unfavorably impact our results of operations depending on the nature and duration of such challenges.
Outlook
Our financial performance and results of operations will depend on future developments and other factors that are highly uncertain, continuously evolving and unpredictable, including the occurrence, spread, severity and duration of any new outbreaks and resurgences of COVID-19, the emergence and spread of new variants of COVID-19, and the ongoing supply, production and logistics challenges.
57

Demand for our COVID-19 testing products declined in the second half of 2022 compared to both the first half of 2022 and the second half of 2021, which may indicate the beginning of a transition to an endemic environment. For 2023, we expect demand for our COVID-19 testing products to fluctuate and pricing pressures to continue as a result of a number of factors, including increased supply, emergence and spread of new variants, effectiveness of global containment efforts and other mitigation efforts. However, in light of our experience to date with the virus and the emergence and impact of new variants, we believe some level of COVID-19 testing may continue for some period of time, even as communities return to more normal practices. We would expect any such normalized demand to continue to experience fluctuations, which may be significant. With respect to our core products, excluding respiratory products, we anticipate revenue growth for 2023.
Because our business environment is highly competitive, our long-term growth and profitability will depend in part on our ability to retain and grow our current customers and attract new customers through developing and delivering new and improved products and services that meet our customers’ needs and expectations, including with respect to product performance, product offerings, cost, automation and other work-flow efficiency. As a result, we expect to continue to maintain our emphasis on R&D investments for longer term growth, including for our next generation platforms and assays, as well as additional assays to be launched on our current platforms. In addition, we expect to continue to evaluate strategic opportunities to expand our product lines and services, production capabilities, technologies and geographic footprint and address other business challenges and opportunities.
While the revenues and financial results from our COVID-19 products are uncertain, we intend to continue our focus on prudently managing our business and delivering improved financial results, while at the same time striving to introduce new products and services into the market.
Results of Operations
Comparison of fiscal years ended 2022, 2021 and 2020
Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31. Fiscal years 2022 and 2021 were 52 weeks and fiscal year 2020 was 53 weeks.
Revenues
The following table compares Total revenues by business unit for fiscal years 2022, 2021 and 2020:
Fiscal Year Ended
(Dollars in millions)202220212020% Change 2022 vs. 2021% Change 2021 vs. 2020
Labs$820.2 $44.8 $50.9 1,731 %(12)%
Transfusion Medicine393.8 — — N/AN/A
Point of Care1,955.3 1,453.3 1,387.8 35 %5 %
Molecular Diagnostics96.7 200.5 223.0 (52)%(10)%
Total revenues$3,266.0 $1,698.6 $1,661.7 92 %2 %
For fiscal year 2022, Total revenues increased to $3,266.0 million from $1,698.6 million for the prior year. The increases in Labs and Transfusion Medicine were primarily related to new revenues from the Combinations. The Point of Care business unit contributed to revenue growth, driven primarily by an increase of $586.1 million in sales of QuickVue SARS Antigen assays, partially offset by lower sales of Sofia assays and $46.7 million lower BNP sales due to the transition of the BNP Business to Beckman. The decrease in revenues related to the transition of the BNP Business did not materially impact our gross profit. Molecular Diagnostics sales decreased by $103.8 million, driven primarily by lower demand and pricing of the Lyra SARS Antigen assay. Currency exchange rate had an unfavorable impact of approximately 300 basis points on the growth rate for fiscal year 2022.
For fiscal year 2021, Total revenues increased to $1,698.6 million from $1,661.7 million for the prior year. The Point of Care business unit was the largest contributor to revenue growth, driven by sales of the QuickVue SARS Antigen assay. Additionally, sales of our other products within our Point of Care business unit increased over the prior year as COVID-19 restrictions began to be lifted and sales of our Triage products approached pre-pandemic levels. Growth in our Triage business was partially offset by lower revenues recognized for the Beckman BNP products due to the transition of this business to Beckman in August 2021. Molecular Diagnostics sales decreased by $22.5 million, driven primarily by decreased pricing for the Lyra SARS Antigen assay, partially offset by higher sales of the Solana SARS Antigen assay. The decrease in Labs sales over the prior year was driven by lower sales of our cell culture products, primarily due to the lack of a respiratory season in early 2021. Favorable currency exchange rate impact for fiscal year 2021 had a minimal impact on the growth rate.
58

Cost of Sales, Excluding Amortization of Intangible Assets
Cost of sales, excluding amortization of intangible assets, increased to $1,330.0 million, or 40.7% of Total revenues, for fiscal year 2022, compared to $420.3 million, or 24.7% of Total revenues, for fiscal year 2021. The increase in cost of sales, excluding amortization of intangible assets, was driven primarily by a large increase in sales of QuickVue SARS Antigen assays in 2022, as well as new product sales in the Labs and Transfusion Medicine business units as a result of the Combinations. We also recorded $60.6 million of expense related to the amortization of the inventory fair value adjustment related to the Combinations during fiscal year 2022. There were also increases in supply chain and other indirect manufacturing costs, which were only partially offset by increased absorption driven by higher production volumes.
Cost of sales, excluding amortization of intangible assets, increased to $420.3 million, or 24.7% of Total revenues, for fiscal year 2021, compared to $305.4 million, or 18.4% of Total revenues, for fiscal year 2020. The increase in cost of sales, excluding amortization of intangible assets, was driven primarily by a shift in product mix from Sofia SARS products to QuickVue SARS products and lower selling prices for our SARS products in fiscal year 2021. Increases in supply chain and other indirect manufacturing costs were more than offset by increased absorption driven by higher production volumes.
Operating Expenses
The following table summarizes operating expenses for fiscal years 2022, 2021 and 2020:
Fiscal Year Ended
(Dollars in millions)2022% of
Total Revenues		2021% of
Total Revenues		2020% of
Total Revenues
Selling, marketing and administrative$621.0 19.0 %$239.6 14.1 %$180.7 10.9 %
Research and development190.5 5.8 %95.7 5.6 %84.3 5.1 %
Amortization of intangible assets132.5 4.1 %27.4 1.6 %27.3 1.6 %
Acquisition and integration costs136.0 4.2 %9.6 0.6 %3.7 0.2 %
Other operating expense, net12.3 0.4 %— — %— — %
Selling, Marketing and Administrative Expenses
Selling, marketing and administrative expenses for fiscal year 2022 increased by $381.4 million, or 159.2%, to $621.0 million from $239.6 million for the prior year, driven primarily by the Combinations which contributed $326.5 million in increased expense, freight expense due to higher sales volume and expedited shipping, product promotional spend associated with the QuickVue At-Home OTC COVID-19 test, professional fees and employee-related costs.
Selling, marketing and administrative expenses for fiscal year 2021 increased by $58.9 million, or 32.6%, to $239.6 million from $180.7 million for the prior year, driven primarily by higher freight expense from greater shipment volumes, higher promotional spending associated with the launch of the QuickVue At-Home OTC COVID-19 test, higher labor costs and increased travel and meeting costs as COVID-19 related travel restrictions eased, partially offset by reduced bad debt expense. The increase was also related to higher compensation costs from increased headcount to support the growth of the business experienced during fiscal year 2021, and higher charitable contributions and stock compensation expense.
Research and Development Expense
Research and development expense for fiscal year 2022 increased by $94.8 million, or 99.1%, to $190.5 million from $95.7 million for the prior year, primarily due to the Combinations which contributed $86.0 million in increased expense, as well as increased costs related to SARS, Sofia and Savanna projects, and increased costs related to compensation driven by increased headcount and clinical trials.
Research and development expense for fiscal year 2021 increased by $11.4 million, or 13.5%, to $95.7 million from $84.3 million for the prior year, primarily due to increased costs related to the Savanna and QuickVue OTC projects, partially offset by decreased spending on Sofia projects. We also incurred higher labor, materials and clinical trials costs as a result of the COVID-19 product development.
Amortization of Intangible Assets
Amortization of intangible assets for fiscal years 2022, 2021 and 2020 was $132.5 million, $27.4 million and $27.3 million, respectively. The increase in amortization expense in fiscal year 2022 compared to the prior year periods was primarily due to the Combinations.
59

Acquisition and Integration Costs
Acquisition and integration costs were $136.0 million, $9.6 million and $3.7 million for fiscal years 2022, 2021 and 2020, respectively. The increase in costs in fiscal year 2022 was primarily due to transaction and integration-related costs attributable to the Combinations. Costs in the prior year periods were primarily related to the evaluation of new business development opportunities, including the Combinations.
Other Operating Expense, Net
Other operating expense, net was $12.3 million for fiscal year 2022, which was related to the profit share expense for our Joint Business with Grifols acquired in connection with the Combinations.
Non-operating Expenses
The following table summarizes non-operating expenses, net for fiscal years 2022, 2021 and 2020:
Fiscal Year Ended
(Dollars in millions)202220212020% Change 2022 vs. 2021% Change 2021 vs. 2020
Interest expense, net$75.7 $5.8 $8.5 N/M(31.8)%
Loss on extinguishment of debt24.0 — 10.4 N/M(100.0)%
Other expense (income), net8.1 (0.1)1.1 N/MN/M
* N/M - Not meaningful
Interest Expense, Net
Interest expense, net was $75.7 million, $5.8 million and $8.5 million for fiscal years 2022, 2021 and 2020, respectively. The increase in interest expense, net in fiscal year 2022 compared to the prior year periods was primarily related to the new Term Loan under the Credit Agreement entered into in connection with the Combinations. See Note 8 to the Consolidated Financial Statements for more information related to our Term Loan.
Interest expense, net prior to the Combinations primarily related to accretion of interest on the deferred consideration, coupon and accretion of interest related to our 3.25% Convertible Senior Notes due 2020 (“Convertible Notes”) (in fiscal year 2020) and interest and amortization of deferred financing costs associated with our previous credit agreement. Interest expense, net for fiscal year 2021 decreased to $5.8 million from $8.5 million for the prior year. The decrease compared to the prior year was primarily due to the maturity of our Convertible Notes in December 2020 and lower deferred consideration liability outstanding during fiscal year 2021.
Loss on Extinguishment of Debt
Loss on extinguishment of debt was $24.0 million for fiscal year 2022, and was related to the extinguishment of the senior notes and former term loans and the revolving credit facility of Ortho in connection with the Combinations.
Loss on extinguishment of debt was $10.4 million for fiscal year 2020, and was related to the extinguishment of $5.9 million in aggregate principal amount of the Convertible Notes, which were converted and settled in cash during the period.
Other Expense (Income), Net
Other expense (income), net was $8.1 million, $(0.1) million and $1.1 million for fiscal years 2022, 2021 and 2020, respectively. Other expense, net in fiscal year 2022 compared to income in fiscal year 2021 was primarily related to net foreign currency losses and loss on investment, partially offset by fair value gains in interest rate caps. Other expense, net during fiscal year 2020 was primarily related to an unfavorable change in fair value of derivative liabilities associated with the Convertible Notes conversion in fiscal year 2020.
Income Taxes
For fiscal years 2022 and 2021, we recognized income tax provisions of $187.2 million in relation to income before taxes of $735.9 million, and $196.1 million in relation to income before taxes of $900.3 million, respectively, resulting in effective tax rates of 25.4% and 21.8%, respectively. The lower tax expense for fiscal year 2022 compared to the prior year was primarily due to a decrease in pre-tax profits and state taxes, foreign income taxed at rates other than the applicable U.S. rate, and an increased deduction for foreign derived intangible income (FDII), partially offset by increases in non-deductible executive compensation, Global Intangible Low-Taxed Income and acquisition-related costs.
60

We recognized an income tax provision of $196.1 million, resulting in an effective tax rate of 21.8% for fiscal year 2021. This effective tax rate is comparable to the effective tax rate of 22.1% for fiscal year 2020. In both years, the effective tax rate differed from the federal statutory rate of 21% due to increases from the state tax provision, slightly offset by tax benefits from the foreign-derived intangible income deduction, excess stock-based compensation deductions and federal and state research credits.
Indemnification Assets
On January 16, 2014, Ortho entered into a stock and asset purchase agreement of (i) certain assets and liabilities and (ii) all of the equity interests and substantially all of the assets and liabilities of certain entities, which, together with their subsidiaries, comprised the Ortho business from Johnson & Johnson. The agreement generally provided that Johnson & Johnson retained all income tax liabilities accrued as of the date of the acquisition, including reserves for unrecognized tax benefits. The indemnification receivable from Johnson & Johnson totaled $16.8 million as of January 1, 2023 and is included as a component of Prepaid expenses and other current assets and Other assets on the Consolidated Balance Sheet. We recorded $0.4 million of interest and penalties during fiscal year 2022.
Segment Results
In the quarter ended July 3, 2022, following the completion of the Combinations, we changed the manner in which we evaluate performance and allocate resources. As a result, we began to operate under three geographically-based reportable segments: North America; EMEA; and China. Our operations in Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” In the fourth quarter of 2022, we revised the internal allocation of certain global costs primarily between the North America segment and Corporate to better align costs that impact us as a whole. Prior periods have been revised to align with the current period presentation.
The key indicators that we monitor are as follows:
•Total revenues — This measure is discussed in the section entitled “Results of Operations.”
•Adjusted EBITDA — Adjusted EBITDA by reportable segment is used by our management to measure and evaluate the internal operating performance of our reportable segments. It is also the basis for calculating certain management incentive compensation programs. We believe that this measurement is useful to investors as a way to analyze the underlying trends in our core business, including at the segment level, consistently across the periods presented and to evaluate performance under management incentive compensation programs. Adjusted EBITDA consists of Net income before Interest expense, net, Provision for (benefit from) income taxes and depreciation and amortization and eliminates (i) certain non-operating income or expense items, and (ii) impacts of certain noncash, unusual or other items that are included in net income and that we do not consider indicative of our ongoing operating performance. See Note 5 to the Consolidated Financial Statements for a reconciliation of Adjusted EBITDA by reportable segment to Income before provision for income taxes.
North America
Total revenues and Adjusted EBITDA for North America were as follows:
Fiscal Year Ended
(Dollars in millions)202220212020% Change 2022 vs. 2021% Change 2021 vs. 2020
Total revenues$2,536.5 $1,500.2 $1,460.7 69 %3 %
Adjusted EBITDA$1,614.6 $1,028.5 $1,205.2 57 %(15)%
Total revenues were $2,536.5 million for fiscal year 2022, compared to Total revenues of $1,500.2 million for fiscal year 2021. During fiscal year 2022, the impact of the Combinations contributed $607.3 million to Total revenues. The remaining increase of $429.0 million was driven primarily by increased demand for the QuickVue SARS Antigen assays and non-SARS related rapid tests, partially offset by a decrease in revenues for the Sofia SARS Antigen assay.
Total revenues were $1,500.2 million for fiscal year 2021, compared to Total revenues of $1,460.7 million for fiscal year 2020. The increase of $39.5 million was driven primarily by increased demand for the QuickVue SARS Antigen assays, offset by a decrease in revenues for the Sofia SARS Antigen assay.
Adjusted EBITDA was $1,614.6 million for fiscal year 2022, compared to Adjusted EBITDA of $1,028.5 million for fiscal year 2021. During fiscal year 2022, the impact of the Combinations contributed $260.7 million to Adjusted EBITDA. The remaining increase of $325.4 million was driven primarily by increased revenues, partially offset by increased distribution and selling costs.
61

Adjusted EBITDA was $1,028.5 million for fiscal year 2021, compared to Adjusted EBITDA of $1,205.2 million for fiscal year 2020. The decrease of $176.7 million was driven primarily by increased distribution and selling costs.
EMEA
Total revenues and Adjusted EBITDA for EMEA were as follows:
Fiscal Year Ended
(Dollars in millions)202220212020% Change 2022 vs. 2021% Change 2021 vs. 2020
Total revenues$206.8 $69.6 $92.9 197 %(25)%
Adjusted EBITDA$31.7 $28.1 $55.5 13 %(49)%
Total revenues were $206.8 million for fiscal year 2022, compared to Total revenues of $69.6 million for fiscal year 2021. During fiscal year 2022, the impact of the Combinations contributed $146.2 million to Total revenues. The remaining decrease of $9.0 million was primarily driven by lower Point of Care revenues due to lower BNP sales from the transition of the BNP Business to Beckman.
Total revenues were $69.6 million for fiscal year 2021, compared to Total revenues of $92.9 million for fiscal year 2020. During fiscal year 2021, Total revenues decreased by $23.3 million, primarily due to lower Molecular Diagnostics and Point of Care revenues, driven by lower Lyra SARS Antigen assay sales.
Adjusted EBITDA was $31.7 million for fiscal year 2022, compared to Adjusted EBITDA of $28.1 million for fiscal year 2021. During fiscal year 2022, the impact of the Combinations contributed $18.1 million to Adjusted EBITDA. The remaining decrease of $14.5 million was driven primarily by lower revenues and increased selling costs.
Adjusted EBITDA was $28.1 million for fiscal year 2021, compared to Adjusted EBITDA of $55.5 million for fiscal year 2020. During fiscal year 2021, Adjusted EBITDA decreased $27.4 million, driven primarily by lower revenues.
China
Total revenues and Adjusted EBITDA for China were as follows:
Fiscal Year Ended
(Dollars in millions)202220212020% Change 2022 vs. 2021% Change 2021 vs. 2020
Total revenues$220.0 $58.0 $62.4 279 %(7)%
Adjusted EBITDA$104.1 $24.1 $30.5 332 %(21)%
Total revenues were $220.0 million for fiscal year 2022, compared to Total revenues of $58.0 million for fiscal year 2021. During fiscal year 2022, the impact of the Combinations contributed $161.3 million to Total revenues. The remaining increase of $0.7 million was primarily driven by increased Point of Care revenues, partially offset by lower BNP sales due to the transition of the BNP Business to Beckman.
Total revenues were $58.0 million for fiscal year 2021, compared to Total revenues of $62.4 million for fiscal year 2020. The decrease of $4.4 million was primarily due to decreased Point of Care revenues, driven by lower BNP sales due to the transition of the BNP Business to Beckman.
Adjusted EBITDA was $104.1 million for fiscal year 2022, compared to Adjusted EBITDA of $24.1 million for fiscal year 2021. During fiscal year 2022, the Combinations were the primary driver of the increase, which contributed $80.7 million to Adjusted EBITDA.
Adjusted EBITDA was $24.1 million for fiscal year 2021, compared to Adjusted EBITDA of $30.5 million for fiscal year 2020. During fiscal year 2021, Adjusted EBITDA decreased $6.4 million, driven primarily by lower revenues.
62

Other
Total revenues and Adjusted EBITDA for Other, which includes our Latin America, Japan and Asia Pacific operating segments, were as follows:
Fiscal Year Ended
(Dollars in millions)202220212020% Change 2022 vs. 2021% Change 2021 vs. 2020
Total revenues$302.7 $70.8 $45.7 328 %55 %
Adjusted EBITDA$92.7 $43.0 $28.0 116 %54 %
Total revenues were $302.7 million for fiscal year 2022, compared to Total revenues of $70.8 million for fiscal year 2021. During fiscal year 2022, the impact of the Combinations contributed $250.5 million to Total revenues. The remaining decrease of $18.6 million was primarily due to lower Point of Care revenues, driven primarily by lower demand for QuickVue SARS Antigen and Sofia assays.
Total revenues were $70.8 million for fiscal year 2021, compared to Total revenues of $45.7 million for fiscal year 2020. During fiscal year 2021, Total revenues increased $25.1 million, primarily due to higher Point of Care revenues, driven by higher demand for QuickVue SARS Antigen and Sofia assays.
Adjusted EBITDA was $92.7 million for fiscal year 2022, compared to Adjusted EBITDA of $43.0 million for fiscal year 2021. During fiscal year 2022, the impact of the Combinations contributed $62.9 million to Adjusted EBITDA. The remaining decrease of $13.2 million was driven primarily by lower revenues.
Adjusted EBITDA was $43.0 million for fiscal year 2021, compared to Adjusted EBITDA of $28.0 million for fiscal year 2020. During fiscal year 2021, Adjusted EBITDA increased $15.0 million, driven primarily by higher revenues.
Liquidity and Capital Resources
As of January 1, 2023 and January 2, 2022, the principal sources of liquidity consisted of the following:
(Dollars in millions)January 1,
2023		January 2,
2022
Cash and cash equivalents$292.9 $802.8 
Marketable securities, current52.1 25.7 
Marketable securities, non-current21.0 37.9 
Total cash, cash equivalents and marketable securities$366.0 $866.4 
Amount available to borrow under the Revolving Credit Facility$786.9 $175.0 
Working capital including cash and cash equivalents and marketable securities, current$568.1 $1,116.8 
As of January 1, 2023, we had $292.9 million in Cash and cash equivalents, a $509.9 million decrease from January 2, 2022. Our cash requirements fluctuate as a result of numerous factors, including cash generated from operations, progress in R&D, capital expansion projects and acquisition and business development activities. On May 27, 2022, we completed the Combinations for total consideration of $4,291.1 million (which is based on the May 26, 2022 closing price of $99.60 per share of Quidel common stock), including $1,747.7 million of cash, net of cash and restricted cash acquired, funded through cash on our balance sheet and incremental borrowings. The incremental borrowings, described below, were also used to repay substantially all of Ortho’s then-outstanding indebtedness. We believe our organizational structure allows us the necessary flexibility to move funds throughout our subsidiaries to meet our operational working capital needs.
Debt Capitalization
On May 27, 2022, we entered into the Credit Agreement by and among us, as borrower, Bank of America, as administrative agent and swing line lender, and the other Lenders party thereto. Pursuant to the Credit Agreement and in connection with the consummation of the Combinations, the Lenders provided us with a $2,750.0 million Term Loan and a $750.0 million Revolving Credit Facility. Effective August 4, 2022, pursuant to the Increase Joinder No. 1 to the Credit Agreement, the Revolving Credit Facility was increased by $50.0 million to $800.0 million. The Financing is guaranteed by the Guarantors and is secured by liens on substantially all of our and the Guarantors’ assets, excluding real property and certain other types of excluded assets. Loans under the Credit Agreement will bear interest at a rate per annum equal to the Term SOFR or Base Rate plus the Applicable Rate (each as defined in the Credit Agreement). As of January 1, 2023, letters of credit issued under the
63

Revolving Credit Facility totaled $13.1 million, which reduced the available amount under the Revolving Credit Facility to $786.9 million.
The Term Loan is subject to quarterly amortization of the principal amount on the last business day of each of our fiscal quarters (commencing on September 30, 2022). The required quarterly payments are 1.875% of the aggregate initial principal amount of the Term Loan through the fiscal second quarter of 2024, and 1.250% thereafter. The final remaining principal installment is due on the maturity date. The Term Loan and the Revolving Credit Facility will mature on May 27, 2027. We must prepay loans outstanding under the Credit Agreement in an amount equal to the Net Cash Proceeds from (i) certain property dispositions and (ii) the receipt of certain other amounts not in the ordinary course of business, such as certain insurance proceeds and condemnation awards, in each case, if not reinvested within a specified time period as contemplated in the Credit Agreement.
The Credit Agreement contains affirmative and negative covenants that are customary for credit agreements of this nature. The negative covenants include, among other things, limitations on asset sales, mergers, indebtedness, liens, investments and transactions with affiliates. The Credit Agreement contains two financial covenants: (i) a maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) as of the last day of each fiscal quarter of (a) 4.50 to 1.00 for the Initial Measurement Period, (b) 4.00 to 1.00 for the first four fiscal quarters ending after the Initial Measurement Period and (c) 3.50 to 1.00 for each fiscal quarter thereafter; and (ii) a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of 3.00 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters. We were in compliance with the financial covenants as of January 1, 2023.
The Credit Agreement was entered into in connection with the Combinations in order to fund a portion of the cash portion of the purchase price as well as to repay substantially all of Ortho’s then-outstanding indebtedness. See Note 2 to the Consolidated Financial Statements for further discussion of the Combinations. In connection with the closing of the Combinations, Quidel terminated its previous $175.0 million revolving credit facility and related credit agreement on May 27, 2022, which did not have an outstanding balance.
In connection with the acquisition of the BNP Business, we had an annual installment payment of $48.0 million payable in 2022 and will have an annual installment payment of $40.0 million payable in 2023. As of January 1, 2023, the remaining payment was recorded at fair value as contingent consideration of $0.1 million and deferred consideration of $39.3 million.
In connection with the Combinations, the Company acquired a receivables purchase agreement (the “RPA”), entered into on June 11, 2021, by and among Ortho-Clinical Diagnostics US FinanceCo I, LLC (“Ortho FinanceCo I”), a wholly owned receivables financing subsidiary of the Company, Wells Fargo Bank, N.A., as administrative agent (the “Agent”), Ortho-Clinical Diagnostics, Inc. (“Ortho,” the “Master Servicer”), and certain Purchasers, as amended on July 20, 2022 (the “RPA Amendment”). Under the RPA, Ortho FinanceCo I may sell receivables in amounts up to a $75.0 million limit, subject to certain conditions, including that, at any date of determination, the aggregate capital paid to Ortho FinanceCo I does not exceed a “capital coverage amount,” equal to an adjusted net receivables pool balance minus a required reserve. Ortho FinanceCo I has guaranteed the prompt payment of the sold receivables, and to secure the prompt payment and performance of such guaranteed obligations, Ortho FinanceCo I has granted a security interest to the Agent, for the benefit of the Purchasers, in all assets of Ortho FinanceCo I. Ortho, in its capacity as Master Servicer under the RPA, is responsible for administering and collecting the receivables and has made customary representations, warranties, covenants and indemnities. The Company has also provided a performance guaranty for the benefit of Ortho FinanceCo I to cause the due and punctual performance by Ortho of its obligations as Master Servicer. The RPA Amendment resulted in a net 50 basis-point reduction of fees and revision of the base interest rate from 1-month LIBOR to 1-month SOFR.
Stock Repurchases
On August 17, 2022, the Board authorized the Stock Repurchase Program, allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024. The Stock Repurchase Program does not obligate the Company to acquire any specific number of shares. Under the Stock Repurchase Program, shares of common stock may be repurchased using a variety of methods, including privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Exchange Act, as part of accelerated stock repurchases and other methods. The timing, manner, price and amount of any repurchases are determined by the Company in its discretion and depend on a variety of factors, including legal requirements, price and economic and market conditions. For the fiscal year ended January 1, 2023, the Company repurchased 953,468 shares of outstanding common stock under the Stock Repurchase Program for approximately $74.3 million. The repurchased shares were retired and returned to the status of authorized but unissued shares of our common stock. As of January 1, 2023, we had approximately $225.7 million available under the Stock Repurchase Program.
64

Cash Flow Summary
Fiscal Year Ended
(In millions)202220212020
Net cash provided by operating activities:$885.3 $805.9 $629.7 
Net cash used for investing activities:(1,644.2)(319.5)(63.3)
Net cash provided by (used for) financing activities:252.0 (173.1)(130.3)
Effect of exchange rates on cash(2.0)(0.4)1.0 
Net (decrease) increase in cash, cash equivalents and restricted cash$(508.9)$312.9 $437.1 
Fiscal Year Ended January 1, 2023
Cash provided by operating activities was $885.3 million for fiscal year 2022, and reflected net income of $548.7 million and non-cash adjustments of $389.8 million, primarily associated with depreciation and amortization, stock-based compensation expense, deferred income taxes, loss on extinguishment of debt and amortization of the inventory fair value step up initially recorded in connection with the Combinations. In addition, we benefited from collections on accounts receivables, which contributed $150.2 million to Cash provided by operating activities, partially offset by net cash outflows related to inventories, prepaid and other current and non-current assets and liabilities as well as income taxes payable and other current and non-current liabilities.
Cash used for investing activities was $1,644.2 million for fiscal year 2022, and was primarily related to the Combinations. We purchased $140.9 million of property, equipment, investments and intangibles and received $18.4 million of proceeds from government assistance allocated to fixed assets. We also purchased $63.7 million and sold $53.4 million of marketable securities during fiscal year 2022. See Note 2 to the Consolidated Financial Statements for further discussion regarding the Combinations.
Cash provided by financing activities was $252.0 million for fiscal year 2022, and was primarily related to proceeds from long-term borrowings, net of debt issuance costs of $2,734.5 million, payments on long-term borrowings and extinguishment costs of $2,388.3 million, repurchases of common stock of $74.3 million and payments of $37.7 million for contingent and deferred consideration.
Fiscal Year Ended January 2, 2022
Cash provided by operating activities was $805.9 million for fiscal year 2021, and reflected net income of $704.2 million and non-cash adjustments of $104.5 million, primarily associated with depreciation and amortization, stock-based compensation expense and accretion of interest on deferred consideration. Partially offsetting these inflows was a net working capital use of cash of $30.7 million, primarily driven by an increase in product inventory associated with the increased demand due to the COVID-19 pandemic and a decrease in income taxes payable, partially offset by a decrease in accounts receivable.
Cash used for investing activities was $319.5 million for fiscal year 2021, and was primarily related to investments in manufacturing equipment, building improvements, Sofia, Solana and Triage instruments available for lease and scientific equipment, partially offset by government proceeds received to fund such investments. Additionally, we purchased $67.4 million of available-for-sale securities and sold $3.8 million of our available-for-sale securities during 2021.
Cash used for financing activities was $173.1 million for fiscal year 2021, and was primarily related to repurchases of common stock of $103.5 million, payments of tax withholdings for vesting of stock-based awards of $37.1 million, and the payment of deferred and contingent consideration of $39.8 million, partially offset by proceeds of $7.6 million from the issuance of common stock under the ESPP and pursuant to stock option exercises.
Fiscal Year Ended January 3, 2021
Cash provided by operating activities was $629.7 million for fiscal year 2020, and reflected net income of $810.3 million and non-cash adjustments of $70.6 million, primarily associated with depreciation and amortization, stock-based compensation expense, deferred taxes, loss on extinguishment of debt and accretion of interest on deferred consideration. Partially offsetting these inflows was a net working capital use of cash of $251.2 million primarily driven by increases in accounts receivable and product inventory, partially offset by increases in income taxes payable and accounts payable.
Cash used for investing activities was $63.3 million for fiscal year 2020, and was primarily related to investments in manufacturing equipment, Sofia, Solana and Triage instruments available for lease, building improvements and purchases of scientific equipment.
Cash used for financing activities was $130.3 million for fiscal year 2020, and was primarily related to repurchases of common stock of $43.7 million, payment of Convertible Notes and derivative liability of $43.4 million, payments of deferred
65

consideration of $42.0 million and acquisition contingent consideration of $6.0 million, partially offset by proceeds of $9.6 million from the issuance of common stock under the ESPP and pursuant to stock option exercises.
Liquidity Outlook
Short-term Liquidity Outlook
Our primary source of liquidity, other than our holdings of Cash and cash equivalents, has been cash flows from operations. Cash generated from operations provides us with the financial flexibility we need to meet normal operating, investing and financing needs. We anticipate that our current Cash and cash equivalents, together with cash provided by operating activities and amounts available under our Revolving Credit Facility, will be sufficient to fund our near-term capital and operating needs for at least the next 12 months.
Normal operating needs include the planned costs to operate our business, including amounts required to fund working capital, R&D and capital expenditures. Our primary short-term needs for capital, which are subject to change, include expenditures related to:
•interest on and repayments of our long-term borrowings, deferred consideration, contingent consideration and lease obligations;
•acquisitions of equipment and other fixed assets in support of our manufacturing facility expansion;
•the continued advancement of R&D efforts;
•our integration of the Ortho business arising from the Combinations;
•support of commercialization efforts related to our current and future products, including support of our direct sales force and field support resources; and
•potential strategic acquisitions and investments.
Due to the risks inherent in the product development process, we are unable to estimate with meaningful certainty the costs we will incur in the continued development of our product candidates for commercialization. Our R&D costs may be substantial as we move product candidates into preclinical and clinical trials and advance our existing product candidates into later stages of development.
The primary purposes of our capital expenditures are to invest in manufacturing capacity expansion, acquire certain of our instruments, acquire scientific equipment, purchase or develop IT and implement facility improvements. We plan to fund the capital expenditures with the cash on our balance sheet.
We are focused on expanding the number of instruments placed in the field and solidifying long-term contractual relationships with customers. In order to achieve this goal, in certain jurisdictions where it is permitted, we have leveraged a reagent rental model that has been recognized as more attractive to certain customers. In this model, we lease, rather than sell, instruments to our customers. Over the term of the contract, the purchase price of the instrument is embedded in the price of the assays and reagents. Going forward, we intend to increase the number of reagent rental placements in developed markets, a strategy that we believe is beneficial to our commercial goals because it lowers our customers’ upfront capital costs and therefore allows purchasing decisions to be made at the lab manager level. For these same reasons, the reagent rental model also benefits our commercial strategy in emerging markets. We believe that the shift in our sales strategy will grow our installed base, thereby increasing sales of higher-margin assays, reagents and other consumables over the life of the customer contracts and enhancing our recurring revenue and cash flows. During fiscal year 2022, we transferred $73.7 million of instrument inventories from Inventories to Property, plant and equipment, net, further increasing our investment in property, plant and equipment.
Long-term Liquidity Outlook
Our future capital requirements and the adequacy of our available funds to service any long-term debt outstanding and to fund working capital expenditures and business development efforts will depend on many factors, including:
•our ability to successfully integrate the recently acquired Ortho business and realize cross-selling revenue synergies;
•our ability to realize revenue growth from our new technologies and create innovative products in our markets;
•outstanding debt and covenant restrictions;
•our ability to leverage our operating expenses to realize operating profits as we grow revenue;
•competing technological and market developments; and
•our entry into strategic collaborations with other companies or acquisitions of other companies or technologies to enhance or complement our product and service offerings.
66

Contractual Obligations
Principal payments required on our long-term debt outstanding as of January 1, 2023 are $207.5 million in fiscal year 2023, $310.2 million in fiscal years 2024 to 2025 and $2,131.2 million in fiscal years 2026 to 2027. See Note 8 to our Consolidated Financial Statements for further discussion of long-term debt. Interest payments required on long-term debt outstanding as of January 1, 2023 are $172.5 million in fiscal year 2023, $258.1 million in fiscal years 2024 to 2025 and $149.7 million in fiscal years 2026 to 2027. Future interest payments include commitment fees on the unused portion of the Revolving Credit Facility and interest payments on our Term Loan. Future interest payments assume January 1, 2023 interest rates will prevail throughout all periods. Actual interest payment amounts may differ in the future based on changes in market interest rates.
As of January 1, 2023, estimated contractual obligations for operating lease payments were $256.5 million, with $32.7 million due in fiscal year 2023, $55.5 million in fiscal years 2024 to 2025, $45.4 million in fiscal years 2026 to 2027 and $122.9 million in fiscal year 2028 and thereafter. The amounts reflect future minimum lease obligations on facilities and equipment under operating leases in place as of January 1, 2023. See Note 9 to our Consolidated Financial Statements for further discussion of operating leases.
We are committed to making annual deferred and contingent consideration payments related to the acquisition of the BNP Business of up to $48 million. The remaining obligation as of January 1, 2023 was $40 million, which is expected to be paid in fiscal year 2023.
In connection with the Combinations, the Company assumed certain defined benefit plan obligations and acquired related plan assets for employees of non-U.S. subsidiaries. We expect to make contributions of $2.0 million to our defined benefit plans in fiscal year 2023. The amount of any contributions is dependent on the future economic environment and investment returns, and we are unable to reasonably estimate pension contributions beyond fiscal year 2023. See Note 15 to our Consolidated Financial Statements for further discussion of our defined benefit plans.
As of January 1, 2023, we had approximately $247.8 million of purchase obligations, which include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including (i) fixed or minimum quantities to be purchased, (ii) fixed, minimum or variable price provisions and (iii) the approximate timing of the transaction, as well as amounts for planned inventory purchases under contractual arrangements. We expect the majority of the payments related to these purchase obligations to be made during fiscal year 2023.
We have entered into various licensing agreements, which largely require payments based on product sales, as well as the achievement of specific milestones. Royalty and license expenses under these various royalty and licensing agreements collectively totaled $1.1 million, $2.0 million and $2.4 million as of January 1, 2023, January 2, 2022 and January 3, 2021, respectively.
As of January 1, 2023, we had approximately $40.0 million of liabilities associated with uncertain tax positions. We cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities, nor the amount of the final cash settlement as of January 1, 2023. See Note 6 to our Consolidated Financial Statements for further discussion of uncertain tax positions.
Recent Accounting Pronouncements
Information about recently adopted and proposed accounting pronouncements is included in Note 1 to our Consolidated Financial Statements set forth in Part II, Item 8 of this Annual Report.
Critical Accounting Estimates
Our discussion and analysis of our financial condition and results of operations are based on our Consolidated Financial Statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to reserve for contractual rebates, goodwill and intangible assets and income taxes. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our Consolidated Financial Statements.
67

Reserve for Contractual Rebates
We record revenues primarily from product sales. These revenues are recorded net of rebates that are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements and promotions. Rebates are calculated based on historical experience, estimated distributor inventory balances, contractual and statutory requirements and other relevant information, and are recorded as a reduction of sales with offsets to trade accounts receivable. The allowance for contractual rebates involves estimating adjustments to revenue based on a high volume of data including inputs from third-party sources. In addition, the determination of such adjustments includes estimating rebate percentages which are dependent on estimated end-user sales mix and customer contractual terms, which vary across customers, the related balance of which was $40.0 million of our rebate reserves at January 1, 2023. Our total rebate reserve was $73.5 million at January 1, 2023.
Goodwill and Intangible Assets
The useful lives of intangible assets with definite lives are based on the expected number of years the asset will generate revenue or otherwise be used by us and the related amortization is based on the straight-line method. Goodwill, which has an indefinite life, is not amortized but instead is tested at least annually for impairment, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include:
•the asset’s ability to continue to generate income from operations and positive cash flow in future periods;
•any volatility or significant decline in our stock price and market capitalization compared to our net book value;
•loss of legal ownership or title to an asset;
•significant changes in our strategic business objectives and utilization of our assets; and
•the impact of significant negative industry or economic trends.
If a change were to occur in any of the above-mentioned factors or estimates, the likelihood of a material change in our reported results would increase.
For goodwill, the entity has the option to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. The quantitative impairment test compares the fair value of a reporting unit with the carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, goodwill is impaired and the loss is recorded. We completed our annual evaluation for impairment of goodwill as of October 2, 2022 and determined that no impairment existed.
Income Taxes
Significant judgment is required in determining our provision for income taxes, current tax assets and liabilities, deferred tax assets and liabilities, and our future taxable income, both as a whole and in various tax jurisdictions, for purposes of assessing our ability to realize future benefit from our deferred tax assets. A valuation allowance may be established to reduce our deferred tax assets to the amount that is considered more likely than not to be realized through the generation of future taxable income and other tax planning opportunities. As of January 1, 2023, we had a valuation allowance of $251.3 million, which represents the portion of our deferred tax assets that management believes is not more likely than not to be realized. We will continue to assess the need for a valuation allowance on our deferred tax assets by evaluating both positive and negative evidence that may exist.
We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained during an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe that we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcome of examinations by tax authorities in determining the adequacy of our provision for income taxes. See Note 6 to our Consolidated Financial Statements for more information on income taxes.
Accounting for Business Combinations
Under the acquisition method of accounting, the cost of an acquired business is assigned to the tangible and identifiable intangible assets acquired and liabilities assumed on the basis of the estimated fair values at the date of acquisition. We assess fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including, but not limited to, an income
68

approach and a market approach, such as the estimation of future cash flows of the acquired business and current selling prices of similar assets. These valuations require us to make estimates and assumptions, especially with respect to intangible assets.
Fair value of the assets acquired and liabilities assumed, including intangible assets, in-process research and development (“IPR&D”), and contingent payments, are measured based on the assumptions and estimations with regards to variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, we determine the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. When applicable, adjustments to inventory are based on the fair market value of inventory and are recognized into income based on the period in which the underlying inventory is sold. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that is not individually identified and separately recognized. Actual results may vary from projected results and assumptions used in the fair value assessments.
If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments identified after the measurement period are recorded in the Consolidated Statements of Income.
Inventories
We periodically review inventory for both potential obsolescence and potential declines in anticipated selling prices. In this review, we make assumptions about the future demand for and market value of the inventory and based on these assumptions estimate the amount of any obsolete, unmarketable, slow moving or overvalued inventory. We write down the value of our inventories by an amount equal to the difference between the cost of the inventory and the net realizable value. If actual market conditions are less favorable than those projected by management at the time of the assessment, however, additional inventory write-downs may be required, which could reduce our earnings.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Our business and financial results are affected by fluctuations in world financial markets, including interest rates and currency exchange rates. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We have policies governing our use of derivative instruments, and we do not enter into financial instruments for trading or speculative purposes.
Interest Rate Risk
We are subject to interest rate market risk in connection with our long-term debt. Our principal interest exposure relates to outstanding amounts under our Credit Agreement. Our Credit Agreement provides for variable rate borrowings of up to $2,750.0 million under the Term Loan and $800.0 million under the Revolving Credit Facility. Assuming facilities under the Credit Agreement are fully drawn, each one-eighth percentage point increase or decrease in the applicable interest rates would correspondingly change our interest expense on our outstanding borrowings under the Credit Agreement by approximately $4.3 million per year before considering the impact of derivative instruments. For further discussion of the risks related to our Credit Agreement, see “Risk Factors—Corporate Finance Risks—Our substantial indebtedness could adversely affect our financial condition, limit our ability to raise additional capital to fund our operations and prevent us from fulfilling our obligations under our indebtedness” in Part I, Item 1A, “Risk Factors” of this Annual Report.
We selectively use derivative instruments to reduce market risk associated with changes in interest rates. The use of derivatives is intended for hedging purposes only, and we do not enter into derivative instruments for speculative purposes.
We have entered into an interest rate swap agreement, which fixed a portion of the variable interest due on our variable rate debt. Under the terms of the agreement, we will pay a fixed rate of 1.58% and receive a variable rate of interest based on the USD-SOFR rate from the counterparty, which is reset every month through December 31, 2023. As of January 1, 2023, the notional amount of the interest rate swap was $500.0 million.
In the fourth quarter of 2022, we entered into interest rate swap contracts, commencing on December 30, 2022, with a total notional value of $1.3 billion through December 29, 2023 and $1.8 billion subsequently, to hedge future interest rate exposures on variable rate debt, including the Revolving Credit Facility and Term Loan. During the fourth quarter of 2022, we terminated our non-designated $1.0 billion notional value 3.428% interest rate cap.
Our current investment policy with respect to our cash and cash equivalents focuses on maintaining acceptable levels of interest rate risk and liquidity. Although we continually evaluate our investments, our cash equivalents as of January 1, 2023 consisted
69

primarily of government money market funds and other high credit quality debt securities. These funds provide daily liquidity and may be subject to interest rate risk and decrease in value if market interest rates increase. We do not expect our operating results or cash flows to be affected to any significant degree by a sudden change in market interest rates.
Foreign Currency Exchange Risk
We are exposed to foreign currency exchange risk by virtue of our international operations. These risks include the translation of local currency balances of foreign subsidiaries, transaction gains and losses associated with intercompany balances with foreign subsidiaries and transactions denominated in currencies other than the functional currency of the local jurisdiction. We derived approximately 25% of our Total revenues for the fiscal year ended January 1, 2023, from operations outside the U.S. For translation of operations in non-U.S. Dollar currencies, the local currency of most entities is the functional currency. Foreign exchange effects from the translation of our balance sheet resulted in a comprehensive loss of $69.8 million for the fiscal year ended January 1, 2023. Foreign exchange effects from the translation of our balance sheet were not material during the fiscal year ended January 2, 2022. Adjustments resulting from the re-measurement of transactions denominated in foreign currencies other than the functional currency of our subsidiaries are expensed as incurred.
In the majority of our jurisdictions, we earn revenue and incur costs in the currency used in such jurisdiction. We incur significant costs in foreign currencies, including Brazilian Real, British Pound, Chinese Yuan/Renminbi, Euro, Indian Rupee, Japanese Yen, Mexican Peso, and the Swiss Franc. As a result, movements in exchange rates cause our revenue and expenses to fluctuate, impacting our profitability and cash flows. Future business operations and opportunities, including the continued expansion of our business outside North America, may further increase the risk that cash flows resulting from these activities may be adversely affected by changes in currency exchange rates.
Like many multi-national companies, we have exposure to the British Pound. We are negatively impacted by a lower British Pound exchange rate from translation impact when compared to the U.S. Dollar, but we also benefit from expenses denominated in British Pound, as well as some cross-border transactions at a lower exchange rate. The magnitude of the impact is dependent on our business volumes in the U.K., forward contract hedge positions, cross currency volume and the exchange rate.
Additionally, in order to fund the purchase price for the assets and capital stock of certain non-U.S. entities, a combination of equity contributions and intercompany loans were utilized to capitalize certain non-U.S. subsidiaries. In many instances, the intercompany loans are denominated in currencies other than the functional currency of the affected subsidiaries. Where intercompany loans are not a component of permanently invested capital of the affected subsidiaries, increases or decreases in the value of the subsidiaries’ functional currency against other currencies will affect our results of operations. During the fiscal year ended January 1, 2023, we recorded net foreign currency exchange loss of $6.0 million. Net foreign currency exchange impact was not material for the fiscal year ended January 2, 2022. The foreign currency gains/losses in each period primarily consist of unrealized gains/losses related to intercompany loans denominated in currencies other than the functional currency of the affected subsidiaries. We may enter into derivative instruments to manage our foreign currency exposure on these intercompany loans in the future.
We have entered into foreign currency forward contracts to manage our foreign currency exposures on foreign currency denominated firm commitments and forecasted foreign currency denominated intercompany and third-party transactions. We had forward contracts outstanding with total notional amount of $1,023.3 million as of January 1, 2023, with maturity dates through December 2023. Foreign currency forward contracts that qualified and were designated for hedge accounting are recorded at their fair value as of January 1, 2023 and the unrealized loss of $7.9 million is reported as a component of Other comprehensive income (loss), all of which is expected to be reclassified to earnings in the next 12 months. Actual gains (losses) upon settlement will be recognized in earnings, within the line item impacted, during the estimated time in which the transactions are incurred. Actual gains upon settlement recognized in earnings during the fiscal year ended January 1, 2023 were $3.5 million. Actual losses/gains upon settlement recognized in earnings during the fiscal year ended January 2, 2022 were not material.
See Note 14 to our Consolidated Financial Statements for additional information related to such forward contracts, which information is incorporated herein by reference.
70

Item 8. Financial Statements and Supplementary Data
Index of Consolidated Financial Statements and Schedule
71

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of QuidelOrtho Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of QuidelOrtho Corporation (the Company) as of January 1, 2023 and January 2, 2022, the related consolidated statements of income, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended January 1, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at January 1, 2023 and January 2, 2022, and the results of its operations and its cash flows for each of the three years in the period ended January 1, 2023, in conformity with US generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of January 1, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 23, 2023 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
72

Reserve for contractual rebates
Description of the MatterAs described in Note 1 and Note 7 to the consolidated financial statements, the Company records revenues from product sales net of contractual rebates that are estimated at the time of sale. As of January 1, 2023, the Company recognized an allowance on accounts receivable of $40.0 million in rebates which are dependent on estimated rebate percentages that vary based on end-user sales mix.
Auditing the Company’s allowance for contractual rebates is especially challenging because the calculation involves estimating adjustments to revenue based upon a high volume of data including inputs from third-party sources, such as distributor inventory levels and historical distributor sales to end users. In addition, the determination of such adjustments includes estimating rebate percentages which are dependent on estimated end-user sales mix and customer contractual terms, which vary across customers.
How We Addressed the Matter in Our Audit

We obtained an understanding, evaluated the design and tested the operating effectiveness of key controls over the Company’s process to calculate the reserves for contractual rebates, including management’s evaluation of third-party data inputs utilized in the reserve calculations, as well as the Company’s data inputs such as accuracy of contractual pricing and reasonableness of estimated end user sales.

Our audit procedures also included, among others, the evaluation of the Company’s retrospective analysis of rebates claimed compared to actual payments issued and performance of analytical procedures and sensitivity analyses over the Company’s significant inputs. We also tested the underlying data used in management’s calculations for accuracy and completeness, which included inspection of source data supporting the inventory levels and agreement of contractual rebate amounts to underlying customer contracts.

73

Valuation of intangible assets acquired in connection with the acquisition of Ortho
Description of the MatterAs described in Note 2 to the consolidated financial statements, on May 27, 2022, Quidel and Ortho consummated the Combinations, with Quidel considered the accounting and legal acquirer for total purchase consideration of approximately $4.3 billion. The transaction was accounted for as a business combination. The Company measured the assets acquired and liabilities assumed at fair value, which resulted in the recognition of approximately $3.2 billion of intangible assets, comprised of customer relationships, developed technology, and trademarks.
Auditing the Company’s accounting for its acquisition of Ortho was complex due to the significant estimation uncertainty in determining the fair value of the identified intangible assets. A significant emphasis is placed on the appropriateness of key estimates used by management to determine the fair value of the acquired intangible assets due to sensitivity of the resulting fair values to these underlying assumptions. The Company used an income approach to measure the intangible assets. The significant assumptions used to estimate the value of the intangible assets included discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates and customer attrition.
How We Addressed the Matter in Our AuditWe obtained an understanding, evaluated the design and tested the operating effectiveness of key controls over the Company's process for determining the fair value of intangible assets acquired. This included controls over management’s development of the above-described assumptions used in the valuation models applied.

To test the estimated fair value of the intangible assets, we performed audit procedures that included, among others, evaluating the Company’s use of the income approach and testing the significant assumptions used in the valuation model, as described above. We evaluated the completeness and accuracy of underlying data used in supporting the assumptions and estimates. We evaluated the reasonableness of projected revenue growth used within the valuations against industry trends and other market information. In addition, we involved valuation specialists to assist in assessing the significant assumptions and methodologies used by the Company.

/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2002.
San Diego, California
February 23, 2023
74

QUIDELORTHO CORPORATION
CONSOLIDATED BALANCE SHEETS
(In millions, except par value)
January 1, 2023January 2, 2022
ASSETS
Current assets:
Cash and cash equivalents$292.9 $802.8 
Marketable securities52.1 25.7 
Accounts receivable, net453.9 378.0 
Inventories524.1 198.8 
Prepaid expenses and other current assets252.1 35.0 
Total current assets1,575.1 1,440.3 
Property, plant and equipment, net1,339.0 349.2 
Marketable securities21.0 37.9 
Right-of-use assets181.0 127.6 
Goodwill2,476.8 337.0 
Intangible assets, net3,123.8 98.7 
Deferred tax asset16.4 20.1 
Other assets122.7 19.6 
Total assets$8,855.8 $2,430.4 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$283.3 $101.5 
Accrued payroll and related expenses139.2 40.4 
Income tax payable51.6 66.9 
Current portion of borrowings207.5 0.3 
Other current liabilities325.4 114.4 
Total current liabilities1,007.0 323.5 
Operating lease liabilities186.4 128.6 
Long-term borrowings2,430.8 0.4 
Deferred tax liability213.2 — 
Other liabilities83.8 48.5 
Total liabilities3,921.2 501.0 
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5.0 shares authorized; none issued or outstanding at January 1, 2023 and January 2, 2022
— — 
Common stock, $0.001 par value per share; 126.2 and 97.5 shares authorized; 66.4 and 41.7 shares issued and outstanding at January 1, 2023 and January 2, 2022, respectively
— — 
Additional paid-in capital2,804.3 279.8 
Accumulated other comprehensive (loss) income(67.6)0.4 
Retained earnings2,197.9 1,649.2 
Total stockholders’ equity4,934.6 1,929.4 
Total liabilities and stockholders’ equity$8,855.8 $2,430.4 

See accompanying notes.
75

QUIDELORTHO CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share data)
 
 Fiscal Year Ended
202220212020
Total revenues$3,266.0 $1,698.6 $1,661.7 
Cost of sales, excluding amortization of intangibles1,330.0 420.3 305.4 
Selling, marketing and administrative621.0 239.6 180.7 
Research and development190.5 95.7 84.3 
Amortization of intangible assets132.5 27.4 27.3 
Acquisition and integration costs136.0 9.6 3.7 
Other operating expenses12.3 — — 
Operating income843.7 906.0 1,060.3 
Interest expense, net75.7 5.8 8.5 
Loss on extinguishment of debt24.0 — 10.4 
Other expense (income), net8.1 (0.1)1.1 
Income before provision for income taxes735.9 900.3 1,040.3 
Provision for income taxes187.2 196.1 230.0 
Net income$548.7 $704.2 $810.3 
Basic earnings per share$9.66 $16.74 $19.24 
Diluted earnings per share$9.56 $16.43 $18.60 
Weighted-average shares outstanding - basic56.8 42.1 42.1 
Weighted-average shares outstanding - diluted57.4 42.9 43.6 

See accompanying notes.

76

QUIDELORTHO CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
 
 Fiscal Year Ended
 202220212020
Net income$548.7 $704.2 $810.3 
Other comprehensive income (loss)
Changes in cumulative translation adjustment, net of tax(69.8)(1.6)2.5 
Changes in unrealized losses from investments, net of tax(0.4)(0.1)— 
Changes from pension and other post-employment benefits, net of tax0.7— — 
Changes in unrealized gains (losses) from cash flow hedges, net of tax:
Net unrealized gains (losses) on derivative instruments6.7 0.1 (3.0)
Reclassification of net realized (gains) losses on derivative instruments included in net income(5.2)2.4 0.5 
Total change in unrealized gains (losses) from cash flow hedges, net of tax1.5 2.5 (2.5)
Comprehensive income$480.7 $705.0 $810.3 

See accompanying notes.

77

QUIDELORTHO CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In millions)
 Common Stock   
SharesParAdditional
paid-in
capital		Accumulated
other
comprehensive (loss) income		Retained
earnings		Total
stockholders’
equity
Balance at December 29, 201941.9 $— $425.6 $(0.4)$134.7 $559.9 
Issuance of common stock under equity compensation plans0.5 — 10.4 — — 10.4 
Stock-based compensation expense— — 19.0 — — 19.0 
Issuance of shares in exchange for Convertible Notes0.2 — 7.2 — — 7.2 
Tax impact from the conversion of Convertible Notes— — 0.1 — — 0.1 
Derivative liabilities - Convertible Notes elected to settle in cash— — (26.2)— — (26.2)
Tax withholdings related to vesting of stock-based awards— (4.3)(4.3)
Repurchases of common stock(0.3)— (43.7)— — (43.7)
Net income— — — — 810.3 810.3 
Balance at January 3, 202142.3 $— $388.1 $(0.4)$945.0 $1,332.7 
Issuance of common stock under equity compensation plans0.6 — 9.6 — — 9.6 
Stock-based compensation expense— — 22.7 — — 22.7 
Tax withholdings related to vesting of stock-based awards(0.2)— (37.1)— — (37.1)
Repurchases of common stock(1.0)— (103.5)— — (103.5)
Other comprehensive income, net of tax— — — 0.8 — 0.8 
Net income— — — — 704.2 704.2 
Balance at January 2, 202241.7 $— $279.8 $0.4 $1,649.2 $1,929.4 
Issuance of common stock under equity compensation plans0.7 — 30.8 — — 30.8 
Stock-based compensation expense— — 45.1 — — 45.1 
Issuance of shares in connection with the Combinations25.1 — 2,495.4 — — 2,495.4 
Issuance of equity replacement awards in connection with the Combinations— — 36.1 — — 36.1 
Tax withholdings related to vesting of stock-based awards(0.1)— (8.6)— — (8.6)
Repurchases of common stock(1.0)— (74.3)— — (74.3)
Other comprehensive loss, net of tax— — — (68.0)— (68.0)
Net income— — — — 548.7 548.7 
Balance at January 1, 202366.4 $— $2,804.3 $(67.6)$2,197.9 $4,934.6 

See accompanying notes.
78

QUIDELORTHO CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
 Fiscal Year Ended
 202220212020
OPERATING ACTIVITIES:
Net income$548.7 $704.2 $810.3 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization283.6 52.7 48.8 
Stock-based compensation expense48.4 25.4 21.0 
Net change in operating lease right-of-use assets and liabilities18.4 3.0 0.4 
Payment of accreted interest on contingent and deferred consideration(10.4)(8.2)— 
Loss on extinguishment of debt24.0 — 10.4 
Unwind inventory fair value adjustment60.6 — — 
Other non-cash, net(34.8)31.6 (10.0)
Changes in assets and liabilities:
Accounts receivable150.2 118.9 (402.1)
Inventories(116.9)(85.0)(54.9)
Prepaid expenses and other current and non-current assets(26.2)(13.3)(14.3)
Accounts payable23.5 10.4 52.2 
Accrued payroll and related expenses18.2 5.0 16.0 
Income taxes payable(26.8)(66.7)137.7 
Other current and non-current liabilities(75.2)27.9 14.2 
Net cash provided by operating activities885.3 805.9 629.7 
INVESTING ACTIVITIES
Acquisitions of property, equipment, investments and intangibles(140.9)(292.8)(64.9)
Acquisition of businesses, net of cash and restricted cash acquired(1,511.4)— — 
Proceeds from government assistance allocated to fixed assets18.4 36.9 1.6 
Purchases of marketable securities(63.7)(67.4)— 
Proceeds from sale of marketable securities53.4 3.8 — 
Net cash used for investing activities(1,644.2)(319.5)(63.3)
FINANCING ACTIVITIES
Proceeds from issuance of common stock26.4 7.6 9.6 
Proceeds from long-term borrowings, net of debt issuance costs2,734.5 — — 
Payments on long-term borrowings and extinguishment costs(2,388.3)(0.3)(0.5)
Payments of tax withholdings related to vesting of stock-based awards(8.6)(37.1)(4.3)
Repurchases of common stock(74.3)(103.5)(43.7)
Principal payments of acquisition contingent consideration(4.2)(4.7)(6.0)
Principal payments of deferred consideration(33.5)(35.1)(42.0)
Payment on Convertible Senior Note and Derivative Liability— — (43.4)
Net cash provided by (used for) financing activities252.0 (173.1)(130.3)
Effect of exchange rates on cash(2.0)(0.4)1.0 
Net (decrease) increase in cash, cash equivalents and restricted cash(508.9)312.9 437.1 
Cash, cash equivalents and restricted cash at beginning of period802.8 489.9 52.8 
Cash, cash equivalents and restricted cash at end of period$293.9 $802.8 $489.9 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for interest$95.1 $— $0.5 
Cash paid during the period for income taxes$264.8 $235.6 $109.9 
Purchase of property, equipment and intangibles by incurring current liabilities$40.4 $10.5 $7.2 
Capital expenditures to be reimbursed under a government contract$— $— $15.9 
Transfer of instrument inventories to fixed assets$73.7 $— $— 
Reduction of other current liabilities upon issuance of restricted share units$4.6 $2.0 $0.8 
Extinguishment of Convertible Notes through issuance of stock$— $— $7.2 
See accompanying notes.
79

QuidelOrtho Corporation
Notes to Consolidated Financial Statements
Note 1. Basis of Presentation and Summary of Significant Accounting Policies
Organization and Business
On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. As a result of the Combinations, QuidelOrtho became the successor issuer to Quidel. The results of operations of Ortho have been included in the Company’s Consolidated Financial Statements from the date of acquisition. See Note 2 for further information regarding the Combinations.
The Company’s mission is to develop and manufacture intelligent diagnostic solutions that transform the power of diagnostics into a healthier future for everyone. The Company’s expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine helps clinicians and patients make better informed decisions across the globe. The Company’s global infrastructure and commercial reach support its customers across more than 130 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. The Company operates globally with manufacturing facilities in the U.S. and U.K. and with sales centers, administrative offices and warehouses located throughout the world.
Basis of Presentation
The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”).
Accounting Periods
The Company follows the concept of a fiscal year that ends on the Sunday nearest to the end of the month of December, and fiscal quarters that end on the Sunday nearest to the end of the months of March, June, and September. For fiscal years 2022, 2021 and 2020, the Company’s fiscal years ended on January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Fiscal years 2022 and 2021 were 52 weeks and fiscal year 2020 was 53 weeks.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The estimates and underlying assumptions can impact all elements of the financial statements, including, but not limited to, accounting for deductions from revenues (e.g. rebates, sales allowances, and discounts), receivable and inventory valuations, fixed asset valuations, useful lives, impairment of goodwill and tangible and intangible assets, the fair value of assets acquired and liabilities assumed in a business combination and related purchase price allocation, long-term employee benefit obligations, income taxes, environmental matters, litigation and allocations of costs. Estimates are based on historical experience, complex judgments, facts and circumstances available at the time and various other assumptions that are believed to be reasonable under the circumstances but are inherently uncertain and unpredictable. Actual results could differ from those estimates.
Reclassifications
Certain prior period amounts were reclassified to conform to the current period presentation, including the separate presentation of Amortization of intangible assets and Interest expense, net, the combination of Selling, marketing and administrative expense, and reclassification of Other current liabilities and Other liabilities, which did not change the reported amounts of Total current liabilities or Total liabilities. Cost of sales, excluding amortization of intangibles for fiscal years 2021 and 2020 excludes $7.4 million and $7.4 million, respectively, of intangibles amortization expense, formerly included in Cost of sales, which has been reclassified to Amortization of intangible assets. Selling, marketing and administrative expense for fiscal years 2021 and 2020 excludes $20.0 million and $19.9 million, respectively, of intangibles amortization expense, formerly included in Sales and marketing expense, which has been reclassified to Amortization of intangible assets. The reclassifications did not have an impact on net assets, Operating income, Net income, Basic or Diluted earnings per share, or cash flows.
Consolidation
The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents
The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. They are carried at cost plus accrued interest, which approximates fair value because of the short-term maturity of these
80

instruments. Cash equivalents include money market funds and debt securities of high quality institutions. Cash balances may exceed government insured limits in certain jurisdictions.
Marketable Securities
The Company invests excess cash balances in investment-grade corporate debt securities, asset-backed securities and U.S. Treasury securities. The Company seeks to diversify investments and limits the amount of investment concentrations for individual institutions, maturities and investment types. These marketable securities are classified as available-for-sale and, accordingly, such securities are recorded at fair value. Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. If any adjustment to fair value reflects a significant decline in the value of the security, the Company evaluates the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to its Consolidated Statements of Income. Marketable securities are classified as non-current when maturities are one year or more.
Accounts Receivable and Allowance for Credit Losses and Concentration of Credit Risk
The Company sells its products directly to physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as to individual, non-professional OTC customers, and other distributors in the U.S. and internationally (see Note 4). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company establishes a reserve based on historical losses, the age of receivables, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts, and specific allowances for large or risky accounts. Amounts later determined to be uncollectible are charged or written off against this allowance. The balance of accounts receivable is net of reserves of $89.1 million and $52.4 million at January 1, 2023 and January 2, 2022, respectively, of which the reserve related to contract rebates was $73.5 million and $40.3 million, respectively.
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash equivalents, marketable securities and trade accounts receivable.
Credit losses are identified when cash flows received are not expected to be sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).
The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories
Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method as follows:
Asset typeUseful life
Building and building improvements
7-47 years
Machinery and equipment
3-15 years
Customer leased instruments
3-8 years
Computer software
3-5 years
Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or the estimated useful lives of the related assets.
When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the accounts and included in determining gain or loss on such disposals. Maintenance and repairs are expensed as incurred; major replacements and improvements that extend the useful life are capitalized.
81

Goodwill
Goodwill represents the excess of purchase price over the fair values of underlying net assets acquired in an acquisition. The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. Beginning in 2022, the Company changed its annual impairment assessment date from December 31 to the first day of the fourth quarter of the fiscal year.
In connection with the Combinations, the manner in which the chief operating decision maker (“CODM”) reviews the Company’s performance and allocates resources changed, resulting in six operating segments: North America, EMEA, China, Latin America, Japan and Asia Pacific. North America, EMEA and China are the Company’s reportable segments; Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” The Company concluded each of these six operating segments is considered a reporting unit for the purpose of allocating goodwill and performing the annual goodwill impairment assessment. Prior to the Combinations, the Company operated as a single reportable segment with one reporting unit.
When testing goodwill for impairment, the Company first has an option to assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that impairment exists. Such qualitative factors may include the following: macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, the Company would be required to perform a quantitative impairment test. Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value of each reporting unit to its carrying value, including goodwill. The Company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. If the fair value of a reporting unit is less than its carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value.
For fiscal year 2022, the Company performed a qualitative goodwill impairment assessment as of the beginning of the fiscal fourth quarter to assess for potential impairment. Based on the qualitative impairment assessment performed by the Company, it was concluded that it is not more likely than not that the fair value of the Company’s reporting units is less than their carrying amounts, and therefore no further impairment testing was necessary.
Intangible Assets
Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life.
Long-lived Assets
The process of evaluating the potential impairment of long-lived assets, such as property, plant and equipment and intangible assets, is subjective and requires judgment. The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of an asset may not be recoverable. If these circumstances exist, recoverability of assets to be held and used is measured by a comparison of the carrying value of an asset group to future undiscounted net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Convertible Debt
The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects the Company’s nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. During fiscal year 2020, the remaining aggregate principal amount of the Company’s Convertible Notes was settled or matured.
Revenue Recognition
The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings,
82

including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based on historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively.
Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service.
During fiscal years 2022 and 2021, the Company generated a portion of its revenue from sales of the QuickVue At-Home OTC COVID-19 tests to retail customers. The Company estimates the transaction price for revenue from sales to retail customers based on historical experience and current trends to evaluate when uncertainties related to right of return provisions are resolved. As of January 1, 2023 and January 2, 2022, due to a lack of history on which to base an estimate of products to be returned from the retailers, the Company established a reserve based on an estimate of total inventory remaining at our retailers which was subject to return.
A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately. The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument was not material for fiscal years 2022, 2021 and 2020.
Government Assistance
During fiscal year 2020, the Company entered into a contract with the National Institutes of Health (“NIH”), through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract originally provided for consideration to the Company of up to $65.0 million and had a performance period of one year, which began in July 2020. During 2021, the Company entered into several amendments to the contract, which added additional deliverables and milestones, as well as extended the performance period. The contract and amendments included key deliverables and milestones that directly supported the upgrade and addition of new manufacturing lines, as well as the outfitting of the new distribution center. The Company also provided instruments and assays to NIH. There were no refund provisions under the contract.
Consideration from the contract was allocated to each deliverable identified within the contract using a relative fair value allocation method and recognized when there was reasonable assurance the Company would meet the milestones and receive the consideration. Consideration allocated to the delivery of instruments and assays was recognized in accordance with the Company’s existing revenue recognition policy described above. Consideration that related to capital expenditures was recorded as a reduction to the carrying value of such assets and amortized over the useful life of the assets. Consideration allocated to the remainder of the contract was recorded as reductions to the related expense. As of January 2, 2022, the Company had achieved and collected payments for all milestones under the NIH contract.
In connection with the Combinations, the Company acquired a previously established agreement between Ortho and the Biomedical Advanced Research and Development Authority (“BARDA”), a division of HHS, which provides funding for Ortho to build manufacturing space and production support equipment to increase COVID-19 assay production capacity, as well as to build a manufacturing facility to produce certain analyzers needed to support COVID-19 testing. Amounts received from BARDA under this grant are recorded as a reduction to the carrying value of the related assets. A portion of the grant is
83

for purposes of reimbursement of certain general and administrative expenses related to the project, which are not capitalized as part of the equipment constructed in connection with the project and are recorded as a reduction to the related expense. The Company received $18.4 million during fiscal year 2022, which was recorded as a reduction to the carrying value of the related assets.
Research and Development Costs
Research and development costs are charged to operations as incurred. Upfront and milestone payments made to third parties in connection with R&D collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties at or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
The Company enters into collaborative arrangements to develop and commercialize intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including R&D, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations.
Product Shipment Costs
Product shipment costs are included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $104.9 million, $29.3 million and $14.2 million for fiscal years 2022, 2021 and 2020, respectively.
Advertising Costs
Advertising costs are expensed as incurred and included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Advertising costs were $26.8 million, $13.7 million and $1.1 million for fiscal years 2022, 2021 and 2020, respectively.
Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision.
The Company does not intend to permanently reinvest earnings of foreign subsidiaries at this time. As such, the Company provides for income taxes and foreign withholding taxes, where applicable, on undistributed earnings. Any repatriation of undistributed earnings would be done at little or no tax cost.
Fair Value of Financial Instruments
The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.
84

Stock-based Compensation
Stock-based compensation, comprised of stock options, restricted stock units (“RSUs”) and restricted stock awards to employees and directors, is measured at fair value on the grant date. Compensation expense is recognized over the requisite service period, which is generally the vesting period, and includes an estimate of the awards that will be forfeited, and an estimate of the level of performance the Company will achieve for performance-based awards.
Leases
Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options.
For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments is incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities.
Operating leases are included in ROU assets, operating lease liabilities and operating lease liabilities non-current in the Consolidated Balance Sheets.
Comprehensive Income
Comprehensive income includes unrealized gains and losses that are related to cumulative translation adjustments; unrealized gains and losses on marketable securities; changes in unamortized pension and post-employment actuarial gains and losses; and changes in the fair value of derivatives that are designated and qualify as cash flow hedging instruments excluded from the Consolidated Statements of Income.
Business Combinations
The cost of an acquired business is assigned to the tangible and identifiable intangible assets acquired and liabilities assumed on the basis of the estimated fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including, but not limited to, an income approach and a market approach, such as the estimation of future cash flows of the acquired business and current selling prices of similar assets. Fair value of the assets acquired and liabilities assumed, including intangible assets, IPR&D, and contingent payments, are measured based on the assumptions and estimations with regards to variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. When applicable, adjustments to inventory are based on the fair market value of inventory and are recognized into income based on the period in which the underlying inventory is sold. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that is not individually identified and separately recognized. Actual results may vary from projected results and assumptions used in the fair value assessments.
Defined Benefit Plans and Other Post-Employment Benefits
In connection with the Combinations, the Company assumed Ortho’s defined benefit plans in certain countries and a retiree healthcare reimbursement plan for certain U.S. employees. Defined benefit plans specify an amount of pension benefit that an employee will receive on retirement, usually dependent on factors such as age, years of service and compensation. The net obligation with respect to defined benefit plans is calculated separately for each plan by estimating the amount of the future benefits that employees have earned in return for their service in the current and prior periods. These benefits are then discounted to determine the present value of the obligations and are then adjusted for the impact of any unamortized prior service costs. The net obligation is then determined with reference to the fair value of the plan assets (if any). The discount rate used is the yield on bonds that are denominated in the currency in which the benefits will be paid and that have maturity dates approximating the terms of the obligations. The calculations are performed by qualified actuaries using the projected unit credit method.
Recent Accounting Pronouncements
In October 2021, the Financial Accounting Standards Board issued guidance which was codified in Accounting Standards Update 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts
85

with Customers. Under the new guidance, an acquirer is required to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. For public business entities, this guidance is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company early adopted the guidance during the first quarter of 2022 with no material impact to the Consolidated Financial Statements.
Note 2. Business Combination
On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. As a result of the Combinations, QuidelOrtho became the successor issuer to Quidel. The Combinations have been accounted for as a business combination using the acquisition method of accounting in conformity with ASC Topic 805, Business Combinations, with Quidel considered the accounting and the legal acquirer. The Combinations enhance the Company’s revenue profile and expand the Company’s geographic footprint and product diversity.
The Combinations were completed for a total consideration of approximately $4.3 billion, which included the fair value of equity issued based on the May 26, 2022 closing price of $99.60 per share of Quidel common stock. Former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho ordinary share. The total purchase consideration was calculated as follows (in millions, except value per share data and Ortho Exchange Ratio):
Total Ortho shares subject to exchange237.487
Ortho Exchange Ratio0.1055
QuidelOrtho shares issued25.055
Value per Quidel share as of May 26, 2022$99.60 
Fair value of stock consideration$2,495.5 
Fair value of replacement equity awards (1)47.9 
Cash consideration (2)1,747.7 
Total purchase consideration$4,291.1 
(1)
Represents the fair value of replacement stock options (which include options with time-based, performance-based, and both performance- and market-based vesting conditions), RSUs and restricted stock outstanding as of May 27, 2022 that are attributable to service prior to the Combinations. The terms of the replacement awards are substantially similar to the former Ortho equity awards for which they were exchanged. The portion of the fair value of the replacement equity awards attributable to service after the Combinations is $46.6 million and will be recognized as compensation expense based on the vesting terms of the replacement equity awards.
(2)
Represents cash consideration of $7.14 per share paid to Ortho shareholders and holders of vested Ortho stock options on the closing date of the Combinations for 237.5 million outstanding Ortho shares and 7.3 million vested Ortho stock options.
The Company funded the cash portion of the purchase price with cash on its balance sheet and a portion of the Term Loan (as defined in Note 8) proceeds from the Financing (as defined in Note 8). See Note 8 for further information regarding the Company’s debt.
86

The components of the preliminary purchase price allocation on the closing date of the Combinations are as follows:
(In millions)Amounts Recognized as of Acquisition Date
(as previously reported)		Measurement Period AdjustmentsAmounts Recognized as of Acquisition Date
(as adjusted)
Cash and cash equivalents$234.5 $— $234.5 
Accounts receivable240.6 — 240.6 
Inventories386.8 (2.4)384.4 
Property, plant and equipment767.5 181.4 948.9 
Goodwill2,291.3 (112.9)2,178.4 
Intangible assets3,133.0 35.0 3,168.0 
Prepaid expenses and other assets287.9 (16.2)271.7 
Total assets7,341.6 84.9 7,426.5 
Accounts payable(135.0)— (135.0)
Accrued payroll and related expenses(80.7)(0.4)(81.1)
Long-term borrowings, including current portion (1)
(2,268.4)— (2,268.4)
Deferred tax liability(215.4)(63.0)(278.4)
Other current and non-current liabilities(351.0)(21.5)(372.5)
Total liabilities(3,050.5)(84.9)(3,135.4)
Total purchase consideration$4,291.1 $— $4,291.1 
(1) Immediately following the closing of the Combinations, the Company repaid long-term borrowings assumed, which consisted of $1,608.4 million aggregate principal amount related to Ortho’s Dollar Term Loan and Euro Term Loan Facilities, $240.0 million aggregate principal amount of 7.375% Senior Notes due 2025 and $405.0 million aggregate principal amount of 7.250% Senior Notes due 2028. The 7.375% and 7.250% Senior Notes were fully discharged following the Combinations. The Company recorded a $23.5 million loss on extinguishment in connection with the Combinations, representing the difference between the reacquisition value, inclusive of $35.9 million of redemption premium, and the net carrying value of the extinguished debt.
The fair value estimates for the assets acquired and liabilities assumed were based on preliminary calculations, and the Company’s estimates and assumptions are subject to change for income tax matters. The Company expects to finalize the valuation as soon as practicable, but no later than one year after the closing date of the Combinations. The measurement period adjustments in the six months ended January 1, 2023 primarily resulted from completing valuations of real estate, personal property and intangible assets and revising the valuation of income tax liabilities. The related impact to net earnings that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the Consolidated Financial Statements.
Inventories acquired included raw materials, work in progress and finished goods. Inventories were recorded at their estimated fair values. Inventories were valued at the estimated selling price less the estimated costs to be incurred to complete and sell the inventories, the associated margins on these activities and holding costs. A step-up in the value of inventory of $61.7 million was recorded in connection with the Combinations. The step-up value was recorded in Cost of sales, excluding amortization of intangibles in the Consolidated Statements of Income as the inventory was sold to customers, and was fully recognized by the end of fiscal year 2022. In fiscal year 2022, $60.6 million of the fair value step-up of inventory was recognized in the Consolidated Statements of Income.
Goodwill represents the excess of the total purchase consideration over the estimated fair value of the net assets acquired, and is primarily attributable to synergies which are expected to expand the Company’s revenue profile and product diversity, as well as Ortho’s assembled workforce. Goodwill is not deductible for tax purposes. The preliminary assignment of goodwill by reportable segment as of the closing date of the Combinations is as follows (in millions):
North America$1,211.5 
EMEA370.0 
China121.6 
Other475.3 
$2,178.4 
87

The following table sets forth the amounts assigned to the identifiable intangible assets acquired (in millions, except years):
Intangible AssetAmortization PeriodFair Value of Assets Acquired
Customer relationships20 years$1,907.0 
Developed technology15 years888.0 
Trademarks15 years373.0 
$3,168.0 
The fair value of customer relationships was estimated using the Multi-Period Excess Earnings Method, which is a form of the income approach. Significant assumptions include: (i) the estimated annual net cash flows, which are a function of expected earnings attributable to the asset, contributory asset charges and the applicable tax rate, and (ii) the discount rate.
The fair value of developed technology and trademarks was estimated using the Relief from Royalty Method, which is another form of the income approach. Significant assumptions include: (i) the estimated annual net cash flows, which are a function of expected earnings attributable to the asset, the probability of use of the asset, the royalty rate and the applicable tax rate, and (ii) the discount rate.
Intangible assets are amortized on a straight-line basis over the amortization periods noted above, which reflects the estimated useful life of the underlying assets.
For fiscal year 2022, the Company incurred $46.9 million of transaction costs related to the Combinations, which primarily consisted of financial advisory, legal, accounting and valuation-related expenses. These expenses were recorded in Acquisition and integration costs in the Consolidated Statements of Income.
The following supplemental pro forma financial information shows the combined results of operations of the Company as if the Combinations had occurred on January 4, 2021, the beginning of the periods presented:
Fiscal Year Ended
(In millions) (unaudited)20222021
Pro forma total revenues$4,051.2 $3,741.4 
Pro forma net income589.3 613.2 
This supplemental pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved had the Combinations been completed at the beginning of fiscal year 2021. In addition, the supplemental pro forma financial information is not a projection of the Company’s future results of operations, nor does it reflect the expected realization of any synergies or cost savings associated with the Combinations. The supplemental pro forma financial information includes adjustments for:
•incremental intangible assets amortization expense to be incurred of $19.6 million and $45.5 million for fiscal years 2022 and 2021, respectively, based on the preliminary fair values of the identifiable intangible assets acquired;
•incremental cost of sales related to the fair value step-up of inventory which is reflected by an adjustment to decrease expense by $60.6 million for fiscal year 2022 and an adjustment to increase expense by $61.7 million for fiscal year 2021;
•decreases in interest expense of $11.2 million and $34.9 million for fiscal years 2022 and 2021, respectively, associated with the issuance of debt to finance the Combinations and to repay Ortho’s then-outstanding indebtedness, including the net impact of the removal of the amortization of the discount on Ortho’s indebtedness and the change in amortization of deferred financing fees;
•the removal of $50.3 million of loss on extinguishment of debt from Ortho’s financial results for fiscal year 2022 and the reclassification of $24.0 million of loss on extinguishment of debt incurred during fiscal year 2022 to fiscal year 2021;
•the reclassification of $12.8 million of expense related to the accelerated vesting of certain stock awards of Ortho’s former chief executive officer from fiscal year 2022 to fiscal year 2021; and
•tax impacts related to the above adjustments.
From the closing date of the Combinations through January 1, 2023, the acquired results of operations of Ortho contributed total revenues of $1,165.2 million and net loss of $126.2 million to the Company’s consolidated results, which included amortization of acquired intangible assets of $104.7 million and recognition in Cost of sales, excluding amortization of intangibles of the fair value step-up of inventory of $60.6 million.
88

Note 3. Computation of Earnings Per Share
Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted EPS is computed based on the sum of the weighted-average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of shares issuable from stock options, unvested RSUs and restricted stock. Potentially dilutive shares of common stock from outstanding stock options and unvested RSUs are determined using the average share price for each period under the treasury stock method.
Potentially dilutive common shares from the Convertible Notes are determined using the if-converted method. Under the provisions of the if-converted method, the Convertible Notes are assumed to be converted and the resulting common shares are included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Notes is added back to net income. The Convertible Notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the notes. The Convertible Notes became convertible on March 31, 2018 and matured on December 15, 2020.
The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods:
Fiscal Year Ended
(In millions)202220212020
Numerator:
Net income used for basic earnings per share$548.7 $704.2 $810.3 
Interest expense on Convertible Notes, net of tax— — 0.4 
Net income used for diluted earnings per share, if-converted method$548.7 $704.2 $810.7 
Denominator:
Basic weighted-average shares of common stock outstanding56.8 42.1 42.1 
Dilutive potential shares issuable from Convertible Notes— — 0.3 
Dilutive potential shares issuable from stock options and unvested RSUs0.6 0.8 1.2 
Diluted weighted-average shares of common stock outstanding57.4 42.9 43.6 
Potentially dilutive shares excluded from calculation due to anti-dilutive effect1.5 0.2 — 
Potentially dilutive shares excluded from the calculation above represent stock options when the combined exercise price and unrecognized stock-based compensation are greater than the average market price for the Company’s common stock because their effect is anti-dilutive.
Note 4. Revenue
Contract Balances
Timing of revenue recognition may differ from timing of invoicing to customers. The Company records an asset when revenue is recognized prior to invoicing a customer (a “contract asset”). Contract assets are included within Prepaid expenses and other current assets or Other assets in the Company’s Consolidated Balance Sheets and are transferred to accounts receivable when the right to payment becomes unconditional. The balance of contract assets recorded in the Company’s Consolidated Balance Sheets as of January 1, 2023 was $49.6 million and was included in Prepaid expenses and other current assets.
The contract asset balance as of January 1, 2023 consisted of the following components, all of which related to agreements acquired by the Company in connection with the Combinations; therefore, no balance existed at January 2, 2022:
•a customer supply agreement under which the difference between the timing of invoicing and revenue recognition resulted in a contract asset of $6.8 million;
•contractual arrangements with certain customers under which the Company invoices the customers based on reportable results generated by its reagents; however, control of the goods transfers to the customers upon shipment or delivery of the products, as determined under the terms of the contract. Using the expected value method, the Company estimates the number of reagents that will generate a reportable result. The Company records the revenue upon shipment and an associated contract asset, and relieves the contract asset upon completion of the invoicing. The balance of the contract asset related to these arrangements was $38.5 million as of January 1, 2023 and was recorded in Prepaid expenses and other current assets; and
89

•one of the Company’s contract manufacturing agreements that recognizes revenue as the products are manufactured. The balance of the contract asset related to this arrangement was $4.3 million as of January 1, 2023.
The Company reviews contract assets for expected credit losses resulting from the collectability of customer accounts. Expected losses are established based on historical losses, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts. No credit losses related to contract assets were recognized during fiscal year 2022.
The Company recognizes a contract liability when a customer pays an invoice prior to the Company transferring control of the goods or services (“contract liabilities”). The Company’s contract liabilities consist of deferred revenue primarily related to customer service contracts. The Company classifies deferred revenue as current or non-current based on the timing of the transfer of control or performance of the service. The balance of the Company’s current deferred revenue was $76.4 million as of January 1, 2023, and $1.9 million as of January 2, 2022. The Company has one arrangement with a customer where the revenue is expected to be recognized beyond one year. The balance of the deferred revenue included in long-term liabilities was $9.4 million as of January 1, 2023 and was included in Other liabilities in the Consolidated Balance Sheets. There was no deferred revenue included in long-term liabilities as of January 2, 2022.
Joint Business with Grifols
In connection with the Combinations, the Company acquired the Joint Business between Ortho and Grifols, under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho’s Hepatitis and HIV diagnostics business. The governance of the Joint Business is shared through a supervisory board made up of equal representation by Ortho and Grifols, which is responsible for all significant decisions relating to the Joint Business that are not exclusively assigned to either Ortho or Grifols, as defined in the Grifols Agreement. The Company’s portion of the pre-tax net profit shared under the Joint Business was $18.6 million during fiscal year 2022. This included the Company’s portion of the pre-tax net profit of $11.1 million during fiscal year 2022 on sales transactions with third parties where the Company is the principal. The Company recognized revenues, cost of sales, excluding amortization of intangibles, and operating expenses, on a gross basis on these sales transactions in their respective lines in the Consolidated Statements of Income. The Company’s portion of the pre-tax net profit also included revenue of $7.5 million from collaboration and royalty agreements during fiscal year 2022, which is presented on a net basis within Total revenues.
Disaggregation of Revenue
Following the Combinations, the Company reorganized its former product categories into four business units. Revenues from the Company’s former Specialized Diagnostic Solutions product category have been included in a new Labs business unit. The Company’s former Rapid Immunoassay and Cardiometabolic Immunoassay product categories now represent its Point of Care business unit. The Molecular Diagnostics business unit represents the former Molecular Diagnostic Solutions product category. In addition, the Company added a Transfusion Medicine business unit.
The following table summarizes Total revenues by business unit:
Fiscal Year Ended
(In millions)202220212020
Labs$820.2 $44.8 $50.9 
Transfusion Medicine393.8 — — 
Point of Care1,955.3 1,453.3 1,387.8 
Molecular Diagnostics96.7 200.5 223.0 
Total revenues$3,266.0 $1,698.6 $1,661.7 
90

Concentration of Revenue and Credit Risk
The Company had sales to individual customers in excess of 10% of Total revenues as follows:
Fiscal Year Ended
202220212020
Customer:
A20 %1 %— %
B11 %24 %29 %
C8 %9 %16 %
D5 %9 %13 %
E3 %7 %10 %
47 %50 %68 %
As of January 1, 2023 and January 2, 2022, customers with balances due in excess of 10% of Accounts receivable, net totaled $161.9 million and $267.3 million, respectively. For fiscal years 2022, 2021 and 2020, sales of COVID-19 products accounted for 44%, 75% and 70% of Total revenues, respectively. For fiscal years 2022, 2021 and 2020, sales of influenza products accounted for 11%, 4% and 8% of Total revenues, respectively.
Note 5. Segment and Geographic Information
In connection with the Combinations, the manner in which the CODM reviews the Company’s performance and allocates resources changed, resulting in three geographically-based reportable segments: North America; EMEA; and China. Although all three segments are engaged in the marketing, distribution and sale of diagnostic instruments and assays for hospitals, retailers, distributors, laboratories and/or blood and plasma centers worldwide, each region is managed separately to better align with the market dynamics of the specific geographic region. Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” Previously, the Company operated as a single reportable segment. Prior periods have been revised to align with the current period presentation.
Total revenues by reportable segment are as follows:
Fiscal Year Ended
(In millions)202220212020
North America$2,536.5 $1,500.2 $1,460.7 
EMEA206.8 69.6 92.9 
China220.0 58.0 62.4 
Other302.7 70.8 45.7 
Total revenues$3,266.0 $1,698.6 $1,661.7 
Beginning in the second quarter of 2022, in connection with the Combinations, the basis by which the Company measures segment profit or loss changed to Adjusted EBITDA in order to manage the Company’s business to better align with the market dynamics of the specific geographic regions in which the Company operates. In the fourth quarter of 2022, the Company revised the internal allocation of certain global costs primarily between the North America segment and Corporate to better align costs that impact the Company as a whole. Prior periods have been revised to align with the current period presentation.
91

The following table sets forth Adjusted EBITDA by segment and the reconciliations to Income before provision for income taxes for fiscal years 2022, 2021 and 2020:
Fiscal Year Ended
(In millions)202220212020
North America$1,614.6 $1,028.5 $1,205.2 
EMEA31.7 28.1 55.5 
China104.1 24.1 30.5 
Other92.7 43.0 28.0 
Total segment Adjusted EBITDA1,843.1 1,123.7 1,319.2 
Corporate (1)
(512.1)(152.9)(203.9)
Depreciation and amortization(283.6)(52.7)(48.8)
Acquisition and integration costs(136.0)(9.6)(3.7)
Interest expense, net(75.7)(5.8)(8.5)
Unwind inventory fair value adjustment(60.6)— — 
Loss on extinguishment of debt(24.0)— (10.4)
(Loss) gain on investments(5.8)1.5 — 
Amortization of deferred cloud computing
    implementation costs		(5.4)(3.7)(1.1)
Employee compensation charges and other costs(3.7)— — 
Impairment of long-lived assets(2.8)— — 
EU medical device regulation transition costs (2)
(1.5)— — 
Tax indemnification expense(0.3)— — 
Change in fair value of acquisition contingencies(0.1)(0.2)(1.4)
Derivative mark-to-market gain (loss)4.4 — (1.1)
Income before provision for income taxes$735.9 $900.3 $1,040.3 
(1) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and IT functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.
(2) Represents incremental consulting costs and R&D manufacturing site costs to align compliance of Ortho’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards.
The CODM does not review capital expenditures, total depreciation and amortization or assets by segment, and therefore this information has been excluded as it does not comprise part of management’s key performance metrics.
The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory:
Long-lived Assets as ofTotal Revenues for Fiscal Year
(In millions)January 1, 2023January 2, 2022202220212020
Domestic$983.0 $347.1 $2,451.7 $1,415.5 $1,452.4 
Foreign356.0 2.1 814.3 283.1 209.3 
Total$1,339.0 $349.2 $3,266.0 $1,698.6 $1,661.7 
92

Note 6. Income Taxes
Significant components of the provision for income taxes were as follows:
Fiscal Year Ended
(In millions)202220212020
Current:
Federal$162.2 $148.8 $198.5 
State48.8 42.4 34.6 
Foreign17.6 2.3 1.1 
Total current provision228.6 193.5 234.2 
Deferred:
Federal(31.9)7.2 (2.9)
State(9.3)(2.6)(1.0)
Foreign(0.2)(2.0)(0.3)
Total deferred provision (benefit)(41.4)2.6 (4.2)
Provision for income taxes$187.2 $196.1 $230.0 
The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods:
Fiscal Year Ended
(In millions)202220212020
United States$672.1 $891.2 $1,035.7 
Foreign63.8 9.1 4.6 
Income before income taxes$735.9 $900.3 $1,040.3 
Significant components of the Company’s deferred tax assets and deferred tax liabilities as of January 1, 2023 and January 2, 2022 are shown below:
(In millions)January 1, 2023January 2, 2022
Deferred tax assets:
Lease liability$51.4 $32.7 
Intangible assets— 2.2 
Allowance for returns and discounts45.9 28.3 
Inventory reserve34.1 6.4 
Stock-based compensation14.6 9.2 
Tax loss and credit carryforwards565.3 10.8 
Research & development expenses50.7 — 
Employee related obligations19.9 5.5 
Other, net16.1 0.8 
Total deferred tax assets798.0 95.9 
Valuation allowance for deferred tax assets(251.3)(2.3)
Total deferred tax assets, net of valuation allowance546.7 93.6 
Deferred tax liabilities:
Right-of-use assets(43.8)(30.1)
Intangible assets(590.2)(0.9)
Property, plant and equipment(109.5)(42.5)
Total deferred tax liabilities(743.5)(73.5)
Net deferred tax assets (liabilities)$(196.8)$20.1 

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. For the fiscal years ended January 1, 2023, January 2, 2022 and January 3, 2021, the Company has demonstrated positive cumulative pre-tax book income. Such objective positive evidence allowed the
93

Company to consider other subjective evidence, such as the Company’s projections for future profitability, to determine the realizability of its deferred tax assets.
The valuation allowance of $251.3 million as of January 1, 2023 represents the portion of the deferred tax asset that management could not conclude was more likely than not to be realized. The Company’s valuation allowance relates primarily to the realization of recorded tax benefits on tax loss carryforwards from operations in Luxembourg and certain U.S. state jurisdictions. The amount of the deferred tax assets considered realizable could be adjusted in the future based on changes in available positive and negative evidence.
As of January 1, 2023, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $879.8 million, of which $473.0 million are subject to expiration through 2037 and $406.8 million are not subject to expiration. In addition, the Company has state NOLs of approximately $530.1 million, which will expire in years 2023 through 2042. As of January 1, 2023, the Company had U.S. federal research credit carryforwards of $14.2 million and federal foreign tax credits of $3.4 million, which will begin to expire in 2034 and 2028, respectively. In addition, the Company had state research credits of $5.9 million, of which none expire, and state business credit carryforwards of $25.6 million, which will begin to expire in 2029. As of January 1, 2023, the Company had $543.8 million of NOL carryforwards in certain non-U.S. jurisdictions, net of uncertain tax positions. Of these, $339.1 million have no expiration and the remaining $204.7 million will expire in years through 2042.
Pursuant to Internal Revenue Code Sections 382 and 383, the Company’s use of its NOL and tax credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three-year period. As a result of an ownership change that occurred in the second quarter of fiscal year 2022, the Company may be limited in its ability to utilize its NOL carryforwards and certain other attributes, starting the ownership change date.
The reconciliation of income tax computed at the federal statutory rate to the provision for income taxes from continuing operations was as follows:
Fiscal Year Ended
(In millions)202220212020
Tax expense at statutory tax rate$154.5 $189.1 $218.5 
State tax expense, net of federal tax29.3 30.1 30.3 
Foreign income taxed at rates other than the applicable U.S. rate(27.5)— — 
Permanent differences12.0 1.8 3.8 
Federal and state research credits—current year(7.3)(7.7)(5.0)
Stock-based compensation1.5 (9.2)(13.9)
Change in valuation allowance26.2 (0.1)(0.1)
Foreign Derived Intangible Income Deduction (FDII)(10.2)(8.4)(8.6)
Other8.7 0.5 5.0 
Provision for income taxes$187.2 $196.1 $230.0 
The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.
The following table summarizes the activity related to the Company’s unrecognized tax benefits:
Fiscal Year Ended
(In millions)202220212020
Beginning balance$17.7 $22.6 $17.2 
Increases due to current year acquisitions27.8 — — 
Increases (decreases) related to prior year tax positions(0.6)0.5 (2.3)
Increases related to current year tax positions1.8 0.9 7.7 
Decreases from voluntary disclosure agreements— (6.3)— 
Decreases due to settlements(6.7)— — 
Ending balance$40.0 $17.7 $22.6 
94


As of January 1, 2023, January 2, 2022 and January 3, 2021, the Company had unrecognized tax benefits of $40.0 million, $17.7 million, and $22.6 million, respectively, of which $28.3 million, $11.3 million and $15.0 million, respectively, would reduce the Company’s annual effective tax rate, if recognized. The Company estimates that within the next 12 months, its uncertain tax positions, excluding interest, will decrease by $2.4 million. The uncertain tax positions relate to an on-going multi-state tax commission audit that is expected to be settled within the next 12 months.
The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax expense. The Company had accrued interest and penalties associated with uncertain tax positions of $8.3 million as of January 1, 2023 and $1.2 million as of January 2, 2022. Interest expense, net of accrued interest (reversed) for fiscal years 2022, 2021 and 2020 was approximately $0.3 million, $0.7 million and $0.1 million, respectively.
The Company is subject to periodic audits by domestic and foreign tax authorities. Due to the carryforward of unutilized credits, the Company’s federal tax years from 2012 and onwards are subject to examination by the U.S. authorities. The Company’s state and foreign tax years for 2001 and onwards are subject to examination by applicable tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.
Ortho is currently under audit in certain jurisdictions for tax years under the responsibility of Johnson & Johnson. Pursuant to the stock and asset purchase agreement entered into by Ortho and Johnson & Johnson in January 2014, Johnson & Johnson retained all income tax liabilities accrued as of the date of acquisition, including reserves for unrecognized tax benefits. Accordingly, all tax liabilities related to these tax years will be indemnified by Johnson & Johnson. As of January 1, 2023, the indemnification receivable from Johnson & Johnson totaled $16.8 million and is included as a component of Prepaid expenses and other current assets and Other assets on the Consolidated Balance Sheet.
The following table summarizes the changes to the valuation allowance for balances for fiscal years 2022, 2021 and 2020:
Beginning BalanceAdditions Due to Current Year AcquisitionsAdditions
(Deductions)
Charged to
Provision for (Benefit From)
Income Taxes		Currency Translation/OtherEnding Balance
Deferred tax valuation allowance
Fiscal year ended January 1, 2023$2.3 223.5 26.2 (0.7)$251.3 
Fiscal year ended January 2, 2022$2.3 — — — $2.3 
Fiscal year ended January 3, 2021$2.4 — (0.1)— $2.3 
Note 7. Balance Sheet Account Details
Cash, Cash Equivalents and Restricted Cash
(In millions)January 1, 2023January 2, 2022
Cash and cash equivalents$292.9 $802.8 
Restricted cash included in Other assets1.0 — 
Cash, cash equivalents and restricted cash$293.9 $802.8 
95

Marketable Securities
The following table is a summary of marketable securities:
January 1, 2023January 2, 2022
(In millions)Amortized CostGross Unrealized LossesFair ValueAmortized CostGross Unrealized LossesFair Value
Corporate bonds40.5 $(0.5)$40.0 $22.3 $— $22.3 
Corporate asset-backed securities6.7 — 6.7 3.4 — 3.4 
U.S. government securities2.0 — 2.0 — — — 
Agency bonds1.0 — 1.0 — — — 
Sovereign government bonds1.9 — 1.9 — — — 
Foreign and other0.5 — 0.5 — — — 
Total marketable securities, current52.6 (0.5)52.1 25.7 — 25.7 
Corporate bonds, non-current13.3 (0.1)13.2 26.8 (0.1)26.7 
Corporate asset-backed securities, non-current7.9 (0.1)7.8 11.2 — 11.2 
Total marketable securities$73.8 $(0.7)$73.1 $63.7 $(0.1)$63.6 
Accounts Receivable, Net
Accounts receivables primarily consist of trade accounts receivables with maturities of one year or less and are presented net of reserves:
(In millions)January 1, 2023January 2, 2022
Accounts receivable$543.0 $430.4 
Allowance for contract rebates and discounts(77.1)(50.7)
Allowance for doubtful accounts(12.0)(1.7)
Total accounts receivable, net$453.9 $378.0 
The allowance for contractual rebates involves estimating adjustments to revenue based on a high volume of data, including inputs from third-party sources. In addition, the determination of such adjustments includes estimating rebate percentages which are dependent on estimated end-user sales mix and customer contractual terms, which vary across customers, the related balance of which was $40.0 million and $40.3 million at January 1, 2023 and January 2, 2022, respectively, and was included in the allowance for contract rebates and discounts.
The following table summarizes changes to the accounts receivable allowance balances for fiscal years 2022, 2021 and 2020:
Balance at
Beginning of
Period		Additions Charged to Expense or as Reductions to Revenue (1)Deductions (2)Balance at end of
period
(In millions)
Fiscal year ended January 1, 2023$52.4 $407.6 $(370.9)$89.1 
Fiscal year ended January 2, 2022$103.4 $456.2 $(507.2)$52.4 
Fiscal year ended January 3, 2021$15.9 $277.0 $(189.5)$103.4 
(1)Includes opening balance of $31.4 million related to the Combinations during fiscal year 2022. Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to selling, marketing and administrative expense.
(2)The deductions represent actual charges against the accrual described above.
96

Inventories
Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Inventories consisted of the following:
(In millions)January 1, 2023January 2, 2022
Raw materials$185.2 $103.2 
Work-in-process (materials, labor and overhead)82.7 36.1 
Finished goods (materials, labor and overhead)295.1 59.5 
Total inventories$563.0 $198.8 
Inventories$524.1 $198.8 
Other assets (1)
38.9 — 
Total inventories$563.0 $198.8 
(1) Other assets includes inventory expected to remain on hand beyond one year.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
(In millions)January 1, 2023January 2, 2022
Prepaid expenses$96.7 $14.6 
Contract assets49.6 — 
Other receivables44.3 15.8 
Income taxes and other tax receivables38.6 — 
Derivatives22.0 0.1 
Other0.9 4.5 
Total prepaid expenses and other current assets$252.1 $35.0 
Property, Plant and Equipment, Net
The following is a summary of property, plant and equipment:
(In millions)January 1, 2023January 2, 2022
Equipment, furniture and fixtures$515.1 $159.0 
Building and improvements364.7 146.8 
Customer leased instruments434.5 68.1 
Land34.5 10.2 
Construction in progress268.4 105.2 
Total property, plant and equipment, gross1,617.2 489.3 
Less: accumulated depreciation and amortization(278.2)(140.1)
Total property, plant and equipment, net$1,339.0 $349.2 
Construction in progress reflects amounts incurred for construction or improvements of property, plant, or equipment that have not been made in service. In addition, construction in progress includes certain instruments that have not been placed at a customer under a lease agreement that will be reclassified to leased instruments once placed at a customer site. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $151.1 million, $24.3 million and $20.8 million for fiscal years 2022, 2021 and 2020, respectively.
97

Goodwill and Intangible Assets
Changes in goodwill were as follows:
(In millions)North AmericaEMEAChinaOtherTotal
Balance at January 2, 2022$337.0 
Impact of reportable segment revisions$336.9 $0.1 $— $— 337.0 
Goodwill acquired1,211.5 370.0 121.6 475.3 2,178.4 
Foreign currency translation(0.7)(11.5)(3.5)(22.9)(38.6)
Balance at January 1, 2023$1,547.7 $358.6 $118.1 $452.4 $2,476.8 
Intangible assets consisted of the following:
January 1, 2023January 2, 2022
DescriptionWeighted-average
useful life
(years)		Gross
assets		Accumulated
amortization		NetGross
assets		Accumulated
amortization		Net
Purchased technology14.3$997.6 $(120.0)$877.6 $112.7 $(78.2)$34.5 
Customer relationships19.22,023.5 (148.9)1,874.6 122.7 (77.3)45.4 
License agreements6.43.8 (3.7)0.1 6.6 (5.7)0.9 
Patent and trademark costs14.7400.5 (32.8)367.7 28.7 (15.7)13.0 
Software development costs4.711.5 (7.7)3.8 11.7 (6.8)4.9 
Total intangible assets$3,436.9 $(313.1)$3,123.8 $282.4 $(183.7)$98.7 
Amortization expense related to the capitalized software costs was $0.9 million, $1.0 million and $0.9 million for fiscal years 2022, 2021 and 2020, respectively. Amortization expense (including capitalized software costs) was $132.5 million, $27.4 million and $27.3 million for fiscal years 2022, 2021 and 2020, respectively.
The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of January 1, 2023 is as follows:
(In millions)
2023$205.4 
2024201.7 
2025188.2 
2026187.1 
2027184.7 
Other Current Liabilities
Other current liabilities consist of the following:
(In millions)January 1, 2023January 2, 2022
Accrued commissions and rebates$55.1 $15.9 
Deferred consideration39.3 41.9 
Deferred revenue76.4 1.9 
Operating lease liabilities24.4 10.0 
Accrued other taxes payable9.3 10.2 
Derivatives19.7 0.3 
Contingent consideration0.1 6.0 
Payables under transition services agreements— 10.9 
Other101.1 17.3 
Total other current liabilities$325.4 $114.4 
98

Note 8. Long-term Borrowings
The components of borrowings were as follows:
(In millions)January 1, 2023January 2, 2022
Term Loan$2,646.9 $— 
Revolving Credit Facility— — 
Financing lease obligation 0.8 0.7 
Other long-term borrowings1.2 — 
Unamortized deferred financing costs(10.6)— 
Total borrowings2,638.3 0.7 
Less: current portion(207.5)(0.3)
Long-term borrowings$2,430.8 $0.4 
On May 27, 2022, the Company entered into a credit agreement (the “Credit Agreement”) by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender (“Bank of America”), and the other lenders and L/C issuers party thereto (together with Bank of America, the “Lenders”). Pursuant to the Credit Agreement and in connection with the consummation of the Combinations, the Lenders provided the Company with a $2,750.0 million senior secured term loan facility (the “Term Loan”) and a $750.0 million revolving credit facility (the “Revolving Credit Facility” and with the Term Loan, the “Financing”). Effective August 4, 2022, pursuant to the Increase Joinder No. 1 to the Credit Agreement, the Revolving Credit Facility increased by $50.0 million to $800.0 million. The Financing is guaranteed by certain material domestic subsidiaries of the Company (the “Guarantors”) and is secured by liens on substantially all of the assets of the Company and the Guarantors, excluding real property and certain other types of excluded assets. Loans under the Credit Agreement will bear interest at a rate per annum equal to the Term SOFR or Base Rate plus the Applicable Rate (each as defined in the Credit Agreement). As of January 1, 2023, letters of credit issued under the Revolving Credit Facility totaled $13.1 million, which reduced the available amount under the Revolving Credit Facility to $786.9 million. In connection with the Credit Agreement, the Company incurred $15.4 million of debt issuance costs, of which $11.9 million was related to the Term Loan and $3.5 million was related to the Revolving Credit Facility. Debt issuance costs related to the issuance of the Term Loan were recorded as a reduction of the principal amount of the borrowings and are amortized using the effective interest method as a component of Interest expense, net over the life of the Term Loan. Debt issuance costs related to the Revolving Credit Facility were recorded as Other assets and are amortized on a straight-line basis over the term of the Revolving Credit Facility.
The Term Loan is subject to quarterly amortization of the principal amount on the last business day of each fiscal quarter of the Company (commencing on September 30, 2022). The required quarterly payments are 1.875% of the aggregate initial principal amount of the Term Loan through the fiscal second quarter of 2024, and 1.250% thereafter. The final remaining principal installment is due on the maturity date. The Term Loan and the Revolving Credit Facility will mature on May 27, 2027. The Company must prepay loans outstanding under the Credit Agreement in an amount equal to the Net Cash Proceeds (as defined in the Credit Agreement) from (i) certain property dispositions and (ii) the receipt of certain other amounts not in the ordinary course of business, such as certain insurance proceeds and condemnation awards, in each case, if not reinvested within a specified time period as contemplated in the Credit Agreement.
The Credit Agreement contains affirmative and negative covenants that are customary for credit agreements of this nature. The negative covenants include, among other things, limitations on asset sales, mergers, indebtedness, liens, investments and transactions with affiliates. The Credit Agreement contains two financial covenants: (i) a maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) as of the last day of each fiscal quarter of (a) 4.50 to 1.00 for the first four fiscal quarters ending after the closing date of the Credit Agreement (the “Initial Measurement Period”), (b) 4.00 to 1.00 for the first four fiscal quarters ending after the Initial Measurement Period and (c) 3.50 to 1.00 for each fiscal quarter thereafter; and (ii) a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of 3.00 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters. The Company was in compliance with the financial covenants as of January 1, 2023.
The Credit Agreement was entered into in connection with the Combinations in order to fund a portion of the cash portion of the purchase price as well as to repay substantially all of Ortho’s then-outstanding indebtedness. See Note 2 for more information regarding the Combinations. In connection with the closing of the Combinations, Quidel terminated its previous $175.0 million revolving credit facility and related credit agreement on May 27, 2022, which did not have an outstanding balance.
99

The following table provides the detailed amounts within Interest expense, net for fiscal years 2022, 2021 and 2020.
Fiscal Year Ended
(In millions)202220212020
Term Loan$73.0 $— $— 
Revolving Credit Facility1.5 0.3 0.3 
Amortization of deferred financing costs2.1 0.4 0.4 
Derivative instruments and other0.4 5.4 7.9 
Interest income(1.3)(0.3)(0.1)
Interest expense, net$75.7 $5.8 $8.5 
The following table provides a schedule of required future repayments of all borrowings outstanding as of January 1, 2023.
(In millions)
2023$207.5 
2024172.7 
2025137.5 
2026137.5 
20271,993.7 
Total$2,648.9 
Note 9. Leases
The Company leases administrative, R&D, sales and marketing and manufacturing facilities and certain equipment under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases, and may contain clauses for rent escalation, renewal options or early termination.
Operating lease cost for fiscal years 2022, 2021 and 2020 was $26.4 million, $15.4 million and $11.2 million, respectively. Variable lease cost for fiscal years 2022, 2021 and 2020 was $5.6 million, $2.7 million and $1.8 million, respectively. Finance leases are immaterial to the Company’s Consolidated Financial Statements.
The supplemental cash flow information related to operating leases during the respective periods was as follows:
Fiscal Year Ended
(In millions)202220212020
Cash paid for amounts included in the measurement of operating
     lease liabilities		$25.2 $12.3 $10.8 
ROU assets obtained in exchange for new lease liabilities$29.9 $37.3 $15.3 
100

The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable operating leases at the end of 2022 were as follows:
(In millions)
2023$32.7
202429.1
202526.4
202624.1
202721.3
Thereafter122.9
Total lease payments256.5
Less: imputed interest(45.7)
Total210.8
Less: current portion(24.4)
Non-current portion$186.4
Weighted average remaining lease term9.7 years
Weighted average discount rate4 %
Summers Ridge Lease — The Company leases four buildings that are located on the Summers Ridge property in San Diego, California with an initial term through January 2033 with options to extend the lease for two additional five-year terms upon satisfaction of certain conditions, which have not been included in the determination of the lease term. The must-take provisions related to the fourth building became effective in November 2022 upon expiration of the previous tenant’s lease. As a result, the Company recorded a ROU asset and a corresponding lease liability of approximately $20.6 million in November 2022.
Note 10. Stockholders' Equity
Preferred Stock
The Company’s Charter authorizes the issuance of up to 5.0 million shares of preferred stock. The Board is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. No shares of preferred stock were outstanding for fiscal years 2022, 2021 or 2020.
Equity Incentive Plan
In connection with the Combinations, the Company assumed Quidel’s 2018 Equity Incentive Plan, as amended and restated (the “Quidel Equity Plan”), including all form of award agreements and grants of awards issued thereunder, and shares of Quidel’s common stock (“Quidel Shares”) subject to the plan were replaced by an equivalent number of shares of QuidelOrtho’s common stock. In connection with the assumption of the Quidel Equity Plan, the Quidel Equity Plan was renamed the “QuidelOrtho Corporation Amended and Restated 2018 Equity Incentive Plan” (the “2018 Plan”) and all references to the “Company” in the Quidel Equity Plan were changed to QuidelOrtho. Also in connection with the Combinations, the Company assumed all obligations of Quidel pursuant to each stock option to purchase a Quidel Share and pursuant to each right to acquire or vest in a Quidel Share that was outstanding immediately prior to the closing of the Combinations, and all agreements relating to such equity awards.
The Company grants stock options, time-based RSUs and performance-based RSUs (“PSUs”) to employees and non-employee directors under the 2018 Plan. Quidel previously granted stock options under its 2016 Equity Incentive Plan (the “2016 Plan”), Amended and Restated 2010 Equity Incentive Plan (the “2010 Plan”) and Amended and Restated 2001 Equity Incentive Plan (the “2001 Plan”). The 2016 Plan, 2010 Plan and 2001 Plan were terminated at the time of adoption of the Quidel Equity Plan, but the terminated plans continue to govern outstanding options granted thereunder.
The Company has stock options, RSUs and PSUs outstanding, which were issued under these equity incentive plans to certain employees and non-employee directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $15.40 to $254.00 per share, and generally vest over four years. As of January 1, 2023, approximately 2.3 million shares of common stock remained available for grant and 4.1 million shares of common stock were reserved for future issuance under the 2018 Plan.
101

RSUs
The Company grants both RSUs and PSUs to certain officers and directors. Until the restrictions lapse, ownership of the shares underlying the affected RSUs or PSUs is conditional upon continuous employment with the Company and/or achievement of certain performance goals.
For fiscal years 2022, 2021 and 2020, the Company granted approximately 0.7 million, 0.1 million and 0.2 million shares of common stock, respectively, of RSUs to certain officers and directors, which either have a time-based, four-year vesting provision or performance-based vesting provision.
During fiscal years 2022, 2021 and 2020, RSUs were granted to certain members of the Board in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants was $0.6 million, $0.6 million and $0.5 million for fiscal years 2022, 2021 and 2020, respectively.
Employee Deferred Bonus Compensation Program
For fiscal years 2022, 2021 and 2020, certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the value of their cash bonus in the form of fully vested RSUs, plus a premium as additional RSUs, issued under the 2018 Plan. The premium RSUs are subject to a one-year vesting requirement from the date of issuance. The additional premium is determined based on the length of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred.
Employee Stock Purchase Plan
In connection with the Combinations, the Company assumed Quidel’s 1983 Employee Stock Purchase Plan, as amended and restated (the “Quidel ESPP”), and the Quidel Shares subject to the Quidel ESPP were replaced by an equivalent number of shares of QuidelOrtho’s common stock. In connection with the assumption of the Quidel ESPP, the Quidel ESPP was renamed the “QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan” (the ESPP) and all references to the “Company” in the Quidel ESPP were changed to QuidelOrtho.
Under the ESPP, full-time employees were allowed to purchase common stock through payroll deductions (which could not exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six-month purchase period. As of January 1, 2023, 736,630 shares of common stock remained available for future issuance.
Stock Repurchase Program
On December 18, 2018, Quidel announced a stock repurchase program to repurchase up to $50.0 million of its common stock, which was authorized by Quidel’s board of directors (the “Quidel Board”) on December 12, 2018. On August 28, 2020, the Board authorized an increase of an additional $150.0 million to Quidel’s existing stock repurchase program authorization, which was announced on September 1, 2020. The Board also extended the stock repurchase program through August 28, 2022. In connection with the consummation of the Combinations, Quidel’s stock repurchase program was terminated. On August 17, 2022, the Board authorized a stock repurchase program, allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024 (the “Stock Repurchase Program”).
During fiscal year 2022, 953,468 shares of outstanding common stock were repurchased under the Stock Repurchase Program. As of January 1, 2023, the Company had approximately $225.7 million available under the Stock Repurchase Program. During fiscal years 2021 and 2020, 957,239 and 257,329 shares of outstanding common stock were repurchased under Quidel’s stock repurchase program.
Note 11. Stock-based Compensation
Stock-based compensation expense was as follows:
Fiscal Year Ended
(In millions)202220212020
Cost of sales$2.9 $2.7 $2.0 
Research and development4.9 4.4 3.4 
Selling, marketing and administrative
27.4 18.3 15.6 
Acquisition and integration costs30.4 — — 
Total stock-based compensation expense$65.6 $25.4 $21.0 
102

The table above includes $17.2 million of compensation expense related to liability-classified awards for fiscal year 2022, which has been or is expected to be settled in cash. These awards represent the $7.14 per share cash settled portion of the replacement awards issued in connection with the Combinations.
For fiscal years 2022, 2021 and 2020, the Company recorded $3.7 million, $3.0 million and $2.2 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 10. During fiscal years 2022, 2021 and 2020, $3.3 million, $2.8 million and $2.1 million, respectively, were initially recorded as a component of accrued payroll and related expenses associated with the deferred bonus compensation program.
Stock Options
A summary of the status of stock option activity for fiscal year 2022 is as follows:
(In thousands, except price data)
SharesWeighted-Average
Exercise Price
Per Share		Weighted-Average
Remaining Contractual Term (In Years)		Aggregate Intrinsic Value
Outstanding at January 2, 2022722 $62.71 
Granted187 100.45 
Stock options assumed in the Combinations1,229 96.10 
Exercised(383)55.15 
Forfeited(99)115.95 
Outstanding at January 1, 20231,656 $90.34 5.53$28,140 
Vested and expected to vest at January 1, 20231,600 $89.23 5.45$28,122 
Exercisable at January 1, 20231,195 $80.53 4.61$26,774 
Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants, including grants related to options assumed in the Combinations presented separately:
Assumed on
Fiscal Year Ended
May 27, 2022 (1)
January 1, 2023January 2, 2022January 3, 2021
Risk-free interest rate2.28 %1.96 %0.48 %1.18 %
Expected option life (in years)1.784.804.995.12
Volatility rate64 %57 %54 %41 %
Dividend rate0 %0 %0 %0 %
Weighted-average grant date fair value$40.57$50.62$106.55$36.84
(1) The replacement stock options granted to Ortho option holders on the closing date of the Combinations were issued consistent with the vesting conditions of the replaced award. The fair value on the closing date of the Combinations attributed to post-combination service, adjusted for estimated forfeitures, is recognized as expensed on a straight-line basis over the remaining vesting period.
The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the US Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations.
The Company’s determination of fair value is affected by the Company’s stock price, as well as a number of assumptions that require judgment. The total intrinsic value was $13.7 million, $9.9 million and $51.8 million for options exercised during fiscal years 2022, 2021, and 2020, respectively. As of January 1, 2023, total unrecognized compensation expense related to stock options was approximately $27.2 million and the related weighted-average period over which it is expected to be recognized is approximately 3.4 years. The maximum contractual term of the Company’s stock options is ten years.
103

RSUs
A summary of the status of RSU activity for fiscal year 2022 is as follows:
(In thousands, except price data)
SharesWeighted-Average
Grant Date
Fair Value
Non-vested at January 2, 2022587 $95.81 
Granted720 97.31 
Stock awards assumed in the Combinations49 99.60 
Vested(248)86.61 
Forfeited(76)100.70 
Non-vested at January 1, 20231,032 $98.89 
The total amount of unrecognized compensation expense related to non-vested RSUs as of January 1, 2023 was approximately $62.7 million, which is expected to be recognized over a weighted-average period of approximately 2.1 years.
The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date. The weighted-average fair value of RSUs granted during the fiscal years ended January 2, 2022 and January 3, 2021 was $188.06 and $101.20, respectively.
Note 12. Commitments and Contingencies
Purchase Obligations
The Company had $247.8 million of purchase obligations as of January 1, 2023, the majority of which is expected to be purchased in the next year. These purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including (i) fixed or minimum quantities to be purchased, (ii) fixed, minimum or variable price provisions and (iii) the approximate timing of the transaction, as well as amounts for planned inventory purchases under contractual arrangements.
Litigation and Other Legal Proceedings
From time to time, the Company is involved in litigation and other legal proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment, and other claims related to its business. The Company accrues for legal claims when, and to the extent that, amounts associated with the claims become probable and are reasonably estimable. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from these matters are inherently difficult to predict. The actual costs of resolving legal claims may be substantially higher or lower than the amounts accrued for those claims. For those matters as to which the Company is not able to estimate a possible loss or range of loss, the Company is not able to determine whether the loss will have a material adverse effect on its business, financial condition, results of operations or liquidity. No accrual has been recorded as of January 1, 2023 and January 2, 2022 related to such matters as they are not probable and/or reasonably estimable.
Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. However, the resolution of, or increase in any accruals for, one or more matters may have a material adverse effect on the Company’s results of operations and cash flows.
Licensing Arrangements
The Company has entered into various licensing and royalty agreements, which largely require payments by the Company based on specified product sales, as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $1.1 million, $2.0 million and $2.4 million for fiscal years 2022, 2021 and 2020, respectively.
104

Note 13. Fair Value Measurements
The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods:
 January 1, 2023January 2, 2022
(In millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$0.6 $2.1 $— $2.7 $204.7 $6.6 $— $211.3 
Marketable securities2.0 71.1 — 73.1 — 63.6 — 63.6 
Derivative assets— 22.0 — 22.0 — 0.1 — 0.1 
Total assets measured at fair value$2.6 $95.2 $— $97.8 $204.7 $70.3 $— $275.0 
Liabilities:
Derivative liabilities$— $21.8 $— $21.8 $— $0.3 $— $0.3 
Contingent consideration— — 0.1 0.1 — — 6.1 6.1 
Deferred consideration— 39.3 — 39.3 — 78.4 — 78.4 
Total liabilities measured at fair value$— $61.1 $0.1 $61.2 $— $78.7 $6.1 $84.8 
There were no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy during fiscal years 2022 and 2021.
Cash equivalents consist of funds held in money market accounts that are valued using quoted prices in active markets for identical instruments and highly liquid corporate debt securities with maturities within three months from purchase. Marketable securities consist of investment-grade corporate and government debt securities, corporate asset-backed securities and commercial paper. Derivative financial instruments are based on observable inputs that are corroborated by market data. Observable inputs include broker quotes, daily market foreign currency rates and forward pricing curves.
In connection with the acquisition of the BNP Business from Alere Inc., the Company will pay annual installments of up to $48.0 million each year through April 2023. The fair value of the payments treated as deferred consideration is calculated based on the net present value of cash payments using an estimated borrowing rate based on a quoted price for a similar liability. The fair value of the payments treated as contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are significant assumptions that are not observed in the market and, therefore, the resulting fair value represents a Level 3 measurement.
Changes in estimated fair value of contingent consideration liabilities from January 3, 2021 through January 1, 2023 were as follows:
(In millions)Contingent Consideration
Liabilities
(Level 3 Measurement)
Balance at January 3, 2021$11.9 
Cash payments(6.0)
Change in estimated fair value, recorded in selling, marketing and administrative expenses0.2 
Balance at January 2, 2022$6.1 
Cash payments(6.0)
Balance at January 1, 2023$0.1 
Financial Instruments Not Measured at Fair Value
The estimated fair value of the Company’s borrowings under the Term Loan was $2,630.3 million at January 1, 2023, compared to the carrying amount, excluding debt issuance costs, of $2,646.9 million. The estimate of fair value is generally based on the quoted market prices for similar issuances of long-term debt with the same maturities, which is classified as a Level 2 input.
105

Note 14. Derivative Instruments and Hedging Activities
The Company selectively uses derivative and non-derivative instruments to manage market risk associated with changes in interest rates and foreign currency exchange rates. The use of derivatives is intended for hedging purposes only, and the Company does not enter into derivative transactions for speculative purposes.
Credit risk represents the Company’s gross exposure to potential accounting loss on derivative instruments that are outstanding or unsettled if all counterparties failed to perform according to the terms of the contract. The Company generally enters into master netting arrangements that reduce credit risk by permitting net settlement of transactions with the same counterparty. The Company does not have any derivative instruments with credit-risk related contingent features that would require it to post collateral.
Interest Rate Hedging Instruments
The Company’s interest rate risk relates primarily to interest rate exposures on variable rate debt, including the Revolving Credit Facility and Term Loan. See Note 8 for additional information on the currently outstanding components of the Revolving Credit Facility and Term Loan. The Company entered into interest rate cap and swap agreements to hedge the related risk of the variability to the Company’s cash flows due to the rates specified for these credit facilities.
The Company designates certain interest rate derivative instruments as cash flow hedges, including the outstanding interest rate swaps. The Company records gains and losses due to changes in fair value of the derivatives within Other comprehensive income (loss) (“OCI”) and reclassifies these amounts to Interest expense, net in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the hedge is prospectively de-designated. Pre-tax unrealized gains of $25.1 million are expected to be reclassified from OCI to earnings in the next 12 months.
The following table summarizes the Company’s interest rate derivative agreements as of January 1, 2023, all of which were interest rate swaps:
Notional Amount
(In millions) (1)
DescriptionHedge DesignationEffective DateExpiration Date
$500.0 
Pay 1.58% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeMay 29, 2022December 31, 2023
397.2 
Pay 3.765% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
144.4 
Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
216.7 
Pay 3.7675% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
288.9 
Pay 3.7575% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
252.8 
Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
(1) The notional value of interest rate swap contracts with an effective date of December 30, 2022, is expected to increase to $1.8 billion on December 29, 2023.
During the fourth quarter of 2022, the Company terminated its non-designated $1.0 billion notional value 3.428% interest rate cap. As a result of this termination in fiscal year 2022, the Company recognized an immaterial gain within Other expense (income), net and received $3.3 million of cash proceeds, presented within operating activities in the Consolidated Statements of Cash Flows.
Currency Hedging Instruments
The Company has currency risk exposures relating primarily to foreign currency denominated monetary assets and liabilities and forecasted foreign currency denominated intercompany and third-party transactions. The Company uses foreign currency forward contracts and may use option contracts and cross currency swaps to manage its currency risk exposures. The Company’s foreign currency forward contracts are denominated primarily in Australian Dollar, Brazilian Real, British Pound, Canadian Dollar, Chilean Peso, Chinese Yuan/Renminbi, Euro, Indian Rupee, Japanese Yen, Mexican Peso, Swiss Franc and the Thai Baht.
The Company designates certain foreign currency forward contracts as cash flow hedges. The Company records gains and losses due to changes in fair value of the derivatives within OCI and reclassifies these amounts to Total revenues and Cost of
106

sales, excluding amortization of intangibles in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the hedge is prospectively de-designated. The pre-tax unrealized loss of $7.9 million within OCI as of January 1, 2023 is expected to be reclassified to earnings in the next 12 months.
The Company also enters into foreign currency forward contracts that are not part of designated hedging relationships and which are intended to mitigate exchange rate risk of monetary assets and liabilities and related forecasted transactions. The Company records these non-designated derivatives at mark-to-market with gains and losses recognized in earnings within Other expense (income), net.
The following table provides details of the currency hedging instruments outstanding as of January 1, 2023:
DescriptionNotional Amount
(In millions)		Hedge Designation
Foreign currency forward contracts$441.6 Cash Flow Hedge
Foreign currency forward contracts581.7 Non-designated
The following table summarizes pre-tax gains and losses from designated derivative and non-derivative instruments within accumulated other comprehensive (loss) income (“AOCI”) for fiscal year 2022:
Designated Hedging Instruments
(In millions)Amount of Loss (Gain) Recognized in OCI on HedgesLocation of Amounts Reclassified From AOCI Into IncomeAmount of Loss (Gain) Reclassified From AOCI Into Income
Foreign currency forward contracts (sales)$1.3 Total revenues$(2.9)
Foreign currency forward contracts (purchases)3.5 Cost of sales, excluding amortization of intangibles(0.6)
Interest rate derivatives(11.4)Interest expense, net(1.7)
Gains and losses from designated derivative and non-derivative instruments within AOCI for fiscal years 2021 and 2020 were not material.
The following table summarizes the fair value of designated and non-designated hedging instruments recognized within the Consolidated Balance Sheets as of January 1, 2023 and January 2, 2022:
(In millions)January 1, 2023January 2, 2022
Designated cash flow hedges
Interest rate derivatives:
Prepaid expenses and other current assets$15.9 $— 
Other liabilities2.1 — 
Foreign currency forward contracts:
Prepaid expenses and other current assets4.6 0.1 
Other current liabilities14.3 0.2 
Non-designated hedging instruments
Foreign currency forward contracts:
Prepaid expenses and other current assets1.5 — 
Other current liabilities5.4 0.1 
Note 15. Long-term Employee Benefits
Defined Benefit Plans and Other Post-employment Benefits
In connection with the Combinations, the Company assumed certain defined benefit plan obligations and acquired related plan assets for employees of non-U.S. subsidiaries.
107

In addition to these defined benefit plans, the Company also assumed one non-U.S. post-employment benefit plan and a replacement retiree health care reimbursement plan for certain U.S employees. The U.S. plan is funded on a pay-as-you-go basis and is not accepting new participants.
Obligation and Funded Status
The measurement date used to determine the defined benefit and other post-employment benefits obligations was January 1, 2023. The following tables set forth the changes to the projected benefit obligations (“PBO”) and plan assets:
Fiscal Year Ended
(In millions)January 1, 2023
Defined Benefit Plans
Change in benefit obligation:
Projected benefit obligation at beginning of year$— 
Service cost1.2 
Interest cost0.4 
Benefits paid(0.3)
Actuarial gain(0.6)
Assumed obligation from the Combinations33.3 
Settlements(0.2)
Foreign currency exchange rate changes0.1 
Projected benefit obligation at end of year$33.9 
Change in plan assets:
Fair value of plan assets at beginning of year$— 
Actual return on plan assets(0.5)
Employer contributions1.6 
Benefits paid(0.3)
Transfers in from the Combinations20.1 
Settlements(0.2)
Foreign currency exchange rate changes(0.1)
Fair value of plan assets at end of year$20.6 
Funded status at end of year$(13.3)
Amounts recognized on the consolidated balance sheets:
Other assets$0.4 
Other current liabilities(0.3)
Other liabilities(13.4)
Net amount recognized$(13.3)
108

Fiscal Year Ended
(In millions)January 1, 2023
Other Post-employment Benefits
Change in benefit obligation:
Projected benefit obligation at beginning of year$18.9 
Service cost0.3 
Interest cost0.4 
Benefits paid(0.7)
Actuarial gain(0.7)
Assumed obligation from the Combinations0.4 
Projected benefit obligation at end of year$18.6 
Amounts recognized on the consolidated balance sheets:
Other current liabilities $(3.5)
Other liabilities(15.1)
Net amount recognized$(18.6)
PBO is the actuarial present value of benefits attributable to employee service rendered to date and reflects the effects of estimated future pay increases. The accumulated benefit obligation (“ABO”) is the actuarial present value of benefits attributable to employee service to date, but does not include the effects of estimated future pay increases.
The following table reflects the ABO for all defined benefit plans as of January 1, 2023. Further, the table reflects the aggregate PBO, ABO and fair value of plan assets for pension plans with PBO in excess of plan assets and for pension plans with ABO in excess of plan assets.
(In millions)January 1, 2023
ABO$27.1 
Plans with PBO in excess of plan assets
PBO$18.3 
Fair value of plan assets5.1
Plans with ABO in excess of plan assets
PBO$17.0 
ABO14.3
Fair value of plan assets3.8
The pretax amounts that are not yet reflected in the net periodic benefit cost and are included in AOCI as of January 1, 2023 include the following:
Fiscal Year Ended
(In millions)2022
Defined Benefit Plans
Accumulated net actuarial gains (losses)$(0.2)
Other Post-employment Benefits
Accumulated net actuarial gains (losses)$0.7 
These accumulated net actuarial gains (losses) for defined benefit plans and other post-employment benefits primarily relate to differences between the actual net periodic expense and the expected net periodic expense from differences in significant assumptions, including primarily return on plan assets and discount rates used in these estimates.
109

Components of Net Periodic Benefit Cost
Net periodic benefit cost for the Company’s defined benefit plans was $1.4 million for the fiscal year ended January 1, 2023 and was primarily related to service cost. Changes in plan assets and benefit obligations recognized in other comprehensive income was not material for fiscal year 2022.
Net periodic benefit cost for the Company’s other post-employment benefit plans was $0.7 million for the fiscal year ended January 1, 2023 and was primarily related to interest cost. Changes in benefit obligations recognized in other comprehensive income was not material for fiscal year 2022.
The components of net periodic benefit cost other than the service cost component are recorded in Other expense (income), net in the Consolidated Statements of Income.
Assumptions and Sensitivities
In connection with the preliminary purchase price allocation for the Combinations, the Company recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following assumptions were used to measure the fair value of the benefit obligations and associated plan assets:
May 27, 2022January 1, 2023
Defined Benefit Plans
Weighted average discount rate2.2 %3.1 %
Weighted average rate of compensation increases2.6 %3.0 %
Other Post-employment Benefit Plans
Weighted average discount rate4.0 %5.5 %
The critical assumptions used in determining the net periodic benefit cost for fiscal year 2022 are as follows:
Defined Benefit Plans
Weighted average discount rate2.2 %
Weighted average expected rate of compensation increases2.6 %
Weighted average expected return on plan assets2.5 %
Other Post-employment Benefit Plans
Weighted average discount rate4.0 %
The discount rates used reflect the expected future cash flow based on plan provisions, participant data and the currencies in which the expected future cash flows will occur. For the majority of defined benefit obligations, the Company utilizes prevailing long-term high quality corporate bond indices applicable to the respective country at the measurement date. In countries where established corporate bond markets do not exist, the Company utilizes other index movement and duration analysis to determine discount rates. The long-term rate of return on plan assets assumptions reflect economic assumptions applicable to each country and assumptions related to the preliminary assessments regarding the type of investments to be held by the respective plans.
The discount rate is determined as of each measurement date, based on a review of yield rates associated with long-term, high-quality corporate bonds. The calculation separately discounts benefit payments using the spot rates from a long-term, high-quality corporate bond yield curve.
The long-term rate of return on plan assets assumption represents the expected average rate of earnings on the funds invested to provide for the benefits included in the benefit obligations and is determined based on a number of factors, including historical market index returns, the anticipated long-term allocation of the plans, historical plan return data, plan expenses and the potential to outperform market index returns.
110

A significant factor in estimating future per capita cost of covered healthcare benefits for retirees is the healthcare cost trend rate assumption. The health care cost trend rate assumptions for other post-retirement benefit plans are as follows:
January 1, 2023
Health care cost trend rate assumed for next year - Pre-656.44 %
Health care cost trend rate assumed for next year - Post-656.10 %
Rate to which the cost trend rate is assumed to decline4.00 %
Year that the trend rate reaches the ultimate trend rate 2047
Anticipated Contributions to Defined Benefit Plans
For funded plans, our policy is to fund amounts for defined benefit plans sufficient to meet minimum requirements set forth in applicable benefit and local tax laws. Based on the same assumptions used to measure the defined benefit obligations at January 1, 2023, the Company expects to contribute $2.0 million to defined benefit plans in fiscal year 2023.
Estimated Future Benefit Payments
The following table reflects the total benefit payments expected to be made for defined benefit plans and other long-term post-employment benefits:
(In millions)Defined Benefit PlansOther Post-employment Benefit Plans
Fiscal Year 2023$1.7 $3.5 
Fiscal Year 20243.54.0
Fiscal Year 20252.13.3
Fiscal Year 20262.22.2
Fiscal Year 20272.31.9
Fiscal Years 2028-203212.65.5
Plan Assets
The tables below present the fair value of the defined benefit pension plans by level within the fair value hierarchy, as described in Note 1, at January 1, 2023.
Fair Value Measurements at January 1, 2023
(In millions)TotalLevel 1Level 2Level 3
U.S. equity securities$2.2 $2.2 $— $— 
Japan equity securities3.7 3.7 — — 
Other international equity securities1.6 1.6 — — 
U.S. government bonds0.2 0.2 — — 
Japan government bonds0.5 0.5 — — 
Other international government bonds1.6 1.6 — — 
Cash and cash equivalents4.7 4.7 — — 
Insurance contracts6.1 — — 6.1 
Total$20.6 $14.5 $— $6.1 
The Company has funded defined benefit plans in Japan, Belgium and Switzerland. The Japanese plan asset consists primarily of Japan equity and government bond securities, U.S. equity and government bond securities, other international equity and debt securities and cash and cash equivalents. The plan assets are invested in assets with quoted prices in active markets and therefore are classified as Level 1 assets. The Company’s investment strategy is to maintain a target rate of return that is higher than that required to maintain sound pension plan management into the future. In order to achieve its investment targets, the Company has established an asset composition ratio which was formulated from a long-term perspective, taking into account the maturity of the pension plan and other factors. The Company considers expected returns and risks of returns, as well as the correlation between the returns of each investment asset, the diversification of its investments, and other factors related to risk management in order to maximize returns in accordance with its targeted asset mix to achieve its investment targets. The target
111

allocation rates of the Japanese plan is 44% for debt securities, 55% for equity securities and 2% for other assets. The Belgium and Switzerland plan assets consist solely of insurance contracts that are pledged on behalf of employees with benefits in certain countries and are classified as Level 3 assets.
The table below presents a roll-forward of activity for the Level 3 assets for fiscal year 2022:
(In millions)Level 3 Assets
Balance at January 2, 2022$— 
Transfers in5.5
Net purchases and settlements0.6
Balance at January 1, 2023$6.1 
Defined Contribution Plans
The Company offers defined contribution plans to eligible employees primarily in the U.S., whereby employees contribute a portion of their compensation. Company matching and other Company contributions are also provided to the plans. Once Company matching contributions have been paid, the Company has no further payment obligations. The Company’s contributions for its employees totaled approximately $15.1 million, $3.8 million and $3.1 million for fiscal years ended 2022, 2021 and 2020, respectively, which are recognized as expense as incurred in the Consolidated Statements of Income. The increase in Company contributions for fiscal year 2022 was due to defined contribution plans assumed in connection with the Combinations.
Note 16. Related Party Transactions
Quotient Limited
As a result of the consummation of the Combinations, the Company acquired Ortho’s Letter Agreement (the “Letter Agreement”), entered into in September 2020, with Quotient Limited (“Quotient”), in which Ortho partnered with Quotient to commercialize, when approved, the next generation product in immunohematology, a transfusion diagnostic patient immunohematology microarray intended for use with Quotient’s MosaiQ instruments (the “IH3 Microarray”) that enables a high level of multiplexing and addresses the ultra-high throughput market. Under the Letter Agreement, Ortho will have the right to distribute, market and sell the IH3 Microarrays in the European Economic Area, the U.K. and Switzerland (collectively, the “European Territory”) and the U.S., solely for use in testing the immunohematological profile of the blood of medical patients in the course of their care or treatment. Quotient retains the right to distribute, market and sell the IH3 Microarrays for use in blood donor testing worldwide and in the patient testing market outside of the European Territory and the U.S. Ortho’s rights with respect to the IH3 Microarray are exclusive so long as Ortho satisfies its obligation to meet annual minimum purchase volume requirements in each territory. Under the Letter Agreement, Ortho also has the non-exclusive right to sell and distribute MosaiQ instruments in the U.S. and the European Territory for use in testing the immunohematological profile of blood of medical patients in the course of their care or treatment.
Under the Letter Agreement, Ortho is also required to purchase the IH3 Microarrays, and the instruments, controls and reagents required for their use, only from Quotient at specified prices. Ortho is also required to make milestone payments to Quotient as specified milestones and benchmarks are achieved. Ortho will be obligated to pay up to $60 million in milestone payments to Quotient upon its achievement of certain regulatory milestones and the achievement by Ortho of commercial sales benchmarks related to MosaiQ, including a milestone payment of up to $25 million upon the achievement by Ortho of certain cumulative gross revenue hurdles. The Company did not make such payments during fiscal year 2022. Due to the Company’s equity method investment held in Quotient, the Company concluded that Quotient is a related party of the Company.
On January 10, 2023, Quotient filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Proceeding”). The Company is evaluating the impact of the Bankruptcy Proceeding and the related changes in Quotient’s business strategy on the Letter Agreement.
Under a separate supply agreement between Ortho and Alba Biosciences, a wholly owned subsidiary of Quotient, which was also acquired by the Company as a result of the consummation of the Combinations, the Company purchased inventories from Alba Biosciences amounting to $15.4 million during fiscal year 2022. As of January 1, 2023, Accounts payable included amounts related to purchases from Alba Biosciences of $3.7 million. Quotient has stated that none of its subsidiaries intend to file voluntary petitions for relief under the Bankruptcy Code, and that each of its subsidiaries expects to continue to operate its respective business in the ordinary course unaffected by the Bankruptcy Proceeding. The Company will continue to monitor the situation.
112

Note 17. Accumulated Other Comprehensive Income (Loss)
The balance of AOCI, net of tax, was as follows for fiscal year 2022:
(In millions)Pension and Other Post-
employment Benefits		Cash Flow HedgesAvailable-for-Sale InvestmentsUnrealized Foreign Currency Translation AdjustmentsAccumulated Other Comprehensive Income (Loss)
Beginning balance$— $— $(0.1)$0.5 $0.4 
Current period deferrals0.7 6.7 (0.4)(69.8)(62.8)
Amounts reclassified to net income— (5.2)— — (5.2)
Net change0.7 1.5 (0.4)(69.8)(68.0)
Ending balance$0.7 $1.5 $(0.5)$(69.3)$(67.6)
Amounts related to fiscal years 2021 and 2020 were not material.
113

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of disclosure controls and procedures: We have performed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of January 1, 2023 at a reasonable assurance level to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures.
Changes in internal control over financial reporting: As of January 1, 2023, management is in the process of integrating the internal controls of the acquired Ortho business into our existing operations as part of planned integration activities. There were no other changes in our internal control over financial reporting during the fiscal quarter ended January 1, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Management’s report on internal control over financial reporting: Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such terms are defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our CEO and CFO, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of January 1, 2023.
In accordance with SEC guidance, we have excluded from the scope of our assessment of internal control over financial reporting the operations and related assets of Ortho, which we acquired on May 27, 2022. At January 1, 2023 and for the period from acquisition through January 1, 2023, total assets and total revenues subject to Ortho’s internal control over financial reporting represented 22% and 36%, respectively, of our consolidated total assets and total revenues as of and for the fiscal year ended January 1, 2023.
The effectiveness of our internal control over financial reporting as of January 1, 2023 has been audited by Ernst & Young LLP, our independent registered public accounting firm, as stated in their report, which is included in this Item 9A.
114

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of QuidelOrtho Corporation
Opinion on Internal Control over Financial Reporting
We have audited QuidelOrtho Corporation’s internal control over financial reporting as of January 1, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, QuidelOrtho Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of January 1, 2023, based on the COSO criteria.
As indicated in the accompanying Management’s Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Ortho which is included in the 2022 consolidated financial statements of the Company and constituted 22% of total assets as of January 1, 2023 and 36% of revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Ortho.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of January 1, 2023 and January 2, 2022, the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows, for each of the three years in the period ended January 1, 2023, and the related notes and our report dated February 23, 2023 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

115

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
San Diego, California
February 23, 2023
116

Item 9B. Other Information
Effective on February 22, 2023, the Board approved a change of the Company’s registered agent and registered office. The Company filed a Change of Registered Agent and/or Registered Office (the “Certificate of Change”) with the Secretary of State of the State of Delaware to change the Company’s registered agent to Registered Agent Solutions, Inc. and its registered office to 838 Walker Road, Suite 21-2, Dover, County of Kent, Delaware 19904. The Certificate of Change was approved by the Board in accordance with Delaware law and has the effect of amending Section 2 of the Company’s Charter.
A copy of the Certificate of Change is attached as Exhibit 3.3 to this Annual Report and incorporated herein by reference.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
117

Part III
Item 10. Directors, Executive Officers and Corporate Governance

The information required by this item is incorporated herein by reference to our 2023 proxy statement to be filed with the SEC within 120 days of the year ended January 1, 2023 (the “2023 Proxy Statement”), including under the headings “Board of Directors and Corporate Governance,” “Information about our Executive Officers,” “Business Ethics and Compliance” and “Delinquent Section 16(a) Reports,” if applicable.
Item 11. Executive Compensation

The information required by this item is incorporated herein by reference to our 2023 Proxy Statement, including under the headings “Executive Compensation,” “Compensation Committee Interlocks and Insider Participation” and “Compensation Committee Report.”
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item is incorporated herein by reference to our 2023 Proxy Statement, including under the headings “Securities Available for Issuance under our Equity Compensation Plans” and “Security Ownership of Certain Beneficial Owners and Management.”
Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item is incorporated herein by reference to our 2023 Proxy Statement, including under the headings “Review and Approval of Related Party Transactions,” “Related Party Transactions” and “Director Independence.”
Item 14. Principal Accountant Fees and Services

The information required by this item is incorporated herein by reference to our 2023 Proxy Statement, including under the heading “Independent Registered Public Accounting Firm.”
118

Part IV
Item 15. Exhibits and Financial Statement Schedules
The following documents are filed as part of this Form 10-K:
 
(a)(1) Financial Statements
The Consolidated Financial Statements required by this Item are submitted in Part II, Item 8 of this Annual Report.
(2) Financial Statement Schedules
Financial Statement Schedules have been omitted because of the absence of conditions under which they are required or because the required information is included in the Consolidated Financial Statements or the Notes thereto.
(3) Exhibits
See Item 15(b) below.
 
(b)Exhibits
The Exhibit Index immediately following this Item 15 is filed as part of, and incorporated by reference into, this Annual Report.
 
(c)Financial Statements required by Regulation S-X which are excluded from this Annual Report by Rule 14(a)-3(b).
Not applicable.
EXHIBIT INDEX

Exhibit NumberDescription
119

Exhibit NumberDescription
120

Exhibit NumberDescription
101*The following financial statements from the Registrant’s Annual Report on Form 10-K for the year ended January 1, 2023, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.
104The cover page from the Registrant’s Annual Report on Form 10-K for the year ended January 1, 2023, formatted in Inline XBRL (included as Exhibit 101).
*Filed herewith.
**Furnished herewith.
(1) Indicates a management plan or compensatory plan or arrangement.
+ Certain identified information has been omitted by means of marking such information with asterisks in reliance on Items 601(b)(2)(ii) and 601(b)(10)(iv) of Regulation S-K, as applicable, because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

Item 16. Form 10-K Summary
None.
121

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
QUIDELORTHO CORPORATION
By
/s/ DOUGLAS C. BRYANT
Date: February 23, 2023
Douglas C. Bryant
President and Chief Executive Officer
(Principal Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
 
SignatureTitleDate
/s/ DOUGLAS C. BRYANT
Director, President and Chief Executive Officer
(Principal Executive Officer)
February 23, 2023
Douglas C. Bryant
/s/ JOSEPH M. BUSKY
Chief Financial Officer
(Principal Financial and Accounting Officer)
February 23, 2023
Joseph M. Busky
/s/ KENNETH F. BUECHLER
Chairman of the Board
February 23, 2023
Kenneth F. Buechler
/s/ EVELYN S. DILSAVER
Director
February 23, 2023
Evelyn S. Dilsaver
/s/ EDWARD L. MICHAEL
Director
February 23, 2023
Edward L. Michael
/s/ MARY LAKE POLAN
Director
February 23, 2023
Mary Lake Polan
/s/ ANN D. RHOADS
Director
February 23, 2023
Ann D. Rhoads
/s/ ROBERT R. SCHMIDT
Director
February 23, 2023
Robert R. Schmidt
/s/ CHRISTOPHER M. SMITH
Director
February 23, 2023
Christopher M. Smith
/s/ MATTHEW W. STROBECK
Director
February 23, 2023
Matthew W. Strobeck
/s/ KENNETH J. WIDDER
Director
February 23, 2023
Kenneth J. Widder
/s/ JOSEPH D. WILKINS JR.
Director
February 23, 2023
Joseph D. Wilkins Jr.
/s/ STEPHEN H. WISE
Director
February 23, 2023
Stephen H. Wise
122
 EX-3.3 2 ex3310-k2022.htm EX-3.3 Document

Exhibit 3.3

STATE OF DELAWARE
CERTIFICATE OF CHANGE OF REGISTERED AGENT
AND/OR REGISTERED OFFICE
QuidelOrtho Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows:
1.The name of the Corporation is QUIDELORTHO CORPORATION.

2.The Registered Office of the Corporation in the State of Delaware is changed to 838 Walker Road, Suite 21-2, Dover, County of Kent, Delaware 19904. The name of the Registered Agent at such address upon whom process against the Corporation may be served is Registered Agent Solutions, Inc.

3.The foregoing change to the Registered Office/Agent was adopted by a resolution of the Board of Directors of the Corporation.


 
By:
 /s/ Phillip S. Askim
Name:
 
Philip S. Askim
Title:
 
Secretary


 EX-4.2 3 ex4210-kx2022.htm EX-4.2 Document
Exhibit 4.2

Description of QuidelOrtho Corporation’s Securities
Registered Pursuant to Section 12 of the
Securities Exchange Act of 1934

The following information is a summary of the material terms of the capital stock of QuidelOrtho Corporation (the “Company”) and is subject to, and qualified in its entirety by reference to, the more complete descriptions of the Company’s capital stock in its Amended and Restated Certificate of Incorporation, as amended (the “Charter”), and its Amended and Restated Bylaws (the “Bylaws”), copies of which are filed as exhibits to the Company’s Annual Report on Form 10-K, to which this exhibit is also appended.
The Company’s authorized capital stock consists of 126,200,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share.
Common Stock
The Charter authorizes the issuance of up to 126,200,000 shares of common stock. All outstanding shares of common stock are validly issued, fully paid and nonassessable.
Voting. Except as otherwise required by law (and subject to the rights of any other outstanding capital stock under the Charter), each outstanding share of common stock is entitled to vote on each matter on which the Company’s stockholders are entitled to vote, and each holder thereof shall be entitled to one vote for each share of common stock held by such holder. Common stockholders do not have cumulative voting rights.
Dividends. Common stockholders have the right to receive dividends when, as and if declared by the Company’s board of directors (the “Board”) from funds legally available therefor.
Special Meetings and Notice Procedures. The Bylaws provide that special meetings of stockholders may only be called by stockholders of record, as of the record date fixed as provided therein, holding in the aggregate not less than 50% of the voting power of the Company’s issued and outstanding capital stock. In addition, the Bylaws establish an advance written notice procedure for stockholders seeking to nominate candidates for election to the Board or to propose matters to be acted upon at stockholders’ meetings. As a result, these provisions of the Bylaws may delay stockholder actions with respect to business combinations or a change in management and may make it more difficult for third parties to acquire control of the Company.
Advanced Notice Bylaws. For director nominations or other business to be properly brought before an annual meeting by a stockholder, such stockholder must generally provide notice to the Company no later than 90 days and no more than 120 days prior to the first anniversary of the date of the prior year’s annual meeting; provided, that if the date of the annual meeting is advanced by more than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year’s annual meeting, such notice must be delivered no more than 120 days prior to such annual meeting nor less than the later of (i) 90 days prior to such annual meeting and (ii) ten days after the day on which public disclosure of the date of such meeting is first made.
Exclusive Jurisdiction. The Bylaws provide that unless the Company selects or consents in writing to the selection of an alternative forum, (i) the sole and exclusive forum for any complaint by any current or former stockholder asserting any internal corporate claims, to the fullest extent permitted by law, and subject to applicable jurisdictional requirements, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware), and (ii) the sole and exclusive forum for any complaint by any current or former stockholder asserting a cause of action arising under the Securities Act of 1933 (the “Securities Act”), to the fullest extent permitted by law, shall be the federal district courts of the United States of America.
Delaware Anti-takeover Statute. The Company has opted out of Section 203 of the Delaware General Corporation Law, which is a statute that (if applicable) would have served to make certain types of unfriendly or hostile corporate takeovers, or other non-board approved transactions involving a corporation and one or more of its significant stockholders, more difficult.
Other Rights. Common stockholders do not have any preemptive, subscription or conversion rights under the Charter.


Preferred Stock
Under the terms of the Charter, the Board is authorized to issue from time to time, without further vote or action by the stockholders, up to an aggregate of 5,000,000 shares of preferred stock in one or more series. The Board is authorized, within the limitations and restrictions stated in the Charter, to determine or alter the rights, preferences, privileges and restrictions granted to or imposed on any wholly unissued series of preferred shares, and the number of shares constituting such series and the designation thereof. No preferred shares are currently outstanding.
The Company currently has no plans to issue any shares of preferred stock, but the Company believes that the ability to issue shares of preferred stock without the expense and delay of a special stockholders’ meeting will provide the Company with increased flexibility in structuring possible future financings and acquisitions, and in meeting other corporate needs that might arise. The Board could issue shares of preferred stock having voting, dividend and liquidation rights superior to those of the shares of common stock, which could adversely affect the voting power of the common stockholders, including the loss of voting control to others, and delay, defer or prevent a change in control of the Company without further action by the stockholders. This could discourage an acquisition attempt or other transaction that stockholders might believe to be in their best interests or in which they might receive a premium for their stock over the then-market price of the stock.
If the Board were to issue a new series of preferred stock, the issuance of such shares could:
•decrease the amount of earnings and assets available for distribution to existing common stockholders;
•make removal of the Company’s management more difficult;
•result in restrictions upon the payment of dividends and other distributions to the existing common stockholders;
•delay or prevent a change in control of the Company; and
•limit the price that investors are willing to pay in the future for shares of common stock.
Registration Rights
Pursuant to a Principal Stockholders Agreement, Carlyle Partners VI Cayman Holdings, L.P. (or its permitted transferees or affiliates) (the “Carlyle Stockholder”) is entitled to demand and piggyback rights with respect to the registration under the Securities Act of shares of common stock held by the Carlyle Stockholder. In certain instances, the Carlyle Stockholder may cause the Company, at the Company’s expense, to file registration statements under the Securities Act covering resales of shares of common stock held by the Carlyle Stockholder or to piggyback on other registration statements in certain circumstances. The Company will pay all expenses related to any demand, piggyback or Form S-3 registration, with the exception of underwriting discounts and commissions.
The Carlyle Stockholder’s demand rights (excluding rights with respect to “shelf” registrations) expire in the event that the Carlyle Stockholder owns less than 5% of the outstanding shares of common stock, and its other registration rights expire on a holder-by-holder basis when a given Carlyle Stockholder owns less than 1% of the outstanding shares of common stock, in each case, only if such Carlyle Stockholder can sell its shares of common stock without volume or manner of sale restrictions under Rule 144 under the Securities Act.
For more information, see the Principal Stockholders Agreement filed as an exhibit to the Company’s Annual Report on Form 10-K, to which this exhibit is also appended.
Transfer Agent and Registrar
Computershare, Inc. serves as the transfer agent and registrar for the Company’s common stock.
Listing
The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “QDEL.”

 EX-21.1 4 ex21110-kx2022.htm EX-21.1 Document

Exhibit 21.1
SUBSIDIARIES OF THE REGISTRANT
 
Legal Name of Subsidiary  Jurisdiction of Incorporation or Organization
Ortho-Clinical Diagnostics FinCo S.à r.l., Barbados branchBarbados
Quidel Canada, ULCCanada
Ortho-Clinical Diagnostics France SASFrance
Quidel Ireland LimitedIreland
Ortho-Clinical Diagnostics K.K. Japan
Ortho-Clinical Diagnostics FinCo S.à r.l.Luxembourg
Ortho-Clinical Diagnostics Holdings Luxembourg S.à r.l. Luxembourg
Ortho-Clinical Diagnostics S.A. Luxembourg
Ortho-Clinical Diagnostics Mexico Operations S de RL de CV Mexico
Crimson OCD (UK) Limited United Kingdom
Ortho-Clinical Diagnostics United Kingdom
Ortho Clinical Diagnostics Holdings LimitedUnited Kingdom
Quidel Cardiovascular Inc.Delaware, United States
Quidel CorporationDelaware, United States
Quidel Services, LLCDelaware, United States
U.S. Crimson Acquisition Inc.Delaware, United States
Ortho-Clinical Diagnostics, Inc. New York, United States
Diagnostic Hybrids, Inc.Ohio, United States


 EX-23.1 5 ex23110-kx2022.htm EX-23.1 Document

Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:

(1) Registration Statement (Form S-8 No. 333-265354) pertaining to the QuidelOrtho Corporation Amended and Restated 2018 Equity Incentive Plan and the QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan, and,
(2) Post-Effective Amendment No. 1 to Registration Statement (Form S-8 No. 333-262434) pertaining to the Quidel Corporation 2016 Equity Incentive Plan, Quidel Corporation 2010 Equity Incentive Plan, Quidel Corporation Amended and Restated 2001 Equity Incentive Plan, Ortho Clinical Diagnostics Holdings plc 2021 Omnibus Incentive Award Plan, and Ortho-Clinical Diagnostics Bermuda Co. Ltd. 2014 Equity Incentive Plan;

of our reports dated February 23, 2023, with respect to the consolidated financial statements of QuidelOrtho Corporation and the effectiveness of internal control over financial reporting of QuidelOrtho Corporation included in this Annual Report (Form 10-K) of QuidelOrtho Corporation for the year ended January 1, 2023.
/s/ Ernst & Young LLP
San Diego, California
February 23, 2023


EX-31.1 6 ex31101012023.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Douglas C. Bryant, certify that:
1.    I have reviewed this annual report on Form 10-K of QuidelOrtho Corporation;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 23, 2023
 
/s/ DOUGLAS C. BRYANT
Douglas C. Bryant
President and Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 7 ex31201012023.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph M. Busky, certify that:
 
1.    I have reviewed this annual report on Form 10-K of QuidelOrtho Corporation;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 23, 2023
 
/s/ JOSEPH M. BUSKY
Joseph M. Busky
Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 8 ex32101012023.htm EX-32.1 Document

Exhibit 32.1
Certifications by the Principal Executive Officer and Principal Financial Officer of Registrant Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Each of the undersigned hereby certifies, in his capacity as an officer of QuidelOrtho Corporation, a Delaware corporation (the “Company”), for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
 
•the Company’s Annual Report on Form 10-K for the period ended January 1, 2023 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
•the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 23, 2023
 
/s/ DOUGLAS C. BRYANT
Douglas C. Bryant
President and Chief Executive Officer
(Principal Executive Officer)
/s/ JOSEPH M. BUSKY
Joseph M. Busky
Chief Financial Officer
(Principal Financial Officer)


 EX-101.SCH 9 qdel-20230101.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Computation of Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Balance Sheet Account Details link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Long-term Borrowings link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Long-term Employee Benefits link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Accumulated Other Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Business Combination (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Computation of Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Balance Sheet Account Details (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Long-term Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Long-term Employee Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Summary of Significant Accounting Policies - Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Business Combination - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Business Combination - Purchase Price by Exchange Ratio (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Business Combination - Summary of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Business Combination - Goodwill Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Business Combination - Purchase Price Allocation of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Business Combination - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Computation of Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Revenue - Concentrations of Revenue and Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Segment and Geographic Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Segment and Geographic Information - Total Revenues by Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Segment and Geographic Information - Reconciliation to Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Segment and Geographic Information - Geographic Territory (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits (Detail) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Income Taxes - Rollforward of Valuation Allowance (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Balance Sheet Account Details - Additional Details (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Balance Sheet Account Details Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Balance Sheet Account Details Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Balance Sheet Account Details Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Balance Sheet Account Details - Accounts Receivable Allowance for Credit Loss Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Balance Sheet Account Details Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Balance Sheet Account Details Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Balance Sheet Account Details Prepaid expenses and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Balance Sheet Account Details - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Balance Sheet Account Details - Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Balance Sheet Account Details - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Balance Sheet Account Details - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Balance Sheet Account Details Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Long-term Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Long-term Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Long-term Borrowings - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Long-term Borrowings - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Long-term Borrowings - Schedule of Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Leases - Components of Lease Expense and Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Leases - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Leases - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - Stock-Based Compensation - Summary of Status of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Stock-Based Compensation - Summary of Status of Stock Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000089 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000090 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000091 - Disclosure - Fair Value Measurements - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000092 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000093 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000094 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000095 - Disclosure - Long-term Employee Benefits - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000096 - Disclosure - Long-term Employee Benefits - Projected Benefit Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000097 - Disclosure - Long-term Employee Benefits - Accumulated Benefit Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 0000098 - Disclosure - Long-term Employee Benefits - Schedule of AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 0000099 - Disclosure - Long-term Employee Benefits - Critical Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 0000100 - Disclosure - Long-term Employee Benefits - Schedule of Health Care Trend Rates (Details) link:presentationLink link:calculationLink link:definitionLink 0000101 - Disclosure - Long-term Employee Benefits - Expected Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000102 - Disclosure - Long-term Employee Benefits - Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 0000103 - Disclosure - Long-term Employee Benefits - Level 3 Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 0000104 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 0000105 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 qdel-20230101_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 qdel-20230101_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 qdel-20230101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Foreign Current Foreign Tax Expense (Benefit) Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Related Party Transactions [Abstract] Deferred tax asset Deferred Income Tax Assets, Net Long-term debt Long-Term Debt, Gross Other Other, Not Including North America, EMEA, And China [Member] Other, Not Including North America, EMEA, And China State tax expense, net of federal tax State and Local Income Tax Expense (Benefit), Continuing Operations Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Debt Instrument [Axis] Debt Instrument [Axis] Total property, plant and equipment, gross Property, Plant and Equipment, Gross Schedule of Defined Benefit Plans Disclosures Schedule of Defined Benefit Plans Disclosures [Table Text Block] Length of time of deferral period, condition two (in years) Length Of Time Of Deferral Period Under Condition Two Length of time of deferral period under condition two. Inventory, Net [Abstract] Inventory, Net [Abstract] Foreign Exchange Contract Foreign Exchange Contract [Member] Prepaid Expense and Other Assets, Current [Abstract] Prepaid Expense and Other Assets, Current [Abstract] Fair Value of Financial Instruments, Policy Fair Value of Financial Instruments, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Credit Agreement Bank Of America Credit Facility [Member] Bank Of America Credit Facility Patent and trademark costs Patents And Trademarks [Member] Patents and trademarks. Fair Value, Option, Eligible Item or Group Financial Instruments [Domain] QuidelOrtho QuidelOrtho [Member] QuidelOrtho Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Net deferred tax assets (liabilities) Deferred Tax Assets, Net Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments Capital expenditures to be reimbursed under a government contract Consideration Received for Capital Expenditures Paid but Not yet Incurred Consideration Received for Capital Expenditures Paid but Not yet Incurred Long-Term Investments Long-Term Investments [Member] Long-Term Investments Measurement Period Adjustments, Intangible Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Issuance of shares in connection with the Combinations (in shares) Stock Issued During Period, Shares, Acquisitions Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Selling, Marketing, and Administrative Expense Selling, Marketing, And Administrative Expense [Member] Selling, Marketing, And Administrative Expense State Current State and Local Tax Expense (Benefit) Cash paid during the period for income taxes Income Taxes Paid Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Potentially dilutive shares excluded from calculation due to anti-dilutive effect Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Lessee, Operating Lease, Liability, to be Paid [Abstract] Lessee, Operating Lease, Liability, to be Paid [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Term Loan Secured Debt [Member] Interest Expense Interest Expense [Member] Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Stock options, granted, exercise price (in usd per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Closing price of Quidel Common Stock (in usd per share) Value per Quidel share as of May 26, 2022 (in usd per share) Business Acquisition, Share Price Hedging Designation [Domain] Hedging Designation [Domain] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Fair value of plan assets at beginning of year Fair value of plan assets at end of year Total Defined Benefit Plan, Plan Assets, Amount Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Stock options cancelled, weighted average exercise price (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Other Other Income Tax Expense (Benefit), Continuing Operations EMEA EMEA Segment [Member] EMEA Segment Entity Address, State or Province Entity Address, State or Province Weighted-Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, fair value weighted average [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, fair value weighted average [Roll Forward] Employee Stock Employee Stock [Member] Outstanding, Weighted-Average Remaining Contractual Term (In Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Pension and Other Post- employment Benefits Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Award Type [Axis] Award Type [Axis] Actuarial gain Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Interest expense on Convertible Notes, net of tax Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Fiscal Year 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Decreases due to settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Customer leased instruments Instruments Available For Lease [Member] Instruments available for lease. Operating lease liabilities Less: current portion Operating Lease, Liability, Current Weighted-Average Grant Date Fair Value, Stock awards assumed in the Combinations (in USD per share) Stock awards assumed in the Combinations (weighted avg grant date fair value) Stock awards assumed in the Combinations (weighted avg grant date fair value) Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Installment payment through April 2023 Business Combination, Contingent Consideration Arrangements, To Be Paid, Remainder Of Fiscal Year Business Combination, Contingent Consideration Arrangements, To Be Paid, Remainder Of Fiscal Year Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Step-Up, Inventory, Value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Step-Up Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Step-Up Long-term borrowings Long-Term Debt, Excluding Current Maturities Total liabilities Liabilities Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Measurement Period Adjustments, Goodwill Goodwill, Purchase Accounting Adjustments INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Customer E Customer E [Member] Customer E Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Document Type Document Type Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Weighted-Average Grant Date Fair Value, Beginning Balance (in USD per share) Weighted-Average Grant Date Fair Value, Ending Balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Cash Flow Hedges Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Period of cumulative changes in ownership (in years) Period Of Cumulative Changes In Ownership Period Of Cumulative Changes In Ownership Business credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards, General Business ESPP QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan "ESPP" [Member] QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan "ESPP" Total deferred provision (benefit) Deferred Income Tax Expense (Benefit) Other assets Assets for Plan Benefits, Defined Benefit Plan Developed technology Developed Technology Rights [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt instrument, Covenant, Leverage Ratio, Minimum Debt instrument, Covenant, Leverage Ratio, Minimum Debt instrument, Covenant, Leverage Ratio, Minimum Income Tax Examination [Table] Income Tax Examination [Table] Interest income Interest Income, Other Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Deductions Accounts Receivable, Allowance for Credit Loss, Writeoff Foreign Derived Intangible Income Deduction (FDII) Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount Debt Disclosure [Abstract] Debt Disclosure [Abstract] Accounts Receivable Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Payables under transition services agreements Payables, Transition Service Agreements Payables, Transition Service Agreements Acquisition and integration costs Acquisition-related Costs [Member] Less: current portion Long-Term Debt, Current Maturities Senior Notes Due 2028 Senior Notes Due 2028 [Member] Senior Notes Due 2028 Net cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Share based liabilities paid Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid Accounting Policies [Abstract] Accounting Policies [Abstract] Interest expense, debt Interest Expense, Debt Lease name [Axis] Lease name [Axis] Lease name Variable lease cost Variable Lease, Cost Line of Credit Line of Credit [Member] Customer A Customer A [Member] Customer A Fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Customer [Axis] Customer [Axis] Interest cost Defined Benefit Plan, Interest Cost Financing lease obligation Finance Lease, Liability, Noncurrent Estimated Fair Value of Each Stock Option Award Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Measurement Period Adjustments, Total Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities Balance Sheet Account Details Supplemental Balance Sheet Disclosures [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Expected weighted-average period of recognition for unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Stock options granted, term (in years) Exercisable, Weighted-Average Remaining Contractual Term (In Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Current period deferrals Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Cash consideration Payments to Acquire Businesses, Gross Derivative Contract [Domain] Derivative Contract [Domain] Gross Profit Gross Profit Amortization Expense Amortization Expense [Member] Amortization Expense Gain (Loss) On Redemption Premium Gain (Loss) On Redemption Premium Gain (Loss) On Redemption Premium Entity Registrant Name Entity Registrant Name Fiscal Year 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Dividend rate (in percent) Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid EMEA EMEA [Member] Change in fair value of acquisition contingencies Change in fair value of acquisition contingencies Change in fair value of acquisition contingencies Leases [Abstract] Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Consolidation, Policy Consolidation, Policy [Policy Text Block] Issuance of equity replacement awards in connection with the Combinations Stock Issued During Period, Value, Equity Replacement Awards, Acquisitions Stock Issued During Period, Value, Equity Replacement Awards, Acquisitions North America North America Segment [Member] North America Segment Minimum Minimum [Member] Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Debt, Net of Issuance Costs Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value per share (in dollars per share) Common Stock, Par or Stated Value Per Share Net unrealized gains (losses) on derivative instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Deferred revenue, current Deferred Revenue, Current Foreign Deferred Foreign Income Tax Expense (Benefit) Title of Individual [Axis] Title of Individual [Axis] Marketable Securities [Line Items] Marketable Securities [Line Items] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Use of Estimates Use of Estimates, Policy [Policy Text Block] Business Combination Business Combination Disclosure [Text Block] Accounts payable Increase (Decrease) in Accounts Payable Total purchase consideration Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Percentage of risk concentration Concentration Risk, Percentage Pro forma net income Business Acquisition, Pro Forma Net Income (Loss) Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Income Taxes Income Tax Disclosure [Text Block] Allowance for returns and discounts Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances Finished goods (materials, labor and overhead) Inventory, Finished Goods, Net of Reserves Cash and cash equivalents Defined Benefit Plan, Cash and Cash Equivalents [Member] Credit Facility [Domain] Credit Facility [Domain] Schedule of Health Care Cost Trend Rates Schedule of Health Care Cost Trend Rates [Table Text Block] Basic earnings per share Earnings Per Share, Basic Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Payments For Inventory Payments For Inventory Payments For Inventory Prepaid expenses Prepaid Expense, Current Deferred consideration Deferred Consideration, Current Deferred Consideration, Current Accumulated net actuarial gains (losses) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, After Combination Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, After Combination Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, After Combination Transfers in from the Combinations Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan Entity Interactive Data Current Entity Interactive Data Current Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Japan government bonds Debt Security, Government, Japan [Member] Debt Security, Government, Japan Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Stock Repurchase Program Stock Repurchase Program [Member] Stock Repurchase Program Other Locations Not Including North America, EMEA, and China [Member] Locations Not Including North America, EMEA, and China Maximum contribution rate (in percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Compensation Expense Related to Stock-Based Compensation Plans Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Other comprehensive loss, net of tax Net change Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common stock under equity compensation plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Repurchases of common stock Payments for Repurchase of Common Stock Other receivables Receivables, Transition Service Agreements Receivables, Transition Service Agreements Income Tax, Policy Income Tax, Policy [Policy Text Block] Measurement Period Adjustments, Accounts Receivable Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable Purchase period (in months) Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Currency Translation/Other Valuation Allowance, Deferred Tax Asset, Increase (Decrease) From Foreign Currency Translation And Other, Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease) From Foreign Currency Translation And Other, Amount Stock options assumed in the Combinations (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price Renewal term (in years) Lessee, Operating Lease, Renewal Term Marketable securities Marketable Securities, Noncurrent Other Other [Member] Other nonreportable segments Allowance for Credit Loss, Receivable, Other, Current Allowance for Credit Loss, Receivable, Other, Current Current assets: Assets, Current [Abstract] Percentage of premium on the amount deferred, condition two (in percent) Percentage Of Premium On Amount Deferred Based On Length Of Time For One Year Under Condition Two Percentage of premium on amount deferred based on length of time for two years under condition two Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Trademarks Trademarks [Member] Fair Value, Recurring Fair Value, Recurring [Member] Exercisable, end of period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related Party Transactions Related Party Transactions Disclosure [Text Block] Amortization of deferred financing costs Debt Related Commitment Fees and Debt Issuance Costs COVID-19 COVID-19 [Member] COVID-19 Pro Forma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Cost of sales, excluding amortization of intangibles Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Payments on long-term borrowings and extinguishment costs Finance Lease, Principal Payments Contingent consideration Business Combination, Contingent Consideration, Liability, Current Derivative, Cap Interest Rate Derivative, Cap Interest Rate Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Total current provision Current Income Tax Expense (Benefit) Impairment or Disposal of Long-Lived Assets, Policy Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Extinguishment of Convertible Notes through issuance of stock Debt Conversion, Converted Instrument, Amount Inventories Increase (Decrease) in Inventories Issuance of shares in exchange for Convertible Notes (in shares) Debt Conversion, Converted Instrument, Shares Issued Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Balance at January 2, 2022 Balance at January 1, 2023 Goodwill Business Unit [Domain] Business Unit [Domain] Business Unit [Domain] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Available-for-Sale Investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Valuation allowance for deferred tax assets Valuation allowance for deferred tax assets Beginning Balance Ending Balance Deferred Tax Assets, Valuation Allowance Deferred tax liability Deferred Income Tax Liabilities, Net Assignment of Goodwill by Reportable Segment Business Combination, Segment Allocation [Table Text Block] Entity Public Float Entity Public Float Balance Sheet Location [Domain] Balance Sheet Location [Domain] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Liability Derivative Liability Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table] Fiscal Year 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year One Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Cumulative changes in ownership (in percent) Cumulative Change In Ownership Percentage Cumulative Change In Ownership Percentage Accounts Receivable Accounts Receivable [Member] Number of countries entity operates Number of Countries in which Entity Operates Common stock, $0.001 par value per share; 126.2 and 97.5 shares authorized; 66.4 and 41.7 shares issued and outstanding at January 1, 2023 and January 2, 2022, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Number of additional terms Lessee, Operating Sublease, Option to Extend, Number of Additional Terms Lessee, Operating Sublease, Option to Extend, Number of Additional Terms Senior Notes Senior Notes [Member] Other current liabilities Liability, Defined Benefit Plan, Current ABO Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Industry And Geographic Information [Abstract] Industry And Geographic Information [Abstract] Industry and Geographic Information [Abstract] Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Changes in cumulative translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Labs Labs [Member] Labs Current liabilities: Liabilities, Current [Abstract] Covenant Period [Axis] Covenant Period [Axis] Covenant Period Subject to expiration through 2042 Subject to expiration through 2042 [Member] Subject to expiration through 2042 Summary of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Accrued commissions and rebates Customer Incentive, Payable, Current Customer Incentive, Payable, Current Weighted-average useful life (years) Finite-Lived Intangible Asset, Useful Life Operating lease cost Operating Lease, Cost Quidel Consolidated Entities Quidel Consolidated Entities [Member] Quidel Consolidated Entities Liabilities Measured at Fair Value on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Measurement Period Adjustments, Cash and Cash Equivalents Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents Goodwill acquired Goodwill, Acquired During Period Pro forma total revenues Business Acquisition, Pro Forma Revenue Total liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Construction in progress Construction in Progress [Member] Senior Notes Due 2025 Senior Notes Due 2025 [Member] Senior Notes Due 2025 Deferred tax assets: Components of Deferred Tax Assets [Abstract] Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets Other Assets, Noncurrent Goodwill and Intangible Assets, Policy Goodwill and Intangible Assets, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Other Ownership Interests [Line Items] Other Ownership Interests [Line Items] Transfer of instrument inventories to fixed assets Noncash of Part Noncash Acquisition, Fixed Assets transferred from inventories Noncash of Part Noncash Acquisition, Fixed Assets transferred from inventories Counterparty Name [Axis] Counterparty Name [Axis] Debt Instrument, Payment Period [Domain] Debt Instrument, Payment Period [Domain] Debt Instrument, Payment Period [Domain] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Schedule of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Quotient Quotient [Member] Quotient Intangible assets Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Interest Rate Derivatives Schedule of Interest Rate Derivatives [Table Text Block] BNP Business BNP Business [Member] BNP Business [Member] Cash paid for amounts included in the measurement of operating lease liabilities Operating Lease, Payments Stock Options Share-Based Payment Arrangement, Option [Member] Interest Rate Swap One Interest Rate Swap One [Member] Interest Rate Swap One Non Employee Director Non Employee Director [Member] Non employee director. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Business Combination, Segment Allocation [Table] Business Combination, Segment Allocation [Table] Summers ridge Summers ridge [Member] Summers ridge Customer B Customer B [Member] Customer B Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Income tax payable Accrued Income Taxes, Current Maximum Maximum [Member] Interest Rate Swap Three Interest Rate Swap Three [Member] Interest Rate Swap Three Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Designated as Hedging Instrument Designated as Hedging Instrument [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Business Acquisition [Line Items] Business Acquisition [Line Items] Measurement Frequency [Domain] Measurement Frequency [Domain] Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Software development costs Computer Software, Intangible Asset [Member] Contractual Obligation, Fiscal Year Maturity Contractual Obligation, Fiscal Year Maturity [Table Text Block] Stock awards assumed in the Combinations (in shares) Stock awards assumed in the Combinations Stock awards assumed in the Combinations Other long-term borrowings Other Long-Term Debt, Noncurrent Measurement Period Adjustments, Inventory Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Deferred Consideration Other Deferred Compensation Arrangements, Liability, Current and Noncurrent Net purchases and settlements Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Defined Benefit Plan, Assumptions Defined Benefit Plan, Assumptions [Table Text Block] Segment and Geographic Information Segment Reporting Disclosure [Text Block] Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Customer D Customer D [Member] Customer D Net deferred tax assets (liabilities) Deferred Tax Liabilities, Net LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] China China [Member] China Long-term Employee Benefits Defined Benefit Plan [Text Block] Inventories Inventory, Net Accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Vested and expected to vest, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Weighted-average shares outstanding - basic Basic weighted-average shares of common stock outstanding Weighted Average Number of Shares Outstanding, Basic Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Target allocation rate (in percent) Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Derivative, Notional Amount Derivative, Notional Amount Preferred stock, $0.001 par value per share; 5.0 shares authorized; none issued or outstanding at January 1, 2023 and January 2, 2022 Preferred Stock, Value, Issued Healthcare cost trend rate for upcoming year (in percent) Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Restricted Stock Restricted Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Income taxes payable Increase (Decrease) in Income Taxes Payable Current portion of borrowings Debt, Current Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Accounts Receivable, Allowance for Credit Loss Balance at Beginning of Period Balance at end of period Accounts Receivable, Allowance for Credit Loss Foreign currency exchange rate changes Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Work-in-process (materials, labor and overhead) Inventory, Work in Process, Net of Reserves Changes from pension and other post-employment benefits, net of tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Customers With Balances Due In Excess of 10% Of Accounts Receivable Customers With Balances Due In Excess of 10% Of Accounts Receivable [Member] Customers With Balances Due In Excess of 10% Of Accounts Receivable Interest expense, net Interest expense, net Interest expense, net Interest Income (Expense), Net Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Reduction of other current liabilities upon issuance of restricted share units Receivable For Stock Option Exercises Receivable For Stock Option Exercises Goodwill [Roll Forward] Goodwill [Roll Forward] Extinguishment of Debt, Amount Extinguishment of Debt, Amount Land Land [Member] Dilutive potential shares issuable from stock options and unvested RSUs Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Percentage of cash value of cash bonus officers can elect to receive in form of restricted stock (in percent) Percentage Of Cash Value Of Cash Bonus Officers Could Elect To Receive In Form Of Restricted Stock Percentage of cash value of cash bonus officers could elect to receive in form of restricted stock. Acquisition of businesses, net of cash and restricted cash acquired Payments to Acquire Businesses, Net of Cash Acquired Level 2 Fair Value, Inputs, Level 2 [Member] Debt, Policy Debt, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Marketable securities Marketable securities, current Marketable Securities, Current Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Interest expense, net of accrued interest reversed Unrecognized Tax Benefits, Interest on Income Taxes Expense Interest Rate Swap Five Interest Rate Swap Five [Member] Interest Rate Swap Five Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Ortho Exchange Ratio (in usd per share) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share Customer Concentration Risk Customer Concentration Risk [Member] Other Other Sundry Liabilities, Current Marketable Securities [Table] Marketable Securities [Table] Interest Rate Swap Four Interest Rate Swap Four [Member] Interest Rate Swap Four Accounts Payable Accounts Payable Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] Unrecognized tax benefits the would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Employee Deferred Bonus Compensation Program Employee Deferred Bonus Compensation Program [Member] Employee Deferred Bonus Compensation Program Schedule of Derivative Assets at Fair Value Schedule of Derivative Assets at Fair Value [Table Text Block] Schedule of Currency Hedging Instruments Schedule of Derivative Instruments [Table Text Block] Other current and non-current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current And Noncurrent Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current And Noncurrent Liabilities, Other Debt Security, Government, Non-US Debt Security, Government, Non-US [Member] Income Tax Authority [Domain] Income Tax Authority [Domain] Contract assets Unbilled Contracts Receivable Additions (Deductions) Charged to Provision for (Benefit From) Income Taxes Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Measurement Period Adjustments, Accounts Receivable, Long-term borrowings, including current portion Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt Purchased technology Purchased Technology [Member] Purchased Technology [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Quotient Subsidiary Quotient Subsidiary [Member] Quotient Subsidiary Credit Facility [Axis] Credit Facility [Axis] Changes in unrealized losses from investments, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Total borrowings Long-Term Debt and Lease Obligation Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Employer contributions to defined contribution plan Defined Contribution Plan, Employer Discretionary Contribution Amount Equity [Abstract] Equity [Abstract] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Discount from market price (in percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date Schedule of Nonvested Share Activity Schedule of Nonvested Share Activity [Table Text Block] Derivative, Fixed Interest Rate Derivative, Fixed Interest Rate Stock options, term (in years) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Employee related obligations Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Marketable Securities [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Debt Instrument, Payment, Period One Debt Instrument, Payment, Period One [Member] Debt Instrument, Payment, Period One Tax withholdings related to vesting of stock-based awards (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Consideration B Consideration B [Member] Consideration B [Member] Income Taxes Disclosure [Line Items] Income Taxes Disclosure [Line Items] Income Taxes Disclosure [Line Items] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Payment of accreted interest on contingent and deferred consideration Payment Of Accreted Interest On Contingent Consideration Liability And Deferred Consideration, Operating Activities Payment Of Accreted Interest On Contingent Consideration Liability And Deferred Consideration, Operating Activities Entity Central Index Key Entity Central Index Key Decreases from voluntary disclosure agreements Unrecognized Tax Benefits, Decrease Resulting From Voluntary Disclosure Agreements Unrecognized Tax Benefits, Decrease Resulting From Voluntary Disclosure Agreements Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Tax withholdings related to vesting of stock-based awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Increases due to current year acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Total purchase consideration Business Combination, Consideration Transferred Concentration Risk, Credit Risk, Policy Concentration Risk, Credit Risk, Policy [Policy Text Block] Entity [Domain] Entity [Domain] Tax impact from the conversion of Convertible Notes Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature City Area Code City Area Code ASSETS Assets [Abstract] Equity Incentive Plan Equity Incentive Plan [Member] Equity Incentive Plan Business Acquisition, Number of Vested Stock Options Acquired Business Acquisition, Number Of Vested Stock Options Acquired Business Acquisition, Number Of Vested Stock Options Acquired Net amount recognized Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 2023 Long-Term Debt, Maturity, Year One Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted-average grant date fair value of stock options granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Agency bonds Agency bonds [Member] Agency bonds Other liabilities Other Liabilities, Noncurrent (Loss) gain on investments Income (Loss) from Equity Method Investments Other current and non-current liabilities Increase (Decrease) in Other Operating Liabilities Influenza Influenza [Member] Influenza Acquisitions of property, equipment, investments and intangibles Payments to Acquire Property, Plant, and Equipment Stock options assumed in the Combinations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease) 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Projected benefit obligation at beginning of year Projected benefit obligation at end of year Defined Benefit Plan, Benefit Obligation Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] ROU assets obtained in exchange for new lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Customer [Domain] Customer [Domain] Amounts reclassified to net income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Weighted average expected rate of compensation increases Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Total lease payments Lessee, Operating Lease, Liability, to be Paid Length of time of deferral period, condition three (in years) Length Of Time Of Deferral Period Under Condition Three Length of time of deferral period under condition three. Measurement Period Adjustments, Total Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets Entity Address, Postal Zip Code Entity Address, Postal Zip Code 2024 Long-Term Debt, Maturity, Year Two Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Total Ortho shares subject to exchange (in shares) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Debt Instrument, Payment Period [Axis] Debt Instrument, Payment Period [Axis] Debt Instrument, Payment Period Business Combinations Policy Business Combinations Policy [Policy Text Block] Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Prepaid expenses and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property, plant and equipment Deferred Tax Liabilities, Property, Plant and Equipment U.S. equity securities Defined Benefit Plan, Equity Securities, US [Member] Software and Software Development Costs Software and Software Development Costs [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Issuance of shares in exchange for Convertible Notes Stock Issued During Period, Value, Conversion of Convertible Securities Long-Lived Assets Long-Lived Assets Defined benefit plan, net periodic benefit cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Length of time of deferral period, condition one (in years) Length Of Time Of Deferral Period Under Condition One Length of time of deferral period under condition one. Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Domestic Domestic Tax Authority [Member] Repayments of Debt Repayments of Debt NOL Expiration Status [Axis] NOL Expiration Status [Axis] NOL Expiration Status Net income Net income Net income Net Income (Loss) Attributable to Parent Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Weighted average rate of compensation increases Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Total assets measured at fair value Assets, Fair Value Disclosure Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Leases Lessee, Operating Leases [Text Block] Long-term borrowings Debt and Lease Obligation Capitalized Computer Software, Amortization Capitalized Computer Software, Amortization Plan Name [Axis] Plan Name [Axis] Reclassification [Table] Reclassification [Table] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Other international government bonds Debt Security, Government, Non-US And Non-Japan [Member] Debt Security, Government, Non-US And Non-Japan Derivative Instrument [Axis] Derivative Instrument [Axis] Number of Operating Segments Number of Operating Segments Goodwill [Line Items] Goodwill [Line Items] Additions Due to Current Year Acquisitions Valuation Allowance, Deferred Tax Asset, Additions From Acquisitions, Amount Valuation Allowance, Deferred Tax Asset, Additions From Acquisitions, Amount Operating loss carryforwards, state and local Deferred Tax Assets, Operating Loss Carryforwards, State and Local Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Level 1 Level 1 Fair Value, Inputs, Level 1 [Member] Dilutive potential shares issuable from Convertible Notes Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Other Current Liabilities Other Current Liabilities [Table Text Block] Assumed obligation from the Combinations Defined Benefit Plan, Benefit Obligation, Business Combination Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Measurement Period Adjustments, Deferred Income Tax Liability Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Derivative assets Derivative Asset Measurement Period Adjustments, Accounts Payable Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Payable Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Payable Cash payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Principal payments of deferred consideration Payment On Acquisition Deferred Consideration Payment On Acquisition Deferred Consideration Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net EU medical device regulation transition costs EU medical device regulation transition costs (2) EU medical device regulation transition costs (2) Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Document Annual Report Document Annual Report Legal Entity [Axis] Legal Entity [Axis] Number of financial covenants Number Of Financial Covenants Number Of Financial Covenants Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Geographical [Axis] Geographical [Axis] Molecular Diagnostics Molecular Diagnostics [Member] Molecular Diagnostics Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Derivatives Derivative Liability, Current Tax indemnification expense Tax Indemnification Income (Expense) Tax Indemnification Income (Expense) Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Postretirement Health Coverage Postretirement Health Coverage [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Line of Credit Facility, Increase (Decrease), Net Line of Credit Facility, Increase (Decrease), Net Fiscal Year 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Segments [Axis] Segments [Axis] Long-term Borrowings Debt Disclosure [Text Block] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Decreases related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Concentration Risk [Table] Concentration Risk [Table] Share-Based Compensation Expense Share-Based Compensation Expense [Member] Share-Based Compensation Expense 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Foreign income taxed at rates other than the applicable U.S. rate Foreign Income Tax Expense (Benefit), Continuing Operations QuidelOrtho shares issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Eligible Item or Group for Fair Value Option Financial Instrument [Axis] 2025 Long-Term Debt, Maturity, Year Three Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Ending after the closing date of the credit agreement Ending After The Closing Date Of The Credit Agreement [Member] Ending After The Closing Date Of The Credit Agreement Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Customer C Customer C [Member] Customer C [Member] Subsequent Event Subsequent Event [Member] Revenue Benchmark Revenue Benchmark [Member] Document Period End Date Document Period End Date Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Earnings Per Share [Abstract] Earnings Per Share [Abstract] Interest Rate Swap Interest Rate Swap [Member] Other liabilities Liability, Defined Benefit Plan Stock options exercised, weighted average exercise price (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Long-Term Debt, Fair Value Long-Term Debt, Fair Value Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Accrued payroll and related expenses Employee-related Liabilities, Current Corporate asset-backed securities Asset-Backed Securities [Member] Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segments [Domain] Segments [Domain] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Computation of Earnings Per Share Earnings Per Share [Text Block] Interest Rate Cap Interest Rate Cap [Member] Accrued other taxes payable Broker-Dealer, Payable to Customer Cash and Cash Equivalents, Policy Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Investments Short-Term Investments [Member] Award Type [Domain] Award Type [Domain] Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Income taxes and other tax receivables Income Taxes Receivable, Current Customers In Excess of 10% Total Revenue Customers In Excess Of 10% Total Revenue [Member] Customers In Excess Of 10% Total Revenue Amounts recognized on the consolidated balance sheets: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Measurement Period Adjustments, Other Current and Non-current Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current And Noncurrent Liabilities, Other Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current And Noncurrent Liabilities, Other Net change in operating lease right-of-use assets and liabilities Change in operating lease right-of-use assets and liabilities Change in operating lease right-of-use assets and liabilities Revenue Total Revenues for Fiscal Year Revenue from Contract with Customer, Including Assessed Tax Marketable Securities Marketable Securities [Table Text Block] China CHINA Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Unrealized Foreign Currency Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Foreign currency exchange rate changes Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Fiscal Years 2028-2032 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Government Assistance Government Assistance [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Debt issuance costs Debt Issuance Costs, Net Auditor Name Auditor Name Defined Benefit Plans Pension Plan [Member] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Other Post-employment Benefits Postemployment Retirement Benefits [Member] Operating loss carryforwards Operating Loss Carryforwards Measurement Period Adjustments, Accrued Payroll and Related Expenses Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Payroll and Related Expenses Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Payroll and Related Expenses Installment payment each year Business Combination, Contingent Consideration Arrangements, To Be Paid, Year One Business Combination, Contingent Consideration Arrangements, To Be Paid, Year One Research and development Research and Development Expense Increases related to prior year tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Vested and expected to vest, Weighted-Average Remaining Contractual Term (In Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Equipment, furniture and fixtures Equipment [Member] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] RSUs Restricted Stock Units (RSUs) [Member] Federal and state research credits—current year Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Total revenues Revenues Total change in unrealized gains (losses) from cash flow hedges, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax State Deferred State and Local Income Tax Expense (Benefit) Amortization of intangible assets Amortization of Intangible Assets Amortization of Intangible Assets Schedule of Goodwill Schedule of Goodwill [Table Text Block] Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Inventory, Policy Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity Balance Balance Stockholders' Equity Attributable to Parent Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain] Weighted-Average Grant Date Fair Value, Forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Tax loss and credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Other, net Deferred Tax Assets, Other Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Schedule of Other Ownership Interests [Table] Schedule of Other Ownership Interests [Table] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Measurement Period Adjustments, Property, Plant, and Equipment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Changes in Estimated Fair Value of Contingent Consideration Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Postretirement Health Coverage - Pre 65 Postretirement Health Coverage - Pre 65 [Member] Postretirement Health Coverage - Pre 65 Percentage of premium on the amount deferred, condition one (in percent) Percentage Of Premium On Amount Deferred Based On Length Of Time For One Year Under Condition One Percentage of premium on amount deferred based on length of time for one year under condition one. 2027 Long-Term Debt, Maturity, Year Five Retained earnings Retained Earnings [Member] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document and Entity Information [Abstract] Common Stock Common Stock [Member] Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Segment Reconciliation [Abstract] Segment Reconciliation [Abstract] Number of reportable segments Number of Reportable Segments Summary of Lease Cost Lease, Cost [Table Text Block] Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Number of shares of common stock available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Revenue Revenue [Policy Text Block] Statement [Table] Statement [Table] Weighted-Average Grant Date Fair Value, Vested (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Issuance of shares in connection with the Combinations Stock Issued During Period, Value, Acquisitions Letter of Credit Letter of Credit [Member] Lease liability Deferred Tax Assets, Lease Liability Deferred Tax Assets, Lease Liability Operating lease liabilities Non-current portion Operating Lease, Liability, Noncurrent Research & development expenses Deferred Tax Assets, Tax Credit Carryforwards, Research Statistical Measurement [Axis] Statistical Measurement [Axis] Principal payments of acquisition contingent consideration Payment for Contingent Consideration Liability, Financing Activities Proceeds from government assistance allocated to fixed assets Proceeds from Contribution in Aid of Construction Allowance for contract rebates and discounts Allowance for contract rebates and discounts Allowance for contract rebates and discounts Other non-cash, net Other Operating Activities, Cash Flow Statement Accounts receivable, net Total accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Purchases of marketable securities Payments to Acquire Marketable Securities U.S. government bonds US Treasury and Government [Member] Equity Components [Axis] Equity Components [Axis] Comprehensive Income, Policy Comprehensive Income, Policy [Policy Text Block] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Statement [Line Items] Statement [Line Items] Restricted stock outstanding, non-vested, beginning (in shares) Restricted stock outstanding, non-vested, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Gross assets Finite-Lived Intangible Assets, Gross Selling, marketing and administrative Selling, General and Administrative Expense Plans with ABO in excess of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract] Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Right-of-use assets Operating Lease, Right-of-Use Asset Repurchases of common stock Stock Repurchased During Period, Value Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Amortization of deferred cloud computing implementation costs Amortization of deferred cloud computing implementation costs Amortization of deferred cloud computing implementation costs Accumulated Other Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] Share based compensation related to accrued payroll and related expenses Employee Benefits and Share-Based Compensation Auditor Firm ID Auditor Firm ID Business Unit [Axis] Business Unit [Axis] Business Unit Document Transition Report Document Transition Report Fiscal Year 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Foreign Foreign Tax Authority [Member] Local Phone Number Local Phone Number Share-based Payment Arrangement, Option, Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating income Operating Income (Loss) Inventory reserve Deferred Tax Assets, Inventory Shipping and Handling Shipping and Handling [Member] Other operating expenses Other Cost and Expense, Operating Insurance contracts Defined Benefit Plan, Insurance Contract [Member] Defined Benefit Plan, Insurance Contract Gross State Research Credits State and Local Jurisdiction [Member] Pension and Other Postretirement Plans, Pensions, Policy Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Number of non-US post employment benefit plans Number Of Non-US Post-Employment Benefit Plans Number Of Non-US Post-Employment Benefit Plans Total liabilities measured at fair value Liabilities, Fair Value Disclosure Repurchases of common stock (in shares) Repurchases of common stock (in shares) Stock Repurchased During Period, Shares Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Property, Plant and Equipment, Policy Property, Plant and Equipment, Policy [Policy Text Block] Preferred stock, par value per share (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Federal Deferred Federal Income Tax Expense (Benefit) License agreements Licensing Agreements [Member] Document Fiscal Period Focus (Q1,Q2,Q3,FY) Document Fiscal Period Focus Restricted Cash, Noncurrent Restricted Cash, Noncurrent Total intrinsic value for options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Derivative [Line Items] Derivative [Line Items] Weighted-average shares outstanding - diluted Diluted weighted-average shares of common stock outstanding Weighted Average Number of Shares Outstanding, Diluted Volatility rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Goodwill and Intangible Assets, Intangible Assets, Policy Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Expected Value Contract Customers Expected Value Contract Customers [Member] Expected Value Contract Customers Inventory Schedule of Inventory, Current [Table Text Block] Expected option life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Long-term borrowings, including current portion (1) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt Other assets, Japan Defined Benefit Plan, Other Assets, Japan [Member] Defined Benefit Plan, Other Assets, Japan Building and improvements Building and Building Improvements [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total marketable securities Marketable Securities MosaicQ MosaicQ [Member] MosaicQ Weighted-Average Grant Date Fair Value, Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Other international equity securities Defined Benefit Plan, Equity Securities, Non-US And Non-Japan [Member] Defined Benefit Plan, Equity Securities, Non-US And Non-Japan Audit Information [Abstract] Audit Information [Abstract] Convertible Senior Notes Convertible Debt [Member] Exercisable, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Product Concentration Risk Product Concentration Risk [Member] Business Acquisition, Number of Common Stock Shares Acquired Business Acquisition, Number of Common Stock Shares Acquired Business Acquisition, Number of Common Stock Shares Acquired Decrease in unrecognized tax benefits is reasonably possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Loss on Extinguishment of Debt Loss On Extinguishment Of Debt [Member] Loss On Extinguishment Of Debt Fair value of replacement equity awards Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Prior To Combination Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Prior To Combination Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement and Third Party Collaborative Arrangement, Transaction with Party to Collaborative Arrangement and Third Party [Member] Unwind inventory fair value adjustment Unwind inventory fair value adjustment Unwind Inventory Fair Value Adjustment Unwind Inventory Fair Value Adjustment Common stock, shares issued (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Additional paid-in capital Common Stock Including Additional Paid in Capital [Member] Impact of reportable segment revisions Goodwill, Impact Of Segment Revisions Goodwill, Impact Of Segment Revisions Acquisition and integration costs Acquisition and integration costs Business Combination, Acquisition Related Costs Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Corporate Corporate and Other [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Product Shipment Cost, Policy Product Shipment Cost, Policy [Policy Text Block] Product Shipment Cost, Policy Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Impairment of Long-Lived Assets Impairment of Long-Lived Assets to be Disposed of Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Total other current liabilities Other Liabilities, Current Accrued payroll and related expenses Increase (Decrease) in Employee Related Liabilities Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Derivative [Table] Derivative [Table] Percentage of premium on the amount deferred, condition three (in percent) Percentage Of Premium On Amount Deferred Based On Length Of Time For One Year Under Condition Three Percentage of premium on amount deferred based on length of time for four years under condition three Contract Consideration Contract Consideration Contract Consideration Stock options outstanding, beginning (in shares) Stock options outstanding, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Postretirement Health Coverage - Post-65 Postretirement Health Coverage - Post-65 [Member] Postretirement Health Coverage - Post-65 Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Change in estimated fair value, recorded in selling, marketing and administrative expenses Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Selling, marketing and administrative Selling and Marketing Expense [Member] Title of Individual [Domain] Title of Individual [Domain] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Reserve for Contract Rebates Reserve for Contract Rebates Reserve for Contract Rebates Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total borrowings Long-Term Debt Other expense (income), net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Transaction costs Business Combination, Consideration Transferred, Transaction Costs Business Combination, Consideration Transferred, Transaction Costs Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Payment on Convertible Senior Note and Derivative Liability Payments on convertible notes and derivative liability Payments on convertible notes and derivative liability Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Cash paid to former Ortho stockholders per Ortho Share (in usd per share) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share Weighted average expected return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Total current assets Assets, Current Japan equity securities Defined Benefit Plan, Equity Securities, Japan [Member] Defined Benefit Plan, Equity Securities, Japan Entity Small Business Entity Small Business Other Commitments [Table] Other Commitments [Table] Balance (in shares) Balance (in shares) Shares, Outstanding Net Finite-Lived Intangible Assets, Net Expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration of revenue and credit risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Allowance for doubtful accounts Allowance for doubtful accounts Allowance for doubtful accounts Number of buildings Number Of Buildings Number Of Buildings Consolidated Entities [Axis] Consolidated Entities [Axis] Costs and Expenses Costs and Expenses Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Deferred Bonus Deferred Bonus [Member] Reclassification [Line Items] Reclassification [Line Items] Issuance of common stock under equity compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Lease liability Total Operating Lease, Liability Share-Based Payment Arrangement Share-Based Payment Arrangement [Policy Text Block] Rate to which the cost trend rate is assumed to decline Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Debt Instrument, Covenant, Interest Coverage Ratio, Minimum Debt Instrument, Covenant, Interest Coverage Ratio, Minimum Debt Instrument, Covenant, Interest Coverage Ratio, Minimum 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Derivative mark-to-market gain (loss) Derivative, Gain (Loss) on Derivative, Net Stock options granted, weighted average exercise price (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Derivative instruments and other Derivative instruments and other Derivative instruments and other Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Debt Securities, Available-for-sale, Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Derivative, Cash Received on Hedge Derivative, Cash Received on Hedge Indemnification receivable Indemnification Receivable Indemnification Receivable Measurement Period Adjustments, Total purchase consideration Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred 2026 Long-Term Debt, Maturity, Year Four Hedging Designation [Axis] Hedging Designation [Axis] Auditor Location Auditor Location Entity Filer Category Entity Filer Category Federal Current Federal Tax Expense (Benefit) Employee compensation charges and other costs Employee compensation charges and other costs Employee compensation charges and other costs Vested and expected to vest, end of period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Plans with PBO in excess of plan assets Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Assets: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Share based compensation expense Total stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 12) Commitments and Contingencies Security Exchange Name Security Exchange Name Stock options outstanding beginning, weighted average exercise price (in USD per share) Stock options outstanding ending, weighted average exercise price (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Other Liabilities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Amortization Period Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Covenant Period [Domain] Covenant Period [Domain] Covenant Period [Domain] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Reclassification of net realized (gains) losses on derivative instruments included in net income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Fair value of stock consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Service cost Defined Benefit Plan, Service Cost NOL Expiration Status [Domain] NOL Expiration Status [Domain] NOL Expiration Status [Domain] Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Entity Voluntary Filers Entity Voluntary Filers Depreciation, Depletion and Amortization, Nonproduction Depreciation, Depletion and Amortization, Nonproduction Not subject to expiration Not subject to expiration [Member] Not subject to expiration Federal foreign tax credits Deferred Tax Assets, Tax Credit Carryforwards, Foreign Revenue Revenue from Contract with Customer [Text Block] Prepaid Expenses and Other Current Assets Schedule of Other Current Assets [Table Text Block] Change in benefit obligation: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] U.S. government securities US Government Debt Securities [Member] Royalty Expense Royalty Expense Derivatives Derivative Asset, Current Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Receivables, Net, Current [Abstract] Receivables, Net, Current [Abstract] Ortho Ortho [Member] Ortho Weighted average discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Payments of tax withholdings related to vesting of stock-based awards Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Remaining authorized amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Prepaid expenses and other current and non-current assets Increase (Decrease) in Prepaid Expenses, Other Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Sales Sales [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Total deferred tax assets Deferred Tax Assets, Gross Schedule of Income before Income Tax, Domestic and Foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Derivative liabilities - Convertible Notes elected to settle in cash Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Unrecognized tax benefits, income tax penalties and interest accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net income used for diluted earnings per share, if-converted method Net Income (Loss) Available to Common Stockholders, Diluted Diluted earnings per share Earnings Per Share, Diluted ABO Defined Benefit Plan, Accumulated Benefit Obligation Exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Right-of-use assets Deferred Tax Liabilities, Right-of-use Assets Deferred Tax Liabilities, Right-of-use Assets Subject to expiration through 2037 Subject to expiration through 2037 [Member] Subject to expiration through 2037 Vested and expected to vest, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Segment Adjusted EBITDA Segment Adjusted EBITDA Segment Adjusted EBITDA 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other Other Assets, Current Unrecognized tax benefits Beginning balance Ending balance Unrecognized Tax Benefits Total deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Intangible assets Deferred Tax Liabilities, Intangible Assets United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Measurement Period Adjustments, Prepaid Expenses and Other Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses And Other Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses And Other Assets Corporate bonds Corporate Debt Securities [Member] Weighted average discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Accounts Receivable, Net Accounts Receivable, Allowance for Credit Loss [Table Text Block] Schedule of Maturity of Operating Lease Liability Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Business Combination Segment Allocation [Line Items] Business Combination Segment Allocation [Line Items] Product and Service [Axis] Product and Service [Axis] Accrued payroll and related expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll Debt Instrument, Payment, Period Two Debt Instrument, Payment, Period Two [Member] Debt Instrument, Payment, Period Two Point of Care Point-of-Care [Member] Point-of-Care Deferred Revenue, Noncurrent Deferred Revenue, Noncurrent Ending after initial measurement period Ending After Initial Measurement Period [Member] Ending After Initial Measurement Period Retirement Plan Type [Axis] Retirement Plan Type [Axis] Inventory, Noncurrent Inventory, Noncurrent Schedule of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Funded status at end of year Defined Benefit Plan, Funded (Unfunded) Status of Plan Transfusion Medicine Transfusion Medicine [Member] Transfusion Medicine Lease name [Domain] Lease name [Domain] Lease name [Domain] Reclassification, Comparability Adjustment Reclassification, Comparability Adjustment [Policy Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Total deferred tax liabilities Deferred Tax Liabilities, Gross Customer 2 Customer 2 [Member] Customer 2 Revenue from Contract with Customer [Abstract] Permanent differences Income Tax Reconciliation Permanent Difference Income tax reconciliation permanent difference. 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five PBO Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Purchase of property, equipment and intangibles by incurring current liabilities Noncash or Part Noncash Acquisition, Fixed Assets Acquired Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Expense, Policy Research and Development Expense, Policy [Policy Text Block] Additions charged to expense or as reductions to revenue Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Unamortized deferred financing costs Debt Issuance Costs, Noncurrent, Net Customer 1 Customer 1 [Member] Customer 1 Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Inventories, including noncurrent portion, net Inventories, including noncurrent portion, net Inventories, including noncurrent portion, net Foreign and other Other Debt Obligations [Member] Transfers in Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3 Other Commitments [Line Items] Other Commitments [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Tax expense at statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Advertising Cost Advertising Cost [Policy Text Block] FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Interest Rate Swap Two Interest Rate Swap Two [Member] Interest Rate Swap Two Advertising Advertising [Member] Stock based compensation expense related to deferred bonus compensation program Deferred Compensation Arrangement with Individual, Compensation Expense Debt Instrument, Covenant, Interest Coverage Ratio, Maximum Debt Instrument, Covenant, Interest Coverage Ratio, Maximum Debt Instrument, Covenant, Interest Coverage Ratio, Maximum North America North America [Member] Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Purchase commitment Purchase Commitment, Remaining Minimum Amount Committed Cost of sales Cost of Sales [Member] PBO Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation EX-101.PRE 13 qdel-20230101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 qdel-20230101_g1.jpg begin 644 qdel-20230101_g1.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - USD ($)
 12 Months Ended
Jan. 01, 2023
Feb. 10, 2023
Jul. 01, 2022
Document And Entity Information [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Jan. 01, 2023    
Document Transition Report false    
Entity File Number 001-41409    
Entity Registrant Name QUIDELORTHO CORP    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 87-4496285    
Entity Address, Address Line One 9975 Summers Ridge Road    
Entity Address, City or Town San Diego    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92121    
City Area Code 858    
Local Phone Number 552-1100    
Title of 12(b) Security Common stock, $0.001 par value    
Trading Symbol QDEL    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 6,008,202,595
Entity Common Stock, Shares Outstanding   66,505,546  
Entity Central Index Key 0001906324    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus (Q1,Q2,Q3,FY) FY    
Amendment Flag false    
Current Fiscal Year End Date --01-01    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
 12 Months Ended
Jan. 01, 2023
Audit Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Location San Diego, California
Auditor Firm ID 42
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Current assets:    
Cash and cash equivalents $ 292.9 $ 802.8
Marketable securities 52.1 25.7
Accounts receivable, net 453.9 378.0
Inventories 524.1 198.8
Prepaid expenses and other current assets 252.1 35.0
Total current assets 1,575.1 1,440.3
Property, plant and equipment, net 1,339.0 349.2
Marketable securities 21.0 37.9
Right-of-use assets 181.0 127.6
Goodwill 2,476.8 337.0
Intangible assets, net 3,123.8 98.7
Deferred tax asset 16.4 20.1
Other assets 122.7 19.6
Total assets 8,855.8 2,430.4
Current liabilities:    
Accounts payable 283.3 101.5
Accrued payroll and related expenses 139.2 40.4
Income tax payable 51.6 66.9
Current portion of borrowings 207.5 0.3
Other current liabilities 325.4 114.4
Total current liabilities 1,007.0 323.5
Operating lease liabilities 186.4 128.6
Long-term borrowings 2,430.8 0.4
Deferred tax liability 213.2 0.0
Other liabilities 83.8 48.5
Total liabilities 3,921.2 501.0
Commitments and contingencies (Note 12)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5.0 shares authorized; none issued or outstanding at January 1, 2023 and January 2, 2022 0.0 0.0
Common stock, $0.001 par value per share; 126.2 and 97.5 shares authorized; 66.4 and 41.7 shares issued and outstanding at January 1, 2023 and January 2, 2022, respectively 0.0 0.0
Additional paid-in capital 2,804.3 279.8
Accumulated other comprehensive (loss) income (67.6) 0.4
Retained earnings 2,197.9 1,649.2
Total stockholders’ equity 4,934.6 1,929.4
Total liabilities and stockholders’ equity $ 8,855.8 $ 2,430.4
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets (Parenthetical) - $ / shares
Jan. 01, 2023
Jan. 02, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000.0 5,000,000.0
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value per share (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 126,200,000 97,500,000
Common stock, shares issued (in shares) 66,400,000 41,700,000
Common stock, shares outstanding (in shares) 66,400,000 41,700,000
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Income - USD ($)
$ in Thousands, shares in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Income Statement [Abstract]      
Total revenues $ 3,266,000 $ 1,698,600 $ 1,661,700
Cost of sales, excluding amortization of intangibles 1,330,000 420,300 305,400
Selling, marketing and administrative 621,000 239,600 180,700
Research and development 190,500 95,700 84,300
Amortization of intangible assets 132,500 27,400 27,300
Acquisition and integration costs 136,000 9,600 3,700
Other operating expenses 12,300 0 0
Operating income 843,700 906,000 1,060,300
Interest expense, net 75,700 5,800 8,500
Loss on extinguishment of debt 24,000 0 10,400
Other expense (income), net 8,100 (100) 1,100
Income before provision for income taxes 735,900 900,300 1,040,300
Provision for income taxes 187,200 196,100 230,000
Net income $ 548,700 $ 704,200 $ 810,300
Basic earnings per share $ 9.66 $ 16.74 $ 19.24
Diluted earnings per share $ 9.56 $ 16.43 $ 18.60
Weighted-average shares outstanding - basic 56.8 42.1 42.1
Weighted-average shares outstanding - diluted 57.4 42.9 43.6
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Statement of Comprehensive Income [Abstract]      
Net income $ 548.7 $ 704.2 $ 810.3
Other comprehensive income (loss)      
Changes in cumulative translation adjustment, net of tax (69.8) (1.6) 2.5
Changes in unrealized losses from investments, net of tax (0.4) (0.1) 0.0
Changes from pension and other post-employment benefits, net of tax 0.7 0.0 0.0
Net unrealized gains (losses) on derivative instruments 6.7 0.1 (3.0)
Reclassification of net realized (gains) losses on derivative instruments included in net income (5.2) 2.4 0.5
Total change in unrealized gains (losses) from cash flow hedges, net of tax 1.5 2.5 (2.5)
Comprehensive income $ 480.7 $ 705.0 $ 810.3
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity Statement - USD ($)
$ in Thousands, shares in Millions
Total
Common Stock
Common Stock
Convertible Senior Notes
Additional paid-in capital
Accumulated other comprehensive income (loss)
Retained earnings
Balance (in shares) at Dec. 29, 2019   41.9        
Balance at Dec. 29, 2019 $ 559,900 $ 0   $ 425,600 $ (400) $ 134,700
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity compensation plans (in shares)   0.5        
Issuance of common stock under equity compensation plans 10,400     10,400    
Stock-based compensation expense 19,000     19,000    
Issuance of shares in exchange for Convertible Notes (in shares)     0.2      
Issuance of shares in exchange for Convertible Notes 7,200     7,200    
Tax impact from the conversion of Convertible Notes 100     100    
Derivative liabilities - Convertible Notes elected to settle in cash (26,200)     (26,200)    
Tax withholdings related to vesting of stock-based awards (4,300)     (4,300)    
Repurchases of common stock (in shares)   (0.3)        
Repurchases of common stock (43,700)     (43,700)    
Net income 810,300         810,300
Balance (in shares) at Jan. 03, 2021   42.3        
Balance at Jan. 03, 2021 1,332,700 $ 0   388,100 (400) 945,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity compensation plans (in shares)   0.6        
Issuance of common stock under equity compensation plans 9,600     9,600    
Stock-based compensation expense 22,700     22,700    
Tax withholdings related to vesting of stock-based awards (in shares)   (0.2)        
Tax withholdings related to vesting of stock-based awards (37,100)     (37,100)    
Repurchases of common stock (in shares)   (1.0)        
Repurchases of common stock (103,500)     (103,500)    
Other comprehensive loss, net of tax 800       800  
Net income 704,200         704,200
Balance (in shares) at Jan. 02, 2022   41.7        
Balance at Jan. 02, 2022 1,929,400 $ 0   279,800 400 1,649,200
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under equity compensation plans (in shares)   0.7        
Issuance of common stock under equity compensation plans 30,800     30,800    
Stock-based compensation expense 45,100     45,100    
Tax withholdings related to vesting of stock-based awards (in shares)   (0.1)        
Tax withholdings related to vesting of stock-based awards (8,600)     (8,600)    
Issuance of shares in connection with the Combinations (in shares)   25.1        
Issuance of shares in connection with the Combinations 2,495,400     2,495,400    
Issuance of equity replacement awards in connection with the Combinations 36,100     36,100    
Repurchases of common stock (in shares)   (1.0)        
Repurchases of common stock (74,300)     (74,300)    
Other comprehensive loss, net of tax (68,000)       (68,000)  
Net income 548,700         548,700
Balance (in shares) at Jan. 01, 2023   66.4        
Balance at Jan. 01, 2023 $ 4,934,600 $ 0   $ 2,804,300 $ (67,600) $ 2,197,900
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
OPERATING ACTIVITIES:      
Net income $ 548.7 $ 704.2 $ 810.3
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 283.6 52.7 48.8
Stock-based compensation expense 48.4 25.4 21.0
Net change in operating lease right-of-use assets and liabilities 18.4 3.0 0.4
Payment of accreted interest on contingent and deferred consideration (10.4) (8.2) 0.0
Loss on extinguishment of debt 24.0 0.0 10.4
Unwind inventory fair value adjustment 60.6 0.0 0.0
Other non-cash, net (34.8) 31.6 (10.0)
Changes in assets and liabilities:      
Accounts receivable 150.2 118.9 (402.1)
Inventories (116.9) (85.0) (54.9)
Prepaid expenses and other current and non-current assets (26.2) (13.3) (14.3)
Accounts payable 23.5 10.4 52.2
Accrued payroll and related expenses 18.2 5.0 16.0
Income taxes payable (26.8) (66.7) 137.7
Other current and non-current liabilities (75.2) 27.9 14.2
Net cash provided by operating activities 885.3 805.9 629.7
INVESTING ACTIVITIES      
Acquisitions of property, equipment, investments and intangibles (140.9) (292.8) (64.9)
Acquisition of businesses, net of cash and restricted cash acquired (1,511.4) 0.0 0.0
Proceeds from government assistance allocated to fixed assets 18.4 36.9 1.6
Purchases of marketable securities (63.7) (67.4) 0.0
Proceeds from sale of marketable securities 53.4 3.8 0.0
Net cash used for investing activities (1,644.2) (319.5) (63.3)
FINANCING ACTIVITIES      
Proceeds from issuance of common stock 26.4 7.6 9.6
Proceeds from long-term borrowings, net of debt issuance costs 2,734.5 0.0 0.0
Payments on long-term borrowings and extinguishment costs (2,388.3) (0.3) (0.5)
Payments of tax withholdings related to vesting of stock-based awards (8.6) (37.1) (4.3)
Repurchases of common stock (74.3) (103.5) (43.7)
Principal payments of acquisition contingent consideration (4.2) (4.7) (6.0)
Principal payments of deferred consideration (33.5) (35.1) (42.0)
Payment on Convertible Senior Note and Derivative Liability 0.0 0.0 (43.4)
Net cash provided by (used for) financing activities 252.0 (173.1) (130.3)
Effect of exchange rates on cash (2.0) (0.4) 1.0
Net (decrease) increase in cash, cash equivalents and restricted cash (508.9) 312.9 437.1
Cash, cash equivalents and restricted cash at beginning of period 802.8 489.9 52.8
Cash, cash equivalents and restricted cash at end of period 293.9 802.8 489.9
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:      
Cash paid during the period for interest 95.1 0.0 0.5
Cash paid during the period for income taxes 264.8 235.6 109.9
Purchase of property, equipment and intangibles by incurring current liabilities 40.4 10.5 7.2
Capital expenditures to be reimbursed under a government contract 0.0 0.0 15.9
Transfer of instrument inventories to fixed assets 73.7 0.0 0.0
Reduction of other current liabilities upon issuance of restricted share units 4.6 2.0 0.8
Extinguishment of Convertible Notes through issuance of stock $ 0.0 $ 0.0 $ 7.2
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
 12 Months Ended
Jan. 01, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Organization and Business
On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. As a result of the Combinations, QuidelOrtho became the successor issuer to Quidel. The results of operations of Ortho have been included in the Company’s Consolidated Financial Statements from the date of acquisition. See Note 2 for further information regarding the Combinations.
The Company’s mission is to develop and manufacture intelligent diagnostic solutions that transform the power of diagnostics into a healthier future for everyone. The Company’s expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine helps clinicians and patients make better informed decisions across the globe. The Company’s global infrastructure and commercial reach support its customers across more than 130 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. The Company operates globally with manufacturing facilities in the U.S. and U.K. and with sales centers, administrative offices and warehouses located throughout the world.
Basis of Presentation
The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”).
Accounting Periods
The Company follows the concept of a fiscal year that ends on the Sunday nearest to the end of the month of December, and fiscal quarters that end on the Sunday nearest to the end of the months of March, June, and September. For fiscal years 2022, 2021 and 2020, the Company’s fiscal years ended on January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Fiscal years 2022 and 2021 were 52 weeks and fiscal year 2020 was 53 weeks.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The estimates and underlying assumptions can impact all elements of the financial statements, including, but not limited to, accounting for deductions from revenues (e.g. rebates, sales allowances, and discounts), receivable and inventory valuations, fixed asset valuations, useful lives, impairment of goodwill and tangible and intangible assets, the fair value of assets acquired and liabilities assumed in a business combination and related purchase price allocation, long-term employee benefit obligations, income taxes, environmental matters, litigation and allocations of costs. Estimates are based on historical experience, complex judgments, facts and circumstances available at the time and various other assumptions that are believed to be reasonable under the circumstances but are inherently uncertain and unpredictable. Actual results could differ from those estimates.
Reclassifications
Certain prior period amounts were reclassified to conform to the current period presentation, including the separate presentation of Amortization of intangible assets and Interest expense, net, the combination of Selling, marketing and administrative expense, and reclassification of Other current liabilities and Other liabilities, which did not change the reported amounts of Total current liabilities or Total liabilities. Cost of sales, excluding amortization of intangibles for fiscal years 2021 and 2020 excludes $7.4 million and $7.4 million, respectively, of intangibles amortization expense, formerly included in Cost of sales, which has been reclassified to Amortization of intangible assets. Selling, marketing and administrative expense for fiscal years 2021 and 2020 excludes $20.0 million and $19.9 million, respectively, of intangibles amortization expense, formerly included in Sales and marketing expense, which has been reclassified to Amortization of intangible assets. The reclassifications did not have an impact on net assets, Operating income, Net income, Basic or Diluted earnings per share, or cash flows.
Consolidation
The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents
The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. They are carried at cost plus accrued interest, which approximates fair value because of the short-term maturity of these
instruments. Cash equivalents include money market funds and debt securities of high quality institutions. Cash balances may exceed government insured limits in certain jurisdictions.
Marketable Securities
The Company invests excess cash balances in investment-grade corporate debt securities, asset-backed securities and U.S. Treasury securities. The Company seeks to diversify investments and limits the amount of investment concentrations for individual institutions, maturities and investment types. These marketable securities are classified as available-for-sale and, accordingly, such securities are recorded at fair value. Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. If any adjustment to fair value reflects a significant decline in the value of the security, the Company evaluates the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to its Consolidated Statements of Income. Marketable securities are classified as non-current when maturities are one year or more.
Accounts Receivable and Allowance for Credit Losses and Concentration of Credit Risk
The Company sells its products directly to physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as to individual, non-professional OTC customers, and other distributors in the U.S. and internationally (see Note 4). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company establishes a reserve based on historical losses, the age of receivables, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts, and specific allowances for large or risky accounts. Amounts later determined to be uncollectible are charged or written off against this allowance. The balance of accounts receivable is net of reserves of $89.1 million and $52.4 million at January 1, 2023 and January 2, 2022, respectively, of which the reserve related to contract rebates was $73.5 million and $40.3 million, respectively.
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash equivalents, marketable securities and trade accounts receivable.
Credit losses are identified when cash flows received are not expected to be sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).
The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories
Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method as follows:
Asset typeUseful life
Building and building improvements
7-47 years
Machinery and equipment
3-15 years
Customer leased instruments
3-8 years
Computer software
3-5 years
Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or the estimated useful lives of the related assets.
When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the accounts and included in determining gain or loss on such disposals. Maintenance and repairs are expensed as incurred; major replacements and improvements that extend the useful life are capitalized.
Goodwill
Goodwill represents the excess of purchase price over the fair values of underlying net assets acquired in an acquisition. The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. Beginning in 2022, the Company changed its annual impairment assessment date from December 31 to the first day of the fourth quarter of the fiscal year.
In connection with the Combinations, the manner in which the chief operating decision maker (“CODM”) reviews the Company’s performance and allocates resources changed, resulting in six operating segments: North America, EMEA, China, Latin America, Japan and Asia Pacific. North America, EMEA and China are the Company’s reportable segments; Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” The Company concluded each of these six operating segments is considered a reporting unit for the purpose of allocating goodwill and performing the annual goodwill impairment assessment. Prior to the Combinations, the Company operated as a single reportable segment with one reporting unit.
When testing goodwill for impairment, the Company first has an option to assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that impairment exists. Such qualitative factors may include the following: macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, the Company would be required to perform a quantitative impairment test. Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value of each reporting unit to its carrying value, including goodwill. The Company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. If the fair value of a reporting unit is less than its carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value.
For fiscal year 2022, the Company performed a qualitative goodwill impairment assessment as of the beginning of the fiscal fourth quarter to assess for potential impairment. Based on the qualitative impairment assessment performed by the Company, it was concluded that it is not more likely than not that the fair value of the Company’s reporting units is less than their carrying amounts, and therefore no further impairment testing was necessary.
Intangible Assets
Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life.
Long-lived Assets
The process of evaluating the potential impairment of long-lived assets, such as property, plant and equipment and intangible assets, is subjective and requires judgment. The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of an asset may not be recoverable. If these circumstances exist, recoverability of assets to be held and used is measured by a comparison of the carrying value of an asset group to future undiscounted net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Convertible Debt
The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects the Company’s nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. During fiscal year 2020, the remaining aggregate principal amount of the Company’s Convertible Notes was settled or matured.
Revenue Recognition
The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings,
including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based on historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively.
Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service.
During fiscal years 2022 and 2021, the Company generated a portion of its revenue from sales of the QuickVue At-Home OTC COVID-19 tests to retail customers. The Company estimates the transaction price for revenue from sales to retail customers based on historical experience and current trends to evaluate when uncertainties related to right of return provisions are resolved. As of January 1, 2023 and January 2, 2022, due to a lack of history on which to base an estimate of products to be returned from the retailers, the Company established a reserve based on an estimate of total inventory remaining at our retailers which was subject to return.
A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately. The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument was not material for fiscal years 2022, 2021 and 2020.
Government Assistance
During fiscal year 2020, the Company entered into a contract with the National Institutes of Health (“NIH”), through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract originally provided for consideration to the Company of up to $65.0 million and had a performance period of one year, which began in July 2020. During 2021, the Company entered into several amendments to the contract, which added additional deliverables and milestones, as well as extended the performance period. The contract and amendments included key deliverables and milestones that directly supported the upgrade and addition of new manufacturing lines, as well as the outfitting of the new distribution center. The Company also provided instruments and assays to NIH. There were no refund provisions under the contract.
Consideration from the contract was allocated to each deliverable identified within the contract using a relative fair value allocation method and recognized when there was reasonable assurance the Company would meet the milestones and receive the consideration. Consideration allocated to the delivery of instruments and assays was recognized in accordance with the Company’s existing revenue recognition policy described above. Consideration that related to capital expenditures was recorded as a reduction to the carrying value of such assets and amortized over the useful life of the assets. Consideration allocated to the remainder of the contract was recorded as reductions to the related expense. As of January 2, 2022, the Company had achieved and collected payments for all milestones under the NIH contract.
In connection with the Combinations, the Company acquired a previously established agreement between Ortho and the Biomedical Advanced Research and Development Authority (“BARDA”), a division of HHS, which provides funding for Ortho to build manufacturing space and production support equipment to increase COVID-19 assay production capacity, as well as to build a manufacturing facility to produce certain analyzers needed to support COVID-19 testing. Amounts received from BARDA under this grant are recorded as a reduction to the carrying value of the related assets. A portion of the grant is
for purposes of reimbursement of certain general and administrative expenses related to the project, which are not capitalized as part of the equipment constructed in connection with the project and are recorded as a reduction to the related expense. The Company received $18.4 million during fiscal year 2022, which was recorded as a reduction to the carrying value of the related assets.
Research and Development Costs
Research and development costs are charged to operations as incurred. Upfront and milestone payments made to third parties in connection with R&D collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties at or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
The Company enters into collaborative arrangements to develop and commercialize intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including R&D, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations.
Product Shipment Costs
Product shipment costs are included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $104.9 million, $29.3 million and $14.2 million for fiscal years 2022, 2021 and 2020, respectively.
Advertising Costs
Advertising costs are expensed as incurred and included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Advertising costs were $26.8 million, $13.7 million and $1.1 million for fiscal years 2022, 2021 and 2020, respectively.
Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision.
The Company does not intend to permanently reinvest earnings of foreign subsidiaries at this time. As such, the Company provides for income taxes and foreign withholding taxes, where applicable, on undistributed earnings. Any repatriation of undistributed earnings would be done at little or no tax cost.
Fair Value of Financial Instruments
The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.
Stock-based Compensation
Stock-based compensation, comprised of stock options, restricted stock units (“RSUs”) and restricted stock awards to employees and directors, is measured at fair value on the grant date. Compensation expense is recognized over the requisite service period, which is generally the vesting period, and includes an estimate of the awards that will be forfeited, and an estimate of the level of performance the Company will achieve for performance-based awards.
Leases
Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options.
For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments is incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities.
Operating leases are included in ROU assets, operating lease liabilities and operating lease liabilities non-current in the Consolidated Balance Sheets.
Comprehensive Income
Comprehensive income includes unrealized gains and losses that are related to cumulative translation adjustments; unrealized gains and losses on marketable securities; changes in unamortized pension and post-employment actuarial gains and losses; and changes in the fair value of derivatives that are designated and qualify as cash flow hedging instruments excluded from the Consolidated Statements of Income.
Business Combinations
The cost of an acquired business is assigned to the tangible and identifiable intangible assets acquired and liabilities assumed on the basis of the estimated fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including, but not limited to, an income approach and a market approach, such as the estimation of future cash flows of the acquired business and current selling prices of similar assets. Fair value of the assets acquired and liabilities assumed, including intangible assets, IPR&D, and contingent payments, are measured based on the assumptions and estimations with regards to variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. When applicable, adjustments to inventory are based on the fair market value of inventory and are recognized into income based on the period in which the underlying inventory is sold. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that is not individually identified and separately recognized. Actual results may vary from projected results and assumptions used in the fair value assessments.
Defined Benefit Plans and Other Post-Employment Benefits
In connection with the Combinations, the Company assumed Ortho’s defined benefit plans in certain countries and a retiree healthcare reimbursement plan for certain U.S. employees. Defined benefit plans specify an amount of pension benefit that an employee will receive on retirement, usually dependent on factors such as age, years of service and compensation. The net obligation with respect to defined benefit plans is calculated separately for each plan by estimating the amount of the future benefits that employees have earned in return for their service in the current and prior periods. These benefits are then discounted to determine the present value of the obligations and are then adjusted for the impact of any unamortized prior service costs. The net obligation is then determined with reference to the fair value of the plan assets (if any). The discount rate used is the yield on bonds that are denominated in the currency in which the benefits will be paid and that have maturity dates approximating the terms of the obligations. The calculations are performed by qualified actuaries using the projected unit credit method.
Recent Accounting Pronouncements
In October 2021, the Financial Accounting Standards Board issued guidance which was codified in Accounting Standards Update 2021-08, Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts
with Customers. Under the new guidance, an acquirer is required to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. For public business entities, this guidance is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company early adopted the guidance during the first quarter of 2022 with no material impact to the Consolidated Financial Statements.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination
 12 Months Ended
Jan. 01, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combination Business Combination
On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. As a result of the Combinations, QuidelOrtho became the successor issuer to Quidel. The Combinations have been accounted for as a business combination using the acquisition method of accounting in conformity with ASC Topic 805, Business Combinations, with Quidel considered the accounting and the legal acquirer. The Combinations enhance the Company’s revenue profile and expand the Company’s geographic footprint and product diversity.
The Combinations were completed for a total consideration of approximately $4.3 billion, which included the fair value of equity issued based on the May 26, 2022 closing price of $99.60 per share of Quidel common stock. Former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho ordinary share. The total purchase consideration was calculated as follows (in millions, except value per share data and Ortho Exchange Ratio):
Total Ortho shares subject to exchange237.487
Ortho Exchange Ratio0.1055
QuidelOrtho shares issued25.055
Value per Quidel share as of May 26, 2022$99.60 
Fair value of stock consideration$2,495.5 
Fair value of replacement equity awards (1)47.9 
Cash consideration (2)1,747.7 
Total purchase consideration$4,291.1 
(1)
Represents the fair value of replacement stock options (which include options with time-based, performance-based, and both performance- and market-based vesting conditions), RSUs and restricted stock outstanding as of May 27, 2022 that are attributable to service prior to the Combinations. The terms of the replacement awards are substantially similar to the former Ortho equity awards for which they were exchanged. The portion of the fair value of the replacement equity awards attributable to service after the Combinations is $46.6 million and will be recognized as compensation expense based on the vesting terms of the replacement equity awards.
(2)
Represents cash consideration of $7.14 per share paid to Ortho shareholders and holders of vested Ortho stock options on the closing date of the Combinations for 237.5 million outstanding Ortho shares and 7.3 million vested Ortho stock options.
The Company funded the cash portion of the purchase price with cash on its balance sheet and a portion of the Term Loan (as defined in Note 8) proceeds from the Financing (as defined in Note 8). See Note 8 for further information regarding the Company’s debt.
The components of the preliminary purchase price allocation on the closing date of the Combinations are as follows:
(In millions)Amounts Recognized as of Acquisition Date
(as previously reported)		Measurement Period AdjustmentsAmounts Recognized as of Acquisition Date
(as adjusted)
Cash and cash equivalents$234.5 $— $234.5 
Accounts receivable240.6 — 240.6 
Inventories386.8 (2.4)384.4 
Property, plant and equipment767.5 181.4 948.9 
Goodwill2,291.3 (112.9)2,178.4 
Intangible assets3,133.0 35.0 3,168.0 
Prepaid expenses and other assets287.9 (16.2)271.7 
Total assets7,341.6 84.9 7,426.5 
Accounts payable(135.0)— (135.0)
Accrued payroll and related expenses(80.7)(0.4)(81.1)
Long-term borrowings, including current portion (1)
(2,268.4)— (2,268.4)
Deferred tax liability(215.4)(63.0)(278.4)
Other current and non-current liabilities(351.0)(21.5)(372.5)
Total liabilities(3,050.5)(84.9)(3,135.4)
Total purchase consideration$4,291.1 $— $4,291.1 
(1) Immediately following the closing of the Combinations, the Company repaid long-term borrowings assumed, which consisted of $1,608.4 million aggregate principal amount related to Ortho’s Dollar Term Loan and Euro Term Loan Facilities, $240.0 million aggregate principal amount of 7.375% Senior Notes due 2025 and $405.0 million aggregate principal amount of 7.250% Senior Notes due 2028. The 7.375% and 7.250% Senior Notes were fully discharged following the Combinations. The Company recorded a $23.5 million loss on extinguishment in connection with the Combinations, representing the difference between the reacquisition value, inclusive of $35.9 million of redemption premium, and the net carrying value of the extinguished debt.
The fair value estimates for the assets acquired and liabilities assumed were based on preliminary calculations, and the Company’s estimates and assumptions are subject to change for income tax matters. The Company expects to finalize the valuation as soon as practicable, but no later than one year after the closing date of the Combinations. The measurement period adjustments in the six months ended January 1, 2023 primarily resulted from completing valuations of real estate, personal property and intangible assets and revising the valuation of income tax liabilities. The related impact to net earnings that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the Consolidated Financial Statements.
Inventories acquired included raw materials, work in progress and finished goods. Inventories were recorded at their estimated fair values. Inventories were valued at the estimated selling price less the estimated costs to be incurred to complete and sell the inventories, the associated margins on these activities and holding costs. A step-up in the value of inventory of $61.7 million was recorded in connection with the Combinations. The step-up value was recorded in Cost of sales, excluding amortization of intangibles in the Consolidated Statements of Income as the inventory was sold to customers, and was fully recognized by the end of fiscal year 2022. In fiscal year 2022, $60.6 million of the fair value step-up of inventory was recognized in the Consolidated Statements of Income.
Goodwill represents the excess of the total purchase consideration over the estimated fair value of the net assets acquired, and is primarily attributable to synergies which are expected to expand the Company’s revenue profile and product diversity, as well as Ortho’s assembled workforce. Goodwill is not deductible for tax purposes. The preliminary assignment of goodwill by reportable segment as of the closing date of the Combinations is as follows (in millions):
North America$1,211.5 
EMEA370.0 
China121.6 
Other475.3 
$2,178.4 
The following table sets forth the amounts assigned to the identifiable intangible assets acquired (in millions, except years):
Intangible AssetAmortization PeriodFair Value of Assets Acquired
Customer relationships20 years$1,907.0 
Developed technology15 years888.0 
Trademarks15 years373.0 
$3,168.0 
The fair value of customer relationships was estimated using the Multi-Period Excess Earnings Method, which is a form of the income approach. Significant assumptions include: (i) the estimated annual net cash flows, which are a function of expected earnings attributable to the asset, contributory asset charges and the applicable tax rate, and (ii) the discount rate.
The fair value of developed technology and trademarks was estimated using the Relief from Royalty Method, which is another form of the income approach. Significant assumptions include: (i) the estimated annual net cash flows, which are a function of expected earnings attributable to the asset, the probability of use of the asset, the royalty rate and the applicable tax rate, and (ii) the discount rate.
Intangible assets are amortized on a straight-line basis over the amortization periods noted above, which reflects the estimated useful life of the underlying assets.
For fiscal year 2022, the Company incurred $46.9 million of transaction costs related to the Combinations, which primarily consisted of financial advisory, legal, accounting and valuation-related expenses. These expenses were recorded in Acquisition and integration costs in the Consolidated Statements of Income.
The following supplemental pro forma financial information shows the combined results of operations of the Company as if the Combinations had occurred on January 4, 2021, the beginning of the periods presented:
Fiscal Year Ended
(In millions) (unaudited)20222021
Pro forma total revenues$4,051.2 $3,741.4 
Pro forma net income589.3 613.2 
This supplemental pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved had the Combinations been completed at the beginning of fiscal year 2021. In addition, the supplemental pro forma financial information is not a projection of the Company’s future results of operations, nor does it reflect the expected realization of any synergies or cost savings associated with the Combinations. The supplemental pro forma financial information includes adjustments for:
•incremental intangible assets amortization expense to be incurred of $19.6 million and $45.5 million for fiscal years 2022 and 2021, respectively, based on the preliminary fair values of the identifiable intangible assets acquired;
•incremental cost of sales related to the fair value step-up of inventory which is reflected by an adjustment to decrease expense by $60.6 million for fiscal year 2022 and an adjustment to increase expense by $61.7 million for fiscal year 2021;
•decreases in interest expense of $11.2 million and $34.9 million for fiscal years 2022 and 2021, respectively, associated with the issuance of debt to finance the Combinations and to repay Ortho’s then-outstanding indebtedness, including the net impact of the removal of the amortization of the discount on Ortho’s indebtedness and the change in amortization of deferred financing fees;
•the removal of $50.3 million of loss on extinguishment of debt from Ortho’s financial results for fiscal year 2022 and the reclassification of $24.0 million of loss on extinguishment of debt incurred during fiscal year 2022 to fiscal year 2021;
•the reclassification of $12.8 million of expense related to the accelerated vesting of certain stock awards of Ortho’s former chief executive officer from fiscal year 2022 to fiscal year 2021; and
•tax impacts related to the above adjustments.
From the closing date of the Combinations through January 1, 2023, the acquired results of operations of Ortho contributed total revenues of $1,165.2 million and net loss of $126.2 million to the Company’s consolidated results, which included amortization of acquired intangible assets of $104.7 million and recognition in Cost of sales, excluding amortization of intangibles of the fair value step-up of inventory of $60.6 million.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Computation of Earnings Per Share
 12 Months Ended
Jan. 01, 2023
Earnings Per Share [Abstract]  
Computation of Earnings Per Share Computation of Earnings Per Share
Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted EPS is computed based on the sum of the weighted-average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of shares issuable from stock options, unvested RSUs and restricted stock. Potentially dilutive shares of common stock from outstanding stock options and unvested RSUs are determined using the average share price for each period under the treasury stock method.
Potentially dilutive common shares from the Convertible Notes are determined using the if-converted method. Under the provisions of the if-converted method, the Convertible Notes are assumed to be converted and the resulting common shares are included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Notes is added back to net income. The Convertible Notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the notes. The Convertible Notes became convertible on March 31, 2018 and matured on December 15, 2020.
The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods:
Fiscal Year Ended
(In millions)202220212020
Numerator:
Net income used for basic earnings per share$548.7 $704.2 $810.3 
Interest expense on Convertible Notes, net of tax— — 0.4 
Net income used for diluted earnings per share, if-converted method$548.7 $704.2 $810.7 
Denominator:
Basic weighted-average shares of common stock outstanding56.8 42.1 42.1 
Dilutive potential shares issuable from Convertible Notes— — 0.3 
Dilutive potential shares issuable from stock options and unvested RSUs0.6 0.8 1.2 
Diluted weighted-average shares of common stock outstanding57.4 42.9 43.6 
Potentially dilutive shares excluded from calculation due to anti-dilutive effect1.5 0.2 — 
Potentially dilutive shares excluded from the calculation above represent stock options when the combined exercise price and unrecognized stock-based compensation are greater than the average market price for the Company’s common stock because their effect is anti-dilutive.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue
 12 Months Ended
Jan. 01, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Contract Balances
Timing of revenue recognition may differ from timing of invoicing to customers. The Company records an asset when revenue is recognized prior to invoicing a customer (a “contract asset”). Contract assets are included within Prepaid expenses and other current assets or Other assets in the Company’s Consolidated Balance Sheets and are transferred to accounts receivable when the right to payment becomes unconditional. The balance of contract assets recorded in the Company’s Consolidated Balance Sheets as of January 1, 2023 was $49.6 million and was included in Prepaid expenses and other current assets.
The contract asset balance as of January 1, 2023 consisted of the following components, all of which related to agreements acquired by the Company in connection with the Combinations; therefore, no balance existed at January 2, 2022:
•a customer supply agreement under which the difference between the timing of invoicing and revenue recognition resulted in a contract asset of $6.8 million;
•contractual arrangements with certain customers under which the Company invoices the customers based on reportable results generated by its reagents; however, control of the goods transfers to the customers upon shipment or delivery of the products, as determined under the terms of the contract. Using the expected value method, the Company estimates the number of reagents that will generate a reportable result. The Company records the revenue upon shipment and an associated contract asset, and relieves the contract asset upon completion of the invoicing. The balance of the contract asset related to these arrangements was $38.5 million as of January 1, 2023 and was recorded in Prepaid expenses and other current assets; and
•one of the Company’s contract manufacturing agreements that recognizes revenue as the products are manufactured. The balance of the contract asset related to this arrangement was $4.3 million as of January 1, 2023.
The Company reviews contract assets for expected credit losses resulting from the collectability of customer accounts. Expected losses are established based on historical losses, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts. No credit losses related to contract assets were recognized during fiscal year 2022.
The Company recognizes a contract liability when a customer pays an invoice prior to the Company transferring control of the goods or services (“contract liabilities”). The Company’s contract liabilities consist of deferred revenue primarily related to customer service contracts. The Company classifies deferred revenue as current or non-current based on the timing of the transfer of control or performance of the service. The balance of the Company’s current deferred revenue was $76.4 million as of January 1, 2023, and $1.9 million as of January 2, 2022. The Company has one arrangement with a customer where the revenue is expected to be recognized beyond one year. The balance of the deferred revenue included in long-term liabilities was $9.4 million as of January 1, 2023 and was included in Other liabilities in the Consolidated Balance Sheets. There was no deferred revenue included in long-term liabilities as of January 2, 2022.
Joint Business with Grifols
In connection with the Combinations, the Company acquired the Joint Business between Ortho and Grifols, under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho’s Hepatitis and HIV diagnostics business. The governance of the Joint Business is shared through a supervisory board made up of equal representation by Ortho and Grifols, which is responsible for all significant decisions relating to the Joint Business that are not exclusively assigned to either Ortho or Grifols, as defined in the Grifols Agreement. The Company’s portion of the pre-tax net profit shared under the Joint Business was $18.6 million during fiscal year 2022. This included the Company’s portion of the pre-tax net profit of $11.1 million during fiscal year 2022 on sales transactions with third parties where the Company is the principal. The Company recognized revenues, cost of sales, excluding amortization of intangibles, and operating expenses, on a gross basis on these sales transactions in their respective lines in the Consolidated Statements of Income. The Company’s portion of the pre-tax net profit also included revenue of $7.5 million from collaboration and royalty agreements during fiscal year 2022, which is presented on a net basis within Total revenues.
Disaggregation of Revenue
Following the Combinations, the Company reorganized its former product categories into four business units. Revenues from the Company’s former Specialized Diagnostic Solutions product category have been included in a new Labs business unit. The Company’s former Rapid Immunoassay and Cardiometabolic Immunoassay product categories now represent its Point of Care business unit. The Molecular Diagnostics business unit represents the former Molecular Diagnostic Solutions product category. In addition, the Company added a Transfusion Medicine business unit.
The following table summarizes Total revenues by business unit:
Fiscal Year Ended
(In millions)202220212020
Labs$820.2 $44.8 $50.9 
Transfusion Medicine393.8 — — 
Point of Care1,955.3 1,453.3 1,387.8 
Molecular Diagnostics96.7 200.5 223.0 
Total revenues$3,266.0 $1,698.6 $1,661.7 
Concentration of Revenue and Credit Risk
The Company had sales to individual customers in excess of 10% of Total revenues as follows:
Fiscal Year Ended
202220212020
Customer:
A20 %1 %— %
B11 %24 %29 %
C8 %9 %16 %
D5 %9 %13 %
E3 %7 %10 %
47 %50 %68 %
As of January 1, 2023 and January 2, 2022, customers with balances due in excess of 10% of Accounts receivable, net totaled $161.9 million and $267.3 million, respectively. For fiscal years 2022, 2021 and 2020, sales of COVID-19 products accounted for 44%, 75% and 70% of Total revenues, respectively. For fiscal years 2022, 2021 and 2020, sales of influenza products accounted for 11%, 4% and 8% of Total revenues, respectively.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Information
 12 Months Ended
Jan. 01, 2023
Industry And Geographic Information [Abstract]  
Segment and Geographic Information Segment and Geographic Information
In connection with the Combinations, the manner in which the CODM reviews the Company’s performance and allocates resources changed, resulting in three geographically-based reportable segments: North America; EMEA; and China. Although all three segments are engaged in the marketing, distribution and sale of diagnostic instruments and assays for hospitals, retailers, distributors, laboratories and/or blood and plasma centers worldwide, each region is managed separately to better align with the market dynamics of the specific geographic region. Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” Previously, the Company operated as a single reportable segment. Prior periods have been revised to align with the current period presentation.
Total revenues by reportable segment are as follows:
Fiscal Year Ended
(In millions)202220212020
North America$2,536.5 $1,500.2 $1,460.7 
EMEA206.8 69.6 92.9 
China220.0 58.0 62.4 
Other302.7 70.8 45.7 
Total revenues$3,266.0 $1,698.6 $1,661.7 
Beginning in the second quarter of 2022, in connection with the Combinations, the basis by which the Company measures segment profit or loss changed to Adjusted EBITDA in order to manage the Company’s business to better align with the market dynamics of the specific geographic regions in which the Company operates. In the fourth quarter of 2022, the Company revised the internal allocation of certain global costs primarily between the North America segment and Corporate to better align costs that impact the Company as a whole. Prior periods have been revised to align with the current period presentation.
The following table sets forth Adjusted EBITDA by segment and the reconciliations to Income before provision for income taxes for fiscal years 2022, 2021 and 2020:
Fiscal Year Ended
(In millions)202220212020
North America$1,614.6 $1,028.5 $1,205.2 
EMEA31.7 28.1 55.5 
China104.1 24.1 30.5 
Other92.7 43.0 28.0 
Total segment Adjusted EBITDA1,843.1 1,123.7 1,319.2 
Corporate (1)
(512.1)(152.9)(203.9)
Depreciation and amortization(283.6)(52.7)(48.8)
Acquisition and integration costs(136.0)(9.6)(3.7)
Interest expense, net(75.7)(5.8)(8.5)
Unwind inventory fair value adjustment(60.6)— — 
Loss on extinguishment of debt(24.0)— (10.4)
(Loss) gain on investments(5.8)1.5 — 
Amortization of deferred cloud computing
    implementation costs		(5.4)(3.7)(1.1)
Employee compensation charges and other costs(3.7)— — 
Impairment of long-lived assets(2.8)— — 
EU medical device regulation transition costs (2)
(1.5)— — 
Tax indemnification expense(0.3)— — 
Change in fair value of acquisition contingencies(0.1)(0.2)(1.4)
Derivative mark-to-market gain (loss)4.4 — (1.1)
Income before provision for income taxes$735.9 $900.3 $1,040.3 
(1) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and IT functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.
(2) Represents incremental consulting costs and R&D manufacturing site costs to align compliance of Ortho’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards.
The CODM does not review capital expenditures, total depreciation and amortization or assets by segment, and therefore this information has been excluded as it does not comprise part of management’s key performance metrics.
The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory:
Long-lived Assets as ofTotal Revenues for Fiscal Year
(In millions)January 1, 2023January 2, 2022202220212020
Domestic$983.0 $347.1 $2,451.7 $1,415.5 $1,452.4 
Foreign356.0 2.1 814.3 283.1 209.3 
Total$1,339.0 $349.2 $3,266.0 $1,698.6 $1,661.7 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
 12 Months Ended
Jan. 01, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Significant components of the provision for income taxes were as follows:
Fiscal Year Ended
(In millions)202220212020
Current:
Federal$162.2 $148.8 $198.5 
State48.8 42.4 34.6 
Foreign17.6 2.3 1.1 
Total current provision228.6 193.5 234.2 
Deferred:
Federal(31.9)7.2 (2.9)
State(9.3)(2.6)(1.0)
Foreign(0.2)(2.0)(0.3)
Total deferred provision (benefit)(41.4)2.6 (4.2)
Provision for income taxes$187.2 $196.1 $230.0 
The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods:
Fiscal Year Ended
(In millions)202220212020
United States$672.1 $891.2 $1,035.7 
Foreign63.8 9.1 4.6 
Income before income taxes$735.9 $900.3 $1,040.3 
Significant components of the Company’s deferred tax assets and deferred tax liabilities as of January 1, 2023 and January 2, 2022 are shown below:
(In millions)January 1, 2023January 2, 2022
Deferred tax assets:
Lease liability$51.4 $32.7 
Intangible assets— 2.2 
Allowance for returns and discounts45.9 28.3 
Inventory reserve34.1 6.4 
Stock-based compensation14.6 9.2 
Tax loss and credit carryforwards565.3 10.8 
Research & development expenses50.7 — 
Employee related obligations19.9 5.5 
Other, net16.1 0.8 
Total deferred tax assets798.0 95.9 
Valuation allowance for deferred tax assets(251.3)(2.3)
Total deferred tax assets, net of valuation allowance546.7 93.6 
Deferred tax liabilities:
Right-of-use assets(43.8)(30.1)
Intangible assets(590.2)(0.9)
Property, plant and equipment(109.5)(42.5)
Total deferred tax liabilities(743.5)(73.5)
Net deferred tax assets (liabilities)$(196.8)$20.1 

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. For the fiscal years ended January 1, 2023, January 2, 2022 and January 3, 2021, the Company has demonstrated positive cumulative pre-tax book income. Such objective positive evidence allowed the
Company to consider other subjective evidence, such as the Company’s projections for future profitability, to determine the realizability of its deferred tax assets.
The valuation allowance of $251.3 million as of January 1, 2023 represents the portion of the deferred tax asset that management could not conclude was more likely than not to be realized. The Company’s valuation allowance relates primarily to the realization of recorded tax benefits on tax loss carryforwards from operations in Luxembourg and certain U.S. state jurisdictions. The amount of the deferred tax assets considered realizable could be adjusted in the future based on changes in available positive and negative evidence.
As of January 1, 2023, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $879.8 million, of which $473.0 million are subject to expiration through 2037 and $406.8 million are not subject to expiration. In addition, the Company has state NOLs of approximately $530.1 million, which will expire in years 2023 through 2042. As of January 1, 2023, the Company had U.S. federal research credit carryforwards of $14.2 million and federal foreign tax credits of $3.4 million, which will begin to expire in 2034 and 2028, respectively. In addition, the Company had state research credits of $5.9 million, of which none expire, and state business credit carryforwards of $25.6 million, which will begin to expire in 2029. As of January 1, 2023, the Company had $543.8 million of NOL carryforwards in certain non-U.S. jurisdictions, net of uncertain tax positions. Of these, $339.1 million have no expiration and the remaining $204.7 million will expire in years through 2042.
Pursuant to Internal Revenue Code Sections 382 and 383, the Company’s use of its NOL and tax credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three-year period. As a result of an ownership change that occurred in the second quarter of fiscal year 2022, the Company may be limited in its ability to utilize its NOL carryforwards and certain other attributes, starting the ownership change date.
The reconciliation of income tax computed at the federal statutory rate to the provision for income taxes from continuing operations was as follows:
Fiscal Year Ended
(In millions)202220212020
Tax expense at statutory tax rate$154.5 $189.1 $218.5 
State tax expense, net of federal tax29.3 30.1 30.3 
Foreign income taxed at rates other than the applicable U.S. rate(27.5)— — 
Permanent differences12.0 1.8 3.8 
Federal and state research credits—current year(7.3)(7.7)(5.0)
Stock-based compensation1.5 (9.2)(13.9)
Change in valuation allowance26.2 (0.1)(0.1)
Foreign Derived Intangible Income Deduction (FDII)(10.2)(8.4)(8.6)
Other8.7 0.5 5.0 
Provision for income taxes$187.2 $196.1 $230.0 
The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.
The following table summarizes the activity related to the Company’s unrecognized tax benefits:
Fiscal Year Ended
(In millions)202220212020
Beginning balance$17.7 $22.6 $17.2 
Increases due to current year acquisitions27.8 — — 
Increases (decreases) related to prior year tax positions(0.6)0.5 (2.3)
Increases related to current year tax positions1.8 0.9 7.7 
Decreases from voluntary disclosure agreements— (6.3)— 
Decreases due to settlements(6.7)— — 
Ending balance$40.0 $17.7 $22.6 

As of January 1, 2023, January 2, 2022 and January 3, 2021, the Company had unrecognized tax benefits of $40.0 million, $17.7 million, and $22.6 million, respectively, of which $28.3 million, $11.3 million and $15.0 million, respectively, would reduce the Company’s annual effective tax rate, if recognized. The Company estimates that within the next 12 months, its uncertain tax positions, excluding interest, will decrease by $2.4 million. The uncertain tax positions relate to an on-going multi-state tax commission audit that is expected to be settled within the next 12 months.
The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax expense. The Company had accrued interest and penalties associated with uncertain tax positions of $8.3 million as of January 1, 2023 and $1.2 million as of January 2, 2022. Interest expense, net of accrued interest (reversed) for fiscal years 2022, 2021 and 2020 was approximately $0.3 million, $0.7 million and $0.1 million, respectively.
The Company is subject to periodic audits by domestic and foreign tax authorities. Due to the carryforward of unutilized credits, the Company’s federal tax years from 2012 and onwards are subject to examination by the U.S. authorities. The Company’s state and foreign tax years for 2001 and onwards are subject to examination by applicable tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.
Ortho is currently under audit in certain jurisdictions for tax years under the responsibility of Johnson & Johnson. Pursuant to the stock and asset purchase agreement entered into by Ortho and Johnson & Johnson in January 2014, Johnson & Johnson retained all income tax liabilities accrued as of the date of acquisition, including reserves for unrecognized tax benefits. Accordingly, all tax liabilities related to these tax years will be indemnified by Johnson & Johnson. As of January 1, 2023, the indemnification receivable from Johnson & Johnson totaled $16.8 million and is included as a component of Prepaid expenses and other current assets and Other assets on the Consolidated Balance Sheet.
The following table summarizes the changes to the valuation allowance for balances for fiscal years 2022, 2021 and 2020:
Beginning BalanceAdditions Due to Current Year AcquisitionsAdditions
(Deductions)
Charged to
Provision for (Benefit From)
Income Taxes		Currency Translation/OtherEnding Balance
Deferred tax valuation allowance
Fiscal year ended January 1, 2023$2.3 223.5 26.2 (0.7)$251.3 
Fiscal year ended January 2, 2022$2.3 — — — $2.3 
Fiscal year ended January 3, 2021$2.4 — (0.1)— $2.3 
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details
 12 Months Ended
Jan. 01, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Account Details Balance Sheet Account Details
Cash, Cash Equivalents and Restricted Cash
(In millions)January 1, 2023January 2, 2022
Cash and cash equivalents$292.9 $802.8 
Restricted cash included in Other assets1.0 — 
Cash, cash equivalents and restricted cash$293.9 $802.8 
Marketable Securities
The following table is a summary of marketable securities:
January 1, 2023January 2, 2022
(In millions)Amortized CostGross Unrealized LossesFair ValueAmortized CostGross Unrealized LossesFair Value
Corporate bonds40.5 $(0.5)$40.0 $22.3 $— $22.3 
Corporate asset-backed securities6.7 — 6.7 3.4 — 3.4 
U.S. government securities2.0 — 2.0 — — — 
Agency bonds1.0 — 1.0 — — — 
Sovereign government bonds1.9 — 1.9 — — — 
Foreign and other0.5 — 0.5 — — — 
Total marketable securities, current52.6 (0.5)52.1 25.7 — 25.7 
Corporate bonds, non-current13.3 (0.1)13.2 26.8 (0.1)26.7 
Corporate asset-backed securities, non-current7.9 (0.1)7.8 11.2 — 11.2 
Total marketable securities$73.8 $(0.7)$73.1 $63.7 $(0.1)$63.6 
Accounts Receivable, Net
Accounts receivables primarily consist of trade accounts receivables with maturities of one year or less and are presented net of reserves:
(In millions)January 1, 2023January 2, 2022
Accounts receivable$543.0 $430.4 
Allowance for contract rebates and discounts(77.1)(50.7)
Allowance for doubtful accounts(12.0)(1.7)
Total accounts receivable, net$453.9 $378.0 
The allowance for contractual rebates involves estimating adjustments to revenue based on a high volume of data, including inputs from third-party sources. In addition, the determination of such adjustments includes estimating rebate percentages which are dependent on estimated end-user sales mix and customer contractual terms, which vary across customers, the related balance of which was $40.0 million and $40.3 million at January 1, 2023 and January 2, 2022, respectively, and was included in the allowance for contract rebates and discounts.
The following table summarizes changes to the accounts receivable allowance balances for fiscal years 2022, 2021 and 2020:
Balance at
Beginning of
Period		Additions Charged to Expense or as Reductions to Revenue (1)Deductions (2)Balance at end of
period
(In millions)
Fiscal year ended January 1, 2023$52.4 $407.6 $(370.9)$89.1 
Fiscal year ended January 2, 2022$103.4 $456.2 $(507.2)$52.4 
Fiscal year ended January 3, 2021$15.9 $277.0 $(189.5)$103.4 
(1)Includes opening balance of $31.4 million related to the Combinations during fiscal year 2022. Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to selling, marketing and administrative expense.
(2)The deductions represent actual charges against the accrual described above.
Inventories
Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Inventories consisted of the following:
(In millions)January 1, 2023January 2, 2022
Raw materials$185.2 $103.2 
Work-in-process (materials, labor and overhead)82.7 36.1 
Finished goods (materials, labor and overhead)295.1 59.5 
Total inventories$563.0 $198.8 
Inventories$524.1 $198.8 
Other assets (1)
38.9 — 
Total inventories$563.0 $198.8 
(1) Other assets includes inventory expected to remain on hand beyond one year.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
(In millions)January 1, 2023January 2, 2022
Prepaid expenses$96.7 $14.6 
Contract assets49.6 — 
Other receivables44.3 15.8 
Income taxes and other tax receivables38.6 — 
Derivatives22.0 0.1 
Other0.9 4.5 
Total prepaid expenses and other current assets$252.1 $35.0 
Property, Plant and Equipment, Net
The following is a summary of property, plant and equipment:
(In millions)January 1, 2023January 2, 2022
Equipment, furniture and fixtures$515.1 $159.0 
Building and improvements364.7 146.8 
Customer leased instruments434.5 68.1 
Land34.5 10.2 
Construction in progress268.4 105.2 
Total property, plant and equipment, gross1,617.2 489.3 
Less: accumulated depreciation and amortization(278.2)(140.1)
Total property, plant and equipment, net$1,339.0 $349.2 
Construction in progress reflects amounts incurred for construction or improvements of property, plant, or equipment that have not been made in service. In addition, construction in progress includes certain instruments that have not been placed at a customer under a lease agreement that will be reclassified to leased instruments once placed at a customer site. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $151.1 million, $24.3 million and $20.8 million for fiscal years 2022, 2021 and 2020, respectively.
Goodwill and Intangible Assets
Changes in goodwill were as follows:
(In millions)North AmericaEMEAChinaOtherTotal
Balance at January 2, 2022$337.0 
Impact of reportable segment revisions$336.9 $0.1 $— $— 337.0 
Goodwill acquired1,211.5 370.0 121.6 475.3 2,178.4 
Foreign currency translation(0.7)(11.5)(3.5)(22.9)(38.6)
Balance at January 1, 2023$1,547.7 $358.6 $118.1 $452.4 $2,476.8 
Intangible assets consisted of the following:
January 1, 2023January 2, 2022
DescriptionWeighted-average
useful life
(years)		Gross
assets		Accumulated
amortization		NetGross
assets		Accumulated
amortization		Net
Purchased technology14.3$997.6 $(120.0)$877.6 $112.7 $(78.2)$34.5 
Customer relationships19.22,023.5 (148.9)1,874.6 122.7 (77.3)45.4 
License agreements6.43.8 (3.7)0.1 6.6 (5.7)0.9 
Patent and trademark costs14.7400.5 (32.8)367.7 28.7 (15.7)13.0 
Software development costs4.711.5 (7.7)3.8 11.7 (6.8)4.9 
Total intangible assets$3,436.9 $(313.1)$3,123.8 $282.4 $(183.7)$98.7 
Amortization expense related to the capitalized software costs was $0.9 million, $1.0 million and $0.9 million for fiscal years 2022, 2021 and 2020, respectively. Amortization expense (including capitalized software costs) was $132.5 million, $27.4 million and $27.3 million for fiscal years 2022, 2021 and 2020, respectively.
The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of January 1, 2023 is as follows:
(In millions)
2023$205.4 
2024201.7 
2025188.2 
2026187.1 
2027184.7 
Other Current Liabilities
Other current liabilities consist of the following:
(In millions)January 1, 2023January 2, 2022
Accrued commissions and rebates$55.1 $15.9 
Deferred consideration39.3 41.9 
Deferred revenue76.4 1.9 
Operating lease liabilities24.4 10.0 
Accrued other taxes payable9.3 10.2 
Derivatives19.7 0.3 
Contingent consideration0.1 6.0 
Payables under transition services agreements— 10.9 
Other101.1 17.3 
Total other current liabilities$325.4 $114.4 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Borrowings
 12 Months Ended
Jan. 01, 2023
Debt Disclosure [Abstract]  
Long-term Borrowings Long-term Borrowings
The components of borrowings were as follows:
(In millions)January 1, 2023January 2, 2022
Term Loan$2,646.9 $— 
Revolving Credit Facility— — 
Financing lease obligation 0.8 0.7 
Other long-term borrowings1.2 — 
Unamortized deferred financing costs(10.6)— 
Total borrowings2,638.3 0.7 
Less: current portion(207.5)(0.3)
Long-term borrowings$2,430.8 $0.4 
On May 27, 2022, the Company entered into a credit agreement (the “Credit Agreement”) by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender (“Bank of America”), and the other lenders and L/C issuers party thereto (together with Bank of America, the “Lenders”). Pursuant to the Credit Agreement and in connection with the consummation of the Combinations, the Lenders provided the Company with a $2,750.0 million senior secured term loan facility (the “Term Loan”) and a $750.0 million revolving credit facility (the “Revolving Credit Facility” and with the Term Loan, the “Financing”). Effective August 4, 2022, pursuant to the Increase Joinder No. 1 to the Credit Agreement, the Revolving Credit Facility increased by $50.0 million to $800.0 million. The Financing is guaranteed by certain material domestic subsidiaries of the Company (the “Guarantors”) and is secured by liens on substantially all of the assets of the Company and the Guarantors, excluding real property and certain other types of excluded assets. Loans under the Credit Agreement will bear interest at a rate per annum equal to the Term SOFR or Base Rate plus the Applicable Rate (each as defined in the Credit Agreement). As of January 1, 2023, letters of credit issued under the Revolving Credit Facility totaled $13.1 million, which reduced the available amount under the Revolving Credit Facility to $786.9 million. In connection with the Credit Agreement, the Company incurred $15.4 million of debt issuance costs, of which $11.9 million was related to the Term Loan and $3.5 million was related to the Revolving Credit Facility. Debt issuance costs related to the issuance of the Term Loan were recorded as a reduction of the principal amount of the borrowings and are amortized using the effective interest method as a component of Interest expense, net over the life of the Term Loan. Debt issuance costs related to the Revolving Credit Facility were recorded as Other assets and are amortized on a straight-line basis over the term of the Revolving Credit Facility.
The Term Loan is subject to quarterly amortization of the principal amount on the last business day of each fiscal quarter of the Company (commencing on September 30, 2022). The required quarterly payments are 1.875% of the aggregate initial principal amount of the Term Loan through the fiscal second quarter of 2024, and 1.250% thereafter. The final remaining principal installment is due on the maturity date. The Term Loan and the Revolving Credit Facility will mature on May 27, 2027. The Company must prepay loans outstanding under the Credit Agreement in an amount equal to the Net Cash Proceeds (as defined in the Credit Agreement) from (i) certain property dispositions and (ii) the receipt of certain other amounts not in the ordinary course of business, such as certain insurance proceeds and condemnation awards, in each case, if not reinvested within a specified time period as contemplated in the Credit Agreement.
The Credit Agreement contains affirmative and negative covenants that are customary for credit agreements of this nature. The negative covenants include, among other things, limitations on asset sales, mergers, indebtedness, liens, investments and transactions with affiliates. The Credit Agreement contains two financial covenants: (i) a maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) as of the last day of each fiscal quarter of (a) 4.50 to 1.00 for the first four fiscal quarters ending after the closing date of the Credit Agreement (the “Initial Measurement Period”), (b) 4.00 to 1.00 for the first four fiscal quarters ending after the Initial Measurement Period and (c) 3.50 to 1.00 for each fiscal quarter thereafter; and (ii) a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of 3.00 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters. The Company was in compliance with the financial covenants as of January 1, 2023.
The Credit Agreement was entered into in connection with the Combinations in order to fund a portion of the cash portion of the purchase price as well as to repay substantially all of Ortho’s then-outstanding indebtedness. See Note 2 for more information regarding the Combinations. In connection with the closing of the Combinations, Quidel terminated its previous $175.0 million revolving credit facility and related credit agreement on May 27, 2022, which did not have an outstanding balance.
The following table provides the detailed amounts within Interest expense, net for fiscal years 2022, 2021 and 2020.
Fiscal Year Ended
(In millions)202220212020
Term Loan$73.0 $— $— 
Revolving Credit Facility1.5 0.3 0.3 
Amortization of deferred financing costs2.1 0.4 0.4 
Derivative instruments and other0.4 5.4 7.9 
Interest income(1.3)(0.3)(0.1)
Interest expense, net$75.7 $5.8 $8.5 
The following table provides a schedule of required future repayments of all borrowings outstanding as of January 1, 2023.
(In millions)
2023$207.5 
2024172.7 
2025137.5 
2026137.5 
20271,993.7 
Total$2,648.9 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Leases
 12 Months Ended
Jan. 01, 2023
Leases [Abstract]  
Leases Leases
The Company leases administrative, R&D, sales and marketing and manufacturing facilities and certain equipment under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases, and may contain clauses for rent escalation, renewal options or early termination.
Operating lease cost for fiscal years 2022, 2021 and 2020 was $26.4 million, $15.4 million and $11.2 million, respectively. Variable lease cost for fiscal years 2022, 2021 and 2020 was $5.6 million, $2.7 million and $1.8 million, respectively. Finance leases are immaterial to the Company’s Consolidated Financial Statements.
The supplemental cash flow information related to operating leases during the respective periods was as follows:
Fiscal Year Ended
(In millions)202220212020
Cash paid for amounts included in the measurement of operating
     lease liabilities		$25.2 $12.3 $10.8 
ROU assets obtained in exchange for new lease liabilities$29.9 $37.3 $15.3 
The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable operating leases at the end of 2022 were as follows:
(In millions)
2023$32.7
202429.1
202526.4
202624.1
202721.3
Thereafter122.9
Total lease payments256.5
Less: imputed interest(45.7)
Total210.8
Less: current portion(24.4)
Non-current portion$186.4
Weighted average remaining lease term9.7 years
Weighted average discount rate4 %
Summers Ridge Lease — The Company leases four buildings that are located on the Summers Ridge property in San Diego, California with an initial term through January 2033 with options to extend the lease for two additional five-year terms upon satisfaction of certain conditions, which have not been included in the determination of the lease term. The must-take provisions related to the fourth building became effective in November 2022 upon expiration of the previous tenant’s lease. As a result, the Company recorded a ROU asset and a corresponding lease liability of approximately $20.6 million in November 2022.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity
 12 Months Ended
Jan. 01, 2023
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Preferred Stock
The Company’s Charter authorizes the issuance of up to 5.0 million shares of preferred stock. The Board is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. No shares of preferred stock were outstanding for fiscal years 2022, 2021 or 2020.
Equity Incentive Plan
In connection with the Combinations, the Company assumed Quidel’s 2018 Equity Incentive Plan, as amended and restated (the “Quidel Equity Plan”), including all form of award agreements and grants of awards issued thereunder, and shares of Quidel’s common stock (“Quidel Shares”) subject to the plan were replaced by an equivalent number of shares of QuidelOrtho’s common stock. In connection with the assumption of the Quidel Equity Plan, the Quidel Equity Plan was renamed the “QuidelOrtho Corporation Amended and Restated 2018 Equity Incentive Plan” (the “2018 Plan”) and all references to the “Company” in the Quidel Equity Plan were changed to QuidelOrtho. Also in connection with the Combinations, the Company assumed all obligations of Quidel pursuant to each stock option to purchase a Quidel Share and pursuant to each right to acquire or vest in a Quidel Share that was outstanding immediately prior to the closing of the Combinations, and all agreements relating to such equity awards.
The Company grants stock options, time-based RSUs and performance-based RSUs (“PSUs”) to employees and non-employee directors under the 2018 Plan. Quidel previously granted stock options under its 2016 Equity Incentive Plan (the “2016 Plan”), Amended and Restated 2010 Equity Incentive Plan (the “2010 Plan”) and Amended and Restated 2001 Equity Incentive Plan (the “2001 Plan”). The 2016 Plan, 2010 Plan and 2001 Plan were terminated at the time of adoption of the Quidel Equity Plan, but the terminated plans continue to govern outstanding options granted thereunder.
The Company has stock options, RSUs and PSUs outstanding, which were issued under these equity incentive plans to certain employees and non-employee directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $15.40 to $254.00 per share, and generally vest over four years. As of January 1, 2023, approximately 2.3 million shares of common stock remained available for grant and 4.1 million shares of common stock were reserved for future issuance under the 2018 Plan.
RSUs
The Company grants both RSUs and PSUs to certain officers and directors. Until the restrictions lapse, ownership of the shares underlying the affected RSUs or PSUs is conditional upon continuous employment with the Company and/or achievement of certain performance goals.
For fiscal years 2022, 2021 and 2020, the Company granted approximately 0.7 million, 0.1 million and 0.2 million shares of common stock, respectively, of RSUs to certain officers and directors, which either have a time-based, four-year vesting provision or performance-based vesting provision.
During fiscal years 2022, 2021 and 2020, RSUs were granted to certain members of the Board in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants was $0.6 million, $0.6 million and $0.5 million for fiscal years 2022, 2021 and 2020, respectively.
Employee Deferred Bonus Compensation Program
For fiscal years 2022, 2021 and 2020, certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the value of their cash bonus in the form of fully vested RSUs, plus a premium as additional RSUs, issued under the 2018 Plan. The premium RSUs are subject to a one-year vesting requirement from the date of issuance. The additional premium is determined based on the length of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred.
Employee Stock Purchase Plan
In connection with the Combinations, the Company assumed Quidel’s 1983 Employee Stock Purchase Plan, as amended and restated (the “Quidel ESPP”), and the Quidel Shares subject to the Quidel ESPP were replaced by an equivalent number of shares of QuidelOrtho’s common stock. In connection with the assumption of the Quidel ESPP, the Quidel ESPP was renamed the “QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan” (the ESPP) and all references to the “Company” in the Quidel ESPP were changed to QuidelOrtho.
Under the ESPP, full-time employees were allowed to purchase common stock through payroll deductions (which could not exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six-month purchase period. As of January 1, 2023, 736,630 shares of common stock remained available for future issuance.
Stock Repurchase Program
On December 18, 2018, Quidel announced a stock repurchase program to repurchase up to $50.0 million of its common stock, which was authorized by Quidel’s board of directors (the “Quidel Board”) on December 12, 2018. On August 28, 2020, the Board authorized an increase of an additional $150.0 million to Quidel’s existing stock repurchase program authorization, which was announced on September 1, 2020. The Board also extended the stock repurchase program through August 28, 2022. In connection with the consummation of the Combinations, Quidel’s stock repurchase program was terminated. On August 17, 2022, the Board authorized a stock repurchase program, allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024 (the “Stock Repurchase Program”).
During fiscal year 2022, 953,468 shares of outstanding common stock were repurchased under the Stock Repurchase Program. As of January 1, 2023, the Company had approximately $225.7 million available under the Stock Repurchase Program. During fiscal years 2021 and 2020, 957,239 and 257,329 shares of outstanding common stock were repurchased under Quidel’s stock repurchase program.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation
 12 Months Ended
Jan. 01, 2023
Equity [Abstract]  
Stock-Based Compensation Stock-based Compensation
Stock-based compensation expense was as follows:
Fiscal Year Ended
(In millions)202220212020
Cost of sales$2.9 $2.7 $2.0 
Research and development4.9 4.4 3.4 
Selling, marketing and administrative
27.4 18.3 15.6 
Acquisition and integration costs30.4 — — 
Total stock-based compensation expense$65.6 $25.4 $21.0 
The table above includes $17.2 million of compensation expense related to liability-classified awards for fiscal year 2022, which has been or is expected to be settled in cash. These awards represent the $7.14 per share cash settled portion of the replacement awards issued in connection with the Combinations.
For fiscal years 2022, 2021 and 2020, the Company recorded $3.7 million, $3.0 million and $2.2 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 10. During fiscal years 2022, 2021 and 2020, $3.3 million, $2.8 million and $2.1 million, respectively, were initially recorded as a component of accrued payroll and related expenses associated with the deferred bonus compensation program.
Stock Options
A summary of the status of stock option activity for fiscal year 2022 is as follows:
(In thousands, except price data)
SharesWeighted-Average
Exercise Price
Per Share		Weighted-Average
Remaining Contractual Term (In Years)		Aggregate Intrinsic Value
Outstanding at January 2, 2022722 $62.71 
Granted187 100.45 
Stock options assumed in the Combinations1,229 96.10 
Exercised(383)55.15 
Forfeited(99)115.95 
Outstanding at January 1, 20231,656 $90.34 5.53$28,140 
Vested and expected to vest at January 1, 20231,600 $89.23 5.45$28,122 
Exercisable at January 1, 20231,195 $80.53 4.61$26,774 
Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants, including grants related to options assumed in the Combinations presented separately:
Assumed on
Fiscal Year Ended
May 27, 2022 (1)
January 1, 2023January 2, 2022January 3, 2021
Risk-free interest rate2.28 %1.96 %0.48 %1.18 %
Expected option life (in years)1.784.804.995.12
Volatility rate64 %57 %54 %41 %
Dividend rate0 %0 %0 %0 %
Weighted-average grant date fair value$40.57$50.62$106.55$36.84
(1) The replacement stock options granted to Ortho option holders on the closing date of the Combinations were issued consistent with the vesting conditions of the replaced award. The fair value on the closing date of the Combinations attributed to post-combination service, adjusted for estimated forfeitures, is recognized as expensed on a straight-line basis over the remaining vesting period.
The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the US Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations.
The Company’s determination of fair value is affected by the Company’s stock price, as well as a number of assumptions that require judgment. The total intrinsic value was $13.7 million, $9.9 million and $51.8 million for options exercised during fiscal years 2022, 2021, and 2020, respectively. As of January 1, 2023, total unrecognized compensation expense related to stock options was approximately $27.2 million and the related weighted-average period over which it is expected to be recognized is approximately 3.4 years. The maximum contractual term of the Company’s stock options is ten years.
RSUs
A summary of the status of RSU activity for fiscal year 2022 is as follows:
(In thousands, except price data)
SharesWeighted-Average
Grant Date
Fair Value
Non-vested at January 2, 2022587 $95.81 
Granted720 97.31 
Stock awards assumed in the Combinations49 99.60 
Vested(248)86.61 
Forfeited(76)100.70 
Non-vested at January 1, 20231,032 $98.89 
The total amount of unrecognized compensation expense related to non-vested RSUs as of January 1, 2023 was approximately $62.7 million, which is expected to be recognized over a weighted-average period of approximately 2.1 years.
The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date. The weighted-average fair value of RSUs granted during the fiscal years ended January 2, 2022 and January 3, 2021 was $188.06 and $101.20, respectively.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
 12 Months Ended
Jan. 01, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Purchase Obligations
The Company had $247.8 million of purchase obligations as of January 1, 2023, the majority of which is expected to be purchased in the next year. These purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including (i) fixed or minimum quantities to be purchased, (ii) fixed, minimum or variable price provisions and (iii) the approximate timing of the transaction, as well as amounts for planned inventory purchases under contractual arrangements.
Litigation and Other Legal Proceedings
From time to time, the Company is involved in litigation and other legal proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment, and other claims related to its business. The Company accrues for legal claims when, and to the extent that, amounts associated with the claims become probable and are reasonably estimable. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from these matters are inherently difficult to predict. The actual costs of resolving legal claims may be substantially higher or lower than the amounts accrued for those claims. For those matters as to which the Company is not able to estimate a possible loss or range of loss, the Company is not able to determine whether the loss will have a material adverse effect on its business, financial condition, results of operations or liquidity. No accrual has been recorded as of January 1, 2023 and January 2, 2022 related to such matters as they are not probable and/or reasonably estimable.
Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. However, the resolution of, or increase in any accruals for, one or more matters may have a material adverse effect on the Company’s results of operations and cash flows.
Licensing Arrangements
The Company has entered into various licensing and royalty agreements, which largely require payments by the Company based on specified product sales, as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $1.1 million, $2.0 million and $2.4 million for fiscal years 2022, 2021 and 2020, respectively.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements
 12 Months Ended
Jan. 01, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods:
 January 1, 2023January 2, 2022
(In millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$0.6 $2.1 $— $2.7 $204.7 $6.6 $— $211.3 
Marketable securities2.0 71.1 — 73.1 — 63.6 — 63.6 
Derivative assets— 22.0 — 22.0 — 0.1 — 0.1 
Total assets measured at fair value$2.6 $95.2 $— $97.8 $204.7 $70.3 $— $275.0 
Liabilities:
Derivative liabilities$— $21.8 $— $21.8 $— $0.3 $— $0.3 
Contingent consideration— — 0.1 0.1 — — 6.1 6.1 
Deferred consideration— 39.3 — 39.3 — 78.4 — 78.4 
Total liabilities measured at fair value$— $61.1 $0.1 $61.2 $— $78.7 $6.1 $84.8 
There were no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy during fiscal years 2022 and 2021.
Cash equivalents consist of funds held in money market accounts that are valued using quoted prices in active markets for identical instruments and highly liquid corporate debt securities with maturities within three months from purchase. Marketable securities consist of investment-grade corporate and government debt securities, corporate asset-backed securities and commercial paper. Derivative financial instruments are based on observable inputs that are corroborated by market data. Observable inputs include broker quotes, daily market foreign currency rates and forward pricing curves.
In connection with the acquisition of the BNP Business from Alere Inc., the Company will pay annual installments of up to $48.0 million each year through April 2023. The fair value of the payments treated as deferred consideration is calculated based on the net present value of cash payments using an estimated borrowing rate based on a quoted price for a similar liability. The fair value of the payments treated as contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are significant assumptions that are not observed in the market and, therefore, the resulting fair value represents a Level 3 measurement.
Changes in estimated fair value of contingent consideration liabilities from January 3, 2021 through January 1, 2023 were as follows:
(In millions)Contingent Consideration
Liabilities
(Level 3 Measurement)
Balance at January 3, 2021$11.9 
Cash payments(6.0)
Change in estimated fair value, recorded in selling, marketing and administrative expenses0.2 
Balance at January 2, 2022$6.1 
Cash payments(6.0)
Balance at January 1, 2023$0.1 
Financial Instruments Not Measured at Fair Value
The estimated fair value of the Company’s borrowings under the Term Loan was $2,630.3 million at January 1, 2023, compared to the carrying amount, excluding debt issuance costs, of $2,646.9 million. The estimate of fair value is generally based on the quoted market prices for similar issuances of long-term debt with the same maturities, which is classified as a Level 2 input.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Derivative Instruments and Hedging Activities
 12 Months Ended
Jan. 01, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities
The Company selectively uses derivative and non-derivative instruments to manage market risk associated with changes in interest rates and foreign currency exchange rates. The use of derivatives is intended for hedging purposes only, and the Company does not enter into derivative transactions for speculative purposes.
Credit risk represents the Company’s gross exposure to potential accounting loss on derivative instruments that are outstanding or unsettled if all counterparties failed to perform according to the terms of the contract. The Company generally enters into master netting arrangements that reduce credit risk by permitting net settlement of transactions with the same counterparty. The Company does not have any derivative instruments with credit-risk related contingent features that would require it to post collateral.
Interest Rate Hedging Instruments
The Company’s interest rate risk relates primarily to interest rate exposures on variable rate debt, including the Revolving Credit Facility and Term Loan. See Note 8 for additional information on the currently outstanding components of the Revolving Credit Facility and Term Loan. The Company entered into interest rate cap and swap agreements to hedge the related risk of the variability to the Company’s cash flows due to the rates specified for these credit facilities.
The Company designates certain interest rate derivative instruments as cash flow hedges, including the outstanding interest rate swaps. The Company records gains and losses due to changes in fair value of the derivatives within Other comprehensive income (loss) (“OCI”) and reclassifies these amounts to Interest expense, net in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the hedge is prospectively de-designated. Pre-tax unrealized gains of $25.1 million are expected to be reclassified from OCI to earnings in the next 12 months.
The following table summarizes the Company’s interest rate derivative agreements as of January 1, 2023, all of which were interest rate swaps:
Notional Amount
(In millions) (1)
DescriptionHedge DesignationEffective DateExpiration Date
$500.0 
Pay 1.58% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeMay 29, 2022December 31, 2023
397.2 
Pay 3.765% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
144.4 
Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
216.7 
Pay 3.7675% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
288.9 
Pay 3.7575% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
252.8 
Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
(1) The notional value of interest rate swap contracts with an effective date of December 30, 2022, is expected to increase to $1.8 billion on December 29, 2023.
During the fourth quarter of 2022, the Company terminated its non-designated $1.0 billion notional value 3.428% interest rate cap. As a result of this termination in fiscal year 2022, the Company recognized an immaterial gain within Other expense (income), net and received $3.3 million of cash proceeds, presented within operating activities in the Consolidated Statements of Cash Flows.
Currency Hedging Instruments
The Company has currency risk exposures relating primarily to foreign currency denominated monetary assets and liabilities and forecasted foreign currency denominated intercompany and third-party transactions. The Company uses foreign currency forward contracts and may use option contracts and cross currency swaps to manage its currency risk exposures. The Company’s foreign currency forward contracts are denominated primarily in Australian Dollar, Brazilian Real, British Pound, Canadian Dollar, Chilean Peso, Chinese Yuan/Renminbi, Euro, Indian Rupee, Japanese Yen, Mexican Peso, Swiss Franc and the Thai Baht.
The Company designates certain foreign currency forward contracts as cash flow hedges. The Company records gains and losses due to changes in fair value of the derivatives within OCI and reclassifies these amounts to Total revenues and Cost of
sales, excluding amortization of intangibles in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the hedge is prospectively de-designated. The pre-tax unrealized loss of $7.9 million within OCI as of January 1, 2023 is expected to be reclassified to earnings in the next 12 months.
The Company also enters into foreign currency forward contracts that are not part of designated hedging relationships and which are intended to mitigate exchange rate risk of monetary assets and liabilities and related forecasted transactions. The Company records these non-designated derivatives at mark-to-market with gains and losses recognized in earnings within Other expense (income), net.
The following table provides details of the currency hedging instruments outstanding as of January 1, 2023:
DescriptionNotional Amount
(In millions)		Hedge Designation
Foreign currency forward contracts$441.6 Cash Flow Hedge
Foreign currency forward contracts581.7 Non-designated
The following table summarizes pre-tax gains and losses from designated derivative and non-derivative instruments within accumulated other comprehensive (loss) income (“AOCI”) for fiscal year 2022:
Designated Hedging Instruments
(In millions)Amount of Loss (Gain) Recognized in OCI on HedgesLocation of Amounts Reclassified From AOCI Into IncomeAmount of Loss (Gain) Reclassified From AOCI Into Income
Foreign currency forward contracts (sales)$1.3 Total revenues$(2.9)
Foreign currency forward contracts (purchases)3.5 Cost of sales, excluding amortization of intangibles(0.6)
Interest rate derivatives(11.4)Interest expense, net(1.7)
Gains and losses from designated derivative and non-derivative instruments within AOCI for fiscal years 2021 and 2020 were not material.
The following table summarizes the fair value of designated and non-designated hedging instruments recognized within the Consolidated Balance Sheets as of January 1, 2023 and January 2, 2022:
(In millions)January 1, 2023January 2, 2022
Designated cash flow hedges
Interest rate derivatives:
Prepaid expenses and other current assets$15.9 $— 
Other liabilities2.1 — 
Foreign currency forward contracts:
Prepaid expenses and other current assets4.6 0.1 
Other current liabilities14.3 0.2 
Non-designated hedging instruments
Foreign currency forward contracts:
Prepaid expenses and other current assets1.5 — 
Other current liabilities5.4 0.1 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits
 12 Months Ended
Jan. 01, 2023
Retirement Benefits [Abstract]  
Long-term Employee Benefits Long-term Employee Benefits
Defined Benefit Plans and Other Post-employment Benefits
In connection with the Combinations, the Company assumed certain defined benefit plan obligations and acquired related plan assets for employees of non-U.S. subsidiaries.
In addition to these defined benefit plans, the Company also assumed one non-U.S. post-employment benefit plan and a replacement retiree health care reimbursement plan for certain U.S employees. The U.S. plan is funded on a pay-as-you-go basis and is not accepting new participants.
Obligation and Funded Status
The measurement date used to determine the defined benefit and other post-employment benefits obligations was January 1, 2023. The following tables set forth the changes to the projected benefit obligations (“PBO”) and plan assets:
Fiscal Year Ended
(In millions)January 1, 2023
Defined Benefit Plans
Change in benefit obligation:
Projected benefit obligation at beginning of year$— 
Service cost1.2 
Interest cost0.4 
Benefits paid(0.3)
Actuarial gain(0.6)
Assumed obligation from the Combinations33.3 
Settlements(0.2)
Foreign currency exchange rate changes0.1 
Projected benefit obligation at end of year$33.9 
Change in plan assets:
Fair value of plan assets at beginning of year$— 
Actual return on plan assets(0.5)
Employer contributions1.6 
Benefits paid(0.3)
Transfers in from the Combinations20.1 
Settlements(0.2)
Foreign currency exchange rate changes(0.1)
Fair value of plan assets at end of year$20.6 
Funded status at end of year$(13.3)
Amounts recognized on the consolidated balance sheets:
Other assets$0.4 
Other current liabilities(0.3)
Other liabilities(13.4)
Net amount recognized$(13.3)
Fiscal Year Ended
(In millions)January 1, 2023
Other Post-employment Benefits
Change in benefit obligation:
Projected benefit obligation at beginning of year$18.9 
Service cost0.3 
Interest cost0.4 
Benefits paid(0.7)
Actuarial gain(0.7)
Assumed obligation from the Combinations0.4 
Projected benefit obligation at end of year$18.6 
Amounts recognized on the consolidated balance sheets:
Other current liabilities $(3.5)
Other liabilities(15.1)
Net amount recognized$(18.6)
PBO is the actuarial present value of benefits attributable to employee service rendered to date and reflects the effects of estimated future pay increases. The accumulated benefit obligation (“ABO”) is the actuarial present value of benefits attributable to employee service to date, but does not include the effects of estimated future pay increases.
The following table reflects the ABO for all defined benefit plans as of January 1, 2023. Further, the table reflects the aggregate PBO, ABO and fair value of plan assets for pension plans with PBO in excess of plan assets and for pension plans with ABO in excess of plan assets.
(In millions)January 1, 2023
ABO$27.1 
Plans with PBO in excess of plan assets
PBO$18.3 
Fair value of plan assets5.1
Plans with ABO in excess of plan assets
PBO$17.0 
ABO14.3
Fair value of plan assets3.8
The pretax amounts that are not yet reflected in the net periodic benefit cost and are included in AOCI as of January 1, 2023 include the following:
Fiscal Year Ended
(In millions)2022
Defined Benefit Plans
Accumulated net actuarial gains (losses)$(0.2)
Other Post-employment Benefits
Accumulated net actuarial gains (losses)$0.7 
These accumulated net actuarial gains (losses) for defined benefit plans and other post-employment benefits primarily relate to differences between the actual net periodic expense and the expected net periodic expense from differences in significant assumptions, including primarily return on plan assets and discount rates used in these estimates.
Components of Net Periodic Benefit Cost
Net periodic benefit cost for the Company’s defined benefit plans was $1.4 million for the fiscal year ended January 1, 2023 and was primarily related to service cost. Changes in plan assets and benefit obligations recognized in other comprehensive income was not material for fiscal year 2022.
Net periodic benefit cost for the Company’s other post-employment benefit plans was $0.7 million for the fiscal year ended January 1, 2023 and was primarily related to interest cost. Changes in benefit obligations recognized in other comprehensive income was not material for fiscal year 2022.
The components of net periodic benefit cost other than the service cost component are recorded in Other expense (income), net in the Consolidated Statements of Income.
Assumptions and Sensitivities
In connection with the preliminary purchase price allocation for the Combinations, the Company recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following assumptions were used to measure the fair value of the benefit obligations and associated plan assets:
May 27, 2022January 1, 2023
Defined Benefit Plans
Weighted average discount rate2.2 %3.1 %
Weighted average rate of compensation increases2.6 %3.0 %
Other Post-employment Benefit Plans
Weighted average discount rate4.0 %5.5 %
The critical assumptions used in determining the net periodic benefit cost for fiscal year 2022 are as follows:
Defined Benefit Plans
Weighted average discount rate2.2 %
Weighted average expected rate of compensation increases2.6 %
Weighted average expected return on plan assets2.5 %
Other Post-employment Benefit Plans
Weighted average discount rate4.0 %
The discount rates used reflect the expected future cash flow based on plan provisions, participant data and the currencies in which the expected future cash flows will occur. For the majority of defined benefit obligations, the Company utilizes prevailing long-term high quality corporate bond indices applicable to the respective country at the measurement date. In countries where established corporate bond markets do not exist, the Company utilizes other index movement and duration analysis to determine discount rates. The long-term rate of return on plan assets assumptions reflect economic assumptions applicable to each country and assumptions related to the preliminary assessments regarding the type of investments to be held by the respective plans.
The discount rate is determined as of each measurement date, based on a review of yield rates associated with long-term, high-quality corporate bonds. The calculation separately discounts benefit payments using the spot rates from a long-term, high-quality corporate bond yield curve.
The long-term rate of return on plan assets assumption represents the expected average rate of earnings on the funds invested to provide for the benefits included in the benefit obligations and is determined based on a number of factors, including historical market index returns, the anticipated long-term allocation of the plans, historical plan return data, plan expenses and the potential to outperform market index returns.
A significant factor in estimating future per capita cost of covered healthcare benefits for retirees is the healthcare cost trend rate assumption. The health care cost trend rate assumptions for other post-retirement benefit plans are as follows:
January 1, 2023
Health care cost trend rate assumed for next year - Pre-656.44 %
Health care cost trend rate assumed for next year - Post-656.10 %
Rate to which the cost trend rate is assumed to decline4.00 %
Year that the trend rate reaches the ultimate trend rate 2047
Anticipated Contributions to Defined Benefit Plans
For funded plans, our policy is to fund amounts for defined benefit plans sufficient to meet minimum requirements set forth in applicable benefit and local tax laws. Based on the same assumptions used to measure the defined benefit obligations at January 1, 2023, the Company expects to contribute $2.0 million to defined benefit plans in fiscal year 2023.
Estimated Future Benefit Payments
The following table reflects the total benefit payments expected to be made for defined benefit plans and other long-term post-employment benefits:
(In millions)Defined Benefit PlansOther Post-employment Benefit Plans
Fiscal Year 2023$1.7 $3.5 
Fiscal Year 20243.54.0
Fiscal Year 20252.13.3
Fiscal Year 20262.22.2
Fiscal Year 20272.31.9
Fiscal Years 2028-203212.65.5
Plan Assets
The tables below present the fair value of the defined benefit pension plans by level within the fair value hierarchy, as described in Note 1, at January 1, 2023.
Fair Value Measurements at January 1, 2023
(In millions)TotalLevel 1Level 2Level 3
U.S. equity securities$2.2 $2.2 $— $— 
Japan equity securities3.7 3.7 — — 
Other international equity securities1.6 1.6 — — 
U.S. government bonds0.2 0.2 — — 
Japan government bonds0.5 0.5 — — 
Other international government bonds1.6 1.6 — — 
Cash and cash equivalents4.7 4.7 — — 
Insurance contracts6.1 — — 6.1 
Total$20.6 $14.5 $— $6.1 
The Company has funded defined benefit plans in Japan, Belgium and Switzerland. The Japanese plan asset consists primarily of Japan equity and government bond securities, U.S. equity and government bond securities, other international equity and debt securities and cash and cash equivalents. The plan assets are invested in assets with quoted prices in active markets and therefore are classified as Level 1 assets. The Company’s investment strategy is to maintain a target rate of return that is higher than that required to maintain sound pension plan management into the future. In order to achieve its investment targets, the Company has established an asset composition ratio which was formulated from a long-term perspective, taking into account the maturity of the pension plan and other factors. The Company considers expected returns and risks of returns, as well as the correlation between the returns of each investment asset, the diversification of its investments, and other factors related to risk management in order to maximize returns in accordance with its targeted asset mix to achieve its investment targets. The target
allocation rates of the Japanese plan is 44% for debt securities, 55% for equity securities and 2% for other assets. The Belgium and Switzerland plan assets consist solely of insurance contracts that are pledged on behalf of employees with benefits in certain countries and are classified as Level 3 assets.
The table below presents a roll-forward of activity for the Level 3 assets for fiscal year 2022:
(In millions)Level 3 Assets
Balance at January 2, 2022$— 
Transfers in5.5
Net purchases and settlements0.6
Balance at January 1, 2023$6.1 
Defined Contribution Plans
The Company offers defined contribution plans to eligible employees primarily in the U.S., whereby employees contribute a portion of their compensation. Company matching and other Company contributions are also provided to the plans. Once Company matching contributions have been paid, the Company has no further payment obligations. The Company’s contributions for its employees totaled approximately $15.1 million, $3.8 million and $3.1 million for fiscal years ended 2022, 2021 and 2020, respectively, which are recognized as expense as incurred in the Consolidated Statements of Income. The increase in Company contributions for fiscal year 2022 was due to defined contribution plans assumed in connection with the Combinations.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions
 12 Months Ended
Jan. 01, 2023
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
Quotient Limited
As a result of the consummation of the Combinations, the Company acquired Ortho’s Letter Agreement (the “Letter Agreement”), entered into in September 2020, with Quotient Limited (“Quotient”), in which Ortho partnered with Quotient to commercialize, when approved, the next generation product in immunohematology, a transfusion diagnostic patient immunohematology microarray intended for use with Quotient’s MosaiQ instruments (the “IH3 Microarray”) that enables a high level of multiplexing and addresses the ultra-high throughput market. Under the Letter Agreement, Ortho will have the right to distribute, market and sell the IH3 Microarrays in the European Economic Area, the U.K. and Switzerland (collectively, the “European Territory”) and the U.S., solely for use in testing the immunohematological profile of the blood of medical patients in the course of their care or treatment. Quotient retains the right to distribute, market and sell the IH3 Microarrays for use in blood donor testing worldwide and in the patient testing market outside of the European Territory and the U.S. Ortho’s rights with respect to the IH3 Microarray are exclusive so long as Ortho satisfies its obligation to meet annual minimum purchase volume requirements in each territory. Under the Letter Agreement, Ortho also has the non-exclusive right to sell and distribute MosaiQ instruments in the U.S. and the European Territory for use in testing the immunohematological profile of blood of medical patients in the course of their care or treatment.
Under the Letter Agreement, Ortho is also required to purchase the IH3 Microarrays, and the instruments, controls and reagents required for their use, only from Quotient at specified prices. Ortho is also required to make milestone payments to Quotient as specified milestones and benchmarks are achieved. Ortho will be obligated to pay up to $60 million in milestone payments to Quotient upon its achievement of certain regulatory milestones and the achievement by Ortho of commercial sales benchmarks related to MosaiQ, including a milestone payment of up to $25 million upon the achievement by Ortho of certain cumulative gross revenue hurdles. The Company did not make such payments during fiscal year 2022. Due to the Company’s equity method investment held in Quotient, the Company concluded that Quotient is a related party of the Company.
On January 10, 2023, Quotient filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Proceeding”). The Company is evaluating the impact of the Bankruptcy Proceeding and the related changes in Quotient’s business strategy on the Letter Agreement.
Under a separate supply agreement between Ortho and Alba Biosciences, a wholly owned subsidiary of Quotient, which was also acquired by the Company as a result of the consummation of the Combinations, the Company purchased inventories from Alba Biosciences amounting to $15.4 million during fiscal year 2022. As of January 1, 2023, Accounts payable included amounts related to purchases from Alba Biosciences of $3.7 million.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Accumulated Other Comprehensive (Loss) Income
 12 Months Ended
Jan. 01, 2023
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive Income (Loss)
The balance of AOCI, net of tax, was as follows for fiscal year 2022:
(In millions)Pension and Other Post-
employment Benefits		Cash Flow HedgesAvailable-for-Sale InvestmentsUnrealized Foreign Currency Translation AdjustmentsAccumulated Other Comprehensive Income (Loss)
Beginning balance$— $— $(0.1)$0.5 $0.4 
Current period deferrals0.7 6.7 (0.4)(69.8)(62.8)
Amounts reclassified to net income— (5.2)— — (5.2)
Net change0.7 1.5 (0.4)(69.8)(68.0)
Ending balance$0.7 $1.5 $(0.5)$(69.3)$(67.6)
Amounts related to fiscal years 2021 and 2020 were not material.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Jan. 01, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”).
Accounting Periods
The Company follows the concept of a fiscal year that ends on the Sunday nearest to the end of the month of December, and fiscal quarters that end on the Sunday nearest to the end of the months of March, June, and September. For fiscal years 2022, 2021 and 2020, the Company’s fiscal years ended on January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Fiscal years 2022 and 2021 were 52 weeks and fiscal year 2020 was 53 weeks.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The estimates and underlying assumptions can impact all elements of the financial statements, including, but not limited to, accounting for deductions from revenues (e.g. rebates, sales allowances, and discounts), receivable and inventory valuations, fixed asset valuations, useful lives, impairment of goodwill and tangible and intangible assets, the fair value of assets acquired and liabilities assumed in a business combination and related purchase price allocation, long-term employee benefit obligations, income taxes, environmental matters, litigation and allocations of costs. Estimates are based on historical experience, complex judgments, facts and circumstances available at the time and various other assumptions that are believed to be reasonable under the circumstances but are inherently uncertain and unpredictable. Actual results could differ from those estimates.
Reclassification, Comparability Adjustment
Reclassifications
Certain prior period amounts were reclassified to conform to the current period presentation, including the separate presentation of Amortization of intangible assets and Interest expense, net, the combination of Selling, marketing and administrative expense, and reclassification of Other current liabilities and Other liabilities, which did not change the reported amounts of Total current liabilities or Total liabilities. Cost of sales, excluding amortization of intangibles for fiscal years 2021 and 2020 excludes $7.4 million and $7.4 million, respectively, of intangibles amortization expense, formerly included in Cost of sales, which has been reclassified to Amortization of intangible assets. Selling, marketing and administrative expense for fiscal years 2021 and 2020 excludes $20.0 million and $19.9 million, respectively, of intangibles amortization expense, formerly included in Sales and marketing expense, which has been reclassified to Amortization of intangible assets. The reclassifications did not have an impact on net assets, Operating income, Net income, Basic or Diluted earnings per share, or cash flows.
Consolidation, Policy
Consolidation
The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents, Policy
Cash and Cash Equivalents
The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. They are carried at cost plus accrued interest, which approximates fair value because of the short-term maturity of these
instruments. Cash equivalents include money market funds and debt securities of high quality institutions. Cash balances may exceed government insured limits in certain jurisdictions.
Marketable Securities
The Company invests excess cash balances in investment-grade corporate debt securities, asset-backed securities and U.S. Treasury securities. The Company seeks to diversify investments and limits the amount of investment concentrations for individual institutions, maturities and investment types. These marketable securities are classified as available-for-sale and, accordingly, such securities are recorded at fair value. Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. If any adjustment to fair value reflects a significant decline in the value of the security, the Company evaluates the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to its Consolidated Statements of Income. Marketable securities are classified as non-current when maturities are one year or more.
Accounts Receivable
Accounts Receivable and Allowance for Credit Losses and Concentration of Credit Risk
The Company sells its products directly to physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as to individual, non-professional OTC customers, and other distributors in the U.S. and internationally (see Note 4). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company establishes a reserve based on historical losses, the age of receivables, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts, and specific allowances for large or risky accounts. Amounts later determined to be uncollectible are charged or written off against this allowance. The balance of accounts receivable is net of reserves of $89.1 million and $52.4 million at January 1, 2023 and January 2, 2022, respectively, of which the reserve related to contract rebates was $73.5 million and $40.3 million, respectively.
Concentration Risk, Credit Risk, Policy
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash equivalents, marketable securities and trade accounts receivable.
Credit losses are identified when cash flows received are not expected to be sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).
The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventory, Policy InventoriesInventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified.
Property, Plant and Equipment, Policy
Property, Plant and Equipment
Property, plant and equipment are recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method as follows:
Asset typeUseful life
Building and building improvements
7-47 years
Machinery and equipment
3-15 years
Customer leased instruments
3-8 years
Computer software
3-5 years
Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or the estimated useful lives of the related assets.
When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the accounts and included in determining gain or loss on such disposals. Maintenance and repairs are expensed as incurred; major replacements and improvements that extend the useful life are capitalized.
Goodwill and Intangible Assets, Policy
Goodwill
Goodwill represents the excess of purchase price over the fair values of underlying net assets acquired in an acquisition. The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. Beginning in 2022, the Company changed its annual impairment assessment date from December 31 to the first day of the fourth quarter of the fiscal year.
In connection with the Combinations, the manner in which the chief operating decision maker (“CODM”) reviews the Company’s performance and allocates resources changed, resulting in six operating segments: North America, EMEA, China, Latin America, Japan and Asia Pacific. North America, EMEA and China are the Company’s reportable segments; Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” The Company concluded each of these six operating segments is considered a reporting unit for the purpose of allocating goodwill and performing the annual goodwill impairment assessment. Prior to the Combinations, the Company operated as a single reportable segment with one reporting unit.
When testing goodwill for impairment, the Company first has an option to assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that impairment exists. Such qualitative factors may include the following: macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, the Company would be required to perform a quantitative impairment test. Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value of each reporting unit to its carrying value, including goodwill. The Company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. If the fair value of a reporting unit is less than its carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value.
For fiscal year 2022, the Company performed a qualitative goodwill impairment assessment as of the beginning of the fiscal fourth quarter to assess for potential impairment. Based on the qualitative impairment assessment performed by the Company, it was concluded that it is not more likely than not that the fair value of the Company’s reporting units is less than their carrying amounts, and therefore no further impairment testing was necessary.
Goodwill and Intangible Assets, Intangible Assets, Policy Intangible AssetsIntangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life.
Impairment or Disposal of Long-Lived Assets, Policy
Long-lived Assets
The process of evaluating the potential impairment of long-lived assets, such as property, plant and equipment and intangible assets, is subjective and requires judgment. The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of an asset may not be recoverable. If these circumstances exist, recoverability of assets to be held and used is measured by a comparison of the carrying value of an asset group to future undiscounted net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Debt, Policy
Convertible Debt
The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects the Company’s nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. During fiscal year 2020, the remaining aggregate principal amount of the Company’s Convertible Notes was settled or matured.
Revenue
Revenue Recognition
The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings,
including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based on historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively.
Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service.
During fiscal years 2022 and 2021, the Company generated a portion of its revenue from sales of the QuickVue At-Home OTC COVID-19 tests to retail customers. The Company estimates the transaction price for revenue from sales to retail customers based on historical experience and current trends to evaluate when uncertainties related to right of return provisions are resolved. As of January 1, 2023 and January 2, 2022, due to a lack of history on which to base an estimate of products to be returned from the retailers, the Company established a reserve based on an estimate of total inventory remaining at our retailers which was subject to return.
A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately. The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument was not material for fiscal years 2022, 2021 and 2020.
Government Assistance
Government Assistance
During fiscal year 2020, the Company entered into a contract with the National Institutes of Health (“NIH”), through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract originally provided for consideration to the Company of up to $65.0 million and had a performance period of one year, which began in July 2020. During 2021, the Company entered into several amendments to the contract, which added additional deliverables and milestones, as well as extended the performance period. The contract and amendments included key deliverables and milestones that directly supported the upgrade and addition of new manufacturing lines, as well as the outfitting of the new distribution center. The Company also provided instruments and assays to NIH. There were no refund provisions under the contract.
Consideration from the contract was allocated to each deliverable identified within the contract using a relative fair value allocation method and recognized when there was reasonable assurance the Company would meet the milestones and receive the consideration. Consideration allocated to the delivery of instruments and assays was recognized in accordance with the Company’s existing revenue recognition policy described above. Consideration that related to capital expenditures was recorded as a reduction to the carrying value of such assets and amortized over the useful life of the assets. Consideration allocated to the remainder of the contract was recorded as reductions to the related expense. As of January 2, 2022, the Company had achieved and collected payments for all milestones under the NIH contract.
In connection with the Combinations, the Company acquired a previously established agreement between Ortho and the Biomedical Advanced Research and Development Authority (“BARDA”), a division of HHS, which provides funding for Ortho to build manufacturing space and production support equipment to increase COVID-19 assay production capacity, as well as to build a manufacturing facility to produce certain analyzers needed to support COVID-19 testing. Amounts received from BARDA under this grant are recorded as a reduction to the carrying value of the related assets. A portion of the grant is
for purposes of reimbursement of certain general and administrative expenses related to the project, which are not capitalized as part of the equipment constructed in connection with the project and are recorded as a reduction to the related expense. The Company received $18.4 million during fiscal year 2022, which was recorded as a reduction to the carrying value of the related assets.
Research and Development Expense, Policy
Research and Development Costs
Research and development costs are charged to operations as incurred. Upfront and milestone payments made to third parties in connection with R&D collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties at or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
The Company enters into collaborative arrangements to develop and commercialize intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including R&D, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations.
Product Shipment Cost, Policy
Product Shipment Costs
Product shipment costs are included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $104.9 million, $29.3 million and $14.2 million for fiscal years 2022, 2021 and 2020, respectively.
Advertising Cost
Advertising Costs
Advertising costs are expensed as incurred and included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Advertising costs were $26.8 million, $13.7 million and $1.1 million for fiscal years 2022, 2021 and 2020, respectively.
Income Tax, Policy
Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision.
The Company does not intend to permanently reinvest earnings of foreign subsidiaries at this time. As such, the Company provides for income taxes and foreign withholding taxes, where applicable, on undistributed earnings. Any repatriation of undistributed earnings would be done at little or no tax cost.
Fair Value of Financial Instruments, Policy
Fair Value of Financial Instruments
The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.
Share-Based Payment Arrangement
Stock-based Compensation
Stock-based compensation, comprised of stock options, restricted stock units (“RSUs”) and restricted stock awards to employees and directors, is measured at fair value on the grant date. Compensation expense is recognized over the requisite service period, which is generally the vesting period, and includes an estimate of the awards that will be forfeited, and an estimate of the level of performance the Company will achieve for performance-based awards.
Leases
Leases
Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options.
For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments is incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities.
Operating leases are included in ROU assets, operating lease liabilities and operating lease liabilities non-current in the Consolidated Balance Sheets.
Comprehensive Income, Policy
Comprehensive Income
Comprehensive income includes unrealized gains and losses that are related to cumulative translation adjustments; unrealized gains and losses on marketable securities; changes in unamortized pension and post-employment actuarial gains and losses; and changes in the fair value of derivatives that are designated and qualify as cash flow hedging instruments excluded from the Consolidated Statements of Income.
Business Combinations Policy
Business Combinations
The cost of an acquired business is assigned to the tangible and identifiable intangible assets acquired and liabilities assumed on the basis of the estimated fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including, but not limited to, an income approach and a market approach, such as the estimation of future cash flows of the acquired business and current selling prices of similar assets. Fair value of the assets acquired and liabilities assumed, including intangible assets, IPR&D, and contingent payments, are measured based on the assumptions and estimations with regards to variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. When applicable, adjustments to inventory are based on the fair market value of inventory and are recognized into income based on the period in which the underlying inventory is sold. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that is not individually identified and separately recognized. Actual results may vary from projected results and assumptions used in the fair value assessments.
Pension and Other Postretirement Plans, Pensions, Policy Defined Benefit Plans and Other Post-Employment BenefitsIn connection with the Combinations, the Company assumed Ortho’s defined benefit plans in certain countries and a retiree healthcare reimbursement plan for certain U.S. employees. Defined benefit plans specify an amount of pension benefit that an employee will receive on retirement, usually dependent on factors such as age, years of service and compensation. The net obligation with respect to defined benefit plans is calculated separately for each plan by estimating the amount of the future benefits that employees have earned in return for their service in the current and prior periods. These benefits are then discounted to determine the present value of the obligations and are then adjusted for the impact of any unamortized prior service costs. The net obligation is then determined with reference to the fair value of the plan assets (if any). The discount rate used is the yield on bonds that are denominated in the currency in which the benefits will be paid and that have maturity dates approximating the terms of the obligations. The calculations are performed by qualified actuaries using the projected unit credit method.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination (Tables)
 12 Months Ended
Jan. 01, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Business Acquisitions, by Acquisition The total purchase consideration was calculated as follows (in millions, except value per share data and Ortho Exchange Ratio):
Total Ortho shares subject to exchange237.487
Ortho Exchange Ratio0.1055
QuidelOrtho shares issued25.055
Value per Quidel share as of May 26, 2022$99.60 
Fair value of stock consideration$2,495.5 
Fair value of replacement equity awards (1)47.9 
Cash consideration (2)1,747.7 
Total purchase consideration$4,291.1 
(1)
Represents the fair value of replacement stock options (which include options with time-based, performance-based, and both performance- and market-based vesting conditions), RSUs and restricted stock outstanding as of May 27, 2022 that are attributable to service prior to the Combinations. The terms of the replacement awards are substantially similar to the former Ortho equity awards for which they were exchanged. The portion of the fair value of the replacement equity awards attributable to service after the Combinations is $46.6 million and will be recognized as compensation expense based on the vesting terms of the replacement equity awards.
(2)
Represents cash consideration of $7.14 per share paid to Ortho shareholders and holders of vested Ortho stock options on the closing date of the Combinations for 237.5 million outstanding Ortho shares and 7.3 million vested Ortho stock options.
The components of the preliminary purchase price allocation on the closing date of the Combinations are as follows:
(In millions)Amounts Recognized as of Acquisition Date
(as previously reported)		Measurement Period AdjustmentsAmounts Recognized as of Acquisition Date
(as adjusted)
Cash and cash equivalents$234.5 $— $234.5 
Accounts receivable240.6 — 240.6 
Inventories386.8 (2.4)384.4 
Property, plant and equipment767.5 181.4 948.9 
Goodwill2,291.3 (112.9)2,178.4 
Intangible assets3,133.0 35.0 3,168.0 
Prepaid expenses and other assets287.9 (16.2)271.7 
Total assets7,341.6 84.9 7,426.5 
Accounts payable(135.0)— (135.0)
Accrued payroll and related expenses(80.7)(0.4)(81.1)
Long-term borrowings, including current portion (1)
(2,268.4)— (2,268.4)
Deferred tax liability(215.4)(63.0)(278.4)
Other current and non-current liabilities(351.0)(21.5)(372.5)
Total liabilities(3,050.5)(84.9)(3,135.4)
Total purchase consideration$4,291.1 $— $4,291.1 
(1) Immediately following the closing of the Combinations, the Company repaid long-term borrowings assumed, which consisted of $1,608.4 million aggregate principal amount related to Ortho’s Dollar Term Loan and Euro Term Loan Facilities, $240.0 million aggregate principal amount of 7.375% Senior Notes due 2025 and $405.0 million aggregate principal amount of 7.250% Senior Notes due 2028. The 7.375% and 7.250% Senior Notes were fully discharged following the Combinations. The Company recorded a $23.5 million loss on extinguishment in connection with the Combinations, representing the difference between the reacquisition value, inclusive of $35.9 million of redemption premium, and the net carrying value of the extinguished debt.
Assignment of Goodwill by Reportable Segment The preliminary assignment of goodwill by reportable segment as of the closing date of the Combinations is as follows (in millions):
North America$1,211.5 
EMEA370.0 
China121.6 
Other475.3 
$2,178.4 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table sets forth the amounts assigned to the identifiable intangible assets acquired (in millions, except years):
Intangible AssetAmortization PeriodFair Value of Assets Acquired
Customer relationships20 years$1,907.0 
Developed technology15 years888.0 
Trademarks15 years373.0 
$3,168.0 
Pro Forma Financial Information
The following supplemental pro forma financial information shows the combined results of operations of the Company as if the Combinations had occurred on January 4, 2021, the beginning of the periods presented:
Fiscal Year Ended
(In millions) (unaudited)20222021
Pro forma total revenues$4,051.2 $3,741.4 
Pro forma net income589.3 613.2 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Computation of Earnings Per Share (Tables)
 12 Months Ended
Jan. 01, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods:
Fiscal Year Ended
(In millions)202220212020
Numerator:
Net income used for basic earnings per share$548.7 $704.2 $810.3 
Interest expense on Convertible Notes, net of tax— — 0.4 
Net income used for diluted earnings per share, if-converted method$548.7 $704.2 $810.7 
Denominator:
Basic weighted-average shares of common stock outstanding56.8 42.1 42.1 
Dilutive potential shares issuable from Convertible Notes— — 0.3 
Dilutive potential shares issuable from stock options and unvested RSUs0.6 0.8 1.2 
Diluted weighted-average shares of common stock outstanding57.4 42.9 43.6 
Potentially dilutive shares excluded from calculation due to anti-dilutive effect1.5 0.2 — 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue (Tables)
 12 Months Ended
Jan. 01, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes Total revenues by business unit:
Fiscal Year Ended
(In millions)202220212020
Labs$820.2 $44.8 $50.9 
Transfusion Medicine393.8 — — 
Point of Care1,955.3 1,453.3 1,387.8 
Molecular Diagnostics96.7 200.5 223.0 
Total revenues$3,266.0 $1,698.6 $1,661.7 
Concentration of revenue and credit risk
The Company had sales to individual customers in excess of 10% of Total revenues as follows:
Fiscal Year Ended
202220212020
Customer:
A20 %1 %— %
B11 %24 %29 %
C8 %9 %16 %
D5 %9 %13 %
E3 %7 %10 %
47 %50 %68 %
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Information (Tables)
 12 Months Ended
Jan. 01, 2023
Industry And Geographic Information [Abstract]  
Revenue from External Customers by Geographic Areas
Total revenues by reportable segment are as follows:
Fiscal Year Ended
(In millions)202220212020
North America$2,536.5 $1,500.2 $1,460.7 
EMEA206.8 69.6 92.9 
China220.0 58.0 62.4 
Other302.7 70.8 45.7 
Total revenues$3,266.0 $1,698.6 $1,661.7 
Schedule of Segment Reporting Information, by Segment
The following table sets forth Adjusted EBITDA by segment and the reconciliations to Income before provision for income taxes for fiscal years 2022, 2021 and 2020:
Fiscal Year Ended
(In millions)202220212020
North America$1,614.6 $1,028.5 $1,205.2 
EMEA31.7 28.1 55.5 
China104.1 24.1 30.5 
Other92.7 43.0 28.0 
Total segment Adjusted EBITDA1,843.1 1,123.7 1,319.2 
Corporate (1)
(512.1)(152.9)(203.9)
Depreciation and amortization(283.6)(52.7)(48.8)
Acquisition and integration costs(136.0)(9.6)(3.7)
Interest expense, net(75.7)(5.8)(8.5)
Unwind inventory fair value adjustment(60.6)— — 
Loss on extinguishment of debt(24.0)— (10.4)
(Loss) gain on investments(5.8)1.5 — 
Amortization of deferred cloud computing
    implementation costs		(5.4)(3.7)(1.1)
Employee compensation charges and other costs(3.7)— — 
Impairment of long-lived assets(2.8)— — 
EU medical device regulation transition costs (2)
(1.5)— — 
Tax indemnification expense(0.3)— — 
Change in fair value of acquisition contingencies(0.1)(0.2)(1.4)
Derivative mark-to-market gain (loss)4.4 — (1.1)
Income before provision for income taxes$735.9 $900.3 $1,040.3 
(1) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and IT functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.
(2) Represents incremental consulting costs and R&D manufacturing site costs to align compliance of Ortho’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory:
Long-lived Assets as ofTotal Revenues for Fiscal Year
(In millions)January 1, 2023January 2, 2022202220212020
Domestic$983.0 $347.1 $2,451.7 $1,415.5 $1,452.4 
Foreign356.0 2.1 814.3 283.1 209.3 
Total$1,339.0 $349.2 $3,266.0 $1,698.6 $1,661.7 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes (Tables)
 12 Months Ended
Jan. 01, 2023
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)
Significant components of the provision for income taxes were as follows:
Fiscal Year Ended
(In millions)202220212020
Current:
Federal$162.2 $148.8 $198.5 
State48.8 42.4 34.6 
Foreign17.6 2.3 1.1 
Total current provision228.6 193.5 234.2 
Deferred:
Federal(31.9)7.2 (2.9)
State(9.3)(2.6)(1.0)
Foreign(0.2)(2.0)(0.3)
Total deferred provision (benefit)(41.4)2.6 (4.2)
Provision for income taxes$187.2 $196.1 $230.0 
Schedule of Income before Income Tax, Domestic and Foreign
The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods:
Fiscal Year Ended
(In millions)202220212020
United States$672.1 $891.2 $1,035.7 
Foreign63.8 9.1 4.6 
Income before income taxes$735.9 $900.3 $1,040.3 
Schedule of Deferred Tax Assets and Liabilities
Significant components of the Company’s deferred tax assets and deferred tax liabilities as of January 1, 2023 and January 2, 2022 are shown below:
(In millions)January 1, 2023January 2, 2022
Deferred tax assets:
Lease liability$51.4 $32.7 
Intangible assets— 2.2 
Allowance for returns and discounts45.9 28.3 
Inventory reserve34.1 6.4 
Stock-based compensation14.6 9.2 
Tax loss and credit carryforwards565.3 10.8 
Research & development expenses50.7 — 
Employee related obligations19.9 5.5 
Other, net16.1 0.8 
Total deferred tax assets798.0 95.9 
Valuation allowance for deferred tax assets(251.3)(2.3)
Total deferred tax assets, net of valuation allowance546.7 93.6 
Deferred tax liabilities:
Right-of-use assets(43.8)(30.1)
Intangible assets(590.2)(0.9)
Property, plant and equipment(109.5)(42.5)
Total deferred tax liabilities(743.5)(73.5)
Net deferred tax assets (liabilities)$(196.8)$20.1 
Schedule of Effective Income Tax Rate Reconciliation
The reconciliation of income tax computed at the federal statutory rate to the provision for income taxes from continuing operations was as follows:
Fiscal Year Ended
(In millions)202220212020
Tax expense at statutory tax rate$154.5 $189.1 $218.5 
State tax expense, net of federal tax29.3 30.1 30.3 
Foreign income taxed at rates other than the applicable U.S. rate(27.5)— — 
Permanent differences12.0 1.8 3.8 
Federal and state research credits—current year(7.3)(7.7)(5.0)
Stock-based compensation1.5 (9.2)(13.9)
Change in valuation allowance26.2 (0.1)(0.1)
Foreign Derived Intangible Income Deduction (FDII)(10.2)(8.4)(8.6)
Other8.7 0.5 5.0 
Provision for income taxes$187.2 $196.1 $230.0 
Schedule of Unrecognized Tax Benefits Roll Forward
The following table summarizes the activity related to the Company’s unrecognized tax benefits:
Fiscal Year Ended
(In millions)202220212020
Beginning balance$17.7 $22.6 $17.2 
Increases due to current year acquisitions27.8 — — 
Increases (decreases) related to prior year tax positions(0.6)0.5 (2.3)
Increases related to current year tax positions1.8 0.9 7.7 
Decreases from voluntary disclosure agreements— (6.3)— 
Decreases due to settlements(6.7)— — 
Ending balance$40.0 $17.7 $22.6 
Summary of Valuation Allowance
The following table summarizes the changes to the valuation allowance for balances for fiscal years 2022, 2021 and 2020:
Beginning BalanceAdditions Due to Current Year AcquisitionsAdditions
(Deductions)
Charged to
Provision for (Benefit From)
Income Taxes		Currency Translation/OtherEnding Balance
Deferred tax valuation allowance
Fiscal year ended January 1, 2023$2.3 223.5 26.2 (0.7)$251.3 
Fiscal year ended January 2, 2022$2.3 — — — $2.3 
Fiscal year ended January 3, 2021$2.4 — (0.1)— $2.3 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details (Tables)
 12 Months Ended
Jan. 01, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash
(In millions)January 1, 2023January 2, 2022
Cash and cash equivalents$292.9 $802.8 
Restricted cash included in Other assets1.0 — 
Cash, cash equivalents and restricted cash$293.9 $802.8 
Marketable Securities
The following table is a summary of marketable securities:
January 1, 2023January 2, 2022
(In millions)Amortized CostGross Unrealized LossesFair ValueAmortized CostGross Unrealized LossesFair Value
Corporate bonds40.5 $(0.5)$40.0 $22.3 $— $22.3 
Corporate asset-backed securities6.7 — 6.7 3.4 — 3.4 
U.S. government securities2.0 — 2.0 — — — 
Agency bonds1.0 — 1.0 — — — 
Sovereign government bonds1.9 — 1.9 — — — 
Foreign and other0.5 — 0.5 — — — 
Total marketable securities, current52.6 (0.5)52.1 25.7 — 25.7 
Corporate bonds, non-current13.3 (0.1)13.2 26.8 (0.1)26.7 
Corporate asset-backed securities, non-current7.9 (0.1)7.8 11.2 — 11.2 
Total marketable securities$73.8 $(0.7)$73.1 $63.7 $(0.1)$63.6 
Accounts Receivable, Net
Accounts receivables primarily consist of trade accounts receivables with maturities of one year or less and are presented net of reserves:
(In millions)January 1, 2023January 2, 2022
Accounts receivable$543.0 $430.4 
Allowance for contract rebates and discounts(77.1)(50.7)
Allowance for doubtful accounts(12.0)(1.7)
Total accounts receivable, net$453.9 $378.0 
The allowance for contractual rebates involves estimating adjustments to revenue based on a high volume of data, including inputs from third-party sources. In addition, the determination of such adjustments includes estimating rebate percentages which are dependent on estimated end-user sales mix and customer contractual terms, which vary across customers, the related balance of which was $40.0 million and $40.3 million at January 1, 2023 and January 2, 2022, respectively, and was included in the allowance for contract rebates and discounts.
The following table summarizes changes to the accounts receivable allowance balances for fiscal years 2022, 2021 and 2020:
Balance at
Beginning of
Period		Additions Charged to Expense or as Reductions to Revenue (1)Deductions (2)Balance at end of
period
(In millions)
Fiscal year ended January 1, 2023$52.4 $407.6 $(370.9)$89.1 
Fiscal year ended January 2, 2022$103.4 $456.2 $(507.2)$52.4 
Fiscal year ended January 3, 2021$15.9 $277.0 $(189.5)$103.4 
(1)Includes opening balance of $31.4 million related to the Combinations during fiscal year 2022. Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to selling, marketing and administrative expense.
(2)The deductions represent actual charges against the accrual described above.
Inventory
Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Inventories consisted of the following:
(In millions)January 1, 2023January 2, 2022
Raw materials$185.2 $103.2 
Work-in-process (materials, labor and overhead)82.7 36.1 
Finished goods (materials, labor and overhead)295.1 59.5 
Total inventories$563.0 $198.8 
Inventories$524.1 $198.8 
Other assets (1)
38.9 — 
Total inventories$563.0 $198.8 
(1) Other assets includes inventory expected to remain on hand beyond one year.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
(In millions)January 1, 2023January 2, 2022
Prepaid expenses$96.7 $14.6 
Contract assets49.6 — 
Other receivables44.3 15.8 
Income taxes and other tax receivables38.6 — 
Derivatives22.0 0.1 
Other0.9 4.5 
Total prepaid expenses and other current assets$252.1 $35.0 
Other Current Liabilities
Other current liabilities consist of the following:
(In millions)January 1, 2023January 2, 2022
Accrued commissions and rebates$55.1 $15.9 
Deferred consideration39.3 41.9 
Deferred revenue76.4 1.9 
Operating lease liabilities24.4 10.0 
Accrued other taxes payable9.3 10.2 
Derivatives19.7 0.3 
Contingent consideration0.1 6.0 
Payables under transition services agreements— 10.9 
Other101.1 17.3 
Total other current liabilities$325.4 $114.4 
Property, Plant and Equipment
The following is a summary of property, plant and equipment:
(In millions)January 1, 2023January 2, 2022
Equipment, furniture and fixtures$515.1 $159.0 
Building and improvements364.7 146.8 
Customer leased instruments434.5 68.1 
Land34.5 10.2 
Construction in progress268.4 105.2 
Total property, plant and equipment, gross1,617.2 489.3 
Less: accumulated depreciation and amortization(278.2)(140.1)
Total property, plant and equipment, net$1,339.0 $349.2 
Schedule of Intangible Assets and Goodwill
Intangible assets consisted of the following:
January 1, 2023January 2, 2022
DescriptionWeighted-average
useful life
(years)		Gross
assets		Accumulated
amortization		NetGross
assets		Accumulated
amortization		Net
Purchased technology14.3$997.6 $(120.0)$877.6 $112.7 $(78.2)$34.5 
Customer relationships19.22,023.5 (148.9)1,874.6 122.7 (77.3)45.4 
License agreements6.43.8 (3.7)0.1 6.6 (5.7)0.9 
Patent and trademark costs14.7400.5 (32.8)367.7 28.7 (15.7)13.0 
Software development costs4.711.5 (7.7)3.8 11.7 (6.8)4.9 
Total intangible assets$3,436.9 $(313.1)$3,123.8 $282.4 $(183.7)$98.7 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of January 1, 2023 is as follows:
(In millions)
2023$205.4 
2024201.7 
2025188.2 
2026187.1 
2027184.7 
Schedule of Goodwill
Changes in goodwill were as follows:
(In millions)North AmericaEMEAChinaOtherTotal
Balance at January 2, 2022$337.0 
Impact of reportable segment revisions$336.9 $0.1 $— $— 337.0 
Goodwill acquired1,211.5 370.0 121.6 475.3 2,178.4 
Foreign currency translation(0.7)(11.5)(3.5)(22.9)(38.6)
Balance at January 1, 2023$1,547.7 $358.6 $118.1 $452.4 $2,476.8 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Borrowings (Tables)
 12 Months Ended
Jan. 01, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
The components of borrowings were as follows:
(In millions)January 1, 2023January 2, 2022
Term Loan$2,646.9 $— 
Revolving Credit Facility— — 
Financing lease obligation 0.8 0.7 
Other long-term borrowings1.2 — 
Unamortized deferred financing costs(10.6)— 
Total borrowings2,638.3 0.7 
Less: current portion(207.5)(0.3)
Long-term borrowings$2,430.8 $0.4 
Schedule of Interest Expense
The following table provides the detailed amounts within Interest expense, net for fiscal years 2022, 2021 and 2020.
Fiscal Year Ended
(In millions)202220212020
Term Loan$73.0 $— $— 
Revolving Credit Facility1.5 0.3 0.3 
Amortization of deferred financing costs2.1 0.4 0.4 
Derivative instruments and other0.4 5.4 7.9 
Interest income(1.3)(0.3)(0.1)
Interest expense, net$75.7 $5.8 $8.5 
Contractual Obligation, Fiscal Year Maturity
The following table provides a schedule of required future repayments of all borrowings outstanding as of January 1, 2023.
(In millions)
2023$207.5 
2024172.7 
2025137.5 
2026137.5 
20271,993.7 
Total$2,648.9 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Leases (Tables)
 12 Months Ended
Jan. 01, 2023
Leases [Abstract]  
Summary of Lease Cost
The supplemental cash flow information related to operating leases during the respective periods was as follows:
Fiscal Year Ended
(In millions)202220212020
Cash paid for amounts included in the measurement of operating
     lease liabilities		$25.2 $12.3 $10.8 
ROU assets obtained in exchange for new lease liabilities$29.9 $37.3 $15.3 
Schedule of Maturity of Operating Lease Liability
The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable operating leases at the end of 2022 were as follows:
(In millions)
2023$32.7
202429.1
202526.4
202624.1
202721.3
Thereafter122.9
Total lease payments256.5
Less: imputed interest(45.7)
Total210.8
Less: current portion(24.4)
Non-current portion$186.4
Weighted average remaining lease term9.7 years
Weighted average discount rate4 %
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation (Tables)
 12 Months Ended
Jan. 01, 2023
Equity [Abstract]  
Compensation Expense Related to Stock-Based Compensation Plans
Stock-based compensation expense was as follows:
Fiscal Year Ended
(In millions)202220212020
Cost of sales$2.9 $2.7 $2.0 
Research and development4.9 4.4 3.4 
Selling, marketing and administrative
27.4 18.3 15.6 
Acquisition and integration costs30.4 — — 
Total stock-based compensation expense$65.6 $25.4 $21.0 
Share-based Payment Arrangement, Option, Activity
A summary of the status of stock option activity for fiscal year 2022 is as follows:
(In thousands, except price data)
SharesWeighted-Average
Exercise Price
Per Share		Weighted-Average
Remaining Contractual Term (In Years)		Aggregate Intrinsic Value
Outstanding at January 2, 2022722 $62.71 
Granted187 100.45 
Stock options assumed in the Combinations1,229 96.10 
Exercised(383)55.15 
Forfeited(99)115.95 
Outstanding at January 1, 20231,656 $90.34 5.53$28,140 
Vested and expected to vest at January 1, 20231,600 $89.23 5.45$28,122 
Exercisable at January 1, 20231,195 $80.53 4.61$26,774 
Estimated Fair Value of Each Stock Option Award The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants, including grants related to options assumed in the Combinations presented separately:
Assumed on
Fiscal Year Ended
May 27, 2022 (1)
January 1, 2023January 2, 2022January 3, 2021
Risk-free interest rate2.28 %1.96 %0.48 %1.18 %
Expected option life (in years)1.784.804.995.12
Volatility rate64 %57 %54 %41 %
Dividend rate0 %0 %0 %0 %
Weighted-average grant date fair value$40.57$50.62$106.55$36.84
(1) The replacement stock options granted to Ortho option holders on the closing date of the Combinations were issued consistent with the vesting conditions of the replaced award. The fair value on the closing date of the Combinations attributed to post-combination service, adjusted for estimated forfeitures, is recognized as expensed on a straight-line basis over the remaining vesting period.
Schedule of Nonvested Share Activity
A summary of the status of RSU activity for fiscal year 2022 is as follows:
(In thousands, except price data)
SharesWeighted-Average
Grant Date
Fair Value
Non-vested at January 2, 2022587 $95.81 
Granted720 97.31 
Stock awards assumed in the Combinations49 99.60 
Vested(248)86.61 
Forfeited(76)100.70 
Non-vested at January 1, 20231,032 $98.89 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements (Tables)
 12 Months Ended
Jan. 01, 2023
Fair Value Disclosures [Abstract]  
Liabilities Measured at Fair Value on Recurring Basis
The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods:
 January 1, 2023January 2, 2022
(In millions)Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Cash equivalents$0.6 $2.1 $— $2.7 $204.7 $6.6 $— $211.3 
Marketable securities2.0 71.1 — 73.1 — 63.6 — 63.6 
Derivative assets— 22.0 — 22.0 — 0.1 — 0.1 
Total assets measured at fair value$2.6 $95.2 $— $97.8 $204.7 $70.3 $— $275.0 
Liabilities:
Derivative liabilities$— $21.8 $— $21.8 $— $0.3 $— $0.3 
Contingent consideration— — 0.1 0.1 — — 6.1 6.1 
Deferred consideration— 39.3 — 39.3 — 78.4 — 78.4 
Total liabilities measured at fair value$— $61.1 $0.1 $61.2 $— $78.7 $6.1 $84.8 
Changes in Estimated Fair Value of Contingent Consideration Liabilities
Changes in estimated fair value of contingent consideration liabilities from January 3, 2021 through January 1, 2023 were as follows:
(In millions)Contingent Consideration
Liabilities
(Level 3 Measurement)
Balance at January 3, 2021$11.9 
Cash payments(6.0)
Change in estimated fair value, recorded in selling, marketing and administrative expenses0.2 
Balance at January 2, 2022$6.1 
Cash payments(6.0)
Balance at January 1, 2023$0.1 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Derivative Instruments and Hedging Activities (Tables)
 12 Months Ended
Jan. 01, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Interest Rate Derivatives
The following table summarizes the Company’s interest rate derivative agreements as of January 1, 2023, all of which were interest rate swaps:
Notional Amount
(In millions) (1)
DescriptionHedge DesignationEffective DateExpiration Date
$500.0 
Pay 1.58% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeMay 29, 2022December 31, 2023
397.2 
Pay 3.765% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
144.4 
Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
216.7 
Pay 3.7675% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
288.9 
Pay 3.7575% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
252.8 
Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)
Designated cash flow hedgeDecember 30, 2022May 27, 2027
(1) The notional value of interest rate swap contracts with an effective date of December 30, 2022, is expected to increase to $1.8 billion on December 29, 2023.
Schedule of Currency Hedging Instruments
The following table provides details of the currency hedging instruments outstanding as of January 1, 2023:
DescriptionNotional Amount
(In millions)		Hedge Designation
Foreign currency forward contracts$441.6 Cash Flow Hedge
Foreign currency forward contracts581.7 Non-designated
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)
The following table summarizes pre-tax gains and losses from designated derivative and non-derivative instruments within accumulated other comprehensive (loss) income (“AOCI”) for fiscal year 2022:
Designated Hedging Instruments
(In millions)Amount of Loss (Gain) Recognized in OCI on HedgesLocation of Amounts Reclassified From AOCI Into IncomeAmount of Loss (Gain) Reclassified From AOCI Into Income
Foreign currency forward contracts (sales)$1.3 Total revenues$(2.9)
Foreign currency forward contracts (purchases)3.5 Cost of sales, excluding amortization of intangibles(0.6)
Interest rate derivatives(11.4)Interest expense, net(1.7)
Schedule of Derivative Assets at Fair Value
The following table summarizes the fair value of designated and non-designated hedging instruments recognized within the Consolidated Balance Sheets as of January 1, 2023 and January 2, 2022:
(In millions)January 1, 2023January 2, 2022
Designated cash flow hedges
Interest rate derivatives:
Prepaid expenses and other current assets$15.9 $— 
Other liabilities2.1 — 
Foreign currency forward contracts:
Prepaid expenses and other current assets4.6 0.1 
Other current liabilities14.3 0.2 
Non-designated hedging instruments
Foreign currency forward contracts:
Prepaid expenses and other current assets1.5 — 
Other current liabilities5.4 0.1 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits (Tables)
 12 Months Ended
Jan. 01, 2023
Retirement Benefits [Abstract]  
Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets The following tables set forth the changes to the projected benefit obligations (“PBO”) and plan assets:
Fiscal Year Ended
(In millions)January 1, 2023
Defined Benefit Plans
Change in benefit obligation:
Projected benefit obligation at beginning of year$— 
Service cost1.2 
Interest cost0.4 
Benefits paid(0.3)
Actuarial gain(0.6)
Assumed obligation from the Combinations33.3 
Settlements(0.2)
Foreign currency exchange rate changes0.1 
Projected benefit obligation at end of year$33.9 
Change in plan assets:
Fair value of plan assets at beginning of year$— 
Actual return on plan assets(0.5)
Employer contributions1.6 
Benefits paid(0.3)
Transfers in from the Combinations20.1 
Settlements(0.2)
Foreign currency exchange rate changes(0.1)
Fair value of plan assets at end of year$20.6 
Funded status at end of year$(13.3)
Amounts recognized on the consolidated balance sheets:
Other assets$0.4 
Other current liabilities(0.3)
Other liabilities(13.4)
Net amount recognized$(13.3)
Fiscal Year Ended
(In millions)January 1, 2023
Other Post-employment Benefits
Change in benefit obligation:
Projected benefit obligation at beginning of year$18.9 
Service cost0.3 
Interest cost0.4 
Benefits paid(0.7)
Actuarial gain(0.7)
Assumed obligation from the Combinations0.4 
Projected benefit obligation at end of year$18.6 
Amounts recognized on the consolidated balance sheets:
Other current liabilities $(3.5)
Other liabilities(15.1)
Net amount recognized$(18.6)
Schedule of Defined Benefit Plans Disclosures
The following table reflects the ABO for all defined benefit plans as of January 1, 2023. Further, the table reflects the aggregate PBO, ABO and fair value of plan assets for pension plans with PBO in excess of plan assets and for pension plans with ABO in excess of plan assets.
(In millions)January 1, 2023
ABO$27.1 
Plans with PBO in excess of plan assets
PBO$18.3 
Fair value of plan assets5.1
Plans with ABO in excess of plan assets
PBO$17.0 
ABO14.3
Fair value of plan assets3.8
The pretax amounts that are not yet reflected in the net periodic benefit cost and are included in AOCI as of January 1, 2023 include the following:
Fiscal Year Ended
(In millions)2022
Defined Benefit Plans
Accumulated net actuarial gains (losses)$(0.2)
Other Post-employment Benefits
Accumulated net actuarial gains (losses)$0.7 
Defined Benefit Plan, Assumptions The following assumptions were used to measure the fair value of the benefit obligations and associated plan assets:
May 27, 2022January 1, 2023
Defined Benefit Plans
Weighted average discount rate2.2 %3.1 %
Weighted average rate of compensation increases2.6 %3.0 %
Other Post-employment Benefit Plans
Weighted average discount rate4.0 %5.5 %
The critical assumptions used in determining the net periodic benefit cost for fiscal year 2022 are as follows:
Defined Benefit Plans
Weighted average discount rate2.2 %
Weighted average expected rate of compensation increases2.6 %
Weighted average expected return on plan assets2.5 %
Other Post-employment Benefit Plans
Weighted average discount rate4.0 %
Schedule of Health Care Cost Trend Rates The health care cost trend rate assumptions for other post-retirement benefit plans are as follows:
January 1, 2023
Health care cost trend rate assumed for next year - Pre-656.44 %
Health care cost trend rate assumed for next year - Post-656.10 %
Rate to which the cost trend rate is assumed to decline4.00 %
Year that the trend rate reaches the ultimate trend rate 2047
Schedule of Expected Benefit Payments
The following table reflects the total benefit payments expected to be made for defined benefit plans and other long-term post-employment benefits:
(In millions)Defined Benefit PlansOther Post-employment Benefit Plans
Fiscal Year 2023$1.7 $3.5 
Fiscal Year 20243.54.0
Fiscal Year 20252.13.3
Fiscal Year 20262.22.2
Fiscal Year 20272.31.9
Fiscal Years 2028-203212.65.5
Schedule of Allocation of Plan Assets
The tables below present the fair value of the defined benefit pension plans by level within the fair value hierarchy, as described in Note 1, at January 1, 2023.
Fair Value Measurements at January 1, 2023
(In millions)TotalLevel 1Level 2Level 3
U.S. equity securities$2.2 $2.2 $— $— 
Japan equity securities3.7 3.7 — — 
Other international equity securities1.6 1.6 — — 
U.S. government bonds0.2 0.2 — — 
Japan government bonds0.5 0.5 — — 
Other international government bonds1.6 1.6 — — 
Cash and cash equivalents4.7 4.7 — — 
Insurance contracts6.1 — — 6.1 
Total$20.6 $14.5 $— $6.1 
The table below presents a roll-forward of activity for the Level 3 assets for fiscal year 2022:
(In millions)Level 3 Assets
Balance at January 2, 2022$— 
Transfers in5.5
Net purchases and settlements0.6
Balance at January 1, 2023$6.1 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Accumulated Other Comprehensive (Loss) Income (Tables)
 12 Months Ended
Jan. 01, 2023
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The balance of AOCI, net of tax, was as follows for fiscal year 2022:
(In millions)Pension and Other Post-
employment Benefits		Cash Flow HedgesAvailable-for-Sale InvestmentsUnrealized Foreign Currency Translation AdjustmentsAccumulated Other Comprehensive Income (Loss)
Beginning balance$— $— $(0.1)$0.5 $0.4 
Current period deferrals0.7 6.7 (0.4)(69.8)(62.8)
Amounts reclassified to net income— (5.2)— — (5.2)
Net change0.7 1.5 (0.4)(69.8)(68.0)
Ending balance$0.7 $1.5 $(0.5)$(69.3)$(67.6)
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies - Reclassifications (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Reclassification [Line Items]      
Amortization of intangible assets $ 132.5 $ 27.4 $ 27.3
Cost of sales      
Reclassification [Line Items]      
Amortization of intangible assets   7.4 7.4
Selling, Marketing, and Administrative Expense      
Reclassification [Line Items]      
Amortization of intangible assets   $ 20.0 $ 19.9
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Details)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
country
segment
Jan. 02, 2022
USD ($)
Jan. 03, 2021
USD ($)
Number of countries entity operates | country 130    
Proceeds from government assistance allocated to fixed assets $ 18.4 $ 36.9 $ 1.6
Amortization of Intangible Assets 132.5 27.4 27.3
Allowance for Credit Loss, Receivable, Other, Current 89.1 52.4  
Reserve for Contract Rebates   73.5 40.3
Contract Consideration $ 65.0    
Number of Operating Segments | segment 6    
Shipping and Handling      
Costs and Expenses $ 104.9 29.3 14.2
Advertising      
Costs and Expenses $ 26.8 $ 13.7 $ 1.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01      
Expected timing of satisfaction, period 1 year    
Minimum | Building and improvements      
Property, Plant and Equipment, Useful Life 7 years    
Minimum | Equipment, furniture and fixtures      
Property, Plant and Equipment, Useful Life 3 years    
Minimum | Customer leased instruments      
Property, Plant and Equipment, Useful Life 3 years    
Minimum | Software and Software Development Costs      
Property, Plant and Equipment, Useful Life 3 years    
Maximum | Building and improvements      
Property, Plant and Equipment, Useful Life 47 years    
Maximum | Equipment, furniture and fixtures      
Property, Plant and Equipment, Useful Life 15 years    
Maximum | Customer leased instruments      
Property, Plant and Equipment, Useful Life 8 years    
Maximum | Software and Software Development Costs      
Property, Plant and Equipment, Useful Life 5 years    
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 7 Months Ended 12 Months Ended
May 27, 2022
May 26, 2022
Jan. 01, 2023
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Business Acquisition [Line Items]            
Amortization of intangible assets       $ 132.5 $ 27.4 $ 27.3
Unwind inventory fair value adjustment       (60.6) 0.0 $ 0.0
Ortho            
Business Acquisition [Line Items]            
Total purchase consideration   $ 4,291.1        
Closing price of Quidel Common Stock (in usd per share)   $ 99.60        
Cash paid to former Ortho stockholders per Ortho Share (in usd per share)   7.14        
Ortho Exchange Ratio (in usd per share)   0.1055        
Step-Up, Inventory, Value $ 61.7   $ 60.6 60.6    
Transaction costs       46.9    
Amortization of intangible assets     $ 104.7      
Pro forma net income       589.3 613.2  
Ortho | Amortization Expense            
Business Acquisition [Line Items]            
Pro forma net income       (19.6) (45.5)  
Ortho | Cost of sales            
Business Acquisition [Line Items]            
Pro forma net income         (61.7)  
Ortho | Interest Expense            
Business Acquisition [Line Items]            
Pro forma net income       (11.2) (34.9)  
Ortho | Loss on Extinguishment of Debt            
Business Acquisition [Line Items]            
Pro forma net income       (24.0) (24.0)  
Ortho | Share-Based Compensation Expense            
Business Acquisition [Line Items]            
Pro forma net income       (12.8) $ (12.8)  
Ortho | Ortho            
Business Acquisition [Line Items]            
Ortho Exchange Ratio (in usd per share)   $ 0.1055        
Ortho | Ortho | Loss on Extinguishment of Debt            
Business Acquisition [Line Items]            
Pro forma net income       $ 50.3    
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination - Purchase Price by Exchange Ratio (Details) - Ortho - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
May 27, 2022
May 26, 2022
Business Acquisition [Line Items]    
Ortho Exchange Ratio (in usd per share)   $ 0.1055
Value per Quidel share as of May 26, 2022 (in usd per share)   $ 99.60
Fair value of stock consideration   $ 2,495.5
Fair value of replacement equity awards   47.9
Cash consideration   1,747.7
Total purchase consideration   $ 4,291.1
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, After Combination $ 46.6  
Cash paid to former Ortho stockholders per Ortho Share (in usd per share)   $ 7.14
Business Acquisition, Number of Common Stock Shares Acquired   237,500
Business Acquisition, Number of Vested Stock Options Acquired   7,300
Ortho    
Business Acquisition [Line Items]    
Total Ortho shares subject to exchange (in shares)   237,487
Ortho Exchange Ratio (in usd per share)   $ 0.1055
QuidelOrtho    
Business Acquisition [Line Items]    
QuidelOrtho shares issued (in shares)   25,055
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination - Summary of Purchase Price (Details) - USD ($)
$ in Millions
 7 Months Ended 12 Months Ended
May 27, 2022
Jan. 01, 2023
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Business Acquisition [Line Items]          
Goodwill   $ 2,476.8 $ 2,476.8 $ 337.0  
Loss on extinguishment of debt     (24.0) $ 0.0 $ (10.4)
Gain (Loss) On Redemption Premium $ 35.9        
Ortho          
Business Acquisition [Line Items]          
Cash and cash equivalents 234.5 234.5 234.5    
Measurement Period Adjustments, Cash and Cash Equivalents   0.0      
Accounts receivable 240.6 240.6 240.6    
Measurement Period Adjustments, Accounts Receivable   0.0      
Inventories 386.8 384.4 384.4    
Measurement Period Adjustments, Inventory   (2.4)      
Property, plant and equipment 767.5 948.9 948.9    
Measurement Period Adjustments, Property, Plant, and Equipment   181.4      
Goodwill 2,291.3 2,178.4 2,178.4    
Measurement Period Adjustments, Goodwill   (112.9)      
Intangible assets 3,133.0 3,168.0 3,168.0    
Measurement Period Adjustments, Intangible Assets   35.0      
Prepaid expenses and other assets 287.9 271.7 271.7    
Measurement Period Adjustments, Prepaid Expenses and Other Assets   (16.2)      
Total assets 7,341.6 7,426.5 7,426.5    
Measurement Period Adjustments, Total Assets   84.9      
Accounts payable (135.0) (135.0) (135.0)    
Measurement Period Adjustments, Accounts Payable   0.0      
Accrued payroll and related expenses (80.7) (81.1) (81.1)    
Measurement Period Adjustments, Accrued Payroll and Related Expenses   (0.4)      
Long-term borrowings, including current portion (1) (2,268.4) (2,268.4) (2,268.4)    
Measurement Period Adjustments, Accounts Receivable, Long-term borrowings, including current portion   0.0      
Deferred tax liability (215.4) (278.4) (278.4)    
Measurement Period Adjustments, Deferred Income Tax Liability   (63.0)      
Other current and non-current liabilities (351.0) (372.5) (372.5)    
Measurement Period Adjustments, Other Current and Non-current Liabilities   (21.5)      
Total liabilities (3,050.5) (3,135.4) (3,135.4)    
Measurement Period Adjustments, Total Liabilities   (84.9)      
Total purchase consideration 4,291.1 4,291.1 $ 4,291.1    
Measurement Period Adjustments, Total purchase consideration   $ 0.0      
Repayments of Debt 1,608.4        
Loss on extinguishment of debt 23.5        
Ortho | Senior Notes Due 2025 | Senior Notes          
Business Acquisition [Line Items]          
Long-term borrowings $ 240.0        
Stated interest rate 7.375%        
Ortho | Senior Notes Due 2028 | Senior Notes          
Business Acquisition [Line Items]          
Long-term borrowings $ 405.0        
Stated interest rate 7.25%        
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination - Goodwill Allocation (Details) - USD ($)
$ in Millions
Jan. 01, 2023
May 27, 2022
Jan. 02, 2022
Business Combination Segment Allocation [Line Items]      
Goodwill $ 2,476.8   $ 337.0
North America      
Business Combination Segment Allocation [Line Items]      
Goodwill 1,547.7  
EMEA      
Business Combination Segment Allocation [Line Items]      
Goodwill 358.6  
China      
Business Combination Segment Allocation [Line Items]      
Goodwill 118.1  
Ortho      
Business Combination Segment Allocation [Line Items]      
Goodwill 2,178.4 $ 2,291.3  
Ortho | North America      
Business Combination Segment Allocation [Line Items]      
Goodwill 1,211.5    
Ortho | EMEA      
Business Combination Segment Allocation [Line Items]      
Goodwill 370.0    
Ortho | China      
Business Combination Segment Allocation [Line Items]      
Goodwill 121.6    
Ortho | Other      
Business Combination Segment Allocation [Line Items]      
Goodwill $ 475.3    
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination - Purchase Price Allocation of Intangible Assets (Details) - Ortho - USD ($)
$ in Millions
 7 Months Ended
Jan. 01, 2023
May 27, 2022
Business Acquisition [Line Items]    
Intangible Assets $ 3,168.0 $ 3,133.0
Customer relationships    
Business Acquisition [Line Items]    
Amortization Period 20 years  
Intangible Assets $ 1,907.0  
Developed technology    
Business Acquisition [Line Items]    
Amortization Period 15 years  
Intangible Assets $ 888.0  
Trademarks    
Business Acquisition [Line Items]    
Amortization Period 15 years  
Intangible Assets $ 373.0  
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination - Pro Forma Information (Details) - USD ($)
$ in Millions
 7 Months Ended 12 Months Ended
Jan. 01, 2023
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]        
Net income   $ 548.7 $ 704.2 $ 810.3
Total revenues   3,266.0 1,698.6 $ 1,661.7
Ortho        
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]        
Pro forma total revenues   4,051.2 3,741.4  
Pro forma net income   $ 589.3 $ 613.2  
Net income $ 126.2      
Total revenues $ 1,165.2      
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Computation of Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Earnings Per Share [Abstract]      
Net income $ 548.7 $ 704.2 $ 810.3
Interest expense on Convertible Notes, net of tax 0.0 0.0 0.4
Net income used for diluted earnings per share, if-converted method $ 548.7 $ 704.2 $ 810.7
Basic weighted-average shares of common stock outstanding 56.8 42.1 42.1
Dilutive potential shares issuable from Convertible Notes 0.0 0.0 0.3
Dilutive potential shares issuable from stock options and unvested RSUs 0.6 0.8 1.2
Diluted weighted-average shares of common stock outstanding 57.4 42.9 43.6
Potentially dilutive shares excluded from calculation due to anti-dilutive effect 1.5 0.2 0.0
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Disaggregation of Revenue [Line Items]      
Deferred revenue, current $ 76,400 $ 1,900  
Deferred Revenue, Noncurrent 9,400    
Revenue 3,266,000 1,698,600 $ 1,661,700
Accounts receivable, net $ 453,900 $ 378,000  
Revenue Benchmark | Product Concentration Risk | COVID-19      
Disaggregation of Revenue [Line Items]      
Percentage of risk concentration 44.00% 75.00% 70.00%
Revenue Benchmark | Product Concentration Risk | Influenza      
Disaggregation of Revenue [Line Items]      
Percentage of risk concentration 11.00% 4.00% 8.00%
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Disaggregation of Revenue [Line Items]      
Gross Profit $ 18,600    
Revenue 7,500    
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement and Third Party      
Disaggregation of Revenue [Line Items]      
Gross Profit 11,100    
Prepaid Expenses and Other Current Assets [Member]      
Disaggregation of Revenue [Line Items]      
Contract assets 49,600    
Customer 1      
Disaggregation of Revenue [Line Items]      
Contract assets 6,800    
Expected Value Contract Customers | Prepaid Expenses and Other Current Assets [Member]      
Disaggregation of Revenue [Line Items]      
Contract assets 38,500    
Customer 2      
Disaggregation of Revenue [Line Items]      
Contract assets 4,300    
Customers With Balances Due In Excess of 10% Of Accounts Receivable | Accounts Receivable | Customer Concentration Risk      
Disaggregation of Revenue [Line Items]      
Accounts receivable, net $ 161,900 $ 267,300  
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Disaggregation of Revenue [Line Items]      
Total revenues $ 3,266.0 $ 1,698.6 $ 1,661.7
Labs      
Disaggregation of Revenue [Line Items]      
Total revenues 820.2 44.8 50.9
Transfusion Medicine      
Disaggregation of Revenue [Line Items]      
Total revenues 393.8 0.0 0.0
Point of Care      
Disaggregation of Revenue [Line Items]      
Total revenues 1,955.3 1,453.3 1,387.8
Molecular Diagnostics      
Disaggregation of Revenue [Line Items]      
Total revenues $ 96.7 $ 200.5 $ 223.0
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue - Concentrations of Revenue and Credit Risk (Details) - Sales - Customer Concentration Risk
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Customer A      
Concentration Risk [Line Items]      
Percentage of risk concentration 20.00% 1.00% 0.00%
Customer B      
Concentration Risk [Line Items]      
Percentage of risk concentration 11.00% 24.00% 29.00%
Customer C      
Concentration Risk [Line Items]      
Percentage of risk concentration 8.00% 9.00% 16.00%
Customer D      
Concentration Risk [Line Items]      
Percentage of risk concentration 5.00% 9.00% 13.00%
Customer E      
Concentration Risk [Line Items]      
Percentage of risk concentration 3.00% 7.00% 10.00%
Customers In Excess of 10% Total Revenue      
Concentration Risk [Line Items]      
Percentage of risk concentration 47.00% 50.00% 68.00%
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Information - Additional Information (Details)
 12 Months Ended
Jan. 01, 2023
segment
Industry And Geographic Information [Abstract]  
Number of reportable segments 3
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Information - Total Revenues by Reportable Segment (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Total revenues $ 3,266.0 $ 1,698.6 $ 1,661.7
North America      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Total revenues 2,536.5 1,500.2 1,460.7
EMEA      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Total revenues 206.8 69.6 92.9
China      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Total revenues 220.0 58.0 62.4
Other      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Total revenues $ 302.7 $ 70.8 $ 45.7
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Information - Reconciliation to Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Segment Adjusted EBITDA $ (1,843,100) $ (1,123,700) $ (1,319,200)
Depreciation and amortization (283,600) (52,700) (48,800)
Acquisition and integration costs (136,000) (9,600) (3,700)
Interest expense, net (75,700) (5,800) (8,500)
Unwind inventory fair value adjustment (60,600) 0 0
Loss on extinguishment of debt (24,000) 0 (10,400)
(Loss) gain on investments (5,800) 1,500 0
Amortization of deferred cloud computing implementation costs (5,400) (3,700) (1,100)
Employee compensation charges and other costs (3,700) 0 0
Impairment of Long-Lived Assets (2,800) 0 0
EU medical device regulation transition costs (1,500) 0 0
Tax indemnification expense (300) 0 0
Change in fair value of acquisition contingencies (100) (200) (1,400)
Derivative mark-to-market gain (loss) $ 4,400 $ 0 $ (1,100)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Income before provision for income taxes Income before provision for income taxes Income before provision for income taxes
Income before provision for income taxes $ 735,900 $ 900,300 $ 1,040,300
North America      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Segment Adjusted EBITDA (1,614,600) (1,028,500) (1,205,200)
EMEA      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Segment Adjusted EBITDA (31,700) (28,100) (55,500)
China      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Segment Adjusted EBITDA (104,100) (24,100) (30,500)
Other      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Segment Adjusted EBITDA (92,700) (43,000) (28,000)
Corporate      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Segment Adjusted EBITDA $ (512,100) $ (152,900) $ (203,900)
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Segment and Geographic Information - Geographic Territory (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Long-Lived Assets $ 1,339,000 $ 349,200  
Total Revenues for Fiscal Year 3,266,000 1,698,600 $ 1,661,700
Domestic      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Long-Lived Assets 983,000 347,100  
Total Revenues for Fiscal Year 2,451,700 1,415,500 1,452,400
Foreign      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Long-Lived Assets 356,000 2,100  
Total Revenues for Fiscal Year $ 814,300 $ 283,100 $ 209,300
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Current:      
Federal $ 162,200 $ 148,800 $ 198,500
State 48,800 42,400 34,600
Foreign 17,600 2,300 1,100
Total current provision 228,600 193,500 234,200
Deferred:      
Federal (31,900) 7,200 (2,900)
State (9,300) (2,600) (1,000)
Foreign (200) (2,000) (300)
Total deferred provision (benefit) (41,400) 2,600 (4,200)
Provision for income taxes $ 187,200 $ 196,100 $ 230,000
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Income Tax Disclosure [Abstract]      
United States $ 672,100 $ 891,200 $ 1,035,700
Foreign 63,800 9,100 4,600
Income before provision for income taxes $ 735,900 $ 900,300 $ 1,040,300
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Dec. 29, 2019
Deferred tax assets:        
Lease liability $ 51.4 $ 32.7    
Intangible assets 0.0 2.2    
Allowance for returns and discounts 45.9 28.3    
Inventory reserve 34.1 6.4    
Stock-based compensation 14.6 9.2    
Tax loss and credit carryforwards 565.3 10.8    
Research & development expenses 50.7 0.0    
Employee related obligations 19.9 5.5    
Other, net 16.1 0.8    
Total deferred tax assets 798.0 95.9    
Valuation allowance for deferred tax assets (251.3) (2.3) $ (2.3) $ (2.4)
Total deferred tax assets, net of valuation allowance 546.7 93.6    
Deferred tax liabilities:        
Right-of-use assets (43.8) (30.1)    
Intangible assets (590.2) (0.9)    
Property, plant and equipment (109.5) (42.5)    
Total deferred tax liabilities (743.5) (73.5)    
Net deferred tax assets (liabilities) $ (196.8)      
Net deferred tax assets (liabilities)   $ 20.1    
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Additional Information (Detail) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Dec. 29, 2019
Income Taxes Disclosure [Line Items]        
Valuation allowance for deferred tax assets $ 251.3 $ 2.3 $ 2.3 $ 2.4
Operating loss carryforwards, state and local 530.1      
Research & development expenses 50.7 0.0    
Federal foreign tax credits $ 3.4      
Cumulative changes in ownership (in percent) 50.00%      
Period of cumulative changes in ownership (in years) 3 years      
Unrecognized tax benefits $ 40.0 17.7 22.6 $ 17.2
Unrecognized tax benefits the would impact effective tax rate 28.3 11.3 15.0  
Decrease in unrecognized tax benefits is reasonably possible 2.4      
Unrecognized tax benefits, income tax penalties and interest accrued 8.3 1.2    
Interest expense, net of accrued interest reversed 0.3 $ 0.7 $ 0.1  
Indemnification receivable 16.8      
Domestic        
Income Taxes Disclosure [Line Items]        
Operating loss carryforwards 879.8      
Foreign        
Income Taxes Disclosure [Line Items]        
Operating loss carryforwards 543.8      
Subject to expiration through 2037 | Domestic        
Income Taxes Disclosure [Line Items]        
Operating loss carryforwards 473.0      
Not subject to expiration | Domestic        
Income Taxes Disclosure [Line Items]        
Operating loss carryforwards 406.8      
Not subject to expiration | Foreign        
Income Taxes Disclosure [Line Items]        
Operating loss carryforwards 339.1      
Subject to expiration through 2042 | Foreign        
Income Taxes Disclosure [Line Items]        
Operating loss carryforwards 204.7      
Gross State Research Credits        
Income Taxes Disclosure [Line Items]        
Research & development expenses 5.9      
Business credit carryforwards 25.6      
Domestic        
Income Taxes Disclosure [Line Items]        
Research & development expenses $ 14.2      
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Income Tax Disclosure [Abstract]      
Tax expense at statutory tax rate $ 154,500 $ 189,100 $ 218,500
State tax expense, net of federal tax 29,300 30,100 30,300
Foreign income taxed at rates other than the applicable U.S. rate (27,500) 0 0
Permanent differences 12,000 1,800 3,800
Federal and state research credits—current year (7,300) (7,700) (5,000)
Stock-based compensation 1,500 (9,200) (13,900)
Change in valuation allowance 26,200 (100) (100)
Foreign Derived Intangible Income Deduction (FDII) (10,200) (8,400) (8,600)
Other 8,700 500 5,000
Provision for income taxes $ 187,200 $ 196,100 $ 230,000
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance $ 17.7 $ 22.6 $ 17.2
Increases due to current year acquisitions 27.8 0.0 0.0
Increases related to prior year tax positions   0.5  
Decreases related to prior year tax positions (0.6)   (2.3)
Increases related to current year tax positions 1.8 0.9 7.7
Decreases from voluntary disclosure agreements 0.0 (6.3) 0.0
Decreases due to settlements (6.7) 0.0 0.0
Ending balance $ 40.0 $ 17.7 $ 22.6
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes - Rollforward of Valuation Allowance (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Income Tax Disclosure [Abstract]      
Beginning Balance $ 2.3 $ 2.3 $ 2.4
Additions Due to Current Year Acquisitions 223.5 0.0 0.0
Additions (Deductions) Charged to Provision for (Benefit From) Income Taxes 26.2 0.0 (0.1)
Currency Translation/Other (0.7) 0.0 0.0
Ending Balance $ 251.3 $ 2.3 $ 2.3
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details - Additional Details (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
May 27, 2022
Dec. 29, 2019
Reserve for Contract Rebates   $ 73.5 $ 40.3    
Accounts Receivable, Allowance for Credit Loss $ 89.1 52.4 103.4   $ 15.9
Depreciation, Depletion and Amortization, Nonproduction 151.1 24.3 20.8    
Capitalized Computer Software, Amortization 0.9 1.0 0.9    
Amortization of intangible assets 132.5 27.4 $ 27.3    
Ortho          
Accounts Receivable, Allowance for Credit Loss       $ 31.4  
Quidel Consolidated Entities          
Reserve for Contract Rebates $ 40.0 $ 40.3      
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Dec. 29, 2019
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]        
Cash and cash equivalents $ 292.9 $ 802.8    
Restricted Cash, Noncurrent 1.0 0.0    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 293.9 $ 802.8 $ 489.9 $ 52.8
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details Marketable Securities (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost $ 73.8 $ 63.7
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.7) (0.1)
Marketable securities, current 52.1 25.7
Marketable securities 21.0 37.9
Total marketable securities 73.1 63.6
Corporate bonds    
Marketable Securities [Line Items]    
Marketable securities, current 40.0 22.3
Marketable securities 13.2 26.7
Corporate asset-backed securities    
Marketable Securities [Line Items]    
Marketable securities, current 6.7 3.4
Marketable securities 7.8 11.2
U.S. government securities    
Marketable Securities [Line Items]    
Marketable securities, current 2.0 0.0
Foreign and other    
Marketable Securities [Line Items]    
Marketable securities, current 0.5 0.0
Debt Security, Government, Non-US    
Marketable Securities [Line Items]    
Marketable securities, current 1.9 0.0
Agency bonds    
Marketable Securities [Line Items]    
Marketable securities, current 1.0 0.0
Short-term Investments    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 52.6 25.7
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.5) 0.0
Short-term Investments | Corporate bonds    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 40.5 22.3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.5) 0.0
Short-term Investments | Corporate asset-backed securities    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 6.7 3.4
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Short-term Investments | U.S. government securities    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 2.0 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Short-term Investments | Foreign and other    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 0.5 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Short-term Investments | Debt Security, Government, Non-US    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 1.9 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Short-term Investments | Agency bonds    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 1.0 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Long-Term Investments | Corporate bonds    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 13.3 26.8
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.1) (0.1)
Long-Term Investments | Corporate asset-backed securities    
Marketable Securities [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 7.9 11.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $ (0.1) $ 0.0
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details Accounts Receivable (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Receivables, Net, Current [Abstract]    
Accounts receivable $ 543.0 $ 430.4
Allowance for contract rebates and discounts 77.1 50.7
Allowance for doubtful accounts 12.0 1.7
Total accounts receivable, net $ 453.9 $ 378.0
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details - Accounts Receivable Allowance for Credit Loss Rollforward (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Balance at Beginning of Period $ 52.4 $ 103.4 $ 15.9
Additions charged to expense or as reductions to revenue 407.6 456.2 277.0
Deductions (370.9) (507.2) (189.5)
Balance at end of period $ 89.1 $ 52.4 $ 103.4
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details Inventory (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Inventory, Net [Abstract]    
Raw materials $ 185.2 $ 103.2
Work-in-process (materials, labor and overhead) 82.7 36.1
Finished goods (materials, labor and overhead) 295.1 59.5
Inventories, including noncurrent portion, net 563.0 198.8
Inventories 524.1 198.8
Inventory, Noncurrent $ 38.9 $ 0.0
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details Prepaid expenses and other current assets (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Prepaid Expense and Other Assets, Current [Abstract]    
Other receivables $ 44.3 $ 15.8
Contract assets 49.6 0.0
Prepaid expenses 96.7 14.6
Income taxes and other tax receivables 38.6 0.0
Derivatives 22.0 0.1
Other 0.9 4.5
Total prepaid expenses and other current assets $ 252.1 $ 35.0
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details - Property, Plant and Equipment (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment, gross $ 1,617.2 $ 489.3
Less: accumulated depreciation and amortization (278.2) (140.1)
Property, plant and equipment, net 1,339.0 349.2
Equipment, furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment, gross 515.1 159.0
Building and improvements    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment, gross 364.7 146.8
Customer leased instruments    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment, gross 434.5 68.1
Land    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment, gross 34.5 10.2
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment, gross $ 268.4 $ 105.2
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details - Goodwill Rollforward (Details)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
Goodwill [Roll Forward]  
Balance at January 2, 2022 $ 337.0
Impact of reportable segment revisions 337.0
Goodwill acquired 2,178.4
Foreign currency translation (38.6)
Balance at January 1, 2023 2,476.8
North America  
Goodwill [Roll Forward]  
Balance at January 2, 2022
Impact of reportable segment revisions 336.9
Goodwill acquired 1,211.5
Foreign currency translation (0.7)
Balance at January 1, 2023 1,547.7
EMEA  
Goodwill [Roll Forward]  
Balance at January 2, 2022
Impact of reportable segment revisions 0.1
Goodwill acquired 370.0
Foreign currency translation (11.5)
Balance at January 1, 2023 358.6
China  
Goodwill [Roll Forward]  
Balance at January 2, 2022
Impact of reportable segment revisions 0.0
Goodwill acquired 121.6
Foreign currency translation (3.5)
Balance at January 1, 2023 118.1
Other  
Goodwill [Roll Forward]  
Balance at January 2, 2022
Impact of reportable segment revisions 0.0
Goodwill acquired 475.3
Foreign currency translation (22.9)
Balance at January 1, 2023 $ 452.4
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details - Goodwill and Intangible Assets (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Finite-Lived Intangible Assets [Line Items]    
Gross assets $ 3,436.9 $ 282.4
Accumulated amortization (313.1) (183.7)
Net 3,123.8 98.7
Goodwill $ 2,476.8 337.0
Purchased technology    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average useful life (years) 14 years 3 months 18 days  
Gross assets $ 997.6 112.7
Accumulated amortization (120.0) (78.2)
Net $ 877.6 34.5
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average useful life (years) 19 years 2 months 12 days  
Gross assets $ 2,023.5 122.7
Accumulated amortization (148.9) (77.3)
Net $ 1,874.6 45.4
License agreements    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average useful life (years) 6 years 4 months 24 days  
Gross assets $ 3.8 6.6
Accumulated amortization (3.7) (5.7)
Net $ 0.1 0.9
Patent and trademark costs    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average useful life (years) 14 years 8 months 12 days  
Gross assets $ 400.5 28.7
Accumulated amortization (32.8) (15.7)
Net $ 367.7 13.0
Software development costs    
Finite-Lived Intangible Assets [Line Items]    
Weighted-average useful life (years) 4 years 8 months 12 days  
Gross assets $ 11.5 11.7
Accumulated amortization (7.7) (6.8)
Net $ 3.8 $ 4.9
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details - Schedule of Future Amortization Expense (Details)
$ in Millions
Jan. 01, 2023
USD ($)
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
2023 $ 205.4
2024 201.7
2025 188.2
2026 187.1
2027 $ 184.7
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheet Account Details Other Current Liabilities (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Other Liabilities Disclosure [Abstract]    
Accrued commissions and rebates $ 55.1 $ 15.9
Deferred consideration 39.3 41.9
Deferred revenue, current $ 76.4 $ 1.9
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total other current liabilities Total other current liabilities
Operating lease liabilities $ 24.4 $ 10.0
Accrued other taxes payable 9.3 10.2
Derivatives 19.7 0.3
Contingent consideration 0.1 6.0
Payables under transition services agreements 0.0 10.9
Other 101.1 17.3
Total other current liabilities $ 325.4 $ 114.4
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Borrowings - Schedule of Borrowings (Details) - USD ($)
$ in Millions
Jan. 01, 2023
May 27, 2022
Jan. 02, 2022
Debt Instrument [Line Items]      
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent   Other Liabilities, Noncurrent
Financing lease obligation $ 0.8   $ 0.7
Other long-term borrowings 1.2   0.0
Unamortized deferred financing costs (10.6)   0.0
Total borrowings 2,638.3   0.7
Less: current portion (207.5)   (0.3)
Long-term borrowings 2,430.8   0.4
Line of Credit | Term Loan | Credit Agreement      
Debt Instrument [Line Items]      
Long-term debt 2,646.9 $ 2,750.0 0.0
Line of Credit | Revolving Credit Facility | Credit Agreement      
Debt Instrument [Line Items]      
Long-term debt $ 0.0 $ 750.0 $ 0.0
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Borrowings - Narrative (Details)
$ in Millions
Aug. 04, 2022
USD ($)
May 27, 2022
USD ($)
Jan. 01, 2023
USD ($)
covenant
Jan. 02, 2022
USD ($)
Debt Instrument [Line Items]        
Number of financial covenants | covenant     2  
Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Debt issuance costs     $ 15.4  
Debt Instrument, Covenant, Leverage Ratio, Maximum     3.50  
Debt instrument, Covenant, Leverage Ratio, Minimum     1.00  
Debt Instrument, Covenant, Interest Coverage Ratio, Minimum     1.00  
Debt Instrument, Covenant, Interest Coverage Ratio, Maximum     3.00  
Credit Agreement | Line of Credit | Ending after the closing date of the credit agreement        
Debt Instrument [Line Items]        
Debt Instrument, Covenant, Leverage Ratio, Maximum     4.50  
Debt instrument, Covenant, Leverage Ratio, Minimum     1.00  
Credit Agreement | Line of Credit | Ending after initial measurement period        
Debt Instrument [Line Items]        
Debt Instrument, Covenant, Leverage Ratio, Maximum     4.00  
Debt instrument, Covenant, Leverage Ratio, Minimum     1.00  
Revolving Credit Facility | Line of Credit        
Debt Instrument [Line Items]        
Extinguishment of Debt, Amount   $ 175.0    
Revolving Credit Facility | Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Long-term debt   750.0 $ 0.0 $ 0.0
Debt issuance costs     3.5  
Line of Credit Facility, Increase (Decrease), Net $ 50.0      
Line of credit, maximum borrowing capacity $ 800.0   $ 786.9  
Revolving Credit Facility | Credit Agreement | Line of Credit | Debt Instrument, Payment, Period One        
Debt Instrument [Line Items]        
Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due     0.01875  
Revolving Credit Facility | Credit Agreement | Line of Credit | Debt Instrument, Payment, Period Two        
Debt Instrument [Line Items]        
Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due     0.01250  
Term Loan | Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Long-term debt   $ 2,750.0 $ 2,646.9 $ 0.0
Debt issuance costs     11.9  
Letter of Credit | Credit Agreement | Line of Credit        
Debt Instrument [Line Items]        
Line of credit, maximum borrowing capacity     $ 13.1  
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Borrowings - Interest Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Debt Instrument [Line Items]      
Amortization of deferred financing costs $ 2.1 $ 0.4 $ 0.4
Derivative instruments and other 0.4 5.4 7.9
Interest income (1.3) (0.3) (0.1)
Interest expense, net 75.7 5.8 8.5
Line of Credit | Term Loan | Credit Agreement      
Debt Instrument [Line Items]      
Interest expense, debt 73.0 0.0 0.0
Line of Credit | Revolving Credit Facility | Credit Agreement      
Debt Instrument [Line Items]      
Interest expense, debt $ 1.5 $ 0.3 $ 0.3
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Borrowings - Schedule of Maturities (Details)
$ in Millions
Jan. 01, 2023
USD ($)
Debt Disclosure [Abstract]  
2023 $ 207.5
2024 172.7
2025 137.5
2026 137.5
2027 1,993.7
Total borrowings $ 2,648.9
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Additional Information (Detail)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
term
building
Jan. 02, 2022
USD ($)
Jan. 03, 2021
USD ($)
Nov. 30, 2022
USD ($)
Other Commitments [Line Items]        
Operating lease cost $ 26.4 $ 15.4 $ 11.2  
Variable lease cost $ 5.6 $ 2.7 $ 1.8  
Number of buildings | building 4      
Number of additional terms | term 2      
Renewal term (in years) 5 years      
Lease liability $ 210.8      
Summers ridge        
Other Commitments [Line Items]        
Lease liability       $ 20.6
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Components of Lease Expense and Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Leases [Abstract]      
Cash paid for amounts included in the measurement of operating lease liabilities $ 25.2 $ 12.3 $ 10.8
ROU assets obtained in exchange for new lease liabilities $ 29.9 $ 37.3 $ 15.3
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.22.4
Leases - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Lessee, Operating Lease, Liability, to be Paid [Abstract]    
2023 $ 32.7  
2024 29.1  
2025 26.4  
2026 24.1  
2027 21.3  
Thereafter 122.9  
Total lease payments 256.5  
Less: imputed interest 45.7  
Total $ 210.8  
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Non-current portion  
Less: current portion $ (24.4) $ (10.0)
Non-current portion $ 186.4 $ 128.6
Weighted average remaining lease term 9 years 8 months 12 days  
Weighted average discount rate 4.00%  
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Aug. 17, 2022
Aug. 28, 2020
Dec. 12, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Preferred stock, shares authorized (in shares) 5,000,000.0 5,000,000.0        
Preferred stock, shares outstanding (in shares) 0 0 0      
Stock options granted, term (in years) 4 years 7 months 9 days          
Granted (in shares) 720,000          
Share based compensation expense $ 65.6 $ 25.4 $ 21.0      
Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares of common stock available for grant (in shares) 2,300,000          
Common stock reserved for future issuance (in shares) 4,100,000          
Employee Deferred Bonus Compensation Program            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Length of time of deferral period, condition one (in years) 1 year          
Percentage of premium on the amount deferred, condition one (in percent) 10.00%          
Length of time of deferral period, condition two (in years) 2 years          
Percentage of premium on the amount deferred, condition two (in percent) 20.00%          
Length of time of deferral period, condition three (in years) 4 years          
Percentage of premium on the amount deferred, condition three (in percent) 30.00%          
Stock Repurchase Program            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock repurchase program, authorized amount       $ 300.0 $ 150.0 $ 50.0
Repurchases of common stock (in shares) 953,468 957,239 257,329      
Remaining authorized amount $ 225.7          
Minimum | Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, granted, exercise price (in usd per share) $ 15.40          
Minimum | Employee Deferred Bonus Compensation Program            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Percentage of cash value of cash bonus officers can elect to receive in form of restricted stock (in percent) 50.00%          
Maximum | Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, granted, exercise price (in usd per share) $ 254.00          
Maximum | Employee Deferred Bonus Compensation Program            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Percentage of cash value of cash bonus officers can elect to receive in form of restricted stock (in percent) 100.00%          
Stock Options | Equity Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options granted, term (in years) 10 years          
Exercise price (in usd per share) 4 years          
Restricted Stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Exercise price (in usd per share) 4 years          
Granted (in shares) 700,000 100,000 200,000      
Restricted Stock | Employee Deferred Bonus Compensation Program            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Exercise price (in usd per share) 1 year          
Restricted Stock | Non Employee Director            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share based compensation expense $ 0.6 $ 0.6 $ 0.5      
Employee Stock | ESPP            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Maximum contribution rate (in percent) 10.00%          
Discount from market price (in percent) 85.00%          
Purchase period (in months) 6 months          
Common stock reserved for future issuance (in shares) 736,630          
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense $ 65.6 $ 25.4 $ 21.0
Cost of sales      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense 2.9 2.7 2.0
Research and development      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense 4.9 4.4 3.4
Selling, marketing and administrative      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense 27.4 18.3 15.6
Acquisition and integration costs      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense $ 30.4 $ 0.0 $ 0.0
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
May 27, 2022
May 26, 2022
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share based liabilities paid     $ 17.2    
Dividend rate (in percent) 0.00%   0.00% 0.00% 0.00%
Total intrinsic value for options exercised     $ 13.7 $ 9.9 $ 51.8
Weighted-Average Grant Date Fair Value, Granted (in USD per share)     $ 97.31    
Deferred Bonus          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock based compensation expense related to deferred bonus compensation program     $ 3.7 3.0 2.2
Share based compensation related to accrued payroll and related expenses     $ 3.3 $ 2.8 $ 2.1
Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock options, term (in years)     10 years    
Ortho          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Cash paid to former Ortho stockholders per Ortho Share (in usd per share)   $ 7.14      
Restricted Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation expense     $ 62.7    
Stock Options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation expense     $ 27.2    
Expected weighted-average period of recognition for unrecognized compensation expense     3 years 4 months 24 days    
RSUs          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expected weighted-average period of recognition for unrecognized compensation expense     2 years 1 month 6 days    
Weighted-Average Grant Date Fair Value, Granted (in USD per share)     $ 188.06 $ 101.20  
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Summary of Status of Stock Option Activity (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Jan. 01, 2023
USD ($)
$ / shares
shares
Shares  
Stock options outstanding, beginning (in shares) | shares 722
Granted (in shares) | shares 187
Stock options assumed in the Combinations (in shares) | shares 1,229
Exercised (in shares) | shares (383)
Forfeited (in shares) | shares (99)
Stock options outstanding, ending (in shares) | shares 1,656
Vested and expected to vest, end of period (in shares) | shares 1,600
Exercisable, end of period (in shares) | shares 1,195
Weighted-Average Exercise Price Per Share  
Stock options outstanding beginning, weighted average exercise price (in USD per share) | $ / shares $ 62.71
Stock options granted, weighted average exercise price (in USD per share) | $ / shares 100.45
Stock options assumed in the Combinations (in USD per share) | $ / shares 96.10
Stock options exercised, weighted average exercise price (in USD per share) | $ / shares 55.15
Stock options cancelled, weighted average exercise price (in USD per share) | $ / shares 115.95
Stock options outstanding ending, weighted average exercise price (in USD per share) | $ / shares 90.34
Vested and expected to vest, end of period (in USD per share) | $ / shares 89.23
Exercisable, end of period (in USD per share) | $ / shares $ 80.53
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]  
Outstanding, Weighted-Average Remaining Contractual Term (In Years) 5 years 6 months 10 days
Vested and expected to vest, Weighted-Average Remaining Contractual Term (In Years) 5 years 5 months 12 days
Exercisable, Weighted-Average Remaining Contractual Term (In Years) 4 years 7 months 9 days
Outstanding, Aggregate Intrinsic Value | $ $ 28,140
Vested and expected to vest, Aggregate Intrinsic Value | $ 28,122
Exercisable, Aggregate Intrinsic Value | $ $ 26,774
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Details) - $ / shares
 12 Months Ended
May 27, 2022
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Equity [Abstract]        
Risk-free interest rate 2.28% 1.96% 0.48% 1.18%
Expected option life (in years) 1 year 9 months 10 days 4 years 9 months 18 days 4 years 11 months 26 days 5 years 1 month 13 days
Volatility rate 64.00% 57.00% 54.00% 41.00%
Dividend rate 0.00% 0.00% 0.00% 0.00%
Weighted-average grant date fair value of stock options granted (in USD per share) $ 40.57 $ 50.62 $ 106.55 $ 36.84
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation - Summary of Status of Stock Awards Activity (Details)
shares in Thousands
 12 Months Ended
Jan. 01, 2023
$ / shares
shares
Shares  
Restricted stock outstanding, non-vested, beginning (in shares) | shares 587
Granted (in shares) | shares 720
Stock awards assumed in the Combinations (in shares) | shares 49
Vested (in shares) | shares (248)
Forfeited (in shares) | shares (76)
Restricted stock outstanding, non-vested, ending (in shares) | shares 1,032
Weighted-Average Grant Date Fair Value  
Weighted-Average Grant Date Fair Value, Beginning Balance (in USD per share) | $ / shares $ 95.81
Weighted-Average Grant Date Fair Value, Granted (in USD per share) | $ / shares 97.31
Weighted-Average Grant Date Fair Value, Stock awards assumed in the Combinations (in USD per share) | $ / shares 99.60
Weighted-Average Grant Date Fair Value, Vested (in USD per share) | $ / shares 86.61
Weighted-Average Grant Date Fair Value, Forfeited (in USD per share) | $ / shares 100.70
Weighted-Average Grant Date Fair Value, Ending Balance (in USD per share) | $ / shares $ 98.89
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Jan. 03, 2021
Other Ownership Interests [Line Items]      
Purchase commitment $ 247.8    
Royalty Expense $ 1.1 $ 2.0 $ 2.4
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Assets:    
Money Market Funds, at Carrying Value $ 2.7 $ 211.3
Total marketable securities 73.1 63.6
Derivative assets 22.0 0.1
Total assets measured at fair value 97.8 275.0
Liabilities:    
Derivative Liability 21.8 0.3
Business Combination, Contingent Consideration, Liability 0.1 6.1
Deferred Consideration 39.3 78.4
Total liabilities measured at fair value 61.2 84.8
Level 1    
Assets:    
Money Market Funds, at Carrying Value 0.6 204.7
Total marketable securities 2.0 0.0
Derivative assets 0.0 0.0
Total assets measured at fair value 2.6 204.7
Liabilities:    
Derivative Liability 0.0 0.0
Business Combination, Contingent Consideration, Liability 0.0 0.0
Deferred Consideration 0.0 0.0
Total liabilities measured at fair value 0.0 0.0
Level 2    
Assets:    
Money Market Funds, at Carrying Value 2.1 6.6
Total marketable securities 71.1 63.6
Derivative assets 22.0 0.1
Total assets measured at fair value 95.2 70.3
Liabilities:    
Derivative Liability 21.8 0.3
Business Combination, Contingent Consideration, Liability 0.0 0.0
Deferred Consideration 39.3 78.4
Total liabilities measured at fair value 61.1 78.7
Level 3    
Assets:    
Money Market Funds, at Carrying Value 0.0 0.0
Total marketable securities 0.0 0.0
Derivative assets 0.0 0.0
Total assets measured at fair value 0.0 0.0
Liabilities:    
Derivative Liability 0.0 0.0
Business Combination, Contingent Consideration, Liability 0.1 6.1
Deferred Consideration 0.0 0.0
Total liabilities measured at fair value $ 0.1 $ 6.1
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements - Additional Information (Details)
$ in Millions
Jan. 01, 2023
USD ($)
Term Loan | Credit Agreement | Line of Credit  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Long-Term Debt, Fair Value $ 2,630.3
Consideration B | BNP Business  
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]  
Installment payment through April 2023 48.0
Installment payment each year $ 48.0
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Details) - Level 3 - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 03, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance $ 6.1  
Cash payments (6.0) $ (6.0)
Change in estimated fair value, recorded in selling, marketing and administrative expenses   (0.2)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance $ 0.1 $ 11.9
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.22.4
Derivative Instruments and Hedging Activities - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Dec. 30, 2023
Derivative [Line Items]    
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net $ 25.1  
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months 7.9  
Interest Rate Cap | Not Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 1,000.0  
Derivative, Cap Interest Rate 3.428%  
Derivative, Cash Received on Hedge $ 3.3  
Interest Rate Swap | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 500.0  
Derivative, Fixed Interest Rate 1.58%  
Interest Rate Swap | Designated as Hedging Instrument | Subsequent Event    
Derivative [Line Items]    
Derivative, Notional Amount   $ 1,800.0
Foreign Exchange Contract | Not Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 581.7  
Foreign Exchange Contract | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount 441.6  
Interest Rate Swap One | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 397.2  
Derivative, Fixed Interest Rate 3.765%  
Interest Rate Swap Two | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 144.4  
Derivative, Fixed Interest Rate 3.7725%  
Interest Rate Swap Three | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 216.7  
Derivative, Fixed Interest Rate 3.7675%  
Interest Rate Swap Four | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 288.9  
Derivative, Fixed Interest Rate 3.7575%  
Interest Rate Swap Five | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative, Notional Amount $ 252.8  
Derivative, Fixed Interest Rate 3.7725%  
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.22.4
Derivative Instruments and Hedging Activities - Schedule of Fair Value (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Derivative [Line Items]    
Derivative assets $ 22.0 $ 0.1
Derivative Liability 21.8 0.3
Interest Rate Swap | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative assets $ 15.9 0.0
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Prepaid expenses and other current assets  
Derivative Liability $ 2.1 0.0
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Noncurrent  
Foreign Exchange Contract | Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative assets $ 4.6 $ 0.1
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Prepaid expenses and other current assets Prepaid expenses and other current assets
Derivative Liability $ 14.3 $ 0.2
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current
Foreign Exchange Contract | Not Designated as Hedging Instrument    
Derivative [Line Items]    
Derivative assets $ 1.5 $ 0.0
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Prepaid expenses and other current assets  
Derivative Liability $ 5.4 $ 0.1
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Liabilities, Current Other Liabilities, Current
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.22.4
Derivative Instruments and Hedging Activities - Schedule of Gain (Loss) (Details)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
Interest Rate Swap | Interest Expense  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax $ (11.4)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (1.7)
Foreign Exchange Contract | Sales  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 1.3
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (2.9)
Foreign Exchange Contract | Cost of sales  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 3.5
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax $ (0.6)
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Narrative (Details)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
post-employmentBenefitPlan
Jan. 02, 2022
USD ($)
Jan. 03, 2021
USD ($)
Defined Benefit Plan Disclosure [Line Items]      
Number of non-US post employment benefit plans | post-employmentBenefitPlan 1    
Employer contributions to defined contribution plan $ 15.1 $ 3.8 $ 3.1
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year 2.0    
Defined Benefit Plans      
Defined Benefit Plan Disclosure [Line Items]      
Defined benefit plan, net periodic benefit cost (credit) 1.4    
Employer contributions 1.6    
Other Post-employment Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Defined benefit plan, net periodic benefit cost (credit) $ 0.7    
Japan government bonds | Level 1 | Fair Value, Recurring      
Defined Benefit Plan Disclosure [Line Items]      
Target allocation rate (in percent) 44.00%    
Japan equity securities | Level 1 | Fair Value, Recurring      
Defined Benefit Plan Disclosure [Line Items]      
Target allocation rate (in percent) 55.00%    
Other assets, Japan | Level 1 | Fair Value, Recurring      
Defined Benefit Plan Disclosure [Line Items]      
Target allocation rate (in percent) 2.00%    
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Projected Benefit Obligations (Details)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
Defined Benefit Plans  
Change in benefit obligation:  
Projected benefit obligation at beginning of year $ 0.0
Service cost 1.2
Interest cost 0.4
Benefits paid (0.3)
Actuarial gain (0.6)
Settlements (0.2)
Foreign currency exchange rate changes 0.1
Assumed obligation from the Combinations 33.3
Projected benefit obligation at end of year 33.9
Change in plan assets:  
Fair value of plan assets at beginning of year 0.0
Actual return on plan assets (0.5)
Employer contributions 1.6
Benefits paid (0.3)
Transfers in from the Combinations 20.1
Settlements (0.2)
Foreign currency exchange rate changes (0.1)
Fair value of plan assets at end of year 20.6
Funded status at end of year (13.3)
Amounts recognized on the consolidated balance sheets:  
Other assets 0.4
Other current liabilities 0.3
Other liabilities 13.4
Net amount recognized (13.3)
Other Post-employment Benefits  
Change in benefit obligation:  
Projected benefit obligation at beginning of year 18.9
Service cost 0.3
Interest cost 0.4
Benefits paid (0.7)
Actuarial gain (0.7)
Assumed obligation from the Combinations 0.4
Projected benefit obligation at end of year 18.6
Amounts recognized on the consolidated balance sheets:  
Other current liabilities 3.5
Other liabilities 15.1
Net amount recognized $ (18.6)
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Accumulated Benefit Obligation (Details)
$ in Millions
Jan. 01, 2023
USD ($)
Retirement Benefits [Abstract]  
ABO $ 27.1
Plans with PBO in excess of plan assets  
PBO 18.3
Fair value of plan assets 5.1
Plans with ABO in excess of plan assets  
PBO 17.0
ABO 14.3
Fair value of plan assets $ 3.8
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Schedule of AOCI (Details)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
Defined Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Accumulated net actuarial gains (losses) $ (0.2)
Other Post-employment Benefits  
Defined Benefit Plan Disclosure [Line Items]  
Accumulated net actuarial gains (losses) $ 0.7
XML 113 R99.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Critical Assumptions Used (Details)
 12 Months Ended
Jan. 01, 2023
May 27, 2022
Defined Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Weighted average discount rate 3.10% 2.20%
Weighted average rate of compensation increases 3.00% 2.60%
Weighted average discount rate 2.20%  
Weighted average expected rate of compensation increases 2.60%  
Weighted average expected return on plan assets 2.50%  
Other Post-employment Benefits    
Defined Benefit Plan Disclosure [Line Items]    
Weighted average discount rate 5.50% 4.00%
Weighted average discount rate 4.00%  
XML 114 R100.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Schedule of Health Care Trend Rates (Details)
Jan. 01, 2023
Postretirement Health Coverage - Pre 65  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Healthcare cost trend rate for upcoming year (in percent) 6.44%
Postretirement Health Coverage - Post-65  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Healthcare cost trend rate for upcoming year (in percent) 6.10%
Postretirement Health Coverage  
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Rate to which the cost trend rate is assumed to decline 4.00%
XML 115 R101.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Expected Benefit Payments (Details)
$ in Millions
Jan. 01, 2023
USD ($)
Defined Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Fiscal Year 2023 $ 1.7
Fiscal Year 2024 3.5
Fiscal Year 2025 2.1
Fiscal Year 2026 2.2
Fiscal Year 2027 2.3
Fiscal Years 2028-2032 12.6
Other Post-employment Benefits  
Defined Benefit Plan Disclosure [Line Items]  
Fiscal Year 2023 3.5
Fiscal Year 2024 4.0
Fiscal Year 2025 3.3
Fiscal Year 2026 2.2
Fiscal Year 2027 1.9
Fiscal Years 2028-2032 $ 5.5
XML 116 R102.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Fair Value Measurement (Details) - USD ($)
$ in Millions
Jan. 01, 2023
Jan. 02, 2022
Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Total $ 6.1 $ 0.0
Fair Value, Recurring    
Defined Benefit Plan Disclosure [Line Items]    
Total 20.6  
Fair Value, Recurring | U.S. equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 2.2  
Fair Value, Recurring | Japan equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 3.7  
Fair Value, Recurring | Other international equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 1.6  
Fair Value, Recurring | U.S. government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.2  
Fair Value, Recurring | Japan government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.5  
Fair Value, Recurring | Other international government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 1.6  
Fair Value, Recurring | Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Total 4.7  
Fair Value, Recurring | Insurance contracts    
Defined Benefit Plan Disclosure [Line Items]    
Total 6.1  
Fair Value, Recurring | Level 1    
Defined Benefit Plan Disclosure [Line Items]    
Total 14.5  
Fair Value, Recurring | Level 1 | U.S. equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 2.2  
Fair Value, Recurring | Level 1 | Japan equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 3.7  
Fair Value, Recurring | Level 1 | Other international equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 1.6  
Fair Value, Recurring | Level 1 | U.S. government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.2  
Fair Value, Recurring | Level 1 | Japan government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.5  
Fair Value, Recurring | Level 1 | Other international government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 1.6  
Fair Value, Recurring | Level 1 | Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Total 4.7  
Fair Value, Recurring | Level 1 | Insurance contracts    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | U.S. equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | Japan equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | Other international equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | U.S. government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | Japan government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | Other international government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 2 | Insurance contracts    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Total 6.1  
Fair Value, Recurring | Level 3 | U.S. equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3 | Japan equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3 | Other international equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3 | U.S. government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3 | Japan government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3 | Other international government bonds    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3 | Cash and cash equivalents    
Defined Benefit Plan Disclosure [Line Items]    
Total 0.0  
Fair Value, Recurring | Level 3 | Insurance contracts    
Defined Benefit Plan Disclosure [Line Items]    
Total $ 6.1  
XML 117 R103.htm IDEA: XBRL DOCUMENT v3.22.4
Long-term Employee Benefits - Level 3 Rollforward (Details) - Level 3
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
Change in plan assets:  
Fair value of plan assets at beginning of year $ 0.0
Transfers in 5.5
Net purchases and settlements 0.6
Fair value of plan assets at end of year $ 6.1
XML 118 R104.htm IDEA: XBRL DOCUMENT v3.22.4
Related Party Transactions (Details)
$ in Millions
 12 Months Ended
Jan. 01, 2023
USD ($)
Quotient Subsidiary  
Related Party Transaction [Line Items]  
Payments For Inventory $ 15.4
Accounts Payable 3.7
Ortho | MosaicQ | Revenue Benchmark  
Related Party Transaction [Line Items]  
Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments 25.0
Ortho | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Quotient  
Related Party Transaction [Line Items]  
Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments $ 60.0
XML 119 R105.htm IDEA: XBRL DOCUMENT v3.22.4
Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2023
Jan. 02, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance $ 0.4  
Current period deferrals (62.8)  
Amounts reclassified to net income (5.2)  
Net change (68.0) $ 0.8
Ending balance (67.6) 0.4
Pension and Other Post- employment Benefits    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance 0.0  
Current period deferrals 0.7  
Amounts reclassified to net income 0.0  
Net change 0.7  
Ending balance 0.7 0.0
Cash Flow Hedges    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance 0.0  
Current period deferrals 6.7  
Amounts reclassified to net income (5.2)  
Net change 1.5  
Ending balance 1.5 0.0
Available-for-Sale Investments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance (0.1)  
Current period deferrals (0.4)  
Amounts reclassified to net income 0.0  
Net change (0.4)  
Ending balance (0.5) (0.1)
Unrealized Foreign Currency Translation Adjustments    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Beginning balance 0.5  
Current period deferrals (69.8)  
Amounts reclassified to net income 0.0  
Net change (69.8)  
Ending balance $ (69.3) $ 0.5
XML 120 qdel-20230101_htm.xml IDEA: XBRL DOCUMENT 0001906324 2022-01-03 2023-01-01 0001906324 2022-07-01 0001906324 2023-02-10 0001906324 2023-01-01 0001906324 2022-01-02 0001906324 2021-01-04 2022-01-02 0001906324 2019-12-30 2021-01-03 0001906324 us-gaap:CommonStockMember 2019-12-29 0001906324 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-29 0001906324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-29 0001906324 us-gaap:RetainedEarningsMember 2019-12-29 0001906324 2019-12-29 0001906324 us-gaap:CommonStockMember 2019-12-30 2021-01-03 0001906324 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-30 2021-01-03 0001906324 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2019-12-30 2021-01-03 0001906324 us-gaap:RetainedEarningsMember 2019-12-30 2021-01-03 0001906324 us-gaap:CommonStockMember 2021-01-03 0001906324 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-01-03 0001906324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-03 0001906324 us-gaap:RetainedEarningsMember 2021-01-03 0001906324 2021-01-03 0001906324 us-gaap:CommonStockMember 2021-01-04 2022-01-02 0001906324 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-01-04 2022-01-02 0001906324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-04 2022-01-02 0001906324 us-gaap:RetainedEarningsMember 2021-01-04 2022-01-02 0001906324 us-gaap:CommonStockMember 2022-01-02 0001906324 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-02 0001906324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-02 0001906324 us-gaap:RetainedEarningsMember 2022-01-02 0001906324 us-gaap:CommonStockMember 2022-01-03 2023-01-01 0001906324 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-03 2023-01-01 0001906324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-03 2023-01-01 0001906324 us-gaap:RetainedEarningsMember 2022-01-03 2023-01-01 0001906324 us-gaap:CommonStockMember 2023-01-01 0001906324 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-01-01 0001906324 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 0001906324 us-gaap:RetainedEarningsMember 2023-01-01 0001906324 us-gaap:CostOfSalesMember 2021-01-04 2022-01-02 0001906324 us-gaap:CostOfSalesMember 2019-12-30 2021-01-03 0001906324 qdel:SellingMarketingAndAdministrativeExpenseMember 2021-01-04 2022-01-02 0001906324 qdel:SellingMarketingAndAdministrativeExpenseMember 2019-12-30 2021-01-03 0001906324 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-03 2023-01-01 0001906324 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-03 2023-01-01 0001906324 srt:MinimumMember us-gaap:EquipmentMember 2022-01-03 2023-01-01 0001906324 srt:MaximumMember us-gaap:EquipmentMember 2022-01-03 2023-01-01 0001906324 srt:MinimumMember qdel:InstrumentsAvailableForLeaseMember 2022-01-03 2023-01-01 0001906324 srt:MaximumMember qdel:InstrumentsAvailableForLeaseMember 2022-01-03 2023-01-01 0001906324 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-03 2023-01-01 0001906324 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-03 2023-01-01 0001906324 2020-07-01 2023-01-01 0001906324 us-gaap:ShippingAndHandlingMember 2022-01-03 2023-01-01 0001906324 us-gaap:ShippingAndHandlingMember 2021-01-04 2022-01-02 0001906324 us-gaap:ShippingAndHandlingMember 2019-12-30 2021-01-03 0001906324 us-gaap:AdvertisingMember 2022-01-03 2023-01-01 0001906324 us-gaap:AdvertisingMember 2021-01-04 2022-01-02 0001906324 us-gaap:AdvertisingMember 2019-12-30 2021-01-03 0001906324 qdel:OrthoMember 2022-05-26 2022-05-26 0001906324 qdel:OrthoMember 2022-05-26 0001906324 qdel:OrthoMember qdel:OrthoMember 2022-05-26 2022-05-26 0001906324 qdel:OrthoMember qdel:QuidelOrthoMember 2022-05-26 2022-05-26 0001906324 qdel:OrthoMember 2022-05-27 2022-05-27 0001906324 qdel:OrthoMember 2022-05-27 0001906324 qdel:OrthoMember 2022-05-27 2023-01-01 0001906324 qdel:OrthoMember 2023-01-01 0001906324 qdel:OrthoMember qdel:SeniorNotesDue2025Member us-gaap:SeniorNotesMember 2022-05-27 0001906324 qdel:OrthoMember qdel:SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2022-05-27 0001906324 2022-05-27 2022-05-27 0001906324 qdel:OrthoMember 2022-01-03 2023-01-01 0001906324 srt:NorthAmericaMember qdel:OrthoMember 2023-01-01 0001906324 us-gaap:EMEAMember qdel:OrthoMember 2023-01-01 0001906324 country:CN qdel:OrthoMember 2023-01-01 0001906324 qdel:LocationsNotIncludingNorthAmericaEMEAAndChinaMember qdel:OrthoMember 2023-01-01 0001906324 qdel:OrthoMember us-gaap:CustomerRelationshipsMember 2022-05-27 2023-01-01 0001906324 qdel:OrthoMember us-gaap:CustomerRelationshipsMember 2023-01-01 0001906324 qdel:OrthoMember us-gaap:DevelopedTechnologyRightsMember 2022-05-27 2023-01-01 0001906324 qdel:OrthoMember us-gaap:DevelopedTechnologyRightsMember 2023-01-01 0001906324 qdel:OrthoMember us-gaap:TrademarksMember 2022-05-27 2023-01-01 0001906324 qdel:OrthoMember us-gaap:TrademarksMember 2023-01-01 0001906324 qdel:OrthoMember 2021-01-04 2022-01-02 0001906324 qdel:OrthoMember qdel:AmortizationExpenseMember 2022-01-03 2023-01-01 0001906324 qdel:OrthoMember qdel:AmortizationExpenseMember 2021-01-04 2022-01-02 0001906324 qdel:OrthoMember us-gaap:CostOfSalesMember 2021-01-04 2022-01-02 0001906324 qdel:OrthoMember us-gaap:InterestExpenseMember 2022-01-03 2023-01-01 0001906324 qdel:OrthoMember us-gaap:InterestExpenseMember 2021-01-04 2022-01-02 0001906324 qdel:OrthoMember qdel:LossOnExtinguishmentOfDebtMember qdel:OrthoMember 2022-01-03 2023-01-01 0001906324 qdel:OrthoMember qdel:LossOnExtinguishmentOfDebtMember 2022-01-03 2023-01-01 0001906324 qdel:OrthoMember qdel:LossOnExtinguishmentOfDebtMember 2021-01-04 2022-01-02 0001906324 qdel:OrthoMember qdel:ShareBasedCompensationExpenseMember 2022-01-03 2023-01-01 0001906324 qdel:OrthoMember qdel:ShareBasedCompensationExpenseMember 2021-01-04 2022-01-02 0001906324 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-01-01 0001906324 qdel:Customer1Member 2023-01-01 0001906324 qdel:ExpectedValueContractCustomersMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-01-01 0001906324 qdel:Customer2Member 2023-01-01 0001906324 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-03 2023-01-01 0001906324 us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementAndThirdPartyMember 2022-01-03 2023-01-01 0001906324 qdel:LabsMember 2022-01-03 2023-01-01 0001906324 qdel:LabsMember 2021-01-04 2022-01-02 0001906324 qdel:LabsMember 2019-12-30 2021-01-03 0001906324 qdel:TransfusionMedicineMember 2022-01-03 2023-01-01 0001906324 qdel:TransfusionMedicineMember 2021-01-04 2022-01-02 0001906324 qdel:TransfusionMedicineMember 2019-12-30 2021-01-03 0001906324 qdel:PointOfCareMember 2022-01-03 2023-01-01 0001906324 qdel:PointOfCareMember 2021-01-04 2022-01-02 0001906324 qdel:PointOfCareMember 2019-12-30 2021-01-03 0001906324 qdel:MolecularDiagnosticsMember 2022-01-03 2023-01-01 0001906324 qdel:MolecularDiagnosticsMember 2021-01-04 2022-01-02 0001906324 qdel:MolecularDiagnosticsMember 2019-12-30 2021-01-03 0001906324 qdel:CustomerAMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:CustomerAMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:CustomerAMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:CustomerBMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:CustomerBMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:CustomerBMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:CustomerCMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:CustomerCMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:CustomerCMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:CustomerDMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:CustomerDMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:CustomerDMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:CustomerEMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:CustomerEMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:CustomerEMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:CustomersInExcessOf10TotalRevenueMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:CustomersInExcessOf10TotalRevenueMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:CustomersInExcessOf10TotalRevenueMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:CustomersWithBalancesDueInExcessOf10OfAccountsReceivableMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 0001906324 qdel:CustomersWithBalancesDueInExcessOf10OfAccountsReceivableMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-02 0001906324 qdel:COVID19Member us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:COVID19Member us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:COVID19Member us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:InfluenzaMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-03 2023-01-01 0001906324 qdel:InfluenzaMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-04 2022-01-02 0001906324 qdel:InfluenzaMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-12-30 2021-01-03 0001906324 qdel:NorthAmericaSegmentMember 2022-01-03 2023-01-01 0001906324 qdel:NorthAmericaSegmentMember 2021-01-04 2022-01-02 0001906324 qdel:NorthAmericaSegmentMember 2019-12-30 2021-01-03 0001906324 qdel:EMEASegmentMember 2022-01-03 2023-01-01 0001906324 qdel:EMEASegmentMember 2021-01-04 2022-01-02 0001906324 qdel:EMEASegmentMember 2019-12-30 2021-01-03 0001906324 qdel:ChinaMember 2022-01-03 2023-01-01 0001906324 qdel:ChinaMember 2021-01-04 2022-01-02 0001906324 qdel:ChinaMember 2019-12-30 2021-01-03 0001906324 qdel:OtherMember 2022-01-03 2023-01-01 0001906324 qdel:OtherMember 2021-01-04 2022-01-02 0001906324 qdel:OtherMember 2019-12-30 2021-01-03 0001906324 us-gaap:CorporateAndOtherMember 2022-01-03 2023-01-01 0001906324 us-gaap:CorporateAndOtherMember 2021-01-04 2022-01-02 0001906324 us-gaap:CorporateAndOtherMember 2019-12-30 2021-01-03 0001906324 us-gaap:DomesticCountryMember 2023-01-01 0001906324 us-gaap:DomesticCountryMember 2022-01-02 0001906324 us-gaap:DomesticCountryMember 2022-01-03 2023-01-01 0001906324 us-gaap:DomesticCountryMember 2021-01-04 2022-01-02 0001906324 us-gaap:DomesticCountryMember 2019-12-30 2021-01-03 0001906324 us-gaap:ForeignCountryMember 2023-01-01 0001906324 us-gaap:ForeignCountryMember 2022-01-02 0001906324 us-gaap:ForeignCountryMember 2022-01-03 2023-01-01 0001906324 us-gaap:ForeignCountryMember 2021-01-04 2022-01-02 0001906324 us-gaap:ForeignCountryMember 2019-12-30 2021-01-03 0001906324 us-gaap:DomesticCountryMember 2023-01-01 0001906324 us-gaap:DomesticCountryMember qdel:SubjectToExpirationThrough2037Member 2023-01-01 0001906324 us-gaap:DomesticCountryMember qdel:NotSubjectToExpirationMember 2023-01-01 0001906324 us-gaap:DomesticCountryMember 2023-01-01 0001906324 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 0001906324 us-gaap:ForeignCountryMember 2023-01-01 0001906324 us-gaap:ForeignCountryMember qdel:NotSubjectToExpirationMember 2023-01-01 0001906324 us-gaap:ForeignCountryMember qdel:SubjectToExpirationThrough2042Member 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:CorporateDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:CorporateDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2023-01-01 0001906324 us-gaap:AssetBackedSecuritiesMember 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2022-01-02 0001906324 us-gaap:AssetBackedSecuritiesMember 2022-01-02 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:USGovernmentDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:USGovernmentDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:ShortTermInvestmentsMember qdel:AgencyBondsMember 2023-01-01 0001906324 qdel:AgencyBondsMember 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember qdel:AgencyBondsMember 2022-01-02 0001906324 qdel:AgencyBondsMember 2022-01-02 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:OtherDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:OtherDebtSecuritiesMember 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember us-gaap:OtherDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:OtherDebtSecuritiesMember 2022-01-02 0001906324 us-gaap:ShortTermInvestmentsMember 2023-01-01 0001906324 us-gaap:ShortTermInvestmentsMember 2022-01-02 0001906324 qdel:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2023-01-01 0001906324 qdel:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2022-01-02 0001906324 qdel:LongTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2023-01-01 0001906324 qdel:LongTermInvestmentsMember us-gaap:AssetBackedSecuritiesMember 2022-01-02 0001906324 qdel:QuidelConsolidatedEntitiesMember 2023-01-01 0001906324 qdel:QuidelConsolidatedEntitiesMember 2022-01-02 0001906324 qdel:OrthoMember 2022-05-27 0001906324 us-gaap:EquipmentMember 2023-01-01 0001906324 us-gaap:EquipmentMember 2022-01-02 0001906324 us-gaap:BuildingAndBuildingImprovementsMember 2023-01-01 0001906324 us-gaap:BuildingAndBuildingImprovementsMember 2022-01-02 0001906324 qdel:InstrumentsAvailableForLeaseMember 2023-01-01 0001906324 qdel:InstrumentsAvailableForLeaseMember 2022-01-02 0001906324 us-gaap:LandMember 2023-01-01 0001906324 us-gaap:LandMember 2022-01-02 0001906324 us-gaap:ConstructionInProgressMember 2023-01-01 0001906324 us-gaap:ConstructionInProgressMember 2022-01-02 0001906324 srt:NorthAmericaMember 2022-01-02 0001906324 us-gaap:EMEAMember 2022-01-02 0001906324 country:CN 2022-01-02 0001906324 qdel:OtherNotIncludingNorthAmericaEMEAAndChinaMember 2022-01-02 0001906324 srt:NorthAmericaMember 2022-01-03 2023-01-01 0001906324 us-gaap:EMEAMember 2022-01-03 2023-01-01 0001906324 country:CN 2022-01-03 2023-01-01 0001906324 qdel:OtherNotIncludingNorthAmericaEMEAAndChinaMember 2022-01-03 2023-01-01 0001906324 srt:NorthAmericaMember 2023-01-01 0001906324 us-gaap:EMEAMember 2023-01-01 0001906324 country:CN 2023-01-01 0001906324 qdel:OtherNotIncludingNorthAmericaEMEAAndChinaMember 2023-01-01 0001906324 qdel:PurchasedTechnologyMember 2022-01-03 2023-01-01 0001906324 qdel:PurchasedTechnologyMember 2023-01-01 0001906324 qdel:PurchasedTechnologyMember 2022-01-02 0001906324 us-gaap:CustomerRelationshipsMember 2022-01-03 2023-01-01 0001906324 us-gaap:CustomerRelationshipsMember 2023-01-01 0001906324 us-gaap:CustomerRelationshipsMember 2022-01-02 0001906324 us-gaap:LicensingAgreementsMember 2022-01-03 2023-01-01 0001906324 us-gaap:LicensingAgreementsMember 2023-01-01 0001906324 us-gaap:LicensingAgreementsMember 2022-01-02 0001906324 qdel:PatentsAndTrademarksMember 2022-01-03 2023-01-01 0001906324 qdel:PatentsAndTrademarksMember 2023-01-01 0001906324 qdel:PatentsAndTrademarksMember 2022-01-02 0001906324 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-03 2023-01-01 0001906324 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-01-01 0001906324 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-01-02 0001906324 us-gaap:SecuredDebtMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-01-01 0001906324 us-gaap:SecuredDebtMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-01-02 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-01-01 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-01-02 0001906324 us-gaap:SecuredDebtMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-05-27 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-05-27 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-08-04 2022-08-04 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-08-04 0001906324 us-gaap:LetterOfCreditMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-01-01 0001906324 qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2023-01-01 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember qdel:DebtInstrumentPaymentPeriodOneMember 2023-01-01 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember qdel:DebtInstrumentPaymentPeriodTwoMember 2023-01-01 0001906324 qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember qdel:EndingAfterTheClosingDateOfTheCreditAgreementMember 2023-01-01 0001906324 qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember qdel:EndingAfterInitialMeasurementPeriodMember 2023-01-01 0001906324 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-05-27 2022-05-27 0001906324 us-gaap:SecuredDebtMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-01-03 2023-01-01 0001906324 us-gaap:SecuredDebtMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2021-01-04 2022-01-02 0001906324 us-gaap:SecuredDebtMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-30 2021-01-03 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2022-01-03 2023-01-01 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2021-01-04 2022-01-02 0001906324 us-gaap:RevolvingCreditFacilityMember qdel:BankOfAmericaCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-30 2021-01-03 0001906324 qdel:SummersRidgeMember 2022-11-30 0001906324 us-gaap:EmployeeStockOptionMember qdel:EquityIncentivePlanMember 2022-01-03 2023-01-01 0001906324 srt:MinimumMember qdel:EquityIncentivePlanMember 2023-01-01 0001906324 srt:MaximumMember qdel:EquityIncentivePlanMember 2023-01-01 0001906324 qdel:EquityIncentivePlanMember 2023-01-01 0001906324 us-gaap:RestrictedStockMember 2022-01-03 2023-01-01 0001906324 us-gaap:RestrictedStockMember 2021-01-04 2022-01-02 0001906324 us-gaap:RestrictedStockMember 2019-12-30 2021-01-03 0001906324 qdel:NonEmployeeDirectorMember us-gaap:RestrictedStockMember 2022-01-03 2023-01-01 0001906324 qdel:NonEmployeeDirectorMember us-gaap:RestrictedStockMember 2021-01-04 2022-01-02 0001906324 qdel:NonEmployeeDirectorMember us-gaap:RestrictedStockMember 2019-12-30 2021-01-03 0001906324 srt:MinimumMember qdel:EmployeeDeferredBonusCompensationProgramMember 2022-01-03 2023-01-01 0001906324 srt:MaximumMember qdel:EmployeeDeferredBonusCompensationProgramMember 2022-01-03 2023-01-01 0001906324 us-gaap:RestrictedStockMember qdel:EmployeeDeferredBonusCompensationProgramMember 2022-01-03 2023-01-01 0001906324 qdel:EmployeeDeferredBonusCompensationProgramMember 2022-01-03 2023-01-01 0001906324 us-gaap:EmployeeStockMember qdel:QuidelOrthoCorporationAmendedAndRestated1983EmployeeStockPurchasePlanESPPMember 2023-01-01 0001906324 us-gaap:EmployeeStockMember qdel:QuidelOrthoCorporationAmendedAndRestated1983EmployeeStockPurchasePlanESPPMember 2022-01-03 2023-01-01 0001906324 qdel:StockRepurchaseProgramMember 2018-12-12 0001906324 qdel:StockRepurchaseProgramMember 2020-08-28 0001906324 qdel:StockRepurchaseProgramMember 2022-08-17 0001906324 qdel:StockRepurchaseProgramMember 2022-01-03 2023-01-01 0001906324 qdel:StockRepurchaseProgramMember 2023-01-01 0001906324 qdel:StockRepurchaseProgramMember 2021-01-04 2022-01-02 0001906324 qdel:StockRepurchaseProgramMember 2019-12-30 2021-01-03 0001906324 us-gaap:CostOfSalesMember 2022-01-03 2023-01-01 0001906324 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-03 2023-01-01 0001906324 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-04 2022-01-02 0001906324 us-gaap:ResearchAndDevelopmentExpenseMember 2019-12-30 2021-01-03 0001906324 us-gaap:SellingAndMarketingExpenseMember 2022-01-03 2023-01-01 0001906324 us-gaap:SellingAndMarketingExpenseMember 2021-01-04 2022-01-02 0001906324 us-gaap:SellingAndMarketingExpenseMember 2019-12-30 2021-01-03 0001906324 us-gaap:AcquisitionRelatedCostsMember 2022-01-03 2023-01-01 0001906324 us-gaap:AcquisitionRelatedCostsMember 2021-01-04 2022-01-02 0001906324 us-gaap:AcquisitionRelatedCostsMember 2019-12-30 2021-01-03 0001906324 us-gaap:DeferredBonusMember 2022-01-03 2023-01-01 0001906324 us-gaap:DeferredBonusMember 2021-01-04 2022-01-02 0001906324 us-gaap:DeferredBonusMember 2019-12-30 2021-01-03 0001906324 us-gaap:EmployeeStockOptionMember 2023-01-01 0001906324 us-gaap:EmployeeStockOptionMember 2022-01-03 2023-01-01 0001906324 srt:MaximumMember 2022-01-03 2023-01-01 0001906324 us-gaap:RestrictedStockMember 2023-01-01 0001906324 us-gaap:RestrictedStockUnitsRSUMember 2022-01-03 2023-01-01 0001906324 us-gaap:RestrictedStockUnitsRSUMember 2021-01-04 2022-01-02 0001906324 us-gaap:FairValueInputsLevel1Member 2023-01-01 0001906324 us-gaap:FairValueInputsLevel2Member 2023-01-01 0001906324 us-gaap:FairValueInputsLevel3Member 2023-01-01 0001906324 us-gaap:FairValueInputsLevel1Member 2022-01-02 0001906324 us-gaap:FairValueInputsLevel2Member 2022-01-02 0001906324 us-gaap:FairValueInputsLevel3Member 2022-01-02 0001906324 qdel:BNPBusinessMember qdel:ConsiderationBMember 2023-01-01 0001906324 us-gaap:FairValueInputsLevel3Member 2021-01-03 0001906324 us-gaap:FairValueInputsLevel3Member 2019-12-30 2021-01-03 0001906324 us-gaap:FairValueInputsLevel3Member 2022-01-03 2023-01-01 0001906324 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 0001906324 qdel:InterestRateSwapOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 0001906324 qdel:InterestRateSwapTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 0001906324 qdel:InterestRateSwapThreeMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 0001906324 qdel:InterestRateSwapFourMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 0001906324 qdel:InterestRateSwapFiveMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 0001906324 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SubsequentEventMember 2023-12-30 0001906324 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2023-01-01 0001906324 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2022-01-03 2023-01-01 0001906324 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-01-01 0001906324 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-01-01 0001906324 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember 2022-01-03 2023-01-01 0001906324 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2022-01-03 2023-01-01 0001906324 us-gaap:InterestRateSwapMember us-gaap:InterestExpenseMember 2022-01-03 2023-01-01 0001906324 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-02 0001906324 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-02 0001906324 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-01-02 0001906324 us-gaap:PensionPlansDefinedBenefitMember 2022-01-02 0001906324 us-gaap:PensionPlansDefinedBenefitMember 2022-01-03 2023-01-01 0001906324 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 0001906324 us-gaap:PostemploymentRetirementBenefitsMember 2022-01-02 0001906324 us-gaap:PostemploymentRetirementBenefitsMember 2022-01-03 2023-01-01 0001906324 us-gaap:PostemploymentRetirementBenefitsMember 2023-01-01 0001906324 us-gaap:PensionPlansDefinedBenefitMember 2022-05-27 0001906324 us-gaap:PostemploymentRetirementBenefitsMember 2022-05-27 0001906324 qdel:PostretirementHealthCoveragePre65Member 2023-01-01 0001906324 qdel:PostretirementHealthCoveragePost65Member 2023-01-01 0001906324 us-gaap:DefinedBenefitPostretirementHealthCoverageMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesJapanMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesJapanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesJapanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesJapanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentJapanMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentJapanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentJapanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentJapanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentNonUSAndNonJapanMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentNonUSAndNonJapanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentNonUSAndNonJapanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DebtSecurityGovernmentNonUSAndNonJapanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanInsuranceContractMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanInsuranceContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanInsuranceContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanInsuranceContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:DefinedBenefitPlanOtherAssetsJapanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 0001906324 qdel:QuotientMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember qdel:OrthoMember 2023-01-01 0001906324 qdel:MosaicQMember us-gaap:SalesRevenueNetMember qdel:OrthoMember 2023-01-01 0001906324 qdel:QuotientSubsidiaryMember 2022-01-03 2023-01-01 0001906324 qdel:QuotientSubsidiaryMember 2023-01-01 0001906324 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-02 0001906324 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-02 0001906324 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-02 0001906324 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-02 0001906324 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-03 2023-01-01 0001906324 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-03 2023-01-01 0001906324 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-01-03 2023-01-01 0001906324 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-03 2023-01-01 0001906324 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 0001906324 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 0001906324 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 0001906324 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 iso4217:USD shares iso4217:USD shares qdel:country qdel:segment pure qdel:covenant qdel:building qdel:term qdel:post-employmentBenefitPlan 0001906324 2022 FY false http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest http://fasb.org/us-gaap/2022#IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent 10-K true 2023-01-01 --01-01 false 001-41409 QUIDELORTHO CORP DE 87-4496285 9975 Summers Ridge Road San Diego CA 92121 858 552-1100 Common stock, $0.001 par value QDEL NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 6008202595 66505546 42 Ernst & Young LLP San Diego, California 292900000 802800000 52100000 25700000 453900000 378000000.0 524100000 198800000 252100000 35000000.0 1575100000 1440300000 1339000000 349200000 21000000.0 37900000 181000000.0 127600000 2476800000 337000000.0 3123800000 98700000 16400000 20100000 122700000 19600000 8855800000 2430400000 283300000 101500000 139200000 40400000 51600000 66900000 207500000 300000 325400000 114400000 1007000000 323500000 186400000 128600000 2430800000 400000 213200000 0 83800000 48500000 3921200000 501000000.0 0.001 0.001 5000000.0 5000000.0 0 0 0 0 0 0 0.001 0.001 126200000 97500000 66400000 66400000 41700000 41700000 0 0 2804300000 279800000 -67600000 400000 2197900000 1649200000 4934600000 1929400000 8855800000 2430400000 3266000000 1698600000 1661700000 1330000000 420300000 305400000 621000000.0 239600000 180700000 190500000 95700000 84300000 132500000 27400000 27300000 136000000.0 9600000 3700000 12300000 0 0 843700000 906000000.0 1060300000 -75700000 -5800000 -8500000 -24000000.0 0 -10400000 -8100000 100000 -1100000 735900000 900300000 1040300000 187200000 196100000 230000000.0 548700000 704200000 810300000 9.66 16.74 19.24 9.56 16.43 18.60 56800000 42100000 42100000 57400000 42900000 43600000 548700000 704200000 810300000 -69800000 -1600000 2500000 -400000 -100000 0 -700000 0 0 6700000 100000 -3000000.0 5200000 -2400000 -500000 1500000 2500000 -2500000 480700000 705000000.0 810300000 41900000 0 425600000 -400000 134700000 559900000 500000 10400000 10400000 19000000.0 19000000.0 200000 7200000 7200000 100000 100000 26200000 26200000 4300000 4300000 300000 43700000 43700000 810300000 810300000 42300000 0 388100000 -400000 945000000.0 1332700000 600000 9600000 9600000 22700000 22700000 200000 37100000 37100000 1000000.0 103500000 103500000 800000 800000 704200000 704200000 41700000 0 279800000 400000 1649200000 1929400000 700000 30800000 30800000 45100000 45100000 25100000 2495400000 2495400000 36100000 36100000 100000 8600000 8600000 1000000.0 74300000 74300000 -68000000.0 -68000000.0 548700000 548700000 66400000 0 2804300000 -67600000 2197900000 4934600000 548700000 704200000 810300000 283600000 52700000 48800000 48400000 25400000 21000000.0 18400000 3000000.0 400000 10400000 8200000 0 -24000000.0 0 -10400000 60600000 0 0 -34800000 31600000 -10000000.0 -150200000 -118900000 402100000 116900000 85000000.0 54900000 26200000 13300000 14300000 23500000 10400000 52200000 18200000 5000000.0 16000000.0 -26800000 -66700000 137700000 -75200000 27900000 14200000 885300000 805900000 629700000 140900000 292800000 64900000 1511400000 0 0 18400000 36900000 1600000 63700000 67400000 0 53400000 3800000 0 -1644200000 -319500000 -63300000 26400000 7600000 9600000 2734500000 0 0 2388300000 300000 500000 8600000 37100000 4300000 74300000 103500000 43700000 4200000 4700000 6000000.0 33500000 35100000 42000000.0 0 0 43400000 252000000.0 -173100000 -130300000 -2000000.0 -400000 1000000.0 -508900000 312900000 437100000 802800000 489900000 52800000 293900000 802800000 489900000 95100000 0 500000 264800000 235600000 109900000 40400000 10500000 7200000 0 0 15900000 73700000 0 0 4600000 2000000.0 800000 0 0 7200000 Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Business</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. As a result of the Combinations, QuidelOrtho became the successor issuer to Quidel. The results of operations of Ortho have been included in the Company’s Consolidated Financial Statements from the date of acquisition. See Note 2 for further information regarding the Combinations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s mission is to develop and manufacture intelligent diagnostic solutions that transform the power of diagnostics into a healthier future for everyone. The Company’s expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine helps clinicians and patients make better informed decisions across the globe. The Company’s global infrastructure and commercial reach support its customers across more than 130 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. The Company operates globally with manufacturing facilities in the U.S. and U.K. and with sales centers, administrative offices and warehouses located throughout the world.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Periods</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year that ends on the Sunday nearest to the end of the month of December, and fiscal quarters that end on the Sunday nearest to the end of the months of March, June, and September. For fiscal years 2022, 2021 and 2020, the Company’s fiscal years ended on January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Fiscal years 2022 and 2021 were 52 weeks and fiscal year 2020 was 53 weeks.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The estimates and underlying assumptions can impact all elements of the financial statements, including, but not limited to, accounting for deductions from revenues (e.g. rebates, sales allowances, and discounts), receivable and inventory valuations, fixed asset valuations, useful lives, impairment of goodwill and tangible and intangible assets, the fair value of assets acquired and liabilities assumed in a business combination and related purchase price allocation, long-term employee benefit obligations, income taxes, environmental matters, litigation and allocations of costs. Estimates are based on historical experience, complex judgments, facts and circumstances available at the time and various other assumptions that are believed to be reasonable under the circumstances but are inherently uncertain and unpredictable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts were reclassified to conform to the current period presentation, including the separate presentation of Amortization of intangible assets and Interest expense, net, the combination of Selling, marketing and administrative expense, and reclassification of Other current liabilities and Other liabilities, which did not change the reported amounts of Total current liabilities or Total liabilities. Cost of sales, excluding amortization of intangibles for fiscal years 2021 and 2020 excludes $7.4 million and $7.4 million, respectively, of intangibles amortization expense, formerly included in Cost of sales, which has been reclassified to Amortization of intangible assets. Selling, marketing and administrative expense for fiscal years 2021 and 2020 excludes $20.0 million and $19.9 million, respectively, of intangibles amortization expense, formerly included in Sales and marketing expense, which has been reclassified to Amortization of intangible assets. The reclassifications did not have an impact on net assets, Operating income, Net income, Basic or Diluted earnings per share, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. They are carried at cost plus accrued interest, which approximates fair value because of the short-term maturity of these </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments. Cash equivalents include money market funds and debt securities of high quality institutions. Cash balances may exceed government insured limits in certain jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests excess cash balances in investment-grade corporate debt securities, asset-backed securities and U.S. Treasury securities. The Company seeks to diversify investments and limits the amount of investment concentrations for individual institutions, maturities and investment types. These marketable securities are classified as available-for-sale and, accordingly, such securities are recorded at fair value. Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. If any adjustment to fair value reflects a significant decline in the value of the security, the Company evaluates the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to its Consolidated Statements of Income. Marketable securities are classified as non-current when maturities are one year or more.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses and Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products directly to physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as to individual, non-professional OTC customers, and other distributors in the U.S. and internationally (see Note 4). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company establishes a reserve based on historical losses, the age of receivables, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts, and specific allowances for large or risky accounts. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts later determined to be uncollectible are charged or written off against this allowance. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he balance of accounts receivable is net of reserves of $89.1 million and $52.4 million at January 1, 2023 and January 2, 2022, respectively, of which the reserve related to contract rebates was $73.5 million and $40.3 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash equivalents, marketable securities and trade accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit losses are identified when cash flows received are not expected to be sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Asset type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Useful life</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7-47 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Customer leased instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or the estimated useful lives of the related assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the accounts and included in determining gain or loss on such disposals. Maintenance and repairs are expensed as incurred; major replacements and improvements that extend the useful life are capitalized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair values of underlying net assets acquired in an acquisition. The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. Beginning in 2022, the Company changed its annual impairment assessment date from December 31 to the first day of the fourth quarter of the fiscal year. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the manner in which the chief operating decision maker (“CODM”) reviews the Company’s performance and allocates resources changed, resulting in six operating segments: North America, EMEA, China, Latin America, Japan and Asia Pacific. North America, EMEA and China are the Company’s reportable segments; Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” The Company concluded each of these six operating segments is considered a reporting unit for the purpose of allocating goodwill and performing the annual goodwill impairment assessment. Prior to the Combinations, the Company operated as a single reportable segment with one reporting unit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When testing goodwill for impairment, the Company first has an option to assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that impairment exists. Such qualitative factors may include the following: macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, the Company would be required to perform a quantitative impairment test. Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value of each reporting unit to its carrying value, including goodwill. The Company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. If the fair value of a reporting unit is less than its carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal year 2022, the Company performed a qualitative goodwill impairment assessment as of the beginning of the fiscal fourth quarter to assess for potential impairment. Based on the qualitative impairment assessment performed by the Company, it was concluded that it is not more likely than not that the fair value of the Company’s reporting units is less than their carrying amounts, and therefore no further impairment testing was necessary.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of evaluating the potential impairment of long-lived assets, such as property, plant and equipment and intangible assets, is subjective and requires judgment. The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of an asset may not be recoverable. If these circumstances exist, recoverability of assets to be held and used is measured by a comparison of the carrying value of an asset group to future undiscounted net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Debt</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects the Company’s nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. During fiscal year 2020, the remaining aggregate principal amount of the Company’s Convertible Notes was settled or matured.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based on historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal years 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company generated a portion of its revenue from sales of the QuickVue At-Home OTC COVID-19 tests to retail customers. The Company estimates the transaction price for revenue from sales to retail customers based on historical experience and current trends to evaluate when uncertainties related to right of return provisions are resolved. As of January 1, 2023 and January 2, 2022, due to a lack of history on which to base an estimate of products to be returned from the retailers, the Company established a reserve based on an estimate of total inventory remaining at our retailers which was subject to return. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately. The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument was not material for fiscal years 2022, 2021 and 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Assistance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, the Company entered into a contract with the National Institutes of Health (“NIH”), through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract originally provided for consideration to the Company of up to $65.0 million and had a performance period of one year, which began in July 2020. During 2021, the Company entered into several amendments to the contract, which added additional deliverables and milestones, as well as extended the performance period. The contract and amendments included key deliverables and milestones that directly supported the upgrade and addition of new manufacturing lines, as well as the outfitting of the new distribution center. The Company also provided instruments and assays to NIH. There were no refund provisions under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from the contract was allocated to each deliverable identified within the contract using a relative fair value allocation method and recognized when there was reasonable assurance the Company would meet the milestones and receive the consideration. Consideration allocated to the delivery of instruments and assays was recognized in accordance with the Company’s existing revenue recognition policy described above. Consideration that related to capital expenditures was recorded as a reduction to the carrying value of such assets and amortized over the useful life of the assets. Consideration allocated to the remainder of the contract was recorded as reductions to the related expense. As of January 2, 2022, the Company had achieved and collected payments for all milestones under the NIH contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the Company acquired a previously established agreement between Ortho and the Biomedical Advanced Research and Development Authority (“BARDA”), a division of HHS, which provides funding for Ortho to build manufacturing space and production support equipment to increase COVID-19 assay production capacity, as well as to build a manufacturing facility to produce certain analyzers needed to support COVID-19 testing. Amounts received from BARDA under this grant are recorded as a reduction to the carrying value of the related assets. A portion of the grant is </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for purposes of reimbursement of certain general and administrative expenses related to the project, which are not capitalized as part of the equipment constructed in connection with the project and are recorded as a reduction to the related expense. The Company received $18.4 million during fiscal year 2022, which was recorded as a reduction to the carrying value of the related assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred. Upfront and milestone payments made to third parties in connection with R&amp;D collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties at or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements to develop and commercialize intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including R&amp;D, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Shipment Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product shipment costs are included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $104.9 million, $29.3 million and $14.2 million for fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Advertising costs were $26.8 million, $13.7 million and $1.1 million for fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to permanently reinvest earnings of foreign subsidiaries at this time. As such, the Company provides for income taxes and foreign withholding taxes, where applicable, on undistributed earnings. Any repatriation of undistributed earnings would be done at little or no tax cost.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation, comprised of stock options, restricted stock units (“RSUs”) and restricted stock awards to employees and directors, is measured at fair value on the grant date. Compensation expense is recognized over the requisite service period, which is generally the vesting period, and includes an estimate of the awards that will be forfeited, and an estimate of the level of performance the Company will achieve for performance-based awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments is incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in ROU assets, operating lease liabilities and operating lease liabilities non-current in the Consolidated Balance Sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income includes unrealized gains and losses that are related to cumulative translation adjustments; unrealized gains and losses on marketable securities; changes in unamortized pension and post-employment actuarial gains and losses; and changes in the fair value of derivatives that are designated and qualify as cash flow hedging instruments excluded from the Consolidated Statements of Income.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of an acquired business is assigned to the tangible and identifiable intangible assets acquired and liabilities assumed on the basis of the estimated fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including, but not limited to, an income approach and a market approach, such as the estimation of future cash flows of the acquired business and current selling prices of similar assets. Fair value of the assets acquired and liabilities assumed, including intangible assets, IPR&amp;D, and contingent payments, are measured based on the assumptions and estimations with regards to variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. When applicable, adjustments to inventory are based on the fair market value of inventory and are recognized into income based on the period in which the underlying inventory is sold. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that is not individually identified and separately recognized. Actual results may vary from projected results and assumptions used in the fair value assessments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Benefit Plans and Other Post-Employment Benefits</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the Company assumed Ortho’s defined benefit plans in certain countries and a retiree healthcare reimbursement plan for certain U.S. employees. Defined benefit plans specify an amount of pension benefit that an employee will receive on retirement, usually dependent on factors such as age, years of service and compensation. The net obligation with respect to defined benefit plans is calculated separately for each plan by estimating the amount of the future benefits that employees have earned in return for their service in the current and prior periods. These benefits are then discounted to determine the present value of the obligations and are then adjusted for the impact of any unamortized prior service costs. The net obligation is then determined with reference to the fair value of the plan assets (if any). The discount rate used is the yield on bonds that are denominated in the currency in which the benefits will be paid and that have maturity dates approximating the terms of the obligations. The calculations are performed by qualified actuaries using the projected unit credit method. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Financial Accounting Standards Board issued guidance which was codified in Accounting Standards Update 2021-08, Business Combinations (Topic 805) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Assets and Contract Liabilities from Contracts </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the new guidance, an acquirer is required to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For public business entities, this guidance is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company early adopted the guidance during the first quarter of 2022 with no material impact to the Consolidated Financial Statements.</span> 130 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Periods</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year that ends on the Sunday nearest to the end of the month of December, and fiscal quarters that end on the Sunday nearest to the end of the months of March, June, and September. For fiscal years 2022, 2021 and 2020, the Company’s fiscal years ended on January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Fiscal years 2022 and 2021 were 52 weeks and fiscal year 2020 was 53 weeks.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The estimates and underlying assumptions can impact all elements of the financial statements, including, but not limited to, accounting for deductions from revenues (e.g. rebates, sales allowances, and discounts), receivable and inventory valuations, fixed asset valuations, useful lives, impairment of goodwill and tangible and intangible assets, the fair value of assets acquired and liabilities assumed in a business combination and related purchase price allocation, long-term employee benefit obligations, income taxes, environmental matters, litigation and allocations of costs. Estimates are based on historical experience, complex judgments, facts and circumstances available at the time and various other assumptions that are believed to be reasonable under the circumstances but are inherently uncertain and unpredictable. Actual results could differ from those estimates.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts were reclassified to conform to the current period presentation, including the separate presentation of Amortization of intangible assets and Interest expense, net, the combination of Selling, marketing and administrative expense, and reclassification of Other current liabilities and Other liabilities, which did not change the reported amounts of Total current liabilities or Total liabilities. Cost of sales, excluding amortization of intangibles for fiscal years 2021 and 2020 excludes $7.4 million and $7.4 million, respectively, of intangibles amortization expense, formerly included in Cost of sales, which has been reclassified to Amortization of intangible assets. Selling, marketing and administrative expense for fiscal years 2021 and 2020 excludes $20.0 million and $19.9 million, respectively, of intangibles amortization expense, formerly included in Sales and marketing expense, which has been reclassified to Amortization of intangible assets. The reclassifications did not have an impact on net assets, Operating income, Net income, Basic or Diluted earnings per share, or cash flows.</span></div> 7400000 7400000 20000000 19900000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. They are carried at cost plus accrued interest, which approximates fair value because of the short-term maturity of these </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments. Cash equivalents include money market funds and debt securities of high quality institutions. Cash balances may exceed government insured limits in certain jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests excess cash balances in investment-grade corporate debt securities, asset-backed securities and U.S. Treasury securities. The Company seeks to diversify investments and limits the amount of investment concentrations for individual institutions, maturities and investment types. These marketable securities are classified as available-for-sale and, accordingly, such securities are recorded at fair value. Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. If any adjustment to fair value reflects a significant decline in the value of the security, the Company evaluates the extent to which the decline is determined to be other-than-temporary and would mark the security to market through a charge to its Consolidated Statements of Income. Marketable securities are classified as non-current when maturities are one year or more.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses and Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells its products directly to physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, leading universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as to individual, non-professional OTC customers, and other distributors in the U.S. and internationally (see Note 4). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company establishes a reserve based on historical losses, the age of receivables, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts, and specific allowances for large or risky accounts. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts later determined to be uncollectible are charged or written off against this allowance. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he balance of accounts receivable is net of reserves of $89.1 million and $52.4 million at January 1, 2023 and January 2, 2022, respectively, of which the reserve related to contract rebates was $73.5 million and $40.3 million, respectively.</span></div> 89100000 52400000 73500000 40300000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash equivalents, marketable securities and trade accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit losses are identified when cash flows received are not expected to be sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.</span></div> InventoriesInventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory periodically for excess, obsolete and impaired inventory and records a reduction to the carrying value when identified. <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at cost and depreciated over the estimated useful lives of the assets using the straight-line method as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Asset type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Useful life</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7-47 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Machinery and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Customer leased instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-8 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-5 years</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or the estimated useful lives of the related assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the accounts and included in determining gain or loss on such disposals. Maintenance and repairs are expensed as incurred; major replacements and improvements that extend the useful life are capitalized.</span></div> P7Y P47Y P3Y P15Y P3Y P8Y P3Y P5Y <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of purchase price over the fair values of underlying net assets acquired in an acquisition. The Company assesses goodwill for impairment at the reporting unit level on an annual basis, or whenever events or changes in circumstances occur that indicate that the fair value of a reporting unit is below its carrying amount. Beginning in 2022, the Company changed its annual impairment assessment date from December 31 to the first day of the fourth quarter of the fiscal year. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the manner in which the chief operating decision maker (“CODM”) reviews the Company’s performance and allocates resources changed, resulting in six operating segments: North America, EMEA, China, Latin America, Japan and Asia Pacific. North America, EMEA and China are the Company’s reportable segments; Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” The Company concluded each of these six operating segments is considered a reporting unit for the purpose of allocating goodwill and performing the annual goodwill impairment assessment. Prior to the Combinations, the Company operated as a single reportable segment with one reporting unit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When testing goodwill for impairment, the Company first has an option to assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that impairment exists. Such qualitative factors may include the following: macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, the Company would be required to perform a quantitative impairment test. Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value of each reporting unit to its carrying value, including goodwill. The Company estimates the fair value of its reporting units by using forecasts of discounted future cash flows and peer market multiples. If the fair value of a reporting unit is less than its carrying value, impairment will be recognized in the amount by which the carrying value exceeds the fair value.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal year 2022, the Company performed a qualitative goodwill impairment assessment as of the beginning of the fiscal fourth quarter to assess for potential impairment. Based on the qualitative impairment assessment performed by the Company, it was concluded that it is not more likely than not that the fair value of the Company’s reporting units is less than their carrying amounts, and therefore no further impairment testing was necessary.</span></div> 6 6 Intangible AssetsIntangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized and amortized on a straight-line basis over the estimated product life. <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of evaluating the potential impairment of long-lived assets, such as property, plant and equipment and intangible assets, is subjective and requires judgment. The Company reviews long-lived assets for impairment when events or changes in circumstances indicate the carrying value of an asset may not be recoverable. If these circumstances exist, recoverability of assets to be held and used is measured by a comparison of the carrying value of an asset group to future undiscounted net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Convertible Debt</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects the Company’s nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. During fiscal year 2020, the remaining aggregate principal amount of the Company’s Convertible Notes was settled or matured.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including special pricing agreements, promotions and other volume-based incentives. Rebates and discounts are calculated based on historical experience, estimated discounting levels and estimated distributor inventory balances and recorded as a reduction of sales with offsets to accounts receivable and other current liabilities, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Revenue is recognized when control of the products is transferred to the customers in an amount that reflects the consideration the Company expects to receive from the customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer, meaning the customer has the ability to use and obtain the benefit of the goods or service. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fiscal years 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company generated a portion of its revenue from sales of the QuickVue At-Home OTC COVID-19 tests to retail customers. The Company estimates the transaction price for revenue from sales to retail customers based on historical experience and current trends to evaluate when uncertainties related to right of return provisions are resolved. As of January 1, 2023 and January 2, 2022, due to a lack of history on which to base an estimate of products to be returned from the retailers, the Company established a reserve based on an estimate of total inventory remaining at our retailers which was subject to return. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property, plant and equipment, net. The instrument is depreciated on a straight-line basis over the lesser of the lease term or life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Income. Instrument and consumables under the reagent rental agreements are deemed two distinct performance obligations. Though the instrument and consumables do not have any use to customers without one another, they are not highly interdependent because they do not significantly affect each other. The Company would be able to fulfill its promise to transfer the instrument even if its customers did not purchase any consumables and the Company would be able to fulfill its promise to provide the consumables even if customers acquired instruments separately. The contract price is allocated between these two performance obligations based on the relative standalone selling prices. The instrument is considered an operating lease and revenue allocated to the instrument was not material for fiscal years 2022, 2021 and 2020.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Assistance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2020, the Company entered into a contract with the National Institutes of Health (“NIH”), through its newly launched Rapid Acceleration of Diagnostics - Advanced Technology Platforms initiative, to support the Company’s expansion of its manufacturing capacity for its diagnostic assays that test for the SARS-CoV-2 antigen. The contract originally provided for consideration to the Company of up to $65.0 million and had a performance period of one year, which began in July 2020. During 2021, the Company entered into several amendments to the contract, which added additional deliverables and milestones, as well as extended the performance period. The contract and amendments included key deliverables and milestones that directly supported the upgrade and addition of new manufacturing lines, as well as the outfitting of the new distribution center. The Company also provided instruments and assays to NIH. There were no refund provisions under the contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from the contract was allocated to each deliverable identified within the contract using a relative fair value allocation method and recognized when there was reasonable assurance the Company would meet the milestones and receive the consideration. Consideration allocated to the delivery of instruments and assays was recognized in accordance with the Company’s existing revenue recognition policy described above. Consideration that related to capital expenditures was recorded as a reduction to the carrying value of such assets and amortized over the useful life of the assets. Consideration allocated to the remainder of the contract was recorded as reductions to the related expense. As of January 2, 2022, the Company had achieved and collected payments for all milestones under the NIH contract.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the Company acquired a previously established agreement between Ortho and the Biomedical Advanced Research and Development Authority (“BARDA”), a division of HHS, which provides funding for Ortho to build manufacturing space and production support equipment to increase COVID-19 assay production capacity, as well as to build a manufacturing facility to produce certain analyzers needed to support COVID-19 testing. Amounts received from BARDA under this grant are recorded as a reduction to the carrying value of the related assets. A portion of the grant is </span></div>for purposes of reimbursement of certain general and administrative expenses related to the project, which are not capitalized as part of the equipment constructed in connection with the project and are recorded as a reduction to the related expense. The Company received $18.4 million during fiscal year 2022, which was recorded as a reduction to the carrying value of the related assets. 65000000 P1Y 18400000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to operations as incurred. Upfront and milestone payments made to third parties in connection with R&amp;D collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties at or subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements to develop and commercialize intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including R&amp;D, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company’s operations.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Shipment Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product shipment costs are included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Shipping and handling costs were $104.9 million, $29.3 million and $14.2 million for fiscal years 2022, 2021 and 2020, respectively.</span></div> 104900000 29300000 14200000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and included in Selling, marketing and administrative expense in the accompanying Consolidated Statements of Income. Advertising costs were $26.8 million, $13.7 million and $1.1 million for fiscal years 2022, 2021 and 2020, respectively.</span></div> 26800000 13700000 1100000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax provision.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to permanently reinvest earnings of foreign subsidiaries at this time. As such, the Company provides for income taxes and foreign withholding taxes, where applicable, on undistributed earnings. Any repatriation of undistributed earnings would be done at little or no tax cost.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents, accounts receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation, comprised of stock options, restricted stock units (“RSUs”) and restricted stock awards to employees and directors, is measured at fair value on the grant date. Compensation expense is recognized over the requisite service period, which is generally the vesting period, and includes an estimate of the awards that will be forfeited, and an estimate of the level of performance the Company will achieve for performance-based awards.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities represent the obligation to make lease payments and right-of-use (“ROU”) assets represent the right to use the underlying asset during the lease term. Lease liabilities and ROU assets are recognized at the commencement date of the lease based on the present value of lease payments over the lease term at the commencement date. When the implicit rate is unknown, an incremental borrowing rate based on the information available at the commencement date is used in determining the present value of the lease payments. Options to extend or terminate the lease are included in the determination of the lease term when it is reasonably certain that the Company will exercise such options. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain classes of assets, the Company accounts for lease and non-lease components as a single lease component. Variable lease payments, including those related to changes in the consumer price index, are recognized in the period in which the obligation for those payments is incurred and are not included in the measurement of the ROU assets or lease liabilities. Short-term leases are excluded from the calculation of the ROU assets and lease liabilities.</span></div>Operating leases are included in ROU assets, operating lease liabilities and operating lease liabilities non-current in the Consolidated Balance Sheets. <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income includes unrealized gains and losses that are related to cumulative translation adjustments; unrealized gains and losses on marketable securities; changes in unamortized pension and post-employment actuarial gains and losses; and changes in the fair value of derivatives that are designated and qualify as cash flow hedging instruments excluded from the Consolidated Statements of Income.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of an acquired business is assigned to the tangible and identifiable intangible assets acquired and liabilities assumed on the basis of the estimated fair values at the date of acquisition. The Company assesses fair value, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, using a variety of methods including, but not limited to, an income approach and a market approach, such as the estimation of future cash flows of the acquired business and current selling prices of similar assets. Fair value of the assets acquired and liabilities assumed, including intangible assets, IPR&amp;D, and contingent payments, are measured based on the assumptions and estimations with regards to variable factors such as the amount and timing of future cash flows for the asset or liability being measured, appropriate risk-adjusted discount rates, nonperformance risk, or other factors that market participants would consider. Upon acquisition, the Company determines the estimated economic lives of the acquired intangible assets for amortization purposes, which are based on the underlying expected cash flows of such assets. When applicable, adjustments to inventory are based on the fair market value of inventory and are recognized into income based on the period in which the underlying inventory is sold. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that is not individually identified and separately recognized. Actual results may vary from projected results and assumptions used in the fair value assessments.</span></div> Defined Benefit Plans and Other Post-Employment BenefitsIn connection with the Combinations, the Company assumed Ortho’s defined benefit plans in certain countries and a retiree healthcare reimbursement plan for certain U.S. employees. Defined benefit plans specify an amount of pension benefit that an employee will receive on retirement, usually dependent on factors such as age, years of service and compensation. The net obligation with respect to defined benefit plans is calculated separately for each plan by estimating the amount of the future benefits that employees have earned in return for their service in the current and prior periods. These benefits are then discounted to determine the present value of the obligations and are then adjusted for the impact of any unamortized prior service costs. The net obligation is then determined with reference to the fair value of the plan assets (if any). The discount rate used is the yield on bonds that are denominated in the currency in which the benefits will be paid and that have maturity dates approximating the terms of the obligations. The calculations are performed by qualified actuaries using the projected unit credit method. Business Combination<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, pursuant to the BCA, Quidel and Ortho consummated the Combinations and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho. As a result of the Combinations, QuidelOrtho became the successor issuer to Quidel. The Combinations have been accounted for as a business combination using the acquisition method of accounting in conformity with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with Quidel considered the accounting and the legal acquirer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Combinations enhance the Company’s revenue profile and expand the Company’s geographic footprint and product diversity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Combinations were completed for a total consideration of approximately $4.3 billion, which included the fair value of equity issued based on the May 26, 2022 closing price of $99.60 per share of Quidel common stock. Former Ortho shareholders received $7.14 in cash and 0.1055 shares of QuidelOrtho common stock for each Ortho ordinary share. The total purchase consideration was calculated as follows (in millions, except value per share data and Ortho Exchange Ratio):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Ortho shares subject to exchange</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.487</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Exchange Ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1055</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QuidelOrtho shares issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.055</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value per Quidel share as of May 26, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replacement equity awards (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Represents the fair value of replacement stock options (which include options with time-based, performance-based, and both performance- and market-based vesting conditions), RSUs and restricted stock outstanding as of May 27, 2022 that are attributable to service prior to the Combinations. The terms of the replacement awards are substantially similar to the former Ortho equity awards for which they were exchanged. The portion of the fair value of the replacement equity awards attributable to service after the Combinations is $46.6 million and will be recognized as compensation expense based on the vesting terms of the replacement equity awards.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Represents cash consideration of $7.14 per share paid to Ortho shareholders and holders of vested Ortho stock options on the closing date of the Combinations for 237.5 million outstanding Ortho shares and 7.3 million vested Ortho stock options.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company funded the cash portion of the purchase price with cash on its balance sheet and a portion of the Term Loan (as defined in Note 8) proceeds from the Financing (as defined in Note 8). See Note 8 for further information regarding the Company’s debt. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the preliminary purchase price allocation on the closing date of the Combinations are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date <br/>(as previously reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,426.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings, including current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,268.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,268.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current and non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,135.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1) Immediately following the closing of the Combinations, the Company repaid long-term borrowings assumed, which consisted of $1,608.4 million aggregate principal amount related to Ortho’s Dollar Term Loan and Euro Term Loan Facilities, $240.0 million aggregate principal amount of 7.375% Senior Notes due 2025 and $405.0 million aggregate principal amount of 7.250% Senior Notes due 2028. The 7.375% and 7.250% Senior Notes were fully discharged following the Combinations. The Company recorded a $23.5 million loss on extinguishment in connection with the Combinations, representing the difference between the reacquisition value, inclusive of $35.9 million of redemption premium, and the net carrying value of the extinguished debt.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value estimates for the assets acquired and liabilities assumed were based on preliminary calculations, and the Company’s estimates and assumptions are subject to change for income tax matters. The Company expects to finalize the valuation as soon as practicable, but no later than one year after the closing date of the Combinations. The measurement period adjustments in the six months ended January 1, 2023 primarily resulted from completing valuations of real estate, personal property and intangible assets and revising the valuation of income tax liabilities. The related impact to net earnings that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories acquired included raw materials, work in progress and finished goods. Inventories were recorded at their estimated fair values. Inventories were valued at the estimated selling price less the estimated costs to be incurred to complete and sell the inventories, the associated margins on these activities and holding costs. A step-up in the value of inventory of $61.7 million was recorded in connection with the Combinations. The step-up value was recorded in Cost of sales, excluding amortization of intangibles in the Consolidated Statements of Income as the inventory was sold to customers, and was fully recognized by the end of fiscal year 2022. In fiscal year 2022, $60.6 million of the fair value step-up of inventory was recognized in the Consolidated Statements of Income.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the total purchase consideration over the estimated fair value of the net assets acquired, and is primarily attributable to synergies which are expected to expand the Company’s revenue profile and product diversity, as well as Ortho’s assembled workforce. Goodwill is not deductible for tax purposes. The preliminary assignment of goodwill by reportable segment as of the closing date of the Combinations is as follows (in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amounts assigned to the identifiable intangible assets acquired (in millions, except years):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Assets Acquired</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of customer relationships was estimated using the Multi-Period Excess Earnings Method, which is a form of the income approach. Significant assumptions include: (i) the estimated annual net cash flows, which are a function of expected earnings attributable to the asset, contributory asset charges and the applicable tax rate, and (ii) the discount rate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of developed technology and trademarks was estimated using the Relief from Royalty Method, which is another form of the income approach. Significant assumptions include: (i) the estimated annual net cash flows, which are a function of expected earnings attributable to the asset, the probability of use of the asset, the royalty rate and the applicable tax rate, and (ii) the discount rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized on a straight-line basis over the amortization periods noted above, which reflects the estimated useful life of the underlying assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal year 2022, the Company incurred $46.9 million of transaction costs related to the Combinations, which primarily consisted of financial advisory, legal, accounting and valuation-related expenses. These expenses were recorded in Acquisition and integration costs in the Consolidated Statements of Income.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following supplemental pro forma financial information shows the combined results of operations of the Company as if the Combinations had occurred on January 4, 2021, the beginning of the periods presented:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:68.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions) (unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,741.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This supplemental pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved had the Combinations been completed at the beginning of fiscal year 2021. In addition, the supplemental pro forma financial information is not a projection of the Company’s future results of operations, nor does it reflect the expected realization of any synergies or cost savings associated with the Combinations. The supplemental pro forma financial information includes adjustments for:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incremental intangible assets amortization expense to be incurred of $19.6 million and $45.5 million for fiscal years 2022 and 2021, respectively, based on the preliminary fair values of the identifiable intangible assets acquired; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incremental cost of sales related to the fair value step-up of inventory which is reflected by an adjustment to decrease expense by $60.6 million for fiscal year 2022 and an adjustment to increase expense by $61.7 million for fiscal year 2021; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreases in interest expense of $11.2 million and $34.9 million for fiscal years 2022 and 2021, respectively, associated with the issuance of debt to finance the Combinations and to repay Ortho’s then-outstanding indebtedness, including the net impact of the removal of the amortization of the discount on Ortho’s indebtedness and the change in amortization of deferred financing fees; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the removal of $50.3 million of loss on extinguishment of debt from Ortho’s financial results for fiscal year 2022 and the reclassification of $24.0 million of loss on extinguishment of debt incurred during fiscal year 2022 to fiscal year 2021; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reclassification of $12.8 million of expense related to the accelerated vesting of certain stock awards of Ortho’s former chief executive officer from fiscal year 2022 to fiscal year 2021; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax impacts related to the above adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the closing date of the Combinations through January 1, 2023, the acquired results of operations of Ortho contributed total revenues of $1,165.2 million and net loss of $126.2 million to the Company’s consolidated results, which included amortization of acquired intangible assets of $104.7 million and recognition in Cost of sales, excluding amortization of intangibles of the fair value step-up of inventory of $60.6 million.</span></div> 4300000000 99.60 7.14 0.1055 The total purchase consideration was calculated as follows (in millions, except value per share data and Ortho Exchange Ratio):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Ortho shares subject to exchange</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.487</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Exchange Ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1055</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QuidelOrtho shares issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.055</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value per Quidel share as of May 26, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of stock consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of replacement equity awards (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Represents the fair value of replacement stock options (which include options with time-based, performance-based, and both performance- and market-based vesting conditions), RSUs and restricted stock outstanding as of May 27, 2022 that are attributable to service prior to the Combinations. The terms of the replacement awards are substantially similar to the former Ortho equity awards for which they were exchanged. The portion of the fair value of the replacement equity awards attributable to service after the Combinations is $46.6 million and will be recognized as compensation expense based on the vesting terms of the replacement equity awards.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Represents cash consideration of $7.14 per share paid to Ortho shareholders and holders of vested Ortho stock options on the closing date of the Combinations for 237.5 million outstanding Ortho shares and 7.3 million vested Ortho stock options.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the preliminary purchase price allocation on the closing date of the Combinations are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date <br/>(as previously reported)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date <br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,133.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,426.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings, including current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,268.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,268.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current and non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(372.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,050.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,135.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1) Immediately following the closing of the Combinations, the Company repaid long-term borrowings assumed, which consisted of $1,608.4 million aggregate principal amount related to Ortho’s Dollar Term Loan and Euro Term Loan Facilities, $240.0 million aggregate principal amount of 7.375% Senior Notes due 2025 and $405.0 million aggregate principal amount of 7.250% Senior Notes due 2028. The 7.375% and 7.250% Senior Notes were fully discharged following the Combinations. The Company recorded a $23.5 million loss on extinguishment in connection with the Combinations, representing the difference between the reacquisition value, inclusive of $35.9 million of redemption premium, and the net carrying value of the extinguished debt.</span></div> 237487000 0.1055 25055000.000 99.60 2495500000 47900000 1747700000 4291100000 46600000 7.14 237500000 7300000 234500000 0 234500000 240600000 0 240600000 386800000 -2400000 384400000 767500000 181400000 948900000 2291300000 -112900000 2178400000 3133000000 35000000.0 3168000000 287900000 -16200000 271700000 7341600000 84900000 7426500000 135000000.0 0 135000000.0 80700000 400000 81100000 2268400000 0 2268400000 215400000 63000000.0 278400000 351000000.0 21500000 372500000 3050500000 84900000 3135400000 4291100000 0 4291100000 1608400000 240000000 0.07375 405000000 0.07250 0.07375 0.07250 23500000 35900000 61700000 60600000 The preliminary assignment of goodwill by reportable segment as of the closing date of the Combinations is as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1211500000 370000000.0 121600000 475300000 2178400000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amounts assigned to the identifiable intangible assets acquired (in millions, except years):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Assets Acquired</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,168.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P20Y 1907000000 P15Y 888000000.0 P15Y 373000000.0 3168000000 46900000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following supplemental pro forma financial information shows the combined results of operations of the Company as if the Combinations had occurred on January 4, 2021, the beginning of the periods presented:</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:68.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions) (unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,741.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4051200000 3741400000 589300000 613200000 -19600000 -45500000 60600000 -61700000 -11200000 -34900000 50300000 -24000000 -24000000 -12800000 -12800000 1165200000 126200000 104700000 60600000 Computation of Earnings Per Share<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (“EPS”) is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted EPS is computed based on the sum of the weighted-average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of shares issuable from stock options, unvested RSUs and restricted stock. Potentially dilutive shares of common stock from outstanding stock options and unvested RSUs are determined using the average share price for each period under the treasury stock method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares from the Convertible Notes are determined using the if-converted method. Under the provisions of the if-converted method, the Convertible Notes are assumed to be converted and the resulting common shares are included in the denominator of the EPS calculation and the interest expense, net of tax, recorded in connection with the Convertible Notes is added back to net income. The Convertible Notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the notes. The Convertible Notes became convertible on March 31, 2018 and matured on December 15, 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income used for basic earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on Convertible Notes, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income used for diluted earnings per share, if-converted method</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average shares of common stock outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential shares issuable from Convertible Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential shares issuable from stock options and unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average shares of common stock outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive shares excluded from the calculation above represent stock options when the combined exercise price and unrecognized stock-based compensation are greater than the average market price for the Company’s common stock because their effect is anti-dilutive.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles net income and the weighted-average shares used in computing basic and diluted EPS in the respective periods:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.268%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income used for basic earnings per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on Convertible Notes, net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income used for diluted earnings per share, if-converted method</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average shares of common stock outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential shares issuable from Convertible Notes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive potential shares issuable from stock options and unvested RSUs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average shares of common stock outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 548700000 704200000 810300000 0 0 400000 548700000 704200000 810700000 56800000 42100000 42100000 0 0 300000 600000 800000 1200000 57400000 42900000 43600000 1500000 200000 0 Revenue<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Timing of revenue recognition may differ from timing of invoicing to customers. The Company records an asset when revenue is recognized prior to invoicing a customer (a “contract asset”). Contract assets are included within Prepaid expenses and other current assets or Other assets in the Company’s Consolidated Balance Sheets and are transferred to accounts receivable when the right to payment becomes unconditional. The balance of contract assets recorded in the Company’s Consolidated Balance Sheets as of January 1, 2023 was $49.6 million and was included in Prepaid expenses and other current assets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract asset balance as of January 1, 2023 consisted of the following components, all of which related to agreements acquired by the Company in connection with the Combinations; therefore, no balance existed at January 2, 2022:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a customer supply agreement under which the difference between the timing of invoicing and revenue recognition resulted in a contract asset of $6.8 million;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contractual arrangements with certain customers under which the Company invoices the customers based on reportable results generated by its reagents; however, control of the goods transfers to the customers upon shipment or delivery of the products, as determined under the terms of the contract. Using the expected value method, the Company estimates the number of reagents that will generate a reportable result. The Company records the revenue upon shipment and an associated contract asset, and relieves the contract asset upon completion of the invoicing. The balance of the contract asset related to these arrangements was $38.5 million as of January 1, 2023 and was recorded in Prepaid expenses and other current assets; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one of the Company’s contract manufacturing agreements that recognizes revenue as the products are manufactured. The balance of the contract asset related to this arrangement was $4.3 million as of January 1, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews contract assets for expected credit losses resulting from the collectability of customer accounts. Expected losses are established based on historical losses, customer mix and credit policies, current economic conditions in customers’ country or industry, and expectations associated with reasonable and supportable forecasts. No credit losses related to contract assets were recognized during fiscal year 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a contract liability when a customer pays an invoice prior to the Company transferring control of the goods or services (“contract liabilities”). The Company’s contract liabilities consist of deferred revenue primarily related to customer service contracts. The Company classifies deferred revenue as current or non-current based on the timing of the transfer of control or performance of the service. The balance of the Company’s current deferred revenue was $76.4 million as of January 1, 2023, and $1.9 million as of January 2, 2022. The Company has one arrangement with a customer where the revenue is expected to be recognized beyond one year. The balance of the deferred revenue included in long-term liabilities was $9.4 million as of January 1, 2023 and was included in Other liabilities in the Consolidated Balance Sheets. There was no deferred revenue included in long-term liabilities as of January 2, 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Joint Business with Grifols</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Combinations, the Company acquired the Joint Business between Ortho and Grifols, under which Ortho and Grifols agreed to pursue a collaboration relating to Ortho’s Hepatitis and HIV diagnostics business. The governance of the Joint Business is shared through a supervisory board made up of equal representation by Ortho and Grifols, which is responsible for all significant decisions relating to the Joint Business that are not exclusively assigned to either Ortho or Grifols, as defined in the Grifols Agreement. The Company’s portion of the pre-tax net profit shared under the Joint Business was $18.6 million during fiscal year 2022. This included the Company’s portion of the pre-tax net profit of $11.1 million during fiscal year 2022 on sales transactions with third parties where the Company is the principal. The Company recognized revenues, cost of sales, excluding amortization of intangibles, and operating expenses, on a gross basis on these sales transactions in their respective lines in the Consolidated Statements of Income. The Company’s portion of the pre-tax net profit also included revenue of $7.5 million from collaboration and royalty agreements during fiscal year 2022, which is presented on a net basis within Total revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Combinations, the Company reorganized its former product categories into four business units. Revenues from the Company’s former Specialized Diagnostic Solutions product category have been included in a new Labs business unit. The Company’s former Rapid Immunoassay and Cardiometabolic Immunoassay product categories now represent its Point of Care business unit. The Molecular Diagnostics business unit represents the former Molecular Diagnostic Solutions product category. In addition, the Company added a Transfusion Medicine business unit. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Total revenues by business unit:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Labs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfusion Medicine</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Revenue and Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had sales to individual customers in excess of 10% of Total revenues as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2023 and January 2, 2022, customers with balances due in excess of 10% of Accounts receivable, net totaled $161.9 million and $267.3 million, respectively. For fiscal years 2022, 2021 and 2020, sales of COVID-19 products accounted for 44%, 75% and 70% of Total revenues, respectively. For fiscal years 2022, 2021 and 2020, sales of influenza products accounted for 11%, 4% and 8% of Total revenues, respectively.</span></div> 49600000 6800000 38500000 4300000 76400000 1900000 9400000 18600000 11100000 7500000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes Total revenues by business unit:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Labs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfusion Medicine</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Point of Care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molecular Diagnostics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 820200000 44800000 50900000 393800000 0 0 1955300000 1453300000 1387800000 96700000 200500000 223000000.0 3266000000 1698600000 1661700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had sales to individual customers in excess of 10% of Total revenues as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.20 0.01 0 0.11 0.24 0.29 0.08 0.09 0.16 0.05 0.09 0.13 0.03 0.07 0.10 0.47 0.50 0.68 161900000 267300000 0.44 0.75 0.70 0.11 0.04 0.08 Segment and Geographic Information<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the manner in which the CODM reviews the Company’s performance and allocates resources changed, resulting in three geographically-based reportable segments: North America; EMEA; and China. Although all three segments are engaged in the marketing, distribution and sale of diagnostic instruments and assays for hospitals, retailers, distributors, laboratories and/or blood and plasma centers worldwide, each region is managed separately to better align with the market dynamics of the specific geographic region. Latin America, Japan and Asia Pacific are immaterial operating segments that are not considered reportable segments and are included in “Other.” Previously, the Company operated as a single reportable segment. Prior periods have been revised to align with the current period presentation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by reportable segment are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2022, in connection with the Combinations, the basis by which the Company measures segment profit or loss changed to Adjusted EBITDA in order to manage the Company’s business to better align with the market dynamics of the specific geographic regions in which the Company operates. In the fourth quarter of 2022, the Company revised the internal allocation of certain global costs primarily between the North America segment and Corporate to better align costs that impact the Company as a whole. Prior periods have been revised to align with the current period presentation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth Adjusted EBITDA by segment and the reconciliations to Income before provision for income taxes for fiscal years 2022, 2021 and 2020:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment Adjusted EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unwind inventory fair value adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred cloud computing<br/>    implementation costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation charges and other costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU medical device regulation transition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax indemnification expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of acquisition contingencies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM180OS9mcmFnOjc2OWMwYmZhMDUwMzQ2NWNiZDRlODY4ZTI4NjAxNzE4L3RhYmxlOmEzNDI4ZWZkZGM1ZjQzOTRhNzBlMWJjMjMxMzExN2U3L3RhYmxlcmFuZ2U6YTM0MjhlZmRkYzVmNDM5NGE3MGUxYmMyMzEzMTE3ZTdfMjEtMC0xLTEtMTU3MjEy_20b65e9f-2d56-4175-802d-602044ff6dba"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM180OS9mcmFnOjc2OWMwYmZhMDUwMzQ2NWNiZDRlODY4ZTI4NjAxNzE4L3RhYmxlOmEzNDI4ZWZkZGM1ZjQzOTRhNzBlMWJjMjMxMzExN2U3L3RhYmxlcmFuZ2U6YTM0MjhlZmRkYzVmNDM5NGE3MGUxYmMyMzEzMTE3ZTdfMjEtMC0xLTEtMTU3MjEy_47de31a9-4764-405d-a5c5-0d659745fdc1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM180OS9mcmFnOjc2OWMwYmZhMDUwMzQ2NWNiZDRlODY4ZTI4NjAxNzE4L3RhYmxlOmEzNDI4ZWZkZGM1ZjQzOTRhNzBlMWJjMjMxMzExN2U3L3RhYmxlcmFuZ2U6YTM0MjhlZmRkYzVmNDM5NGE3MGUxYmMyMzEzMTE3ZTdfMjEtMC0xLTEtMTU3MjEy_85bb417f-1b71-45c4-918a-a500a4fa1622">Derivative mark-to-market gain (loss)</span></span></span></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and IT functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.</span></div><div style="margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Represents incremental consulting costs and R&amp;D manufacturing site costs to align compliance of Ortho’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM does not review capital expenditures, total depreciation and amortization or assets by segment, and therefore this information has been excluded as it does not comprise part of management’s key performance metrics.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived Assets as of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues for Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues by reportable segment are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2536500000 1500200000 1460700000 206800000 69600000 92900000 220000000.0 58000000.0 62400000 302700000 70800000 45700000 3266000000 1698600000 1661700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth Adjusted EBITDA by segment and the reconciliations to Income before provision for income taxes for fiscal years 2022, 2021 and 2020:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment Adjusted EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,123.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(283.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unwind inventory fair value adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred cloud computing<br/>    implementation costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation charges and other costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EU medical device regulation transition costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax indemnification expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of acquisition contingencies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM180OS9mcmFnOjc2OWMwYmZhMDUwMzQ2NWNiZDRlODY4ZTI4NjAxNzE4L3RhYmxlOmEzNDI4ZWZkZGM1ZjQzOTRhNzBlMWJjMjMxMzExN2U3L3RhYmxlcmFuZ2U6YTM0MjhlZmRkYzVmNDM5NGE3MGUxYmMyMzEzMTE3ZTdfMjEtMC0xLTEtMTU3MjEy_20b65e9f-2d56-4175-802d-602044ff6dba"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM180OS9mcmFnOjc2OWMwYmZhMDUwMzQ2NWNiZDRlODY4ZTI4NjAxNzE4L3RhYmxlOmEzNDI4ZWZkZGM1ZjQzOTRhNzBlMWJjMjMxMzExN2U3L3RhYmxlcmFuZ2U6YTM0MjhlZmRkYzVmNDM5NGE3MGUxYmMyMzEzMTE3ZTdfMjEtMC0xLTEtMTU3MjEy_47de31a9-4764-405d-a5c5-0d659745fdc1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM180OS9mcmFnOjc2OWMwYmZhMDUwMzQ2NWNiZDRlODY4ZTI4NjAxNzE4L3RhYmxlOmEzNDI4ZWZkZGM1ZjQzOTRhNzBlMWJjMjMxMzExN2U3L3RhYmxlcmFuZ2U6YTM0MjhlZmRkYzVmNDM5NGE3MGUxYmMyMzEzMTE3ZTdfMjEtMC0xLTEtMTU3MjEy_85bb417f-1b71-45c4-918a-a500a4fa1622">Derivative mark-to-market gain (loss)</span></span></span></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and IT functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.</span></div>(2) Represents incremental consulting costs and R&amp;D manufacturing site costs to align compliance of Ortho’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards. 1614600000 1028500000 1205200000 31700000 28100000 55500000 104100000 24100000 30500000 92700000 43000000.0 28000000.0 1843100000 1123700000 1319200000 512100000 152900000 203900000 283600000 52700000 48800000 136000000.0 9600000 3700000 -75700000 -5800000 -8500000 60600000 0 0 -24000000.0 0 -10400000 -5800000 1500000 0 5400000 3700000 1100000 3700000 0 0 2800000 0 0 1500000 0 0 -300000 0 0 100000 200000 1400000 4400000 0 -1100000 735900000 900300000 1040300000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-lived Assets as of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenues for Fiscal Year</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,266.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 983000000.0 347100000 2451700000 1415500000 1452400000 356000000.0 2100000 814300000 283100000 209300000 1339000000 349200000 3266000000 1698600000 1661700000 Income Taxes<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company’s deferred tax assets and deferred tax liabilities as of January 1, 2023 and January 2, 2022 are shown below:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for returns and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(743.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. For the fiscal years ended January 1, 2023, January 2, 2022 and January 3, 2021, the Company has demonstrated positive cumulative pre-tax book income. Such objective positive evidence allowed the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company to consider other subjective evidence, such as the Company’s projections for future profitability, to determine the realizability of its deferred tax assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance of $251.3 million as of January 1, 2023 represents the portion of the deferred tax asset that management could not conclude was more likely than not to be realized. The Company’s valuation allowance relates primarily to the realization of recorded tax benefits on tax loss carryforwards from operations in Luxembourg and certain U.S. state jurisdictions. The amount of the deferred tax assets considered realizable could be adjusted in the future based on changes in available positive and negative evidence.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2023, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $879.8 million, of which $473.0 million are subject to expiration through 2037 and $406.8 million are not subject to expiration. In addition, the Company has state NOLs of approximately $530.1 million, which will expire in years 2023 through 2042. As of January 1, 2023, the Company had U.S. federal research credit carryforwards of $14.2 million and federal foreign tax credits of $3.4 million, which will begin to expire in 2034 and 2028, respectively. In addition, the Company had state research credits of $5.9 million, of which none expire, and state business credit carryforwards of $25.6 million, which will begin to expire in 2029. As of January 1, 2023, the Company had $543.8 million of NOL carryforwards in certain non-U.S. jurisdictions, net of uncertain tax positions. Of these, $339.1 million have no expiration and the remaining $204.7 million will expire in years through 2042.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Internal Revenue Code Sections 382 and 383, the Company’s use of its NOL and tax credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three-year period. As a result of an ownership change that occurred in the second quarter of fiscal year 2022, the Company may be limited in its ability to utilize its NOL carryforwards and certain other attributes, starting the ownership change date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income tax computed at the federal statutory rate to the provision for income taxes from continuing operations was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax expense, net of federal tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxed at rates other than the applicable U.S. rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research credits—current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Derived Intangible Income Deduction (FDII)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company’s unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases from voluntary disclosure agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>As of January 1, 2023, January 2, 2022 and January 3, 2021, the Company had unrecognized tax benefits of $40.0 million, $17.7 million, and $22.6 million, respectively, of which $28.3 million, $11.3 million and $15.0 million, respectively, would reduce the Company’s annual effective tax rate, if recognized. The Company estimates that within the next 12 months, its uncertain tax positions, excluding interest, will decrease by $2.4 million. The uncertain tax positions relate to an on-going multi-state tax commission audit that is expected to be settled within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of the income tax expense. The Company had accrued interest and penalties associated with uncertain tax positions of $8.3 million as of January 1, 2023 and $1.2 million as of January 2, 2022. Interest expense, net of accrued interest (reversed) for fiscal years 2022, 2021 and 2020 was approximately $0.3 million, $0.7 million and $0.1 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to periodic audits by domestic and foreign tax authorities. Due to the carryforward of unutilized credits, the Company’s federal tax years from 2012 and onwards are subject to examination by the U.S. authorities. The Company’s state and foreign tax years for 2001 and onwards are subject to examination by applicable tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho is currently under audit in certain jurisdictions for tax years under the responsibility of Johnson &amp; Johnson. Pursuant to the stock and asset purchase agreement entered into by Ortho and Johnson &amp; Johnson in January 2014, Johnson &amp; Johnson retained all income tax liabilities accrued as of the date of acquisition, including reserves for unrecognized tax benefits. Accordingly, all tax liabilities related to these tax years will be indemnified by Johnson &amp; Johnson. As of January 1, 2023, the indemnification receivable from Johnson &amp; Johnson totaled $16.8 million and is included as a component of Prepaid expenses and other current assets and Other assets on the Consolidated Balance Sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes to the valuation allowance for balances for fiscal years 2022, 2021 and 2020: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions Due to Current Year Acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>(Deductions)<br/>Charged to<br/>Provision for (Benefit From)<br/>Income Taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation/Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 1, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 3, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the provision for income taxes were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred provision (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 162200000 148800000 198500000 48800000 42400000 34600000 17600000 2300000 1100000 228600000 193500000 234200000 -31900000 7200000 -2900000 -9300000 -2600000 -1000000.0 -200000 -2000000.0 -300000 -41400000 2600000 -4200000 187200000 196100000 230000000.0 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s income before income taxes was subject to taxes in the following jurisdictions for the following periods:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 672100000 891200000 1035700000 63800000 9100000 4600000 735900000 900300000 1040300000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company’s deferred tax assets and deferred tax liabilities as of January 1, 2023 and January 2, 2022 are shown below:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for returns and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss and credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &amp; development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(743.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 51400000 32700000 0 2200000 45900000 28300000 34100000 6400000 14600000 9200000 565300000 10800000 50700000 0 19900000 5500000 16100000 800000 798000000.0 95900000 251300000 2300000 546700000 93600000 43800000 30100000 590200000 900000 109500000 42500000 743500000 73500000 196800000 20100000 251300000 879800000 473000000 406800000 530100000 14200000 3400000 5900000 25600000 543800000 339100000 204700000 0.50 P3Y <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income tax computed at the federal statutory rate to the provision for income taxes from continuing operations was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax expense, net of federal tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxed at rates other than the applicable U.S. rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research credits—current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Derived Intangible Income Deduction (FDII)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 154500000 189100000 218500000 29300000 30100000 30300000 -27500000 0 0 12000000.0 1800000 3800000 7300000 7700000 5000000.0 1500000 -9200000 -13900000 26200000 -100000 -100000 10200000 8400000 8600000 8700000 500000 5000000.0 187200000 196100000 230000000.0 0.50 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company’s unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to current year acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases from voluntary disclosure agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 17700000 22600000 17200000 27800000 0 0 600000 500000 2300000 1800000 900000 7700000 0 6300000 0 6700000 0 0 40000000.0 17700000 22600000 40000000 17700000 22600000 28300000 11300000 15000000 2400000 8300000 1200000 300000 700000 100000 16800000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes to the valuation allowance for balances for fiscal years 2022, 2021 and 2020: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions Due to Current Year Acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions<br/>(Deductions)<br/>Charged to<br/>Provision for (Benefit From)<br/>Income Taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation/Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 1, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 3, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2300000 223500000 26200000 -700000 251300000 2300000 0 0 0 2300000 2400000 0 -100000 0 2300000 Balance Sheet Account Details<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of marketable securities:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate asset-backed securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivables primarily consist of trade accounts receivables with maturities of one year or less and are presented net of reserves:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for contract rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for contractual rebates involves estimating adjustments to revenue based on a high volume of data, including inputs from third-party sources. In addition, the determination of such adjustments includes estimating rebate percentages which are dependent on estimated end-user sales mix and customer contractual terms, which vary across customers, the related balance of which was $40.0 million and $40.3 million at January 1, 2023 and January 2, 2022, respectively, and was included in the allowance for contract rebates and discounts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes to the accounts receivable allowance balances for fiscal years 2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions Charged to Expense or as Reductions to Revenue (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of<br/>period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 1, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 2, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes opening balance of $31.4 million related to the Combinations during fiscal year 2022. Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to selling, marketing and administrative expense.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">The deductions represent actual charges against the accrual described above.</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Inventories consisted of the following:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process (materials, labor and overhead)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods (materials, labor and overhead)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Other assets includes inventory expected to remain on hand beyond one year.</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes and other tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment, Net</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of property, plant and equipment:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer leased instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress reflects amounts incurred for construction or improvements of property, plant, or equipment that have not been made in service. In addition, construction in progress includes certain instruments that have not been placed at a customer under a lease agreement that will be reclassified to leased instruments once placed at a customer site. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $151.1 million, $24.3 million and $20.8 million for fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in goodwill were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">North America</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EMEA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">China</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of reportable segment revisions</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>useful life<br/>(years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent and trademark costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to the capitalized software costs was $0.9 million, $1.0 million and $0.9 million for fiscal years 2022, 2021 and 2020, respectively. Amortization expense (including capitalized software costs) was $132.5 million, $27.4 million and $27.3 million for fiscal years 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of January 1, 2023 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions and rebates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181NS9mcmFnOmM0N2ViYzRjMWMxYzQ1OGY4MTE3ZGI3OGNlNWRhMTk5L3RhYmxlOjBmYWQwOWMyZDdhZDQ0MTBhYzViYWZlNThkOTRhMDgzL3RhYmxlcmFuZ2U6MGZhZDA5YzJkN2FkNDQxMGFjNWJhZmU1OGQ5NGEwODNfNC0wLTEtMS0xMzEzNTQ_0f8c8f58-9d12-4d17-8fbc-d825ba44221f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181NS9mcmFnOmM0N2ViYzRjMWMxYzQ1OGY4MTE3ZGI3OGNlNWRhMTk5L3RhYmxlOjBmYWQwOWMyZDdhZDQ0MTBhYzViYWZlNThkOTRhMDgzL3RhYmxlcmFuZ2U6MGZhZDA5YzJkN2FkNDQxMGFjNWJhZmU1OGQ5NGEwODNfNC0wLTEtMS0xMzEzNTQ_880c791b-4ec8-4f84-8f64-932d31f418cc">Operating lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables under transition services agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 292900000 802800000 1000000.0 0 293900000 802800000 <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of marketable securities:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sovereign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate asset-backed securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 40500000 500000 40000000.0 22300000 0 22300000 6700000 0 6700000 3400000 0 3400000 2000000.0 0 2000000.0 0 0 0 1000000.0 0 1000000.0 0 0 0 1900000 0 1900000 0 0 0 500000 0 500000 0 0 0 52600000 500000 52100000 25700000 0 25700000 13300000 100000 13200000 26800000 100000 26700000 7900000 100000 7800000 11200000 0 11200000 73800000 700000 73100000 63700000 100000 63600000 <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivables primarily consist of trade accounts receivables with maturities of one year or less and are presented net of reserves:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for contract rebates and discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for contractual rebates involves estimating adjustments to revenue based on a high volume of data, including inputs from third-party sources. In addition, the determination of such adjustments includes estimating rebate percentages which are dependent on estimated end-user sales mix and customer contractual terms, which vary across customers, the related balance of which was $40.0 million and $40.3 million at January 1, 2023 and January 2, 2022, respectively, and was included in the allowance for contract rebates and discounts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes to the accounts receivable allowance balances for fiscal years 2022, 2021 and 2020:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of<br/>Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions Charged to Expense or as Reductions to Revenue (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions (2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of<br/>period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 1, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 2, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal year ended January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">Includes opening balance of $31.4 million related to the Combinations during fiscal year 2022. Primarily represents charges for contract rebate allowances recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to selling, marketing and administrative expense.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">The deductions represent actual charges against the accrual described above.</span></div> 543000000.0 430400000 77100000 50700000 12000000.0 1700000 453900000 378000000.0 40000000 40300000 52400000 407600000 370900000 89100000 103400000 456200000 507200000 52400000 15900000 277000000.0 189500000 103400000 31400000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Inventories consisted of the following:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process (materials, labor and overhead)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods (materials, labor and overhead)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Other assets includes inventory expected to remain on hand beyond one year.</span></div> 185200000 103200000 82700000 36100000 295100000 59500000 563000000.0 198800000 524100000 198800000 38900000 0 563000000.0 198800000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes and other tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 96700000 14600000 49600000 0 44300000 15800000 38600000 0 22000000.0 100000 900000 4500000 252100000 35000000.0 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of property, plant and equipment:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer leased instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 515100000 159000000.0 364700000 146800000 434500000 68100000 34500000 10200000 268400000 105200000 1617200000 489300000 278200000 140100000 1339000000 349200000 151100000 24300000 20800000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in goodwill were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">North America</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EMEA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">China</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of reportable segment revisions</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,476.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 337000000.0 336900000 100000 0 0 337000000.0 1211500000 370000000.0 121600000 475300000 2178400000 -700000 -11500000 -3500000 -22900000 -38600000 1547700000 358600000 118100000 452400000 2476800000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average<br/>useful life<br/>(years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent and trademark costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,436.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P14Y3M18D 997600000 120000000.0 877600000 112700000 78200000 34500000 P19Y2M12D 2023500000 148900000 1874600000 122700000 77300000 45400000 P6Y4M24D 3800000 3700000 100000 6600000 5700000 900000 P14Y8M12D 400500000 32800000 367700000 28700000 15700000 13000000.0 P4Y8M12D 11500000 7700000 3800000 11700000 6800000 4900000 3436900000 313100000 3123800000 282400000 183700000 98700000 900000 1000000 900000 132500000 27400000 27300000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected future annual amortization expense of the Company’s finite-lived intangible assets held as of January 1, 2023 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 205400000 201700000 188200000 187100000 184700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consist of the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions and rebates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181NS9mcmFnOmM0N2ViYzRjMWMxYzQ1OGY4MTE3ZGI3OGNlNWRhMTk5L3RhYmxlOjBmYWQwOWMyZDdhZDQ0MTBhYzViYWZlNThkOTRhMDgzL3RhYmxlcmFuZ2U6MGZhZDA5YzJkN2FkNDQxMGFjNWJhZmU1OGQ5NGEwODNfNC0wLTEtMS0xMzEzNTQ_0f8c8f58-9d12-4d17-8fbc-d825ba44221f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181NS9mcmFnOmM0N2ViYzRjMWMxYzQ1OGY4MTE3ZGI3OGNlNWRhMTk5L3RhYmxlOjBmYWQwOWMyZDdhZDQ0MTBhYzViYWZlNThkOTRhMDgzL3RhYmxlcmFuZ2U6MGZhZDA5YzJkN2FkNDQxMGFjNWJhZmU1OGQ5NGEwODNfNC0wLTEtMS0xMzEzNTQ_880c791b-4ec8-4f84-8f64-932d31f418cc">Operating lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables under transition services agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 55100000 15900000 39300000 41900000 76400000 1900000 24400000 10000000.0 9300000 10200000 19700000 300000 100000 6000000.0 0 10900000 101100000 17300000 325400000 114400000 Long-term Borrowings<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of borrowings were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181OC9mcmFnOjExNzI1MjBjZjJlNzRhNDZiNmI4ZmE2NzVjM2JlN2RiL3RhYmxlOmM5MWJjOWIyY2E3NjQ2MjJhZWYyN2VjYzEyZjE2Y2QwL3RhYmxlcmFuZ2U6YzkxYmM5YjJjYTc2NDYyMmFlZjI3ZWNjMTJmMTZjZDBfMy0wLTEtMS0xMzEzNTQ_26d85a02-c68a-4ee5-9df2-e87ee1c2d7c7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181OC9mcmFnOjExNzI1MjBjZjJlNzRhNDZiNmI4ZmE2NzVjM2JlN2RiL3RhYmxlOmM5MWJjOWIyY2E3NjQ2MjJhZWYyN2VjYzEyZjE2Y2QwL3RhYmxlcmFuZ2U6YzkxYmM5YjJjYTc2NDYyMmFlZjI3ZWNjMTJmMTZjZDBfMy0wLTEtMS0xMzEzNTQ_e5befb23-578c-41f5-b6a3-5c4ff25f15aa">Financing lease obligation</span></span> </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2022, the Company entered into a credit agreement (the “Credit Agreement”) by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender (“Bank of America”), and the other lenders and L/C issuers party thereto (together with Bank of America, the “Lenders”). Pursuant to the Credit Agreement and in connection with the consummation of the Combinations, the Lenders provided the Company with a $2,750.0 million senior secured term loan facility (the “Term Loan”) and a $750.0 million revolving credit facility (the “Revolving Credit Facility” and with the Term Loan, the “Financing”). Effective August 4, 2022, pursuant to the Increase Joinder No. 1 to the Credit Agreement, the Revolving Credit Facility increased by $50.0 million to $800.0 million. The Financing is guaranteed by certain material domestic subsidiaries of the Company (the “Guarantors”) and is secured by liens on substantially all of the assets of the Company and the Guarantors, excluding real property and certain other types of excluded assets. Loans under the Credit Agreement will bear interest at a rate per annum equal to the Term SOFR or Base Rate plus the Applicable Rate (each as defined in the Credit Agreement). As of January 1, 2023, letters of credit issued under the Revolving Credit Facility totaled $13.1 million, which reduced the available amount under the Revolving Credit Facility to $786.9 million. In connection with the Credit Agreement, the Company incurred $15.4 million of debt issuance costs, of which $11.9 million was related to the Term Loan and $3.5 million was related to the Revolving Credit Facility. Debt issuance costs related to the issuance of the Term Loan were recorded as a reduction of the principal amount of the borrowings and are amortized using the effective interest method as a component of Interest expense, net over the life of the Term Loan. Debt issuance costs related to the Revolving Credit Facility were recorded as Other assets and are amortized on a straight-line basis over the term of the Revolving Credit Facility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan is subject to quarterly amortization of the principal amount on the last business day of each fiscal quarter of the Company (commencing on September 30, 2022). The required quarterly payments are 1.875% of the aggregate initial principal amount of the Term Loan through the fiscal second quarter of 2024, and 1.250% thereafter. The final remaining principal installment is due on the maturity date. The Term Loan and the Revolving Credit Facility will mature on May 27, 2027. The Company must prepay loans outstanding under the Credit Agreement in an amount equal to the Net Cash Proceeds (as defined in the Credit Agreement) from (i) certain property dispositions and (ii) the receipt of certain other amounts not in the ordinary course of business, such as certain insurance proceeds and condemnation awards, in each case, if not reinvested within a specified time period as contemplated in the Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains affirmative and negative covenants that are customary for credit agreements of this nature. The negative covenants include, among other things, limitations on asset sales, mergers, indebtedness, liens, investments and transactions with affiliates. The Credit Agreement contains two financial covenants: (i) a maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) as of the last day of each fiscal quarter of (a) 4.50 to 1.00 for the first four fiscal quarters ending after the closing date of the Credit Agreement (the “Initial Measurement Period”), (b) 4.00 to 1.00 for the first four fiscal quarters ending after the Initial Measurement Period and (c) 3.50 to 1.00 for each fiscal quarter thereafter; and (ii) a minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of 3.00 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters. The Company was in compliance with the financial covenants as of January 1, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement was entered into in connection with the Combinations in order to fund a portion of the cash portion of the purchase price as well as to repay substantially all of Ortho’s then-outstanding indebtedness. See Note 2 for more information regarding the Combinations. In connection with the closing of the Combinations, Quidel terminated its previous $175.0 million revolving credit facility and related credit agreement on May 27, 2022, which did not have an outstanding balance. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the detailed amounts within Interest expense, net for fiscal years 2022, 2021 and 2020.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a schedule of required future repayments of all borrowings outstanding as of January 1, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of borrowings were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181OC9mcmFnOjExNzI1MjBjZjJlNzRhNDZiNmI4ZmE2NzVjM2JlN2RiL3RhYmxlOmM5MWJjOWIyY2E3NjQ2MjJhZWYyN2VjYzEyZjE2Y2QwL3RhYmxlcmFuZ2U6YzkxYmM5YjJjYTc2NDYyMmFlZjI3ZWNjMTJmMTZjZDBfMy0wLTEtMS0xMzEzNTQ_26d85a02-c68a-4ee5-9df2-e87ee1c2d7c7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM181OC9mcmFnOjExNzI1MjBjZjJlNzRhNDZiNmI4ZmE2NzVjM2JlN2RiL3RhYmxlOmM5MWJjOWIyY2E3NjQ2MjJhZWYyN2VjYzEyZjE2Y2QwL3RhYmxlcmFuZ2U6YzkxYmM5YjJjYTc2NDYyMmFlZjI3ZWNjMTJmMTZjZDBfMy0wLTEtMS0xMzEzNTQ_e5befb23-578c-41f5-b6a3-5c4ff25f15aa">Financing lease obligation</span></span> </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term borrowings</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2646900000 0 0 0 800000 700000 1200000 0 10600000 0 2638300000 700000 207500000 300000 2430800000 400000 2750000000 750000000 50000000 800000000 13100000 786900000 15400000 11900000 3500000 0.01875 0.01250 2 4.50 1.00 4.00 1.00 3.50 1.00 3.00 1.00 175000000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the detailed amounts within Interest expense, net for fiscal years 2022, 2021 and 2020.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 73000000.0 0 0 1500000 300000 300000 2100000 400000 400000 400000 5400000 7900000 1300000 300000 100000 -75700000 -5800000 -8500000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a schedule of required future repayments of all borrowings outstanding as of January 1, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 207500000 172700000 137500000 137500000 1993700000 2648900000 Leases<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases administrative, R&amp;D, sales and marketing and manufacturing facilities and certain equipment under various non-cancelable lease agreements. Facility leases generally provide for periodic rent increases, and may contain clauses for rent escalation, renewal options or early termination.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost for fiscal years 2022, 2021 and 2020 was $26.4 million, $15.4 million and $11.2 million, respectively. Variable lease cost for fiscal years 2022, 2021 and 2020 was $5.6 million, $2.7 million and $1.8 million, respectively. Finance leases are immaterial to the Company’s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental cash flow information related to operating leases during the respective periods was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating <br/>     lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable operating leases at the end of 2022 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM18yMTQ2L2ZyYWc6NjQwMDVlYTBhNDI2NGM3MDhiNzk2NTRkZGVlMzEyNjgvdGFibGU6OTk1Y2ViMGQ1M2M2NGZkYTlhNTUwNmRiMzIyNjU3YzUvdGFibGVyYW5nZTo5OTVjZWIwZDUzYzY0ZmRhOWE1NTA2ZGIzMjI2NTdjNV8xMS0wLTEtMS0xNDY1NDA_52daf024-3344-479d-91fd-7852367e94b4">Less: current portion</span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM18yMTQ2L2ZyYWc6NjQwMDVlYTBhNDI2NGM3MDhiNzk2NTRkZGVlMzEyNjgvdGFibGU6OTk1Y2ViMGQ1M2M2NGZkYTlhNTUwNmRiMzIyNjU3YzUvdGFibGVyYW5nZTo5OTVjZWIwZDUzYzY0ZmRhOWE1NTA2ZGIzMjI2NTdjNV8xMi0wLTEtMS0xNDY1NDI_efc8d3a9-227d-46ac-a5aa-c3af10fbb89c">Non-current portion</span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Summers Ridge Lease — The Company leases four buildings that are located on the Summers Ridge property in San Diego, California with an initial term through January 2033 with options to extend the lease for two additional five-year terms upon satisfaction of certain conditions, which have not been included in the determination of the lease term. The must-take provisions related to the fourth building became effective in November 2022 upon expiration of the previous tenant’s lease. As a result, the Company recorded a ROU asset and a corresponding lease liability of approximately $20.6 million in November 2022. 26400000 15400000 11200000 5600000 2700000 1800000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental cash flow information related to operating leases during the respective periods was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating <br/>     lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25200000 12300000 10800000 29900000 37300000 15300000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable operating leases at the end of 2022 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.7)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM18yMTQ2L2ZyYWc6NjQwMDVlYTBhNDI2NGM3MDhiNzk2NTRkZGVlMzEyNjgvdGFibGU6OTk1Y2ViMGQ1M2M2NGZkYTlhNTUwNmRiMzIyNjU3YzUvdGFibGVyYW5nZTo5OTVjZWIwZDUzYzY0ZmRhOWE1NTA2ZGIzMjI2NTdjNV8xMS0wLTEtMS0xNDY1NDA_52daf024-3344-479d-91fd-7852367e94b4">Less: current portion</span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM18yMTQ2L2ZyYWc6NjQwMDVlYTBhNDI2NGM3MDhiNzk2NTRkZGVlMzEyNjgvdGFibGU6OTk1Y2ViMGQ1M2M2NGZkYTlhNTUwNmRiMzIyNjU3YzUvdGFibGVyYW5nZTo5OTVjZWIwZDUzYzY0ZmRhOWE1NTA2ZGIzMjI2NTdjNV8xMi0wLTEtMS0xNDY1NDI_efc8d3a9-227d-46ac-a5aa-c3af10fbb89c">Non-current portion</span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 32700000 29100000 26400000 24100000 21300000 122900000 256500000 45700000 210800000 24400000 186400000 P9Y8M12D 0.04 4 2 P5Y 20600000 Stockholders' Equity<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Charter authorizes the issuance of up to 5.0 million shares of preferred stock. The Board is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. No shares of preferred stock were outstanding for fiscal years 2022, 2021 or 2020.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the Company assumed Quidel’s 2018 Equity Incentive Plan, as amended and restated (the “Quidel Equity Plan”), including all form of award agreements and grants of awards issued thereunder, and shares of Quidel’s common stock (“Quidel Shares”) subject to the plan were replaced by an equivalent number of shares of QuidelOrtho’s common stock. In connection with the assumption of the Quidel Equity Plan, the Quidel Equity Plan was renamed the “QuidelOrtho Corporation Amended and Restated 2018 Equity Incentive Plan” (the “2018 Plan”) and all references to the “Company” in the Quidel Equity Plan were changed to QuidelOrtho. Also in connection with the Combinations, the Company assumed all obligations of Quidel pursuant to each stock option to purchase a Quidel Share and pursuant to each right to acquire or vest in a Quidel Share that was outstanding immediately prior to the closing of the Combinations, and all agreements relating to such equity awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options, time-based RSUs and performance-based RSUs (“PSUs”) to employees and non-employee directors under the 2018 Plan. Quidel previously granted stock options under its 2016 Equity Incentive Plan (the “2016 Plan”), Amended and Restated 2010 Equity Incentive Plan (the “2010 Plan”) and Amended and Restated 2001 Equity Incentive Plan (the “2001 Plan”). The 2016 Plan, 2010 Plan and 2001 Plan were terminated at the time of adoption of the Quidel Equity Plan, but the terminated plans continue to govern outstanding options granted thereunder. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has stock options, RSUs and PSUs outstanding, which were issued under these equity incentive plans to certain employees and non-employee directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $15.40 to $254.00 per share, and generally vest over four years. As of January 1, 2023, approximately 2.3 million shares of common stock remained available for grant and 4.1 million shares of common stock were reserved for future issuance under the 2018 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants both RSUs and PSUs to certain officers and directors. Until the restrictions lapse, ownership of the shares underlying the affected RSUs or PSUs is conditional upon continuous employment with the Company and/or achievement of certain performance goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years 2022, 2021 and 2020, the Company granted approximately 0.7 million, 0.1 million and 0.2 million shares of common stock, respectively, of RSUs to certain officers and directors, which either have a time-based, four-year vesting provision or performance-based vesting provision. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal years 2022, 2021 and 2020, RSUs were granted to certain members of the Board in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants was $0.6 million, $0.6 million and $0.5 million for fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Deferred Bonus Compensation Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years 2022, 2021 and 2020, certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the value of their cash bonus in the form of fully vested RSUs, plus a premium as additional RSUs, issued under the 2018 Plan. The premium RSUs are subject to a one-year vesting requirement from the date of issuance. The additional premium is determined based on the length of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the Company assumed Quidel’s 1983 Employee Stock Purchase Plan, as amended and restated (the “Quidel ESPP”), and the Quidel Shares subject to the Quidel ESPP were replaced by an equivalent number of shares of QuidelOrtho’s common stock. In connection with the assumption of the Quidel ESPP, the Quidel ESPP was renamed the “QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan” (the ESPP) and all references to the “Company” in the Quidel ESPP were changed to QuidelOrtho.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ESPP, full-time employees were allowed to purchase common stock through payroll deductions (which could not exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six-month purchase period. As of January 1, 2023, 736,630 shares of common stock remained available for future issuance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2018, Quidel announced a stock repurchase program to repurchase up to $50.0 million of its common stock, which was authorized by Quidel’s board of directors (the “Quidel Board”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on December 12, 2018. On August 28, 2020, the Board authorized an increase of an additional $150.0 million to Quidel’s existing stock repurchase program authorization, which was announced on September 1, 2020. The Board also extended the stock repurchase program through August 28, 2022. In connection with the consummation of the Combinations, Quidel’s stock repurchase program was terminated. On August 17, 2022, the Board authorized a stock repurchase program, allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024 (the “Stock Repurchase Program”).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2022, 953,468 shares of outstanding common stock were repurchased under the Stock Repurchase Program. As of January 1, 2023, the Company had approximately $225.7 million available under the Stock Repurchase Program. During fiscal years 2021 and 2020, 957,239 and 257,329 shares of outstanding common stock were repurchased under Quidel’s stock repurchase program.</span></div> 5000000 0 0 0 P10Y 15.40 254.00 P4Y 2300000 4100000 700000 100000 200000 P4Y 600000 600000 500000 0.50 1 P1Y P1Y 0.10 P2Y 0.20 P4Y 0.30 0.10 0.85 P6M 736630 50000000 150000000 300000000 953468 225700000 957239 257329 Stock-based Compensation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above includes $17.2 million of compensation expense related to liability-classified awards for fiscal year 2022, which has been or is expected to be settled in cash. These awards represent the $7.14 per share cash settled portion of the replacement awards issued in connection with the Combinations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal years 2022, 2021 and 2020, the Company recorded $3.7 million, $3.0 million and $2.2 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 10. During fiscal years 2022, 2021 and 2020, $3.3 million, $2.8 million and $2.1 million, respectively, were initially recorded as a component of accrued payroll and related expenses associated with the deferred bonus compensation program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of stock option activity for fiscal year 2022 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:37.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except price data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 2, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options assumed in the Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.23 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.53 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,774 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants, including grants related to options assumed in the Combinations presented separately:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assumed on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">May 27, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$106.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36.84</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) The replacement stock options granted to Ortho option holders on the closing date of the Combinations were issued consistent with the vesting conditions of the replaced award. The fair value on the closing date of the Combinations attributed to post-combination service, adjusted for estimated forfeitures, is recognized as expensed on a straight-line basis over the remaining vesting period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the US Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s determination of fair value is affected by the Company’s stock price, as well as a number of assumptions that require judgment. The total intrinsic value was $13.7 million, $9.9 million and $51.8 million for options exercised during fiscal years 2022, 2021, and 2020, respectively. As of January 1, 2023, total unrecognized compensation expense related to stock options was approximately $27.2 million and the related weighted-average period over which it is expected to be recognized is approximately 3.4 years. The maximum contractual term of the Company’s stock options is ten years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of RSU activity for fiscal year 2022 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except price data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at January 2, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards assumed in the Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.89 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized compensation expense related to non-vested RSUs as of January 1, 2023 was approximately $62.7 million, which is expected to be recognized over a weighted-average period of approximately 2.1 years.</span></div>The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date. The weighted-average fair value of RSUs granted during the fiscal years ended January 2, 2022 and January 3, 2021 was $188.06 and $101.20, respectively. <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2900000 2700000 2000000.0 4900000 4400000 3400000 27400000 18300000 15600000 30400000 0 0 65600000 25400000 21000000.0 17200000 7.14 3700000 3000000 2200000 3300000 2800000 2100000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of stock option activity for fiscal year 2022 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:37.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.692%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except price data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 2, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.71 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options assumed in the Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.23 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,122 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.53 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,774 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 722000 62.71 187000 100.45 1229000 96.10 383000 55.15 99000 115.95 1656000 90.34 P5Y6M10D 28140000 1600000 89.23 P5Y5M12D 28122000 1195000 80.53 P4Y7M9D 26774000 The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants, including grants related to options assumed in the Combinations presented separately:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assumed on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">May 27, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$106.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36.84</span></td></tr></table>(1) The replacement stock options granted to Ortho option holders on the closing date of the Combinations were issued consistent with the vesting conditions of the replaced award. The fair value on the closing date of the Combinations attributed to post-combination service, adjusted for estimated forfeitures, is recognized as expensed on a straight-line basis over the remaining vesting period. 0.0228 0.0196 0.0048 0.0118 P1Y9M10D P4Y9M18D P4Y11M26D P5Y1M13D 0.64 0.57 0.54 0.41 0 0 0 0 40.57 50.62 106.55 36.84 0 13700000 9900000 51800000 27200000 P3Y4M24D P10Y <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of RSU activity for fiscal year 2022 is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except price data)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at January 2, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock awards assumed in the Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.89 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 587000 95.81 720000 97.31 49000 99.60 248000 86.61 76000 100.70 1032000 98.89 62700000 P2Y1M6D 188.06 101.20 Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $247.8 million of purchase obligations as of January 1, 2023, the majority of which is expected to be purchased in the next year. These purchase obligations include agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including (i) fixed or minimum quantities to be purchased, (ii) fixed, minimum or variable price provisions and (iii) the approximate timing of the transaction, as well as amounts for planned inventory purchases under contractual arrangements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in litigation and other legal proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment, and other claims related to its business. The Company accrues for legal claims when, and to the extent that, amounts associated with the claims become probable and are reasonably estimable. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. Estimates of probable losses resulting from these matters are inherently difficult to predict. The actual costs of resolving legal claims may be substantially higher or lower than the amounts accrued for those claims. For those matters as to which the Company is not able to estimate a possible loss or range of loss, the Company is not able to determine whether the loss will have a material adverse effect on its business, financial condition, results of operations or liquidity. No accrual has been recorded as of January 1, 2023 and January 2, 2022 related to such matters as they are not probable and/or reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. However, the resolution of, or increase in any accruals for, one or more matters may have a material adverse effect on the Company’s results of operations and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensing Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various licensing and royalty agreements, which largely require payments by the Company based on specified product sales, as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $1.1 million, $2.0 million and $2.4 million for fiscal years 2022, 2021 and 2020, respectively.</span></div> 247800000 1100000 2000000 2400000 Fair Value Measurements<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy during fiscal years 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of funds held in money market accounts that are valued using quoted prices in active markets for identical instruments and highly liquid corporate debt securities with maturities within three months from purchase. Marketable securities consist of investment-grade corporate and government debt securities, corporate asset-backed securities and commercial paper. Derivative financial instruments are based on observable inputs that are corroborated by market data. Observable inputs include broker quotes, daily market foreign currency rates and forward pricing curves</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the BNP Business from Alere Inc., the Company will pay annual installments of up to $48.0 million each year through April 2023. The fair value of the payments treated as deferred consideration i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s calculated based on the net present value of cash payments using an estimated borrowing rate based on a quoted price for a similar liability. The fair value of the payments treated as contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are significant assumptions that are not observed in the market and, therefore, the resulting fair value represents a Level 3 measurement. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimated fair value of contingent consideration liabilities from January 3, 2021 through January 1, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration<br/>Liabilities<br/>(Level 3 Measurement)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, marketing and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div>The estimated fair value of the Company’s borrowings under the Term Loan was $2,630.3 million at January 1, 2023, compared to the carrying amount, excluding debt issuance costs, of $2,646.9 million. The estimate of fair value is generally based on the quoted market prices for similar issuances of long-term debt with the same maturities, which is classified as a Level 2 input. <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 600000 2100000 0 2700000 204700000 6600000 0 211300000 2000000.0 71100000 0 73100000 0 63600000 0 63600000 0 22000000.0 0 22000000.0 0 100000 0 100000 2600000 95200000 0 97800000 204700000 70300000 0 275000000.0 0 21800000 0 21800000 0 300000 0 300000 0 0 100000 100000 0 0 6100000 6100000 0 39300000 0 39300000 0 78400000 0 78400000 0 61100000 100000 61200000 0 78700000 6100000 84800000 48000000 48000000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimated fair value of contingent consideration liabilities from January 3, 2021 through January 1, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration<br/>Liabilities<br/>(Level 3 Measurement)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value, recorded in selling, marketing and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11900000 6000000.0 -200000 6100000 6000000.0 100000 2630300000 2646900000 Derivative Instruments and Hedging Activities<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company selectively uses derivative and non-derivative instruments to manage market risk associated with changes in interest rates and foreign currency exchange rates. The use of derivatives is intended for hedging purposes only, and the Company does not enter into derivative transactions for speculative purposes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk represents the Company’s gross exposure to potential accounting loss on derivative instruments that are outstanding or unsettled if all counterparties failed to perform according to the terms of the contract. The Company generally enters into master netting arrangements that reduce credit risk by permitting net settlement of transactions with the same counterparty. The Company does not have any derivative instruments with credit-risk related contingent features that would require it to post collateral.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Hedging Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s interest rate risk relates primarily to interest rate exposures on variable rate debt, including the Revolving Credit Facility and Term Loan. See Note 8 for additional information on the currently outstanding components of the Revolving Credit Facility and Term Loan. The Company entered into interest rate cap and swap agreements to hedge the related risk of the variability to the Company’s cash flows due to the rates specified for these credit facilities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designates certain interest rate derivative instruments as cash flow hedges, including the outstanding interest rate swaps. The Company records gains and losses due to changes in fair value of the derivatives within Other comprehensive income (loss) (“OCI”) and reclassifies these amounts to Interest expense, net in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the hedge is prospectively de-designated. Pre-tax unrealized gains of $25.1 million are expected to be reclassified from OCI to earnings in the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s interest rate derivative agreements as of January 1, 2023, all of which were interest rate swaps:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.303%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Notional Amount</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(In millions) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Hedge Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Expiration Date</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">500.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 1.58% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 29, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 31, 2023</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">397.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.765% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">144.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">216.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7675% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">288.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7575% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">252.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notional value of interest rate swap contracts with an effective date of December 30, 2022, is expected to increase to $1.8 billion on December 29, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company terminated its non-designated $1.0 billion notional value 3.428% interest rate cap. As a result of this termination in fiscal year 2022, the Company recognized an immaterial gain within Other expense (income), net and received $3.3 million of cash proceeds, presented within operating activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency Hedging Instruments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has currency risk exposures relating primarily to foreign currency denominated monetary assets and liabilities and forecasted foreign currency denominated intercompany and third-party transactions. The Company uses foreign currency forward contracts and may use option contracts and cross currency swaps to manage its currency risk exposures. The Company’s foreign currency forward contracts are denominated primarily in Australian Dollar, Brazilian Real, British Pound, Canadian Dollar, Chilean Peso, Chinese Yuan/Renminbi, Euro, Indian Rupee, Japanese Yen, Mexican Peso, Swiss Franc and the Thai Baht.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designates certain foreign currency forward contracts as cash flow hedges. The Company records gains and losses due to changes in fair value of the derivatives within OCI and reclassifies these amounts to Total revenues and Cost of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales, excluding amortization of intangibles in the same period or periods for which the underlying hedged transaction affects earnings. In the event the Company determines the hedged transaction is no longer probable to occur or concludes the hedge relationship is no longer effective, the hedge is prospectively de-designated. The pre-tax unrealized loss of $7.9 million within OCI as of January 1, 2023 is expected to be reclassified to earnings in the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into foreign currency forward contracts that are not part of designated hedging relationships and which are intended to mitigate exchange rate risk of monetary assets and liabilities and related forecasted transactions. The Company records these non-designated derivatives at mark-to-market with gains and losses recognized in earnings within Other expense (income), net. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of the currency hedging instruments outstanding as of January 1, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Notional Amount<br/>(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Hedge Designation</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">441.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash Flow Hedge</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Non-designated</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes pre-tax gains and losses from designated derivative and non-derivative instruments within accumulated other comprehensive (loss) income (“AOCI”) for fiscal year 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designated Hedging Instruments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Loss (Gain) Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Amounts Reclassified From AOCI Into Income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Loss (Gain) Reclassified From AOCI Into Income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts (sales)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts (purchases)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from designated derivative and non-derivative instruments within AOCI for fiscal years 2021 and 2020 were not material.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of designated and non-designated hedging instruments recognized within the Consolidated Balance Sheets as of January 1, 2023 and January 2, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMy0wLTEtMS0xNjEzNjE_8e8541e0-b8c0-4ccb-9851-8e78a9a9d7b9">Prepaid expenses and other current assets</span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfNS0wLTEtMS0xODQ2ODg_16833bb7-8f5c-4c67-9572-099ee990353c">Other liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfNS0wLTEtMS0xMzEzNTQ_1aade369-617d-4858-9f93-a42c32ce04e5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfNS0wLTEtMS0xMzEzNTQ_404f6aa7-f400-4bbd-9da9-c9cf0a9655cd">Prepaid expenses and other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfOC0wLTEtMS0xODQ2OTE_088572b4-7a08-4b4e-b2e6-000ed47087ed"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfOC0wLTEtMS0xODQ2OTE_19d98dcd-ed96-44a3-823a-c36b63d6e75b">Other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-designated hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMTItMC0xLTEtMTMxMzU0_8f09703c-ef6f-46cb-9ad7-ab88fdd85c2e">Prepaid expenses and other current assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMTUtMC0xLTEtMTg0Njk1_150f7767-588f-46cf-8fbf-367ffa97bb7f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMTUtMC0xLTEtMTg0Njk1_a91820c5-90db-41af-9417-d922922db7bc">Other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 25100000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s interest rate derivative agreements as of January 1, 2023, all of which were interest rate swaps:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.303%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Notional Amount</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(In millions) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Hedge Designation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Expiration Date</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">500.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 1.58% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 29, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 31, 2023</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">397.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.765% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">144.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">216.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7675% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">288.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7575% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">252.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pay 3.7725% fixed, receive floating rate (1-month USD-SOFR)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designated cash flow hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 27, 2027</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notional value of interest rate swap contracts with an effective date of December 30, 2022, is expected to increase to $1.8 billion on December 29, 2023.</span> 500000000.0 0.0158 397200000 0.03765 144400000 0.037725 216700000 0.037675 288900000 0.037575 252800000 0.037725 1800000000 1000000000 0.03428 3300000 -7900000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of the currency hedging instruments outstanding as of January 1, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.610%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Notional Amount<br/>(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Hedge Designation</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">441.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash Flow Hedge</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Non-designated</span></td></tr></table></div> 441600000 581700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes pre-tax gains and losses from designated derivative and non-derivative instruments within accumulated other comprehensive (loss) income (“AOCI”) for fiscal year 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Designated Hedging Instruments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Loss (Gain) Recognized in OCI on Hedges</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Amounts Reclassified From AOCI Into Income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Loss (Gain) Reclassified From AOCI Into Income</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts (sales)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts (purchases)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization of intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1300000 -2900000 3500000 -600000 -11400000 -1700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of designated and non-designated hedging instruments recognized within the Consolidated Balance Sheets as of January 1, 2023 and January 2, 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated cash flow hedges</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivatives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMy0wLTEtMS0xNjEzNjE_8e8541e0-b8c0-4ccb-9851-8e78a9a9d7b9">Prepaid expenses and other current assets</span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfNS0wLTEtMS0xODQ2ODg_16833bb7-8f5c-4c67-9572-099ee990353c">Other liabilities</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfNS0wLTEtMS0xMzEzNTQ_1aade369-617d-4858-9f93-a42c32ce04e5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfNS0wLTEtMS0xMzEzNTQ_404f6aa7-f400-4bbd-9da9-c9cf0a9655cd">Prepaid expenses and other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfOC0wLTEtMS0xODQ2OTE_088572b4-7a08-4b4e-b2e6-000ed47087ed"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfOC0wLTEtMS0xODQ2OTE_19d98dcd-ed96-44a3-823a-c36b63d6e75b">Other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-designated hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMTItMC0xLTEtMTMxMzU0_8f09703c-ef6f-46cb-9ad7-ab88fdd85c2e">Prepaid expenses and other current assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMTUtMC0xLTEtMTg0Njk1_150f7767-588f-46cf-8fbf-367ffa97bb7f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNmNDlkZDIzMDE2NTQxOWViMWZhOWY0Nzk2OTk4YTIzL3NlYzozZjQ5ZGQyMzAxNjU0MTllYjFmYTlmNDc5Njk5OGEyM183MC9mcmFnOjE4ZjYzYjhhOWQ1ZDRmZjc5MGU4NzRhNmE2MWY3Y2MyL3RhYmxlOmZiNDIwZGVhZTQzZTQzMGJhNTIxNThmNzlkOTY0NjNhL3RhYmxlcmFuZ2U6ZmI0MjBkZWFlNDNlNDMwYmE1MjE1OGY3OWQ5NjQ2M2FfMTUtMC0xLTEtMTg0Njk1_a91820c5-90db-41af-9417-d922922db7bc">Other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15900000 0 2100000 0 4600000 100000 14300000 200000 1500000 0 5400000 100000 Long-term Employee Benefits<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Benefit Plans and Other Post-employment Benefits</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Combinations, the Company assumed certain defined benefit plan obligations and acquired related plan assets for employees of non-U.S. subsidiaries. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these defined benefit plans, the Company also assumed one non-U.S. post-employment benefit plan and a replacement retiree health care reimbursement plan for certain U.S employees. The U.S. plan is funded on a pay-as-you-go basis and is not accepting new participants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obligation and Funded Status </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement date used to determine the defined benefit and other post-employment benefits obligations was January 1, 2023. The following tables set forth the changes to the projected benefit obligations (“PBO”) and plan assets:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assumed obligation from the Combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">33.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in plan assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Transfers in from the Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Funded status at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(13.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts recognized on the consolidated balance sheets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(13.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assumed obligation from the Combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts recognized on the consolidated balance sheets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net amount recognized</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(18.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PBO is the actuarial present value of benefits attributable to employee service rendered to date and reflects the effects of estimated future pay increases. The accumulated benefit obligation (“ABO”) is the actuarial present value of benefits attributable to employee service to date, but does not include the effects of estimated future pay increases. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the ABO for all defined benefit plans as of January 1, 2023. Further, the table reflects the aggregate PBO, ABO and fair value of plan assets for pension plans with PBO in excess of plan assets and for pension plans with ABO in excess of plan assets. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ABO</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plans with PBO in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PBO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plans with ABO in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PBO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ABO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.8</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pretax amounts that are not yet reflected in the net periodic benefit cost and are included in AOCI as of January 1, 2023 include the following: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated net actuarial gains (losses)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefits</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated net actuarial gains (losses)</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.7 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These accumulated net actuarial gains (losses) for defined benefit plans and other post-employment benefits primarily relate to differences between the actual net periodic expense and the expected net periodic expense from differences in significant assumptions, including primarily return on plan assets and discount rates used in these estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost for the Company’s defined benefit plans was $1.4 million for the fiscal year ended January 1, 2023 and was primarily related to service cost. Changes in plan assets and benefit obligations recognized in other comprehensive income was not material for fiscal year 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost for the Company’s other post-employment benefit plans was $0.7 million for the fiscal year ended January 1, 2023 and was primarily related to interest cost. Changes in benefit obligations recognized in other comprehensive income was not material for fiscal year 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost other than the service cost component are recorded in Other expense (income), net in the Consolidated Statements of Income. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assumptions and Sensitivities </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preliminary purchase price allocation for the Combinations, the Company recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following assumptions were used to measure the fair value of the benefit obligations and associated plan assets:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">May 27, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average rate of compensation increases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions used in determining the net periodic benefit cost for fiscal year 2022 are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average expected rate of compensation increases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rates used reflect the expected future cash flow based on plan provisions, participant data and the currencies in which the expected future cash flows will occur. For the majority of defined benefit obligations, the Company utilizes prevailing long-term high quality corporate bond indices applicable to the respective country at the measurement date. In countries where established corporate bond markets do not exist, the Company utilizes other index movement and duration analysis to determine discount rates. The long-term rate of return on plan assets assumptions reflect economic assumptions applicable to each country and assumptions related to the preliminary assessments regarding the type of investments to be held by the respective plans. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate is determined as of each measurement date, based on a review of yield rates associated with long-term, high-quality corporate bonds. The calculation separately discounts benefit payments using the spot rates from a long-term, high-quality corporate bond yield curve. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term rate of return on plan assets assumption represents the expected average rate of earnings on the funds invested to provide for the benefits included in the benefit obligations and is determined based on a number of factors, including historical market index returns, the anticipated long-term allocation of the plans, historical plan return data, plan expenses and the potential to outperform market index returns.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant factor in estimating future per capita cost of covered healthcare benefits for retirees is the healthcare cost trend rate assumption. The health care cost trend rate assumptions for other post-retirement benefit plans are as follows: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year - Pre-65</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year - Post-65</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2047</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anticipated Contributions to Defined Benefit Plans </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For funded plans, our policy is to fund amounts for defined benefit plans sufficient to meet minimum requirements set forth in applicable benefit and local tax laws. Based on the same assumptions used to measure the defined benefit obligations at January 1, 2023, the Company expects to contribute $2.0 million to defined benefit plans in fiscal year 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Future Benefit Payments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total benefit payments expected to be made for defined benefit plans and other long-term post-employment benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Other Post-employment Benefit Plans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Years 2028-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.5</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan Assets </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the fair value of the defined benefit pension plans by level within the fair value hierarchy, as described in Note 1, at January 1, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fair Value Measurements at January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. equity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other international equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other international government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded defined benefit plans in Japan, Belgium and Switzerland. The Japanese plan asset consists primarily of Japan equity and government bond securities, U.S. equity and government bond securities, other international equity and debt securities and cash and cash equivalents. The plan assets are invested in assets with quoted prices in active markets and therefore are classified as Level 1 assets. The Company’s investment strategy is to maintain a target rate of return that is higher than that required to maintain sound pension plan management into the future. In order to achieve its investment targets, the Company has established an asset composition ratio which was formulated from a long-term perspective, taking into account the maturity of the pension plan and other factors. The Company considers expected returns and risks of returns, as well as the correlation between the returns of each investment asset, the diversification of its investments, and other factors related to risk management in order to maximize returns in accordance with its targeted asset mix to achieve its investment targets. The target </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocation rates of the Japanese plan is 44% for debt securities, 55% for equity securities and 2% for other assets. The Belgium and Switzerland plan assets consist solely of insurance contracts that are pledged on behalf of employees with benefits in certain countries and are classified as Level 3 assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a roll-forward of activity for the Level 3 assets for fiscal year 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 3 Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 2, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Transfers in</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net purchases and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.6</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 1, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defined Contribution Plans </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company offers defined contribution plans to eligible employees primarily in the U.S., whereby employees contribute a portion of their compensation. Company matching and other Company contributions are also provided to the plans. Once Company matching contributions have been paid, the Company has no further payment obligations. The Company’s contributions for its employees totaled approximately $15.1 million, $3.8 million and $3.1 million for fiscal years ended 2022, 2021 and 2020, respectively, which are recognized as expense as incurred in the Consolidated Statements of Income. The increase in Company contributions for fiscal year 2022 was due to defined contribution plans assumed in connection with the Combinations.</span></div> 1 The following tables set forth the changes to the projected benefit obligations (“PBO”) and plan assets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assumed obligation from the Combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">33.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in plan assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Employer contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Transfers in from the Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Foreign currency exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Funded status at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(13.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts recognized on the consolidated balance sheets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net amount recognized</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(13.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in benefit obligation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assumed obligation from the Combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Projected benefit obligation at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts recognized on the consolidated balance sheets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net amount recognized</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(18.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table> 0 1200000 400000 300000 -600000 33300000 -200000 100000 33900000 0 -500000 1600000 300000 20100000 200000 -100000 20600000 -13300000 400000 300000 13400000 -13300000 18900000 300000 400000 700000 -700000 400000 18600000 3500000 15100000 -18600000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the ABO for all defined benefit plans as of January 1, 2023. Further, the table reflects the aggregate PBO, ABO and fair value of plan assets for pension plans with PBO in excess of plan assets and for pension plans with ABO in excess of plan assets. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ABO</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plans with PBO in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PBO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plans with ABO in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PBO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ABO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.8</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pretax amounts that are not yet reflected in the net periodic benefit cost and are included in AOCI as of January 1, 2023 include the following: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fiscal Year Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated net actuarial gains (losses)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefits</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated net actuarial gains (losses)</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.7 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 27100000 18300000 5100000 17000000.0 14300000 3800000 -200000 700000 1400000 700000 The following assumptions were used to measure the fair value of the benefit obligations and associated plan assets:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">May 27, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average rate of compensation increases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefit Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical assumptions used in determining the net periodic benefit cost for fiscal year 2022 are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average expected rate of compensation increases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Post-employment Benefit Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">%</span></td></tr></table></div> 0.022 0.031 0.026 0.030 0.040 0.055 0.022 0.026 0.025 0.040 The health care cost trend rate assumptions for other post-retirement benefit plans are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year - Pre-65</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year - Post-65</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2047</span></td></tr></table> 0.0644 0.0610 0.0400 2000000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total benefit payments expected to be made for defined benefit plans and other long-term post-employment benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Defined Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Other Post-employment Benefit Plans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Year 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fiscal Years 2028-2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.5</span></td></tr></table></div> 1700000 3500000 3500000 4000000.0 2100000 3300000 2200000 2200000 2300000 1900000 12600000 5500000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present the fair value of the defined benefit pension plans by level within the fair value hierarchy, as described in Note 1, at January 1, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Fair Value Measurements at January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. equity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other international equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other international government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Insurance contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a roll-forward of activity for the Level 3 assets for fiscal year 2022:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Level 3 Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 2, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Transfers in</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net purchases and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.6</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 1, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 2200000 2200000 0 0 3700000 3700000 0 0 1600000 1600000 0 0 200000 200000 0 0 500000 500000 0 0 1600000 1600000 0 0 4700000 4700000 0 0 6100000 0 0 6100000 20600000 14500000 0 6100000 0.44 0.55 0.02 0 5500000 600000 6100000 15100000 3800000 3100000 Related Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quotient Limited</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the consummation of the Combinations, the Company acquired Ortho’s Letter Agreement (the “Letter Agreement”), entered into in September 2020, with Quotient Limited (“Quotient”), in which Ortho partnered with Quotient to commercialize, when approved, the next generation product in immunohematology, a transfusion diagnostic patient immunohematology microarray intended for use with Quotient’s MosaiQ instruments (the “IH3 Microarray”) that enables a high level of multiplexing and addresses the ultra-high throughput market. Under the Letter Agreement, Ortho will have the right to distribute, market and sell the IH3 Microarrays in the European Economic Area, the U.K. and Switzerland (collectively, the “European Territory”) and the U.S., solely for use in testing the immunohematological profile of the blood of medical patients in the course of their care or treatment. Quotient retains the right to distribute, market and sell the IH3 Microarrays for use in blood donor testing worldwide and in the patient testing market outside of the European Territory and the U.S. Ortho’s rights with respect to the IH3 Microarray are exclusive so long as Ortho satisfies its obligation to meet annual minimum purchase volume requirements in each territory. Under the Letter Agreement, Ortho also has the non-exclusive right to sell and distribute MosaiQ instruments in the U.S. and the European Territory for use in testing the immunohematological profile of blood of medical patients in the course of their care or treatment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Letter Agreement, Ortho is also required to purchase the IH3 Microarrays, and the instruments, controls and reagents required for their use, only from Quotient at specified prices. Ortho is also required to make milestone payments to Quotient as specified </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestones and benchmarks are achieved. Ortho will be obligated to pay up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in milestone payments to Quotient upon its achievement of certain regulatory milestones and the achievement by Ortho of commercial sales benchmarks related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MosaiQ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including a milestone payment of up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the achievement by Ortho of certain cumulative gross revenue hurdl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es. The Company did not make such payments during fiscal year 2022. Due to the Company’s equity method investment held in Quotient, the Company concluded that Quotient is a related party of the Company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2023, Quotient filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Proceeding”). The Company is evaluating the impact of the Bankruptcy Proceeding and the related changes in Quotient’s business strategy on the Letter Agreement.</span></div>Under a separate supply agreement between Ortho and Alba Biosciences, a wholly owned subsidiary of Quotient, which was also acquired by the Company as a result of the consummation of the Combinations, the Company purchased inventories from Alba Biosciences amounting to $15.4 million during fiscal year 2022. As of January 1, 2023, Accounts payable included amounts related to purchases from Alba Biosciences of $3.7 million. 60000000 25000000 15400000 3700000 Accumulated Other Comprehensive Income (Loss) <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of AOCI, net of tax, was as follows for fiscal year 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension and Other Post-<br/>employment Benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-Sale Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period deferrals</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts related to fiscal years 2021 and 2020 were not material.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of AOCI, net of tax, was as follows for fiscal year 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension and Other Post-<br/>employment Benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-Sale Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Foreign Currency Translation Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period deferrals</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0 0 -100000 500000 400000 700000 6700000 -400000 -69800000 -62800000 0 5200000 0 0 5200000 700000 1500000 -400000 -69800000 -68000000.0 700000 1500000 -500000 -69300000 -67600000 EXCEL 121 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 122 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 123 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 124 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 391 615 1 false 152 0 false 10 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.quidel.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.quidel.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://www.quidel.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Income Sheet http://www.quidel.com/role/ConsolidatedStatementsofIncome Consolidated Statements of Income Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Stockholders' Equity Statement Sheet http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement Consolidated Statements of Stockholders' Equity Statement Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statements of Cash Flows Sheet http://www.quidel.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.quidel.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Business Combination Sheet http://www.quidel.com/role/BusinessCombination Business Combination Notes 10 false false R11.htm 0000011 - Disclosure - Computation of Earnings Per Share Sheet http://www.quidel.com/role/ComputationofEarningsPerShare Computation of Earnings Per Share Notes 11 false false R12.htm 0000012 - Disclosure - Revenue Sheet http://www.quidel.com/role/Revenue Revenue Notes 12 false false R13.htm 0000013 - Disclosure - Segment and Geographic Information Sheet http://www.quidel.com/role/SegmentandGeographicInformation Segment and Geographic Information Notes 13 false false R14.htm 0000014 - Disclosure - Income Taxes Sheet http://www.quidel.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 0000015 - Disclosure - Balance Sheet Account Details Sheet http://www.quidel.com/role/BalanceSheetAccountDetails Balance Sheet Account Details Notes 15 false false R16.htm 0000016 - Disclosure - Long-term Borrowings Sheet http://www.quidel.com/role/LongtermBorrowings Long-term Borrowings Notes 16 false false R17.htm 0000017 - Disclosure - Leases Sheet http://www.quidel.com/role/Leases Leases Notes 17 false false R18.htm 0000018 - Disclosure - Stockholders' Equity Sheet http://www.quidel.com/role/StockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 0000019 - Disclosure - Stock-Based Compensation Sheet http://www.quidel.com/role/StockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.quidel.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Fair Value Measurements Sheet http://www.quidel.com/role/FairValueMeasurements Fair Value Measurements Notes 21 false false R22.htm 0000022 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivities Derivative Instruments and Hedging Activities Notes 22 false false R23.htm 0000023 - Disclosure - Long-term Employee Benefits Sheet http://www.quidel.com/role/LongtermEmployeeBenefits Long-term Employee Benefits Notes 23 false false R24.htm 0000024 - Disclosure - Related Party Transactions Sheet http://www.quidel.com/role/RelatedPartyTransactions Related Party Transactions Notes 24 false false R25.htm 0000025 - Disclosure - Accumulated Other Comprehensive (Loss) Income Sheet http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncome Accumulated Other Comprehensive (Loss) Income Notes 25 false false R26.htm 0000026 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.quidel.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 0000027 - Disclosure - Business Combination (Tables) Sheet http://www.quidel.com/role/BusinessCombinationTables Business Combination (Tables) Tables http://www.quidel.com/role/BusinessCombination 27 false false R28.htm 0000028 - Disclosure - Computation of Earnings Per Share (Tables) Sheet http://www.quidel.com/role/ComputationofEarningsPerShareTables Computation of Earnings Per Share (Tables) Tables http://www.quidel.com/role/ComputationofEarningsPerShare 28 false false R29.htm 0000029 - Disclosure - Revenue (Tables) Sheet http://www.quidel.com/role/RevenueTables Revenue (Tables) Tables http://www.quidel.com/role/Revenue 29 false false R30.htm 0000030 - Disclosure - Segment and Geographic Information (Tables) Sheet http://www.quidel.com/role/SegmentandGeographicInformationTables Segment and Geographic Information (Tables) Tables http://www.quidel.com/role/SegmentandGeographicInformation 30 false false R31.htm 0000031 - Disclosure - Income Taxes (Tables) Sheet http://www.quidel.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.quidel.com/role/IncomeTaxes 31 false false R32.htm 0000032 - Disclosure - Balance Sheet Account Details (Tables) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsTables Balance Sheet Account Details (Tables) Tables http://www.quidel.com/role/BalanceSheetAccountDetails 32 false false R33.htm 0000033 - Disclosure - Long-term Borrowings (Tables) Sheet http://www.quidel.com/role/LongtermBorrowingsTables Long-term Borrowings (Tables) Tables http://www.quidel.com/role/LongtermBorrowings 33 false false R34.htm 0000034 - Disclosure - Leases (Tables) Sheet http://www.quidel.com/role/LeasesTables Leases (Tables) Tables http://www.quidel.com/role/Leases 34 false false R35.htm 0000035 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.quidel.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.quidel.com/role/StockBasedCompensation 35 false false R36.htm 0000036 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.quidel.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.quidel.com/role/FairValueMeasurements 36 false false R37.htm 0000037 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivities 37 false false R38.htm 0000038 - Disclosure - Long-term Employee Benefits (Tables) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsTables Long-term Employee Benefits (Tables) Tables http://www.quidel.com/role/LongtermEmployeeBenefits 38 false false R39.htm 0000039 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) Sheet http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeTables Accumulated Other Comprehensive (Loss) Income (Tables) Tables http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncome 39 false false R40.htm 0000040 - Disclosure - Summary of Significant Accounting Policies - Reclassifications (Details) Sheet http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails Summary of Significant Accounting Policies - Reclassifications (Details) Details 40 false false R41.htm 0000041 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies 41 false false R42.htm 0000042 - Disclosure - Business Combination - Narrative (Details) Sheet http://www.quidel.com/role/BusinessCombinationNarrativeDetails Business Combination - Narrative (Details) Details 42 false false R43.htm 0000043 - Disclosure - Business Combination - Purchase Price by Exchange Ratio (Details) Sheet http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails Business Combination - Purchase Price by Exchange Ratio (Details) Details 43 false false R44.htm 0000044 - Disclosure - Business Combination - Summary of Purchase Price (Details) Sheet http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails Business Combination - Summary of Purchase Price (Details) Details 44 false false R45.htm 0000045 - Disclosure - Business Combination - Goodwill Allocation (Details) Sheet http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails Business Combination - Goodwill Allocation (Details) Details 45 false false R46.htm 0000046 - Disclosure - Business Combination - Purchase Price Allocation of Intangible Assets (Details) Sheet http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails Business Combination - Purchase Price Allocation of Intangible Assets (Details) Details 46 false false R47.htm 0000047 - Disclosure - Business Combination - Pro Forma Information (Details) Sheet http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails Business Combination - Pro Forma Information (Details) Details 47 false false R48.htm 0000048 - Disclosure - Computation of Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails Computation of Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details) Details 48 false false R49.htm 0000049 - Disclosure - Revenue - Narrative (Details) Sheet http://www.quidel.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 49 false false R50.htm 0000050 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 50 false false R51.htm 0000051 - Disclosure - Revenue - Concentrations of Revenue and Credit Risk (Details) Sheet http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails Revenue - Concentrations of Revenue and Credit Risk (Details) Details 51 false false R52.htm 0000052 - Disclosure - Segment and Geographic Information - Additional Information (Details) Sheet http://www.quidel.com/role/SegmentandGeographicInformationAdditionalInformationDetails Segment and Geographic Information - Additional Information (Details) Details 52 false false R53.htm 0000053 - Disclosure - Segment and Geographic Information - Total Revenues by Reportable Segment (Details) Sheet http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails Segment and Geographic Information - Total Revenues by Reportable Segment (Details) Details 53 false false R54.htm 0000054 - Disclosure - Segment and Geographic Information - Reconciliation to Income (Details) Sheet http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails Segment and Geographic Information - Reconciliation to Income (Details) Details 54 false false R55.htm 0000055 - Disclosure - Segment and Geographic Information - Geographic Territory (Details) Sheet http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails Segment and Geographic Information - Geographic Territory (Details) Details 55 false false R56.htm 0000056 - Disclosure - Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) Sheet http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) Details 56 false false R57.htm 0000057 - Disclosure - Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) Sheet http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) Details 57 false false R58.htm 0000058 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) Sheet http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) Details 58 false false R59.htm 0000059 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 59 false false R60.htm 0000060 - Disclosure - Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) Sheet http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) Details 60 false false R61.htm 0000061 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits (Detail) Sheet http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail Income Taxes - Summary of Unrecognized Tax Benefits (Detail) Details 61 false false R62.htm 0000062 - Disclosure - Income Taxes - Rollforward of Valuation Allowance (Details) Sheet http://www.quidel.com/role/IncomeTaxesRollforwardofValuationAllowanceDetails Income Taxes - Rollforward of Valuation Allowance (Details) Details 62 false false R63.htm 0000063 - Disclosure - Balance Sheet Account Details - Additional Details (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails Balance Sheet Account Details - Additional Details (Details) Details 63 false false R64.htm 0000064 - Disclosure - Balance Sheet Account Details Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsCashCashEquivalentsandRestrictedCashDetails Balance Sheet Account Details Cash, Cash Equivalents and Restricted Cash (Details) Details 64 false false R65.htm 0000065 - Disclosure - Balance Sheet Account Details Marketable Securities (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails Balance Sheet Account Details Marketable Securities (Details) Details 65 false false R66.htm 0000066 - Disclosure - Balance Sheet Account Details Accounts Receivable (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableDetails Balance Sheet Account Details Accounts Receivable (Details) Details 66 false false R67.htm 0000067 - Disclosure - Balance Sheet Account Details - Accounts Receivable Allowance for Credit Loss Rollforward (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableAllowanceforCreditLossRollforwardDetails Balance Sheet Account Details - Accounts Receivable Allowance for Credit Loss Rollforward (Details) Details 67 false false R68.htm 0000068 - Disclosure - Balance Sheet Account Details Inventory (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails Balance Sheet Account Details Inventory (Details) Details 68 false false R69.htm 0000069 - Disclosure - Balance Sheet Account Details Prepaid expenses and other current assets (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails Balance Sheet Account Details Prepaid expenses and other current assets (Details) Details 69 false false R70.htm 0000070 - Disclosure - Balance Sheet Account Details - Property, Plant and Equipment (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails Balance Sheet Account Details - Property, Plant and Equipment (Details) Details 70 false false R71.htm 0000071 - Disclosure - Balance Sheet Account Details - Goodwill Rollforward (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails Balance Sheet Account Details - Goodwill Rollforward (Details) Details 71 false false R72.htm 0000072 - Disclosure - Balance Sheet Account Details - Goodwill and Intangible Assets (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails Balance Sheet Account Details - Goodwill and Intangible Assets (Details) Details 72 false false R73.htm 0000073 - Disclosure - Balance Sheet Account Details - Schedule of Future Amortization Expense (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsScheduleofFutureAmortizationExpenseDetails Balance Sheet Account Details - Schedule of Future Amortization Expense (Details) Details 73 false false R74.htm 0000074 - Disclosure - Balance Sheet Account Details Other Current Liabilities (Details) Sheet http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails Balance Sheet Account Details Other Current Liabilities (Details) Details 74 false false R75.htm 0000075 - Disclosure - Long-term Borrowings - Schedule of Borrowings (Details) Sheet http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails Long-term Borrowings - Schedule of Borrowings (Details) Details 75 false false R76.htm 0000076 - Disclosure - Long-term Borrowings - Narrative (Details) Sheet http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails Long-term Borrowings - Narrative (Details) Details 76 false false R77.htm 0000077 - Disclosure - Long-term Borrowings - Interest Expense (Details) Sheet http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails Long-term Borrowings - Interest Expense (Details) Details 77 false false R78.htm 0000078 - Disclosure - Long-term Borrowings - Schedule of Maturities (Details) Sheet http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails Long-term Borrowings - Schedule of Maturities (Details) Details 78 false false R79.htm 0000079 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.quidel.com/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 79 false false R80.htm 0000080 - Disclosure - Leases - Components of Lease Expense and Supplemental Cash Flow Information (Details) Sheet http://www.quidel.com/role/LeasesComponentsofLeaseExpenseandSupplementalCashFlowInformationDetails Leases - Components of Lease Expense and Supplemental Cash Flow Information (Details) Details 80 false false R81.htm 0000081 - Disclosure - Leases - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) Sheet http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail Leases - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) Details 81 false false R82.htm 0000082 - Disclosure - Stockholders' Equity (Details) Sheet http://www.quidel.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.quidel.com/role/StockholdersEquity 82 false false R83.htm 0000083 - Disclosure - Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Details) Sheet http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Details) Details 83 false false R84.htm 0000084 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 84 false false R85.htm 0000085 - Disclosure - Stock-Based Compensation - Summary of Status of Stock Option Activity (Details) Sheet http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails Stock-Based Compensation - Summary of Status of Stock Option Activity (Details) Details 85 false false R86.htm 0000086 - Disclosure - Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Details) Sheet http://www.quidel.com/role/StockBasedCompensationEstimatedFairValueofEachStockOptionAwardDetails Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Details) Details 86 false false R87.htm 0000087 - Disclosure - Stock-Based Compensation - Summary of Status of Stock Awards Activity (Details) Sheet http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails Stock-Based Compensation - Summary of Status of Stock Awards Activity (Details) Details 87 false false R88.htm 0000088 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.quidel.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.quidel.com/role/CommitmentsandContingencies 88 false false R89.htm 0000089 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 89 false false R90.htm 0000090 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 90 false false R91.htm 0000091 - Disclosure - Fair Value Measurements - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Details) Details 91 false false R92.htm 0000092 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details) Sheet http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails Derivative Instruments and Hedging Activities - Narrative (Details) Details 92 false false R93.htm 0000093 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value (Details) Sheet http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails Derivative Instruments and Hedging Activities - Schedule of Fair Value (Details) Details 93 false false R94.htm 0000094 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Gain (Loss) (Details) Sheet http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails Derivative Instruments and Hedging Activities - Schedule of Gain (Loss) (Details) Details 94 false false R95.htm 0000095 - Disclosure - Long-term Employee Benefits - Narrative (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails Long-term Employee Benefits - Narrative (Details) Details 95 false false R96.htm 0000096 - Disclosure - Long-term Employee Benefits - Projected Benefit Obligations (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails Long-term Employee Benefits - Projected Benefit Obligations (Details) Details 96 false false R97.htm 0000097 - Disclosure - Long-term Employee Benefits - Accumulated Benefit Obligation (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails Long-term Employee Benefits - Accumulated Benefit Obligation (Details) Details 97 false false R98.htm 0000098 - Disclosure - Long-term Employee Benefits - Schedule of AOCI (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails Long-term Employee Benefits - Schedule of AOCI (Details) Details 98 false false R99.htm 0000099 - Disclosure - Long-term Employee Benefits - Critical Assumptions Used (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails Long-term Employee Benefits - Critical Assumptions Used (Details) Details 99 false false R100.htm 0000100 - Disclosure - Long-term Employee Benefits - Schedule of Health Care Trend Rates (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails Long-term Employee Benefits - Schedule of Health Care Trend Rates (Details) Details 100 false false R101.htm 0000101 - Disclosure - Long-term Employee Benefits - Expected Benefit Payments (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails Long-term Employee Benefits - Expected Benefit Payments (Details) Details 101 false false R102.htm 0000102 - Disclosure - Long-term Employee Benefits - Fair Value Measurement (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails Long-term Employee Benefits - Fair Value Measurement (Details) Details 102 false false R103.htm 0000103 - Disclosure - Long-term Employee Benefits - Level 3 Rollforward (Details) Sheet http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails Long-term Employee Benefits - Level 3 Rollforward (Details) Details 103 false false R104.htm 0000104 - Disclosure - Related Party Transactions (Details) Sheet http://www.quidel.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.quidel.com/role/RelatedPartyTransactions 104 false false R105.htm 0000105 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details) Sheet http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails Accumulated Other Comprehensive (Loss) Income (Details) Details http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeTables 105 false false All Reports Book All Reports qdel-20230101.htm ex21110-kx2022.htm ex23110-kx2022.htm ex31101012023.htm ex31201012023.htm ex32101012023.htm ex3310-k2022.htm ex4210-kx2022.htm qdel-20230101.xsd qdel-20230101_cal.xml qdel-20230101_def.xml qdel-20230101_lab.xml qdel-20230101_pre.xml qdel-20230101_g1.jpg http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 126 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "qdel-20230101.htm": { "axisCustom": 5, "axisStandard": 38, "baseTaxonomies": { "http://fasb.org/srt/2022": 3, "http://fasb.org/us-gaap/2022": 1465, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 391, "dts": { "calculationLink": { "local": [ "qdel-20230101_cal.xml" ] }, "definitionLink": { "local": [ "qdel-20230101_def.xml" ] }, "inline": { "local": [ "qdel-20230101.htm" ] }, "labelLink": { "local": [ "qdel-20230101_lab.xml" ] }, "presentationLink": { "local": [ "qdel-20230101_pre.xml" ] }, "schema": { "local": [ "qdel-20230101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 960, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 18, "http://xbrl.sec.gov/dei/2022": 4, "total": 22 }, "keyCustom": 82, "keyStandard": 533, "memberCustom": 68, "memberStandard": 76, "nsprefix": "qdel", "nsuri": "http://www.quidel.com/20230101", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.quidel.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Business Combination", "menuCat": "Notes", "order": "10", "role": "http://www.quidel.com/role/BusinessCombination", "shortName": "Business Combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i540f7f793fd04c839206ebb5b0358715_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000100 - Disclosure - Long-term Employee Benefits - Schedule of Health Care Trend Rates (Details)", "menuCat": "Details", "order": "100", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails", "shortName": "Long-term Employee Benefits - Schedule of Health Care Trend Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i540f7f793fd04c839206ebb5b0358715_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i35d69af972a5473d9ed9d36362e44f1c_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000101 - Disclosure - Long-term Employee Benefits - Expected Benefit Payments (Details)", "menuCat": "Details", "order": "101", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails", "shortName": "Long-term Employee Benefits - Expected Benefit Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i35d69af972a5473d9ed9d36362e44f1c_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i87739d9ff1164341869f275d7515bfa0_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000102 - Disclosure - Long-term Employee Benefits - Fair Value Measurement (Details)", "menuCat": "Details", "order": "102", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "shortName": "Long-term Employee Benefits - Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i84040d4283884f6a84783625920ce885_I20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ia7f8cf6bfe1a44d39464f574aebbaee6_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000103 - Disclosure - Long-term Employee Benefits - Level 3 Rollforward (Details)", "menuCat": "Details", "order": "103", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails", "shortName": "Long-term Employee Benefits - Level 3 Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i57f2fc7be241453caa885125b94cc667_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i82381d8a554b4e9fafeedc2bad2f78b5_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:PaymentsForInventory", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000104 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "104", "role": "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i82381d8a554b4e9fafeedc2bad2f78b5_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:PaymentsForInventory", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000105 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)", "menuCat": "Details", "order": "105", "role": "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "shortName": "Accumulated Other Comprehensive (Loss) Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Computation of Earnings Per Share", "menuCat": "Notes", "order": "11", "role": "http://www.quidel.com/role/ComputationofEarningsPerShare", "shortName": "Computation of Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Revenue", "menuCat": "Notes", "order": "12", "role": "http://www.quidel.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Segment and Geographic Information", "menuCat": "Notes", "order": "13", "role": "http://www.quidel.com/role/SegmentandGeographicInformation", "shortName": "Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "14", "role": "http://www.quidel.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Balance Sheet Account Details", "menuCat": "Notes", "order": "15", "role": "http://www.quidel.com/role/BalanceSheetAccountDetails", "shortName": "Balance Sheet Account Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Long-term Borrowings", "menuCat": "Notes", "order": "16", "role": "http://www.quidel.com/role/LongtermBorrowings", "shortName": "Long-term Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Leases", "menuCat": "Notes", "order": "17", "role": "http://www.quidel.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "18", "role": "http://www.quidel.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "19", "role": "http://www.quidel.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.quidel.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "20", "role": "http://www.quidel.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "21", "role": "http://www.quidel.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Derivative Instruments and Hedging Activities", "menuCat": "Notes", "order": "22", "role": "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivities", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Long-term Employee Benefits", "menuCat": "Notes", "order": "23", "role": "http://www.quidel.com/role/LongtermEmployeeBenefits", "shortName": "Long-term Employee Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "24", "role": "http://www.quidel.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Accumulated Other Comprehensive (Loss) Income", "menuCat": "Notes", "order": "25", "role": "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncome", "shortName": "Accumulated Other Comprehensive (Loss) Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "26", "role": "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Business Combination (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.quidel.com/role/BusinessCombinationTables", "shortName": "Business Combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Computation of Earnings Per Share (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.quidel.com/role/ComputationofEarningsPerShareTables", "shortName": "Computation of Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.quidel.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "3", "role": "http://www.quidel.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Segment and Geographic Information (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.quidel.com/role/SegmentandGeographicInformationTables", "shortName": "Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.quidel.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Balance Sheet Account Details (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsTables", "shortName": "Balance Sheet Account Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Long-term Borrowings (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.quidel.com/role/LongtermBorrowingsTables", "shortName": "Long-term Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.quidel.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.quidel.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.quidel.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Long-term Employee Benefits (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsTables", "shortName": "Long-term Employee Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeTables", "shortName": "Accumulated Other Comprehensive (Loss) Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Reclassifications (Details)", "menuCat": "Details", "order": "40", "role": "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails", "shortName": "Summary of Significant Accounting Policies - Reclassifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "if53164b442544928a949984d5e6b875b_D20210104-20220102", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "41", "role": "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Business Combination - Narrative (Details)", "menuCat": "Details", "order": "42", "role": "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "shortName": "Business Combination - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i2eb7a9cdc2594559817d2254ffaf41ff_D20220527-20220527", "decimals": "-5", "lang": "en-US", "name": "qdel:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryStepUp", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i67bf919247b648f69579092ab7ac222d_D20220526-20220526", "decimals": "INF", "first": true, "lang": "en-US", "name": "qdel:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Business Combination - Purchase Price by Exchange Ratio (Details)", "menuCat": "Details", "order": "43", "role": "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "shortName": "Business Combination - Purchase Price by Exchange Ratio (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i67bf919247b648f69579092ab7ac222d_D20220526-20220526", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Business Combination - Summary of Purchase Price (Details)", "menuCat": "Details", "order": "44", "role": "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "shortName": "Business Combination - Summary of Purchase Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "idfb066e2fab945c2aba416f8b112a61f_D20220527-20220527", "decimals": "-5", "lang": "en-US", "name": "qdel:GainLossOnRedemptionPremium", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Business Combination - Goodwill Allocation (Details)", "menuCat": "Details", "order": "45", "role": "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails", "shortName": "Business Combination - Goodwill Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ifb8d8ecb2e5545bbbaeaa1361cd5ce06_I20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ia8565bc625944a70a5eec47ca737756a_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Business Combination - Purchase Price Allocation of Intangible Assets (Details)", "menuCat": "Details", "order": "46", "role": "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails", "shortName": "Business Combination - Purchase Price Allocation of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i152b902bf9eb4778aac3284da4f95eb7_D20220527-20230101", "decimals": null, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Business Combination - Pro Forma Information (Details)", "menuCat": "Details", "order": "47", "role": "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails", "shortName": "Business Combination - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i5ffdfbba419644b6a52189dd78b6576a_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Computation of Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details)", "menuCat": "Details", "order": "48", "role": "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails", "shortName": "Computation of Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Revenue - Narrative (Details)", "menuCat": "Details", "order": "49", "role": "http://www.quidel.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredRevenueNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Income", "menuCat": "Statements", "order": "5", "role": "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "50", "role": "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i492d334790d64ff6b21e4e4484466016_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i0d84f22271794079a3ff36a9604f1518_D20220103-20230101", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Revenue - Concentrations of Revenue and Credit Risk (Details)", "menuCat": "Details", "order": "51", "role": "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "shortName": "Revenue - Concentrations of Revenue and Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i0d84f22271794079a3ff36a9604f1518_D20220103-20230101", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Segment and Geographic Information - Additional Information (Details)", "menuCat": "Details", "order": "52", "role": "http://www.quidel.com/role/SegmentandGeographicInformationAdditionalInformationDetails", "shortName": "Segment and Geographic Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Segment and Geographic Information - Total Revenues by Reportable Segment (Details)", "menuCat": "Details", "order": "53", "role": "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails", "shortName": "Segment and Geographic Information - Total Revenues by Reportable Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "icf3d9f40f8f1402c8778e02daaed0269_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:SegmentAdjustedEBITDA", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Segment and Geographic Information - Reconciliation to Income (Details)", "menuCat": "Details", "order": "54", "role": "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "shortName": "Segment and Geographic Information - Reconciliation to Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:SegmentAdjustedEBITDA", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Segment and Geographic Information - Geographic Territory (Details)", "menuCat": "Details", "order": "55", "role": "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails", "shortName": "Segment and Geographic Information - Geographic Territory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail)", "menuCat": "Details", "order": "56", "role": "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail", "shortName": "Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail)", "menuCat": "Details", "order": "57", "role": "http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail", "shortName": "Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:DeferredTaxAssetsLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)", "menuCat": "Details", "order": "58", "role": "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail", "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:DeferredTaxAssetsLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Income Taxes - Additional Information (Detail)", "menuCat": "Details", "order": "59", "role": "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "menuCat": "Statements", "order": "6", "role": "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail)", "menuCat": "Details", "order": "60", "role": "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail", "shortName": "Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits (Detail)", "menuCat": "Details", "order": "61", "role": "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail", "shortName": "Income Taxes - Summary of Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Income Taxes - Rollforward of Valuation Allowance (Details)", "menuCat": "Details", "order": "62", "role": "http://www.quidel.com/role/IncomeTaxesRollforwardofValuationAllowanceDetails", "shortName": "Income Taxes - Rollforward of Valuation Allowance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "qdel:ValuationAllowanceDeferredTaxAssetAdditionsFromAcquisitionsAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:ReserveForContractRebates", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Balance Sheet Account Details - Additional Details (Details)", "menuCat": "Details", "order": "63", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails", "shortName": "Balance Sheet Account Details - Additional Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Balance Sheet Account Details Cash, Cash Equivalents and Restricted Cash (Details)", "menuCat": "Details", "order": "64", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsCashCashEquivalentsandRestrictedCashDetails", "shortName": "Balance Sheet Account Details Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Balance Sheet Account Details Marketable Securities (Details)", "menuCat": "Details", "order": "65", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails", "shortName": "Balance Sheet Account Details Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Balance Sheet Account Details Accounts Receivable (Details)", "menuCat": "Details", "order": "66", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableDetails", "shortName": "Balance Sheet Account Details Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Balance Sheet Account Details - Accounts Receivable Allowance for Credit Loss Rollforward (Details)", "menuCat": "Details", "order": "67", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableAllowanceforCreditLossRollforwardDetails", "shortName": "Balance Sheet Account Details - Accounts Receivable Allowance for Credit Loss Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Balance Sheet Account Details Inventory (Details)", "menuCat": "Details", "order": "68", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails", "shortName": "Balance Sheet Account Details Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:ReceivablesTransitionServiceAgreements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Balance Sheet Account Details Prepaid expenses and other current assets (Details)", "menuCat": "Details", "order": "69", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails", "shortName": "Balance Sheet Account Details Prepaid expenses and other current assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:ReceivablesTransitionServiceAgreements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ic6a38eea2456467596236365d0aad2ed_I20191229", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity Statement", "menuCat": "Statements", "order": "7", "role": "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement", "shortName": "Consolidated Statements of Stockholders' Equity Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ic6a38eea2456467596236365d0aad2ed_I20191229", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Balance Sheet Account Details - Property, Plant and Equipment (Details)", "menuCat": "Details", "order": "70", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails", "shortName": "Balance Sheet Account Details - Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Balance Sheet Account Details - Goodwill Rollforward (Details)", "menuCat": "Details", "order": "71", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails", "shortName": "Balance Sheet Account Details - Goodwill Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "qdel:GoodwillImpactOfSegmentRevisions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Balance Sheet Account Details - Goodwill and Intangible Assets (Details)", "menuCat": "Details", "order": "72", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails", "shortName": "Balance Sheet Account Details - Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Balance Sheet Account Details - Schedule of Future Amortization Expense (Details)", "menuCat": "Details", "order": "73", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsScheduleofFutureAmortizationExpenseDetails", "shortName": "Balance Sheet Account Details - Schedule of Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:CustomerIncentivePayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Balance Sheet Account Details Other Current Liabilities (Details)", "menuCat": "Details", "order": "74", "role": "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Account Details Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "qdel:CustomerIncentivePayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Long-term Borrowings - Schedule of Borrowings (Details)", "menuCat": "Details", "order": "75", "role": "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails", "shortName": "Long-term Borrowings - Schedule of Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "qdel:NumberOfFinancialCovenants", "reportCount": 1, "unique": true, "unitRef": "covenant", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Long-term Borrowings - Narrative (Details)", "menuCat": "Details", "order": "76", "role": "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "shortName": "Long-term Borrowings - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "qdel:NumberOfFinancialCovenants", "reportCount": 1, "unique": true, "unitRef": "covenant", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Long-term Borrowings - Interest Expense (Details)", "menuCat": "Details", "order": "77", "role": "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "shortName": "Long-term Borrowings - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Long-term Borrowings - Schedule of Maturities (Details)", "menuCat": "Details", "order": "78", "role": "http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails", "shortName": "Long-term Borrowings - Schedule of Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Leases - Additional Information (Detail)", "menuCat": "Details", "order": "79", "role": "http://www.quidel.com/role/LeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "8", "role": "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Leases - Components of Lease Expense and Supplemental Cash Flow Information (Details)", "menuCat": "Details", "order": "80", "role": "http://www.quidel.com/role/LeasesComponentsofLeaseExpenseandSupplementalCashFlowInformationDetails", "shortName": "Leases - Components of Lease Expense and Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Leases - Commitments for Minimum Rentals under Non-cancelable Leases (Detail)", "menuCat": "Details", "order": "81", "role": "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail", "shortName": "Leases - Commitments for Minimum Rentals under Non-cancelable Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "82", "role": "http://www.quidel.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesOutstanding", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ib3e997afea8f4a9e9289b94b57e2b5ba_I20210103", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Details)", "menuCat": "Details", "order": "83", "role": "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails", "shortName": "Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "id687ed163a764700b5334f96e9a5d09d_D20220103-20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "84", "role": "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Stock-Based Compensation - Summary of Status of Stock Option Activity (Details)", "menuCat": "Details", "order": "85", "role": "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Summary of Status of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "idfb066e2fab945c2aba416f8b112a61f_D20220527-20220527", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Details)", "menuCat": "Details", "order": "86", "role": "http://www.quidel.com/role/StockBasedCompensationEstimatedFairValueofEachStockOptionAwardDetails", "shortName": "Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "idfb066e2fab945c2aba416f8b112a61f_D20220527-20220527", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Stock-Based Compensation - Summary of Status of Stock Awards Activity (Details)", "menuCat": "Details", "order": "87", "role": "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails", "shortName": "Stock-Based Compensation - Summary of Status of Stock Awards Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49c77116984443739087649f7f9f23bf_I20220102", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "88", "role": "http://www.quidel.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "89", "role": "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.quidel.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ibd4820b387cf4d0f8c3cb629799f7edb_D20220103-20230101", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i74dc4c63dc714e9eae59cb55bce0fa74_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - Fair Value Measurements - Additional Information (Details)", "menuCat": "Details", "order": "90", "role": "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i74dc4c63dc714e9eae59cb55bce0fa74_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ia7f8cf6bfe1a44d39464f574aebbaee6_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - Fair Value Measurements - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Details)", "menuCat": "Details", "order": "91", "role": "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ia7f8cf6bfe1a44d39464f574aebbaee6_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000092 - Disclosure - Derivative Instruments and Hedging Activities - Narrative (Details)", "menuCat": "Details", "order": "92", "role": "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "shortName": "Derivative Instruments and Hedging Activities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000093 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Fair Value (Details)", "menuCat": "Details", "order": "93", "role": "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i9baeff4766f84153af026a4710f3ad4d_I20230101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ie2eeeaa0c04d450da8e635f21187bcb3_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000094 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Gain (Loss) (Details)", "menuCat": "Details", "order": "94", "role": "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Gain (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "ie2eeeaa0c04d450da8e635f21187bcb3_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "qdel:NumberOfNonUSPostEmploymentBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "post-employmentbenefitplan", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000095 - Disclosure - Long-term Employee Benefits - Narrative (Details)", "menuCat": "Details", "order": "95", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "shortName": "Long-term Employee Benefits - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "INF", "first": true, "lang": "en-US", "name": "qdel:NumberOfNonUSPostEmploymentBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "post-employmentbenefitplan", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i843541865bef4f52b4c37655790f48dc_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000096 - Disclosure - Long-term Employee Benefits - Projected Benefit Obligations (Details)", "menuCat": "Details", "order": "96", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails", "shortName": "Long-term Employee Benefits - Projected Benefit Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i843541865bef4f52b4c37655790f48dc_I20220102", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000097 - Disclosure - Long-term Employee Benefits - Accumulated Benefit Obligation (Details)", "menuCat": "Details", "order": "97", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails", "shortName": "Long-term Employee Benefits - Accumulated Benefit Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i49025bf143db4674b2c0bbe97fcb70ec_I20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i1f7c5427dea645f3960a320026b29118_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000098 - Disclosure - Long-term Employee Benefits - Schedule of AOCI (Details)", "menuCat": "Details", "order": "98", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails", "shortName": "Long-term Employee Benefits - Schedule of AOCI (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i1f7c5427dea645f3960a320026b29118_D20220103-20230101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i35d69af972a5473d9ed9d36362e44f1c_I20230101", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000099 - Disclosure - Long-term Employee Benefits - Critical Assumptions Used (Details)", "menuCat": "Details", "order": "99", "role": "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails", "shortName": "Long-term Employee Benefits - Critical Assumptions Used (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "qdel-20230101.htm", "contextRef": "i35d69af972a5473d9ed9d36362e44f1c_I20230101", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } } }, "segmentCount": 152, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails", "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r926", "r927", "r928" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r926", "r927", "r928" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r926", "r927", "r928" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r926", "r927", "r928" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus (Q1,Q2,Q3,FY)" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r924" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r924" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r924" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r930" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r924" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r924" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r924" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r924" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r926", "r927", "r928" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r923" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r925" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.quidel.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "qdel_AgencyBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency bonds", "label": "Agency bonds [Member]", "terseLabel": "Agency bonds" } } }, "localname": "AgencyBondsMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "qdel_AllowanceForContractRebatesAndDiscounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allowance for contract rebates and discounts", "label": "Allowance for contract rebates and discounts", "terseLabel": "Allowance for contract rebates and discounts" } } }, "localname": "AllowanceForContractRebatesAndDiscounts", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "qdel_AllowanceForDoubtfulAccounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allowance for doubtful accounts", "label": "Allowance for doubtful accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccounts", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "qdel_AmortizationExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization Expense", "label": "Amortization Expense [Member]", "terseLabel": "Amortization Expense" } } }, "localname": "AmortizationExpenseMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_AmortizationOfDeferredCloudComputingImplementationCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of deferred cloud computing implementation costs", "label": "Amortization of deferred cloud computing implementation costs", "negatedTerseLabel": "Amortization of deferred cloud computing implementation costs" } } }, "localname": "AmortizationOfDeferredCloudComputingImplementationCosts", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.quidel.com/20230101", "xbrltype": "stringItemType" }, "qdel_BNPBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BNP Business [Member]", "label": "BNP Business [Member]", "terseLabel": "BNP Business" } } }, "localname": "BNPBusinessMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "qdel_BankOfAmericaCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank Of America Credit Facility", "label": "Bank Of America Credit Facility [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "BankOfAmericaCreditFacilityMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "qdel_BusinessAcquisitionNumberOfCommonStockSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Number of Common Stock Shares Acquired", "label": "Business Acquisition, Number of Common Stock Shares Acquired", "terseLabel": "Business Acquisition, Number of Common Stock Shares Acquired" } } }, "localname": "BusinessAcquisitionNumberOfCommonStockSharesAcquired", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "sharesItemType" }, "qdel_BusinessAcquisitionNumberOfVestedStockOptionsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Number Of Vested Stock Options Acquired", "label": "Business Acquisition, Number Of Vested Stock Options Acquired", "terseLabel": "Business Acquisition, Number of Vested Stock Options Acquired" } } }, "localname": "BusinessAcquisitionNumberOfVestedStockOptionsAcquired", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "sharesItemType" }, "qdel_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableAfterCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, After Combination", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, After Combination", "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, After Combination" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableAfterCombination", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Cash Paid Per Acquiree Share", "terseLabel": "Cash paid to former Ortho stockholders per Ortho Share (in usd per share)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableCashPaidPerAcquireeShare", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "qdel_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued", "terseLabel": "Total Ortho shares subject to exchange (in shares)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssued", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "sharesItemType" }, "qdel_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share", "terseLabel": "Ortho Exchange Ratio (in usd per share)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableEntitySharesIssuedPerAcquireeShare", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "perShareItemType" }, "qdel_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePriorToCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Prior To Combination", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Prior To Combination", "terseLabel": "Fair value of replacement equity awards" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePriorToCombination", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationConsiderationTransferredTransactionCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Transaction Costs", "label": "Business Combination, Consideration Transferred, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessCombinationConsiderationTransferredTransactionCosts", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationContingentConsiderationArrangementsToBePaidRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, To Be Paid, Remainder Of Fiscal Year", "label": "Business Combination, Contingent Consideration Arrangements, To Be Paid, Remainder Of Fiscal Year", "terseLabel": "Installment payment through April 2023" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsToBePaidRemainderOfFiscalYear", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationContingentConsiderationArrangementsToBePaidYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, To Be Paid, Year One", "label": "Business Combination, Contingent Consideration Arrangements, To Be Paid, Year One", "terseLabel": "Installment payment each year" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsToBePaidYearOne", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayable": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 2.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Payable", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Payable", "negatedTerseLabel": "Measurement Period Adjustments, Accounts Payable" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayable", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 7.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable", "terseLabel": "Measurement Period Adjustments, Accounts Receivable" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedPayrollAndRelatedExpenses": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 1.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Payroll and Related Expenses", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accrued Payroll and Related Expenses", "negatedTerseLabel": "Measurement Period Adjustments, Accrued Payroll and Related Expenses" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccruedPayrollAndRelatedExpenses", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets", "totalLabel": "Measurement Period Adjustments, Total Assets" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCashAndCashEquivalents": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 2.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash And Cash Equivalents", "terseLabel": "Measurement Period Adjustments, Cash and Cash Equivalents" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCashAndCashEquivalents", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAndNoncurrentLiabilitiesOther": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 3.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current And Noncurrent Liabilities, Other", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Current And Noncurrent Liabilities, Other", "negatedTerseLabel": "Measurement Period Adjustments, Other Current and Non-current Liabilities" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCurrentAndNoncurrentLiabilitiesOther", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 5.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability", "negatedTerseLabel": "Measurement Period Adjustments, Deferred Income Tax Liability" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Liabilities", "negatedTotalLabel": "Measurement Period Adjustments, Total Liabilities" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLongTermDebt": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 4.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt", "negatedTerseLabel": "Measurement Period Adjustments, Accounts Receivable, Long-term borrowings, including current portion" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLongTermDebt", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 6.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses And Other Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses And Other Assets", "terseLabel": "Measurement Period Adjustments, Prepaid Expenses and Other Assets" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesAndOtherAssets", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayroll": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Payroll", "negatedTerseLabel": "Accrued payroll and related expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPayroll", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "totalLabel": "Total assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAndNoncurrentLiabilitiesOther": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current And Noncurrent Liabilities, Other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current And Noncurrent Liabilities, Other", "negatedTerseLabel": "Other current and non-current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAndNoncurrentLiabilitiesOther", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryStepUp": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Step-Up", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory, Step-Up", "terseLabel": "Step-Up, Inventory, Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventoryStepUp", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_BusinessUnitAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Unit", "label": "Business Unit [Axis]", "terseLabel": "Business Unit [Axis]" } } }, "localname": "BusinessUnitAxis", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "qdel_BusinessUnitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Unit [Domain]", "label": "Business Unit [Domain]", "terseLabel": "Business Unit [Domain]" } } }, "localname": "BusinessUnitDomain", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "qdel_COVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19", "label": "COVID-19 [Member]", "terseLabel": "COVID-19" } } }, "localname": "COVID19Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_ChangeInFairValueOfAcquisitionContingencies": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of acquisition contingencies", "label": "Change in fair value of acquisition contingencies", "negatedTerseLabel": "Change in fair value of acquisition contingencies" } } }, "localname": "ChangeInFairValueOfAcquisitionContingencies", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_ChangeInOperatingLeaseRightOfUseAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in operating lease right-of-use assets and liabilities", "label": "Change in operating lease right-of-use assets and liabilities", "terseLabel": "Net change in operating lease right-of-use assets and liabilities" } } }, "localname": "ChangeInOperatingLeaseRightOfUseAssetsAndLiabilities", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "qdel_ChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "China", "label": "China [Member]", "terseLabel": "China" } } }, "localname": "ChinaMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "qdel_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments", "terseLabel": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Milestone Payments" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "qdel_ConsiderationBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consideration B [Member]", "label": "Consideration B [Member]", "terseLabel": "Consideration B" } } }, "localname": "ConsiderationBMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "qdel_ConsiderationReceivedForCapitalExpendituresPaidButNotYetIncurred": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration Received for Capital Expenditures Paid but Not yet Incurred", "label": "Consideration Received for Capital Expenditures Paid but Not yet Incurred", "terseLabel": "Capital expenditures to be reimbursed under a government contract" } } }, "localname": "ConsiderationReceivedForCapitalExpendituresPaidButNotYetIncurred", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "qdel_ContractConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract Consideration", "label": "Contract Consideration", "terseLabel": "Contract Consideration" } } }, "localname": "ContractConsideration", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "qdel_CovenantPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period", "label": "Covenant Period [Axis]", "terseLabel": "Covenant Period [Axis]" } } }, "localname": "CovenantPeriodAxis", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "qdel_CovenantPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period [Domain]", "label": "Covenant Period [Domain]", "terseLabel": "Covenant Period [Domain]" } } }, "localname": "CovenantPeriodDomain", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_CumulativeChangeInOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Change In Ownership Percentage", "label": "Cumulative Change In Ownership Percentage", "terseLabel": "Cumulative changes in ownership (in percent)" } } }, "localname": "CumulativeChangeInOwnershipPercentage", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "qdel_Customer1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 1", "label": "Customer 1 [Member]", "terseLabel": "Customer 1" } } }, "localname": "Customer1Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_Customer2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 2", "label": "Customer 2 [Member]", "terseLabel": "Customer 2" } } }, "localname": "Customer2Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "domainItemType" }, "qdel_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "domainItemType" }, "qdel_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C [Member]", "label": "Customer C [Member]", "terseLabel": "Customer C" } } }, "localname": "CustomerCMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "domainItemType" }, "qdel_CustomerDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer D", "label": "Customer D [Member]", "terseLabel": "Customer D" } } }, "localname": "CustomerDMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "domainItemType" }, "qdel_CustomerEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer E", "label": "Customer E [Member]", "terseLabel": "Customer E" } } }, "localname": "CustomerEMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "domainItemType" }, "qdel_CustomerIncentivePayableCurrent": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Customer Incentive, Payable, Current", "label": "Customer Incentive, Payable, Current", "terseLabel": "Accrued commissions and rebates" } } }, "localname": "CustomerIncentivePayableCurrent", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "qdel_CustomersInExcessOf10TotalRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customers In Excess Of 10% Total Revenue", "label": "Customers In Excess Of 10% Total Revenue [Member]", "terseLabel": "Customers In Excess of 10% Total Revenue" } } }, "localname": "CustomersInExcessOf10TotalRevenueMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "domainItemType" }, "qdel_CustomersWithBalancesDueInExcessOf10OfAccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customers With Balances Due In Excess of 10% Of Accounts Receivable", "label": "Customers With Balances Due In Excess of 10% Of Accounts Receivable [Member]", "terseLabel": "Customers With Balances Due In Excess of 10% Of Accounts Receivable" } } }, "localname": "CustomersWithBalancesDueInExcessOf10OfAccountsReceivableMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_DebtInstrumentCovenantInterestCoverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Maximum", "terseLabel": "Debt Instrument, Covenant, Interest Coverage Ratio, Maximum" } } }, "localname": "DebtInstrumentCovenantInterestCoverageRatioMaximum", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "qdel_DebtInstrumentCovenantInterestCoverageRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum", "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum", "terseLabel": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum" } } }, "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "qdel_DebtInstrumentCovenantLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "terseLabel": "Debt Instrument, Covenant, Leverage Ratio, Maximum" } } }, "localname": "DebtInstrumentCovenantLeverageRatioMaximum", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "qdel_DebtInstrumentCovenantLeverageRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, Covenant, Leverage Ratio, Minimum", "label": "Debt instrument, Covenant, Leverage Ratio, Minimum", "terseLabel": "Debt instrument, Covenant, Leverage Ratio, Minimum" } } }, "localname": "DebtInstrumentCovenantLeverageRatioMinimum", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "qdel_DebtInstrumentPaymentPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment Period", "label": "Debt Instrument, Payment Period [Axis]", "terseLabel": "Debt Instrument, Payment Period [Axis]" } } }, "localname": "DebtInstrumentPaymentPeriodAxis", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "stringItemType" }, "qdel_DebtInstrumentPaymentPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment Period [Domain]", "label": "Debt Instrument, Payment Period [Domain]", "terseLabel": "Debt Instrument, Payment Period [Domain]" } } }, "localname": "DebtInstrumentPaymentPeriodDomain", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_DebtInstrumentPaymentPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Period One", "label": "Debt Instrument, Payment, Period One [Member]", "terseLabel": "Debt Instrument, Payment, Period One" } } }, "localname": "DebtInstrumentPaymentPeriodOneMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_DebtInstrumentPaymentPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Period Two", "label": "Debt Instrument, Payment, Period Two [Member]", "terseLabel": "Debt Instrument, Payment, Period Two" } } }, "localname": "DebtInstrumentPaymentPeriodTwoMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_DebtInstrumentPeriodicPaymentPercentOfInitialPrincipalAmountDue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due", "label": "Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due", "terseLabel": "Debt Instrument, Periodic Payment, Percent Of Initial Principal Amount Due" } } }, "localname": "DebtInstrumentPeriodicPaymentPercentOfInitialPrincipalAmountDue", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "pureItemType" }, "qdel_DebtSecurityGovernmentJapanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Security, Government, Japan", "label": "Debt Security, Government, Japan [Member]", "terseLabel": "Japan government bonds" } } }, "localname": "DebtSecurityGovernmentJapanMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_DebtSecurityGovernmentNonUSAndNonJapanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Security, Government, Non-US And Non-Japan", "label": "Debt Security, Government, Non-US And Non-Japan [Member]", "terseLabel": "Other international government bonds" } } }, "localname": "DebtSecurityGovernmentNonUSAndNonJapanMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "qdel_DeferredConsiderationCurrent": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Consideration, Current", "label": "Deferred Consideration, Current", "terseLabel": "Deferred consideration" } } }, "localname": "DeferredConsiderationCurrent", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "qdel_DeferredTaxAssetsLeaseLiability": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Lease Liability", "label": "Deferred Tax Assets, Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiability", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "qdel_DeferredTaxLiabilitiesRightofuseAssets": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Right-of-use Assets", "label": "Deferred Tax Liabilities, Right-of-use Assets", "negatedTerseLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesRightofuseAssets", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "qdel_DefinedBenefitPlanEquitySecuritiesJapanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Equity Securities, Japan", "label": "Defined Benefit Plan, Equity Securities, Japan [Member]", "terseLabel": "Japan equity securities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesJapanMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Equity Securities, Non-US And Non-Japan", "label": "Defined Benefit Plan, Equity Securities, Non-US And Non-Japan [Member]", "terseLabel": "Other international equity securities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesNonUSAndNonJapanMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "qdel_DefinedBenefitPlanInsuranceContractMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Insurance Contract", "label": "Defined Benefit Plan, Insurance Contract [Member]", "terseLabel": "Insurance contracts" } } }, "localname": "DefinedBenefitPlanInsuranceContractMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "qdel_DefinedBenefitPlanOtherAssetsJapanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Other Assets, Japan", "label": "Defined Benefit Plan, Other Assets, Japan [Member]", "terseLabel": "Other assets, Japan" } } }, "localname": "DefinedBenefitPlanOtherAssetsJapanMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_DerivativeInstrumentsAndOther": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative instruments and other", "label": "Derivative instruments and other", "terseLabel": "Derivative instruments and other" } } }, "localname": "DerivativeInstrumentsAndOther", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "qdel_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document And Entity Information [Abstract]", "terseLabel": "Document And Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.quidel.com/20230101", "xbrltype": "stringItemType" }, "qdel_EMEASegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EMEA Segment", "label": "EMEA Segment [Member]", "terseLabel": "EMEA" } } }, "localname": "EMEASegmentMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "qdel_EUMedicalDeviceRegulationTransitionCosts2": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "EU medical device regulation transition costs (2)", "label": "EU medical device regulation transition costs (2)", "negatedTerseLabel": "EU medical device regulation transition costs" } } }, "localname": "EUMedicalDeviceRegulationTransitionCosts2", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_EmployeeCompensationChargesAndOtherCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employee compensation charges and other costs", "label": "Employee compensation charges and other costs", "negatedTerseLabel": "Employee compensation charges and other costs" } } }, "localname": "EmployeeCompensationChargesAndOtherCosts", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_EmployeeDeferredBonusCompensationProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Deferred Bonus Compensation Program", "label": "Employee Deferred Bonus Compensation Program [Member]", "terseLabel": "Employee Deferred Bonus Compensation Program" } } }, "localname": "EmployeeDeferredBonusCompensationProgramMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "qdel_EndingAfterInitialMeasurementPeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ending After Initial Measurement Period", "label": "Ending After Initial Measurement Period [Member]", "terseLabel": "Ending after initial measurement period" } } }, "localname": "EndingAfterInitialMeasurementPeriodMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_EndingAfterTheClosingDateOfTheCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ending After The Closing Date Of The Credit Agreement", "label": "Ending After The Closing Date Of The Credit Agreement [Member]", "terseLabel": "Ending after the closing date of the credit agreement" } } }, "localname": "EndingAfterTheClosingDateOfTheCreditAgreementMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan", "label": "Equity Incentive Plan [Member]", "terseLabel": "Equity Incentive Plan" } } }, "localname": "EquityIncentivePlanMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "qdel_ExpectedValueContractCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected Value Contract Customers", "label": "Expected Value Contract Customers [Member]", "terseLabel": "Expected Value Contract Customers" } } }, "localname": "ExpectedValueContractCustomersMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_GainLossOnRedemptionPremium": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Redemption Premium", "label": "Gain (Loss) On Redemption Premium", "terseLabel": "Gain (Loss) On Redemption Premium" } } }, "localname": "GainLossOnRedemptionPremium", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_GoodwillImpactOfSegmentRevisions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Goodwill, Impact Of Segment Revisions", "label": "Goodwill, Impact Of Segment Revisions", "terseLabel": "Impact of reportable segment revisions" } } }, "localname": "GoodwillImpactOfSegmentRevisions", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "qdel_IncomeTaxReconciliationPermanentDifference": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation permanent difference.", "label": "Income Tax Reconciliation Permanent Difference", "terseLabel": "Permanent differences" } } }, "localname": "IncomeTaxReconciliationPermanentDifference", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "qdel_IncomeTaxesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Taxes Disclosure [Line Items]", "label": "Income Taxes Disclosure [Line Items]", "terseLabel": "Income Taxes Disclosure [Line Items]" } } }, "localname": "IncomeTaxesDisclosureLineItems", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "qdel_IndemnificationReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indemnification Receivable", "label": "Indemnification Receivable", "terseLabel": "Indemnification receivable" } } }, "localname": "IndemnificationReceivable", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "qdel_IndustryAndGeographicInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Industry and Geographic Information [Abstract]", "label": "Industry And Geographic Information [Abstract]", "terseLabel": "Industry And Geographic Information [Abstract]" } } }, "localname": "IndustryAndGeographicInformationAbstract", "nsuri": "http://www.quidel.com/20230101", "xbrltype": "stringItemType" }, "qdel_InfluenzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Influenza", "label": "Influenza [Member]", "terseLabel": "Influenza" } } }, "localname": "InfluenzaMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_InstrumentsAvailableForLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments available for lease.", "label": "Instruments Available For Lease [Member]", "terseLabel": "Customer leased instruments" } } }, "localname": "InstrumentsAvailableForLeaseMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "qdel_InterestRateSwapFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Five", "label": "Interest Rate Swap Five [Member]", "terseLabel": "Interest Rate Swap Five" } } }, "localname": "InterestRateSwapFiveMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_InterestRateSwapFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Four", "label": "Interest Rate Swap Four [Member]", "terseLabel": "Interest Rate Swap Four" } } }, "localname": "InterestRateSwapFourMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_InterestRateSwapOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap One", "label": "Interest Rate Swap One [Member]", "terseLabel": "Interest Rate Swap One" } } }, "localname": "InterestRateSwapOneMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_InterestRateSwapThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Three", "label": "Interest Rate Swap Three [Member]", "terseLabel": "Interest Rate Swap Three" } } }, "localname": "InterestRateSwapThreeMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_InterestRateSwapTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Two", "label": "Interest Rate Swap Two [Member]", "terseLabel": "Interest Rate Swap Two" } } }, "localname": "InterestRateSwapTwoMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_InventoriesIncludingNoncurrentPortionNet": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories, including noncurrent portion, net", "label": "Inventories, including noncurrent portion, net", "totalLabel": "Inventories, including noncurrent portion, net" } } }, "localname": "InventoriesIncludingNoncurrentPortionNet", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "qdel_LabsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Labs", "label": "Labs [Member]", "terseLabel": "Labs" } } }, "localname": "LabsMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "qdel_LeaseNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease name", "label": "Lease name [Axis]", "terseLabel": "Lease name [Axis]" } } }, "localname": "LeaseNameAxis", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "qdel_LeaseNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease name [Domain]", "label": "Lease name [Domain]", "terseLabel": "Lease name [Domain]" } } }, "localname": "LeaseNameDomain", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "qdel_LengthOfTimeOfDeferralPeriodUnderConditionOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Length of time of deferral period under condition one.", "label": "Length Of Time Of Deferral Period Under Condition One", "terseLabel": "Length of time of deferral period, condition one (in years)" } } }, "localname": "LengthOfTimeOfDeferralPeriodUnderConditionOne", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "qdel_LengthOfTimeOfDeferralPeriodUnderConditionThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Length of time of deferral period under condition three.", "label": "Length Of Time Of Deferral Period Under Condition Three", "terseLabel": "Length of time of deferral period, condition three (in years)" } } }, "localname": "LengthOfTimeOfDeferralPeriodUnderConditionThree", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "qdel_LengthOfTimeOfDeferralPeriodUnderConditionTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Length of time of deferral period under condition two.", "label": "Length Of Time Of Deferral Period Under Condition Two", "terseLabel": "Length of time of deferral period, condition two (in years)" } } }, "localname": "LengthOfTimeOfDeferralPeriodUnderConditionTwo", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "qdel_LesseeOperatingSubleaseOptionToExtendNumberOfAdditionalTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Sublease, Option to Extend, Number of Additional Terms", "label": "Lessee, Operating Sublease, Option to Extend, Number of Additional Terms", "terseLabel": "Number of additional terms" } } }, "localname": "LesseeOperatingSubleaseOptionToExtendNumberOfAdditionalTerms", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "qdel_LocationsNotIncludingNorthAmericaEMEAAndChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Locations Not Including North America, EMEA, and China", "label": "Locations Not Including North America, EMEA, and China [Member]", "terseLabel": "Other" } } }, "localname": "LocationsNotIncludingNorthAmericaEMEAAndChinaMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails" ], "xbrltype": "domainItemType" }, "qdel_LongTermInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-Term Investments", "label": "Long-Term Investments [Member]", "terseLabel": "Long-Term Investments" } } }, "localname": "LongTermInvestmentsMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "qdel_LossOnExtinguishmentOfDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss On Extinguishment Of Debt", "label": "Loss On Extinguishment Of Debt [Member]", "terseLabel": "Loss on Extinguishment of Debt" } } }, "localname": "LossOnExtinguishmentOfDebtMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_MolecularDiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular Diagnostics", "label": "Molecular Diagnostics [Member]", "terseLabel": "Molecular Diagnostics" } } }, "localname": "MolecularDiagnosticsMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "qdel_MosaicQMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MosaicQ", "label": "MosaicQ [Member]", "terseLabel": "MosaicQ" } } }, "localname": "MosaicQMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "qdel_NOLExpirationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NOL Expiration Status", "label": "NOL Expiration Status [Axis]", "terseLabel": "NOL Expiration Status [Axis]" } } }, "localname": "NOLExpirationStatusAxis", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "qdel_NOLExpirationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NOL Expiration Status [Domain]", "label": "NOL Expiration Status [Domain]", "terseLabel": "NOL Expiration Status [Domain]" } } }, "localname": "NOLExpirationStatusDomain", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "qdel_NonEmployeeDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non employee director.", "label": "Non Employee Director [Member]", "terseLabel": "Non Employee Director" } } }, "localname": "NonEmployeeDirectorMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "qdel_NoncashOfPartNoncashAcquisitionFixedAssetsTransferredFromInventories": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash of Part Noncash Acquisition, Fixed Assets transferred from inventories", "label": "Noncash of Part Noncash Acquisition, Fixed Assets transferred from inventories", "terseLabel": "Transfer of instrument inventories to fixed assets" } } }, "localname": "NoncashOfPartNoncashAcquisitionFixedAssetsTransferredFromInventories", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "qdel_NorthAmericaSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "North America Segment", "label": "North America Segment [Member]", "terseLabel": "North America" } } }, "localname": "NorthAmericaSegmentMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "qdel_NotSubjectToExpirationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Not subject to expiration", "label": "Not subject to expiration [Member]", "terseLabel": "Not subject to expiration" } } }, "localname": "NotSubjectToExpirationMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "qdel_NumberOfBuildings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Buildings", "label": "Number Of Buildings", "terseLabel": "Number of buildings" } } }, "localname": "NumberOfBuildings", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "qdel_NumberOfFinancialCovenants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Financial Covenants", "label": "Number Of Financial Covenants", "terseLabel": "Number of financial covenants" } } }, "localname": "NumberOfFinancialCovenants", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "integerItemType" }, "qdel_NumberOfNonUSPostEmploymentBenefitPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Non-US Post-Employment Benefit Plans", "label": "Number Of Non-US Post-Employment Benefit Plans", "terseLabel": "Number of non-US post employment benefit plans" } } }, "localname": "NumberOfNonUSPostEmploymentBenefitPlans", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "integerItemType" }, "qdel_OrthoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ortho", "label": "Ortho [Member]", "terseLabel": "Ortho" } } }, "localname": "OrthoMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails", "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails", "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "qdel_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other nonreportable segments", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "qdel_OtherNotIncludingNorthAmericaEMEAAndChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other, Not Including North America, EMEA, And China", "label": "Other, Not Including North America, EMEA, And China [Member]", "terseLabel": "Other" } } }, "localname": "OtherNotIncludingNorthAmericaEMEAAndChinaMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "qdel_PatentsAndTrademarksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patents and trademarks.", "label": "Patents And Trademarks [Member]", "terseLabel": "Patent and trademark costs" } } }, "localname": "PatentsAndTrademarksMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "qdel_PayablesTransitionServiceAgreements": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payables, Transition Service Agreements", "label": "Payables, Transition Service Agreements", "terseLabel": "Payables under transition services agreements" } } }, "localname": "PayablesTransitionServiceAgreements", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "qdel_PaymentOfAccretedInterestOnContingentConsiderationLiabilityAndDeferredConsiderationOperatingActivities": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Accreted Interest On Contingent Consideration Liability And Deferred Consideration, Operating Activities", "label": "Payment Of Accreted Interest On Contingent Consideration Liability And Deferred Consideration, Operating Activities", "negatedTerseLabel": "Payment of accreted interest on contingent and deferred consideration" } } }, "localname": "PaymentOfAccretedInterestOnContingentConsiderationLiabilityAndDeferredConsiderationOperatingActivities", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "qdel_PaymentOnAcquisitionDeferredConsideration": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment On Acquisition Deferred Consideration", "label": "Payment On Acquisition Deferred Consideration", "negatedTerseLabel": "Principal payments of deferred consideration" } } }, "localname": "PaymentOnAcquisitionDeferredConsideration", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "qdel_PaymentsForInventory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Inventory", "label": "Payments For Inventory", "terseLabel": "Payments For Inventory" } } }, "localname": "PaymentsForInventory", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "qdel_PaymentsOnConvertibleNotesAndDerivativeLiability": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments on convertible notes and derivative liability", "label": "Payments on convertible notes and derivative liability", "negatedTerseLabel": "Payment on Convertible Senior Note and Derivative Liability" } } }, "localname": "PaymentsOnConvertibleNotesAndDerivativeLiability", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "qdel_PercentageOfCashValueOfCashBonusOfficersCouldElectToReceiveInFormOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cash value of cash bonus officers could elect to receive in form of restricted stock.", "label": "Percentage Of Cash Value Of Cash Bonus Officers Could Elect To Receive In Form Of Restricted Stock", "terseLabel": "Percentage of cash value of cash bonus officers can elect to receive in form of restricted stock (in percent)" } } }, "localname": "PercentageOfCashValueOfCashBonusOfficersCouldElectToReceiveInFormOfRestrictedStock", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "qdel_PercentageOfPremiumOnAmountDeferredBasedOnLengthOfTimeForOneYearUnderConditionOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of premium on amount deferred based on length of time for one year under condition one.", "label": "Percentage Of Premium On Amount Deferred Based On Length Of Time For One Year Under Condition One", "terseLabel": "Percentage of premium on the amount deferred, condition one (in percent)" } } }, "localname": "PercentageOfPremiumOnAmountDeferredBasedOnLengthOfTimeForOneYearUnderConditionOne", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "qdel_PercentageOfPremiumOnAmountDeferredBasedOnLengthOfTimeForOneYearUnderConditionThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of premium on amount deferred based on length of time for four years under condition three", "label": "Percentage Of Premium On Amount Deferred Based On Length Of Time For One Year Under Condition Three", "terseLabel": "Percentage of premium on the amount deferred, condition three (in percent)" } } }, "localname": "PercentageOfPremiumOnAmountDeferredBasedOnLengthOfTimeForOneYearUnderConditionThree", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "qdel_PercentageOfPremiumOnAmountDeferredBasedOnLengthOfTimeForOneYearUnderConditionTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of premium on amount deferred based on length of time for two years under condition two", "label": "Percentage Of Premium On Amount Deferred Based On Length Of Time For One Year Under Condition Two", "terseLabel": "Percentage of premium on the amount deferred, condition two (in percent)" } } }, "localname": "PercentageOfPremiumOnAmountDeferredBasedOnLengthOfTimeForOneYearUnderConditionTwo", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "qdel_PeriodOfCumulativeChangesInOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period Of Cumulative Changes In Ownership", "label": "Period Of Cumulative Changes In Ownership", "terseLabel": "Period of cumulative changes in ownership (in years)" } } }, "localname": "PeriodOfCumulativeChangesInOwnership", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "qdel_PointOfCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Point-of-Care", "label": "Point-of-Care [Member]", "terseLabel": "Point of Care" } } }, "localname": "PointOfCareMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "qdel_PostretirementHealthCoveragePost65Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Postretirement Health Coverage - Post-65", "label": "Postretirement Health Coverage - Post-65 [Member]", "terseLabel": "Postretirement Health Coverage - Post-65" } } }, "localname": "PostretirementHealthCoveragePost65Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "domainItemType" }, "qdel_PostretirementHealthCoveragePre65Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Postretirement Health Coverage - Pre 65", "label": "Postretirement Health Coverage - Pre 65 [Member]", "terseLabel": "Postretirement Health Coverage - Pre 65" } } }, "localname": "PostretirementHealthCoveragePre65Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "domainItemType" }, "qdel_ProductShipmentCostPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Shipment Cost, Policy", "label": "Product Shipment Cost, Policy [Policy Text Block]", "terseLabel": "Product Shipment Cost, Policy" } } }, "localname": "ProductShipmentCostPolicyPolicyTextBlock", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "qdel_PurchasedTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased Technology [Member]", "label": "Purchased Technology [Member]", "terseLabel": "Purchased technology" } } }, "localname": "PurchasedTechnologyMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "qdel_QuidelConsolidatedEntitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quidel Consolidated Entities", "label": "Quidel Consolidated Entities [Member]", "terseLabel": "Quidel Consolidated Entities" } } }, "localname": "QuidelConsolidatedEntitiesMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails" ], "xbrltype": "domainItemType" }, "qdel_QuidelOrthoCorporationAmendedAndRestated1983EmployeeStockPurchasePlanESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan \"ESPP\"", "label": "QuidelOrtho Corporation Amended and Restated 1983 Employee Stock Purchase Plan \"ESPP\" [Member]", "terseLabel": "ESPP" } } }, "localname": "QuidelOrthoCorporationAmendedAndRestated1983EmployeeStockPurchasePlanESPPMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "qdel_QuidelOrthoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "QuidelOrtho", "label": "QuidelOrtho [Member]", "terseLabel": "QuidelOrtho" } } }, "localname": "QuidelOrthoMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "domainItemType" }, "qdel_QuotientMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quotient", "label": "Quotient [Member]", "terseLabel": "Quotient" } } }, "localname": "QuotientMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "qdel_QuotientSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quotient Subsidiary", "label": "Quotient Subsidiary [Member]", "terseLabel": "Quotient Subsidiary" } } }, "localname": "QuotientSubsidiaryMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "qdel_ReceivableForStockOptionExercises": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivable For Stock Option Exercises", "label": "Receivable For Stock Option Exercises", "terseLabel": "Reduction of other current liabilities upon issuance of restricted share units" } } }, "localname": "ReceivableForStockOptionExercises", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "qdel_ReceivablesTransitionServiceAgreements": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables, Transition Service Agreements", "label": "Receivables, Transition Service Agreements", "terseLabel": "Other receivables" } } }, "localname": "ReceivablesTransitionServiceAgreements", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "qdel_ReserveForContractRebates": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reserve for Contract Rebates", "label": "Reserve for Contract Rebates", "terseLabel": "Reserve for Contract Rebates" } } }, "localname": "ReserveForContractRebates", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "qdel_SegmentAdjustedEBITDA": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Segment Adjusted EBITDA", "label": "Segment Adjusted EBITDA", "negatedTerseLabel": "Segment Adjusted EBITDA" } } }, "localname": "SegmentAdjustedEBITDA", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_SellingMarketingAndAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Selling, Marketing, And Administrative Expense", "label": "Selling, Marketing, And Administrative Expense [Member]", "terseLabel": "Selling, Marketing, and Administrative Expense" } } }, "localname": "SellingMarketingAndAdministrativeExpenseMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "qdel_SeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2025", "label": "Senior Notes Due 2025 [Member]", "terseLabel": "Senior Notes Due 2025" } } }, "localname": "SeniorNotesDue2025Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "qdel_SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Notes Due 2028", "label": "Senior Notes Due 2028 [Member]", "terseLabel": "Senior Notes Due 2028" } } }, "localname": "SeniorNotesDue2028Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "qdel_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "terseLabel": "Purchase period (in months)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "qdel_ShareBasedCompensationExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Expense", "label": "Share-Based Compensation Expense [Member]", "terseLabel": "Share-Based Compensation Expense" } } }, "localname": "ShareBasedCompensationExpenseMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "qdel_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "stringItemType" }, "qdel_SharebasedCompensationArrangementbySharebasedPaymentAwardfairvalueweightedaverageRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, fair value weighted average [Roll Forward]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, fair value weighted average [Roll Forward]", "terseLabel": "Weighted-Average Exercise Price Per Share" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardfairvalueweightedaverageRollForward", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "qdel_StockAwardsAssumedInTheCombinations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock awards assumed in the Combinations", "label": "Stock awards assumed in the Combinations", "terseLabel": "Stock awards assumed in the Combinations (in shares)" } } }, "localname": "StockAwardsAssumedInTheCombinations", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "qdel_StockAwardsAssumedInTheCombinationsWeightedAvgGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock awards assumed in the Combinations (weighted avg grant date fair value)", "label": "Stock awards assumed in the Combinations (weighted avg grant date fair value)", "terseLabel": "Weighted-Average Grant Date Fair Value, Stock awards assumed in the Combinations (in USD per share)" } } }, "localname": "StockAwardsAssumedInTheCombinationsWeightedAvgGrantDateFairValue", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "qdel_StockIssuedDuringPeriodValueEquityReplacementAwardsAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Equity Replacement Awards, Acquisitions", "label": "Stock Issued During Period, Value, Equity Replacement Awards, Acquisitions", "terseLabel": "Issuance of equity replacement awards in connection with the Combinations" } } }, "localname": "StockIssuedDuringPeriodValueEquityReplacementAwardsAcquisitions", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "qdel_StockRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program", "label": "Stock Repurchase Program [Member]", "terseLabel": "Stock Repurchase Program" } } }, "localname": "StockRepurchaseProgramMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "qdel_SubjectToExpirationThrough2037Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject to expiration through 2037", "label": "Subject to expiration through 2037 [Member]", "terseLabel": "Subject to expiration through 2037" } } }, "localname": "SubjectToExpirationThrough2037Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "qdel_SubjectToExpirationThrough2042Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject to expiration through 2042", "label": "Subject to expiration through 2042 [Member]", "terseLabel": "Subject to expiration through 2042" } } }, "localname": "SubjectToExpirationThrough2042Member", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "qdel_SummersRidgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summers ridge", "label": "Summers ridge [Member]", "terseLabel": "Summers ridge" } } }, "localname": "SummersRidgeMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "qdel_TaxIndemnificationIncomeExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tax Indemnification Income (Expense)", "label": "Tax Indemnification Income (Expense)", "terseLabel": "Tax indemnification expense" } } }, "localname": "TaxIndemnificationIncomeExpense", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_TransfusionMedicineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transfusion Medicine", "label": "Transfusion Medicine [Member]", "terseLabel": "Transfusion Medicine" } } }, "localname": "TransfusionMedicineMember", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "qdel_UnrecognizedTaxBenefitsDecreaseResultingFromVoluntaryDisclosureAgreements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Decrease Resulting From Voluntary Disclosure Agreements", "label": "Unrecognized Tax Benefits, Decrease Resulting From Voluntary Disclosure Agreements", "negatedTerseLabel": "Decreases from voluntary disclosure agreements" } } }, "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromVoluntaryDisclosureAgreements", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "qdel_UnwindInventoryFairValueAdjustment": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unwind Inventory Fair Value Adjustment", "label": "Unwind Inventory Fair Value Adjustment", "negatedTerseLabel": "Unwind inventory fair value adjustment", "terseLabel": "Unwind inventory fair value adjustment" } } }, "localname": "UnwindInventoryFairValueAdjustment", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "qdel_ValuationAllowanceDeferredTaxAssetAdditionsFromAcquisitionsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Additions From Acquisitions, Amount", "label": "Valuation Allowance, Deferred Tax Asset, Additions From Acquisitions, Amount", "terseLabel": "Additions Due to Current Year Acquisitions" } } }, "localname": "ValuationAllowanceDeferredTaxAssetAdditionsFromAcquisitionsAmount", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesRollforwardofValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "qdel_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseFromForeignCurrencyTranslationAndOtherAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) From Foreign Currency Translation And Other, Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease) From Foreign Currency Translation And Other, Amount", "terseLabel": "Currency Translation/Other" } } }, "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseFromForeignCurrencyTranslationAndOtherAmount", "nsuri": "http://www.quidel.com/20230101", "presentation": [ "http://www.quidel.com/role/IncomeTaxesRollforwardofValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r355", "r721", "r722", "r724", "r725", "r777", "r854", "r858", "r983", "r986", "r987", "r1069", "r1070", "r1071" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r355", "r721", "r722", "r724", "r725", "r777", "r854", "r858", "r983", "r986", "r987", "r1069", "r1070", "r1071" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r1068" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Contractual Obligation, Fiscal Year Maturity" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r353", "r354", "r500", "r529", "r868", "r876", "r878" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r430", "r896", "r990", "r1058" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r484", "r485", "r486", "r487", "r630", "r809", "r828", "r855", "r856", "r893", "r911", "r921", "r988", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails", "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r484", "r485", "r486", "r487", "r630", "r809", "r828", "r855", "r856", "r893", "r911", "r921", "r988", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails", "http://www.quidel.com/role/StockholdersEquityDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r430", "r896", "r990", "r1058" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of North America.", "label": "North America [Member]", "terseLabel": "North America" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails", "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails" ], "xbrltype": "domainItemType" }, "srt_PayablesToCustomers": { "auth_ref": [ "r1072" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to customer by broker-dealer.", "label": "Broker-Dealer, Payable to Customer", "terseLabel": "Accrued other taxes payable" } } }, "localname": "PayablesToCustomers", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r426", "r813", "r894", "r919", "r980", "r981", "r990", "r1057" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r426", "r813", "r894", "r919", "r980", "r981", "r990", "r1057" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r484", "r485", "r486", "r487", "r583", "r630", "r662", "r663", "r664", "r785", "r809", "r828", "r855", "r856", "r893", "r911", "r921", "r979", "r988", "r1050", "r1051", "r1052", "r1053", "r1054" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails", "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r484", "r485", "r486", "r487", "r583", "r630", "r662", "r663", "r664", "r785", "r809", "r828", "r855", "r856", "r893", "r911", "r921", "r979", "r988", "r1050", "r1051", "r1052", "r1053", "r1054" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails", "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r353", "r354", "r500", "r529", "r877", "r878" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r427", "r428", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r857", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r895", "r920", "r990" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails", "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails", "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r427", "r428", "r839", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r857", "r859", "r895", "r920", "r990" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails", "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails", "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r957", "r1046" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r17", "r918" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r256", "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r964" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r308", "r432", "r433", "r871" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r841" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r432", "r433" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "verboseLabel": "Total accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r2", "r248", "r269" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income tax payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r32", "r36", "r204", "r939", "r940", "r941" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Pension and Other Post- employment Benefits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r109", "r301" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r324", "r333", "r723", "r940", "r941" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r320", "r321", "r322", "r324", "r333", "r940", "r941" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "terseLabel": "Available-for-Sale Investments" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r34", "r35", "r36", "r310", "r823", "r833", "r834" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r333", "r334", "r747", "r748", "r749", "r750", "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r33", "r36", "r204", "r771", "r829", "r830", "r939", "r940", "r941", "r950", "r951", "r952" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r30", "r36", "r204", "r334", "r335", "r748", "r749", "r750", "r751", "r752", "r939" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Unrealized Foreign Currency Translation Adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Amortization Period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AcquisitionRelatedCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).", "label": "Acquisition-related Costs [Member]", "terseLabel": "Acquisition and integration costs" } } }, "localname": "AcquisitionRelatedCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r9", "r918" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Tax withholdings related to vesting of stock-based awards" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r121", "r126", "r702" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature", "terseLabel": "Tax impact from the conversion of Convertible Notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "negatedTerseLabel": "Derivative liabilities - Convertible Notes elected to settle in cash" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r160", "r161", "r633" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Cost" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingMember": { "auth_ref": [ "r991" ], "lang": { "en-us": { "role": { "documentation": "Announcement promoting product, service, or event.", "label": "Advertising [Member]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r666" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share based compensation expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r311", "r436", "r443", "r445", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Balance\u00a0at\u00a0end\u00a0of period", "periodStartLabel": "Balance\u00a0at Beginning\u00a0of Period", "terseLabel": "Accounts Receivable, Allowance for Credit Loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableAllowanceforCreditLossRollforwardDetails", "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "auth_ref": [ "r964" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Additions charged to expense or as reductions to revenue" } } }, "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableAllowanceforCreditLossRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableAllowanceforCreditLossRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Deductions" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAccountsReceivableAllowanceforCreditLossRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [ "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on receivable, classified as other and current.", "label": "Allowance for Credit Loss, Receivable, Other, Current", "terseLabel": "Allowance for Credit Loss, Receivable, Other, Current" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r62", "r96", "r103" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails", "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive shares excluded from calculation due to anti-dilutive effect" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r901", "r958" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]", "terseLabel": "Corporate asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r246", "r268", "r305", "r348", "r410", "r416", "r422", "r441", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r721", "r724", "r745", "r918", "r984", "r985", "r1047" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r296", "r316", "r348", "r441", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r721", "r724", "r745", "r918", "r984", "r985", "r1047" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r438", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Debt Securities, Available-for-sale, Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r637", "r638", "r639", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r661", "r662", "r663", "r664", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r211", "r214" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r717", "r905", "r908" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails", "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r179", "r180", "r717", "r905", "r908" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails", "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "QuidelOrtho shares issued (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]", "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]" } } }, "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Schedule of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]", "terseLabel": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table]" } } }, "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r1032", "r1033" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Pro Forma Financial Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Closing price of Quidel Common Stock (in usd per share)", "verboseLabel": "Value per Quidel share as of May 26, 2022 (in usd per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r715", "r716" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Pro forma net income" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r715", "r716" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Pro forma total revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r177" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedTerseLabel": "Acquisition and integration costs", "terseLabel": "Acquisition and integration costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r190", "r191", "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r190", "r191" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Fair value of stock consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r189", "r192", "r720" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r189", "r193" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r197", "r718" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "auth_ref": [ "r184" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "negatedTotalLabel": "Measurement Period Adjustments, Total purchase consideration" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": { "auth_ref": [ "r184" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 1.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "terseLabel": "Measurement Period Adjustments, Intangible Assets" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": { "auth_ref": [ "r184" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 3.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory", "terseLabel": "Measurement Period Adjustments, Inventory" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment": { "auth_ref": [ "r184" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 4.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to property, plant, and equipment acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment", "terseLabel": "Measurement Period Adjustments, Property, Plant, and Equipment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 4.0, "parentTag": "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 5.0, "parentTag": "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 7.0, "parentTag": "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "negatedTerseLabel": "Long-term borrowings, including current portion (1)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r181", "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 3.0, "parentTag": "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets", "verboseLabel": "Intangible Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r181", "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 2.0, "parentTag": "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r181", "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 1.0, "parentTag": "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r182" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSegmentAllocationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Combination Segment Allocation [Line Items]", "terseLabel": "Business Combination Segment Allocation [Line Items]" } } }, "localname": "BusinessCombinationSegmentAllocationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSegmentAllocationTable": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about goodwill in a business combination.", "label": "Business Combination, Segment Allocation [Table]", "terseLabel": "Business Combination, Segment Allocation [Table]" } } }, "localname": "BusinessCombinationSegmentAllocationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSegmentAllocationTableTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill in a business combination.", "label": "Business Combination, Segment Allocation [Table Text Block]", "terseLabel": "Assignment of Goodwill by Reportable Segment" } } }, "localname": "BusinessCombinationSegmentAllocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations Policy" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "auth_ref": [ "r285", "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for amortization of capitalized computer software costs.", "label": "Capitalized Computer Software, Amortization", "terseLabel": "Capitalized Computer Software, Amortization" } } }, "localname": "CapitalizedComputerSoftwareAmortization1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r64", "r299", "r869" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsCashCashEquivalentsandRestrictedCashDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r58", "r64", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsCashCashEquivalentsandRestrictedCashDetails", "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r58", "r237" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementAndThirdPartyMember": { "auth_ref": [ "r1034" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between party to collaborative arrangement and third party.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement and Third Party [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement and Third Party" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementAndThirdPartyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r1034" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r26", "r257", "r276" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r112", "r482", "r483", "r842", "r982" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock).", "label": "Common Stock Including Additional Paid in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r950", "r951", "r1038" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r121" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r918" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value per share; 126.2 and 97.5 shares authorized; 66.4 and 41.7 shares issued and outstanding at January\u00a01, 2023 and January\u00a02, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r38", "r329", "r331", "r338", "r818", "r825" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r51", "r337", "r817", "r824" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income, Policy" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r914", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software development costs" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r76", "r77", "r234", "r235", "r430", "r841" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r76", "r77", "r234", "r235", "r430", "r835", "r841" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r76", "r77", "r234", "r235", "r430", "r841", "r1060" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r264", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Risk, Credit Risk, Policy" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r76", "r77", "r234", "r235", "r430" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of risk concentration" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r73", "r76", "r77", "r78", "r234", "r236", "r841" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r76", "r77", "r234", "r235", "r430", "r841" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r202", "r879" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation, Policy" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r543", "r544", "r556" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "verboseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r116", "r497", "r498", "r509", "r510", "r511", "r515", "r516", "r517", "r518", "r519", "r888", "r889", "r890", "r891", "r892" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateAndOtherMember": { "auth_ref": [ "r955" ], "lang": { "en-us": { "role": { "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.", "label": "Corporate and Other [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateAndOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r901", "r903", "r1059" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "auth_ref": [ "r942", "r943" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "terseLabel": "Cost of sales, excluding amortization of intangibles" } } }, "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails", "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Costs and Expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r948", "r1028", "r1031" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r948", "r1028" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r174", "r699", "r708", "r948" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r948", "r1028", "r1031" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r74", "r430" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r255", "r278" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "terseLabel": "Long-term borrowings" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r67", "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Extinguishment of Convertible Notes through issuance of stock" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r67", "r69" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Issuance of shares in exchange for Convertible Notes (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r306" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Current portion of borrowings" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r120", "r346", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r513", "r520", "r521", "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-term Borrowings" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r247", "r251", "r266", "r355", "r497", "r498", "r499", "r500", "r501", "r503", "r509", "r510", "r511", "r512", "r514", "r515", "r516", "r517", "r518", "r519", "r756", "r888", "r889", "r890", "r891", "r892", "r946" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r251", "r266", "r524" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r23", "r498" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r24", "r355", "r497", "r498", "r499", "r500", "r501", "r503", "r509", "r510", "r511", "r512", "r514", "r515", "r516", "r517", "r518", "r519", "r756", "r888", "r889", "r890", "r891", "r892", "r946" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r24", "r122", "r123", "r124", "r125", "r238", "r239", "r241", "r263", "r355", "r497", "r498", "r499", "r500", "r501", "r503", "r509", "r510", "r511", "r512", "r514", "r515", "r516", "r517", "r518", "r519", "r522", "r756", "r888", "r889", "r890", "r891", "r892", "r946" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Debt, Policy" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r49" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredBonusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An contractual arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a bonus, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to individual, group and entity-wide performance goals, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and profit sharing.", "label": "Deferred Bonus [Member]", "terseLabel": "Deferred Bonus" } } }, "localname": "DeferredBonusMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "auth_ref": [ "r130", "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Compensation Expense", "terseLabel": "Stock based compensation expense related to deferred bonus compensation program" } } }, "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r948", "r1029", "r1031" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r240", "r989" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r240" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Noncurrent, Net", "negatedTerseLabel": "Unamortized deferred financing costs" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r174", "r948", "r1029" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r680", "r681" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r62", "r174", "r700", "r707", "r708", "r948" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred provision (benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r5", "r6", "r249", "r265", "r693" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r680", "r681" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r934" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue, current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r935" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred Revenue, Noncurrent" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r948", "r1029", "r1031" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r694" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory reserve" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r1026" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r1026" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r172", "r1027" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "Operating loss carryforwards, state and local" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other, net" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r170", "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax loss and credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "auth_ref": [ "r170", "r172", "r1027" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign", "terseLabel": "Federal foreign tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": { "auth_ref": [ "r170", "r172", "r1027" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business", "terseLabel": "Business credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r170", "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research & development expenses" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Employee related obligations" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": { "auth_ref": [ "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances", "terseLabel": "Allowance for returns and discounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r695" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance for deferred tax assets", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Valuation allowance for deferred tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.quidel.com/role/IncomeTaxesRollforwardofValuationAllowanceDetails", "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r163", "r1026" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTerseLabel": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r172", "r1027" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r591" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "ABO" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r574", "r903" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r567" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Actuarial gain" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "auth_ref": [ "r133", "r134" ], "calculation": { "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "totalLabel": "Net amount recognized" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Amounts recognized on the consolidated balance sheets:" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r245", "r267", "r559", "r560", "r582", "r903" ], "calculation": { "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Other assets" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsTransferredToFromPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from assets transferred into (from) plan.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan", "terseLabel": "Transfers in from the Combinations" } } }, "localname": "DefinedBenefitPlanAssetsTransferredToFromPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Weighted average discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Weighted average rate of compensation increases" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r605" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Weighted average discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r607", "r624" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "terseLabel": "Weighted average expected return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Weighted average expected rate of compensation increases" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r562" ], "calculation": { "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Projected benefit obligation at end of year", "periodStartLabel": "Projected benefit obligation at beginning of year" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r569", "r626" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation": { "auth_ref": [ "r571" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in benefit obligation of defined benefit plan from business combination.", "label": "Defined Benefit Plan, Benefit Obligation, Business Combination", "terseLabel": "Assumed obligation from the Combinations" } } }, "localname": "DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r610", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "auth_ref": [ "r901" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change in benefit obligation:" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change in plan assets:" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r576", "r585", "r623", "r901", "r902", "r903", "r904" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Employer contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": { "auth_ref": [ "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, US [Member]", "terseLabel": "U.S. equity securities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "Fiscal Years 2028-2032" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "Fiscal Year 2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "Fiscal Year 2027" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "Fiscal Year 2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "Fiscal Year 2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "Fiscal Year 2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r593", "r904" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r573", "r584", "r585", "r586", "r901", "r902", "r903" ], "calculation": { "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets at end of year", "periodStartLabel": "Fair value of plan assets at beginning of year", "terseLabel": "Total" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r568" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency exchange rate changes" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r559", "r582", "r903" ], "calculation": { "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status at end of year" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "terseLabel": "Healthcare cost trend rate for upcoming year (in percent)" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r561", "r565", "r596", "r617", "r903", "r904" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r594", "r615", "r903", "r904" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "terseLabel": "Defined benefit plan, net periodic benefit cost (credit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "auth_ref": [ "r613", "r903" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": { "auth_ref": [ "r613", "r903" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "PBO" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]", "terseLabel": "Plans with ABO in excess of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "auth_ref": [ "r613", "r614", "r903" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "terseLabel": "ABO" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r613", "r614", "r903" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "auth_ref": [ "r993" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "PBO" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r578", "r994" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency exchange rate changes" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r583", "r903" ], "lang": { "en-us": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Target allocation rate (in percent)" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]", "terseLabel": "Plans with PBO in excess of plan assets" } } }, "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsAccumulatedBenefitObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": { "auth_ref": [ "r588", "r903" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement", "terseLabel": "Net purchases and settlements" } } }, "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r563", "r595", "r616", "r903", "r904" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r564" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "terseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r581" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanTextBlock": { "auth_ref": [ "r625", "r812", "r903" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for defined benefit plan.", "label": "Defined Benefit Plan [Text Block]", "terseLabel": "Long-term Employee Benefits" } } }, "localname": "DefinedBenefitPlanTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": { "auth_ref": [ "r589", "r903" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3", "terseLabel": "Transfers in" } } }, "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "terseLabel": "Rate to which the cost trend rate is assumed to decline" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r139", "r140", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPostretirementHealthCoverageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide postretirement health benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Postretirement Health Coverage [Member]", "terseLabel": "Postretirement Health Coverage" } } }, "localname": "DefinedBenefitPostretirementHealthCoverageMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer contributions to defined contribution plan" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r62", "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r62", "r405" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "negatedTerseLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative asset.", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r317", "r318", "r744", "r878" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative assets" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails", "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r317" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails": { "order": 6.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivatives" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCapInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract.", "label": "Derivative, Cap Interest Rate", "terseLabel": "Derivative, Cap Interest Rate" } } }, "localname": "DerivativeCapInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeCashReceivedOnHedge": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash received during the period on settlement of a hedge.", "label": "Derivative, Cash Received on Hedge", "terseLabel": "Derivative, Cash Received on Hedge" } } }, "localname": "DerivativeCashReceivedOnHedge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Derivative, Fixed Interest Rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r1037" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Derivative mark-to-market gain (loss)" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r1037" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r212", "r213", "r217", "r219", "r878" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r224", "r732" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r317", "r318", "r744", "r878" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails", "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r317" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Derivatives" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative liability.", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r1035", "r1036" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r206", "r207", "r208", "r209", "r210", "r215", "r217", "r220", "r221", "r222", "r732" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "terseLabel": "Interest expense on Convertible Notes, net of tax" } } }, "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r555", "r894", "r895", "r896", "r897", "r898", "r899", "r900" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r990" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r636", "r667", "r668", "r670", "r675", "r912" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails", "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r339", "r361", "r362", "r363", "r364", "r365", "r369", "r371", "r383", "r384", "r385", "r389", "r735", "r736", "r819", "r826", "r883" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r339", "r361", "r362", "r363", "r364", "r365", "r371", "r383", "r384", "r385", "r389", "r735", "r736", "r819", "r826", "r883" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r386", "r387", "r388", "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Computation of Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r746" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Share based compensation related to accrued payroll and related expenses" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r669" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected weighted-average period of recognition for unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r1021" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment, furniture and fixtures" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r121", "r291", "r333", "r334", "r335", "r356", "r357", "r358", "r360", "r366", "r368", "r392", "r442", "r542", "r671", "r672", "r673", "r703", "r704", "r734", "r747", "r748", "r749", "r750", "r751", "r752", "r771", "r829", "r830", "r831" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of Debt, Amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]", "terseLabel": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished.", "label": "Extinguishment of Debt, Type [Domain]", "terseLabel": "Extinguishment of Debt, Type [Domain]" } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]", "terseLabel": "Assets:" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r225", "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r511", "r585", "r586", "r587", "r588", "r589", "r590", "r738", "r782", "r783", "r784", "r889", "r890", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r737", "r738", "r739", "r740", "r743" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r511", "r585", "r590", "r738", "r782", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "verboseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r511", "r585", "r590", "r738", "r783", "r889", "r890", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r511", "r585", "r586", "r587", "r588", "r589", "r590", "r738", "r784", "r889", "r890", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Liabilities Measured at Fair Value on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Changes in Estimated Fair Value of Contingent Consideration Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r741" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in estimated fair value, recorded in selling, marketing and administrative expenses" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Cash payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance", "periodStartLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r511", "r585", "r586", "r587", "r588", "r589", "r590", "r782", "r783", "r784", "r889", "r890", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.quidel.com/role/FairValueMeasurementsChangesinEstimatedFairValueofContingentConsiderationLiabilitiesDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsLevel3RollforwardDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments, Policy" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r758" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Financing lease obligation" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r760", "r765" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payments on long-term borrowings and extinguishment costs" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r439", "r440", "r444", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r522", "r540", "r732", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r886", "r960", "r961", "r962", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Eligible Item or Group for Fair Value Option" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted-average useful life (years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r303", "r475" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsScheduleofFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r473", "r474", "r475", "r476", "r814", "r815" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r102", "r815" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r97", "r101" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r102", "r814" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r223" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "negatedTerseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r878", "r901", "r916" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r992", "r1059" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Debt Security, Government, Non-US" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r349" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "Foreign income taxed at rates other than the applicable U.S. rate" } } }, "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r62", "r117", "r118" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows", "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r302", "r461", "r816", "r887", "r918", "r966", "r973" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 6.0, "parentTag": "qdel_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 }, "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at January 1, 2023", "periodStartLabel": "Balance at January 2, 2022", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails", "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationGoodwillAllocationDetails", "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r463", "r887" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Policy" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r94", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, Policy" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r467" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r176", "r972" ], "calculation": { "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails": { "order": 5.0, "parentTag": "qdel_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Measurement Period Adjustments, Goodwill" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GovernmentAssistancePolicyTextBlock": { "auth_ref": [ "r754", "r755" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for government assistance.", "label": "Government Assistance [Policy Text Block]", "terseLabel": "Government Assistance" } } }, "localname": "GovernmentAssistancePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r46", "r348", "r410", "r415", "r421", "r424", "r441", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r745", "r885", "r984" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r209", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r62", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "negatedTerseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r105", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment or Disposal of Long-Lived Assets, Policy" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r350", "r709" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r40", "r244", "r260", "r282", "r410", "r415", "r421", "r424", "r820", "r885" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r350", "r709" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesScheduleofIncomebeforeBenefitProvisionforIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r41", "r62", "r92", "r259", "r280", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "(Loss) gain on investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r477", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails", "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails", "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r351", "r684", "r691", "r698", "r705", "r710", "r712", "r713", "r714" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r352", "r367", "r368", "r408", "r682", "r706", "r711", "r827" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/IncomeTaxesComponentsofBenefitProvisionforIncomeTaxesDetail", "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r332", "r678", "r679", "r691", "r692", "r697", "r701" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax, Policy" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r1023" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r683" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Tax expense at statutory tax rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r1023" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "terseLabel": "Stock-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r1023" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "negatedTerseLabel": "Foreign Derived Intangible Income Deduction (FDII)" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r1023" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedLabel": "Federal and state research credits\u2014current year" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r59", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r254", "r279", "r936" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income taxes and other tax receivables" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued payroll and related expenses" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other current and non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other current and non-current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r379", "r380", "r385" ], "calculation": { "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Dilutive potential shares issuable from Convertible Notes" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r372", "r373", "r374", "r385", "r635" ], "calculation": { "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive potential shares issuable from stock options and unvested RSUs" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r95", "r100" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r49", "r517", "r526", "r891", "r892" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense, debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of Interest Expense" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r262" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTerseLabel": "Interest expense, net", "negatedTotalLabel": "Interest expense, net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest Income, Other", "negatedTerseLabel": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r342", "r344", "r345" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r915" ], "lang": { "en-us": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "Interest Rate Cap" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r223" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r915" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r93", "r873" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails_1": { "order": 1.0, "parentTag": "qdel_InventoriesIncludingNoncurrentPortionNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods (materials, labor and overhead)" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r313", "r870", "r918" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails": { "order": 2.0, "parentTag": "qdel_InventoriesIncludingNoncurrentPortionNet", "weight": 1.0 }, "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r933" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails": { "order": 1.0, "parentTag": "qdel_InventoriesIncludingNoncurrentPortionNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventory, Noncurrent" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r298", "r312", "r391", "r456", "r457", "r458", "r811", "r880" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, Policy" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r93", "r875" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails_1": { "order": 2.0, "parentTag": "qdel_InventoriesIncludingNoncurrentPortionNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r93", "r874" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails_1": { "order": 3.0, "parentTag": "qdel_InventoriesIncludingNoncurrentPortionNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process (materials, labor and overhead)" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r991" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r1044" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1045" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "Schedule of Maturity of Operating Lease Liability" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r769" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r1043" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r770" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r20", "r348", "r441", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r722", "r724", "r725", "r745", "r884", "r984", "r1047", "r1048" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r253", "r274", "r918", "r947", "r963", "r1040" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r22", "r297", "r348", "r441", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r722", "r724", "r725", "r745", "r918", "r984", "r1047", "r1048" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "License agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r946" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Line of Credit Facility, Increase (Decrease), Net" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r251", "r271", "r510", "r525", "r889", "r890" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Total borrowings" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r3" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "totalLabel": "Total borrowings" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedTerseLabel": "Less: current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Long-Term Debt, Fair Value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r114", "r355", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r114", "r355", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r114", "r355", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r114", "r355", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r114", "r355", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term borrowings" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r24", "r115" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails", "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Total marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails", "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]" } } }, "localname": "MarketableSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "verboseLabel": "Marketable securities, current" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money Market Funds, at Carrying Value" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r343" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used for) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r343" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r58", "r60", "r63" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r42", "r63", "r261", "r281", "r295", "r327", "r330", "r335", "r348", "r359", "r361", "r362", "r363", "r364", "r367", "r368", "r381", "r410", "r415", "r421", "r424", "r441", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r736", "r745", "r885", "r984" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails", "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails", "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows", "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r370", "r375", "r376", "r377", "r378", "r382", "r385" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income used for diluted earnings per share, if-converted method" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r67", "r68", "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Purchase of property, equipment and intangibles by incurring current liabilities" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r428" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-Lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails", "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonrecurringAdjustmentAxis": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Axis]", "terseLabel": "Nonrecurring Adjustment [Axis]" } } }, "localname": "NonrecurringAdjustmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentDomain": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Domain]", "terseLabel": "Nonrecurring Adjustment [Domain]" } } }, "localname": "NonrecurringAdjustmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfCountriesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of countries in which the entity operates as of balance sheet date.", "label": "Number of Countries in which Entity Operates", "terseLabel": "Number of countries entity operates" } } }, "localname": "NumberOfCountriesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r956" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r956" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r410", "r415", "r421", "r424", "r885" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r763", "r917" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r758" ], "calculation": { "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail", "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r758" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 }, "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails", "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails", "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r758" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "netLabel": "Operating lease liabilities", "terseLabel": "Non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets", "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r761", "r765" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesComponentsofLeaseExpenseandSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r757" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r768", "r917" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r767", "r917" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesCommitmentsforMinimumRentalsunderNoncancelableLeasesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r315", "r918" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r304" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r36", "r39", "r334", "r747", "r749", "r752", "r939" ], "calculation": { "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Current period deferrals" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r319", "r323" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "totalLabel": "Total change in unrealized gains (losses) from cash flow hedges, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r319", "r323" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Net unrealized gains (losses) on derivative instruments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r319", "r323", "r727", "r728", "r731" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r323", "r325" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedTerseLabel": "Reclassification of net realized (gains) losses on derivative instruments included in net income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r323", "r325", "r729" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r29" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Changes in cumulative translation adjustment, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r200", "r201", "r203", "r328", "r331" ], "calculation": { "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss, net of tax", "totalLabel": "Net change" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r31", "r34", "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Accumulated net actuarial gains (losses)" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "auth_ref": [ "r34", "r37", "r326", "r602" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "negatedTerseLabel": "Changes from pension and other post-employment benefits, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r320", "r323" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Changes in unrealized losses from investments, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r47" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost and Expense, Operating", "terseLabel": "Other operating expenses" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r959", "r965", "r992", "r1039" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Foreign and other" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the liabilities for deferred compensation arrangements classified as other.", "label": "Other Deferred Compensation Arrangements, Liability, Current and Noncurrent", "terseLabel": "Deferred Consideration" } } }, "localname": "OtherDeferredCompensationArrangementsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r1022" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other current and other deferred income tax expense (benefit) attributable to continuing operations.", "label": "Other Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "Other" } } }, "localname": "OtherIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r918" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "totalLabel": "Total other current liabilities", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]", "terseLabel": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-Term Debt, Noncurrent", "terseLabel": "Other long-term borrowings" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other expense (income), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOwnershipInterestsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Ownership Interests [Line Items]", "terseLabel": "Other Ownership Interests [Line Items]" } } }, "localname": "OtherOwnershipInterestsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r21", "r113" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Principal payments of acquisition contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r56" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r341" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payments of tax withholdings related to vesting of stock-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r53", "r719" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r53" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of businesses, net of cash and restricted cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r90" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r54" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property, equipment, investments and intangibles" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r2", "r559", "r560", "r582", "r903" ], "calculation": { "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "terseLabel": "Other current liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r250", "r270", "r560", "r582" ], "calculation": { "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Liability, Defined Benefit Plan", "terseLabel": "Other liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "auth_ref": [ "r139", "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "terseLabel": "Pension and Other Postretirement Plans, Pensions, Policy" } } }, "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r131", "r559", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r605", "r607", "r608", "r610", "r611", "r612", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r628", "r631", "r903", "r904", "r908", "r909", "r910" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Defined Benefit Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r610", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentRetirementBenefitsMember": { "auth_ref": [ "r131", "r132" ], "lang": { "en-us": { "role": { "documentation": "Special and contractual termination benefits provided in connection with termination of employment and payable upon retirement, but not payable from defined benefit plan. Excludes benefits payable upon termination from defined benefit pension and other postretirement plan, and postemployment benefits payable before retirement.", "label": "Postemployment Retirement Benefits [Member]", "terseLabel": "Other Post-employment Benefits" } } }, "localname": "PostemploymentRetirementBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r7", "r527" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r7", "r527" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r7", "r918" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value per share; 5.0 shares authorized; none issued or outstanding at January\u00a01, 2023 and January\u00a02, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r937" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]", "terseLabel": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r314", "r459", "r460", "r872" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r932" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification, Comparability Adjustment" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromContributionInAidOfConstruction": { "auth_ref": [ "r52" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from developers, builders, governmental agencies and municipalities that provide the entity with cash to extend its construction services to their properties.", "label": "Proceeds from Contribution in Aid of Construction", "terseLabel": "Proceeds from government assistance allocated to fixed assets" } } }, "localname": "ProceedsFromContributionInAidOfConstruction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r340" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r55" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sale of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r108", "r300" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r110", "r275", "r822", "r918" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails", "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r110", "r843", "r844" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment, Policy" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r4", "r252", "r272" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Purchase commitment" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current [Abstract]", "terseLabel": "Receivables, Net, Current [Abstract]" } } }, "localname": "ReceivablesNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r36", "r39", "r334", "r747", "r751", "r752", "r939" ], "calculation": { "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified to net income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification [Line Items]", "terseLabel": "Reclassification [Line Items]" } } }, "localname": "ReclassificationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationTable": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification [Table]", "terseLabel": "Reclassification [Table]" } } }, "localname": "ReclassificationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reconciliation [Abstract]", "terseLabel": "Segment Reconciliation [Abstract]" } } }, "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r84", "r86" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r944" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r162", "r286", "r1055" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r840", "r933", "r945" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted Cash, Noncurrent" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsCashCashEquivalentsandRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r126", "r273", "r832", "r834", "r918" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r291", "r356", "r357", "r358", "r360", "r366", "r368", "r442", "r671", "r672", "r673", "r703", "r704", "r734", "r829", "r831" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r131", "r132", "r559", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r605", "r607", "r608", "r610", "r611", "r612", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r628", "r629", "r631", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r131", "r132", "r559", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r605", "r607", "r608", "r610", "r611", "r612", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r628", "r629", "r631", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofHealthCareTrendRatesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r401", "r402", "r414", "r419", "r420", "r426", "r427", "r430", "r554", "r555", "r813" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Total Revenues for Fiscal Year", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueNarrativeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r545", "r546", "r547", "r548", "r549", "r550", "r552", "r553", "r557", "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue from External Customers by Geographic Areas" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r881", "r882" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r336", "r348", "r401", "r402", "r414", "r419", "r420", "r426", "r427", "r430", "r441", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r745", "r820", "r984" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationProFormaInformationDetails", "http://www.quidel.com/role/ConsolidatedStatementsofIncome", "http://www.quidel.com/role/RevenueDisaggregationofRevenueDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r766", "r917" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for new lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesComponentsofLeaseExpenseandSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty Expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofGainLossDetails", "http://www.quidel.com/role/RevenueConcentrationsofRevenueandCreditRiskDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r430", "r954" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r36", "r1041", "r1042" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Allocation of Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Defined Benefit Plan, Assumptions" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r903", "r993" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r179", "r180", "r717" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationNarrativeDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails", "http://www.quidel.com/role/BusinessCombinationPurchasePricebyExchangeRatioDetails", "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r24", "r122", "r123", "r124", "r125", "r238", "r239", "r241", "r263", "r889", "r891", "r949" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r139", "r140", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsCriticalAssumptionsUsedDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsExpectedBenefitPaymentsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsNarrativeDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsProjectedBenefitObligationsDetails", "http://www.quidel.com/role/LongtermEmployeeBenefitsScheduleofAOCIDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "auth_ref": [ "r139", "r140", "r141", "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative assets at fair value.", "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Assets at Fair Value" } } }, "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r206", "r207", "r208", "r209", "r210", "r215", "r217", "r220", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Currency Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r157", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Compensation Expense Related to Stock-Based Compensation Plans" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r97", "r101", "r814" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillandIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r887" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r887", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.", "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]", "terseLabel": "Schedule of Health Care Cost Trend Rates" } } }, "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r948" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of Interest Rate Derivatives" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r14", "r15", "r16" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Share Activity" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherOwnershipInterestsTable": { "auth_ref": [ "r127", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Schedule of other units or shares or classes of ownership in a partnership. This schedule ordinarily includes a description of the ownership interest detailing special or unusual rights; the capital contributed to and the capital account balance of the other unit holders for the partnerships; number of units of other ownership interest authorized to be issued, issued, and outstanding in the partnerships; aggregate cumulative cash distributions made to, and aggregate cumulative net income shared by, the other unit holders in the partnership.", "label": "Schedule of Other Ownership Interests [Table]", "terseLabel": "Schedule of Other Ownership Interests [Table]" } } }, "localname": "ScheduleOfOtherOwnershipInterestsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r45", "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r82", "r83", "r85", "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r632", "r634", "r637", "r638", "r639", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r661", "r662", "r663", "r664", "r665" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r148", "r151", "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Estimated Fair Value of Each Stock Option Award" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r913", "r1025" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r73", "r76", "r77", "r78", "r234", "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Concentration of revenue and credit risk" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Term Loan" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quidel.com/role/LongtermBorrowingsInterestExpenseDetails", "http://www.quidel.com/role/LongtermBorrowingsNarrativeDetails", "http://www.quidel.com/role/LongtermBorrowingsScheduleofBorrowingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r398", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r430", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r480", "r481", "r887", "r1057" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r398", "r399", "r400", "r410", "r413", "r418", "r422", "r423", "r424", "r425", "r426", "r429", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationGeographicTerritoryDetails", "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Selling, marketing and administrative" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationCompensationExpenseRelatedtoStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, marketing and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationSummaryofPurchasePriceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r61" ], "calculation": { "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r912" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Discount from market price (in percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted stock outstanding, non-vested, ending (in shares)", "periodStartLabel": "Restricted stock outstanding, non-vested, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending Balance (in USD per share)", "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning Balance (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid": { "auth_ref": [ "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid to settle liability for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Share-Based Liabilities Paid", "terseLabel": "Share based liabilities paid" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value, Vested (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend rate", "verboseLabel": "Dividend rate (in percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockBasedCompensationEstimatedFairValueofEachStockOptionAwardDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationEstimatedFairValueofEachStockOptionAwardDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationEstimatedFairValueofEachStockOptionAwardDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum contribution rate (in percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares of common stock available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable, end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, end of period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r656" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value for options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of stock options granted (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationEstimatedFairValueofEachStockOptionAwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Stock options outstanding, ending (in shares)", "periodStartLabel": "Stock options outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Stock options outstanding ending, weighted average exercise price (in USD per share)", "periodStartLabel": "Stock options outstanding beginning, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest, end of period (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r657" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)", "terseLabel": "Stock options assumed in the Combinations (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r637", "r638", "r639", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r661", "r662", "r663", "r664", "r665" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Stock options exercised, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Stock options cancelled, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Stock options granted, weighted average exercise price (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price", "terseLabel": "Stock options assumed in the Combinations (in USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r640", "r659", "r660", "r661", "r662", "r665", "r674", "r675" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Payment Arrangement" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected option life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationEstimatedFairValueofEachStockOptionAwardDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options granted, term (in years)", "verboseLabel": "Exercisable, Weighted-Average Remaining Contractual Term (In Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, Weighted-Average Remaining Contractual Term (In Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r658" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest, Weighted-Average Remaining Contractual Term (In Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested and expected to vest, end of period (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options, term (in years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Stock options, granted, exercise price (in usd per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Tax withholdings related to vesting of stock-based awards (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r991" ], "lang": { "en-us": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r836", "r837", "r838", "r922" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Short-term Investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and Software Development Costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r948", "r1022", "r1030" ], "calculation": { "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "State tax expense, net of federal tax" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesReconciliationofIncomeTaxComputedatFederalStatutoryRateDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "Gross State Research Credits" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r294", "r398", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r424", "r430", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r478", "r480", "r481", "r887", "r1057" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SegmentandGeographicInformationReconciliationtoIncomeDetails", "http://www.quidel.com/role/SegmentandGeographicInformationTotalRevenuesbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r28", "r121", "r291", "r333", "r334", "r335", "r356", "r357", "r358", "r360", "r366", "r368", "r392", "r442", "r542", "r671", "r672", "r673", "r703", "r704", "r734", "r747", "r748", "r749", "r750", "r751", "r752", "r771", "r829", "r830", "r831" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails", "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r356", "r357", "r358", "r392", "r813" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsAdditionalDetailsDetails", "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement", "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r7", "r8", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of shares in connection with the Combinations (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r121", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under equity compensation plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r8", "r121", "r126", "r646" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockBasedCompensationSummaryofStatusofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r28", "r121", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of shares in connection with the Combinations" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r28", "r121", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of shares in exchange for Convertible Notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r126", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under equity compensation plans" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining authorized amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r7", "r8", "r121", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchases of common stock (in shares)", "terseLabel": "Repurchases of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement", "http://www.quidel.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r7", "r8", "r121", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r89", "r918", "r947", "r963", "r1040" ], "calculation": { "http://www.quidel.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets", "http://www.quidel.com/role/ConsolidatedStatementsofStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r198", "r199", "r205", "r291", "r292", "r334", "r356", "r357", "r358", "r360", "r366", "r442", "r542", "r671", "r672", "r673", "r703", "r704", "r734", "r747", "r748", "r752", "r771", "r830", "r831", "r947", "r963", "r1040" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r128", "r347", "r528", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r733" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r753", "r778" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r753", "r778" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r753", "r778" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/DerivativeInstrumentsandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Summary of Valuation Allowance" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r938" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Account Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r288", "r289", "r290", "r434", "r435", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BusinessCombinationPurchasePriceAllocationofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r439", "r440", "r522", "r540", "r732", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r960", "r961", "r962", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Fair Value, Option, Eligible Item or Group" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r1034" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/RelatedPartyTransactionsDetails", "http://www.quidel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r1056" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r821", "r901", "r1059" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. government bonds" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LongtermEmployeeBenefitsFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnbilledContractsReceivable": { "auth_ref": [ "r810" ], "calculation": { "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.", "label": "Unbilled Contracts Receivable", "terseLabel": "Contract assets" } } }, "localname": "UnbilledContractsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/BalanceSheetAccountDetailsPrepaidexpensesandothercurrentassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r677", "r686" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r687" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Decreases related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r689" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Decreases due to settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r685" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Increases due to current year acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r688" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases related to current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r687" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases related to prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesSummaryofUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": { "auth_ref": [ "r1024" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense for an underpayment of income taxes.", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense", "terseLabel": "Interest expense, net of accrued interest reversed" } } }, "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r690" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits the would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r79", "r80", "r81", "r393", "r394", "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r696" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Additions (Deductions) Charged to Provision for (Benefit From) Income Taxes" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/IncomeTaxesRollforwardofValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r764", "r917" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r370", "r385" ], "calculation": { "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding - diluted", "totalLabel": "Diluted weighted-average shares of common stock outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails", "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r369", "r385" ], "calculation": { "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average shares of common stock outstanding", "verboseLabel": "Weighted-average shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.quidel.com/role/ComputationofEarningsPerShareCalculationofBasicandDilutedEarningsPerShareDetails", "http://www.quidel.com/role/ConsolidatedStatementsofIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1006": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1061": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1062": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1063": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1064": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1065": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1066": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1067": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1068": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1069": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1070": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1071": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1072": { "Name": "Rule 15c3-1", "Number": "240", "Publisher": "SEC", "Section": "15c3-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=SL65897772-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235042", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "715", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472162&loc=d3e58407-109430", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r857": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r858": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r859": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r861": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r862": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r863": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r864": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r865": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r866": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r867": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r868": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r923": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r924": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r925": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r926": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r927": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r928": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r929": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r931": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r972": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r982": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" } }, "version": "2.2" } ZIP 127 0001906324-23-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001906324-23-000014-xbrl.zip M4$L#!!0 ( !.*5U;MIRG4500 +LL 2 97@R,3$Q,"UK>#(P,C(N M:'1M[5IM<]I&$/[>7[&1ITD[@UX V:X%9L81I"8F)D503SYU3KH#;BSIU+L3 MF/SZGMZ"'?R2=-QIB\P'#6)O5[O/\]QQDK;[JC]VIY\^#F IHQ ^SMZ.ABYH MNFE>M5W3[$_[<#[], +;L)HPY2@65%(6H] T!Y<::$LI$\ %7F(AK MT/5RE,N2#:>+I826U6K#%>/7=(4*NZ0R)+TJ3MM'+1_:Z\Y9+-7UN/(OOA9A=H))$TWDQ4-#/ M1.6DTLM/UT7*QRI.2&-2E=!L94D/;I;4I_+U0?/(ZK2:1O-NVK>K1WRA ) L M4:XJ]JT" H4XX?]2!=[LK3?L#\\FPX$'XW

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

:,&TC7U'*_I M,+1C+9W)M'*2UW(+0C[/\K8,2XUJ"RRC^K#2*SU$:(\7F^Y+,'&:"W$LN8)K/Z%T@ M6;"A;"G#QF?K$"U)TY[G__W-/SM(V*+C($1V\FTPMEB7URVXN94.K$?)'MR6 M!T<,3*ZJ'%D]83>EP#E!E2BVUS+H4LX]N?CSN??8X"/"B(M=](M*1^E% M5_F^OFVT847LSY1I59+G7 M>]&WE$;LF]NR7:??.]6AIDX-P?S(,@6DI1&'9!.7T"$:MZ/9 @T!1\S#BX1; MB^^W]?<,Z4EP46-LJ[I[/:\GHRRS<#LQ2G5TH:OX%@S/:;9K<1'%7&O1M9-' M#3?-]H;S!/ID<^RNQUX6SS[-9MG5"LX>SW$3_#9\!">7,GQ12VLG,$1(M*Y& M9D:Q35M&"("S$E1\:R/^PKRX^!D@A+A:5XR.RJ9),NA()_ND3W$D(&+80?J- M[ _#L1 U?A=W S@LP2RJA45^ )%WLH2F_ALHM%_W*$W:G:@.+#-JY4;Z8__) M*R6\8!RDFPI#2F==O/[^OD2_']1Q]<.80BUOVBM46Q;#[SXF6-TT+R\LW/R' MEA>%H8*XU9W.?<@T=MNE4#OYX?&[9N.G$JERHE9E>W,5_5 ++(9W5'331 20A-UH&^ MP3*@JF@00R^')[,O0,&0C 2YAH#HY_ M\N55L8"&"/(1HYBBJNOFQK6*&995Z*(3T9@ M JJC[,EY;Z7/7@HX\>FIPL_D@YX65T*4A*AJ0[5;#FW'$#2\ .*L&]D_V)M2 M44[P^L 9P'(9!PV@M1E:1!_%"CT^G3L00[(ZE>MG.#EOZ6?DV&52%4U"B^1X M4>?W3EA=4F!T[*V>GF2:ZMG%%]S,=9BDB7S6D?EMO/&?^OLIE E,$UIM_ ?Z M \E,J]%+;$^\0<_9Z0?MX?NGIIV2U#@1:/[+3?X^[(+!=T=F*N*%', M6Y#.4)GQ43\J'9L\];;OU\V^3W(>_)4[Z/<_5!_P1Z^/FH',&0LXBLO ?^91 M3G'7K>]RI>/5^2BH?_3&K0M:RXFJ?DKPI.7VH /0\^G^J]U9D8[>G*OWW+'8F\1VE! MK]K&4.#TEE>A(5DMQG2ZNB:T2N9PQF[8I+]705"G%P52DD,U=C?3)/BQ!MD\ M>=NZ+I[EP6NYI&2)D?\#4+O51E&>"2PWN$\4UE-BIVP+_<5,LL4ZH^]^,&EI M9\X+8 *TW9KS-->H52)7A%P*ZIW4NA:D \/O&I=H0!D*A AZ1^%M$%,Q(OF. MNWZH&?7+B;[KID/K?Q)6BY["#;D*KFYH&&3T\9&S"#H'*G+(V"V3ZL8K@EY_@!VD@@@2=EF?V% G53UN-=%2NM3B MR0<.]4W5-C47#F9Y2 IIYZ"S>.Y']"C+87W%R4$_)UDG.JTR@6K$=>.:PV1, M?KIX?5$LOAZBOQ:TZ,[2@#PV><.*\$F,C<8F&J-^W-C2U%>-%OGI[W3IG][0 M,P;?J-F'FM'AR]#?4OG^^755E_C&CV5U6]:"?J-F%VF.LX2K%2?3G?%K/6V/ M-TH4(PZ)>+L_Q=MLJ[\/532!A].S99>I9ZI'-X+!'%)9S, .[0AZL2M_:=R4 M)X\F/S"R=JQ, =")&>L.(F#\'&D^@>5[>G";SQ4U;?7SCWID(J$,M!%/BS+@^ROG!/'I^Z\# TKMV31AB@U7C\:?,FMFHNDI&FC=X MR$+UMRSK-V1OB+(ZO3%Z.5P_F/?#<$I!.75[R$7#J(^GI\SS6EQQ?:^HV'1POQ!3D\G(*$.8CS/B$>.-&"S78&S!\[UH_HW"FZ6LZZ0N,M M)#B%/K\XU+MFK>+-4FL^.;_S&\_&15D@$).3Z:=&:+2JR9+**5GB43&$^A_E MM/.+HE-!$64%<6.-F^T,YJMN]):I47ER>YQ]>G>^I;'.,/4U/S_M#%J.M&MH M]&IX+"]R MI]BN:=K@\VN)YP_+I0U2#:2<5?[@T6E5HSUYZFAC9Z^<[#G++0=VPY%%>5OM M4.M=?/+)OQT9BXTHXY*SC?;K]>(_RWJ(WMV__Y\GGSW^RY-B\?3QTV>)-0#J MS]VH$3S7&79&RX9EC54[IY+XU3U9=IGA9H8>8797C%B9_)D_P\QT1)$C;X5. MKYNW0H^ZJ1.RU#$I28P@C=',R,1 M$3(E'CRM/OB&/O37!-IMCK&AN.NM?'D MRG7T+&K$CM3->;A%_L>A@+!E5$ -NR+^2;:,XJT5/"I[N/@># MC' ;'.8@IR@4O#0"W'YR0]QHYVI32IO4IE1:)G15G&%6=\&LGIQA5K_7V/ZN M?LOM=6"EL['ECB%WE43;)_PA%''$=UV[?5V8!47_VK81IF\T,M#IVP& TM 2 M#]V*^XM=%7 '%(P#D_$5-HNO?[IT=HM(I8^2%'*G"NUJ@7W>Y9W=WK_-%PB9 M&-1008O]!1I7(7@Z.;?\\OX.T,):$S:F7L$K-UD[ HY5QAWD=*N<]\9S:O+,W+!09CD"U<\I!!AW? L(X8N M)^NL5^7RG.@AXW^_A>;D 13B NDBD;?L1^IDV6O/42.SHZ)VS&36_3"F5Y3: M5WU(CSFY*R^PW$T1IJZ\[##46_J?;N 6$-."BYN/YTSJ>YOH7Z(HNZ7".[\, ME?:RB<#W01(T[#&JM>)'[3L7BV^J6E559F[*%\5-W$B$=78?BA#V(UGD4?.6 M.:2^1C?)9^L#VI.,[R* /7E[RB3T5</<_8PX1DV1M;AT13UB)81\M56^Y6.F\[XE7H[<< MI]":&>]UON$R6.JXI4:_.=(:U!R:T<[IK8PX+U7Y_6)G^JK1\N63-?N-/ ,M MJD$>1&YX[(EX!VR)W H' X/SL'!/S\2Z*1D;2%@AI#@E6>4R'!QH)(*AZP9; MU)D%E/S'!D;6()PCE^2FS6W[L;!^J/2-N\Y*ON30R>\\]PS/C2IPX'\$;.CEMB%*(,V*AWR6<;-'-D-.#&CC#O+8QX MY,:J0U0AHW,A3E@#QV RS,(WF143#$Z:F:_CG06S)%">VL9\H+S'4XL-N!7H MU:9^EN5DLLP]0.YR./';(X\"[_6HRW:Q^-9)0JH8"PK:DJ,7S:ZQDT>E%.+R MYU3%T\=/GQ;39)N?GY15&TTU ?RI:*6ZRXY"VZ_5;$[?D5R:K?1JC1K'/V>Z M_&_HXT2P-U?ZN@,K4?S*.BSQ-]6RJ:0')>G-2MG=]UL*+BOKNI M=XJ!E9;OK-GM8D65PC,#2(^&_O 4/=]H.\9ILAI,N"BG5=-NN]J\GS3&<\T:JA"(FU\UR:Z6)U1>QC;YL212]+CI)L>?NKC7T MZ[@5M,62X%N&!LV 3L?@<8T)04/-8!--0F>NC6^Y%%C&E+([[Q.I'&F"[[&> M4,XP?S&+A[RFQ6&7T_MZ\V^.+08X9*;WAT3CMVB&C7?(6*: M#)P;MYEAPA$"8 ",N73PV2TD>,O3",+-Q9X50,''';_9]D(T"@(3:61O MMJI%[];V#HV><29OAFTMI!3DT<5 LD)+@,K;&!@C,>"/_23_GJV2OW#(TF4D M^AHX"JR:0XPY'K)"P<5Q>*G5I<<%-[% M"<9DG"C+[F6>_I^G#$]6ZU(3[PZ)I3T04FPG*4P^-T=*['-S^SIZH]_H;8&;HQNGAO$AQ/F&*6WP97,H0-I\:E0A06,1Z4L$M!OG29T&5VB M./R=@RUR>$]G&&54:;S8SVB&7KT/4]1V] W(6W'FY*[[Z*,Y;M*QZL2Q4 B' MU)PO/3T7ZG]/[J6L'X'29]VP_ 50Y48D.\JN:U85(G,X%582 MTV-L2P+%:JO&'531)JV#=_UY[3*=+Y?2U S>!LG=>;/Y]Z'I2R+J'B0'5<97 MW7".H7P;?$V##&][I;@#YBY4 7"^\$@W\3XAZ^ATX>NXAQXZ;BG,3\O>9TJ2 M:>%6DZS6DQ@=1 ,D(1Q2?#$97 MFC6E1X ./9LS@AL3(3\W6E!B4=CY&(XAU[]-/'YR*R.DS*-&W& TGEADO-Z, M$M*Q :H$]*]@!3P&VVZ\F+,]SF3S."BZMCR.R50EM$YL_1QL#)U?BFD@BD6H M,"OF72&]=&!FU3)N/YY72VK":FR MY*GX&C9M)]AE\6*358I^\V2SHQ4 T1C-E5C8S.A8"FZTM#*.!N]?1VMFRT_*6IK.>1AA>+[UU72O[\ MMC(6JI:V#6\U6==L(=X"? #]%T:$G&/W,_Z:.I7,3DF#^?=!%'\WY$$P:Q.G MR"GN7<;(,/@WR]^8O2FC421#2QXYLP692H'J&LR9(O4#X^@,(?&7@N^\(Y4N MK1O):PBZR&M^JA2:3XFGVF+N0M/['ZJPC>LIN7?T91%J,.[UPPSL\MB,L,(2 MUQ?]S/B=[>K0$ALRIH=?5'"V"DZC<&]?5JUST-DOLE/-*I98AL.>4;H$QCI- M4S"RKL?#'.:!I3QJ*XH*\.#6#>#4TI&HBS5/YEQ[TKXDX+WXNV,L+B;*J645]M&YWR+OKLSHISX0H>&.5S"B\! MNFFV)!6F-4:N?]6@B&WZ)LZ0:3>NPIIK:LF#V)7;S5!+E<5!K:F[7U%SZW(G M]+L %GOO8V9(KMB=X@CR8>HVRX2C-[[%W<; M>(=)Y>6ELG$=PQ+<5@J7PG99$XPD[1L.1A -#P-YJW8U[$0M7*M$#@,+R@BMW=D];^65I"V7*U-"-5''6 ) ;Y!O M]M56%!0 ?4#:N&GO&CPO+T5KM>'PH W+@1K"D/35B-K5^I.I;%HM8AE:8,"P ML)'S)\0]YB^GP:BMHT*D]GAIFF,P/2%JYVU4.SH*YDI;DRGT*M$\'5EJFB/: M*VI&9C=#;RK\)ES#G&NU\);FY%SF'[!LMD+7A%C =U%H0LYTD%>K1I)<30YG M5 %QRNTW=UTT4<-KNYE6K'D%1I^\NCIA6 :]WIB6S(K [%PB;W)TS!FY8H@$ MI)O&0.G_;.*9LOBK#CY^\FU\XF:;BQ:CIV-27)F6?3YINHHQ;AL2+@)@M/1&2.&*DIE)#2\)2H'/K#E:CPLTPM5 MG= U,I *G;MQ6<^_]S@S/GH/',J*1[86)\H:='0]3I%(Y8)+&_JJ@^9'DRW& MQ;P.\/2&9)0!FTI)^/"6A'8ZWV&5S><(#WTNXM]1Q']V+N+_7F,KI='C-NU8 M94F#OWN>5K1/B,2,B-$&72PN[7 @IXS"]-""J 6J'56X[20E=H_G M$NEB<[NBEQ[6SO)158EC)>Y]I4PPY8F8S(X9;1TPR3^,5\L]>H2Q9%EE%939 MT;\#OG5/SK 3=/9^FD>$

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�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�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य़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�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end

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